<SEC-DOCUMENT>0001628280-20-015726.txt : 20201105
<SEC-HEADER>0001628280-20-015726.hdr.sgml : 20201105
<ACCEPTANCE-DATETIME>20201105160037
ACCESSION NUMBER:		0001628280-20-015726
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201105
DATE AS OF CHANGE:		20201105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardiff Oncology, Inc.
		CENTRAL INDEX KEY:			0001213037
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				272004382
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35558
		FILM NUMBER:		201290287

	BUSINESS ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-952-7570

	MAIL ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trovagene, Inc.
		DATE OF NAME CHANGE:	20130304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrovaGene Inc.
		DATE OF NAME CHANGE:	20110830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XENOMICS INC
		DATE OF NAME CHANGE:	20040719
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>crdf-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:899aa37a-8922-454a-a94d-f1f600203a5a,g:092e8a26-8aea-4f93-acda-3be57db43dca,d:0ff27e3402fc47278eb8617e2a08b771--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:crdf="http://www.cardiffoncology.com/20200930" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>crdf-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80L2ZyYWc6NWQ4NTQzMDhjMjMwNDlmMDk2YjNmNWFkNzkxMDAxMzcvdGFibGU6MDViNDk4MjJlNjZhNGM5YWEwMTJlOTNjOTRmYmYzZDIvdGFibGVyYW5nZTowNWI0OTgyMmU2NmE0YzlhYTAxMmU5M2M5NGZiZjNkMl80LTEtMS0xLTA_40125a37-4d6c-47a5-bc41-64f22422fbe8">0001213037</ix:nonNumeric><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80L2ZyYWc6NWQ4NTQzMDhjMjMwNDlmMDk2YjNmNWFkNzkxMDAxMzcvdGFibGU6MDViNDk4MjJlNjZhNGM5YWEwMTJlOTNjOTRmYmYzZDIvdGFibGVyYW5nZTowNWI0OTgyMmU2NmE0YzlhYTAxMmU5M2M5NGZiZjNkMl83LTEtMS0xLTA_db645fee-ee93-4e37-83da-c6fbf87a7c34">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80L2ZyYWc6NWQ4NTQzMDhjMjMwNDlmMDk2YjNmNWFkNzkxMDAxMzcvdGFibGU6MDViNDk4MjJlNjZhNGM5YWEwMTJlOTNjOTRmYmYzZDIvdGFibGVyYW5nZTowNWI0OTgyMmU2NmE0YzlhYTAxMmU5M2M5NGZiZjNkMl84LTEtMS0xLTA_5f1b863b-57f9-4174-9c3c-753b3373fa7c">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80L2ZyYWc6NWQ4NTQzMDhjMjMwNDlmMDk2YjNmNWFkNzkxMDAxMzcvdGFibGU6MDViNDk4MjJlNjZhNGM5YWEwMTJlOTNjOTRmYmYzZDIvdGFibGVyYW5nZTowNWI0OTgyMmU2NmE0YzlhYTAxMmU5M2M5NGZiZjNkMl8xMi0xLTEtMS0w_d5357793-aa49-4d53-916a-a2068b227fe1">2020</ix:nonNumeric><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80L2ZyYWc6NWQ4NTQzMDhjMjMwNDlmMDk2YjNmNWFkNzkxMDAxMzcvdGFibGU6MDViNDk4MjJlNjZhNGM5YWEwMTJlOTNjOTRmYmYzZDIvdGFibGVyYW5nZTowNWI0OTgyMmU2NmE0YzlhYTAxMmU5M2M5NGZiZjNkMl8xMy0xLTEtMS0w_d4b1f678-8004-448b-b370-7050fa380d32">Q3</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="crdf-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ic23a800c65404ec9a95b7240a59525a9_I20201030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="if99a8ed180cc459681d3588755b7784f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1f73b5fbce249928d3fd6362296a372_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2d6ca3e50fe457a9eb38c4d29349a61_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if77d4dc67bc04941b7ea951868ce010e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64433fb437b14e2797a35696e3126e7f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d39276c8b7149b69b1e0641629d29d6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63c477ad569243b4b07aafdf89f0eb4a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f3c98f923a849c790c797406aeb0d7a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ac167662d264ce29cc6bdaf26de9a0b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60ddc19ccbda40389020c27451bc6aab_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f397383420f42f49ba5adbf81294e83_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a0e35fa886e4b33918433a1b304329c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8c5bb2609e8479dad4e32ccd15c3b2a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i206237eca5cf411b89a567e3e300cf34_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i440ceb711f7c45eaab28660fa0a6c49c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a1c6cfd3bf54dffbfab3dca4b84b7ce_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i355e679510824d7b8627423cf0866836_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacd4e3fe0e164beea6824f1f787dbb03_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8558b18d83f4b29acd586d939030fb4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i969cd75c1e19434b854579b8223eca1f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a4d70afca204fcbbdba84e5be3dd359_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44c0a4463d8b467eb6707129cf69494a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aea61419554483ab22c33a2aa6fdddc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie81e092c24a3460ca593f690506ba45c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e4e419343594d71afb1d77399f4daad_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6962b9056174c398b78bd1a322ad590_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e7a4e37750d41c2b7bd2a4475f50b9d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i892bb4bca35e42edb3fbf0ca66a798a4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a5b54961e1a408da4efa7c4a015db44_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i105b5086b9d140d382a2cf18218bbcdf_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i986c4f37b62f4001bb38dfa79cf80042_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a78e5a7b2ff488abd9e098d74a099e8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd6fb8040cf1408a9b85618f489130ce_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2007c264c51a44a98c0f645dc1f8ba51_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c0977b1d8e8404aaa3b657703fb8dd5_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c907bcbc06d4d318ec339547451ef5b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70a77dc066834b05be99f8161e3fb65c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4334ae12820e4b96abd660da1706eef0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaa519b044634475a9a19ebc2fdfafde_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8646b250083b422d8f1430bffcbe6b73_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6160228ffe834aa18b13f335f5d812ad_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00b92270816642589793666319d5f182_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5b2f533f0534d78844b49d29954c8e4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37f5de467cd94aab8302da68767238f2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf1a9dc0b4284431b4cef397cfcd0b83_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i179c2b18280246c8ada7c878931742fb_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5ff2e0258b7445fb9a110a10dccadb7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6d7f037cf0b4b8792ebe716a72da81c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c90af801967473ab9d203d9d12c323f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4056f199424143e290a92a502f0c74a0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i249b89eeb0194442ab7d9ffdd4dc0dc1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01fc0539599a4354836f19a58664e5a7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4aff4ec96d0b44fd96cf76b82d788da4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54a56210ecbf42aea170e8ae37fe336e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i068dca4a9a24460485c15359caa4f37b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3585b22f6f334b64b4a9a946e0b1754f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacde1c89795341d7a6585a9ca67ff1ef_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68416144d86546848c61077e3daaae71_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8388a4c16204624a7b7ce5524a8ab3d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf7bcf08b2e0459b88c7b9896849b386_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20ddc05282304186b85c0c5e82d9c3dc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec08f4c1e8014a62bb515c9760634ec7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if04bc8a88dbf4923b75de662fba8bcac_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7f9daee734141178c3262a70ac3d9f9_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4094a45bf8304a038d7489696b49f0ee_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe3da09bc10142fa86a695704e95333d_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i686b763ed80c42debf1673b939ce8436_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3e995f613e04a30b83a190600e73d1d_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i795f824a2e0848ec9e08218e1e384119_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ab978b16413492fa60c4cc6dc4f989a_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2b9bfad02a04a619ec5166a7e949cf7_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fbe7725163e40c4a4a41af38a99b6e5_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad21cf8f4ef74076934e4cd2f244fe43_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i869616a16b38489397727b402aca4049_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d83f131001e47c7b941410eeb7dfb34_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie62f103ee8e84d74b05d78ebcb684bb0_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6408fd73dd948b2bedb47f26bd26ece_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8356a82f43e649ce8d9fc4f3bdeaf910_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dd92383a8974c29a26c20ba1c50c24e_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd90d3836ae44a5288cf14214ce01d23_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ee69498ef64ee98c7d13fd73810b69_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i102d06ccc049420ea4a988739f4e1f5a_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bcee1f60daa4ba798ca5869fb08d829_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i963638cbd5724619a756ba6fac98c0d7_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40293b1c801f4325997aad38bcf3edfe_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73a60988cd7742b186d790b4be820c3a_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bfc5f134f7e4fb0b0329e2e588c22d9_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a44d42518d247568f1e2b1a8b580163_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida7da958772f451988cb48e47b519200_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d0f3a37ba3f419f9e5fc2d23d7be984_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0315ca5a43e14290ba86e2502d1e7df3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d41d866570f426f80638fbc27922861_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2a52fc6ccc044c4b200ae25cc1f0627_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i713cb493491f49ab95402bed132c3427_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70118ce382b54129a01f304d79e91011_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie295404f651a43699515699a65360c65_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a436b27140f418b9f00effe44febb9a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i601506d900b640889cfe25c06b9517ad_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c512dc917a44fa4935298acc4757d46_D20201002-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-02</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id02c2a45ee9d4832a6e43bb343c46f06_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ae86bd676e644578010b6922e11b5af_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id797d8f2971c433b85a9c8e933191c14_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i922cd50fe23c43afbd32e28dc822bb14_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9deeeca3150647ec9217fa02ab61c9ad_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c1dff24e4584a7c84ebc91d6aae1001_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b110679c7614e04bf79a89353cde89c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14bb2d1b3ff242f28e82eda2a47f119b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff6cc44df61b4043b78740d1bee0959b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic763b33eacc24b9da821d145ed6ebff6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if44f824383a040f084fa2c0d3ddf921b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86a4592371ee47e585775ef7ab0a392a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5366ec380ebb435dbfde066020aa5925_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66b2709deee64adcb18d9c2af9b4467b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58bccc712f204dd9aa339aff63845a18_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb19cb296ec14221a57f41b82c172241_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3207f5a1740243bcb1976b54a554df1c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie609985fe35541f19bd9585994dad17f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1be75556eccc47a1806b67aaab547b18_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic730906a9b7146d1b973c557bc30b530_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1fd079695bc43f594a3fe0cf305011d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13bcac6c13f146b59174b71aabe0cc5b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i186aff4c8c0e467286405c76465b4ba0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1235b538bb13457d894f3ca7cec6739c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3da0359f941e46dfada6dc17aa275971_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>crdf:lease</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="renewal_option"><xbrli:measure>crdf:renewal_option</xbrli:measure></xbrli:unit><xbrli:context id="i3ffb8f629fcb46718f4c859a146c71fd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">crdf:AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib123867495f94547b6cb9b6106e13878_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia632870d35b34e9dbf2630ee46469e33_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i252b5a3294c7458b81a17c82715f2098_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1791fb1fc4d4c5d9d1db0ecd2bdad61_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16ba3ca0f0224c749930d1fc21651e07_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90efbe055b164d5c97f3d098c16522c7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad3f1104f4364db7ab0e9e5d2154e3b1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieef3ac4d1b1741f39df174c71b480929_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id831883b118a48e387be55b132ff3344_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i048344a9062f4510a9cbff0eebd42e0b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i578319d576ac40ef82ce89b1e70413e3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30cf812ae8ab4b1fabcfb5a73eeb1c7d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfd53102430c43678b9eae10ab1d3201_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2ccfbfb002346579e7acceabf1ee362_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i344555a942b24c73861cf579aa6c6b32_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if89380272ed24b2cbde3226e6b36b53d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9154e610b334767a4b96b097661f34f_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i142d89ee985546c591160d9c6e366b3a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6d4972e6afd4ac69b9a8f6a86fcc5fb_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb6ee131f889432ba4524b13c5e5ca50_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83ac99d4b3ff4e2fb15a26aced83a7a1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if51ce0d70552424db9d6267694e4b4e3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i412c95ab862b4b7aad07c1a3835d9cb8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic64a7bb878fa4c36bcfb2c9240e8fd4c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcd94fffab0343acb682f8189e2a383b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f3906c2627e45ebbf6c1fd90f256031_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a725951ef874d2f949c21c129a5effc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd6b8b4cf5a542a297c33f23f0231c1b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b057edf8d344b4491e948f3e69dfbe2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2deab4e6786544879aa966ac0a102502_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55f43f9e04394c4795b66f2466f5c7a4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iade2911f07fe4bd58a7771f4d8ff5609_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5631259573e042a39f4be4eceee56516_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87383483b52740ad89c088078af10f5e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ecb4a9d6a954fab97ac2a9e46298476_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i959cddd1d9ca46a1ae94c9e574311f33_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i046408524fc84867a0e1a4a0d4d161cc_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8619936082e4b66a9d9afbba2b5f205_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida9ccce01325454aa5cdd8a070b92b32_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i892b1dd1549d490f9a6e0de63da8493e_I20190605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crdf:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcaf805475824b1c97f6e483866ff34f_I20190606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crdf:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a5cf127866f4450ba5177b5b209e29e_I20200415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crdf:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabec5ed6104d47f69e84008a3df403c9_I20200416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crdf:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i972ffd28b08d461a8a8f34ee29c25c72_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crdf:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0736ee7158d4ee1952c5ed8ecafc35d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8e40e0994bb469c98f27ccf0cf198f8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd88fd532f594f72a9d627dfe035ac48_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57c92be504a54fbda158b82418700c3b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85c6c9f6f5d545a68d3ccd6f9971a221_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b1f3d6a8b304f008d1560110f698bb3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idea78c0fd4d44a8084b8b53c668496d2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i488747dd585c416195aa8719cfb75a37_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia99ee4a1746f4fe4ab0a83e29d9ebce8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie25dc1818267487abf4d33e2c6debe5c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6788da5ccc444936ac79910ced50285e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2758eaad8b58491c9ca8fda860044695_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6045af669a3745cd84ac6c08b964f8db_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87e30ab734dd4d1c81c49063fddfc61c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89e52a934cce4337b884a4e1340a6e33_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a73b848ad3a456ab8efe3f435c2cc17_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dd384648729485e814847bb936c3e19_D20190125-20190125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-25</xbrli:startDate><xbrli:endDate>2019-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42c394bde6f545e8b27bd5ddd62298f4_D20190125-20190125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-25</xbrli:startDate><xbrli:endDate>2019-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6306bd3082c44e75b9d4bb83e91ac1d5_I20190125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9473042322684048b0e1c330a634200d_D20190125-20190125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-25</xbrli:startDate><xbrli:endDate>2019-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if90d90503a6a456396e7a7c6dd952122_I20190125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39ceaeb412fa40d2948c4049aa876acc_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica50461d886a437e9c053eb1e77b24bf_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e9dce01464f42658cfd49145c156296_I20190125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic492c1a7e6d541e3879728394630480b_D20190125-20190125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-25</xbrli:startDate><xbrli:endDate>2019-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i802925f6b20a4ab883a3e64399b2625e_D20200508-20200508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-08</xbrli:startDate><xbrli:endDate>2020-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafcaa2b479f245d0bd1d92340c68caa8_D20200508-20200508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-08</xbrli:startDate><xbrli:endDate>2020-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76014c469f9d4b79ad388b4bd5ef655f_D20200508-20200508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-08</xbrli:startDate><xbrli:endDate>2020-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i237b058632024beea09d8f721dc6c2fb_I20200508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6bd6d0b8e894e96b013f0f9d4a47eb5_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fa6df7a14994c2f9f5cf33cda5a8363_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0134e1c7efdb4726b66acda8a7eadf9b_I20200508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b91e6f08a864448b74ef428e982d96b_D20200508-20200508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-08</xbrli:startDate><xbrli:endDate>2020-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5c36764fe274b08925b71b22a4d62aa_D20200615-20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crdf:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-15</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c6e0349b8984c0c91135effa1fe723b_D20200615-20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-15</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f789e5648a44a9ebd4b303e67d1385f_I20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1ab4f2aeab147b0810f2c0e9bca7283_I20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e16f37428d6480ca95ace2934d30b33_D20200615-20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesNWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-15</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f44ab1b15204ed1b2aa74e76adaa3eb_I20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesNWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a1b1259103d4e9aae05e28f31feec2a_D20200615-20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-15</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib02c4909f8dd4c1390ce2b2d6f67d719_D20200330-20200330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-30</xbrli:startDate><xbrli:endDate>2020-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ec1ce35bd704b2a8bec37b6d629c0a9_I20200330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesIWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifba3ba46775046ecb40386b74aace6e0_I20200330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesJWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i974ceaa146934ff9a98da6f12360fc49_D20200330-20200330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesJWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-30</xbrli:startDate><xbrli:endDate>2020-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieef62941a8724a6eb7609cc6f162b59d_D20200409-20200409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-09</xbrli:startDate><xbrli:endDate>2020-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfd5397c17484e7d996cff5cd20825d2_I20200409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesKWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97c8fab924224323b855bff2be4699fb_I20200409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesLWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6178fac3fa4f4c6e91065959e9e43ff8_D20200409-20200409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesLWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-09</xbrli:startDate><xbrli:endDate>2020-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae68d7d006fe4e14b9a1eeee4dd8bc44_D20200511-20200511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-11</xbrli:startDate><xbrli:endDate>2020-05-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ed3fc7af1634151b2096d32abc0f74d_I20200511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-05-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cca101c80a44226a89c8c35200266b8_D20200514-20200514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-14</xbrli:startDate><xbrli:endDate>2020-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieda19dd800d74d44bd5230900bc96c90_I20200514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if100dfb4b4384fd0bb32098df385547f_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8617217253414190b2251159121acc8a_I20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesMWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f94e8c81c344800b60b03a24b2933a5_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesMWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibff09abd8c4041f78419c55803eaf58b_D20170301-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crdf:NorvianoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24aa660d59c2466faf23e2429d2aa751_I20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crdf:NorvianoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if25db31f1cc14bd8ad1940aa6a08ec7e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17f7e87656404afa93a7d1e1581c3052_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i608690ce785549468033da705f15e7f0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58ff4aad5faa4a528942057efea92b13_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a08aa2fda7c4db799f75bc79a5a0e5b_I20200415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crdf:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic032311ae02d403789f39a7132fe94f9_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbbee8b1f9a244e8ad1c0673daa3a0b1_D20201002-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-02</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4884eb0a36754efda6090e87871a157e_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2917c1b61fd347ec893f35bbe6cd7228_D20201019-20201019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crdf:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-19</xbrli:startDate><xbrli:endDate>2020-10-19</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtMS0xLTEtMA_4c625304-18b6-48ac-a97f-84c5bf85ccfd id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtNy0xLTEtMA_1d5eb083-686d-4d30-b1b9-5da8e39d29d5 id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtNS0xLTEtMA_7e0aca0a-36dd-4ec7-9639-c05471553428 id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtMTUtMS0xLTA_af12d379-5662-465f-8a93-94f0111d55cd id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtMy0xLTEtMA_785dc728-fb40-48ed-8571-ce68880992ec id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtOS0xLTEtMA_4eafee9b-816d-4fd7-9875-e9faaca48aa5" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RleHRyZWdpb246ZTA5MGZmN2Q3Zjc4NDBjM2E4N2ZmYzlkNjJhM2M4YjVfMjg5_b065a1c7-ef82-41c7-88d8-90b2e32f5fef" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i0ff27e3402fc47278eb8617e2a08b771_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGV4dHJlZ2lvbjo2ZjliYTBiODgwNGY0OGE1YWE4MTBjZDM2YmRkNmE1OV8xODY0_3f46f769-611e-4634-88bb-c6d834f008a2">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6MGYyNDA4ZmNmZGM3NGQ2Y2JlNjg3NTlmOGU3ZGQ1ZDEvdGFibGVyYW5nZTowZjI0MDhmY2ZkYzc0ZDZjYmU2ODc1OWY4ZTdkZDVkMV8wLTAtMS0xLTA_f5a8acf9-104d-4984-9091-d1ac94afce12">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT UNDER SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGV4dHJlZ2lvbjo2ZjliYTBiODgwNGY0OGE1YWE4MTBjZDM2YmRkNmE1OV8xMzg_0a38ff2c-4caf-49dc-83ba-88d3670552e1">September 30, 2020</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6MmY1NDBhMWEzNTFmNGI2YTk0MzI2MTJhODc3MzYyNGMvdGFibGVyYW5nZToyZjU0MGExYTM1MWY0YjZhOTQzMjYxMmE4NzczNjI0Y18wLTAtMS0xLTA_be7aa431-516b-4d22-a5ce-55c566f3dd33">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT UNDER SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER <ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGV4dHJlZ2lvbjo2ZjliYTBiODgwNGY0OGE1YWE4MTBjZDM2YmRkNmE1OV8xODY1_bb6006e1-77a4-4319-9a09-d89738a33353">001-35558</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGV4dHJlZ2lvbjo2ZjliYTBiODgwNGY0OGE1YWE4MTBjZDM2YmRkNmE1OV8xODYw_c0b91d2b-6348-4e04-8ae3-8522543078c8">CARDIFF ONCOLOGY,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact Name of registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:48.552%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6YTdkMmZkMGZkNWNhNDMxYmFlMTE5YWI5MjdlY2U0ZjIvdGFibGVyYW5nZTphN2QyZmQwZmQ1Y2E0MzFiYWUxMTlhYjkyN2VjZTRmMl8wLTAtMS0xLTA_1bcd50ba-4772-4c4c-80cd-86ce0957bebc">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6YTdkMmZkMGZkNWNhNDMxYmFlMTE5YWI5MjdlY2U0ZjIvdGFibGVyYW5nZTphN2QyZmQwZmQ1Y2E0MzFiYWUxMTlhYjkyN2VjZTRmMl8wLTItMS0xLTA_76af0fb9-6c7b-4446-bbdd-7b12c013e0c5">27-2004382</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6YTdkMmZkMGZkNWNhNDMxYmFlMTE5YWI5MjdlY2U0ZjIvdGFibGVyYW5nZTphN2QyZmQwZmQ1Y2E0MzFiYWUxMTlhYjkyN2VjZTRmMl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpjNWU2ODVhNzkyNzY0YzI2OWUwMWRjMWE3ZTFmMGVkZV80_60f9d3a0-59c2-461e-998d-7ef7df1ad9fe">11055 Flintkote Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6YTdkMmZkMGZkNWNhNDMxYmFlMTE5YWI5MjdlY2U0ZjIvdGFibGVyYW5nZTphN2QyZmQwZmQ1Y2E0MzFiYWUxMTlhYjkyN2VjZTRmMl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpjNWU2ODVhNzkyNzY0YzI2OWUwMWRjMWE3ZTFmMGVkZV84_72348bf7-55c0-49c7-b110-fe9f09851c9b">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6YTdkMmZkMGZkNWNhNDMxYmFlMTE5YWI5MjdlY2U0ZjIvdGFibGVyYW5nZTphN2QyZmQwZmQ1Y2E0MzFiYWUxMTlhYjkyN2VjZTRmMl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpjNWU2ODVhNzkyNzY0YzI2OWUwMWRjMWE3ZTFmMGVkZV8xMg_3ac26502-021f-460d-86db-ed6c109901cd">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6YTdkMmZkMGZkNWNhNDMxYmFlMTE5YWI5MjdlY2U0ZjIvdGFibGVyYW5nZTphN2QyZmQwZmQ1Y2E0MzFiYWUxMTlhYjkyN2VjZTRmMl8zLTItMS0xLTA_e70b6266-5208-43bd-881c-c2cb0803db88">92121</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6YTdkMmZkMGZkNWNhNDMxYmFlMTE5YWI5MjdlY2U0ZjIvdGFibGVyYW5nZTphN2QyZmQwZmQ1Y2E0MzFiYWUxMTlhYjkyN2VjZTRmMl82LTAtMS0xLTAvdGV4dHJlZ2lvbjpiMjQzMmYyZGQyMzg0MmIyOTEwYTlmMjA0NGQ2NzU3Yl81_b3166f97-f1d4-4ee3-b266-26a12c4af748">858</ix:nonNumeric>) <ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6YTdkMmZkMGZkNWNhNDMxYmFlMTE5YWI5MjdlY2U0ZjIvdGFibGVyYW5nZTphN2QyZmQwZmQ1Y2E0MzFiYWUxMTlhYjkyN2VjZTRmMl82LTAtMS0xLTAvdGV4dHJlZ2lvbjpiMjQzMmYyZGQyMzg0MmIyOTEwYTlmMjA0NGQ2NzU3Yl85_74cb4d0f-8f95-45be-952b-04385dd98ced">952-7570</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:31.862%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.725%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title&#160;of&#160;each&#160;class:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading&#160;Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6MDg2MzZiY2M4ZmU4NGRhNjlhMTFjNjM0ZWUxMWUwZjAvdGFibGVyYW5nZTowODYzNmJjYzhmZTg0ZGE2OWExMWM2MzRlZTExZTBmMF8xLTAtMS0xLTA_a2364e60-3762-49e1-8628-32552b79dc2b">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6MDg2MzZiY2M4ZmU4NGRhNjlhMTFjNjM0ZWUxMWUwZjAvdGFibGVyYW5nZTowODYzNmJjYzhmZTg0ZGE2OWExMWM2MzRlZTExZTBmMF8xLTItMS0xLTA_a5ae9a3c-14fa-43f3-9082-d06044d3cefc">CRDF</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Capital Market</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the issuer (1)&#160;filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGV4dHJlZ2lvbjo2ZjliYTBiODgwNGY0OGE1YWE4MTBjZDM2YmRkNmE1OV8xODYx_4b8c770a-bbf5-48e6-8cc6-6a12a7ac1dd3">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160; No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGV4dHJlZ2lvbjo2ZjliYTBiODgwNGY0OGE1YWE4MTBjZDM2YmRkNmE1OV8xODYy_3562cbbe-fd20-41a2-b3ad-0cec803b477b">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160; No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:17.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.999%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6OTQ2YTNjZjViNDVlNDUxMjk4ZDc3ZGQ3YTY2YjE4MTUvdGFibGVyYW5nZTo5NDZhM2NmNWI0NWU0NTEyOThkNzdkZDdhNjZiMTgxNV8wLTQtMS0xLTAvdGV4dHJlZ2lvbjozMjY5NDNkYjJlMDk0N2Q2YjNiYTA1MTM0YjQ3ZTI5M180_75221fc8-ba54-46dd-8c58-910ec2078782">Non-accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company&#160;<ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6OTQ2YTNjZjViNDVlNDUxMjk4ZDc3ZGQ3YTY2YjE4MTUvdGFibGVyYW5nZTo5NDZhM2NmNWI0NWU0NTEyOThkNzdkZDdhNjZiMTgxNV8wLTYtMS0xLTAvdGV4dHJlZ2lvbjo1YzUyNzdjNjNlOTU0MDhmOTFlN2Y3NmY3ZDJhMjcxM18zMA_7d9f1d51-6c7f-4981-890b-3c7535702244">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company <ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6OTQ2YTNjZjViNDVlNDUxMjk4ZDc3ZGQ3YTY2YjE4MTUvdGFibGVyYW5nZTo5NDZhM2NmNWI0NWU0NTEyOThkNzdkZDdhNjZiMTgxNV8wLTgtMS0xLTAvdGV4dHJlZ2lvbjowMDlmMDFhZjIwYjQ0YmY1OWNlNDMyNzBlNGFjZmU4Yl8yOA_e6690835-0917-4eff-9675-451abdbf700c">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGV4dHJlZ2lvbjo2ZjliYTBiODgwNGY0OGE1YWE4MTBjZDM2YmRkNmE1OV8xODYz_10e34622-46bb-4cb7-9a72-d250bb343fab">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160; No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;30, 2020, the issuer had <ix:nonFraction unitRef="shares" contextRef="ic23a800c65404ec9a95b7240a59525a9_I20201030" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGV4dHJlZ2lvbjo2ZjliYTBiODgwNGY0OGE1YWE4MTBjZDM2YmRkNmE1OV8xODA4_2573e1c1-42e5-41e7-9ef2-540bc21db5c5">35,324,607</ix:nonFraction> shares of Common Stock issued and outstanding.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0ff27e3402fc47278eb8617e2a08b771_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_10">PART&#160;I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_13">Item 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_13">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_16">Condensed Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_16">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_22">Condensed Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_22">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_25">Condensed Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_25">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_31">Condensed Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_31">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_37">Notes to Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_37">11</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_73">Item 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_73">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_73">22</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_91">Item 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_91">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_88">30</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_94">Item 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_94">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_94">30</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_97">PART&#160;II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_97">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_100">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_100">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_100">31</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_103">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_103">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_103">31</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_106">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_106">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_106">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_109">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_109">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_109">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_112">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_112">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_112">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_115">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_115">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_115">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_118">Item 6:</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_118">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_118">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_121">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i0ff27e3402fc47278eb8617e2a08b771_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="i0ff27e3402fc47278eb8617e2a08b771_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i0ff27e3402fc47278eb8617e2a08b771_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMy0xLTEtMS0w_020cfc48-c5b3-471f-9194-860a94515924">36,405,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMy0zLTEtMS0w_3c23091f-855b-4c70-824f-aeda0642f323">10,195,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfNC0xLTEtMS0w_89984d52-f823-42ec-ae16-a7cae8223fdf">204,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfNC0zLTEtMS0w_cffdcd99-e6b2-4260-87b3-51fb6d779904">203,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfNS0xLTEtMS0w_8129cbb5-fbc0-4c02-8d34-b30cdb2921b4">1,578,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfNS0zLTEtMS0w_3f6eb429-0b4c-40dd-ad4e-b7276822ef45">954,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfNi0xLTEtMS0w_1c36d3fe-ba78-4a7d-aaed-835e280d53e5">38,188,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfNi0zLTEtMS0w_85663a25-2b9e-4da0-899b-417c5d78b872">11,353,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfNy0xLTEtMS0w_9d4bc052-592c-4899-890c-65d99ec6eaae">682,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfNy0zLTEtMS0w_d792d098-2312-4009-b360-799d6217454e">877,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfOC0xLTEtMS0w_c425ddd8-c5af-490b-b76c-09bec6a216e8">423,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfOC0zLTEtMS0w_e4f312ce-e189-4865-825f-ab1f02937cdf">697,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfOS0xLTEtMS0w_0105e7a4-791a-4709-8bd6-c53c8a2f8942">155,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfOS0zLTEtMS0w_c3d8cc55-ba84-4a21-bca5-da06d21acb2e">157,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTAtMS0xLTEtMA_e3e04ec4-a3ef-4aab-8d27-6bb82658cf52">39,450,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTAtMy0xLTEtMA_1e22f284-e525-4c2d-b6db-aa8e947cd24e">13,086,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTQtMS0xLTEtMA_b0413ec9-ac54-4648-8f5c-a4bcca3cb608">610,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTQtMy0xLTEtMA_b46df5c1-3462-43e6-ad9b-11f426d31aae">656,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTUtMS0xLTEtMA_879e74b5-9c3d-4aa2-833d-02bdad82c893">3,643,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTUtMy0xLTEtMA_3bca3fb5-7818-4965-a22e-840dbbc18e35">3,260,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTYtMS0xLTEtMA_fa6f9b09-22b1-4fc8-bfbf-7ef6a827ac7a">305,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:NotesPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTYtMy0xLTEtMA_5ad0842e-6354-4405-b76c-674e825a190e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTctMS0xLTEtMA_21540351-46e1-4ce9-a57f-1b42bbefe6cb">883,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTctMy0xLTEtMA_3ccd2d9b-1ddb-4273-a1ba-da442dee3a83">865,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTktMS0xLTEtMA_b7eaaf21-2fc0-4110-b154-311058f770d0">5,442,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTktMy0xLTEtMA_efdda2e9-5379-4729-9a35-c9056f43e588">4,781,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments&#8212;warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMjAtMS0xLTEtMA_d2e01387-015b-4479-a02a-521cef88b8bd">190,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMjAtMy0xLTEtMA_e53ad50c-82a4-4f4d-ad20-f5a3faee55ce">4,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMjItMS0xLTEtMA_984da937-bfe7-43bd-ba6d-4f0b5deb477d">207,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMjItMy0xLTEtMA_e68b7a12-2f97-4404-b0c1-4fc0a490034a">860,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMjQtMS0xLTEtMA_ce8f3441-ed4f-4f05-bf08-7134ae1b41ad">88,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMjQtMy0xLTEtMA_8f0733cf-4d73-4d0f-aa05-93ebfb6b835d">128,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMjUtMS0xLTEtMA_80b3bfa2-858d-42da-b8ae-9f2df30331ec">5,927,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMjUtMy0xLTEtMA_894cb7ee-3dce-4278-bc0d-0777870ed555">5,775,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 8)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMjctMS0xLTEtMA_66a6c99d-3c36-4994-9fbd-ab93a92623ef"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMjctMy0xLTEtMA_1cb526e2-74a1-4cf3-ae9b-52b0cd727931"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, <ix:nonFraction unitRef="shares" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmUyMTc2NDE2OGFjOTQzYzE4YjBmNDM5MzNiZmRhYzEzXzIx_6c1bdc6a-a705-46b9-902b-69cb0f830c53"><ix:nonFraction unitRef="shares" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmUyMTc2NDE2OGFjOTQzYzE4YjBmNDM5MzNiZmRhYzEzXzIx_daa393b1-2c02-4717-84ee-0ea60106f8b6">20,000,000</ix:nonFraction></ix:nonFraction> shares authorized; (Note 7)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzAtMS0xLTEtMA_40bd6981-99b7-4b80-9890-be538ce33770">926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzAtMy0xLTEtMA_16873f02-7748-4c80-98db-5d1472cbf1c1">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBjMThiYzk0OTRmMDQxNmY5Y2I3ZjQzYzMwOGQ1YTljXzE5_98f7f002-6610-44d8-849e-67d7136bb48a"><ix:nonFraction unitRef="usdPerShare" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBjMThiYzk0OTRmMDQxNmY5Y2I3ZjQzYzMwOGQ1YTljXzE5_9bfa225f-f4f5-4771-ad5d-0c83948af2a4">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBjMThiYzk0OTRmMDQxNmY5Y2I3ZjQzYzMwOGQ1YTljXzMz_8b02efd1-cd98-41e1-9835-ea31ef8af8cd"><ix:nonFraction unitRef="shares" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBjMThiYzk0OTRmMDQxNmY5Y2I3ZjQzYzMwOGQ1YTljXzMz_edd5df38-460d-4da5-b908-29733c18f83a">150,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBjMThiYzk0OTRmMDQxNmY5Y2I3ZjQzYzMwOGQ1YTljXzU1_9b5e30bc-0ba5-4318-bbad-316c5bd85aeb"><ix:nonFraction unitRef="shares" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBjMThiYzk0OTRmMDQxNmY5Y2I3ZjQzYzMwOGQ1YTljXzU1_f41f5180-e47a-4d25-8b06-7edc918af62c">26,285,743</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBjMThiYzk0OTRmMDQxNmY5Y2I3ZjQzYzMwOGQ1YTljXzYy_66964b14-1db8-41f2-8853-674b1ca47b64"><ix:nonFraction unitRef="shares" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBjMThiYzk0OTRmMDQxNmY5Y2I3ZjQzYzMwOGQ1YTljXzYy_a5b84f57-527b-42fd-abf9-4adc60c77bfb">8,593,633</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September 30, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzEtMS0xLTEtMA_91d42959-a00e-4427-a81c-b3c65bd9edfa">10,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzEtMy0xLTEtMA_c02399eb-d1dd-4f7a-9726-0600686d24ba">8,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzItMS0xLTEtMA_66d791bc-13ab-4526-82d4-42b110e0b61a">260,807,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzItMy0xLTEtMA_cb3072aa-81f2-4277-9663-0026e7eb1bf3">217,172,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="crdf:Servicereceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzMtMS0xLTEtMA_b5d84ed2-16d6-4d91-b283-b04befdd67f3">2,403,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="crdf:Servicereceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzMtMy0xLTEtMA_e592a2f2-044c-483a-81ba-ef2bb3fafa3e">971,673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzQtMS0xLTEtMA_ca0f882d-1d3c-4161-b568-ef0b56be7a8a">224,892,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzQtMy0xLTEtMA_3f75610e-19ee-4659-bfd8-769fef98d9e0">208,897,883</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzUtMS0xLTEtMA_7075879d-aa31-49eb-a904-0d109a36a81b">33,522,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzUtMy0xLTEtMA_87c4f00c-4838-40d3-ba9e-dc7d50e44742">7,311,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzYtMS0xLTEtMA_cee6a17c-b62e-4521-9859-8621ed921286">39,450,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzYtMy0xLTEtMA_2d3110df-f44b-4b0b-8e81-2dac140af974">13,086,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i0ff27e3402fc47278eb8617e2a08b771_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMy0xLTEtMS0w_10fdabf0-0536-4279-9ca5-57d3e1e73d95">136,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMy0zLTEtMS0w_43fb2993-4c8a-49b5-a0cf-919e0fc3fcf0">51,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMy01LTEtMS0w_b555ed6b-0934-4453-8c14-6438c7c3bf18">246,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMy03LTEtMS0w_d80e93ab-548b-4e52-8091-30f6528d9724">150,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueNotFromContractWithCustomer" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfNC0xLTEtMS0w_916a96e4-68f0-4515-a790-dacb979d6cc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueNotFromContractWithCustomer" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfNC0zLTEtMS0w_e9ab7753-6807-4466-b433-a65a4dd07e16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueNotFromContractWithCustomer" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfNC01LTEtMS0w_da21cd75-cb09-4696-abe8-e6192864a46b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfNC03LTEtMS0w_2579de74-51ab-4795-8754-07356573a536">1,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfNS0xLTEtMS0w_af6f7c4e-bbb4-4460-b2c6-6fc60aa41f97">136,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfNS0zLTEtMS0w_b644110a-4e6a-4acc-ad85-741b825b3401">51,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfNS01LTEtMS0w_8767ea6b-5653-4f1a-9495-14d4aea3139f">246,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfNS03LTEtMS0w_3f66c64b-3877-4990-9921-575517a890c4">152,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfOC0xLTEtMS0w_b1cc103d-d96f-4517-874b-6e2dc85d75b9">2,854,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfOC0zLTEtMS0w_b66b22fb-a470-4f6e-a0f1-0760081e3532">2,818,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfOC01LTEtMS0w_8a5e0fa6-30fa-404a-a18d-1ba20c740bcc">8,036,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfOC03LTEtMS0w_dca9d5df-6710-4b16-b3b9-f66125b030ca">8,297,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfOS0xLTEtMS0w_144802a8-3b90-4b79-a7d6-3a3d05079ac9">1,644,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfOS0zLTEtMS0w_45acc83c-f8bc-4f44-9a9b-3ad18537fa46">1,440,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfOS01LTEtMS0w_2627ff96-38d0-4772-98a0-e19cb752d75a">4,799,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfOS03LTEtMS0w_0396556d-55c6-4169-88fd-dff10307c2af">4,243,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTItMS0xLTEtMA_f001389a-e845-4bf5-bdaa-4dda3f1c68f5">4,499,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTItMy0xLTEtMA_86da6b3b-8441-4000-9822-5239d1b8181b">4,259,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTItNS0xLTEtMA_69b3c4f7-b954-4872-a318-b34d92dde7ee">12,835,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTItNy0xLTEtMA_3431aa82-9d0d-40c4-adec-2b58de9448b3">12,541,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTQtMS0xLTEtMA_276c5f61-1cd6-4b3b-84f6-b1c6aab0eca5">4,362,622</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTQtMy0xLTEtMA_df604be0-3059-4d5b-979a-a5552a1d5c5b">4,207,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTQtNS0xLTEtMA_2b28f540-2523-4c37-bf53-e8534f70fe3a">12,588,944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTQtNy0xLTEtMA_ee887822-4d02-41e3-97a5-8151119569a4">12,389,198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTYtMS0xLTEtMA_7104c953-1d32-4e35-8fd6-44ec17c4b08c">15,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTYtMy0xLTEtMA_b37de085-e8cd-44e1-a87f-0cfccebd56f1">53,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTYtNS0xLTEtMA_6cda0b76-1844-45ab-8014-a858bafbb3db">67,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTYtNy0xLTEtMA_c360f246-85b0-4eaa-a5cd-55e1809fd0fd">188,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from change in fair value of derivative financial instruments&#8212;warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTgtMS0xLTEtMA_1c2b2f85-48eb-42f4-a8d8-bd0a6aa47f00">144,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTgtMy0xLTEtMA_97da3d28-6c90-4808-ab28-c783cc4dfa81">13,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTgtNS0xLTEtMA_84b294f9-6ee8-42f7-b5de-e31b31378054">186,072</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTgtNy0xLTEtMA_a32181a4-10a9-47d6-b2eb-a95627b7f877">27,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjAtMS0xLTEtMA_6ef71712-4d4e-45e3-a35f-4d698a5660b3">5,738</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjAtMy0xLTEtMA_9c11a798-8ca0-4537-8892-c96e54f0cb24">1,103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjAtNS0xLTEtMA_cd221f8b-4dd5-4807-9c73-892692443c5f">1,967</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjAtNy0xLTEtMA_d66eefee-73b5-49f5-8d6a-fdd9710febc0">2,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjEtMS0xLTEtMA_dffc0d9a-6030-4bed-9de1-1d07def27c97">4,496,531</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjEtMy0xLTEtMA_0a08f6e7-8d17-4c9b-a2a0-727140d8d78c">4,141,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjEtNS0xLTEtMA_72839286-a363-462f-a25c-9478a8e6021f">12,709,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjEtNy0xLTEtMA_54545e13-da0c-4aba-81f3-a9bf9d6dc84a">12,171,623</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjMtMS0xLTEtMA_fb380ebf-20a1-4d79-bd7c-92fbc8f83821">6,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjMtMy0xLTEtMA_c3ab970d-2d47-49e3-934f-125d8693becb">6,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjMtNS0xLTEtMA_3e4188b6-2939-4507-8371-bc10286d3a80">18,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjMtNy0xLTEtMA_7f325bd6-9b10-43bf-9429-c62a856e0a40">18,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6ca3e50fe457a9eb38c4d29349a61_D20200701-20200930" decimals="0" format="ixt:zerodash" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjUtMS0xLTEtMA_06b5d1e8-6786-4733-91a9-e706fb115f0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if77d4dc67bc04941b7ea951868ce010e_D20190701-20190930" decimals="0" format="ixt:zerodash" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjUtMy0xLTEtMA_f186101d-100c-4c56-84ad-91be759c500b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64433fb437b14e2797a35696e3126e7f_D20200101-20200930" decimals="0" format="ixt:zerodash" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjUtNS0xLTEtMA_f52621aa-d929-4d09-ab11-9804cd2f5b87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d39276c8b7149b69b1e0641629d29d6_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjUtNy0xLTEtMA_a3fad938-5eec-4d20-b087-19affcebb47a">268,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized on beneficial conversion features of Series D Convertible Preferred Stock issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63c477ad569243b4b07aafdf89f0eb4a_D20200701-20200930" decimals="0" format="ixt:zerodash" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjYtMS0xLTEtMA_101193ab-b128-45c0-b976-76a008d11754">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f3c98f923a849c790c797406aeb0d7a_D20190701-20190930" decimals="0" format="ixt:zerodash" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjYtMy0xLTEtMA_eec397d9-7f61-4717-91a8-ff60cde0549c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ac167662d264ce29cc6bdaf26de9a0b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjYtNS0xLTEtMA_b8286bd8-ce07-49d3-a189-f24fb14dca8e">601,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60ddc19ccbda40389020c27451bc6aab_D20190101-20190930" decimals="0" format="ixt:zerodash" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjYtNy0xLTEtMA_6ac0a4e3-61c8-424d-a8de-e1f211939923">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized on beneficial conversion features of Series E Convertible Preferred Stock issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f397383420f42f49ba5adbf81294e83_D20200701-20200930" decimals="0" format="ixt:zerodash" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjctMS0xLTEtMA_2a8f035a-cd20-406b-9bae-ba452be50f91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a0e35fa886e4b33918433a1b304329c_D20190701-20190930" decimals="0" format="ixt:zerodash" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjctMy0xLTEtMA_692036e1-11c1-435c-a57f-d7c9f19bb237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8c5bb2609e8479dad4e32ccd15c3b2a_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjctNS0xLTEtMA_843daf3b-b310-4513-939f-d46c5662dd73">2,664,717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206237eca5cf411b89a567e3e300cf34_D20190101-20190930" decimals="0" format="ixt:zerodash" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjctNy0xLTEtMA_62ebc515-b1aa-4faa-8571-ba63e953b24c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjktMS0xLTEtMA_950a49fe-a5d4-4878-95a5-6424e50a4b39">4,502,591</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjktMy0xLTEtMA_65c2d2a1-7f51-450b-b1cf-6ba3a0a0efb5">4,147,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjktNS0xLTEtMA_cfdfcd76-3e4d-4657-9764-4682d6568959">15,994,289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjktNy0xLTEtMA_69e4ca27-d484-4e4e-94da-ac935490b08d">12,458,072</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMzEtMS0xLTEtMA_4037322e-6773-420c-9a81-e90136248bdb">0.19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMzEtMy0xLTEtMA_801f0d55-cb88-4f41-8b83-bc0c12baf3a2">0.69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMzEtNS0xLTEtMA_b9e50df9-c1b3-4e2c-9874-39a426ef3d77">1.00</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMzEtNy0xLTEtMA_19160ee6-d17c-4b4c-bbae-915723dff06f">2.40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8212; basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMzQtMS0xLTEtMA_a1fae025-478b-494c-a747-5bb4c7e8a8d3">23,341,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMzQtMy0xLTEtMA_a46de72b-8618-4312-a058-893a76f987d0">6,024,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMzQtNS0xLTEtMA_a0cdc9e3-370a-4725-9923-79aac143eee8">15,941,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMzQtNy0xLTEtMA_2a62c5a5-c38c-4976-ae21-aeca5d44281d">5,180,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed financial statements.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i0ff27e3402fc47278eb8617e2a08b771_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.675%"><tr><td style="width:1.0%"></td><td style="width:31.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.609%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.161%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Service Receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i440ceb711f7c45eaab28660fa0a6c49c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMS0xLTEtMS0w_9940ac53-b2a2-4e46-a6af-b4674a4abd20">60,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i440ceb711f7c45eaab28660fa0a6c49c_I20191231" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMS0zLTEtMS0w_65494afa-6bfa-4e9c-b469-1f2ca43b48ff">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a1c6cfd3bf54dffbfab3dca4b84b7ce_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMS01LTEtMS0w_730f4f7c-33d6-44a0-a511-c164034c72a2">8,593,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a1c6cfd3bf54dffbfab3dca4b84b7ce_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMS03LTEtMS0w_6303b0ea-c9bc-4099-a5fd-12d842a1bde0">8,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355e679510824d7b8627423cf0866836_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMS05LTEtMS0w_05c2399f-f542-47e7-b6df-f342644ceb1e">217,172,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacd4e3fe0e164beea6824f1f787dbb03_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMS0xMS0xLTEtMA_73c24bcd-8646-4a0a-86e4-28290acc1b7a">971,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8558b18d83f4b29acd586d939030fb4_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMS0xMy0xLTEtMA_54492993-0ffc-4153-8c87-a2bc012e5787">208,897,883</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMS0xNS0xLTEtMA_8ab8189f-df66-4d6e-bd0a-cb055f0ccb2d">7,311,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i969cd75c1e19434b854579b8223eca1f_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMi05LTEtMS0w_e06b335b-1005-4246-835e-e9dd4491e0c6">177,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a4d70afca204fcbbdba84e5be3dd359_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMi0xNS0xLTEtMA_3905dbb1-e334-41ce-b892-1f3c1a78499f">177,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Sale of common stock and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44c0a4463d8b467eb6707129cf69494a_D20200101-20200331" decimals="INF" sign="-" format="ixt:numdotdecimal" name="crdf:SaleOfStockCommonAndWarrantsNetShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMy01LTEtMS0w_f53cadf9-ecc1-4102-aeed-89786d894feb">800,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44c0a4463d8b467eb6707129cf69494a_D20200101-20200331" decimals="0" sign="-" name="crdf:SaleOfStockValueCommonAndWarrantsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMy03LTEtMS0w_850648ba-3630-40ba-9935-62f81b7bdbdb">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i969cd75c1e19434b854579b8223eca1f_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="crdf:SaleOfStockValueCommonAndWarrantsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMy05LTEtMS0w_86ad3744-19d1-4ff1-bc18-e643cb8fc632">999,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a4d70afca204fcbbdba84e5be3dd359_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="crdf:SaleOfStockValueCommonAndWarrantsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMy0xNS0xLTEtMA_864e9396-352f-4b09-966f-0a9cdb666214">1,000,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44c0a4463d8b467eb6707129cf69494a_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfNC01LTEtMS0w_a9de07ba-55df-4a84-9267-bec4ba39d944">1,610,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44c0a4463d8b467eb6707129cf69494a_D20200101-20200331" decimals="0" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfNC03LTEtMS0w_3532f122-9923-451a-bf5f-b9bfa608bfc7">161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i969cd75c1e19434b854579b8223eca1f_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfNC05LTEtMS0w_b95ee26e-b25e-4980-b1fb-42e430515249">1,456,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a4d70afca204fcbbdba84e5be3dd359_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfNC0xNS0xLTEtMA_1ea26c47-8629-417f-9dd1-949d4c5ea73e">1,456,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44c0a4463d8b467eb6707129cf69494a_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfNS01LTEtMS0w_f2b2afac-ac70-493f-8ed6-5fac727efe34">6,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44c0a4463d8b467eb6707129cf69494a_D20200101-20200331" decimals="0" name="crdf:StockIssuedDuringPeriodValueRestrictedStockUnitsReleases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfNS03LTEtMS0w_2648f34f-2e79-440a-aff6-4fcd071bc424">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i969cd75c1e19434b854579b8223eca1f_D20200101-20200331" decimals="0" sign="-" name="crdf:StockIssuedDuringPeriodValueRestrictedStockUnitsReleases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfNS05LTEtMS0w_e78e874d-7c74-452b-b18a-4725020b06b8">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preferred stock dividend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1aea61419554483ab22c33a2aa6fdddc_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfNi0xMy0xLTEtMA_87269283-6b22-4d68-8b58-6eb5945dec3b">6,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a4d70afca204fcbbdba84e5be3dd359_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfNi0xNS0xLTEtMA_a03bb9d3-d30e-4b71-88e1-acad1cab180d">6,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81e092c24a3460ca593f690506ba45c_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfOC0xMS0xLTEtMA_fe441af1-b935-4491-a536-b9f50122eddd">293,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a4d70afca204fcbbdba84e5be3dd359_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfOC0xNS0xLTEtMA_443efa08-b8af-451e-a47b-057b5aaa217a">293,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1aea61419554483ab22c33a2aa6fdddc_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfOS0xMy0xLTEtMA_e4f952ca-5ad1-4992-a84c-8bb8b352bb19">4,088,562</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a4d70afca204fcbbdba84e5be3dd359_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfOS0xNS0xLTEtMA_d0eab07e-a3cb-4ec3-916a-afebcf1eb2ac">4,088,562</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e4e419343594d71afb1d77399f4daad_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTAtMS0xLTEtMA_b1738aa6-40df-4e57-bc56-332c59862340">60,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4e419343594d71afb1d77399f4daad_I20200331" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTAtMy0xLTEtMA_1ff7fb7c-13e3-41fe-a8e7-0c7c76b95089">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6962b9056174c398b78bd1a322ad590_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTAtNS0xLTEtMA_8810b13d-e715-4b31-b029-acc7f92fd37a">11,010,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6962b9056174c398b78bd1a322ad590_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTAtNy0xLTEtMA_ee22ca43-5aa0-4930-9826-746b3244b2fd">8,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e7a4e37750d41c2b7bd2a4475f50b9d_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTAtOS0xLTEtMA_269868f8-a5db-451b-bc88-9301315819e4">219,805,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i892bb4bca35e42edb3fbf0ca66a798a4_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTAtMTEtMS0xLTA_3f46292d-5a7b-471a-b413-f0602efd4596">678,656</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a5b54961e1a408da4efa7c4a015db44_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTAtMTMtMS0xLTA_c6daaa98-5e58-478f-aafd-e35f50e05b7b">212,992,505</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i105b5086b9d140d382a2cf18218bbcdf_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTAtMTUtMS0xLTA_d2cbe47c-ce5b-4f4c-8bf6-a250c37beeef">6,143,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i986c4f37b62f4001bb38dfa79cf80042_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTEtOS0xLTEtMA_186e6508-ba9f-43a4-8d74-c59b1b44d878">281,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTEtMTUtMS0xLTA_a4aa213a-b2bf-4ade-8f59-b2fe2e14b481">281,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a78e5a7b2ff488abd9e098d74a099e8_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTItMS0xLTEtMA_59d51080-974f-493d-8a74-cad1ef90a2e1">154,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a78e5a7b2ff488abd9e098d74a099e8_D20200401-20200630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTItMy0xLTEtMA_23ff41cf-5d02-479d-89db-4cb57b7f2011">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd6fb8040cf1408a9b85618f489130ce_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTItNS0xLTEtMA_b59e92ce-991e-4da9-84d3-a104ce97fa80">602,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd6fb8040cf1408a9b85618f489130ce_D20200401-20200630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTItNy0xLTEtMA_22c4a930-8941-4a20-ad16-a053b64db4a5">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i986c4f37b62f4001bb38dfa79cf80042_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTItOS0xLTEtMA_db714c41-94e8-4a78-aa9f-a86395f62b33">2,292,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2007c264c51a44a98c0f645dc1f8ba51_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTItMTEtMS0xLTA_2c01a8fa-1d39-46c7-9748-068c1c370ac1">2,300,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTItMTUtMS0xLTA_f52e5a8a-cb8a-4eef-847b-77ff588bb606">7,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized on beneficial conversion features of Series D Convertible Preferred Stock issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c0977b1d8e8404aaa3b657703fb8dd5_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTMtOS0xLTEtMA_3b589d66-99aa-4377-903e-c48f1381e4c0">601,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c907bcbc06d4d318ec339547451ef5b_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTMtMTMtMS0xLTA_73d8be87-7870-499a-9318-3cd8298a92e2">601,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized on beneficial conversion features of Series E Convertible Preferred Stock issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70a77dc066834b05be99f8161e3fb65c_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTQtOS0xLTEtMA_997902b3-811e-4535-a1d0-42db066f013d">2,664,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4334ae12820e4b96abd660da1706eef0_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTQtMTMtMS0xLTA_a7de9347-4d64-4651-8a8c-d810c7514071">2,664,717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of common stock, preferred stock and warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a78e5a7b2ff488abd9e098d74a099e8_D20200401-20200630" decimals="INF" sign="-" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtMS0xLTEtMA_4c625304-18b6-48ac-a97f-84c5bf85ccfd">865,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a78e5a7b2ff488abd9e098d74a099e8_D20200401-20200630" decimals="0" sign="-" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtMy0xLTEtMA_785dc728-fb40-48ed-8571-ce68880992ec">866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd6fb8040cf1408a9b85618f489130ce_D20200401-20200630" decimals="INF" sign="-" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtNS0xLTEtMA_7e0aca0a-36dd-4ec7-9639-c05471553428">4,689,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd6fb8040cf1408a9b85618f489130ce_D20200401-20200630" decimals="0" sign="-" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtNy0xLTEtMA_1d5eb083-686d-4d30-b1b9-5da8e39d29d5">469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i986c4f37b62f4001bb38dfa79cf80042_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtOS0xLTEtMA_4eafee9b-816d-4fd7-9875-e9faaca48aa5">17,277,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtMTUtMS0xLTA_af12d379-5662-465f-8a93-94f0111d55cd">17,278,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd6fb8040cf1408a9b85618f489130ce_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTYtNS0xLTEtMA_aa7bc6e1-15d5-42f7-bacf-6a803cc09322">3,473,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd6fb8040cf1408a9b85618f489130ce_D20200401-20200630" decimals="0" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTYtNy0xLTEtMA_63ccb7a5-3646-429d-a280-71cf8fd52e9a">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i986c4f37b62f4001bb38dfa79cf80042_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTYtOS0xLTEtMA_f4bae235-bfab-4725-bf32-b6830d853c2e">4,604,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTYtMTUtMS0xLTA_8b51e67b-8ca5-425f-abd4-195ad796bda5">4,605,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd6fb8040cf1408a9b85618f489130ce_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTctNS0xLTEtMA_c8a7d040-2de9-4279-ab5d-b5ff158ff900">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon conversion of Series D Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibaa519b044634475a9a19ebc2fdfafde_D20200401-20200630" decimals="INF" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTgtMS0xLTEtMA_1804698b-73f6-4fc1-bce9-695982c0c9ba">154,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibaa519b044634475a9a19ebc2fdfafde_D20200401-20200630" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTgtMy0xLTEtMA_ba6a3012-c375-46cc-8c46-fcd66ec12ddc">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8646b250083b422d8f1430bffcbe6b73_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTgtNS0xLTEtMA_420b6f54-d27e-49d2-a826-557ef2beeae2">1,546,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8646b250083b422d8f1430bffcbe6b73_D20200401-20200630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTgtNy0xLTEtMA_838df534-8611-4b33-9218-a22304ccdaec">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c0977b1d8e8404aaa3b657703fb8dd5_D20200401-20200630" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTgtOS0xLTEtMA_0b777b17-5c3e-4a45-bb60-93322e1886f3">140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6160228ffe834aa18b13f335f5d812ad_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTktMTMtMS0xLTA_eb9ad7ec-3dc5-4c26-93c2-e1b605a57f64">6,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTktMTUtMS0xLTA_36f9ee03-62cd-4c64-8784-123d37841d26">6,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2007c264c51a44a98c0f645dc1f8ba51_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjAtMTEtMS0xLTA_ade7a87d-e0ae-465c-a657-3ffad02a0bb7">213,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjAtMTUtMS0xLTA_c6946183-2719-4a5d-80eb-f7befe10da9d">213,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6160228ffe834aa18b13f335f5d812ad_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjEtMTMtMS0xLTA_03d1bf5c-1e69-4505-8186-a65c31ddbad3">4,124,532</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjEtMTUtMS0xLTA_7338fe07-4386-4eca-97ba-94fab2786a56">4,124,532</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00b92270816642589793666319d5f182_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjItMS0xLTEtMA_2e594e6d-fbb3-410a-9bfa-1acbbc3c5d2a">926,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b92270816642589793666319d5f182_I20200630" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjItMy0xLTEtMA_78729be6-13e2-421e-81c6-6a5c080cb96b">926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5b2f533f0534d78844b49d29954c8e4_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjItNS0xLTEtMA_e990d0c9-659b-4e59-9fbd-932eb22618d8">21,325,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5b2f533f0534d78844b49d29954c8e4_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjItNy0xLTEtMA_3510a9ba-1899-485e-84b5-e733c0ab5214">9,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37f5de467cd94aab8302da68767238f2_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjItOS0xLTEtMA_fc49946e-3c46-41b0-ae3f-0e9b0eba13f3">247,528,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf1a9dc0b4284431b4cef397cfcd0b83_I20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjItMTEtMS0xLTA_a61a7080-42f1-41e9-8207-9e44a121da40">2,765,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i179c2b18280246c8ada7c878931742fb_I20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjItMTMtMS0xLTA_661fa2b2-0291-4418-ab9c-07331f8c90f6">220,389,581</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5ff2e0258b7445fb9a110a10dccadb7_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjItMTUtMS0xLTA_5a787e2a-4c5f-4f69-854a-6d6db729d3e3">24,384,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6d7f037cf0b4b8792ebe716a72da81c_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjMtOS0xLTEtMzA1_878e976b-2897-4c63-99b1-b3b53241739f">361,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjMtMTUtMS0xLTMwNQ_ac5576bb-d77f-44f9-825d-ad527bfff714">361,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c90af801967473ab9d203d9d12c323f_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjUtNS0xLTEtMzA1_7376108c-695d-4f9f-961b-02f1cac92bab">4,956,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c90af801967473ab9d203d9d12c323f_D20200701-20200930" decimals="0" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjUtNy0xLTEtMzA1_e7018653-5977-4ec0-a2af-3fd39a6a0b38">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6d7f037cf0b4b8792ebe716a72da81c_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjUtOS0xLTEtMzA1_a2e43f73-7356-4713-884d-7776a80efedf">12,910,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjUtMTUtMS0xLTMwNQ_84a6fd5c-72d4-4b82-b682-7d689d470f4c">12,910,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c90af801967473ab9d203d9d12c323f_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjYtNS0xLTEtNDMz_5a9d9f3b-14a9-483a-a4f7-8c54ec4c9d01">3,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6d7f037cf0b4b8792ebe716a72da81c_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjYtOS0xLTEtNDMz_73e9ae6d-1d2a-468d-8052-1043a63b2675">6,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjYtMTUtMS0xLTQzMw_eaa05525-11d4-4ea6-ba10-81ecc8465921">6,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.675%"><tr><td style="width:1.0%"></td><td style="width:31.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.609%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.161%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Service Receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c90af801967473ab9d203d9d12c323f_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjYtNS0xLTEtMzA1_a1e82e9c-5434-4a05-85fe-5075d25a68a4">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4056f199424143e290a92a502f0c74a0_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjctMTMtMS0xLTMwNQ_5fb3ff3a-e226-4fd5-81ad-07af7de47bf9">6,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjctMTUtMS0xLTMwNQ_d98b81c8-67ff-4921-b14e-243484300a16">6,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i249b89eeb0194442ab7d9ffdd4dc0dc1_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjgtMTEtMS0xLTMwNQ_04d63874-475d-49c9-9b14-10938abb6124">361,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjgtMTUtMS0xLTMwNQ_3b075c3f-4674-429c-9823-05b3464230dd">361,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4056f199424143e290a92a502f0c74a0_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjktMTMtMS0xLTMwNQ_317e9f67-4893-4b8f-9d8a-3db6199b2677">4,496,531</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjktMTUtMS0xLTMwNQ_699efedb-6630-42b5-ae4b-ae779f5dd72d">4,496,531</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01fc0539599a4354836f19a58664e5a7_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMzAtMS0xLTEtMzA1_98246375-9c98-4e4b-822b-2c53c051575f">926,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01fc0539599a4354836f19a58664e5a7_I20200930" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMzAtMy0xLTEtMzA1_2e1ea900-bc82-4621-bcbb-f6df5aa3a926">926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4aff4ec96d0b44fd96cf76b82d788da4_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMzAtNS0xLTEtMzA1_b9ce230f-ab08-497b-8ed9-5e7fd967c848">26,285,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aff4ec96d0b44fd96cf76b82d788da4_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMzAtNy0xLTEtMzA1_3a06ed4e-7151-4b8a-802d-c8b0a4120830">10,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54a56210ecbf42aea170e8ae37fe336e_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMzAtOS0xLTEtMzA1_69a1bf24-6db7-4fd8-a482-d21cdb77d5c7">260,807,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i068dca4a9a24460485c15359caa4f37b_I20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMzAtMTEtMS0xLTMwNQ_3493deaa-80a1-4451-a8dc-20c2daf0610e">2,403,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3585b22f6f334b64b4a9a946e0b1754f_I20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMzAtMTMtMS0xLTMwNQ_f274b990-123d-4e86-9d3b-348a6c7bf9b5">224,892,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMzAtMTUtMS0xLTMwNQ_c6adf9c6-1c3b-458b-bd4e-3308c02af705">33,522,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RleHRyZWdpb246ZTA5MGZmN2Q3Zjc4NDBjM2E4N2ZmYzlkNjJhM2M4YjVfMjg5_b065a1c7-ef82-41c7-88d8-90b2e32f5fef" footnoteRole="http://www.xbrl.org/2003/role/footnote">Net of expenses of $<ix:nonFraction unitRef="usd" contextRef="i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="crdf:CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RleHRyZWdpb246ZTA5MGZmN2Q3Zjc4NDBjM2E4N2ZmYzlkNjJhM2M4YjVfMTEw_01b63ad6-0e1a-48ed-a8cd-ab8aedc19ca3">616,143</ix:nonFraction>, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $<ix:nonFraction unitRef="usd" contextRef="i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="crdf:WarrantsFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RleHRyZWdpb246ZTA5MGZmN2Q3Zjc4NDBjM2E4N2ZmYzlkNjJhM2M4YjVfMjA4_54838357-e9fb-47d6-9566-2b8ff53ccea3">370,666</ix:nonFraction>.</ix:footnote></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.675%"><tr><td style="width:1.0%"></td><td style="width:31.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.609%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.161%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Service Receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iacde1c89795341d7a6585a9ca67ff1ef_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMS0xLTEtMS0w_acbe2232-55fe-4fb6-bd26-8418fa35c3cd">60,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacde1c89795341d7a6585a9ca67ff1ef_I20181231" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMS0zLTEtMS0w_2d17f66a-6e71-47cf-b0ed-bd11b5e68963">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68416144d86546848c61077e3daaae71_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMS01LTEtMS0w_93916a79-19de-4908-9822-34ea55b85963">3,831,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68416144d86546848c61077e3daaae71_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMS03LTEtMS0w_830eead3-a0c0-4c26-b8af-6f0bf6c21313">7,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8388a4c16204624a7b7ce5524a8ab3d_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMS05LTEtMS0w_ac940e16-2a0a-4b69-9699-83b7a7dcf4be">202,267,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7bcf08b2e0459b88c7b9896849b386_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMS0xMS0xLTEtMA_e5a7fc9c-a931-49d6-896a-286b34c553fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20ddc05282304186b85c0c5e82d9c3dc_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMS0xMy0xLTEtMA_e53989e4-b66e-4d8e-ade4-68283cfa6728">192,191,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec08f4c1e8014a62bb515c9760634ec7_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMS0xNS0xLTEtMA_db2b72f3-dc8f-40ff-86ed-638fa86f1b5f">10,084,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if04bc8a88dbf4923b75de662fba8bcac_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMi05LTEtMS0w_d6442acf-e7ab-4124-b9e1-868574b05a4c">200,067</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7f9daee734141178c3262a70ac3d9f9_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMi0xNS0xLTEtMA_2c16e985-32b0-46cc-bea8-571bc78931cf">200,067</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount of $<ix:nonFraction unitRef="usd" contextRef="ia7f9daee734141178c3262a70ac3d9f9_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="crdf:CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNS0wLTEtMS0wL3RleHRyZWdpb246MjNjNjY0Y2I1ZWNlNDlkY2JlYzBlNGFmZTExYzdlZWRfMTMw_7897e4e3-2e29-4cd2-a397-15ed6102a18d">40,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia7f9daee734141178c3262a70ac3d9f9_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="crdf:DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNS0wLTEtMS0wL3RleHRyZWdpb246MjNjNjY0Y2I1ZWNlNDlkY2JlYzBlNGFmZTExYzdlZWRfMTM3_c917adb6-48cc-4f8b-a90a-01186732ae0a">235,640</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4094a45bf8304a038d7489696b49f0ee_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNS0xLTEtMS0w_39f7a667-b09e-4d04-aaa2-cab2632af995">200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4094a45bf8304a038d7489696b49f0ee_D20190101-20190331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNS0zLTEtMS0w_6c53ab99-d080-449c-916a-8648a38a1ae6">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe3da09bc10142fa86a695704e95333d_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNS01LTEtMS0w_a9ee6bf4-3133-499b-9d02-4a90a2541279">183,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe3da09bc10142fa86a695704e95333d_D20190101-20190331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNS03LTEtMS0w_3bd80a0a-8d5e-4518-a7fe-300fdbf32770">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if04bc8a88dbf4923b75de662fba8bcac_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNS05LTEtMS0w_1047e271-58a4-4b5e-8d52-ae92a4befbd1">1,634,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i686b763ed80c42debf1673b939ce8436_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNS0xMS0xLTEtMA_9d303485-4202-4628-857b-bf8258b7d58e">1,675,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7f9daee734141178c3262a70ac3d9f9_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNS0xNS0xLTEtMA_4b9cdac4-3cd1-46c3-b717-4b9bfa66f66f">40,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if04bc8a88dbf4923b75de662fba8bcac_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNi05LTEtMS0w_55297423-e02c-4558-b10f-7832d3a04c39">268,269</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3e995f613e04a30b83a190600e73d1d_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNi0xMy0xLTEtMA_995479e9-5a42-4b53-8b55-56b58472a53a">268,269</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe3da09bc10142fa86a695704e95333d_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNy01LTEtMS0w_b930724c-2115-4baf-9ecd-60ddd160d470">497,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe3da09bc10142fa86a695704e95333d_D20190101-20190331" decimals="0" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNy03LTEtMS0w_1730abad-aa4c-4d1e-a53c-cc9d646125b4">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if04bc8a88dbf4923b75de662fba8bcac_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNy05LTEtMS0w_955855ce-a24d-4464-8f87-3e3f8b176eda">3,282,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7f9daee734141178c3262a70ac3d9f9_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNy0xNS0xLTEtMA_5841c8fb-7d24-4c01-91e9-fcfdc1e28035">3,282,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe3da09bc10142fa86a695704e95333d_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfOC01LTEtMS0w_e1608faa-54c7-4fd6-9ef3-35e7c9762af0">6,362</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe3da09bc10142fa86a695704e95333d_D20190101-20190331" decimals="0" name="crdf:StockIssuedDuringPeriodValueRestrictedStockUnitsReleases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfOC03LTEtMS0w_1b8f5a0d-afdd-4bf1-8437-1386e87fe68d">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if04bc8a88dbf4923b75de662fba8bcac_D20190101-20190331" decimals="0" sign="-" name="crdf:StockIssuedDuringPeriodValueRestrictedStockUnitsReleases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfOC05LTEtMS0w_c8cd1877-9d95-458d-9d5e-3b9785cdce6f">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3e995f613e04a30b83a190600e73d1d_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTAtMTMtMS0xLTA_056ae514-e702-4a3e-aaa0-73b9f7056cea">6,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7f9daee734141178c3262a70ac3d9f9_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTAtMTUtMS0xLTA_3b6f6fbf-ede2-4135-88fc-08bc24220417">6,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for share rounding as a result of reverse stock split</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe3da09bc10142fa86a695704e95333d_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTEtNS0xLTEtMA_986476b5-4b26-4c00-a635-2a9d6c60a5ce">6,466</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i686b763ed80c42debf1673b939ce8436_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTMtMTEtMS0xLTA_28f59fc4-a059-4d5c-98f1-81f3a4049ae2">70,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7f9daee734141178c3262a70ac3d9f9_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTMtMTUtMS0xLTA_e8347a60-ad7a-4058-9e39-466a18a684de">70,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3e995f613e04a30b83a190600e73d1d_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTQtMTMtMS0xLTA_84b60369-e306-44d7-a04e-61122d53770f">3,904,771</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7f9daee734141178c3262a70ac3d9f9_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTQtMTUtMS0xLTA_d6b15ba6-8cc2-46f7-9748-b38c94aec400">3,904,771</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i795f824a2e0848ec9e08218e1e384119_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTUtMS0xLTEtMA_15faab81-a7fe-4f93-a512-73d00d054690">260,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i795f824a2e0848ec9e08218e1e384119_I20190331" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTUtMy0xLTEtMA_0f8a5a23-1776-4660-adfa-1484d1a9c429">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ab978b16413492fa60c4cc6dc4f989a_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTUtNS0xLTEtMA_10943c0b-e7ee-4fe6-9f09-c354a8e343f3">4,525,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab978b16413492fa60c4cc6dc4f989a_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTUtNy0xLTEtMA_4b23945b-338b-4113-ae56-a07071ae6bcb">7,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b9bfad02a04a619ec5166a7e949cf7_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTUtOS0xLTEtMA_8f932126-6818-4fca-9566-2e1218e93795">207,652,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fbe7725163e40c4a4a41af38a99b6e5_I20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTUtMTEtMS0xLTA_1ac499c8-8b99-4cac-832c-9ef24045510f">1,604,513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad21cf8f4ef74076934e4cd2f244fe43_I20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTUtMTMtMS0xLTA_b413a89e-5c51-4308-8ef6-958923300c19">196,370,315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i869616a16b38489397727b402aca4049_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTUtMTUtMS0xLTA_75dc0c68-c006-4817-9021-6185dff2cfd9">9,686,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d83f131001e47c7b941410eeb7dfb34_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTYtOS0xLTEtMA_b43499ba-0e65-423a-9e00-76915e8005b7">148,834</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie62f103ee8e84d74b05d78ebcb684bb0_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTYtMTUtMS0xLTA_73e6535d-4dec-4fc5-a564-bfa4bcfa963e">148,834</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of common stock and warrants, net of expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6408fd73dd948b2bedb47f26bd26ece_D20190401-20190630" decimals="INF" sign="-" format="ixt:numdotdecimal" name="crdf:SaleOfStockCommonAndWarrantsNetShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTctNS0xLTEtMA_c474444a-9dd5-49f3-bb99-7b8645d79ed2">421,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6408fd73dd948b2bedb47f26bd26ece_D20190401-20190630" decimals="0" sign="-" name="crdf:SaleOfStockValueCommonAndWarrantsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTctNy0xLTEtMA_59d525ee-8856-4176-a8e2-d9a49da45f55">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d83f131001e47c7b941410eeb7dfb34_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="crdf:SaleOfStockValueCommonAndWarrantsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTctOS0xLTEtMA_dd575d7b-44b7-41d3-b726-d28c9bb4da01">2,902,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie62f103ee8e84d74b05d78ebcb684bb0_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="crdf:SaleOfStockValueCommonAndWarrantsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTctMTUtMS0xLTA_7e1dbd26-56a1-4ddf-9119-4fbffaf4655c">2,902,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6408fd73dd948b2bedb47f26bd26ece_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTgtNS0xLTEtMA_c7460913-71db-4db7-b580-b5f292a5045d">156,353</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6408fd73dd948b2bedb47f26bd26ece_D20190401-20190630" decimals="0" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTgtNy0xLTEtMA_ac070147-c7b3-45d1-9745-c027504289c6">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d83f131001e47c7b941410eeb7dfb34_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTgtOS0xLTEtMA_e7ea36ba-a0ff-4cbd-a6ca-ee812a496928">1,548</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie62f103ee8e84d74b05d78ebcb684bb0_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTgtMTUtMS0xLTA_4b9c08e1-4de8-45c7-83b4-366175fe2f31">1,564</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6408fd73dd948b2bedb47f26bd26ece_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTktNS0xLTEtMA_99959c6f-b5ee-4f6e-b15a-249f7733950e">4,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon conversion of Series C Convertible Preferred Stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8356a82f43e649ce8d9fc4f3bdeaf910_D20190401-20190630" decimals="INF" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjAtMS0xLTEtMA_b7579f18-152f-4b8c-9f76-73934f2b07fc">200,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8356a82f43e649ce8d9fc4f3bdeaf910_D20190401-20190630" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjAtMy0xLTEtMA_f483216f-f21e-4646-a1a3-9be01eaa74b1">200</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2dd92383a8974c29a26c20ba1c50c24e_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjAtNS0xLTEtMA_3249eef3-047a-4966-a466-4743cd4455d4">333,333</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd92383a8974c29a26c20ba1c50c24e_D20190401-20190630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjAtNy0xLTEtMA_e2c79538-820a-4e90-b237-b5f9c8c14bb1">33</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd90d3836ae44a5288cf14214ce01d23_D20190401-20190630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjAtOS0xLTEtMA_f51fe125-4a25-417f-b9b1-dfe4001011cf">167</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98ee69498ef64ee98c7d13fd73810b69_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjEtMTMtMS0xLTA_1f30498e-a8cb-43b6-9820-f9becfcd3df5">6,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie62f103ee8e84d74b05d78ebcb684bb0_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjEtMTUtMS0xLTA_a1f011ce-2731-49e5-a913-6bb978dc6cc3">6,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i102d06ccc049420ea4a988739f4e1f5a_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjItMTEtMS0xLTA_bf6c582e-0502-4475-9fa9-6345a04441f1">240,279</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie62f103ee8e84d74b05d78ebcb684bb0_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjItMTUtMS0xLTA_2a902f4b-5f8e-4dd3-83b1-04d6ad81d75b">240,279</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98ee69498ef64ee98c7d13fd73810b69_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjMtMTMtMS0xLTA_6802f2dd-c0fe-412e-8b18-6d0375354a89">4,125,303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie62f103ee8e84d74b05d78ebcb684bb0_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjMtMTUtMS0xLTA_81dbf013-4c65-4dfd-9809-58efb645ea71">4,125,303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2019</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bcee1f60daa4ba798ca5869fb08d829_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjQtMS0xLTEtMA_aec61df1-d765-4901-b917-b3a863a59865">60,600</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bcee1f60daa4ba798ca5869fb08d829_I20190630" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjQtMy0xLTEtMA_87e70759-a6b8-44c0-a1c6-d7ef5bc486d1">60</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i963638cbd5724619a756ba6fac98c0d7_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjQtNS0xLTEtMA_b6403a08-b67e-4046-a61f-2c649ee94912">5,441,390</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i963638cbd5724619a756ba6fac98c0d7_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjQtNy0xLTEtMA_b9f5f915-7015-4cc1-ac2c-938a6a963c8d">7,997</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40293b1c801f4325997aad38bcf3edfe_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjQtOS0xLTEtMA_7ccec530-de40-4669-9eac-9ffb76d03eda">210,706,090</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73a60988cd7742b186d790b4be820c3a_I20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjQtMTEtMS0xLTA_37d03dd2-0661-46ac-a401-5ab0250dee85">1,364,234</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3bfc5f134f7e4fb0b0329e2e588c22d9_I20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjQtMTMtMS0xLTA_b9d3b4fb-2c7c-4be1-a929-2763591908e6">200,501,678</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a44d42518d247568f1e2b1a8b580163_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjQtMTUtMS0xLTA_693b82db-f360-4e53-86fc-b5e3211c2a77">8,848,235</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida7da958772f451988cb48e47b519200_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjUtOS0xLTEtMA_1f23df98-91fa-49e4-aa92-e183c74cfaf6">266,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjUtMTUtMS0xLTA_bfa46409-e637-4394-b74d-da178916b039">266,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of common stock and warrants, net of expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d0f3a37ba3f419f9e5fc2d23d7be984_D20190701-20190930" decimals="INF" sign="-" format="ixt:numdotdecimal" name="crdf:SaleOfStockCommonAndWarrantsNetShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjYtNS0xLTEtMA_fcd9df26-63c3-4982-8056-3a6bcc1d2441">271,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0f3a37ba3f419f9e5fc2d23d7be984_D20190701-20190930" decimals="0" sign="-" name="crdf:SaleOfStockValueCommonAndWarrantsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjYtNy0xLTEtMA_efe31155-e3d5-41f6-a706-c822c00270b9">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida7da958772f451988cb48e47b519200_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="crdf:SaleOfStockValueCommonAndWarrantsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjYtOS0xLTEtMA_35df548d-2930-4ef8-a62d-c0306ce6dbed">1,483,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="crdf:SaleOfStockValueCommonAndWarrantsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjYtMTUtMS0xLTA_9b7366ec-45d2-4b89-bc02-f237cfe8a3d1">1,483,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d0f3a37ba3f419f9e5fc2d23d7be984_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjctNS0xLTEtMA_dbbb12a4-f862-4ac1-b4cb-413b18c149f6">717,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0f3a37ba3f419f9e5fc2d23d7be984_D20190701-20190930" decimals="0" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjctNy0xLTEtMA_8568c99c-353f-4b37-903d-0ed519f143b2">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida7da958772f451988cb48e47b519200_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjctOS0xLTEtMA_bc15c77f-04da-4282-b51c-8a0e5ba2bd60">7,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjctMTUtMS0xLTA_02bf20ea-922a-44fd-95bb-027292146901">7,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d0f3a37ba3f419f9e5fc2d23d7be984_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjgtNS0xLTEtMA_4e26757e-c946-4809-9a41-8d72f59245e4">5,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0315ca5a43e14290ba86e2502d1e7df3_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjktMTMtMS0xLTA_ba7c52c0-375e-45a5-ac81-af2a6006995c">6,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjktMTUtMS0xLTA_a136c111-982e-4adb-8f9c-cb405bad6163">6,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.675%"><tr><td style="width:1.0%"></td><td style="width:31.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.609%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.161%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Service Receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d41d866570f426f80638fbc27922861_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzAtMTEtMS0xLTEyMTg_683a03af-fcbd-4d73-bae3-a872fa77f709">198,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzAtMTUtMS0xLTEyMTg_dc6c1a04-f5f9-4285-99cb-6771cb92d8f3">198,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0315ca5a43e14290ba86e2502d1e7df3_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzEtMTMtMS0xLTA_6a15a3f2-d9ce-484c-a215-df037eda3f7d">4,141,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzEtMTUtMS0xLTA_a9d8ee6e-7edc-4530-91f7-438c779a959b">4,141,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2a52fc6ccc044c4b200ae25cc1f0627_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzItMS0xLTEtMA_d6cb6d65-e2a4-4b87-84dc-960d2175e728">60,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2a52fc6ccc044c4b200ae25cc1f0627_I20190930" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzItMy0xLTEtMA_a9c2fde0-40fb-406c-b752-63331f86eb28">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i713cb493491f49ab95402bed132c3427_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzItNS0xLTEtMA_6acde8a6-f061-4432-97a0-cdaf45fd622e">6,436,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i713cb493491f49ab95402bed132c3427_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzItNy0xLTEtMA_592f602b-87d0-46bc-b9da-b1ee10691bd1">8,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70118ce382b54129a01f304d79e91011_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzItOS0xLTEtMA_8d9068d6-c878-4b4f-84a1-283ea1971bf5">212,463,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie295404f651a43699515699a65360c65_I20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzItMTEtMS0xLTA_6ae7e1a9-90bb-4fdf-b712-d99db92b536e">1,165,966</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a436b27140f418b9f00effe44febb9a_I20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzItMTMtMS0xLTA_60970ea8-e9de-4735-b9ad-79446af93d24">204,649,287</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i601506d900b640889cfe25c06b9517ad_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzItMTUtMS0xLTA_d60ffda1-c0bc-41c7-b3a2-41293d59d942">6,655,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i0ff27e3402fc47278eb8617e2a08b771_31"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMy0xLTEtMS0w_d04d6544-acea-4a75-bf8e-015cedcffad1">12,709,625</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMy0zLTEtMS0w_f3bf0f1e-6cab-4b9c-9057-6365e1ff24b1">12,171,623</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNi0xLTEtMS0w_06366568-fd78-4913-8074-cb040cef7467">34,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:OperatingLeaseImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNi0zLTEtMS0w_a8463575-fcbb-432f-b0cc-82eb0d3075ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNy0xLTEtMS0w_fa185617-26fb-45aa-9933-28a014ea8de3">348,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNy0zLTEtMS0w_c037c1b2-b633-4278-9a27-25032de018b6">372,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfOC0xLTEtMS0w_8cb0205e-450b-4111-bde9-a4dd3a46b860">820,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfOC0zLTEtMS0w_d87f489d-af2d-4db4-82b7-ee24817e0097">615,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments&#8212;warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMTYtMS0xLTEtMA_32c0490d-0a41-445b-b695-5a8c13c1af0e">186,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMTYtMy0xLTEtMA_70998c19-1cff-424c-bb2c-259e9c583a1c">27,359</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="crdf:Releaseofclinicaltrialfundingcommitmentforservicesreceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMTctMS0xLTEtMA_eff88bb3-48d3-4f04-84d8-4b958135cac2">868,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="crdf:Releaseofclinicaltrialfundingcommitmentforservicesreceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMTctMy0xLTEtMA_aca802ae-6cb8-4aa0-9b4c-177860debd56">509,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMTktMS0xLTEtMA_83c11d7b-51ec-48d3-bf12-49ba76e5e1e1">1,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMTktMy0xLTEtMA_89382f7f-52c7-4365-a423-6150994109c7">68,145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjAtMS0xLTEtMA_cf3baa8c-0350-4538-9386-3e3b72278793">886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjAtMy0xLTEtMA_2fbec4c9-7bbb-4a5c-a304-8eca822d2ba0">15,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjEtMS0xLTEtMA_59bdb0e7-f4e8-41af-900a-4d5b961640a6">623,902</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjEtMy0xLTEtMA_55bbe483-2e83-4451-96fe-ec16797cc301">277,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjItMS0xLTEtMA_3246c5d3-ba96-4d7e-aba2-516df36f1439">240,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjItMy0xLTEtMA_1f8b0043-6f48-4a35-b2a3-0a7f056ac6de">224,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjMtMS0xLTEtMA_ecd15e8a-2f67-4c85-9905-4d8d098e1953">318,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjMtMy0xLTEtMA_18da7c57-4aec-4d67-a7eb-1b507315350b">837,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="crdf:IncreaseDecreaseInOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjQtMS0xLTEtMA_0481a8ed-5b3e-42b2-911e-0272075aad66">635,630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="crdf:IncreaseDecreaseInOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjQtMy0xLTEtMA_8095946c-73b7-40e4-95d7-2f641c9cc184">576,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjUtMS0xLTEtMA_f5c1e66f-075e-405b-9fe7-6bc465a11c29">39,916</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjUtMy0xLTEtMA_03da71de-d88a-4e05-85b1-e08e7dde64fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjYtMS0xLTEtMA_db514af0-c8f4-4f0e-9cc4-6742ec93fd88">11,191,025</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjYtMy0xLTEtMA_0abc40eb-9106-414e-a6c6-cd3ef377f98c">9,990,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMzAtMS0xLTEtMA_8087b244-8aed-4b9e-ab6e-8868868f23dc">153,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMzAtMy0xLTEtMA_178ae92e-03eb-4a69-b9db-faa0dfbc47f9">67,622</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMzQtMS0xLTEtMA_db2d39de-0c35-44d7-9cad-f5d8e09c3834">153,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMzQtMy0xLTEtMA_1a2ab7d8-0281-495e-afb3-8559218a9c79">67,622</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of common stock, preferred stock and warrants, net of expenses of $<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjRiMDViNzVkNTk3MTQzZDc5ZDBlMTFiZDczOTJiZDkxXzkw_aeb4a3e6-791e-4261-89f8-79f68b9ad5cc">633,807</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjRiMDViNzVkNTk3MTQzZDc5ZDBlMTFiZDczOTJiZDkxXzk3_996bd915-a006-4277-bca3-c69a54f41275">97,260</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMzctMS0xLTEtMA_5dd3b1ed-d1fb-4257-b427-c00112aa5c9f">18,278,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMzctMy0xLTEtMA_63a94f93-6cfc-4626-96b1-5fe28af3c431">4,386,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs related to the clinical trial funding commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMzktMS0xLTEtMA_145782f4-abba-4b65-b650-dbf81c5f8286">7,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMzktMy0xLTEtMA_d5f80fe8-ed94-4f6b-aec2-03e47e6072cc">40,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNDAtMS0xLTEtMA_8750aed8-af2f-4da2-b211-f162b8e05521">6,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNDAtMy0xLTEtMA_574bd6d5-b3ff-45fb-ba9f-ab02cd2c2def">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNDEtMS0xLTEtMA_45d16c47-87a1-4b84-b263-c88a54fba8c8">18,972,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNDEtMy0xLTEtMA_f4307e77-32dc-4555-90d6-c77f1d8acbfd">3,291,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings under note payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNDMtMS0xLTEtMA_fb0b9bed-6904-4fea-93f7-ed7727c63cf7">305,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNDMtMy0xLTEtMA_88ae1b19-b96a-4e48-b5dd-21374c190f0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNDctMS0xLTEtMA_bef6893e-7d03-460c-9758-03fc595d27af">37,554,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNDctMy0xLTEtMA_fc359da4-17ed-4d00-9019-4d2737b7183f">7,637,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNDktMS0xLTEtMA_4ae55e32-69ee-4b22-ad98-adcd7f8410ab">26,210,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNDktMy0xLTEtMA_dc9f2241-82e4-4ab3-b7a6-12199fb7edef">2,420,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;Beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNTAtMS0xLTEtMA_8c8cece7-07b2-4c33-9591-34337f646a77">10,195,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec08f4c1e8014a62bb515c9760634ec7_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNTAtMy0xLTEtMA_39794a42-dd1c-4042-8e11-11f68ac84dc5">11,453,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;End of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNTEtMS0xLTEtMA_3025aaa6-e6fd-4ef4-9aba-b2d7642b4e6e">36,405,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i601506d900b640889cfe25c06b9517ad_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNTEtMy0xLTEtMA_1397d070-9a04-4b3f-89f7-374776f251d2">9,032,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplementary disclosure of cash flow activity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" name="us-gaap:IncomeTaxesPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNTQtMS0xLTEtMA_b8cf9d51-c1e0-4e90-a4c3-4a2c2381fd17">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" name="us-gaap:IncomeTaxesPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNTQtMy0xLTEtMA_47513dd8-dda5-471c-bf9d-fa5ed48fdc03">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="crdf:PreferredStockDividendAccrued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjAtMS0xLTEtMA_e2a08900-ceb4-48cf-8f5f-69f57ca99cba">18,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="crdf:PreferredStockDividendAccrued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjAtMy0xLTEtMA_e61454e5-e8d2-4a6b-b3e0-bcdaa5ae45bf">18,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized for beneficial conversion features of Series C Convertible Preferred Stock issuance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64433fb437b14e2797a35696e3126e7f_D20200101-20200930" decimals="0" format="ixt:zerodash" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjItMS0xLTEtMA_cf5cf451-28d3-436c-8281-f91f00b38d00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d39276c8b7149b69b1e0641629d29d6_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjItMy0xLTEtMA_9c2d0cea-5717-457c-a748-75edc4ffe232">268,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized for beneficial conversion features of Series D Convertible Preferred Stock issuance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac167662d264ce29cc6bdaf26de9a0b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjMtMS0xLTEtMA_abaac088-d467-4b71-8504-115a9c70e6fc">601,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60ddc19ccbda40389020c27451bc6aab_D20190101-20190930" decimals="0" format="ixt:zerodash" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjMtMy0xLTEtMA_c99d17ae-1440-404c-9dac-7542244b89e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized for beneficial conversion features of Series E Convertible Preferred Stock issuance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c5bb2609e8479dad4e32ccd15c3b2a_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjQtMS0xLTEtMA_d6e8be0e-f065-483e-97eb-aac5c66f3741">2,664,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206237eca5cf411b89a567e3e300cf34_D20190101-20190930" decimals="0" format="ixt:zerodash" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjQtMy0xLTEtMA_b77613e5-7f5a-41a5-ad5a-931fbee7e534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, Series C Convertible Preferred Stock and warrants issued in connection with clinical trial funding commitment, net of discount of $<ix:nonFraction unitRef="usd" contextRef="i1d39276c8b7149b69b1e0641629d29d6_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="crdf:DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOjRkMTlkM2IyOGE0MjQ5NmI5NzlhN2VlMjMwOGI1NGQwXzE0OA_13e6af16-98c6-4801-9482-a6d2db90ebf2">235,640</ix:nonFraction></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64433fb437b14e2797a35696e3126e7f_D20200101-20200930" decimals="0" format="ixt:zerodash" name="crdf:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjUtMS0xLTEtMA_b51f5569-1fe8-4efb-8694-2851729352f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d39276c8b7149b69b1e0641629d29d6_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="crdf:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjUtMy0xLTEtMA_aa495ca5-7aa1-4407-b12f-1ed1fe89ce2b">1,675,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, Series D Convertible Preferred Stock and warrants issued in connection with clinical trial funding commitment, net of discount of $<ix:nonFraction unitRef="usd" contextRef="i7ac167662d264ce29cc6bdaf26de9a0b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="crdf:DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjYtMC0xLTEtMC90ZXh0cmVnaW9uOmFmMDM1ZTE2ZWJiMjRlOGVhZmRiMzcyOTdlMzVhYzNiXzE0OA_95a38dba-ddde-4021-a032-829be0145cc6">488,270</ix:nonFraction></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac167662d264ce29cc6bdaf26de9a0b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="crdf:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjYtMS0xLTEtMA_5ceb2e4c-bcb6-4fbb-bf49-2750c5cf1302">2,300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60ddc19ccbda40389020c27451bc6aab_D20190101-20190930" decimals="0" format="ixt:zerodash" name="crdf:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjYtMy0xLTEtMA_70762c1b-d1bd-489b-882d-ae103c08b16b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued upon conversion of Series C Convertible Preferred Stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64433fb437b14e2797a35696e3126e7f_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjgtMS0xLTEtMA_cf6f7a80-835b-422d-bd17-ff0acb7c6d2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d39276c8b7149b69b1e0641629d29d6_D20190101-20190930" decimals="0" name="us-gaap:ConversionOfStockAmountIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjgtMy0xLTEtMA_f8ed3497-95fd-4e0a-93e9-1e29a7287f57">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued upon conversion of Series D Convertible Preferred Stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac167662d264ce29cc6bdaf26de9a0b_D20200101-20200930" decimals="0" name="us-gaap:ConversionOfStockAmountIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjktMS0xLTEtMA_3d59858b-c7b5-43a3-8f0f-79c7c010b31d">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60ddc19ccbda40389020c27451bc6aab_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjktMy0xLTEtMA_4626c89c-846c-4df7-b94b-6437f87ef578">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:83.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed financial statements.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i0ff27e3402fc47278eb8617e2a08b771_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY,&#160;INC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i0ff27e3402fc47278eb8617e2a08b771_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80MC9mcmFnOmIxOGMzMDI4Y2VjZjQ0ZmM5Mjc3ZDNkMWE4ZTBiMmFhL3RleHRyZWdpb246YjE4YzMwMjhjZWNmNDRmYzkyNzdkM2QxYThlMGIyYWFfMzE4OQ_c7896124-5f4a-48d9-86e6-51e6ac8635f5" continuedAt="id35079e3ca0f4c038e42270d488b47c6" escape="true">Organization and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="id35079e3ca0f4c038e42270d488b47c6" continuedAt="i98fd9609683e497682a990f6ce4867e9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Organization and Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology,&#160;Inc. (&#8220;Cardiff Oncology&#8221; or the &#8220;Company&#8221;) headquartered in San Diego, California, is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, Zytiga&#174;-resistant metastatic castration-resistant prostate cancer and relapsed or refractory acute myeloid leukemia. Our goal is to overcome resistance, improve response to treatment and increase overall survival. Through the integration of tumor genomics and biomarker technology, we are able to assess patient response to treatment.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements of Cardiff Oncology have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and the rules&#160;and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form&#160;10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules&#160;and regulations. The unaudited interim condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company&#8217;s financial position and the results of its operations and cash flows for the periods presented. The unaudited condensed balance sheet at December&#160;31, 2019 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December&#160;31, 2019 included in the Company&#8217;s annual report on Form&#160;10-K filed with the SEC on February&#160;27, 2020.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net losses since its inception and has negative operating cash flows. As of September&#160;30, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80MC9mcmFnOmIxOGMzMDI4Y2VjZjQ0ZmM5Mjc3ZDNkMWE4ZTBiMmFhL3RleHRyZWdpb246YjE4YzMwMjhjZWNmNDRmYzkyNzdkM2QxYThlMGIyYWFfMjM1Ng_34759b75-2c4b-45e7-b1e7-fb9df579fce1">36.4</ix:nonFraction>&#160;million in cash and cash equivalents and believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.  </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 2, 2020 the Company closed an underwritten public offering of its common stock for gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i5c512dc917a44fa4935298acc4757d46_D20201002-20201002" decimals="-5" format="ixt:numdotdecimal" name="crdf:SaleOfStockConsiderationReceivedOnTransactionGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80MC9mcmFnOmIxOGMzMDI4Y2VjZjQ0ZmM5Mjc3ZDNkMWE4ZTBiMmFhL3RleHRyZWdpb246YjE4YzMwMjhjZWNmNDRmYzkyNzdkM2QxYThlMGIyYWFfMTA5OTUxMTYzMTg0Mw_6f7bb485-10bc-4d54-ab53-638b0e77d9c8">100.9</ix:nonFraction>&#160;million. See Note 11 to the condensed financial statements for further information.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the foreseeable future, the Company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company&#8217;s stockholders may experience additional dilution. The economic effects of COVID-19 could also have an adverse effect on the Company's ability to raise additional capital. See Note 10 to the condensed financial statements for further information.</span></div></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i98fd9609683e497682a990f6ce4867e9">As of October 31, 2020 the Company had $<ix:nonFraction unitRef="usd" contextRef="id02c2a45ee9d4832a6e43bb343c46f06_I20201031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80MC9mcmFnOmIxOGMzMDI4Y2VjZjQ0ZmM5Mjc3ZDNkMWE4ZTBiMmFhL3RleHRyZWdpb246YjE4YzMwMjhjZWNmNDRmYzkyNzdkM2QxYThlMGIyYWFfMTA5OTUxMTYzMTgyOQ_7fa969c4-0fbc-46a6-a55b-c3d4215f9c14">131.8</ix:nonFraction>&#160;million in cash and cash equivalents.</ix:continuation> </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div id="i0ff27e3402fc47278eb8617e2a08b771_43"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RleHRyZWdpb246ZjVhZjgxYzI3NGQxNDIyNjk1MTIyZjgyMTEwNzZmODVfMTcyNg_09ef5dbf-2668-49a4-867f-c10aef1c6dc9" continuedAt="if4780108bca04f28aeac1670732bb288" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="if4780108bca04f28aeac1670732bb288" continuedAt="i8a3ecd7d4e3e4a57ab4f50445c0b39b4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020, there have been no changes to the Company&#8217;s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2019.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><ix:continuation id="i8a3ecd7d4e3e4a57ab4f50445c0b39b4" continuedAt="i40e611cd0a4449e281556ba3de49c5da"><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RleHRyZWdpb246ZjVhZjgxYzI3NGQxNDIyNjk1MTIyZjgyMTEwNzZmODVfMTcyOQ_6fed67c8-3e76-486f-95ef-ee8875575b3e" continuedAt="ia7533d45eff34020895921e8fad4c9d1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia7533d45eff34020895921e8fad4c9d1">Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.</ix:continuation> Shares used in calculating diluted net loss per common share exclude as anti-dilutive the following share equivalents:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RleHRyZWdpb246ZjVhZjgxYzI3NGQxNDIyNjk1MTIyZjgyMTEwNzZmODVfMTcyNA_f2f7c9c6-895b-45a2-8e6f-d40539490bdb" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss used for basic and diluted loss per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfNS0xLTEtMS0w_5f9f0a26-5e3a-4e06-a4e2-b0a0e9b5f0af">4,502,591</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfNS0zLTEtMS0w_cbafbfe0-09e6-49be-aa76-6d2a51db66b1">4,147,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfNS01LTEtMS0w_2d4d10ee-25cb-46e9-af2f-f707525a4baf">15,994,289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfNS03LTEtMS0w_d3799bcd-800f-4e80-af04-72c3a31cafed">12,458,072</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfOC0xLTEtMS0w_a1fae025-478b-494c-a747-5bb4c7e8a8d3">23,341,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfOC0zLTEtMS0w_a46de72b-8618-4312-a058-893a76f987d0">6,024,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfOC01LTEtMS0w_a0cdc9e3-370a-4725-9923-79aac143eee8">15,941,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfOC03LTEtMS0w_2a62c5a5-c38c-4976-ae21-aeca5d44281d">5,180,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfMTMtMS0xLTEtMA_4037322e-6773-420c-9a81-e90136248bdb">0.19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfMTMtMy0xLTEtMA_801f0d55-cb88-4f41-8b83-bc0c12baf3a2">0.69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfMTMtNS0xLTEtMA_b9e50df9-c1b3-4e2c-9874-39a426ef3d77">1.00</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfMTMtNy0xLTEtMA_19160ee6-d17c-4b4c-bbae-915723dff06f">2.40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RleHRyZWdpb246ZjVhZjgxYzI3NGQxNDIyNjk1MTIyZjgyMTEwNzZmODVfMTc0MQ_cb719f2c-12e8-4c5a-91a7-d8fdd844daf9" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase Common Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ae86bd676e644578010b6922e11b5af_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfMi0xLTEtMS0w_74788ab5-afe6-4787-8e7d-da3c754fd159">1,920,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id797d8f2971c433b85a9c8e933191c14_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfMi0zLTEtMS0w_96057f1d-4b6f-44e0-9d87-1c0a899adb39">1,016,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase Common Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i922cd50fe23c43afbd32e28dc822bb14_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfMy0xLTEtMS0w_f16ecc32-09a0-48e9-a2e9-37280bddd5fe">7,373,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9deeeca3150647ec9217fa02ab61c9ad_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfMy0zLTEtMS0w_065f678d-f414-4283-962a-661c1d7c771e">4,870,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c1dff24e4584a7c84ebc91d6aae1001_D20200101-20200930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfNC0xLTEtMS0w_a6dc47b5-13f4-4182-bbc2-fb7fdc56a47b">991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b110679c7614e04bf79a89353cde89c_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfNC0zLTEtMS0w_a55b8e9c-7561-41f4-9315-3c4d61a8c944">14,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14bb2d1b3ff242f28e82eda2a47f119b_D20200101-20200930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfNS0xLTEtMS0w_e64d3c57-d934-4c3e-97ad-288913f939ca">877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff6cc44df61b4043b78740d1bee0959b_D20190101-20190930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfNS0zLTEtMS0w_1c4dcd22-66f6-4fd2-a2e7-1fcde8893a30">877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic763b33eacc24b9da821d145ed6ebff6_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfNy0xLTEtMS0w_64dc17a3-1967-4a02-b962-a05d5dda78bf">3,548,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if44f824383a040f084fa2c0d3ddf921b_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfNy0zLTEtMS0w_adee745a-be5e-4c40-9d4b-82944aa1c550">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfOC0xLTEtMS0w_d1d44da8-ddfe-45a2-a993-bb4984e303b9">12,844,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfOC0zLTEtMS0w_e4843ee1-68ff-4fc1-a4f6-e630e7091a95">5,901,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RleHRyZWdpb246ZjVhZjgxYzI3NGQxNDIyNjk1MTIyZjgyMTEwNzZmODVfMTc0Mw_ba2e6fea-6561-4b5d-be84-e108099de9c5" continuedAt="i21f12fbe0f304885ba261cf293c0b854" escape="true">Recently Adopted Accounting Pronouncement</ix:nonNumeric></span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><ix:continuation id="i40e611cd0a4449e281556ba3de49c5da" continuedAt="i7a07b7eb71854c4881052b6d592787bd"><ix:continuation id="i21f12fbe0f304885ba261cf293c0b854" continuedAt="ic137ffeb8df44b88bc793f36eacd90d9"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU&#160;No. 2018-13 ("ASU 2018-13"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes to the Disclosure Requirements for Fair Value Measurement</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7a07b7eb71854c4881052b6d592787bd"><ix:continuation id="ic137ffeb8df44b88bc793f36eacd90d9">. This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard is effective for all entities for financial statements issued for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company has prospectively adopted ASU 2018-13 as of January 1, 2020 for periods presented after adoption. The adoption of ASU 2018-13 did not have a material impact on the Company's financial statements.</ix:continuation></ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i0ff27e3402fc47278eb8617e2a08b771_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;<ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RleHRyZWdpb246YjNlZTAyY2Y5NzE2NDVmZjgzNTAyODMxY2YxMmZmZjBfODU3_535dda22-de0b-43a0-ba58-015db4314c98" continuedAt="ifc71ade2356e4a74bf4ff7764db72199" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ifc71ade2356e4a74bf4ff7764db72199"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RleHRyZWdpb246YjNlZTAyY2Y5NzE2NDVmZjgzNTAyODMxY2YxMmZmZjBfODU0_3c689aad-1459-46a2-9dc8-8b2c5d1b8dd2" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:41.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86a4592371ee47e585775ef7ab0a392a_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMy0xLTEtMS0w_64f0c42d-33e9-483e-a974-ef244467ed76">35,536,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5366ec380ebb435dbfde066020aa5925_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMy0zLTEtMS0w_123774bb-32bf-481e-9a8f-db3c62978947">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b2709deee64adcb18d9c2af9b4467b_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMy01LTEtMS0w_b7e5bf62-c611-4ff0-9103-e8e081f93435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58bccc712f204dd9aa339aff63845a18_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMy03LTEtMS0w_88182f25-4048-4466-bad7-404b491c912b">35,536,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86a4592371ee47e585775ef7ab0a392a_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfOC0xLTEtMS0w_c01594af-ff32-4dab-8567-542334fdd0af">35,536,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5366ec380ebb435dbfde066020aa5925_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfOC0zLTEtMS0w_ee84ee88-7324-4cc7-8344-4aee946b40ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b2709deee64adcb18d9c2af9b4467b_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfOC01LTEtMS0w_4ff85d0d-807c-4035-9b5d-baf2af87954c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58bccc712f204dd9aa339aff63845a18_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfOC03LTEtMS0w_0abf35c7-355a-49e1-b6f4-e132358b38ea">35,536,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants (2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86a4592371ee47e585775ef7ab0a392a_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMTAtMS0xLTEtMA_6a3c07fc-c91c-4865-8254-bcb5cc114fb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5366ec380ebb435dbfde066020aa5925_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMTAtMy0xLTEtMA_1a064f53-6e25-4991-bde5-f6cdc4fcf1db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b2709deee64adcb18d9c2af9b4467b_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMTAtNS0xLTEtMA_fb66035a-9f17-46ee-8800-f10bfd8b5da2">190,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58bccc712f204dd9aa339aff63845a18_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMTAtNy0xLTEtMA_c84ba16d-9f0a-4efc-98ea-bc7fd453e1a7">190,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86a4592371ee47e585775ef7ab0a392a_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMTEtMS0xLTEtMA_92c20864-f177-4c34-866c-3b131402b2d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5366ec380ebb435dbfde066020aa5925_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMTEtMy0xLTEtMA_8e6d0488-c021-4ef9-b77c-4304364b63a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b2709deee64adcb18d9c2af9b4467b_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMTEtNS0xLTEtMA_1bd0706c-919f-405c-967c-e93315e60598">190,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58bccc712f204dd9aa339aff63845a18_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMTEtNy0xLTEtMA_ad0f4b32-78eb-4b84-a15e-0fd1c4f831e5">190,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:41.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund (1)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb19cb296ec14221a57f41b82c172241_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfMy0xLTEtMS0w_dbcaab73-228e-48ca-aa7f-5973f3a70a01">10,131,240</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3207f5a1740243bcb1976b54a554df1c_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfMy0zLTEtMS0w_6e45a4ed-bcd0-426d-9fa0-92bbeb22b187">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie609985fe35541f19bd9585994dad17f_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfMy01LTEtMS0w_e9df899f-1489-4a7c-bbf3-50d368519e3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be75556eccc47a1806b67aaab547b18_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfMy03LTEtMS0w_0fdaa368-7e6b-436c-ae79-857046477767">10,131,240</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb19cb296ec14221a57f41b82c172241_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfNy0xLTEtMS0w_a857d598-e36f-48f0-8777-55bd9716b3eb">10,131,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3207f5a1740243bcb1976b54a554df1c_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfNy0zLTEtMS0w_f6ef5095-123e-4c61-a531-9daf95bcfaec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie609985fe35541f19bd9585994dad17f_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfNy01LTEtMS0w_517bb4a3-d3dd-424f-8ca6-6dc244b7d9ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be75556eccc47a1806b67aaab547b18_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfNy03LTEtMS0w_81a1a7a1-e742-4920-8373-1a2ad16da95a">10,131,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants (2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb19cb296ec14221a57f41b82c172241_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfOS0xLTEtMS0w_4b267911-0727-4087-8aca-ec6e8aa79870">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3207f5a1740243bcb1976b54a554df1c_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfOS0zLTEtMS0w_b732d3c0-fb29-4bcd-8be3-37cbcaf89ed3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie609985fe35541f19bd9585994dad17f_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfOS01LTEtMS0w_7cc8b222-2d26-4e2c-b22d-7e3637dfbe9d">4,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be75556eccc47a1806b67aaab547b18_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfOS03LTEtMS0w_d38b2c1c-b890-4db6-bd17-eec4225659bd">4,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb19cb296ec14221a57f41b82c172241_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfMTAtMS0xLTEtMA_9ca0d6d8-386c-4ea6-b4d1-d0ff02c1bd10">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3207f5a1740243bcb1976b54a554df1c_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfMTAtMy0xLTEtMA_defa9c4a-8ab6-45db-b78a-82363bce8e7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie609985fe35541f19bd9585994dad17f_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfMTAtNS0xLTEtMA_736368f0-949c-483c-90f1-53e8e7e7423f">4,127</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be75556eccc47a1806b67aaab547b18_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfMTAtNy0xLTEtMA_777be175-35ec-405b-815d-530a24e0264a">4,127</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;Included as a component of cash and cash equivalents on the accompanying condensed balance sheets.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments that trade infrequently and therefore have little or no price transparency are classified as Level 3. See Note 6 to the condensed financial statements for further information.</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div id="i0ff27e3402fc47278eb8617e2a08b771_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RleHRyZWdpb246M2JlMjYzZjhkOTYxNDg2NjgwY2MxYjk1MzJmNjFjNGVfODk_b28d6a69-852e-4bc1-bbc2-4624b5cd1717" continuedAt="i939bdf33ff7c4a0cbdf4df0f151bb3a1" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i939bdf33ff7c4a0cbdf4df0f151bb3a1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RleHRyZWdpb246M2JlMjYzZjhkOTYxNDg2NjgwY2MxYjk1MzJmNjFjNGVfOTI_45779f46-50f6-44c6-8c67-adbd3ad0d251" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic730906a9b7146d1b973c557bc30b530_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfMS0xLTEtMS0w_70be0cac-489c-41c0-9fcd-1f3adf59d6e9">805,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1fd079695bc43f594a3fe0cf305011d_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfMS0zLTEtMS0w_202167dc-9df4-4185-be9b-5596ed9b086d">775,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13bcac6c13f146b59174b71aabe0cc5b_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfMi0xLTEtMS0w_f40f65af-b322-41ac-a250-3e1ee0be5084">1,962,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i186aff4c8c0e467286405c76465b4ba0_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfMi0zLTEtMS0w_27c74d2e-c968-4d60-9df9-e337d5d9b272">1,962,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1235b538bb13457d894f3ca7cec6739c_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfMy0xLTEtMS0w_a480cebb-0456-4c35-b98b-7d0569778b66">867,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3da0359f941e46dfada6dc17aa275971_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfMy0zLTEtMS0w_1f5f3062-d790-416d-8fb4-fb271f3bc64b">744,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfNC0xLTEtMS0w_4078264b-11cf-4d26-a35d-17541616719b">3,635,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfNC0zLTEtMS0w_c67e26ec-4d59-4223-851e-80f960e4886e">3,482,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfNS0xLTEtMS0w_36caf9ad-cce7-4222-9e74-7636610428e0">2,953,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfNS0zLTEtMS0w_ffbc9627-a7dd-419b-be46-baea3c3b522a">2,604,293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfNi0xLTEtMS0w_a29711e5-3ab7-44ed-973f-0c59ea7ac1c0">682,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfNi0zLTEtMS0w_89af86df-e8c0-4b6d-a4c8-405e72bc6794">877,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i0ff27e3402fc47278eb8617e2a08b771_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMjkwOQ_e1bdda56-392f-4799-8666-9dab5690dbcb" continuedAt="i7b73f0635c154e3c8eb2385b28bc019c" escape="true"><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMjkyNA_5ddfc3b9-5f95-43f4-a870-491a1ea7821b" continuedAt="i17cb8a48dce84bc3bbe5c0480ddc9533" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:continuation id="i7b73f0635c154e3c8eb2385b28bc019c" continuedAt="icd9062a402414822b4790171ad16de43"><ix:continuation id="i17cb8a48dce84bc3bbe5c0480ddc9533" continuedAt="i080627c247d748bba8527a1b4b46ddbb"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As a lessee, the Company&#8217;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company (as a sublessor) also subleases portions of its facility to third parties under <ix:nonFraction unitRef="lease" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="crdf:LessorNumberOfSubleases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMTY0OTI2NzQ0NTU1Ng_116d99d8-2a66-4516-be81-efb5be01a622">three</ix:nonFraction> separate subleases. All of these subleases have been determined to be operating leases and are accounted for separately from the head lease. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Facility Lease </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases a building in San Diego under an operating lease that expires on December&#160;31, 2021. The lease currently requires fixed monthly rent payments of approximately $<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="crdf:LesseeOperatingLeaseMonthlyRentPayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfNjE0_9c0a4558-0bae-4f45-b9a3-e6bd0299cdde">78,000</ix:nonFraction>, with <ix:nonFraction unitRef="number" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="INF" name="crdf:LesseeOperatingLeaseAnnualRentIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfNjIz_e55965e6-5488-4d2d-bc85-304e19a5e2fd">3</ix:nonFraction>% annual escalation. The lease also contains <ix:nonFraction unitRef="renewal_option" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="crdf:LesseeOperatingLeaseNumberOfRenewalOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfNjY5_45b02aec-3cbb-4549-86ce-6df0af1b45b4">one</ix:nonFraction> <ix:nonNumeric contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMjkxMQ_3aa7936c-4a07-4952-8fb7-6d328615ba78">five-year</ix:nonNumeric> renewal option with minimum monthly rent equal to the then-current fair market value, subject to a <ix:nonFraction unitRef="number" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="INF" name="crdf:LesseeOperatingLeaseAnnualRentIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfNzc5_38e08069-8817-4bb1-b191-223b5d5f4cde">3</ix:nonFraction>% annual increase. As the Company is not reasonably certain to exercise this option, it has not been included in the calculation of the lease liability or right-of-use asset related to this lease.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility Subleases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased the space to third parties under <ix:nonFraction unitRef="lease" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="crdf:LessorNumberOfSubleases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMTE1NA_df6e18c1-4eb7-4926-9ba1-1948fa61bdbd">three</ix:nonFraction> separate sublease agreements, which all expire December 31, 2021. The Company recorded a cease-use loss liability and expense in 2018 pursuant to ASC 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, representing the total expected shortfall in sublease income for two of the subleases as compared to its required payments for those spaces under the remainder of the master lease term. This liability was being amortized over the remaining lease term until the adoption of ASC 842, whereupon the remaining cease-use loss liability of approximately $<ix:nonFraction unitRef="usd" contextRef="i3ffb8f629fcb46718f4c859a146c71fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMTc2OA_5fd1693f-b8e1-46e7-a523-10e9f026d790">487,000</ix:nonFraction> was eliminated and treated as a reduction to the beginning ROU asset value for the master lease as of January 1, 2019. Income will continue to be recognized on a straight-line basis over the term of the sublease.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Right-of-Use Assets</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded an impairment loss of $<ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" name="us-gaap:OperatingLeaseImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMTA5OTUxMTYzMTY0OQ_eb1e4332-20a1-4ce7-a50c-7d39126f4143">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMjA2Mw_39c0e6e8-a117-4eb1-aced-d69505431eb8">34,169</ix:nonFraction> for the three and  nine months ended September 30, 2020, respectively.  The loss related to a vacated portion of the facility that was no longer being subleased. The Company determined that the prolonged loss of sublease income and an adverse commercial real estate market caused by COVID-19 were indicators of impairment. A fair value approach using quoted prices for similar assets was used to determine the impairment loss.  The loss was recorded within operating expenses in the condensed statement of operations.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMjkyNQ_247fbf5b-cd71-4f0f-af8f-8a85830fc6f7" continuedAt="i222edbe6a6fb463d84b4886013d23bfb" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfMi0xLTEtMS0w_155b94e7-8bcc-4680-a0a7-c1db7bc6aadd">98,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfMi0zLTEtMS0w_561dcf6d-8e7c-4d48-a82d-3817cb222de5">191,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfMi01LTEtMS0w_b41863da-5988-4db2-a290-2c944b014ad7">344,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfMi03LTEtMS0w_414dea1d-701e-4ec0-b384-c777d67287da">578,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating sublease income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfMy0xLTEtMS0w_0ebde78f-1830-40f4-9ed7-9f336010e986">72,793</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfMy0zLTEtMS0w_a2b56999-0a51-457f-a485-dfa411b2f7be">99,937</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfMy01LTEtMS0w_7a0c6886-8c48-401e-bb37-ef393c3686d3">218,380</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfMy03LTEtMS0w_c30824e7-36e9-4fe4-b7ab-f3d56656ddc8">299,812</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfNC0xLTEtMS0w_5caae347-0abd-4753-a26b-e0e7640d512e">26,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfNC0zLTEtMS0w_f4d705a6-bf9f-483d-8b06-17cd13d039e3">91,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfNC01LTEtMS0w_5fd6e232-d22f-44cd-9a9f-65e25de0c3ca">126,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfNC03LTEtMS0w_dbdc14b0-1414-4674-bbd7-9e58b32f9696">279,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:33.75pt"><span><br/></span></div><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="crdf:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMjkwNQ_fc537d0f-c576-41ca-ac29-3260bf9c6769" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfMS0xLTEtMS0w_abcc3464-48f0-40cc-a937-5a164235ffeb">423,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfMS0zLTEtMS0w_9aceb7e3-b12c-47fd-bb7d-49d1b92b7006">697,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfMy0xLTEtMS0w_6e16dd25-511e-4d04-9902-13c8ca54a825">883,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfMy0zLTEtMS0w_d2431c72-7b24-45f7-8621-33bc40f3044b">865,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfNC0xLTEtMS0w_191c1818-bd64-4527-9495-b7817f743b54">207,178</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfNC0zLTEtMS0w_2aa403b1-b020-486f-b0a1-1d7fc556bad9">860,963</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfNS0xLTEtMS0w_782ac0ce-955d-4d44-b0fd-bf9be70cd4f4">1,090,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfNS0zLTEtMS0w_6062cfff-1363-4a09-a44c-950244d292d2">1,726,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfNy0xLTEtMS0w_821fdcd1-4677-42a7-85df-e3d66efa2f5a">1.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfNy0zLTEtMS0w_f5fc7a3e-a379-4fab-8c91-e0047a9f4697">2.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfOC0xLTEtMS0w_8227b566-26ad-4760-a2e5-5dbd2b759ca4">6.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfOC0zLTEtMS0w_804a7bd1-51ee-4b64-95de-c5ad07385cc2">6.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><ix:continuation id="icd9062a402414822b4790171ad16de43"><ix:continuation id="i080627c247d748bba8527a1b4b46ddbb"><ix:continuation id="i222edbe6a6fb463d84b4886013d23bfb"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjY3Mjc5M2ZhMTlmMzQxZWM5Mzk5MTY0NjI0OWFhYjgzL3RhYmxlcmFuZ2U6NjcyNzkzZmExOWYzNDFlYzkzOTkxNjQ2MjQ5YWFiODNfMy0xLTEtMS0w_d2d13dfe-6cbc-4d62-9be2-1287582759df">236,748</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjY3Mjc5M2ZhMTlmMzQxZWM5Mzk5MTY0NjI0OWFhYjgzL3RhYmxlcmFuZ2U6NjcyNzkzZmExOWYzNDFlYzkzOTkxNjQ2MjQ5YWFiODNfMy0zLTEtMS0w_1e83b3ef-796c-4690-9981-568b73d191fd">229,927</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjY3Mjc5M2ZhMTlmMzQxZWM5Mzk5MTY0NjI0OWFhYjgzL3RhYmxlcmFuZ2U6NjcyNzkzZmExOWYzNDFlYzkzOTkxNjQ2MjQ5YWFiODNfMy01LTEtMS0w_e88bfd83-5c31-4552-a510-28783f93d88a">706,211</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjY3Mjc5M2ZhMTlmMzQxZWM5Mzk5MTY0NjI0OWFhYjgzL3RhYmxlcmFuZ2U6NjcyNzkzZmExOWYzNDFlYzkzOTkxNjQ2MjQ5YWFiODNfMy03LTEtMS0w_ba8e7d36-89a0-4873-bffe-8f72a8f7192e">685,865</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMjkxNA_a870dc6d-d130-4991-b7fb-83c3c31a1d72" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Sublease Income </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Net Operating Leases </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (excluding the nine months ended September 30, 2020)</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfMi0xLTEtMS0w_4069354b-9015-4970-acec-714e78b15f16">159,167</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfMi0zLTEtMS0w_ff47ec26-cc16-4742-9148-905a451daed9">72,793</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfMi01LTEtMS0w_c129ace0-1fc9-48f9-8baf-aa6e72da3471">86,374</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfMy0xLTEtMS0w_8af22723-6b75-460e-98ae-00f6c62315d0">968,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfMy0zLTEtMS0w_68733e90-5176-4d3d-bd3e-97a9f58aef7f">403,345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfMy01LTEtMS0w_3c88ed1b-d5b3-484a-9179-667e22b2bafa">564,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfNC0xLTEtMS0w_8291f4b3-2462-43ab-bf2d-fbef7ce23a03">5,868</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfNC0zLTEtMS0w_cb16d3c7-3398-428f-a9f4-fceecb6a2a7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfNC01LTEtMS0w_3a28371d-60b4-4f61-ad19-bca8b15b8511">5,868</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfNS0xLTEtMS0w_715419c1-b72a-484c-8c1c-5706341d97d5">3,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfNS0zLTEtMS0w_16d09eab-26a9-4fb0-8424-f0123d47a119">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfNS01LTEtMS0w_7fcd3c8b-f0fb-4f4f-a3c1-a63cc930d65e">3,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfNi0xLTEtMS0w_7afbddc5-7d2b-41b1-aaf1-0608c0d03ba9">1,136,623</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfNi0zLTEtMS0w_cd206ab6-7f7c-473c-b7c1-86d7dd8e5539">476,138</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfNi01LTEtMS0w_91860c5e-2b71-4363-bc54-e70a96ecf167">660,485</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfNy0xLTEtMS0w_b1e2a091-c29a-48a8-81e4-e2b58a01d688">45,911</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfOC0xLTEtMS0w_fa9ba3c7-e896-4468-8226-4d9fc5528440">1,090,712</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i0ff27e3402fc47278eb8617e2a08b771_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;<ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RleHRyZWdpb246NTY3OTM0MzkxZDQzNDQ2YjliYzE5NDBlMGRjOGMyZWJfMTkzMA_2f380153-26e9-4c4a-97f6-1b19b9a90236" continuedAt="i3353b5d23f904eb1bca986b48a00d9bc" escape="true">Derivative Financial Instruments &#8212; Warrants</ix:nonNumeric></span></div><ix:continuation id="i3353b5d23f904eb1bca986b48a00d9bc" continuedAt="i9fa25f0b7b024e81a9994890bb114f8f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon the Company&#8217;s analysis of the criteria contained in ASC Topic 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 815-40&#8221;) or ASC Topic 480-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 480-10&#8221;), Cardiff Oncology determined that certain warrants issued in connection with the execution of certain equity financings must be recorded as derivative liabilities.&#160;In accordance with ASC 815-40 and ASC 480-10, the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant change in fair value is being recorded in the Company&#8217;s condensed statements of operations.&#160;The Company estimates the fair value of these warrants using the Black-Scholes option pricing model.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="ib123867495f94547b6cb9b6106e13878_D20200101-20200930" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RleHRyZWdpb246NTY3OTM0MzkxZDQzNDQ2YjliYzE5NDBlMGRjOGMyZWJfMTkxNg_820e4a92-a94c-4e20-be85-464b93ff575e" continuedAt="i39b52804aadc4857b2bf7d680f9e3c6f" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of assumptions and weighted averages used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated were:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Range:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated fair value of Cardiff Oncology common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ia632870d35b34e9dbf2630ee46469e33_D20200101-20200930" decimals="2" name="crdf:EstimatedFairValueOfWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfMy0xLTEtMS0wL3RleHRyZWdpb246MDVjYmFiN2ZkOTRhNDIyNjk4OTgwN2Y3YzZhMWE0YTBfNA_87340382-7880-42d5-9e85-39a02091b567">1.01</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i252b5a3294c7458b81a17c82715f2098_D20200101-20200930" decimals="2" name="crdf:EstimatedFairValueOfWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfMy0xLTEtMS0wL3RleHRyZWdpb246MDVjYmFiN2ZkOTRhNDIyNjk4OTgwN2Y3YzZhMWE0YTBfOQ_b3ab0677-f6d7-40a9-9f84-fb6a40d37cfd">14.19</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ib1791fb1fc4d4c5d9d1db0ecd2bdad61_D20190101-20190930" decimals="2" name="crdf:EstimatedFairValueOfWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfMy0zLTEtMS0wL3RleHRyZWdpb246MTdiYWNiMmQ3ZWU2NGRiMDhhNWJjZjVjY2MxNzI2MDNfNA_01dd34f5-c300-4765-8508-d88fdb9ee9e4">1.51</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i16ba3ca0f0224c749930d1fc21651e07_D20190101-20190930" decimals="2" name="crdf:EstimatedFairValueOfWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfMy0zLTEtMS0wL3RleHRyZWdpb246MTdiYWNiMmQ3ZWU2NGRiMDhhNWJjZjVjY2MxNzI2MDNfOQ_f4603d2a-13ea-4eaa-8ad9-b6670c979ed4">3.75</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected warrant term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i90efbe055b164d5c97f3d098c16522c7_I20200930" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNC0xLTEtMS0wL3RleHRyZWdpb246MDQ1NTNlMDg0NDkyNDM4MGFiNzVmYTc5YTQ3NjdjNGRfNA_b2367153-400b-4be2-aa67-b5fc983c006c">2.3</ix:nonNumeric> - <ix:nonNumeric contextRef="iad3f1104f4364db7ab0e9e5d2154e3b1_I20200930" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNC0xLTEtMS0wL3RleHRyZWdpb246MDQ1NTNlMDg0NDkyNDM4MGFiNzVmYTc5YTQ3NjdjNGRfOQ_d331ca13-00ce-45a9-9ef2-9f9285a0f165">3.1</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieef3ac4d1b1741f39df174c71b480929_I20190930" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNC0zLTEtMS0wL3RleHRyZWdpb246ZjI3Y2RhZjA3NmM3NGQ3YzkyY2FjODFjZTU1YTA5MDRfNA_118c05d9-4778-43fd-afe2-0b16558cfda0">3.3</ix:nonNumeric> - <ix:nonNumeric contextRef="id831883b118a48e387be55b132ff3344_I20190930" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNC0zLTEtMS0wL3RleHRyZWdpb246ZjI3Y2RhZjA3NmM3NGQ3YzkyY2FjODFjZTU1YTA5MDRfOQ_a72049ce-9301-4784-a525-ca6ab237a00c">4.1</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i048344a9062f4510a9cbff0eebd42e0b_I20200930" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNS0xLTEtMS0wL3RleHRyZWdpb246NWVjNGZlYjUzNmQ1NDBiNTg2MDdkM2Y4ZWNiNTMyY2FfNA_10b2983e-cf03-4822-94ed-5015b128d59d">0.14</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="i578319d576ac40ef82ce89b1e70413e3_I20200930" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNS0xLTEtMS0wL3RleHRyZWdpb246NWVjNGZlYjUzNmQ1NDBiNTg2MDdkM2Y4ZWNiNTMyY2FfOQ_4be43429-afa9-477a-a024-f94b41819669">1.62</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i30cf812ae8ab4b1fabcfb5a73eeb1c7d_I20190930" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNS0zLTEtMS0wL3RleHRyZWdpb246N2ViZDIwM2M5ZTljNGY5MmIyOGZlZDY0MjcxYTYxYjBfNA_6de43eba-47f6-4a03-b6d0-034a76308e3f">1.56</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="icfd53102430c43678b9eae10ab1d3201_I20190930" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNS0zLTEtMS0wL3RleHRyZWdpb246N2ViZDIwM2M5ZTljNGY5MmIyOGZlZDY0MjcxYTYxYjBfOQ_11ab9f62-152e-49f0-b610-b618205edcc9">2.49</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2ccfbfb002346579e7acceabf1ee362_I20200930" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNi0xLTEtMS0wL3RleHRyZWdpb246OGNiN2RiZjNjZTllNGMyMWEwNGQyZWQyOTBiMjc3YzhfNA_9b0be662-1860-41ab-bd68-bc0b1fdff78c">110</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="i344555a942b24c73861cf579aa6c6b32_I20200930" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNi0xLTEtMS0wL3RleHRyZWdpb246OGNiN2RiZjNjZTllNGMyMWEwNGQyZWQyOTBiMjc3YzhfOQ_995a5e05-3591-4717-9727-d1d2600c6714">118</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if89380272ed24b2cbde3226e6b36b53d_I20190930" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNi0zLTEtMS0wL3RleHRyZWdpb246NTFhOWZlYzk3YWI2NDlmMjhmZTFhZDE2ZGNiMTYxNTZfNA_bc28885c-cb2f-4f5c-84cb-d5cfce6ef086">102</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="id9154e610b334767a4b96b097661f34f_I20190930" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNi0zLTEtMS0wL3RleHRyZWdpb246NTFhOWZlYzk3YWI2NDlmMjhmZTFhZDE2ZGNiMTYxNTZfOQ_e443d7b7-ac6a-4a25-affe-ee8856820776">106</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i142d89ee985546c591160d9c6e366b3a_I20200930" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNy0xLTEtMS0w_d30ed84d-02b8-4d7f-aad7-e4e60808d36a">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6d4972e6afd4ac69b9a8f6a86fcc5fb_I20190331" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNy0zLTEtMS0w_29480b31-d298-449c-ae71-92e5d6836ef7">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Cardiff Oncology common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ifb6ee131f889432ba4524b13c5e5ca50_D20200101-20200930" decimals="2" name="crdf:EstimatedFairValueOfWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfMTEtMS0xLTEtMA_08c56c4c-a0a7-4793-84a0-d902341fd4a0">14.19</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected warrant term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i83ac99d4b3ff4e2fb15a26aced83a7a1_I20200930" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfMTItMS0xLTEtMA_e13fe102-5b90-4217-97e9-7c7935769c51">2.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if51ce0d70552424db9d6267694e4b4e3_I20200930" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfMTMtMS0xLTEtMA_cd8ef034-4110-4ed3-b9ff-3614c0e71c7c">0.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i412c95ab862b4b7aad07c1a3835d9cb8_I20200930" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfMTQtMS0xLTEtMA_dc4619b6-2035-466c-92f6-dc74c0a4fcf1">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic64a7bb878fa4c36bcfb2c9240e8fd4c_I20200930" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfMTUtMS0xLTEtMA_23399231-00f3-490f-ac58-3f98e7dd37b4">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Weighted average is only disclosed for periods after January 1, 2020 under the adoption of ASU 2018-13. </span></div></ix:nonNumeric><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i39b52804aadc4857b2bf7d680f9e3c6f">(2) The weighted average was calculated using the relative fair value method.</ix:continuation> </span></div></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><ix:continuation id="i9fa25f0b7b024e81a9994890bb114f8f"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility is based on historical volatility of Cardiff Oncology&#8217;s common stock.&#160;The warrants have a transferability provision and based on guidance provided in Staff Accounting Bulletin (&#8220;SAB&#8221;) No. 107, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;SAB No. 107&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for instruments issued with such a provision, Cardiff Oncology used the remaining contractual term as the expected term of the warrants.&#160;The risk-free rate is based on the U.S.&#160;Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="ib123867495f94547b6cb9b6106e13878_D20200101-20200930" name="crdf:ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RleHRyZWdpb246NTY3OTM0MzkxZDQzNDQ2YjliYzE5NDBlMGRjOGMyZWJfMTkyOQ_e64af923-0727-4322-b9dd-5a26483d62fa" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of changes in the Company&#8217;s derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative<br/>Instrument<br/>Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifcd94fffab0343acb682f8189e2a383b_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmIxZDI2MmQwZjQxZDQwYzZiMGUxNzQ4MTdjMmYwY2YyL3RhYmxlcmFuZ2U6YjFkMjYyZDBmNDFkNDBjNmIwZTE3NDgxN2MyZjBjZjJfMS00LTEtMS0w_5127655a-ff9e-4b59-8cc4-818e53ef6703">64,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd94fffab0343acb682f8189e2a383b_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmIxZDI2MmQwZjQxZDQwYzZiMGUxNzQ4MTdjMmYwY2YyL3RhYmxlcmFuZ2U6YjFkMjYyZDBmNDFkNDBjNmIwZTE3NDgxN2MyZjBjZjJfMS02LTEtMS0w_3951acdf-3665-4508-b05f-fb80d75091c1">4,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants during the period recognized as a loss in the condensed statements of operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f3906c2627e45ebbf6c1fd90f256031_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmIxZDI2MmQwZjQxZDQwYzZiMGUxNzQ4MTdjMmYwY2YyL3RhYmxlcmFuZ2U6YjFkMjYyZDBmNDFkNDBjNmIwZTE3NDgxN2MyZjBjZjJfMy02LTEtMS0w_72fb9abd-6318-4298-9e05-d5850cb2a394">186,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a725951ef874d2f949c21c129a5effc_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmIxZDI2MmQwZjQxZDQwYzZiMGUxNzQ4MTdjMmYwY2YyL3RhYmxlcmFuZ2U6YjFkMjYyZDBmNDFkNDBjNmIwZTE3NDgxN2MyZjBjZjJfNC00LTEtMS0w_df9b61dc-4129-43a9-b392-d8e9cb3dd4ef">64,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a725951ef874d2f949c21c129a5effc_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmIxZDI2MmQwZjQxZDQwYzZiMGUxNzQ4MTdjMmYwY2YyL3RhYmxlcmFuZ2U6YjFkMjYyZDBmNDFkNDBjNmIwZTE3NDgxN2MyZjBjZjJfNC02LTEtMS0w_65e0a884-bb6b-4bfc-893d-5374829cf86b">190,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i0ff27e3402fc47278eb8617e2a08b771_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;<ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTEwNTk_62a82b34-64e1-40ca-8637-4e37cfae63d3" continuedAt="i2ad12aaeb32d490984b3da7912b0abf2" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i2ad12aaeb32d490984b3da7912b0abf2" continuedAt="ia1e846728dea4f16a5e3377fbf23577f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTEwNTM_43919ad6-808a-4fad-a86e-98913b756742" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6b8b4cf5a542a297c33f23f0231c1b_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfMy0xLTEtMS0w_873a5a29-31a3-4c6b-a943-179c40271852">104,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b057edf8d344b4491e948f3e69dfbe2_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfMy0zLTEtMS0w_8e904f9f-67d2-4a92-83f7-d2dc75f7bf2d">104,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2deab4e6786544879aa966ac0a102502_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfMy01LTEtMS0w_efc33c57-bcd7-4456-95a1-84f977e444ab">251,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55f43f9e04394c4795b66f2466f5c7a4_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfMy03LTEtMS0w_0e603535-3dfb-4afb-b951-fc60a06fdf77">300,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iade2911f07fe4bd58a7771f4d8ff5609_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfNC0xLTEtMS0w_1136134f-4785-4273-80ce-cd09b1ed463a">257,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5631259573e042a39f4be4eceee56516_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfNC0zLTEtMS0w_c51cdfff-ad2d-4138-a41a-25b5c9863301">162,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87383483b52740ad89c088078af10f5e_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfNC01LTEtMS0w_fd18e313-5578-44ce-8f7c-62d443f76a13">569,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ecb4a9d6a954fab97ac2a9e46298476_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfNC03LTEtMS0w_8ebf5203-af04-4f28-9d9b-620bce66fb51">314,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfNy0xLTEtMS0w_a9710908-dd68-4124-b711-ba31e6aaf35e">361,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfNy0zLTEtMS0w_94eb8614-c9d2-4f4a-b0ec-e5e5fa77710a">266,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfNy01LTEtMS0w_a7cf48e3-3e6b-4632-ac8a-544c534df594">820,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfNy03LTEtMS0w_59d91162-df79-45b8-9c37-0cd47c3b0ec9">615,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized compensation cost related to non-vested stock options outstanding at September&#160;30, 2020 and 2019, net of estimated forfeitures, was $<ix:nonFraction unitRef="usd" contextRef="i959cddd1d9ca46a1ae94c9e574311f33_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMzEz_e1fda553-2ab2-4e11-832a-eed4887edeae">2,388,077</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i046408524fc84867a0e1a4a0d4d161cc_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMzIw_c49e7dd9-8383-429d-9b51-d3bd3320cb92">1,476,725</ix:nonFraction>, respectively, which is expected to be recognized over a weighted-average remaining vesting period of <ix:nonNumeric contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNDI1_025d0856-1803-4beb-a226-9b960e7160e9">2.2</ix:nonNumeric> and <ix:nonNumeric contextRef="ia8619936082e4b66a9d9afbba2b5f205_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNDMy_eff0284c-490e-4215-a548-450ae5d11b6f">2.4</ix:nonNumeric> years, respectively.&#160;The weighted-average remaining contractual term of outstanding options as of September&#160;30, 2020 was approximately <ix:nonNumeric contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNTQ4_1c40a17e-978a-448c-a56c-06f8f6bd2493">9.1</ix:nonNumeric> years. The total fair value of stock options vested during the nine months ended September 30, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNjIz_4d5efb58-db2f-43f6-9418-a25bd4092140">770,582</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNjMw_8c6946c6-8c4e-48a1-8b4a-d880426a008b">321,870</ix:nonFraction>, respectively.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTEwNTQ_59be20dd-6fc0-4d40-89e5-41b49dbb8b5d" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmY0YjNkZTM5YWZmYTRhYWZhZTQ1OGU4ZDhkZDRkZWJjL3RhYmxlcmFuZ2U6ZjRiM2RlMzlhZmZhNGFhZmFlNDU4ZThkOGRkNGRlYmNfMi0xLTEtMS0w_e72b81d1-383f-4c4b-8af3-66cc37fb02bb">0.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8619936082e4b66a9d9afbba2b5f205_D20190101-20190930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmY0YjNkZTM5YWZmYTRhYWZhZTQ1OGU4ZDhkZDRkZWJjL3RhYmxlcmFuZ2U6ZjRiM2RlMzlhZmZhNGFhZmFlNDU4ZThkOGRkNGRlYmNfMi0zLTEtMS0w_c86dfd50-1bf1-4990-b9eb-90e7e65f3292">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmY0YjNkZTM5YWZmYTRhYWZhZTQ1OGU4ZDhkZDRkZWJjL3RhYmxlcmFuZ2U6ZjRiM2RlMzlhZmZhNGFhZmFlNDU4ZThkOGRkNGRlYmNfMy0xLTEtMS0w_ddbb02c9-08ce-43a8-9685-ba0d1908dc3e">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8619936082e4b66a9d9afbba2b5f205_D20190101-20190930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmY0YjNkZTM5YWZmYTRhYWZhZTQ1OGU4ZDhkZDRkZWJjL3RhYmxlcmFuZ2U6ZjRiM2RlMzlhZmZhNGFhZmFlNDU4ZThkOGRkNGRlYmNfMy0zLTEtMS0w_a810b66f-1227-441b-95df-692bfaf84d1f">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmY0YjNkZTM5YWZmYTRhYWZhZTQ1OGU4ZDhkZDRkZWJjL3RhYmxlcmFuZ2U6ZjRiM2RlMzlhZmZhNGFhZmFlNDU4ZThkOGRkNGRlYmNfNC0xLTEtMS0w_0e5af2e8-5617-4b4d-b35b-01abada33b01">104.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8619936082e4b66a9d9afbba2b5f205_D20190101-20190930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmY0YjNkZTM5YWZmYTRhYWZhZTQ1OGU4ZDhkZDRkZWJjL3RhYmxlcmFuZ2U6ZjRiM2RlMzlhZmZhNGFhZmFlNDU4ZThkOGRkNGRlYmNfNC0zLTEtMS0w_80d9d422-0c0d-4a45-b75d-85eeda01ea30">95.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmY0YjNkZTM5YWZmYTRhYWZhZTQ1OGU4ZDhkZDRkZWJjL3RhYmxlcmFuZ2U6ZjRiM2RlMzlhZmZhNGFhZmFlNDU4ZThkOGRkNGRlYmNfNS0xLTEtMS0w_b7a6329a-86fd-41e1-914b-2c7986f2d517">5.9</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia8619936082e4b66a9d9afbba2b5f205_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmY0YjNkZTM5YWZmYTRhYWZhZTQ1OGU4ZDhkZDRkZWJjL3RhYmxlcmFuZ2U6ZjRiM2RlMzlhZmZhNGFhZmFlNDU4ZThkOGRkNGRlYmNfNS0zLTEtMS0w_d6822633-faf2-44cb-9a5e-e86a77c933eb">5.9</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><ix:continuation id="ia1e846728dea4f16a5e3377fbf23577f" continuedAt="if11fc47fda1a4b6f8c2b3bef2507fc46"><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTEwNDI_87302131-d4ff-477b-b7fb-f416f77729bf" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity and changes in stock options outstanding is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida9ccce01325454aa5cdd8a070b92b32_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfMS0xLTEtMS0w_7d0d4a14-9801-408f-a082-1040fbe13cab">1,015,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ida9ccce01325454aa5cdd8a070b92b32_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfMS0zLTEtMS0w_be2244f2-d6f2-48fe-99e2-dbbb2617d12c">12.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida9ccce01325454aa5cdd8a070b92b32_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfMS01LTEtMS0w_60085a8f-406e-42ee-ab77-8ddbaee30a2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfMi0xLTEtMS0w_dc95671e-89ee-4915-9b84-061c46bff21a">969,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfMi0zLTEtMS0w_83b9355a-40f1-405b-90fd-002656da7079">2.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfMy0xLTEtMS0w_a489a29b-af4d-4fe7-b9a2-479d94862959">3,333</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfMy0zLTEtMS0w_c34c079a-77c8-4276-ad8e-07454cef0742">2.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled / Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfNC0xLTEtMS0w_01b2511f-b98e-4ef0-a892-7e431ef0f79a">46,069</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfNC0zLTEtMS0w_75c6e98b-6b90-4209-8c2c-6f1268e0767f">12.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="crdf:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfNS0xLTEtMS0w_06baa9c9-154e-43b7-b4b4-14c44a18fa8e">15,275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930" decimals="2" name="crdf:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfNS0zLTEtMS0w_328c6b4d-35af-4a73-af9f-da2a64cdc02f">8.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i959cddd1d9ca46a1ae94c9e574311f33_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfNi0xLTEtMS0w_14dcb721-5164-463e-9cd3-4d3e50b5f308">1,920,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i959cddd1d9ca46a1ae94c9e574311f33_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfNi0zLTEtMS0w_8218039c-dad1-4680-b547-0225a7a60d2f">7.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959cddd1d9ca46a1ae94c9e574311f33_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfNi01LTEtMS0w_4fa88497-ac84-4588-ae6d-52a9abbf1f36">21,766,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i959cddd1d9ca46a1ae94c9e574311f33_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfNy0xLTEtMS0w_cbbe4dc4-21c8-4de6-9740-05009c8ef90e">441,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i959cddd1d9ca46a1ae94c9e574311f33_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfNy0zLTEtMS0w_d0f755da-bc3e-4749-befb-c10136830522">24.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959cddd1d9ca46a1ae94c9e574311f33_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfNy01LTEtMS0w_0b856f1e-b133-4ed1-99b3-7a9dacb4c07b">4,507,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2019, the number of authorized shares in the Cardiff Oncology 2014 Equity Incentive Plan (&#8220;2014 EIP&#8221;) was increased from <ix:nonFraction unitRef="shares" contextRef="i892b1dd1549d490f9a6e0de63da8493e_I20190605" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTEwOA_66dc708a-5178-445e-a631-83d3ceb12a3c">243,056</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="ibcaf805475824b1c97f6e483866ff34f_I20190606" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTExNA_c71d5fb1-507b-4a6f-9644-2305f2c70fed">1,243,056</ix:nonFraction>. On April 16, 2020 the 2014 EIP was amended to increase the number of shares of common stock reserved for issuance thereunder to <ix:nonFraction unitRef="shares" contextRef="i8a5cf127866f4450ba5177b5b209e29e_I20200415" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTI0Ng_fbfb3867-26e6-49a0-997a-32e9b8883770">2,243,056</ix:nonFraction> from <ix:nonFraction unitRef="shares" contextRef="iabec5ed6104d47f69e84008a3df403c9_I20200416" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTI1NA_2a1ccfd6-9975-464a-901e-363f5118f139">1,243,056</ix:nonFraction>. As of September&#160;30, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i972ffd28b08d461a8a8f34ee29c25c72_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTI3OQ_b21abced-fe02-4ed9-b458-7f60f2e36ae8">258,497</ix:nonFraction> shares available for issuance under the 2014 EIP.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTEwNjE_2ea323bb-ff66-48ee-a19f-a6ce31590386" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU activity is presented below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair Value<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0736ee7158d4ee1952c5ed8ecafc35d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmQyN2E1MmFhMjg3ZDQzOTU4ZmFjYjRmNmY2NmRjNjA1L3RhYmxlcmFuZ2U6ZDI3YTUyYWEyODdkNDM5NThmYWNiNGY2ZjY2ZGM2MDVfMS0xLTEtMS0w_e6bf886e-4c2b-4797-8e3f-785dff783f18">11,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia0736ee7158d4ee1952c5ed8ecafc35d_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmQyN2E1MmFhMjg3ZDQzOTU4ZmFjYjRmNmY2NmRjNjA1L3RhYmxlcmFuZ2U6ZDI3YTUyYWEyODdkNDM5NThmYWNiNGY2ZjY2ZGM2MDVfMS0zLTEtMS0w_1885a1e7-848a-4943-b1fd-ca8374991474">15.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0736ee7158d4ee1952c5ed8ecafc35d_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmQyN2E1MmFhMjg3ZDQzOTU4ZmFjYjRmNmY2NmRjNjA1L3RhYmxlcmFuZ2U6ZDI3YTUyYWEyODdkNDM5NThmYWNiNGY2ZjY2ZGM2MDVfMS01LTEtMS0w_768ece1f-e575-41e4-9f91-104f65768fca">14,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia8e40e0994bb469c98f27ccf0cf198f8_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmQyN2E1MmFhMjg3ZDQzOTU4ZmFjYjRmNmY2NmRjNjA1L3RhYmxlcmFuZ2U6ZDI3YTUyYWEyODdkNDM5NThmYWNiNGY2ZjY2ZGM2MDVfMy0xLTEtMS0w_60bc90c1-5084-4e3e-b421-069a0695b32d">10,310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia8e40e0994bb469c98f27ccf0cf198f8_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmQyN2E1MmFhMjg3ZDQzOTU4ZmFjYjRmNmY2NmRjNjA1L3RhYmxlcmFuZ2U6ZDI3YTUyYWEyODdkNDM5NThmYWNiNGY2ZjY2ZGM2MDVfMy0zLTEtMS0w_8949d327-3ea8-4359-ba36-5f7dee91a608">9.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e40e0994bb469c98f27ccf0cf198f8_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmQyN2E1MmFhMjg3ZDQzOTU4ZmFjYjRmNmY2NmRjNjA1L3RhYmxlcmFuZ2U6ZDI3YTUyYWEyODdkNDM5NThmYWNiNGY2ZjY2ZGM2MDVfMy01LTEtMS0w_2c69b443-e40f-4ace-8105-b8fc61848d84">22,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding, September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd88fd532f594f72a9d627dfe035ac48_I20200930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmQyN2E1MmFhMjg3ZDQzOTU4ZmFjYjRmNmY2NmRjNjA1L3RhYmxlcmFuZ2U6ZDI3YTUyYWEyODdkNDM5NThmYWNiNGY2ZjY2ZGM2MDVfNS0xLTEtMS0w_c28e4f63-ed2a-4f2b-9b76-28c0582a26d9">991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd88fd532f594f72a9d627dfe035ac48_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmQyN2E1MmFhMjg3ZDQzOTU4ZmFjYjRmNmY2NmRjNjA1L3RhYmxlcmFuZ2U6ZDI3YTUyYWEyODdkNDM5NThmYWNiNGY2ZjY2ZGM2MDVfNS0zLTEtMS0w_3fad2aec-91ab-4bb7-b407-1b06f86e01ef">73.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd88fd532f594f72a9d627dfe035ac48_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmQyN2E1MmFhMjg3ZDQzOTU4ZmFjYjRmNmY2NmRjNjA1L3RhYmxlcmFuZ2U6ZDI3YTUyYWEyODdkNDM5NThmYWNiNGY2ZjY2ZGM2MDVfNS01LTEtMS0w_47ffd7f8-84bc-4385-8d63-52c0064ef63c">14,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of vested RSUs during the nine months ended September 30, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="ia8e40e0994bb469c98f27ccf0cf198f8_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTQ3Mw_ab18b0e4-0926-4897-aadc-b8b0edaa2caa">100,585</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i57c92be504a54fbda158b82418700c3b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTQ4MA_649b8ad3-19a5-459e-afa3-3969fdef2d76">169,563</ix:nonFraction>, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTEwNDM_2214372c-d929-4466-a7e5-3d0e72398869" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining&#160;Contractual<br/>Term</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmZlYWRkY2RmNWMwZTQ3MjZhNDIwNjJjYTczMjFkZmM0L3RhYmxlcmFuZ2U6ZmVhZGRjZGY1YzBlNDcyNmE0MjA2MmNhNzMyMWRmYzRfMS0xLTEtMS0w_b9cbfae0-537d-4f8d-9c95-cd27b4d44a69">10,589,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231" decimals="2" name="crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmZlYWRkY2RmNWMwZTQ3MjZhNDIwNjJjYTczMjFkZmM0L3RhYmxlcmFuZ2U6ZmVhZGRjZGY1YzBlNDcyNmE0MjA2MmNhNzMyMWRmYzRfMS0zLTEtMS0w_618c7ab2-47c4-4834-98e1-e663946b5b8d">4.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i85c6c9f6f5d545a68d3ccd6f9971a221_D20200101-20200630" format="ixt-sec:duryear" name="crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmZlYWRkY2RmNWMwZTQ3MjZhNDIwNjJjYTczMjFkZmM0L3RhYmxlcmFuZ2U6ZmVhZGRjZGY1YzBlNDcyNmE0MjA2MmNhNzMyMWRmYzRfMS01LTEtMS0w_8306cd3c-fefa-4558-868c-c36b85fae8ba">3.7</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="crdf:ClassOfWarrantOrRightNumberGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmZlYWRkY2RmNWMwZTQ3MjZhNDIwNjJjYTczMjFkZmM0L3RhYmxlcmFuZ2U6ZmVhZGRjZGY1YzBlNDcyNmE0MjA2MmNhNzMyMWRmYzRfMi0xLTEtMS0w_08d9ca0f-e6d0-4f10-9bf5-0935c597b265">5,831,451</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="2" name="crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmZlYWRkY2RmNWMwZTQ3MjZhNDIwNjJjYTczMjFkZmM0L3RhYmxlcmFuZ2U6ZmVhZGRjZGY1YzBlNDcyNmE0MjA2MmNhNzMyMWRmYzRfMi0zLTEtMS0w_9f86ba2c-3680-478e-9dbd-2284675b9bc6">1.70</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="crdf:ClassOfWarrantOrRightNumberExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmZlYWRkY2RmNWMwZTQ3MjZhNDIwNjJjYTczMjFkZmM0L3RhYmxlcmFuZ2U6ZmVhZGRjZGY1YzBlNDcyNmE0MjA2MmNhNzMyMWRmYzRfMy0xLTEtMS0w_71fa03dc-d2b2-4282-bdc7-189ed95e9a0b">9,047,582</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" decimals="2" name="crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmZlYWRkY2RmNWMwZTQ3MjZhNDIwNjJjYTczMjFkZmM0L3RhYmxlcmFuZ2U6ZmVhZGRjZGY1YzBlNDcyNmE0MjA2MmNhNzMyMWRmYzRfMy0zLTEtMS0w_8fb76398-ca36-40c1-891b-40d03e543715">2.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, September 30, 2020</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmZlYWRkY2RmNWMwZTQ3MjZhNDIwNjJjYTczMjFkZmM0L3RhYmxlcmFuZ2U6ZmVhZGRjZGY1YzBlNDcyNmE0MjA2MmNhNzMyMWRmYzRfNS0xLTEtMS0w_f66461de-cff6-491e-be8a-c805fb76e73e">7,373,351</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if99a8ed180cc459681d3588755b7784f_I20200930" decimals="2" name="crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmZlYWRkY2RmNWMwZTQ3MjZhNDIwNjJjYTczMjFkZmM0L3RhYmxlcmFuZ2U6ZmVhZGRjZGY1YzBlNDcyNmE0MjA2MmNhNzMyMWRmYzRfNS0zLTEtMS0w_b06e4aae-46d2-4f06-8dc8-c3287564c969">4.54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" format="ixt-sec:duryear" name="crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmZlYWRkY2RmNWMwZTQ3MjZhNDIwNjJjYTczMjFkZmM0L3RhYmxlcmFuZ2U6ZmVhZGRjZGY1YzBlNDcyNmE0MjA2MmNhNzMyMWRmYzRfNS01LTEtMS0w_a520dec6-1e9c-4d27-b9b6-221742b1c863">4.3</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluded from the table above are <ix:nonFraction unitRef="shares" contextRef="i7b1f3d6a8b304f008d1560110f698bb3_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="crdf:ClassOfWarrantOrRightNumberGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTA5OTUxMTYzOTU5OQ_cd33678e-ccc3-4185-958a-696fbd748bd6">992,039</ix:nonFraction> pre-funded warrants that were exercised during the nine months ended September 30, 2020. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><ix:continuation id="if11fc47fda1a4b6f8c2b3bef2507fc46" continuedAt="i94867149c5804ab4bac917fa25927548"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTEwNDQ_d89b9293-3888-4ae8-b18d-81065285e1ea" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our Company's classes of preferred stock is presented below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares designated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation preference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idea78c0fd4d44a8084b8b53c668496d2_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfMi0yLTEtMS0w_6246cb37-cb4b-46de-b926-b21d4126dd88">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idea78c0fd4d44a8084b8b53c668496d2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfMi00LTEtMS0w_81c055a5-a9e4-4bef-926e-039b090f48be">277,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea78c0fd4d44a8084b8b53c668496d2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockLiquidationPreferenceValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfMi02LTEtMS0w_406ea6ba-db7d-47fd-aa3f-4693e04ef7e6">606,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idea78c0fd4d44a8084b8b53c668496d2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfMi04LTEtMS0w_2c21cf65-f952-4a92-b51b-a77d126cd1cd">60,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i488747dd585c416195aa8719cfb75a37_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfMi0xMC0xLTEtMA_65eb5189-2c6d-4bef-a2a4-e3fa834ae12e">60,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia99ee4a1746f4fe4ab0a83e29d9ebce8_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfMy0yLTEtMS0w_5933240e-3c8f-4cb3-ae7a-f501ce2094f1">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia99ee4a1746f4fe4ab0a83e29d9ebce8_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfMy00LTEtMS0w_0c541f25-3a53-483b-80e7-112d24347be4">8,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia99ee4a1746f4fe4ab0a83e29d9ebce8_I20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfMy04LTEtMS0w_b9ed4145-130f-4d39-a2e4-600ce337cdcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie25dc1818267487abf4d33e2c6debe5c_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfMy0xMC0xLTEtMA_a82fcd87-6a9f-43d8-9db8-7bea89c83141">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6788da5ccc444936ac79910ced50285e_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNC0yLTEtMS0w_cc534e83-4ded-471b-a9a8-23ac315a74ab">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6788da5ccc444936ac79910ced50285e_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNC00LTEtMS0w_3d4837bc-c5b7-41eb-af66-b57006220a92">200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6788da5ccc444936ac79910ced50285e_I20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNC04LTEtMS0w_e1a865fd-aa6e-4927-ba59-5d15739d871c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2758eaad8b58491c9ca8fda860044695_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNC0xMC0xLTEtMA_af34e056-58c8-45e1-9402-f7babd19bafc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6045af669a3745cd84ac6c08b964f8db_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNS0yLTEtMS0w_a166201c-0452-4f26-be15-95545160e7e7">0.0001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6045af669a3745cd84ac6c08b964f8db_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNS00LTEtMS0w_e6b0328b-b614-479c-9bcb-ce91e67e466b">154,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6045af669a3745cd84ac6c08b964f8db_I20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNS04LTEtMS0w_2559eed5-fda6-48e3-9027-0fa1a9dddcf5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87e30ab734dd4d1c81c49063fddfc61c_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNS0xMC0xLTEtMA_ad8d3acf-8f64-44a1-964b-4591bc72fc64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i89e52a934cce4337b884a4e1340a6e33_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNi0yLTEtMS0w_de020208-eb89-49c3-8213-c7e7f9ffe55d">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89e52a934cce4337b884a4e1340a6e33_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNi00LTEtMS0w_db55a1bb-218a-4fed-b3a8-ec29140d2741">865,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89e52a934cce4337b884a4e1340a6e33_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNi04LTEtMS0w_1adea359-74df-40b2-86cf-ab467970ea02">865,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a73b848ad3a456ab8efe3f435c2cc17_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNi0xMC0xLTEtMA_9b265408-dc04-4f06-a820-4aafaac2429e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series C Convertible Preferred Stock and Service Receivable</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2019, the Company entered into a Master Services Agreement and a Stock and Warrant Subscription Agreement with PoC Capital, LLC (&#8220;PoC&#8221;), whereby PoC agreed to finance $<ix:nonFraction unitRef="usd" contextRef="i5dd384648729485e814847bb936c3e19_D20190125-20190125" decimals="-3" format="ixt:numdotdecimal" name="crdf:AmountFinancedUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTk5NA_05a277b1-0b56-44e2-b845-87e57fb7c2da">1.675</ix:nonFraction> million for the development costs associated with Phase 1b/2 study of onvansertib in combination with FOLFIRI and Avastin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with metastatic Colorectal Cancer (&#8220;mCRC&#8221;) harboring KRAS mutation in exchange for (i)<ix:nonFraction unitRef="shares" contextRef="i42c394bde6f545e8b27bd5ddd62298f4_D20190125-20190125" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMjIxMA_7a92d446-c696-4df0-8003-fbaa158e6edc">183,334</ix:nonFraction> shares of common stock, (ii) warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i5dd384648729485e814847bb936c3e19_D20190125-20190125" decimals="INF" format="ixt:numdotdecimal" name="crdf:ClassOfWarrantOrRightNumberGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMjI3OQ_3c6a188b-e6f6-4945-91a2-24b29cd809bb">150,000</ix:nonFraction> shares of common stock, with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6306bd3082c44e75b9d4bb83e91ac1d5_I20190125" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMjMzMg_10efd2ef-6102-4e01-a416-69f6f8a87bd9">3.762</ix:nonFraction> per share, expiring on January 25, 2024, and (iii) <ix:nonFraction unitRef="shares" contextRef="i9473042322684048b0e1c330a634200d_D20190125-20190125" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMjM4Ng_a0a60c80-1fa3-4a6b-88f1-5c3ec3e047b6">200,000</ix:nonFraction> shares of Series C Convertible Preferred Stock, each share of which was convertible into <ix:nonFraction unitRef="shares" contextRef="if90d90503a6a456396e7a7c6dd952122_I20190125" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMjQ3OA_7419681d-4bb2-4c36-938f-abc2a09758c6">1.67</ix:nonFraction> shares of common stock. In April of 2019, all <ix:nonFraction unitRef="shares" contextRef="i39ceaeb412fa40d2948c4049aa876acc_D20190401-20190430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMjUyNw_240cba9b-01d0-4b32-bf90-cf72507f03f9">200,000</ix:nonFraction> shares of Series C Convertible Preferred Stock were converted into <ix:nonFraction unitRef="shares" contextRef="ica50461d886a437e9c053eb1e77b24bf_D20190401-20190430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMjU5Nw_b4f4c179-7735-4aed-be58-89b3c25eb0ff">333,333</ix:nonFraction> shares of the Company's common stock.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the awards issued under this transaction and determined they should be classified as equity. These equity awards were fully vested and non-forfeitable. Since the equity awards were for clinical trial services yet to be provided, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i1e9dce01464f42658cfd49145c156296_I20190125" decimals="-3" format="ixt:numdotdecimal" name="crdf:Servicereceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMjk5Nw_64950b96-4288-488a-942b-4ec86d616252">1.675</ix:nonFraction> million service receivables as contra equity. The Company releases the service receivables as clinical trial services are performed. The conversion feature of the Series C Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series C Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $<ix:nonFraction unitRef="usd" contextRef="ic492c1a7e6d541e3879728394630480b_D20190125-20190125" decimals="-5" format="ixt:numdotdecimal" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMzQ4NQ_8b984d6c-e634-44e8-9934-d2a213c765fc">0.3</ix:nonFraction> million related to the beneficial conversion feature arising from the issuance of Series C Convertible Preferred Stock. This non-cash deemed dividend increased the Company&#8217;s net loss attributable to common stockholders and net loss per share.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series D Convertible Preferred Stock and Service Receivable</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 8, 2020, the Company entered into a Stock and Warrant Subscription Agreement with PoC, whereby PoC agreed to finance an additional $<ix:nonFraction unitRef="usd" contextRef="i802925f6b20a4ab883a3e64399b2625e_D20200508-20200508" decimals="-5" format="ixt:numdotdecimal" name="crdf:AmountFinancedUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMzkyMw_5a52bccc-d8ff-47ea-b02d-94d11552a219">2.3</ix:nonFraction> million for a clinical trial in exchange for (i) <ix:nonFraction unitRef="shares" contextRef="iafcaa2b479f245d0bd1d92340c68caa8_D20200508-20200508" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMzk2Nw_f0e0808b-0798-497f-a012-310a883ca02a">602,833</ix:nonFraction> shares of its common stock (the &#8220;Common Stock&#8221;), (ii) <ix:nonFraction unitRef="shares" contextRef="i76014c469f9d4b79ad388b4bd5ef655f_D20200508-20200508" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNDAyNA_71c4f2d0-468f-4130-8624-dbb1a8b8154f">154,670</ix:nonFraction> shares of its Series D Preferred Stock (as defined below) and (iii) a warrant exercisable for <ix:nonFraction unitRef="shares" contextRef="i237b058632024beea09d8f721dc6c2fb_I20200508" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNDEzNw_05de494a-c7e2-4ffc-97b3-0516671171ae">859,813</ix:nonFraction> shares of its Common Stock. In exchange, PoC is funding our clinical development of onvansertib in metastatic colorectal cancer pursuant to a Master Services Agreement dated as of January 25, 2019 by and among the Company, Integrium, LLC and PoC, as amended. The warrant will be exercisable six months following the date of issuance at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i237b058632024beea09d8f721dc6c2fb_I20200508" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNDYzNQ_143712c8-1cb1-425f-bd81-ed0bd06b0616">1.50</ix:nonFraction> per share and will expire on November 7, 2025. In June of 2020, all <ix:nonFraction unitRef="shares" contextRef="if6bd6d0b8e894e96b013f0f9d4a47eb5_D20200601-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNDcwNg_b63da646-ab49-4ce9-ae9d-71220ad24cae">154,670</ix:nonFraction> Series D Preferred Stock were converted to <ix:nonFraction unitRef="shares" contextRef="i4fa6df7a14994c2f9f5cf33cda5a8363_D20200601-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNDc1Mg_8bc6ed3f-87f1-40fe-b2f2-1f4f5ebd9a7b">1,546,700</ix:nonFraction> shares of Common Stock. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the awards issued under this transaction and determined they should be classified as equity. These equity awards were fully vested and non-forfeitable. Since the equity awards were for clinical trial services yet to be provided, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i0134e1c7efdb4726b66acda8a7eadf9b_I20200508" decimals="-5" format="ixt:numdotdecimal" name="crdf:Servicereceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNTEzOA_a8be1a77-3c26-4d4e-a454-8d02f37a63ef">2.3</ix:nonFraction>&#160;million service receivables as contra equity. The Company releases the service receivables as clinical trial services are performed. The conversion feature of the Series D Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series D Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $<ix:nonFraction unitRef="usd" contextRef="i6b91e6f08a864448b74ef428e982d96b_D20200508-20200508" decimals="-5" format="ixt:numdotdecimal" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNTYyNg_88e8c82b-40b6-469c-afe1-d6330373ea67">0.6</ix:nonFraction>&#160;million related to the beneficial conversion feature arising from the issuance of Series D Convertible Preferred Stock. This non-cash deemed dividend increased the Company&#8217;s net loss attributable to common stockholders and net loss per share.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:continuation id="i94867149c5804ab4bac917fa25927548" continuedAt="ie02bfefbe2c341a981331f8e09426904"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series E Convertible Preferred Stock</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2020 the Company entered into a Securities Purchase Agreement with Acorn Bioventures LP ("Acorn"), CDK Associates, L.L.C. (&#8220;CDK&#8221;) and Third Street Holdings LLC (&#8220;Third Street&#8221;), pursuant to which the Company agreed to offer, issue and sell to Acorn, CDK and Third Street, (i) in a registered direct offering, an aggregate of <ix:nonFraction unitRef="shares" contextRef="ie5c36764fe274b08925b71b22a4d62aa_D20200615-20200615" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNjI2Mw_ff9e74be-f316-4203-8bea-ccd120f255c5">1,984,328</ix:nonFraction> shares of common stock and (ii) in a concurrent private placement, (a) an aggregate of <ix:nonFraction unitRef="shares" contextRef="i4c6e0349b8984c0c91135effa1fe723b_D20200615-20200615" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNjM1Mw_cd820b52-8ec1-439f-92d2-1663fffbb63d">865,824</ix:nonFraction> shares of Series E Preferred Stock (&#8220;Series E Preferred Stock&#8221;) and (b) Series N warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i1f789e5648a44a9ebd4b303e67d1385f_I20200615" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNjQ2NA_a4c78e1b-230a-4ab7-8b90-d7177195a270">2,213,115</ix:nonFraction> shares of Common Stock. The Series E Preferred Stock is convertible at any time determined by dividing the $<ix:nonFraction unitRef="usdPerShare" contextRef="if1ab4f2aeab147b0810f2c0e9bca7283_I20200615" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNjU3NA_a2ad3f7a-fb74-4a4c-a744-aa91f4468421">10</ix:nonFraction> stated value per share of the Series E Preferred Stock by a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if1ab4f2aeab147b0810f2c0e9bca7283_I20200615" decimals="INF" name="crdf:PreferredStockConvertibleConversionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNjY1Nw_6dbd570d-4c2c-43b6-9af7-27e3759d171b">2.44</ix:nonFraction> per share, subject to adjustment in accordance with the Certificate of Designation. The Series N Warrants will be exercisable <ix:nonNumeric contextRef="i5e16f37428d6480ca95ace2934d30b33_D20200615-20200615" format="ixt-sec:durwordsen" name="crdf:ClassOfWarrantOrRightMonthsUntilExercisable" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNjc4Ng_592ff86e-9dc8-43fd-a115-ae61f25bd953">six months</ix:nonNumeric> following the date of issuance at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8f44ab1b15204ed1b2aa74e76adaa3eb_I20200615" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNjg0NA_eb1170e9-ce39-4342-b6b4-1a84d5ab1a01">2.39</ix:nonFraction> per share and will expire on December 16, 2025. As of September&#160;30, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i89e52a934cce4337b884a4e1340a6e33_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNjkxNg_112280e6-abf1-47b4-9134-f3850069fc93">865,824</ix:nonFraction> shares of Series E Convertible Preferred Stock outstanding.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion feature of the Series E Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series E Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $<ix:nonFraction unitRef="usd" contextRef="i3a1b1259103d4e9aae05e28f31feec2a_D20200615-20200615" decimals="-5" format="ixt:numdotdecimal" name="crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNzM0MA_58eb30d8-b478-48fd-afd3-2dc8bbd0cd5f">2.7</ix:nonFraction>&#160;million related to the beneficial conversion feature arising from the issuance of Series E Convertible Preferred Stock. This non-cash deemed dividend increased the Company&#8217;s net loss attributable to common stockholders and net loss per share.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In conjunction with the June 15, 2020 offering, we issued <ix:nonFraction unitRef="shares" contextRef="i1f789e5648a44a9ebd4b303e67d1385f_I20200615" decimals="INF" format="ixt:numdotdecimal" name="crdf:ClassOfWarrantOrRightIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNzYzNw_b00edf90-1bd1-41f3-a4dc-f5560896b3be">184,426</ix:nonFraction> warrants as an advisory fee. These warrants are exercisable <ix:nonNumeric contextRef="i3a1b1259103d4e9aae05e28f31feec2a_D20200615-20200615" format="ixt-sec:durwordsen" name="crdf:ClassOfWarrantOrRightMonthsUntilExercisable" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNzcwMA_fcedde50-54ac-4ee1-a397-a28ea94588f4">six months</ix:nonNumeric> following the date of issuance at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1f789e5648a44a9ebd4b303e67d1385f_I20200615" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNzc1OA_5793c808-64c8-4104-910a-ddaa4f015810">3.05</ix:nonFraction> per share and will expire <ix:nonNumeric contextRef="i3a1b1259103d4e9aae05e28f31feec2a_D20200615-20200615" format="ixt-sec:duryear" name="crdf:ClassOfWarrantOrRightExpirationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNzc4Nw_d1d4e087-3b48-491d-bf34-23ed15d8cd81">5.5</ix:nonNumeric> years following the date of issuance. These warrants are classified as equity and its estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="i3a1b1259103d4e9aae05e28f31feec2a_D20200615-20200615" decimals="0" format="ixt:numdotdecimal" name="crdf:WarrantsFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNzg5NA_3f9509e6-fee3-4a9d-ae20-7564eea846a1">370,666</ix:nonFraction> was recognized as additional paid in capital on the issuance date. The estimated fair value is determined using the Black-Scholes Option Pricing Model which is based on the value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Purchase Agreements with Lincoln Park Capital Fund, LLC</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 30, 2020, the Company entered into a Securities Purchase Agreement with Lincoln Park Capital Fund, LLC (&#8220;LPC&#8221;), pursuant to which the Company agreed to offer, issue and sell to LPC, (i) in a registered direct offering, an aggregate of (a) <ix:nonFraction unitRef="shares" contextRef="ib02c4909f8dd4c1390ce2b2d6f67d719_D20200330-20200330" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfODYyMA_731784b3-58de-45e4-bedf-cc790b227311">800,000</ix:nonFraction> shares of common stock and (b) Series I warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i5ec1ce35bd704b2a8bec37b6d629c0a9_I20200330" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfODY5MA_dd2346af-0651-493d-b2c9-48ca3ea02455">131,967</ix:nonFraction> shares (the &#8220;Series I Warrant Shares&#8221;) of  common stock. In a concurrent private placement, the Company also sold to LPC Series J warrants (the &#8220;Series J Warrants&#8221;) to purchase <ix:nonFraction unitRef="shares" contextRef="ifba3ba46775046ecb40386b74aace6e0_I20200330" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfODg3MA_f15527df-b3a8-4dee-a375-1b40a538702f">one</ix:nonFraction> share of common stock for each Share and for each Series I Warrant purchased for cash in the registered direct offering. The Series J Warrants are exercisable <ix:nonNumeric contextRef="i974ceaa146934ff9a98da6f12360fc49_D20200330-20200330" format="ixt-sec:durwordsen" name="crdf:ClassOfWarrantOrRightMonthsUntilExercisable" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTAzMg_b174b68c-58ff-4552-b808-02139805da56">six months</ix:nonNumeric> following the date of issuance at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifba3ba46775046ecb40386b74aace6e0_I20200330" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTA5MA_d83fbde5-6e56-4d09-85f9-8b0618f67de0">0.948</ix:nonFraction> per share and will expire <ix:nonNumeric contextRef="i974ceaa146934ff9a98da6f12360fc49_D20200330-20200330" format="ixt-sec:duryear" name="crdf:ClassOfWarrantOrRightExpirationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTExOQ_887f8371-b829-44db-9329-43d2be1ca753">5.5</ix:nonNumeric> years following the date of issuance. The gross proceeds from this purchase were $<ix:nonFraction unitRef="usd" contextRef="ib02c4909f8dd4c1390ce2b2d6f67d719_D20200330-20200330" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTE5Nw_9631f665-bab9-4219-8010-30e1ae6a78af">1.0</ix:nonFraction>&#160;million.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 9, 2020, the Company entered into a Securities Purchase Agreement with LPC, pursuant to which the Company agreed to offer, issue and sell to LPC, (i) in a registered direct offering, an aggregate of (a) <ix:nonFraction unitRef="shares" contextRef="ieef62941a8724a6eb7609cc6f162b59d_D20200409-20200409" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTQxNg_ba4e8438-992e-478c-ab30-d3a9ecc447f6">904,970</ix:nonFraction> shares of common stock and (b) Series K warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="ibfd5397c17484e7d996cff5cd20825d2_I20200409" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTQ4Ng_607036b4-14d7-4188-adde-1524036ac95c">255,000</ix:nonFraction> shares (the &#8220;Series K Warrant Shares&#8221;) of common stock. In a concurrent private placement, the Company also sold to LPC Series L warrants (the &#8220;Series L Warrants&#8221;) to purchase <ix:nonFraction unitRef="shares" contextRef="i97c8fab924224323b855bff2be4699fb_I20200409" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTY2NQ_32ab74df-f4cd-4d81-81d2-5c7f662eebaa">one</ix:nonFraction> share of Common Stock for each Share and for each Series K Warrant purchased for cash in the registered direct offering. The Series L Warrants are exercisable <ix:nonNumeric contextRef="i6178fac3fa4f4c6e91065959e9e43ff8_D20200409-20200409" format="ixt-sec:durwordsen" name="crdf:ClassOfWarrantOrRightMonthsUntilExercisable" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTgyNw_ce363bd7-7fbb-429e-9be0-4e9ad34381b8">six months</ix:nonNumeric> following the date of issuance at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i97c8fab924224323b855bff2be4699fb_I20200409" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTg4NQ_755042bf-7ba1-463b-893f-564c29074740">0.81</ix:nonFraction> per share and will expire <ix:nonNumeric contextRef="i6178fac3fa4f4c6e91065959e9e43ff8_D20200409-20200409" format="ixt-sec:duryear" name="crdf:ClassOfWarrantOrRightExpirationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTkxNA_cb86c7a8-7b9b-4d87-9fc2-a6280865cb30">5.5</ix:nonNumeric> years following the date of issuance. The gross proceeds from this purchase were $<ix:nonFraction unitRef="usd" contextRef="ieef62941a8724a6eb7609cc6f162b59d_D20200409-20200409" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTk5Mg_7808de89-d6f3-4c9a-94d4-200e0fd8c3e8">1.1</ix:nonFraction>&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Purchase Agreement With Certain Directors and Executives</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 11, 2020 and May 14, 2020, the Company entered into Securities Purchase Agreements with certain directors and executives of the Company pursuant to which the Company sold <ix:nonFraction unitRef="shares" contextRef="iae68d7d006fe4e14b9a1eeee4dd8bc44_D20200511-20200511" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTAyNDQ_fe0561db-f2f8-4dfc-a572-530ac43d99f2">447,761</ix:nonFraction> shares of common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6ed3fc7af1634151b2096d32abc0f74d_I20200511" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTAyOTM_e03e5596-b12a-4959-bf4b-a7d0f78d84fe">1.34</ix:nonFraction> per share and <ix:nonFraction unitRef="shares" contextRef="i2cca101c80a44226a89c8c35200266b8_D20200514-20200514" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTAzMTA_17daabf5-59de-4a9b-821f-71afb40ee45c">146,854</ix:nonFraction> shares of common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ieda19dd800d74d44bd5230900bc96c90_I20200514" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTAzNTk_cf664c81-fb82-4adb-9457-61f9f6a5ed73">1.43</ix:nonFraction> per share. The gross proceeds from these purchases were $<ix:nonFraction unitRef="usd" contextRef="i2cca101c80a44226a89c8c35200266b8_D20200514-20200514" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTA0MTg_6a553896-f0ba-4358-b5ae-1da9b268f11a">810,000</ix:nonFraction>. </span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:continuation id="ie02bfefbe2c341a981331f8e09426904" continuedAt="i2dcd038649d64d16b924e9a48a612c71">Securities Purchase Agreement with Acorn Bioventures LP</ix:continuation></span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i2dcd038649d64d16b924e9a48a612c71">On May 26, 2020, the Company entered into a Securities Purchase Agreement with Acorn, pursuant to which the Company agreed to offer, issue and sell to Acorn, (i) in a registered direct offering, an aggregate of <ix:nonFraction unitRef="shares" contextRef="if100dfb4b4384fd0bb32098df385547f_D20200526-20200526" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTA2OTI_4d9a3e15-27a1-4e29-8372-77290f0108b4">1,205,400</ix:nonFraction> shares of common stock and (ii) in a concurrent private placement, Series M warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i8617217253414190b2251159121acc8a_I20200526" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTA3OTg_a28c5465-b3e4-4250-96ba-bf693f533663">482,160</ix:nonFraction> shares of common stock. The Series M Warrants are exercisable <ix:nonNumeric contextRef="i0f94e8c81c344800b60b03a24b2933a5_D20200526-20200526" format="ixt-sec:durwordsen" name="crdf:ClassOfWarrantOrRightMonthsUntilExercisable" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTA4NjM_e6d9edf4-2fb5-455b-bfbb-9cf13e42f73e">six months</ix:nonNumeric> following the date of issuance at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8617217253414190b2251159121acc8a_I20200526" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTA5MjE_17ad4f4f-f8cf-4984-8401-23bdca0242ef">2.024</ix:nonFraction> per share and will expire <ix:nonNumeric contextRef="i0f94e8c81c344800b60b03a24b2933a5_D20200526-20200526" format="ixt-sec:duryear" name="crdf:ClassOfWarrantOrRightExpirationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTA5NTA_93aadb76-f56c-40f1-81dc-38d34268e728">5.5</ix:nonNumeric> years following the date of issuance. The gross proceeds from this purchase were $<ix:nonFraction unitRef="usd" contextRef="if100dfb4b4384fd0bb32098df385547f_D20200526-20200526" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTEwMjg_74ccc31f-6cf3-4b17-a6ae-0d27525d5e38">2.5</ix:nonFraction>&#160;million.</ix:continuation> </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div id="i0ff27e3402fc47278eb8617e2a08b771_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82MS9mcmFnOjk0MTUxZGQwNzNiYjRhMDdiZWNkYmZjNzUzZDViZmI4L3RleHRyZWdpb246OTQxNTFkZDA3M2JiNGEwN2JlY2RiZmM3NTNkNWJmYjhfMjEzNg_effbbbb3-bc2b-4933-96c6-1481061f2d05" continuedAt="i5fe5cabba32843c6b93af0060aed4d51" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i5fe5cabba32843c6b93af0060aed4d51"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain executive agreements provide for severance payments in case of terminations without cause or certain change of control scenarios. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development and Clinical Trial Agreements</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Cardiff Oncology refers to as onvansertib.  Onvansertib is an oral, investigative drug and a highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine PLK1. The Company plans to develop onvansertib in patients with leukemias/lymphomas and solid tumor cancers. Upon execution of the agreement, the Company paid $<ix:nonFraction unitRef="usd" contextRef="ibff09abd8c4041f78419c55803eaf58b_D20170301-20170331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82MS9mcmFnOjk0MTUxZGQwNzNiYjRhMDdiZWNkYmZjNzUzZDViZmI4L3RleHRyZWdpb246OTQxNTFkZDA3M2JiNGEwN2JlY2RiZmM3NTNkNWJmYjhfNzYx_7a7c3600-ecc4-4475-9686-506ae38c8017">2.0</ix:nonFraction> million in license fees which were expensed to research and development costs. The Company was committed to order $<ix:nonFraction unitRef="usd" contextRef="i24aa660d59c2466faf23e2429d2aa751_I20170331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82MS9mcmFnOjk0MTUxZGQwNzNiYjRhMDdiZWNkYmZjNzUzZDViZmI4L3RleHRyZWdpb246OTQxNTFkZDA3M2JiNGEwN2JlY2RiZmM3NTNkNWJmYjhfODcw_441b0e42-c23b-4c61-b9f6-dbf5f2dbe857">1.0</ix:nonFraction> million of future services provided by Nerviano, such as the cost to manufacture drug product, no later than June 30, 2019, and these services have been purchased. Terms of the agreement also provide for the Company to pay development milestones and royalties based on sales volume.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to various agreements under which it licenses technology on an exclusive basis in the field of human diagnostics and oncology therapeutics. License fees are generally calculated as a percentage of product revenues, with rates that vary by agreement. For the nine months ended September&#160;30, 2020 and 2019, payments have not been material.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise from time to time that may harm the Company&#8217;s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company&#8217;s business or financial condition.</span></div></ix:continuation><div><span><br/></span></div><div id="i0ff27e3402fc47278eb8617e2a08b771_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82NC9mcmFnOmIxMDI5ZTdhYjk3ODQ3MGM4ZjM2NjNlNTFlN2NhZGM5L3RleHRyZWdpb246YjEwMjllN2FiOTc4NDcwYzhmMzY2M2U1MWU3Y2FkYzlfODEx_b04aa050-6ce1-4775-9ede-fe1475816699" continuedAt="ibad9af169b2d44e287381681a765659c" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibad9af169b2d44e287381681a765659c">In November 2018, the Company entered into a Material Transfer Agreement (&#8220;MTA&#8221;) with Leucadia Life Sciences (&#8220;Leucadia&#8221;) pursuant to which Leucadia will develop a PCR-based assay for onvansertib for Acute Myeloid Leukemia (&#8220;AML&#8221;). The Company&#8217;s Executive Chairman, Dr. Thomas Adams, is a principal stockholder of Leucadia.&#160;In connection with the MTA, the Company entered into a consulting agreement with Tommy Adams, Co-Founder &amp; Chief Operating Officer of Leucadia, who is the son of Dr. Adams. During the three months ended September 30, 2020 and 2019 the Company incurred and recorded research and development expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="if25db31f1cc14bd8ad1940aa6a08ec7e_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82NC9mcmFnOmIxMDI5ZTdhYjk3ODQ3MGM4ZjM2NjNlNTFlN2NhZGM5L3RleHRyZWdpb246YjEwMjllN2FiOTc4NDcwYzhmMzY2M2U1MWU3Y2FkYzlfNjM5_a3e1cc0e-0889-4355-9ad8-95f864e46270">281,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i17f7e87656404afa93a7d1e1581c3052_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82NC9mcmFnOmIxMDI5ZTdhYjk3ODQ3MGM4ZjM2NjNlNTFlN2NhZGM5L3RleHRyZWdpb246YjEwMjllN2FiOTc4NDcwYzhmMzY2M2U1MWU3Y2FkYzlfNjQ2_5e26181d-5be1-4559-b63e-1aff538497d6">242,000</ix:nonFraction>, respectively, during the nine months ended September 30, 2020 and 2019 the Company incurred and recorded approximately $<ix:nonFraction unitRef="usd" contextRef="i608690ce785549468033da705f15e7f0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82NC9mcmFnOmIxMDI5ZTdhYjk3ODQ3MGM4ZjM2NjNlNTFlN2NhZGM5L3RleHRyZWdpb246YjEwMjllN2FiOTc4NDcwYzhmMzY2M2U1MWU3Y2FkYzlfNzMz_f1aa6f90-19de-448e-966e-58ccbd990051">810,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i58ff4aad5faa4a528942057efea92b13_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82NC9mcmFnOmIxMDI5ZTdhYjk3ODQ3MGM4ZjM2NjNlNTFlN2NhZGM5L3RleHRyZWdpb246YjEwMjllN2FiOTc4NDcwYzhmMzY2M2U1MWU3Y2FkYzlfNzQw_7b97c789-54eb-4cc4-a678-d73e149e8732">745,000</ix:nonFraction>, respectively, for services performed by Leucadia and Tommy Adams.</ix:continuation></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i0ff27e3402fc47278eb8617e2a08b771_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82Ny9mcmFnOjE1ODM4MTEwZWNhZDRjNDQ5MjUzMTYxZGYxNTZmNzY0L3RleHRyZWdpb246MTU4MzgxMTBlY2FkNGM0NDkyNTMxNjFkZjE1NmY3NjRfMzQ2Nw_fd3e702f-422a-4863-a731-e64ffdf62d68" continuedAt="if5b12bd10345413a9ac0eb57d6da5bd1" escape="true">COVID-19</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="if5b12bd10345413a9ac0eb57d6da5bd1"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 outbreak in the United States has caused significant business disruption. The extent of the impact of COVID-19 on the Company's future operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, and impact on the Company's clinical trials, employees and vendors, all of which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may impact the Company's future financial condition or results of operations is uncertain. While there has not been a material impact on the Company's condensed financial statements for the three or nine months ended September&#160;30, 2020, a prolonged outbreak could have a material adverse impact on financial results and business operations of the Company, including the timing and ability of the Company to complete certain clinical trials and other efforts required to advance the development of its drugs and raise additional capital.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the pandemic, the Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;) was signed into law on March 27, 2020.  The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#8217;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company is utilizing the deferment of employer social security payments. The CARES Act did not have a material impact on our income tax provision for the three or nine months ended September&#160;30, 2020. We continue to monitor changes and revisions of the CARES Act and its impact on our financial position, results of operations and cash flows.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Small Business Administration Payroll Protection Program Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On April 15, 2020, the Company was granted a loan (the &#8220;Loan&#8221;) from JPMorgan Chase Bank, N.A. in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i9a08aa2fda7c4db799f75bc79a5a0e5b_I20200415" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82Ny9mcmFnOjE1ODM4MTEwZWNhZDRjNDQ5MjUzMTYxZGYxNTZmNzY0L3RleHRyZWdpb246MTU4MzgxMTBlY2FkNGM0NDkyNTMxNjFkZjE1NmY3NjRfMTgyOQ_ac1b1d8a-b617-4b38-a25c-1c42889a3c8f">305,000</ix:nonFraction>, pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under Division A, Title I of the CARES Act with an interest rate of <ix:nonFraction unitRef="number" contextRef="i9a08aa2fda7c4db799f75bc79a5a0e5b_I20200415" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82Ny9mcmFnOjE1ODM4MTEwZWNhZDRjNDQ5MjUzMTYxZGYxNTZmNzY0L3RleHRyZWdpb246MTU4MzgxMTBlY2FkNGM0NDkyNTMxNjFkZjE1NmY3NjRfMTA5OTUxMTYzNDUzMg_e6b5616c-cec9-44ec-8811-0d068a557d66">0.98</ix:nonFraction>% per annum. On October 19, 2020 the Company repaid in full the outstanding principal and interest of the PPP Loan.</span></div></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div id="i0ff27e3402fc47278eb8617e2a08b771_70"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV83MC9mcmFnOjQxZDUyMjlhNDYxNzQ3MzFhOTQ0M2EyZGIzYWIwNDVkL3RleHRyZWdpb246NDFkNTIyOWE0NjE3NDczMWE5NDQzYTJkYjNhYjA0NWRfMzI4_e27a552f-9db4-4b33-803e-2021a252e94f" continuedAt="i8fc04c22b3694768b3481a326965843b" escape="true">Subsequent Events</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i8fc04c22b3694768b3481a326965843b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Underwritten Public Offering</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 2, 2020 the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i5c512dc917a44fa4935298acc4757d46_D20201002-20201002" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV83MC9mcmFnOjQxZDUyMjlhNDYxNzQ3MzFhOTQ0M2EyZGIzYWIwNDVkL3RleHRyZWdpb246NDFkNTIyOWE0NjE3NDczMWE5NDQzYTJkYjNhYjA0NWRfMTA5OTUxMTYzMTYyOA_a624d00f-aa2d-462b-99e0-75cb71490161">6,500,000</ix:nonFraction> shares of its common stock at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic032311ae02d403789f39a7132fe94f9_I20201002" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV83MC9mcmFnOjQxZDUyMjlhNDYxNzQ3MzFhOTQ0M2EyZGIzYWIwNDVkL3RleHRyZWdpb246NDFkNTIyOWE0NjE3NDczMWE5NDQzYTJkYjNhYjA0NWRfMTA5OTUxMTYzMTYzOQ_2086a2bd-bdd3-4d32-bcba-b8a4e46237b5">13.50</ix:nonFraction> per share. In addition, the underwriters exercised in full an option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="icbbee8b1f9a244e8ad1c0673daa3a0b1_D20201002-20201002" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV83MC9mcmFnOjQxZDUyMjlhNDYxNzQ3MzFhOTQ0M2EyZGIzYWIwNDVkL3RleHRyZWdpb246NDFkNTIyOWE0NjE3NDczMWE5NDQzYTJkYjNhYjA0NWRfMTA5OTUxMTYzMTY3OA_6bb9127b-0d7b-4f22-bf86-6a2254be1f79">975,000</ix:nonFraction> shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering were sold by the Company, with gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i5c512dc917a44fa4935298acc4757d46_D20201002-20201002" decimals="-5" format="ixt:numdotdecimal" name="crdf:SaleOfStockConsiderationReceivedOnTransactionGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV83MC9mcmFnOjQxZDUyMjlhNDYxNzQ3MzFhOTQ0M2EyZGIzYWIwNDVkL3RleHRyZWdpb246NDFkNTIyOWE0NjE3NDczMWE5NDQzYTJkYjNhYjA0NWRfMTA5OTUxMTYzMTY0Nw_a57a6aaa-7503-48fe-aac5-4885e8e920a9">100.9</ix:nonFraction>&#160;million, and net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i5c512dc917a44fa4935298acc4757d46_D20201002-20201002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV83MC9mcmFnOjQxZDUyMjlhNDYxNzQ3MzFhOTQ0M2EyZGIzYWIwNDVkL3RleHRyZWdpb246NDFkNTIyOWE0NjE3NDczMWE5NDQzYTJkYjNhYjA0NWRfMTA5OTUxMTYzMTY2Mw_c46a074c-2a06-4f9f-8dfb-01206315ba3b">94.0</ix:nonFraction>&#160;million, after deducting underwriting discounts, commissions and estimated offering expenses. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise of Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From October 1 through October 31, 2020 the Company received proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i4884eb0a36754efda6090e87871a157e_D20201001-20201031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV83MC9mcmFnOjQxZDUyMjlhNDYxNzQ3MzFhOTQ0M2EyZGIzYWIwNDVkL3RleHRyZWdpb246NDFkNTIyOWE0NjE3NDczMWE5NDQzYTJkYjNhYjA0NWRfMTA5OTUxMTYzMTYwMQ_4142c0de-3e05-41d8-bc49-95d38093a4be">3.4</ix:nonFraction>&#160;million from the exercise of <ix:nonFraction unitRef="shares" contextRef="i4884eb0a36754efda6090e87871a157e_D20201001-20201031" decimals="INF" format="ixt:numdotdecimal" name="crdf:ClassOfWarrantOrRightNumberExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV83MC9mcmFnOjQxZDUyMjlhNDYxNzQ3MzFhOTQ0M2EyZGIzYWIwNDVkL3RleHRyZWdpb246NDFkNTIyOWE0NjE3NDczMWE5NDQzYTJkYjNhYjA0NWRfMTA5OTUxMTYzMTYxNQ_aa535ac2-b3aa-43b8-b8f4-b929a629fc4a">1.6</ix:nonFraction>&#160;million warrants. The warrants exercised during the relevant period were from various prior equity offerings. </span></div><div style="text-align:justify;text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repayment of Small Business Administration Payroll Protection Program Loan</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 19, 2020 the Company repaid in full the PPP Loan principal of $<ix:nonFraction unitRef="usd" contextRef="i2917c1b61fd347ec893f35bbe6cd7228_D20201019-20201019" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV83MC9mcmFnOjQxZDUyMjlhNDYxNzQ3MzFhOTQ0M2EyZGIzYWIwNDVkL3RleHRyZWdpb246NDFkNTIyOWE0NjE3NDczMWE5NDQzYTJkYjNhYjA0NWRfMTA5OTUxMTYzMTU5MQ_2fc1633b-fbe0-4046-ac6d-c7098af58eea">305,000</ix:nonFraction> and interest for the period the loan was outstanding.</span></div></ix:continuation><div style="text-align:justify;text-indent:33.75pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i0ff27e3402fc47278eb8617e2a08b771_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form&#160;10-Q includes forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).&#160;All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding the future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.&#160;These forward-looking statements are subject to a number of risks, uncertainties and assumptions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our business and financial performance may be affected by the factors that are discussed under &#8220;Risk Factors&#8221; in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019, filed on February&#160;27, 2020.&#160;Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for us to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events.&#160;We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur.&#160;Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis is qualified in its entirety by, and should be read in conjunction with, the more detailed information set forth in the financial statements and the notes thereto appearing elsewhere in this Quarterly Report on Form&#160;10-Q. This discussion should not be construed to imply that the results discussed herein will necessarily continue into the future, or that any conclusion reached herein will necessarily be indicative of actual operating results in the future.&#160;Such discussion represents only the best present assessment of our management.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage, biotechnology company, developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, extend duration of response and increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 ("PLK1") inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We licensed onvansertib from Nerviano Medical Sciences ("NMS") in March, 2017, pursuant to a license agreement with NMS dated March 13, 2017. This exclusive, world-wide license agreement includes 3 issued patents for onvansertib which cover composition of matter, salt forms of onvansertib and combination of onvansertib with other drugs. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onvansertib is highly potent against the PLK1 enzyme (concentration for 50% inhibition [IC50] = 2nM), whereas low or no activity was observed on a panel of 63 kinases (IC50&gt;500 nM), including the PLK members PLK2 and PLK3 (IC50&gt;10 &#956;M).  Onvansertib was developed to have ideal pharmacokinetics, including oral bioavailability and administration and a drug half-life of approximately 24 hours, allowing for flexible dosing and scheduling, and is well tolerated and safe with only mild to moderate side effects reported to-date. A Phase 1 safety study of onvansertib was successfully completed in patients with advanced metastatic solid tumors and published in 2017 in Investigational New Drugs. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PLK1, a serine/threonine kinase, is a master regulator of mitotic progression with various roles and localizations during the different mitotic phases. Upon PLK1 depletion in cancer cells by RNA interference ("RNAi"), inhibition of proliferation and decreased viability, resulting from cell cycle arrest with 4N DNA content followed by apoptosis, are observed. PLK1 depletion also results in an increase in the number of cells containing abnormal spindle formation and misaligned chromosomes. Expression of PLK1 is seen in all proliferating normal tissues, and PLK1 is overexpressed in a number of tumors (including breast, prostate, ovary, lung, gastric and colon cancers), as well as in hematologic cancers.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onvansertib has been tested for antiproliferative activity on a panel of 148 tumor cell lines and appeared highly active with an IC50 (a measure concentration for 50% target inhibition) below 100 nM in 75 cell lines and IC50 values below 1 uM in 133 out of 148 cell lines. Onvansertib also appears active in cells expressing multi-drug resistant (&#8220;MDR&#8221;) transporter proteins and we believe its apparent ability to overcome the MDR transporter resistance mechanism in cancer cells could prove useful in broader drug combination applications.  Additionally, onvansertib has been tested in in-vivo xenograft and transgenic models of different cancer types with the demonstration of tumor growth inhibition or tumor regression.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In in-vitro and in-vivo preclinical studies, synergy (interaction of discrete drugs such that the total effect is greater than the sum of the individual effects) has been demonstrated with onvansertib when used in combination with numerous different chemotherapies, including irinotecan, 5-FU, cisplatin, cytarabine, doxorubicin, gemcitabine and paclitaxel, as well as targeted therapeutics, such as abiraterone acetate ("Zytiga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), histone deacetylase (&#8220;HDAC&#8221;) inhibitors, such as belinostat ("Beleodaq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), quizartinib ("AC220"), a development stage FLT3 inhibitor, and bortezomib ("Velcade</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"). These therapies are used clinically for the treatment of solid tumor cancers, leukemias and lymphomas including metastatic colorectal cancer ("mCRC"), metastatic castration resistant prostate cancer ("mCRPC"), pancreatic cancer, triple negative breast cancer (&#8220;TNBC&#8221;), acute myeloid leukemia ("AML") and other hematological malignancies. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the high-selectivity of onvansertib to PLK1, its 24-hour half-life and oral bioavailability, as well as its demonstrated safety and tolerability, with expected on-target, easy to manage and reversible side effects, may prove beneficial in addressing clinical therapeutic needs across a variety of cancers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Clinical Program Updates</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have three active clinical trials: </span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TROV-054 is a Phase 1b/2 open-label clinical trial of onvansertib in combination with FOLFIRI and bevacizumab ("Avastin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the second line treatment of patients with KRAS-mutated mCRC, which is being conducted at 6 clinical trial sites across the U.S. - USC Norris Comprehensive Cancer Center, The Mayo Clinic Cancer Centers, Kansas University Medical Center ("KUMC") and CARTI Cancer Center; </span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TROV-053 is a Phase 2 open-label clinical trial of onvansertib in combination with abiraterone acetate (Zytiga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and prednisone in patients with mCRPC, which is being conducted at Beth Israel Deaconess Medical Center ("BIDMC"), Dana-Farber Cancer Institute ("DFCI"), and Massachusetts General Hospital ("MGH"); </span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TROV-052 is a Phase 2 open-label clinical trial of onvansertib in combination with standard-of-care chemotherapy, decitabine, in patients with relapsed or refractory AML, which is being conducted at nine sites across the U.S. The Phase 1b portion of the AML trial was completed in the fourth quarter of 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">KRAS-mutated mCRC</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TROV-054 is a Phase 1b/2 study of onvansertib for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer ("mCRC") in combination with standard-of-care FOLFIRI and bevacizumab (Avastin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of this study is to evaluate the dose-limiting toxicities ("DLTs") and maximum tolerated dose ("MTD") or recommended Phase 2 dose ("RP2D") of onvansertib in combination with FOLFIRI and bevacizumab (Phase 1b) and to continue to assess the safety and preliminary efficacy of onvansertib in combination with FOLFIRI and bevacizumab (Phase 2).</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rationale for this clinical trial is based on three key principles including synthetic lethality, synergy and proof-of-concept clinical benefit. Synthetic lethality arises when a combination of deficiencies in the expression of two genes leads to cell death, whereas a deficiency in only one of these genes does not. The deficiencies can arise through mutations, epigenetic alterations or inhibitors of the protein encoded by one of the genes. In reference to onvansertib, CRC tumor cells harboring KRAS mutations are more vulnerable to cell death with PLK1 inhibition versus KRAS wild-type isogenic cells. Synergy occurs when the combination of two drugs results in an unexpected greater activity than an expected additive effect of the two drugs. Onvansertib in combination with irinotecan and 5-FU (components of FOLFIRI) demonstrate synergy in colorectal cancer cell lines and the combination has demonstrated significantly greater tumor growth inhibition than either drug alone.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proof-of-concept clinical response has been demonstrated in a previously completed Phase 1 trial in solid tumors in which 3 of 5 patients showing stable disease had a KRAS mutation; 2 in colorectal cancer and 1 in pancreatic cancer.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data presented on September 17, 2020, at the European Society for Medical Oncology ("ESMO") conference, demonstrated the safety and efficacy of onvansertib.  Of the 11 patients evaluable for efficacy, 10 of 11 (91%) patients achieved disease control (SD &#8211; stable disease plus PR &#8211; partial response) with only 1 patient progressing in &lt;6 months while on treatment. Five (45%) patients achieved a partial response (PR); 4 patients had a confirmed PR (&#8805; 30% tumor shrinkage) with 1 patient going on to curative surgery; 1 patient with an initial PR went off study prior to confirmatory scan due to a non-treatment related event. All 5 PRs were associated with different KRAS mutation variants, including the most common that comprise nearly 80% of mutations in CRC. Eight of 11 (73%) patients demonstrated durable response ranging from 6 to &gt;12 months, and 4 patients remain on treatment. Onvansertib in combination with FOLFIRI and bevacizumab is safe and well tolerated with only 9% of adverse events being grade 3 or 4 and all being resolved within 2.5 weeks. Of the 11 patients, 8 had previously received bevacizumab as first line treatment, including the 4 patients who remain on treatment.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">Key News Releases</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 17, 2020, we announced an electronic poster presentation of clinical data further demonstrating the safety, efficacy and durability of response of onvansertib in KRAS-mutated mCRC patients at the European Society of Medical Oncology ("ESMO") Virtual Congress 2020.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2020, we announced the initiation of our Expanded Access Program ("EAP") for onvansertib, in combination with standard-of-care FOLFIRI and bevacizumab, for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer ("mCRC"). This announcement followed the FDA granting Fast Track Designation for onvansertib in KRAS-mutated mCRC.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">mCRPC</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TROV-053 is a Phase 2 study of onvansertib in combination with Zytiga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (abiraterone) and prednisone for the treatment of patients with metastatic castration resistant prostate cancer ("mCRPC").</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of this study is to observe the effects of onvansertib in combination with abiraterone and prednisone on disease control as assessed by prostate specific antigen ("PSA") decline or stabilization after 12 weeks of study treatment in patients with mCRPC showing early signs of resistance to abiraterone.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rationale for this trial is based on the mechanism of action ("MOA") of onvansertib and Zytiga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the synergy of these two drugs when used in combination. Onvansertib inhibits tumor cell division (mitosis) by inducing G2/M arrest of tumor cells and the combination of onvansertib and Zytiga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> significantly increases mitotic arrest and is synergistic when used in combination.  Additionally, PLK1 inhibition appears to enhance the efficacy of androgen signaling blockade in castration-resistant prostate cancer.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data presented on October 20, 2020, at the 27th Annual Prostate Cancer Foundation ("PCF") Scientific Retreat, demonstrated the efficacy of onvansertib across all three cohorts of patients. The trial is on track to meet prespecified criteria for success on its primary endpoint, with 31% (8/26) disease control rate in evaluable patients in cohorts A and B. Two of three patients treated as of the data cutoff date in cohort C achieved the primary efficacy endpoint at 12 weeks. Recent collaborative studies with Massachusetts Institute of Technology ("MIT") and Decipher Biosciences suggest that prostate cancer patients with the clinically defined basal molecular tumor subtype may be more likely to respond to onvansertib being added to ongoing abiraterone therapy.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Key News Releases</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 20, 2020, we announced an electronic poster presentation of clinical data further demonstrating the safety, efficacy and durability of response of onvansertib in patients with mCRPC at the 27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> annual Prostate Cancer Foundation ("PCF") Scientific Retreat.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">AML</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TROV-052 is a Phase 2 Study of onvansertib in combination with standard-of-care chemotherapy, decitabine, for the treatment of patients with relapsed or refractory acute myeloid leukemia ("AML").  The Phase 1b portion of this trial was completed in the fourth quarter of 2019.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of this trial is to evaluate the DLTs and MTD or RP2D of onvansertib (Phase 1b &#8211; completed in October 2019). In Phase 2, the objective is to assess the safety, tolerability and preliminary efficacy of the combination of onvansertib at </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the RP2D and decitabine in patients with relapsed or refractory AML. Additionally, as a correlative objective, this trial is evaluating potential pharmacodynamic ("PD") and diagnostic biomarkers of onvansertib in patients with AML. We were granted Orphan Drug Designation ("ODD") for onvansertib for the treatment of AML from the FDA and the European Commission.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rationale for this trial is based on the need for new and better therapeutic options for patients in the relapsed or refractory AML setting. Current treatment options are often limited by the patient&#8217;s age and health status. Combination treatment with onvansertib and standard-of-care chemotherapy may provide a new safe and effective therapeutic option.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data presented on June 12, 2020 at the European Hematology Association ("EHA") conference, demonstrated the safety and efficacy of onvansertib in patients. In the completed Phase 1b portion of this trial, the RP2D was established at onvansertib 60 mg/m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Onvansertib adverse events were primarily on-target hematological events, in accordance with the mechanism of action, and were reversible and manageable. Anti-leukemic activity was observed at a wide range of onvansertib dose levels (27 to 90 mg/m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and the complete response rate achieved in patients was 24% through all dose levels, and 31% at the 4 higher dose levels (27 to 90 mg/m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Decreases in mutant ctDNA after 1 cycle of treatment were highly predictive of clinical response and target engagement (biomarker positivity) in circulating blast cells was associated with a greater decrease in bone marrow blast cells. Phase 2 is enrolling patients and is ongoing.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Financial and Company Updates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">Financial</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">On September 29, 2020 we announced pricing of an underwritten public offering of 6,500,000 shares of our common stock at a price of $13.50 per share. The underwriters had an option to purchase an additional 975,000 shares, which was exercised in the full. The offering was completed on October 2, 2020 and the gross proceeds were $100.9 million. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">Company</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 8, 2020 we changed our company name from Trovagene, Inc. to Cardiff Oncology, Inc., and our Nasdaq ticker symbol to &#8216;CRDF.&#8217; The web address for the Cardiff Oncology website is www.cardiffoncology.com. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 8, 2020 Mark Erlander, PhD, assumed the role of Chief Executive Officer and Thomas Adams, PhD, transitioned from Chief Executive Officer and Chairman to Executive Chairman.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 22, 2020, we announced the election of three new independent Directors to our Board of Directors; Dr. James Armitage, Dr. Gary Pace and Ms. L&#226;le White. Each new Director brings extensive and relevant experience to our company.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accumulated deficit through September&#160;30, 2020 is $224.9 million.&#160;To date, we have generated minimal revenues and expect to incur additional losses to perform further research and development activities.&#160;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug development efforts are in their early stages, and we cannot make estimates of the costs or the time that our development efforts will take to complete, or the timing and amount of revenues related to the sale of our drugs.&#160;The risk of completion of any program is high because of the many uncertainties involved in developing new drug candidates to market, including the long duration of clinical testing, the specific performance of proposed products under stringent clinical trial protocols, extended regulatory approval and review cycles, our ability to raise additional capital, the nature and timing of research and development expenses, and competing technologies being developed by organizations with significantly greater resources.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no off-balance sheet arrangements as of September&#160;30, 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting policies are described in ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS of our Annual Report on Form&#160;10-K as of and for the year ended December&#160;31, 2019, filed with the SEC on February&#160;27, 2020.&#160;There have been no changes to our critical accounting policies since December&#160;31, 2019.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i0ff27e3402fc47278eb8617e2a08b771_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2020 and 2019 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total revenues consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:46.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,714&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,401&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,687&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,714&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in royalty income for the three months ended September 30, 2020 as compared to the prior period is primarily from fluctuations of our sales-based or usage-based royalties on other intellectual property licenses, unrelated to onvansertib. Revenue recognition of the royalty depends on the timing and overall sales activities of the licensees. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and staff costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials, outside services, and lab supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,151,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,854,812&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,818,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,988&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $35,988 for the three months ended September 30, 2020 compared to the same period in 2019.&#160;The overall increase in research and development expenses was primarily due to costs associated with clinical programs and outside service costs for three ongoing clinical trials related to the development of our lead drug candidate, onvansertib. Facilities and other decreased primarily due to decreased travel and conference expenses to present data related to our lead drug candidate, onvansertib. Due to COVID-19 presentation of data has transitioned to virtual conferences. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and staff costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519,883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside services and professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,644,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,872&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $203,872 for the three months ended September 30, 2020 compared to the same period in 2019.&#160;The significant components of the increase were primarily due to the increase in stock-based compensation, salaries and staff costs, facilities and other costs, partially offset by a reduction in outside services. The increase in stock-based compensation is primarily due to stock options granted in June 2020. The increase in salaries and staff </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs is primarily due to annual increases in salary and promotions.  The increase in facilities and other cost was due to an increase in insurance costs for the three months ended September 30, 2020 as compared to the same period of 2019. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $15,864 for the three months ended September 30, 2020 as compared to $53,700 for the same period of 2019. The decrease of interest income is primarily due to lower interest rates for three months ended September 30, 2020 as compared to the same period of 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Derivative Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued warrants that are accounted for as derivative liabilities.&#160;As of September&#160;30, 2020, the derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants liabilities were revalued to $190,199, resulting in an increase in value of $144,035 from June&#160;30, 2020, based primarily upon the fluctuation in our stock price as well as the changes in the expected term, volatility, and risk-free interest rates for the expected term.&#160;The increase in value upon remeasurement at September&#160;30, 2020 was recorded as a loss from the change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants in the condensed statement of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss and per share amounts were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common&#160;shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,502,591)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,147,609)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding &#8212; basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,341,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,024,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,316,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $354,982 increase in net loss attributable to common shareholders was primarily the result of an increase of operating expenses and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an increase in the loss recorded from the change in fair value of derivative financial instruments during the three months ended September&#160;30, 2020, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to the same period in the prior year. The $0.50 decrease in basic net loss per share was impacted by the increase in basic weighted average shares outstanding resulting primarily from the issuance of approximately 19.8 million shares of common stock and common stock equivalents from October 1, 2019 through September&#160;30, 2020. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div id="i0ff27e3402fc47278eb8617e2a08b771_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2020 and 2019 </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total revenues consisted of the following: &#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:46.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,683&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in revenues for the nine months ended September 30, 2020 as compared to the prior period is primarily from fluctuations of our sales-based or usage-based royalties on other intellectual property licenses, unrelated to onvansertib. Revenue recognition of the royalty depends on the timing and overall sales activities of the licensees. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and staff costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,261,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,079)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials, outside services, and lab supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,933,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,115,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181,915)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,036,225&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,297,763&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261,538)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased by $261,538 for the nine months ended September 30, 2020 compared to the same period in 2019.&#160;The overall decrease in research and development expenses was primarily due to costs associated with clinical programs and outside service costs for three ongoing clinical trials related to the development of our lead drug candidate, onvansertib. Facilities and other decreased primarily due to decreased travel and conference expenses to present data related to our lead drug candidate, onvansertib. Due to COVID-19 presentation of data has transitioned to virtual conferences. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and staff costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565,021&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside services and professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,541,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,884)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,196,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,799,457&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,243,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555,967&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $555,967 for the nine months ended September 30, 2020 compared to the same period in 2019.&#160;The significant components of the increase were primarily due to the increase in stock-based compensation, salaries and staff costs, facilities and other costs, partially offset by a reduction in outside services. The increase in stock-based compensation is primarily due to stock options granted in June 2019 and June 2020. The increase in salaries and staff costs is primarily due to annual salary increases and promotions. The increase in facilities and other cost was due to an increase in insurance costs for the nine months ended September 30, 2020 as compared to the same period of 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income and Expense</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $67,358 for the nine months ended September 30, 2020 as compared to $188,204 for the same period of 2019. The decrease of interest income is primarily due to lower interest rates for nine months ended September 30, 2020 as compared to the same period of 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Derivative Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued warrants that are accounted for as derivative liabilities.&#160;As of September&#160;30, 2020, the derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants liabilities were revalued to $190,199, resulting in an increase in value of $186,072 from December&#160;31, 2019, based primarily upon the fluctuation in our stock price as well as the changes in the expected term, volatility, and risk-free interest rates for the expected term.&#160;The increase in value upon remeasurement at September&#160;30, 2020 was recorded as a loss from the change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants in the condensed statement of operations.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss and per share amounts were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common&#160;shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,994,289)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,458,072)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,536,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.00)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding &#8212; basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,941,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,180,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,761,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $3,536,217 increase</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in net loss attributable to common shareholders was primarily the result of an increase of $3.0 million attributable to the d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eemed dividends recognized on beneficial conversion features of convertible preferred stock issuances, an increase in the loss recorded from the change in fair value of derivative financial instruments, an increase in operating expense and a decrease in interest income, for the nine months ended September 30, 2020 compared to the same period in the prior year. The $1.40 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decrease in basic net loss per share was impacted by the increase in basic weighted average shares outstanding resulting primarily from the issuance of approximately 19.8 million shares of common stock and common stock equivalents from October 1, 2019 through September&#160;30, 2020. </span></div><div><span><br/></span></div><div id="i0ff27e3402fc47278eb8617e2a08b771_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 outbreak in the United States has caused business disruptions. The extent of the impact of COVID-19 on our operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, and impact on our clinical trials, employees and vendors, all of which are uncertain and cannot be predicted. The economic effects of the outbreak could also have an adverse effect on our ability to raise additional capital. At this point, the extent to which COVID-19 may impact our future financial condition or results of operations is uncertain.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we had $36,405,432 in cash and cash equivalents.&#160;Net cash used in operating activities for the nine months ended September 30, 2020 was $11,191,025, compared to $9,990,636 for the nine months ended September&#160;30, 2019.&#160;Our use of cash was primarily a result of the net loss of $12,709,625 for the nine months ended September 30, 2020, adjusted for non-cash items related to release of clinical trial funding commitment of $868,093, stock-based compensation of $820,969, and depreciation and amortization of $348,748.&#160;The net change in our operating assets and liabilities was $739,451 increasing cash used in operations.&#160;At our current and anticipated level of operating loss, we expect to continue to incur an operating cash outflow for the next several years.</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $153,784 during the nine months ended September 30, 2020, compared to $67,622 for the same period in 2019, which were for capital expenditures.</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided in financing activities was $37,554,949 during the nine months ended September 30, 2020, compared to $7,637,331 for the same period in 2019. Net cash provided in financing activities during the nine months ended September 30, 2020&#160;was primarily from $18.3 million of proceeds from the sale of common stock, preferred stock and warrants and from $19.0 million of proceeds from the exercise of warrants. Net cash provided in financing activities during the nine months ended September 30, 2019 was primarily from $3.3 million of proceeds from the exercise of warrants and $4.4 million from the sale of common stock and warrants.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, and December&#160;31, 2019, we had working capital of $32,746,587 and $6,571,985, respectively.&#160;</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception and have negative operating cash flows. As of September&#160;30, 2020, we had $36.4 million in cash and cash equivalents and we believe we have sufficient cash to meet our funding requirements for at least the next 12 months following the issuance date of these financial statements.  </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the foreseeable future, the Company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company&#8217;s stockholders may experience additional dilution. The economic effects of COVID-19 could also have an adverse effect on the Company's ability to raise additional capital. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Public Offerings</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 2, 2020, we announced the completion of an underwritten public offering of 6,500,000 shares of our common stock at a price to the public of $13.50 per share.  In addition, the underwriters exercised in full an option to purchase an additional 975,000 shares of common stock at the public offering price, less the underwriting discounts and commissions.  All of the shares in the offering were sold by us, with gross proceeds of approximately $100.9 million and net proceeds of approximately $94.0 million, after deducting underwriting discounts and commissions and estimated offering expenses. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTRACTUAL OBLIGATIONS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our contractual obligations see (i)&#160;our Financial Statements and Notes to Financial Statements Note 10. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and (ii)&#160;Item 7 Management Discussion and Analysis of Financial Condition and Results of Operations &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Obligations and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, included in our Annual Report on Form&#160;10-K as of December&#160;31, 2019. There have been no material changes to our contractual obligations in our Form&#160;10-K for the year ended December&#160;31, 2019.</span></div><div><span><br/></span></div><div id="i0ff27e3402fc47278eb8617e2a08b771_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="i0ff27e3402fc47278eb8617e2a08b771_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have performed an evaluation under the supervision and with the participation of our management, including our principal executive officer (CEO) and principal financial officer (VP, Finance), of the effectiveness of our disclosure controls and procedures, as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).&#160;Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of September&#160;30, 2020 to provide reasonable assurance that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives as specified above. Management does not expect, however, that our disclosure controls and procedures will prevent or detect all errors and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within our company have been detected.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control&#160;over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting during the three months ended September&#160;30, 2020 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i0ff27e3402fc47278eb8617e2a08b771_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II.&#160; OTHER INFORMATION</span></div><div><span><br/></span></div><div id="i0ff27e3402fc47278eb8617e2a08b771_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i0ff27e3402fc47278eb8617e2a08b771_103"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes from the risk factors disclosed in our Form&#160;10-K for the year ended December&#160;31, 2019, except for the following.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outbreak of the novel coronavirus disease, COVID-19, could materially adversely impact our business, results of operations and financial condition, including our clinical trials.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the World Health Organization declared the outbreak of COVID-19 as a &#8220;Public Health Emergency of International Concern,&#8221; which continues to spread throughout the world and has adversely impacted global commercial activity and contributed to significant declines and volatility in financial markets. The COVID-19 outbreak and government responses are creating disruption in global supply chains and adversely impacting many industries. The outbreak could have a continued material adverse impact on economic and market conditions and trigger a period of global economic slowdown. We continue to monitor the impact of the COVID-19 outbreak closely. The extent to which the COVID-19 outbreak will impact our operations or financial results is uncertain.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. While the extent of the impact of the COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis such as the COVID-19 pandemic could have a material adverse effect on our business, financial condition and results of operations. As a result of the COVID-19 pandemic, we may experience disruptions that could severely impact our business and clinical trials, including:</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">delays or difficulties in enrolling and retaining patients in our clinical trials;</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures (such as endoscopies that are deemed non-essential), which may impact the integrity of subject data and clinical study endpoints;</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;<br/></span></div><div style="padding-left:36pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">interruption of, or delays in receiving, supplies of our product candidate from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">limitations on employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">interruption or delays to our sourced clinical activities; and</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">changes in clinical site procedures and requirements as well as regulatory requirements for conducting clinical trials during the pandemic.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects from the COVID-19 virus. For example, in March 2020, the FDA issued guidance, which FDA subsequently updated, on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical trial report contingency measures implemented to manage the trial, and any disruption of the trial as a result of the COVID-19 pandemic; a list of all subjects affected by the COVID-19 pandemic related study disruption by unique subject identifier and by investigational site and a description of how the individual&#8217;s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the trial.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to revolve rapidly, with the status of operations and government restrictions evolving weekly. The extent to which the outbreak impacts our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of the COVID-19 pandemic on our business operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted, including the duration of the pandemic, the ultimate geographic spread of the disease, additional or modified government actions, new information that will emerge concerning the severity and impact of COVID-19 and the actions taken to contain COVID-19 or address its impact in the short and long term, among others. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy. We will continue to monitor the situation closely.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our business could be materially adversely affected by other business disruptions to us or our third-party providers that could materially adversely affect our potential future revenue and financial condition and increase our costs and expenses. Our operations, and those of our contract research organizations ("CROs"), contract manufacturing organizations ("CMOs"), and other contractors, consultants and third parties could be subject to other global pandemics, earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could materially adversely affect our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce and process our product candidate. Our ability to obtain clinical supplies of our product candidate could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span><br/></span></div><div id="i0ff27e3402fc47278eb8617e2a08b771_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div><span><br/></span></div><div id="i0ff27e3402fc47278eb8617e2a08b771_109"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i0ff27e3402fc47278eb8617e2a08b771_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="i0ff27e3402fc47278eb8617e2a08b771_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i0ff27e3402fc47278eb8617e2a08b771_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description&#160;of&#160;Exhibit</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020014034/ex11crdf093020.htm">Underwriting Agreement, dated September 29, 2020</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020014034/ex11crdf093020.htm"> </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020014034/ex11crdf093020.htm"> </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020014034/ex11crdf093020.htm">(incorporated by reference to Exhibit 1.1 to the Company&#8217;s Form 8-K filed on September 30, 2020).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf-093020exhibit311.htm">Certification of Principal Executive Officer required by Rule&#160;13a-14(a)/15d-14(a)&#160;under the Exchange Act.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf-093020exhibit312.htm">Certification of Principal Financial Officer required by Rule&#160;13a-14(a)/15d-14(a)&#160;under the Exchange Act.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf-093020exhibit321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf-093020exhibit322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - the cover page from the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 is formatted in Inline XBRL</span></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i0ff27e3402fc47278eb8617e2a08b771_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="#i0ff27e3402fc47278eb8617e2a08b771_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARDIFF ONCOLOGY,&#160;INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARDIFF ONCOLOGY,&#160;INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brigitte Lindsay</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brigitte Lindsay</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VP, Finance </span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>crdf-093020exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ibdca3f1e9dfb4f99a4c0d80562e882de_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark Erlander, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form&#160;10-Q of Cardiff Oncology,&#160;Inc. (the &#8220;Registrant&#8221;)&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer </font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>crdf-093020exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i37251253fc4a489fa96b6547581c541d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brigitte Lindsay, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form&#160;10-Q of Cardiff Oncology,&#160;Inc. (the &#8220;Registrant&#8221;)&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brigitte Lindsay</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brigitte Lindsay</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VP, Finance </font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>crdf-093020exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="id5257df3b0584d3ca64d67cba9e4cdda_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Cardiff Oncology,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the three months ended September&#160;30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;I, Mark Erlander, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167;&#160;1350, as adopted pursuant to &#167;&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer </font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>crdf-093020exhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i6c6490ae383d4082918928f1f127f8c4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Cardiff Oncology,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the three months ended September&#160;30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;I, Brigitte Lindsay, VP, Finance of the Company, certify, pursuant to 18 U.S.C. &#167;&#160;1350, as adopted pursuant to &#167;&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Brigitte Lindsay</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brigitte Lindsay</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VP, Finance </font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>crdf-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:899aa37a-8922-454a-a94d-f1f600203a5a,g:092e8a26-8aea-4f93-acda-3be57db43dca-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:crdf="http://www.cardiffoncology.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardiffoncology.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cardiffoncology.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETS" roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETSParenthetical" roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>1005006 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical" roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical">
        <link:definition>1007008 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationDetails" roleURI="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNetLossPerShareDetails" roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesNetLossPerShareDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.cardiffoncology.com/role/FairValueMeasurements">
        <link:definition>2108103 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsTables">
        <link:definition>2309302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails">
        <link:definition>2410404 - Disclosure - Fair Value Measurements - Fair Value of Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.cardiffoncology.com/role/PropertyandEquipment">
        <link:definition>2111104 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.cardiffoncology.com/role/PropertyandEquipmentTables">
        <link:definition>2312303 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.cardiffoncology.com/role/PropertyandEquipmentDetails">
        <link:definition>2413405 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cardiffoncology.com/role/Leases">
        <link:definition>2114105 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cardiffoncology.com/role/LeasesTables">
        <link:definition>2315304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cardiffoncology.com/role/LeasesNarrativeDetails">
        <link:definition>2416406 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>2417407 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetInformationDetails" roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>2418408 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowInformationDetails" roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails">
        <link:definition>2419409 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsDetails" roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>2420410 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>2420410 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsWarrants" roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants">
        <link:definition>2121106 - Disclosure - Derivative Financial Instruments - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsWarrantsTables" roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables">
        <link:definition>2322305 - Disclosure - Derivative Financial Instruments - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsWarrantsDetails" roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails">
        <link:definition>2423411 - Disclosure - Derivative Financial Instruments - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.cardiffoncology.com/role/StockholdersEquity">
        <link:definition>2124107 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityTables">
        <link:definition>2325306 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockbasedCompensationExpenseDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails">
        <link:definition>2426412 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionActivityDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails">
        <link:definition>2427413 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRestrictedStockUnitsDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails">
        <link:definition>2428414 - Disclosure - Stockholders' Equity - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityWarrantsDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails">
        <link:definition>2429415 - Disclosure - Stockholders' Equity - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityPreferredStockDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails">
        <link:definition>2430416 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySeriesCConvertiblePreferredStockDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails">
        <link:definition>2431417 - Disclosure - Stockholders' Equity - Series C Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySeriesDConvertiblePreferredStockDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails">
        <link:definition>2432418 - Disclosure - Stockholders' Equity - Series D Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySeriesEConvertiblePreferredStockDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails">
        <link:definition>2433419 - Disclosure - Stockholders' Equity - Series E Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySecuritiesPurchaseAgreementDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails">
        <link:definition>2434420 - Disclosure - Stockholders' Equity - Securities Purchase Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingencies">
        <link:definition>2135108 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2436421 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.cardiffoncology.com/role/RelatedPartyTransactions">
        <link:definition>2137109 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2438422 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COVID19" roleURI="http://www.cardiffoncology.com/role/COVID19">
        <link:definition>2139110 - Disclosure - COVID-19</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COVID19Details" roleURI="http://www.cardiffoncology.com/role/COVID19Details">
        <link:definition>2440423 - Disclosure - COVID-19 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.cardiffoncology.com/role/SubsequentEvents">
        <link:definition>2141111 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.cardiffoncology.com/role/SubsequentEventsDetails">
        <link:definition>2442424 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="crdf_IncreaseDecreaseInOperatingLeaseLiability" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" abstract="false" name="DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_DerivativeFinancialInstrumentsLiabilityRollForward" abstract="true" name="DerivativeFinancialInstrumentsLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="crdf_SeriesLWarrantsMember" abstract="true" name="SeriesLWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_SeriesKWarrantMember" abstract="true" name="SeriesKWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" abstract="true" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" abstract="false" name="CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="crdf_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" abstract="true" name="LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_PreferredStockDividendAccrued" abstract="false" name="PreferredStockDividendAccrued" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" abstract="true" name="ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_NorvianoMember" abstract="true" name="NorvianoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightExpirationTerm" abstract="false" name="ClassOfWarrantOrRightExpirationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseNumberOfRenewalOptions" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" abstract="false" name="Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_SeriesBConvertiblePreferredStockMember" abstract="true" name="SeriesBConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_PaycheckProtectionProgramCARESActMember" abstract="true" name="PaycheckProtectionProgramCARESActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_SeriesAConvertiblePreferredStockMember" abstract="true" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" abstract="false" name="LesseeOperatingLeaseAnnualRentIncreasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_RegisteredDirectOfferingMember" abstract="true" name="RegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_EquityIncentivePlan2014Member" abstract="true" name="EquityIncentivePlan2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_SeriesNWarrantMember" abstract="true" name="SeriesNWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_WarrantsFairValue" abstract="false" name="WarrantsFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased" abstract="false" name="StockIssuedDuringPeriodRestrictedStockUnitsReleased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_FurnitureAndOfficeEquipmentMember" abstract="true" name="FurnitureAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="crdf_ReleaseOfClinicalTrialFundingCommitment" abstract="false" name="ReleaseOfClinicalTrialFundingCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightNumberExercised" abstract="false" name="ClassOfWarrantOrRightNumberExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_SeriesMWarrantMember" abstract="true" name="SeriesMWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightIssued" abstract="false" name="ClassOfWarrantOrRightIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_BlackScholesOptionPricingMethodMember" abstract="true" name="BlackScholesOptionPricingMethodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightMonthsUntilExercisable" abstract="false" name="ClassOfWarrantOrRightMonthsUntilExercisable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" abstract="false" name="DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_SaleOfStockValueCommonAndWarrantsNet" abstract="false" name="SaleOfStockValueCommonAndWarrantsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_SeriesCConvertiblePreferredStockMember" abstract="true" name="SeriesCConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_SeriesJWarrantMember" abstract="true" name="SeriesJWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_SaleOfStockConsiderationReceivedOnTransactionGross" abstract="false" name="SaleOfStockConsiderationReceivedOnTransactionGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_PreferredStockConvertibleConversionPrice" abstract="false" name="PreferredStockConvertibleConversionPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases" abstract="false" name="StockIssuedDuringPeriodValueRestrictedStockUnitsReleases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived" abstract="false" name="Releaseofclinicaltrialfundingcommitmentforservicesreceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="crdf_AmountFinancedUnderAgreement" abstract="false" name="AmountFinancedUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" abstract="false" name="ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="crdf_ServiceReceivableMember" abstract="true" name="ServiceReceivableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightNumberGranted" abstract="false" name="ClassOfWarrantOrRightNumberGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_SeriesEConvertiblePreferredStockMember" abstract="true" name="SeriesEConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_SeriesDConvertiblePreferredStockMember" abstract="true" name="SeriesDConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseMonthlyRentPayment" abstract="false" name="LesseeOperatingLeaseMonthlyRentPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_WarrantsAndRightsRollForward" abstract="true" name="WarrantsAndRightsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_SaleOfStockCommonAndWarrantsNetShares" abstract="false" name="SaleOfStockCommonAndWarrantsNetShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" abstract="false" name="BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember" abstract="true" name="AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="crdf_EstimatedFairValueOfWarrant" abstract="false" name="EstimatedFairValueOfWarrant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="crdf_LessorNumberOfSubleases" abstract="false" name="LessorNumberOfSubleases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="crdf_Servicereceivable" abstract="false" name="Servicereceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_SeriesIWarrantMember" abstract="true" name="SeriesIWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>crdf-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:899aa37a-8922-454a-a94d-f1f600203a5a,g:092e8a26-8aea-4f93-acda-3be57db43dca-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CoverPage" xlink:type="simple" xlink:href="crdf-20200930.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d08f3bd5-1aa6-4d15-bbb7-20ff93e412f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5ac2b895-0a19-4851-b14e-ea006e84f8ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d08f3bd5-1aa6-4d15-bbb7-20ff93e412f5" xlink:to="loc_us-gaap_AssetsCurrent_5ac2b895-0a19-4851-b14e-ea006e84f8ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_36463dbc-5826-442a-a934-91af6cada57d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d08f3bd5-1aa6-4d15-bbb7-20ff93e412f5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_36463dbc-5826-442a-a934-91af6cada57d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_90607ade-ddea-4970-8c38-f0a5990e78cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d08f3bd5-1aa6-4d15-bbb7-20ff93e412f5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_90607ade-ddea-4970-8c38-f0a5990e78cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ad19e86e-e737-4525-976c-6263d67db097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d08f3bd5-1aa6-4d15-bbb7-20ff93e412f5" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ad19e86e-e737-4525-976c-6263d67db097" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b33883ce-30a7-49bf-974c-9b95b2d9ae25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_56648026-081f-42ab-89f1-67d84a0a2abb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b33883ce-30a7-49bf-974c-9b95b2d9ae25" xlink:to="loc_us-gaap_AccountsPayableCurrent_56648026-081f-42ab-89f1-67d84a0a2abb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_82b73ef4-6d21-4f7d-af40-41adbbd5d23f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b33883ce-30a7-49bf-974c-9b95b2d9ae25" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_82b73ef4-6d21-4f7d-af40-41adbbd5d23f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_358ee5c3-e2de-4756-9d06-dea019a016d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b33883ce-30a7-49bf-974c-9b95b2d9ae25" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_358ee5c3-e2de-4756-9d06-dea019a016d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_e2c751ad-775a-4154-8b5b-c3cfc9b569de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b33883ce-30a7-49bf-974c-9b95b2d9ae25" xlink:to="loc_us-gaap_NotesPayableCurrent_e2c751ad-775a-4154-8b5b-c3cfc9b569de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_deeb8ce3-8516-44da-ae6f-9abf985261c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_acbb986a-19fc-4f12-a6b2-2a221fbf76a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_deeb8ce3-8516-44da-ae6f-9abf985261c9" xlink:to="loc_us-gaap_Liabilities_acbb986a-19fc-4f12-a6b2-2a221fbf76a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_fd439542-4b55-4ea0-a6e6-2cbcc6ee9032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_deeb8ce3-8516-44da-ae6f-9abf985261c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_fd439542-4b55-4ea0-a6e6-2cbcc6ee9032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4231465c-ffc9-4c85-a53b-c8b00a3e20ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_deeb8ce3-8516-44da-ae6f-9abf985261c9" xlink:to="loc_us-gaap_StockholdersEquity_4231465c-ffc9-4c85-a53b-c8b00a3e20ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d76c70d7-bb29-415e-b691-970e7d431453" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_92cc4c14-1a29-4df5-81b8-46428af11f40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d76c70d7-bb29-415e-b691-970e7d431453" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_92cc4c14-1a29-4df5-81b8-46428af11f40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b1e90b17-90ad-4891-8d18-cb7ac91beee8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d76c70d7-bb29-415e-b691-970e7d431453" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b1e90b17-90ad-4891-8d18-cb7ac91beee8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_22a4f99e-355c-41d6-b2c3-674f97173532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d76c70d7-bb29-415e-b691-970e7d431453" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_22a4f99e-355c-41d6-b2c3-674f97173532" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_67e7b42d-707a-41f8-a5dd-2fa8f5bf447e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_17027ea5-2909-45f8-904a-b2c0ae327641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_67e7b42d-707a-41f8-a5dd-2fa8f5bf447e" xlink:to="loc_us-gaap_LiabilitiesCurrent_17027ea5-2909-45f8-904a-b2c0ae327641" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_be2ed17d-888a-416e-bca4-ce6e45f473fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_67e7b42d-707a-41f8-a5dd-2fa8f5bf447e" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_be2ed17d-888a-416e-bca4-ce6e45f473fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ac370782-1a3e-4f94-879a-2ad19e96f1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_67e7b42d-707a-41f8-a5dd-2fa8f5bf447e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ac370782-1a3e-4f94-879a-2ad19e96f1a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8fd3ca55-a40c-491a-bcdf-9aa5923d2030" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_67e7b42d-707a-41f8-a5dd-2fa8f5bf447e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8fd3ca55-a40c-491a-bcdf-9aa5923d2030" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6ff6ea48-2c3e-448a-a588-582d37e13228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3f81406d-4feb-4d36-a114-3442d110f1cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6ff6ea48-2c3e-448a-a588-582d37e13228" xlink:to="loc_us-gaap_PreferredStockValue_3f81406d-4feb-4d36-a114-3442d110f1cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8eb15a18-3a3e-4de8-ad5f-e803350db424" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6ff6ea48-2c3e-448a-a588-582d37e13228" xlink:to="loc_us-gaap_CommonStockValue_8eb15a18-3a3e-4de8-ad5f-e803350db424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0427204c-b932-4116-b896-383af26a4646" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6ff6ea48-2c3e-448a-a588-582d37e13228" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0427204c-b932-4116-b896-383af26a4646" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Servicereceivable_872552a8-489f-495a-a7e3-494223c95eba" xlink:href="crdf-20200930.xsd#crdf_Servicereceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6ff6ea48-2c3e-448a-a588-582d37e13228" xlink:to="loc_crdf_Servicereceivable_872552a8-489f-495a-a7e3-494223c95eba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_df67d5cd-f9a1-44df-a030-6e820f963c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6ff6ea48-2c3e-448a-a588-582d37e13228" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_df67d5cd-f9a1-44df-a030-6e820f963c0b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8879c484-7a8c-4be6-aa2a-7ddfcc1b025e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_881df471-71d8-4a16-80a4-1927f73a9a56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8879c484-7a8c-4be6-aa2a-7ddfcc1b025e" xlink:to="loc_us-gaap_NetIncomeLoss_881df471-71d8-4a16-80a4-1927f73a9a56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_4bcd923a-5e98-4e7c-9fde-b076798ee69f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8879c484-7a8c-4be6-aa2a-7ddfcc1b025e" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_4bcd923a-5e98-4e7c-9fde-b076798ee69f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_14443502-084b-4b1c-80df-4f6f81502669" xlink:href="crdf-20200930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8879c484-7a8c-4be6-aa2a-7ddfcc1b025e" xlink:to="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_14443502-084b-4b1c-80df-4f6f81502669" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_67fce781-e8dc-4d47-8cfe-c9d610c7d129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c4a5f32a-0750-4097-bc77-fdca3521d3e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_67fce781-e8dc-4d47-8cfe-c9d610c7d129" xlink:to="loc_us-gaap_Revenues_c4a5f32a-0750-4097-bc77-fdca3521d3e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_12a9e976-ae4f-4e15-bcdf-d0f7ecab11ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_67fce781-e8dc-4d47-8cfe-c9d610c7d129" xlink:to="loc_us-gaap_OperatingExpenses_12a9e976-ae4f-4e15-bcdf-d0f7ecab11ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0ed3d82e-597c-43e9-bba6-aa33e7850504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_61895cd0-432a-4fdd-8fe2-5e02c15b0061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_0ed3d82e-597c-43e9-bba6-aa33e7850504" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_61895cd0-432a-4fdd-8fe2-5e02c15b0061" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8e23613-0266-45d0-b696-31d62984cef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_0ed3d82e-597c-43e9-bba6-aa33e7850504" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8e23613-0266-45d0-b696-31d62984cef0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bfe0e399-27c9-4c23-b7d2-8659de259193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_002df039-6fa4-484b-bba4-db555b40f88e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_bfe0e399-27c9-4c23-b7d2-8659de259193" xlink:to="loc_us-gaap_OperatingIncomeLoss_002df039-6fa4-484b-bba4-db555b40f88e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_43727436-52a9-483f-a5ed-2059b4b55df8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_bfe0e399-27c9-4c23-b7d2-8659de259193" xlink:to="loc_us-gaap_InterestIncomeOperating_43727436-52a9-483f-a5ed-2059b4b55df8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_8d034428-a96f-4ccb-a1a1-36848f9eaf5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_bfe0e399-27c9-4c23-b7d2-8659de259193" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_8d034428-a96f-4ccb-a1a1-36848f9eaf5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b26ffbfb-4855-4500-a574-be7e2340e52f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_bfe0e399-27c9-4c23-b7d2-8659de259193" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b26ffbfb-4855-4500-a574-be7e2340e52f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c283fd26-5bbe-423e-91f7-4b23cca2cfd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ac3c63d2-1346-41bd-883b-f7b72f998a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c283fd26-5bbe-423e-91f7-4b23cca2cfd8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ac3c63d2-1346-41bd-883b-f7b72f998a0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3341b61e-bec9-4e2d-a658-eb32ec7cf9e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c283fd26-5bbe-423e-91f7-4b23cca2cfd8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3341b61e-bec9-4e2d-a658-eb32ec7cf9e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8e6c448f-c328-4af0-8eb9-f61f089d2278" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c41aa8f-4e9c-41eb-9f97-23f9ed9ad441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8e6c448f-c328-4af0-8eb9-f61f089d2278" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c41aa8f-4e9c-41eb-9f97-23f9ed9ad441" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_19909663-77bb-40ca-a116-d44c812af0ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8e6c448f-c328-4af0-8eb9-f61f089d2278" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_19909663-77bb-40ca-a116-d44c812af0ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f90927b7-9af7-4e9e-877e-1ed441d8fb57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8e6c448f-c328-4af0-8eb9-f61f089d2278" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f90927b7-9af7-4e9e-877e-1ed441d8fb57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39110d0-fc20-4677-acbb-bfbc2c14cf28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_de3f24d8-47b9-4484-97f7-eb94c6829589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39110d0-fc20-4677-acbb-bfbc2c14cf28" xlink:to="loc_us-gaap_NetIncomeLoss_de3f24d8-47b9-4484-97f7-eb94c6829589" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_321a9009-8ae6-4b51-bbe7-75daeb48fb9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39110d0-fc20-4677-acbb-bfbc2c14cf28" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_321a9009-8ae6-4b51-bbe7-75daeb48fb9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a06827f3-567c-4a76-b364-7105643126bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39110d0-fc20-4677-acbb-bfbc2c14cf28" xlink:to="loc_us-gaap_ShareBasedCompensation_a06827f3-567c-4a76-b364-7105643126bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_15d037e2-609c-48bb-91a2-1e51f9037291" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39110d0-fc20-4677-acbb-bfbc2c14cf28" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_15d037e2-609c-48bb-91a2-1e51f9037291" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived_986ef4d6-acbc-4881-ae11-d8bc71db61de" xlink:href="crdf-20200930.xsd#crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39110d0-fc20-4677-acbb-bfbc2c14cf28" xlink:to="loc_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived_986ef4d6-acbc-4881-ae11-d8bc71db61de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_161db8cf-5b97-4f2f-a135-113ae1e6253d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39110d0-fc20-4677-acbb-bfbc2c14cf28" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_161db8cf-5b97-4f2f-a135-113ae1e6253d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b5fc27c0-a0df-4d2f-bb57-69366f136b48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39110d0-fc20-4677-acbb-bfbc2c14cf28" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b5fc27c0-a0df-4d2f-bb57-69366f136b48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_c0039e7c-eb46-4938-9989-5864b2d15c01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39110d0-fc20-4677-acbb-bfbc2c14cf28" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_c0039e7c-eb46-4938-9989-5864b2d15c01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_95cfacbf-47bb-4921-be4f-4f689bacc234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39110d0-fc20-4677-acbb-bfbc2c14cf28" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_95cfacbf-47bb-4921-be4f-4f689bacc234" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability_69a8cdad-1ea4-49bc-92ef-edf0709b9805" xlink:href="crdf-20200930.xsd#crdf_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39110d0-fc20-4677-acbb-bfbc2c14cf28" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability_69a8cdad-1ea4-49bc-92ef-edf0709b9805" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_88c9789c-b43e-419c-b643-2b9990a657cd" xlink:href="crdf-20200930.xsd#crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39110d0-fc20-4677-acbb-bfbc2c14cf28" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_88c9789c-b43e-419c-b643-2b9990a657cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c0d47a17-700e-4a63-b201-f797366bdbb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39110d0-fc20-4677-acbb-bfbc2c14cf28" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c0d47a17-700e-4a63-b201-f797366bdbb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_110fa0d8-32a1-4236-9997-fa864c9c44a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b39110d0-fc20-4677-acbb-bfbc2c14cf28" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_110fa0d8-32a1-4236-9997-fa864c9c44a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4021c7a8-823b-44fa-8651-744b7aa52afc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a151c2ff-e798-4563-bcd1-aeabb4201e37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4021c7a8-823b-44fa-8651-744b7aa52afc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a151c2ff-e798-4563-bcd1-aeabb4201e37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_352b0367-1e09-4a05-91ab-5b284c20b196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4021c7a8-823b-44fa-8651-744b7aa52afc" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_352b0367-1e09-4a05-91ab-5b284c20b196" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_242280fb-9364-49a7-8376-7f607d788f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4021c7a8-823b-44fa-8651-744b7aa52afc" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_242280fb-9364-49a7-8376-7f607d788f84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_58f81a26-3713-4512-abb0-21c289b6acdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4021c7a8-823b-44fa-8651-744b7aa52afc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_58f81a26-3713-4512-abb0-21c289b6acdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d487d6cd-ff78-4d5d-bfe7-1b87bebd3baa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4021c7a8-823b-44fa-8651-744b7aa52afc" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d487d6cd-ff78-4d5d-bfe7-1b87bebd3baa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c955a57-7f71-4297-9c4d-3fadd830dc05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6fe89839-7830-47bb-83ba-e6a7ee0b48af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c955a57-7f71-4297-9c4d-3fadd830dc05" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6fe89839-7830-47bb-83ba-e6a7ee0b48af" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="crdf-20200930.xsd#OrganizationandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="crdf-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="crdf-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="crdf-20200930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesNetLossPerShareDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#SummaryofSignificantAccountingPoliciesNetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesNetLossPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="crdf-20200930.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="crdf-20200930.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_004196b4-34c3-46e5-b63a-07fda87e1ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_78f6415a-433a-426c-8872-4e7333d93cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_004196b4-34c3-46e5-b63a-07fda87e1ecf" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_78f6415a-433a-426c-8872-4e7333d93cd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a5d1d4ba-cb6e-44fd-abb2-3a49e0c3b99d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_f45f0fa8-aeea-4a06-bf95-f9e281984074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a5d1d4ba-cb6e-44fd-abb2-3a49e0c3b99d" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_f45f0fa8-aeea-4a06-bf95-f9e281984074" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="crdf-20200930.xsd#PropertyandEquipment"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/PropertyandEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="crdf-20200930.xsd#PropertyandEquipmentTables"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/PropertyandEquipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#PropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_36797dd2-aecc-4144-b132-0247534dc0f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d73b36b3-d18a-43c3-98fa-d5e96991914c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_36797dd2-aecc-4144-b132-0247534dc0f8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d73b36b3-d18a-43c3-98fa-d5e96991914c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ac29fb40-0b77-4caa-bab1-0aa8ac24d8f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_36797dd2-aecc-4144-b132-0247534dc0f8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ac29fb40-0b77-4caa-bab1-0aa8ac24d8f3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/Leases" xlink:type="simple" xlink:href="crdf-20200930.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesTables" xlink:type="simple" xlink:href="crdf-20200930.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_1ab05fd4-3382-4b0a-aed1-139bfe7a0bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_1de5d695-3b69-498b-ba88-4b1408bca385" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_1ab05fd4-3382-4b0a-aed1-139bfe7a0bc3" xlink:to="loc_us-gaap_OperatingLeaseCost_1de5d695-3b69-498b-ba88-4b1408bca385" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_0f92ff5c-fab3-459e-959f-7bce6d845182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_1ab05fd4-3382-4b0a-aed1-139bfe7a0bc3" xlink:to="loc_us-gaap_SubleaseIncome_0f92ff5c-fab3-459e-959f-7bce6d845182" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_acd8d4d4-0d7c-427d-9515-ee260f00f350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ac1a6c12-bb44-46f6-beb6-77f9f410a8b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_acd8d4d4-0d7c-427d-9515-ee260f00f350" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ac1a6c12-bb44-46f6-beb6-77f9f410a8b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f22e1b6e-d665-4e25-b5f1-169928c58fe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_acd8d4d4-0d7c-427d-9515-ee260f00f350" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f22e1b6e-d665-4e25-b5f1-169928c58fe8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#LeasesSupplementalCashFlowInformationDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_94f8a4fa-40ea-41d6-9653-282ef7ad8958" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8a44ea40-2127-49ac-aa0c-3b3580da8378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_94f8a4fa-40ea-41d6-9653-282ef7ad8958" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8a44ea40-2127-49ac-aa0c-3b3580da8378" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_c3fe8edf-d71b-42f5-8b3f-06b4a7c2c8f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_94f8a4fa-40ea-41d6-9653-282ef7ad8958" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_c3fe8edf-d71b-42f5-8b3f-06b4a7c2c8f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne_18daf0b6-63d1-477b-88a0-7ce5e4406622" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_744c4faf-4532-4f7f-8ca5-fe8f7b4296c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne_18daf0b6-63d1-477b-88a0-7ce5e4406622" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_744c4faf-4532-4f7f-8ca5-fe8f7b4296c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9bdf6a4d-6470-444f-b51e-3327c719b8e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne_18daf0b6-63d1-477b-88a0-7ce5e4406622" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9bdf6a4d-6470-444f-b51e-3327c719b8e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_e75b0f12-92b7-450c-8c3c-2923bb671a97" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_13983a15-9c4b-4196-80ba-98df6b74d2c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_e75b0f12-92b7-450c-8c3c-2923bb671a97" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_13983a15-9c4b-4196-80ba-98df6b74d2c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_f5ed818b-0e29-40ac-804f-a94cf82729a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_e75b0f12-92b7-450c-8c3c-2923bb671a97" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_f5ed818b-0e29-40ac-804f-a94cf82729a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_461f669c-5465-4be3-b1ce-fa9b053bb9de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_657531e8-4969-4359-a81f-589ff519d9cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_461f669c-5465-4be3-b1ce-fa9b053bb9de" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_657531e8-4969-4359-a81f-589ff519d9cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0d4d8470-580b-4a5a-b6d0-78e402006ea6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_461f669c-5465-4be3-b1ce-fa9b053bb9de" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0d4d8470-580b-4a5a-b6d0-78e402006ea6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e79b2d1e-af87-482e-a98c-b1d0d8877cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_461f669c-5465-4be3-b1ce-fa9b053bb9de" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e79b2d1e-af87-482e-a98c-b1d0d8877cb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_48036645-08c7-4d4c-9617-af341ca6bedf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_461f669c-5465-4be3-b1ce-fa9b053bb9de" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_48036645-08c7-4d4c-9617-af341ca6bedf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_70692280-04eb-4d7c-a35d-25389ccdc60c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_59e0a14d-9a84-442f-b755-6fad276c0293" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_70692280-04eb-4d7c-a35d-25389ccdc60c" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_59e0a14d-9a84-442f-b755-6fad276c0293" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_5c57f75c-6a42-4cb4-a627-93f89bc1742c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_70692280-04eb-4d7c-a35d-25389ccdc60c" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_5c57f75c-6a42-4cb4-a627-93f89bc1742c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_043f8eee-f9d8-46c2-9791-8dd400255fef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_70692280-04eb-4d7c-a35d-25389ccdc60c" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_043f8eee-f9d8-46c2-9791-8dd400255fef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_3533074d-2f29-48a3-9935-1b7877cadece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_70692280-04eb-4d7c-a35d-25389ccdc60c" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_3533074d-2f29-48a3-9935-1b7877cadece" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear_6c0f6618-212c-45ca-a9cf-14118b2bf2a0" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8e23d910-7b8e-4739-8a48-51756c908e7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear_6c0f6618-212c-45ca-a9cf-14118b2bf2a0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8e23d910-7b8e-4739-8a48-51756c908e7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_afef6c97-e66d-417f-a872-783550269877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear_6c0f6618-212c-45ca-a9cf-14118b2bf2a0" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_afef6c97-e66d-417f-a872-783550269877" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_9a5e2c31-7c43-4741-8a0b-a20fe83396fe" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_81b83b93-3f30-4f6b-a263-288bc64b1632" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_9a5e2c31-7c43-4741-8a0b-a20fe83396fe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_81b83b93-3f30-4f6b-a263-288bc64b1632" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_ffbfaeea-0933-46f0-85c1-42148d93d9f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_9a5e2c31-7c43-4741-8a0b-a20fe83396fe" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_ffbfaeea-0933-46f0-85c1-42148d93d9f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="crdf-20200930.xsd#LeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17483b31-d973-4de8-9636-9ac19882ce0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f7b9295c-7100-4fb0-b7d8-e3f0467b7add" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17483b31-d973-4de8-9636-9ac19882ce0a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f7b9295c-7100-4fb0-b7d8-e3f0467b7add" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_49a97285-23e8-46b3-85b5-54b42b87b29b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17483b31-d973-4de8-9636-9ac19882ce0a" xlink:to="loc_us-gaap_OperatingLeaseLiability_49a97285-23e8-46b3-85b5-54b42b87b29b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_78b59085-737e-4498-ad57-cd4d3164244e" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne_b77592c1-18da-4a46-a046-31b1662f3d18" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_78b59085-737e-4498-ad57-cd4d3164244e" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne_b77592c1-18da-4a46-a046-31b1662f3d18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_8edbb87d-854b-489b-a2d9-7b63da3f529c" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_78b59085-737e-4498-ad57-cd4d3164244e" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_8edbb87d-854b-489b-a2d9-7b63da3f529c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear_dba7fad9-d338-4603-83ea-2fba9125408b" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_78b59085-737e-4498-ad57-cd4d3164244e" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear_dba7fad9-d338-4603-83ea-2fba9125408b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_bfef5e87-192c-463a-9876-8bdd92e4c0ba" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_78b59085-737e-4498-ad57-cd4d3164244e" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_bfef5e87-192c-463a-9876-8bdd92e4c0ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants" xlink:type="simple" xlink:href="crdf-20200930.xsd#DerivativeFinancialInstrumentsWarrants"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables" xlink:type="simple" xlink:href="crdf-20200930.xsd#DerivativeFinancialInstrumentsWarrantsTables"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#DerivativeFinancialInstrumentsWarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquity" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquityStockbasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquityStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquityRestrictedStockUnitsDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquityWarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquityPreferredStockDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquitySeriesCConvertiblePreferredStockDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquitySeriesDConvertiblePreferredStockDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquitySeriesEConvertiblePreferredStockDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquitySecuritiesPurchaseAgreementDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="crdf-20200930.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#CommitmentsandContingenciesDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="crdf-20200930.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#RelatedPartyTransactionsDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/COVID19" xlink:type="simple" xlink:href="crdf-20200930.xsd#COVID19"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/COVID19" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/COVID19Details" xlink:type="simple" xlink:href="crdf-20200930.xsd#COVID19Details"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/COVID19Details" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SubsequentEvents" xlink:type="simple" xlink:href="crdf-20200930.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SubsequentEventsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>crdf-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:899aa37a-8922-454a-a94d-f1f600203a5a,g:092e8a26-8aea-4f93-acda-3be57db43dca-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CoverPage" xlink:type="simple" xlink:href="crdf-20200930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/CoverPage" xlink:type="extended" id="i843387adb0cd44e9a3613f198e0fa9f7_CoverPage"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended" id="iaa972723d46e4cb2b0a79467186cef19_CONDENSEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="extended" id="i5817e566cfdf4a64935a7f7d7c7ffd2a_CONDENSEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i575c98d7359146bebee9a14638b6bd73_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1acee142-2cea-4099-9a73-691a72c1d8db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_RevenuesAbstract_1acee142-2cea-4099-9a73-691a72c1d8db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_27a4c8b6-49b7-4d54-b705-4f79ed933c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1acee142-2cea-4099-9a73-691a72c1d8db" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_27a4c8b6-49b7-4d54-b705-4f79ed933c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_644e9396-5082-4ca2-80d6-f03e81b0b190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1acee142-2cea-4099-9a73-691a72c1d8db" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_644e9396-5082-4ca2-80d6-f03e81b0b190" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b1b08b67-abc7-47e1-89e5-c875ff91581a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1acee142-2cea-4099-9a73-691a72c1d8db" xlink:to="loc_us-gaap_Revenues_b1b08b67-abc7-47e1-89e5-c875ff91581a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6a8fb4bf-baab-4a4a-ae5c-7d6880edad74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6a8fb4bf-baab-4a4a-ae5c-7d6880edad74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ac96ccba-36ee-4b8d-919c-5e6fc6d8ec55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6a8fb4bf-baab-4a4a-ae5c-7d6880edad74" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ac96ccba-36ee-4b8d-919c-5e6fc6d8ec55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_14897bd1-75de-41cb-94f4-c999f24657ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6a8fb4bf-baab-4a4a-ae5c-7d6880edad74" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_14897bd1-75de-41cb-94f4-c999f24657ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_50c33d10-3eed-407e-be7f-6a82390e3b8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6a8fb4bf-baab-4a4a-ae5c-7d6880edad74" xlink:to="loc_us-gaap_OperatingExpenses_50c33d10-3eed-407e-be7f-6a82390e3b8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0ea6b3d5-5131-4a33-a408-90b4fe48e97b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_OperatingIncomeLoss_0ea6b3d5-5131-4a33-a408-90b4fe48e97b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_036ed423-59fe-471a-b517-a47ac1c8f7a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_InterestIncomeOperating_036ed423-59fe-471a-b517-a47ac1c8f7a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_3fa4c28c-ae93-492c-90db-aeb41f62981e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_3fa4c28c-ae93-492c-90db-aeb41f62981e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_eee84673-1fcd-4535-ba99-bff7258d389e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_eee84673-1fcd-4535-ba99-bff7258d389e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6444aeb1-f644-46bb-8e1a-d5d3883310ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_NetIncomeLoss_6444aeb1-f644-46bb-8e1a-d5d3883310ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_94d87724-878d-4d94-b681-144ac5017a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_94d87724-878d-4d94-b681-144ac5017a0d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_c378bf9b-0022-44b5-9f26-242e8ffa64ae" xlink:href="crdf-20200930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_c378bf9b-0022-44b5-9f26-242e8ffa64ae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5d0d481d-ea72-4573-af5b-ce6d713a8b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5d0d481d-ea72-4573-af5b-ce6d713a8b9b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_5f7b9a2f-c1e3-4339-a269-1bd48f9719a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_5f7b9a2f-c1e3-4339-a269-1bd48f9719a2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_edd584f5-618a-4586-82d5-2bec36af6a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_edd584f5-618a-4586-82d5-2bec36af6a0d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5bcf293f-549b-4413-bd1a-3192ae1e1171" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_StatementTable_5bcf293f-549b-4413-bd1a-3192ae1e1171" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_88086a12-1e43-4ba3-a231-a29cb2d44ade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5bcf293f-549b-4413-bd1a-3192ae1e1171" xlink:to="loc_us-gaap_StatementClassOfStockAxis_88086a12-1e43-4ba3-a231-a29cb2d44ade" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_88086a12-1e43-4ba3-a231-a29cb2d44ade_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_88086a12-1e43-4ba3-a231-a29cb2d44ade" xlink:to="loc_us-gaap_ClassOfStockDomain_88086a12-1e43-4ba3-a231-a29cb2d44ade_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_164e3e98-97dd-42b4-9b23-dfe21c7416f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_88086a12-1e43-4ba3-a231-a29cb2d44ade" xlink:to="loc_us-gaap_ClassOfStockDomain_164e3e98-97dd-42b4-9b23-dfe21c7416f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_5632bbf3-957c-4426-82d3-15cfaec53b07" xlink:href="crdf-20200930.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_164e3e98-97dd-42b4-9b23-dfe21c7416f1" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_5632bbf3-957c-4426-82d3-15cfaec53b07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_ddff7d3b-b9c5-4179-96ad-bfba10fe14bb" xlink:href="crdf-20200930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_164e3e98-97dd-42b4-9b23-dfe21c7416f1" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_ddff7d3b-b9c5-4179-96ad-bfba10fe14bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_98cf9022-c349-49bd-a011-0fb4c2e4eb1c" xlink:href="crdf-20200930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_164e3e98-97dd-42b4-9b23-dfe21c7416f1" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_98cf9022-c349-49bd-a011-0fb4c2e4eb1c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="icbd83ab808ee40788b51f912d91a9ea6_CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_828d1362-8168-41ce-83dd-4f1cf3298fd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_828d1362-8168-41ce-83dd-4f1cf3298fd3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_52c2fab1-984b-4bf0-8dab-f89aff9a140b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_SharesIssued_52c2fab1-984b-4bf0-8dab-f89aff9a140b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_27f63b76-846f-4123-bfd1-4faf4b92cb57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_StockholdersEquity_27f63b76-846f-4123-bfd1-4faf4b92cb57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e8d082d2-e2bc-4636-b603-9aee4cbf381f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e8d082d2-e2bc-4636-b603-9aee4cbf381f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SaleOfStockCommonAndWarrantsNetShares_0fd3c552-7af4-40ba-9e51-34c4d92c7914" xlink:href="crdf-20200930.xsd#crdf_SaleOfStockCommonAndWarrantsNetShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_crdf_SaleOfStockCommonAndWarrantsNetShares_0fd3c552-7af4-40ba-9e51-34c4d92c7914" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SaleOfStockValueCommonAndWarrantsNet_d5fd8cb1-e05e-4bf1-a9b4-d18ac2461de7" xlink:href="crdf-20200930.xsd#crdf_SaleOfStockValueCommonAndWarrantsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_crdf_SaleOfStockValueCommonAndWarrantsNet_d5fd8cb1-e05e-4bf1-a9b4-d18ac2461de7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_86b8362c-45d3-4407-bc42-85b3243c9873" xlink:href="crdf-20200930.xsd#crdf_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_86b8362c-45d3-4407-bc42-85b3243c9873" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised_7879479e-e5b9-4989-8aca-7e1b808eb820" xlink:href="crdf-20200930.xsd#crdf_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised_7879479e-e5b9-4989-8aca-7e1b808eb820" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased_dc1499a2-77e5-49d6-877b-6b7d13d64e5e" xlink:href="crdf-20200930.xsd#crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased_dc1499a2-77e5-49d6-877b-6b7d13d64e5e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases_d7dcef22-58cd-4a1b-a30f-495ab7f3dbd7" xlink:href="crdf-20200930.xsd#crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases_d7dcef22-58cd-4a1b-a30f-495ab7f3dbd7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_9d5a9661-1d8e-4399-b9e9-4b7f86347df9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_DividendsPreferredStock_9d5a9661-1d8e-4399-b9e9-4b7f86347df9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitment_c6cc1c7a-ac7e-49e9-af17-653a6d322b6d" xlink:href="crdf-20200930.xsd#crdf_ReleaseOfClinicalTrialFundingCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_crdf_ReleaseOfClinicalTrialFundingCommitment_c6cc1c7a-ac7e-49e9-af17-653a6d322b6d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4757a2f5-737a-45c8-9137-c1e118a0fff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_NetIncomeLoss_4757a2f5-737a-45c8-9137-c1e118a0fff3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_b0f66044-3130-4348-8d8a-bc8e72251855" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_b0f66044-3130-4348-8d8a-bc8e72251855" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_530ec235-b85c-4f09-b0d0-ef9e393ddc65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_530ec235-b85c-4f09-b0d0-ef9e393ddc65" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_985fac38-ae8e-4d09-9ffd-20e2cf6df8a0" xlink:href="crdf-20200930.xsd#crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_985fac38-ae8e-4d09-9ffd-20e2cf6df8a0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7ec3182a-b714-4dd5-85c1-481452627980" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7ec3182a-b714-4dd5-85c1-481452627980" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c51a9d05-d8f8-47fc-b4eb-e02a0f6a206c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c51a9d05-d8f8-47fc-b4eb-e02a0f6a206c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_733f77ec-dcb9-4e62-98e1-bf5abd9ed014" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_733f77ec-dcb9-4e62-98e1-bf5abd9ed014" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_4e680ee0-09e0-43a3-992e-a9cf9510313d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_4e680ee0-09e0-43a3-992e-a9cf9510313d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_23401bc2-8685-4e8f-8660-4ad80ad16d37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_23401bc2-8685-4e8f-8660-4ad80ad16d37" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ed785297-3d61-494a-93cb-d726f07071d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ed785297-3d61-494a-93cb-d726f07071d9" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_e7d5de11-7295-4348-a545-639dd8c6a5f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_e7d5de11-7295-4348-a545-639dd8c6a5f1" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_520ca675-e64a-43d3-bd37-fe55623e0937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_af4842ae-2810-45e6-ba8b-5fe3d24b7a8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d3071484-af33-4d74-8e58-a0590df02ca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_828d1362-8168-41ce-83dd-4f1cf3298fd3" xlink:to="loc_us-gaap_StatementTable_d3071484-af33-4d74-8e58-a0590df02ca2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2823bd7c-9b38-4836-b595-16ee1c52278a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d3071484-af33-4d74-8e58-a0590df02ca2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2823bd7c-9b38-4836-b595-16ee1c52278a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2823bd7c-9b38-4836-b595-16ee1c52278a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2823bd7c-9b38-4836-b595-16ee1c52278a" xlink:to="loc_us-gaap_EquityComponentDomain_2823bd7c-9b38-4836-b595-16ee1c52278a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d7778e4d-371c-4730-b7b5-696d95e5dd41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2823bd7c-9b38-4836-b595-16ee1c52278a" xlink:to="loc_us-gaap_EquityComponentDomain_d7778e4d-371c-4730-b7b5-696d95e5dd41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_c4473f38-55ae-4bc0-9831-838d484cc1d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d7778e4d-371c-4730-b7b5-696d95e5dd41" xlink:to="loc_us-gaap_PreferredStockMember_c4473f38-55ae-4bc0-9831-838d484cc1d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b4e656e9-252d-4997-8adc-d1526cabfa2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d7778e4d-371c-4730-b7b5-696d95e5dd41" xlink:to="loc_us-gaap_CommonStockMember_b4e656e9-252d-4997-8adc-d1526cabfa2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1125cd69-1cf0-43df-9076-01b8fe954f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d7778e4d-371c-4730-b7b5-696d95e5dd41" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1125cd69-1cf0-43df-9076-01b8fe954f6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivableMember_a1f5ff86-394d-4e28-bd05-d9e815af40f3" xlink:href="crdf-20200930.xsd#crdf_ServiceReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d7778e4d-371c-4730-b7b5-696d95e5dd41" xlink:to="loc_crdf_ServiceReceivableMember_a1f5ff86-394d-4e28-bd05-d9e815af40f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_fcb6b65e-a412-492e-9344-4c44a43c136a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d7778e4d-371c-4730-b7b5-696d95e5dd41" xlink:to="loc_us-gaap_RetainedEarningsMember_fcb6b65e-a412-492e-9344-4c44a43c136a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f0cda30f-e75c-4e4c-b878-025439e206d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d3071484-af33-4d74-8e58-a0590df02ca2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f0cda30f-e75c-4e4c-b878-025439e206d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f0cda30f-e75c-4e4c-b878-025439e206d8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f0cda30f-e75c-4e4c-b878-025439e206d8" xlink:to="loc_us-gaap_ClassOfStockDomain_f0cda30f-e75c-4e4c-b878-025439e206d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f0671912-fd6a-498d-a318-e48d5b699874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f0cda30f-e75c-4e4c-b878-025439e206d8" xlink:to="loc_us-gaap_ClassOfStockDomain_f0671912-fd6a-498d-a318-e48d5b699874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_9f38dc83-3f6f-4a4b-85fa-e098da16f127" xlink:href="crdf-20200930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f0671912-fd6a-498d-a318-e48d5b699874" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_9f38dc83-3f6f-4a4b-85fa-e098da16f127" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_48bc956f-71c5-4e74-b261-adfa30f014de" xlink:href="crdf-20200930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f0671912-fd6a-498d-a318-e48d5b699874" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_48bc956f-71c5-4e74-b261-adfa30f014de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_c2bfb423-5999-4d45-b95e-231e71a99b9f" xlink:href="crdf-20200930.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f0671912-fd6a-498d-a318-e48d5b699874" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_c2bfb423-5999-4d45-b95e-231e71a99b9f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended" id="i389771583f1a4f718b942af428c17bd0_CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="icbdf15aaa87f4422b083e07faebfde3a_CONDENSEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6a083088-35d5-4dfa-8790-65bdccf9f886" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_91d45d40-e9d6-4bd5-84f8-01b64d88a7e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a083088-35d5-4dfa-8790-65bdccf9f886" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_91d45d40-e9d6-4bd5-84f8-01b64d88a7e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ff6474af-8bac-4e90-b9b0-2a3adfb45109" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_91d45d40-e9d6-4bd5-84f8-01b64d88a7e9" xlink:to="loc_us-gaap_NetIncomeLoss_ff6474af-8bac-4e90-b9b0-2a3adfb45109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c02cf9a-7336-4931-9cc9-633a1507f816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_91d45d40-e9d6-4bd5-84f8-01b64d88a7e9" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c02cf9a-7336-4931-9cc9-633a1507f816" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_567107b0-175c-4bb4-8ebc-fee66f7a8140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c02cf9a-7336-4931-9cc9-633a1507f816" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_567107b0-175c-4bb4-8ebc-fee66f7a8140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_85ec136f-3e90-465e-bc53-935f15ca1f00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c02cf9a-7336-4931-9cc9-633a1507f816" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_85ec136f-3e90-465e-bc53-935f15ca1f00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_04732b6f-1a5e-438e-892f-96e2fbf80bd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c02cf9a-7336-4931-9cc9-633a1507f816" xlink:to="loc_us-gaap_ShareBasedCompensation_04732b6f-1a5e-438e-892f-96e2fbf80bd3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_b505950d-8ec1-491f-b0a2-476918284510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c02cf9a-7336-4931-9cc9-633a1507f816" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_b505950d-8ec1-491f-b0a2-476918284510" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived_5c2ed2e5-86f8-4927-aa95-b6599f0ef4f5" xlink:href="crdf-20200930.xsd#crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c02cf9a-7336-4931-9cc9-633a1507f816" xlink:to="loc_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived_5c2ed2e5-86f8-4927-aa95-b6599f0ef4f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c28ad4e0-2ba9-4d1f-a1d4-cd983035a509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c02cf9a-7336-4931-9cc9-633a1507f816" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c28ad4e0-2ba9-4d1f-a1d4-cd983035a509" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_32d00772-bf47-4ec8-b449-27c94f9cf51d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c28ad4e0-2ba9-4d1f-a1d4-cd983035a509" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_32d00772-bf47-4ec8-b449-27c94f9cf51d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ed362dc6-387c-45a2-9152-a62c48a87a61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c28ad4e0-2ba9-4d1f-a1d4-cd983035a509" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ed362dc6-387c-45a2-9152-a62c48a87a61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_6e084ada-a543-4752-b885-de0c9331b0cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c28ad4e0-2ba9-4d1f-a1d4-cd983035a509" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_6e084ada-a543-4752-b885-de0c9331b0cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_6fdb6a17-8ec2-46bf-97b2-6e0b0a13edf5" xlink:href="crdf-20200930.xsd#crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c28ad4e0-2ba9-4d1f-a1d4-cd983035a509" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_6fdb6a17-8ec2-46bf-97b2-6e0b0a13edf5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0629d373-4f96-4513-9678-87e25524b338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c28ad4e0-2ba9-4d1f-a1d4-cd983035a509" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0629d373-4f96-4513-9678-87e25524b338" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability_bdbb68e8-19ce-4937-97c5-90f64b1f736e" xlink:href="crdf-20200930.xsd#crdf_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c28ad4e0-2ba9-4d1f-a1d4-cd983035a509" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability_bdbb68e8-19ce-4937-97c5-90f64b1f736e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_88fbde45-9833-4269-a04a-558c7cf1f925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c28ad4e0-2ba9-4d1f-a1d4-cd983035a509" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_88fbde45-9833-4269-a04a-558c7cf1f925" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70082ede-0ab1-47ef-9084-5c014d91e223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_91d45d40-e9d6-4bd5-84f8-01b64d88a7e9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70082ede-0ab1-47ef-9084-5c014d91e223" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2489ba82-81c5-41ed-bc5a-f886ea0c9c8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a083088-35d5-4dfa-8790-65bdccf9f886" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2489ba82-81c5-41ed-bc5a-f886ea0c9c8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b43b280c-66ce-4a79-b86e-48be9bbe0551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2489ba82-81c5-41ed-bc5a-f886ea0c9c8e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b43b280c-66ce-4a79-b86e-48be9bbe0551" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_03c4a5e4-04ff-4e43-8afd-728c32f7105d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2489ba82-81c5-41ed-bc5a-f886ea0c9c8e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_03c4a5e4-04ff-4e43-8afd-728c32f7105d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_38d5a68b-653f-4ed6-94a3-7557fb0df24f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a083088-35d5-4dfa-8790-65bdccf9f886" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_38d5a68b-653f-4ed6-94a3-7557fb0df24f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cc161005-5293-4cd3-86cb-322419ce7948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_38d5a68b-653f-4ed6-94a3-7557fb0df24f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cc161005-5293-4cd3-86cb-322419ce7948" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_101ad24f-9b66-4102-b2f5-5a0cef150f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_38d5a68b-653f-4ed6-94a3-7557fb0df24f" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_101ad24f-9b66-4102-b2f5-5a0cef150f9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_46068466-a5d3-447a-a9c2-daa5100954b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_38d5a68b-653f-4ed6-94a3-7557fb0df24f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_46068466-a5d3-447a-a9c2-daa5100954b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_5e8ea592-b976-463c-a789-8764262aee5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_38d5a68b-653f-4ed6-94a3-7557fb0df24f" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_5e8ea592-b976-463c-a789-8764262aee5c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3350a6ba-6467-42d1-915d-54c1e944912e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_38d5a68b-653f-4ed6-94a3-7557fb0df24f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3350a6ba-6467-42d1-915d-54c1e944912e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19e27075-a532-4945-a598-c070610a381e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_38d5a68b-653f-4ed6-94a3-7557fb0df24f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19e27075-a532-4945-a598-c070610a381e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0841d5f8-849c-4d6f-8441-e2f2ccaca4d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a083088-35d5-4dfa-8790-65bdccf9f886" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0841d5f8-849c-4d6f-8441-e2f2ccaca4d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9fa8f46b-8bc5-4a6f-a184-812b09719ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a083088-35d5-4dfa-8790-65bdccf9f886" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9fa8f46b-8bc5-4a6f-a184-812b09719ca6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4504e91e-6d35-401f-9582-b1e67698793d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6fff5643-2d69-4910-a340-26666ffbec01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a083088-35d5-4dfa-8790-65bdccf9f886" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6fff5643-2d69-4910-a340-26666ffbec01" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_cdfdbe38-39f6-467c-be7c-db0f6ba17a5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6fff5643-2d69-4910-a340-26666ffbec01" xlink:to="loc_us-gaap_IncomeTaxesPaid_cdfdbe38-39f6-467c-be7c-db0f6ba17a5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_899369ab-3093-436a-9c69-d985892a66d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a083088-35d5-4dfa-8790-65bdccf9f886" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_899369ab-3093-436a-9c69-d985892a66d8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockDividendAccrued_573c9049-8d50-4f34-891f-9f936e89d827" xlink:href="crdf-20200930.xsd#crdf_PreferredStockDividendAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_899369ab-3093-436a-9c69-d985892a66d8" xlink:to="loc_crdf_PreferredStockDividendAccrued_573c9049-8d50-4f34-891f-9f936e89d827" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_9cbf18c5-2d6b-4cc2-a3bd-6bd76b246f93" xlink:href="crdf-20200930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_899369ab-3093-436a-9c69-d985892a66d8" xlink:to="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_9cbf18c5-2d6b-4cc2-a3bd-6bd76b246f93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_9106582b-b990-4fad-926d-91a3d292ff24" xlink:href="crdf-20200930.xsd#crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_899369ab-3093-436a-9c69-d985892a66d8" xlink:to="loc_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_9106582b-b990-4fad-926d-91a3d292ff24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_224920ac-2666-415b-ba2c-3d3446ae5350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_899369ab-3093-436a-9c69-d985892a66d8" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_224920ac-2666-415b-ba2c-3d3446ae5350" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_37aba0f8-d1d6-465b-a88a-f51241d17c87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6a083088-35d5-4dfa-8790-65bdccf9f886" xlink:to="loc_us-gaap_StatementTable_37aba0f8-d1d6-465b-a88a-f51241d17c87" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_21433e89-3afb-4035-8efd-1a8d4af4e154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_37aba0f8-d1d6-465b-a88a-f51241d17c87" xlink:to="loc_us-gaap_StatementClassOfStockAxis_21433e89-3afb-4035-8efd-1a8d4af4e154" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_21433e89-3afb-4035-8efd-1a8d4af4e154_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_21433e89-3afb-4035-8efd-1a8d4af4e154" xlink:to="loc_us-gaap_ClassOfStockDomain_21433e89-3afb-4035-8efd-1a8d4af4e154_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b12d24c2-134c-4adf-b479-9d1d39e91baa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_21433e89-3afb-4035-8efd-1a8d4af4e154" xlink:to="loc_us-gaap_ClassOfStockDomain_b12d24c2-134c-4adf-b479-9d1d39e91baa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_2853bfb1-7416-4889-b47a-b8c6beb9956a" xlink:href="crdf-20200930.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b12d24c2-134c-4adf-b479-9d1d39e91baa" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_2853bfb1-7416-4889-b47a-b8c6beb9956a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_ddcd9505-905f-4286-ae50-ffb70bb63250" xlink:href="crdf-20200930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b12d24c2-134c-4adf-b479-9d1d39e91baa" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_ddcd9505-905f-4286-ae50-ffb70bb63250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_c08e042c-4476-4d3d-b9d6-98d1603d456e" xlink:href="crdf-20200930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b12d24c2-134c-4adf-b479-9d1d39e91baa" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_c08e042c-4476-4d3d-b9d6-98d1603d456e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="extended" id="ic12e5d93bef84bcda8f6694dac6642dd_CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3b316630-4e6d-47b0-bb88-f822b639e85e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_e0212bda-db5f-4667-8e8d-b002e73a2345" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3b316630-4e6d-47b0-bb88-f822b639e85e" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_e0212bda-db5f-4667-8e8d-b002e73a2345" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_39acdbf4-d191-4926-98be-6d3f45d8162a" xlink:href="crdf-20200930.xsd#crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3b316630-4e6d-47b0-bb88-f822b639e85e" xlink:to="loc_crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_39acdbf4-d191-4926-98be-6d3f45d8162a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ffa0aed8-1ed8-4a19-82fb-50a1d4fb2927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3b316630-4e6d-47b0-bb88-f822b639e85e" xlink:to="loc_us-gaap_StatementTable_ffa0aed8-1ed8-4a19-82fb-50a1d4fb2927" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9ce4d871-cb83-47fe-a5a9-436af25e7105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ffa0aed8-1ed8-4a19-82fb-50a1d4fb2927" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9ce4d871-cb83-47fe-a5a9-436af25e7105" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9ce4d871-cb83-47fe-a5a9-436af25e7105_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9ce4d871-cb83-47fe-a5a9-436af25e7105" xlink:to="loc_us-gaap_ClassOfStockDomain_9ce4d871-cb83-47fe-a5a9-436af25e7105_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b240580b-0bc1-4bf6-bc89-2afde2af7cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9ce4d871-cb83-47fe-a5a9-436af25e7105" xlink:to="loc_us-gaap_ClassOfStockDomain_b240580b-0bc1-4bf6-bc89-2afde2af7cb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_aca69b82-319e-4612-8d2e-54112dfa8e27" xlink:href="crdf-20200930.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b240580b-0bc1-4bf6-bc89-2afde2af7cb4" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_aca69b82-319e-4612-8d2e-54112dfa8e27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_b01a2f1d-05d5-4be0-93b8-9ddd9c27628a" xlink:href="crdf-20200930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b240580b-0bc1-4bf6-bc89-2afde2af7cb4" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_b01a2f1d-05d5-4be0-93b8-9ddd9c27628a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="crdf-20200930.xsd#OrganizationandBasisofPresentation"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation" xlink:type="extended" id="i5bacf852704f45a28da2ed3c7cfebcdb_OrganizationandBasisofPresentation"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended" id="i572e890255cb488588581f11831fabb5_OrganizationandBasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_061693f2-74d6-425a-b637-af2e265db1da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41181ea6-d01f-49f7-8d3f-1fc27bda82dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_061693f2-74d6-425a-b637-af2e265db1da" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41181ea6-d01f-49f7-8d3f-1fc27bda82dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SaleOfStockConsiderationReceivedOnTransactionGross_f766aea0-9a60-4fe5-8735-559eab42f708" xlink:href="crdf-20200930.xsd#crdf_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_061693f2-74d6-425a-b637-af2e265db1da" xlink:to="loc_crdf_SaleOfStockConsiderationReceivedOnTransactionGross_f766aea0-9a60-4fe5-8735-559eab42f708" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_eb4f97e4-c202-4c08-9335-08da01d59bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_061693f2-74d6-425a-b637-af2e265db1da" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_eb4f97e4-c202-4c08-9335-08da01d59bb1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a99d3128-d7fb-4c2f-afa5-dcd50ae667e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_eb4f97e4-c202-4c08-9335-08da01d59bb1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a99d3128-d7fb-4c2f-afa5-dcd50ae667e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a99d3128-d7fb-4c2f-afa5-dcd50ae667e9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a99d3128-d7fb-4c2f-afa5-dcd50ae667e9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a99d3128-d7fb-4c2f-afa5-dcd50ae667e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a098b54a-3ea5-45d2-9331-adfef633fd24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a99d3128-d7fb-4c2f-afa5-dcd50ae667e9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a098b54a-3ea5-45d2-9331-adfef633fd24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5b39f3f4-555d-4766-9a50-692458659974" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a098b54a-3ea5-45d2-9331-adfef633fd24" xlink:to="loc_us-gaap_SubsequentEventMember_5b39f3f4-555d-4766-9a50-692458659974" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="crdf-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="if6b0ce2d661845a2ba9676b4bbb00a14_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="crdf-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="if88c4e50b3174f75a5f567a5f7dcfdb4_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="crdf-20200930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="ida9b69b54e4e4c56a2fc98fe51b7e9b1_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesNetLossPerShareDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#SummaryofSignificantAccountingPoliciesNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesNetLossPerShareDetails" xlink:type="extended" id="i7cf6a2e974de44d29a39aff812557e70_SummaryofSignificantAccountingPoliciesNetLossPerShareDetails"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="extended" id="i88f704b2a30d4bbf91155d88bd37f637_SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_715e3842-7178-429d-b66d-3c6bd1e60d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f4bb6b00-95fe-4001-94d6-baf341732b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_715e3842-7178-429d-b66d-3c6bd1e60d19" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f4bb6b00-95fe-4001-94d6-baf341732b79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5b7fddad-8fce-4a4b-b585-64d416699558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_715e3842-7178-429d-b66d-3c6bd1e60d19" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5b7fddad-8fce-4a4b-b585-64d416699558" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93af4579-d038-49a7-b039-ca221a826e95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5b7fddad-8fce-4a4b-b585-64d416699558" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93af4579-d038-49a7-b039-ca221a826e95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_93af4579-d038-49a7-b039-ca221a826e95_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93af4579-d038-49a7-b039-ca221a826e95" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_93af4579-d038-49a7-b039-ca221a826e95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7619f52-7083-48bc-ab21-cab5df404d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93af4579-d038-49a7-b039-ca221a826e95" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7619f52-7083-48bc-ab21-cab5df404d8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5a9674e5-5395-461d-aa07-a6cbe8817dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7619f52-7083-48bc-ab21-cab5df404d8c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5a9674e5-5395-461d-aa07-a6cbe8817dc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4d785191-99b4-4ef5-9e20-dcdfd1b49ed9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7619f52-7083-48bc-ab21-cab5df404d8c" xlink:to="loc_us-gaap_WarrantMember_4d785191-99b4-4ef5-9e20-dcdfd1b49ed9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3f3e67e0-5170-447d-a533-3637211c9c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7619f52-7083-48bc-ab21-cab5df404d8c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3f3e67e0-5170-447d-a533-3637211c9c7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_f6bf559f-432e-4c12-b7a3-5eac728b2f35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7619f52-7083-48bc-ab21-cab5df404d8c" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_f6bf559f-432e-4c12-b7a3-5eac728b2f35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_4ef76b55-2133-41ce-9bd8-f05368760caf" xlink:href="crdf-20200930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7619f52-7083-48bc-ab21-cab5df404d8c" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_4ef76b55-2133-41ce-9bd8-f05368760caf" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="crdf-20200930.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurements" xlink:type="extended" id="id8491ed81b064557a62124191f57cace_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="crdf-20200930.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i32e9a1c74a6941a5b99cab952a9dd4c7_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="extended" id="i3fbcccf54d6b4895a2a5f164f5c0127c_FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916d060f-0cd8-489d-8c15-696dec85ae0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_e246eb13-63a4-40da-b17f-3ce3521b567a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916d060f-0cd8-489d-8c15-696dec85ae0e" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_e246eb13-63a4-40da-b17f-3ce3521b567a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_b24fca6f-7876-47fc-99b0-d9356e007706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e246eb13-63a4-40da-b17f-3ce3521b567a" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_b24fca6f-7876-47fc-99b0-d9356e007706" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_75f527e2-4ace-4d4b-b1cf-c368b42b5046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e246eb13-63a4-40da-b17f-3ce3521b567a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_75f527e2-4ace-4d4b-b1cf-c368b42b5046" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_cb3dc4d9-6b0e-476b-9bd4-d889ebaf6e04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916d060f-0cd8-489d-8c15-696dec85ae0e" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_cb3dc4d9-6b0e-476b-9bd4-d889ebaf6e04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_e10381e1-1ad5-42e4-9fdb-7430ce6a9223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_cb3dc4d9-6b0e-476b-9bd4-d889ebaf6e04" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_e10381e1-1ad5-42e4-9fdb-7430ce6a9223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_97e297bc-50d2-49d1-a503-4a31331bd828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_cb3dc4d9-6b0e-476b-9bd4-d889ebaf6e04" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_97e297bc-50d2-49d1-a503-4a31331bd828" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eeadf1c4-109b-4dd2-b5bf-fa13c9c64fb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916d060f-0cd8-489d-8c15-696dec85ae0e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eeadf1c4-109b-4dd2-b5bf-fa13c9c64fb9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_c043797c-daa3-45fe-81e5-1d7af6bbc482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eeadf1c4-109b-4dd2-b5bf-fa13c9c64fb9" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_c043797c-daa3-45fe-81e5-1d7af6bbc482" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c043797c-daa3-45fe-81e5-1d7af6bbc482_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_c043797c-daa3-45fe-81e5-1d7af6bbc482" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c043797c-daa3-45fe-81e5-1d7af6bbc482_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_99ebc217-2a62-4e75-bdcd-821b23a2b042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_c043797c-daa3-45fe-81e5-1d7af6bbc482" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_99ebc217-2a62-4e75-bdcd-821b23a2b042" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_bdafb923-b506-46a3-ba4a-6d109f0df01c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_99ebc217-2a62-4e75-bdcd-821b23a2b042" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_bdafb923-b506-46a3-ba4a-6d109f0df01c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_54fc2f18-3138-469b-b594-1cae5b038074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_99ebc217-2a62-4e75-bdcd-821b23a2b042" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_54fc2f18-3138-469b-b594-1cae5b038074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1359ef9c-603a-4829-b244-b4f726cf0e38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eeadf1c4-109b-4dd2-b5bf-fa13c9c64fb9" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1359ef9c-603a-4829-b244-b4f726cf0e38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1359ef9c-603a-4829-b244-b4f726cf0e38_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1359ef9c-603a-4829-b244-b4f726cf0e38" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1359ef9c-603a-4829-b244-b4f726cf0e38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8142fb61-3a04-4854-8ee1-9e9384e39f76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1359ef9c-603a-4829-b244-b4f726cf0e38" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8142fb61-3a04-4854-8ee1-9e9384e39f76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_003c8f63-9420-4c21-af25-ff5ebdfac6e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8142fb61-3a04-4854-8ee1-9e9384e39f76" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_003c8f63-9420-4c21-af25-ff5ebdfac6e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b4345f9-1db7-4a2e-b668-49ddc657e660" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eeadf1c4-109b-4dd2-b5bf-fa13c9c64fb9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b4345f9-1db7-4a2e-b668-49ddc657e660" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8b4345f9-1db7-4a2e-b668-49ddc657e660_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b4345f9-1db7-4a2e-b668-49ddc657e660" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8b4345f9-1db7-4a2e-b668-49ddc657e660_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_80ca45e0-734a-4384-a1d6-e60bf2fcf8a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b4345f9-1db7-4a2e-b668-49ddc657e660" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_80ca45e0-734a-4384-a1d6-e60bf2fcf8a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_973d0594-aab2-46c0-b8a7-b753af588d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_80ca45e0-734a-4384-a1d6-e60bf2fcf8a5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_973d0594-aab2-46c0-b8a7-b753af588d6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_35b9fbcc-60b1-4439-8d89-4e60e0b22ee1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_80ca45e0-734a-4384-a1d6-e60bf2fcf8a5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_35b9fbcc-60b1-4439-8d89-4e60e0b22ee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e0c7db48-1f94-4a44-98f7-4eef372317a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_80ca45e0-734a-4384-a1d6-e60bf2fcf8a5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e0c7db48-1f94-4a44-98f7-4eef372317a0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="crdf-20200930.xsd#PropertyandEquipment"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/PropertyandEquipment" xlink:type="extended" id="ida35b8b2cb50465ba2c3589e504d7069_PropertyandEquipment"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="crdf-20200930.xsd#PropertyandEquipmentTables"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/PropertyandEquipmentTables" xlink:type="extended" id="i49162b9b3816408d9b4c191ef2361e41_PropertyandEquipmentTables"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#PropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/PropertyandEquipmentDetails" xlink:type="extended" id="i0aacd6d8062646b6907908c00e9683ce_PropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5f0202dd-6fd3-44dd-bc7a-f0887d6257bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ff0edf1a-37c3-4900-aa3b-727866e61032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5f0202dd-6fd3-44dd-bc7a-f0887d6257bb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ff0edf1a-37c3-4900-aa3b-727866e61032" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_99f64cc1-1afe-41bf-9fc6-fdee022a3b24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5f0202dd-6fd3-44dd-bc7a-f0887d6257bb" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_99f64cc1-1afe-41bf-9fc6-fdee022a3b24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ff4de8ea-2ad9-405b-97c6-0e639af43684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5f0202dd-6fd3-44dd-bc7a-f0887d6257bb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ff4de8ea-2ad9-405b-97c6-0e639af43684" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_020cafba-13e3-41cc-8bec-9b5960470a7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5f0202dd-6fd3-44dd-bc7a-f0887d6257bb" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_020cafba-13e3-41cc-8bec-9b5960470a7b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bd412e43-d624-44c5-a6bb-feeff879d411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_020cafba-13e3-41cc-8bec-9b5960470a7b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bd412e43-d624-44c5-a6bb-feeff879d411" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bd412e43-d624-44c5-a6bb-feeff879d411_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bd412e43-d624-44c5-a6bb-feeff879d411" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bd412e43-d624-44c5-a6bb-feeff879d411_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b2206d82-e725-4683-b2a7-b3f78db8f66d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bd412e43-d624-44c5-a6bb-feeff879d411" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b2206d82-e725-4683-b2a7-b3f78db8f66d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_FurnitureAndOfficeEquipmentMember_4567b451-1a28-43b2-aa44-10dd3d3b9667" xlink:href="crdf-20200930.xsd#crdf_FurnitureAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b2206d82-e725-4683-b2a7-b3f78db8f66d" xlink:to="loc_crdf_FurnitureAndOfficeEquipmentMember_4567b451-1a28-43b2-aa44-10dd3d3b9667" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2a4bd4bc-d4eb-49ea-a6e9-052b99d78d7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b2206d82-e725-4683-b2a7-b3f78db8f66d" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2a4bd4bc-d4eb-49ea-a6e9-052b99d78d7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_0515360f-bcac-4c78-bfd9-88479f2ea7e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b2206d82-e725-4683-b2a7-b3f78db8f66d" xlink:to="loc_us-gaap_EquipmentMember_0515360f-bcac-4c78-bfd9-88479f2ea7e2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/Leases" xlink:type="simple" xlink:href="crdf-20200930.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/Leases" xlink:type="extended" id="i58c7d57b64384c61aea2cfa13022e2ac_Leases"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesTables" xlink:type="simple" xlink:href="crdf-20200930.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/LeasesTables" xlink:type="extended" id="ie1fcee30e4e34def9abe400f20203f39_LeasesTables"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i4313caaddc4a4d45bb99119fdb9df80b_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_34330868-7a2b-43b6-8235-0e76bcac613e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LessorNumberOfSubleases_ac20435e-1c75-445e-b6c1-a0cd8f3f255b" xlink:href="crdf-20200930.xsd#crdf_LessorNumberOfSubleases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_34330868-7a2b-43b6-8235-0e76bcac613e" xlink:to="loc_crdf_LessorNumberOfSubleases_ac20435e-1c75-445e-b6c1-a0cd8f3f255b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment_210e6c62-af5c-452e-9e21-c2c216b937f0" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseMonthlyRentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_34330868-7a2b-43b6-8235-0e76bcac613e" xlink:to="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment_210e6c62-af5c-452e-9e21-c2c216b937f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_1d23075b-953b-4e42-908f-5620702bf664" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_34330868-7a2b-43b6-8235-0e76bcac613e" xlink:to="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_1d23075b-953b-4e42-908f-5620702bf664" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseNumberOfRenewalOptions_91ab1dcf-e6e0-46a1-b17b-dbedf273cb42" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_34330868-7a2b-43b6-8235-0e76bcac613e" xlink:to="loc_crdf_LesseeOperatingLeaseNumberOfRenewalOptions_91ab1dcf-e6e0-46a1-b17b-dbedf273cb42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d635a4a7-15f7-42d7-b8f9-c5d01e3e102c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_34330868-7a2b-43b6-8235-0e76bcac613e" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d635a4a7-15f7-42d7-b8f9-c5d01e3e102c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c4277eed-3b71-481c-8269-4a34aefc8b8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_34330868-7a2b-43b6-8235-0e76bcac613e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c4277eed-3b71-481c-8269-4a34aefc8b8c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_ff3a1bdd-f9dc-46e5-a5e9-8d64e53920b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_34330868-7a2b-43b6-8235-0e76bcac613e" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_ff3a1bdd-f9dc-46e5-a5e9-8d64e53920b2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_b1e2a935-4bb0-4aa2-9e56-4f50a42f3f54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_34330868-7a2b-43b6-8235-0e76bcac613e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_b1e2a935-4bb0-4aa2-9e56-4f50a42f3f54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a3862411-30c0-4115-ac14-73004ee1607f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b1e2a935-4bb0-4aa2-9e56-4f50a42f3f54" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a3862411-30c0-4115-ac14-73004ee1607f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a3862411-30c0-4115-ac14-73004ee1607f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a3862411-30c0-4115-ac14-73004ee1607f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a3862411-30c0-4115-ac14-73004ee1607f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_245d34e1-76fc-47a1-aa69-c931a3222a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a3862411-30c0-4115-ac14-73004ee1607f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_245d34e1-76fc-47a1-aa69-c931a3222a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember_33b70379-6903-4f88-9392-8486e5cd93da" xlink:href="crdf-20200930.xsd#crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_245d34e1-76fc-47a1-aa69-c931a3222a6d" xlink:to="loc_crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember_33b70379-6903-4f88-9392-8486e5cd93da" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended" id="i1a8d779af43d4c37ac637cb3d2f8abb4_LeasesComponentsofLeaseExpenseDetails"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended" id="i26776241a6044e44be482f8dd63c9e55_LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#LeasesSupplementalCashFlowInformationDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended" id="ie4491dad48434c939c09a021c065a2af_LeasesSupplementalCashFlowInformationDetails"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended" id="if57d40414a5e416fbddd02474951fc77_LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants" xlink:type="simple" xlink:href="crdf-20200930.xsd#DerivativeFinancialInstrumentsWarrants"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants" xlink:type="extended" id="i8320240d091e4f9e97738b9e848a99a1_DerivativeFinancialInstrumentsWarrants"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables" xlink:type="simple" xlink:href="crdf-20200930.xsd#DerivativeFinancialInstrumentsWarrantsTables"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables" xlink:type="extended" id="i12b8fe9854534edc83312113c0c372b5_DerivativeFinancialInstrumentsWarrantsTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_ddf4d715-acf6-4eaa-acf3-b795cad08a9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_dd0e40b7-ed42-4327-8762-e5194d6b5366" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_ddf4d715-acf6-4eaa-acf3-b795cad08a9a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_dd0e40b7-ed42-4327-8762-e5194d6b5366" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_1cc979ca-3427-422a-bf73-86d8229c252e" xlink:href="crdf-20200930.xsd#crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_ddf4d715-acf6-4eaa-acf3-b795cad08a9a" xlink:to="loc_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_1cc979ca-3427-422a-bf73-86d8229c252e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_21b2d620-5a63-4aff-b0ae-7c63710f586a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_ddf4d715-acf6-4eaa-acf3-b795cad08a9a" xlink:to="loc_us-gaap_DerivativeTable_21b2d620-5a63-4aff-b0ae-7c63710f586a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_49c21e1e-fc93-4904-a49f-11a7947a5ae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_21b2d620-5a63-4aff-b0ae-7c63710f586a" xlink:to="loc_us-gaap_ValuationTechniqueAxis_49c21e1e-fc93-4904-a49f-11a7947a5ae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_49c21e1e-fc93-4904-a49f-11a7947a5ae5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_49c21e1e-fc93-4904-a49f-11a7947a5ae5" xlink:to="loc_us-gaap_ValuationTechniqueDomain_49c21e1e-fc93-4904-a49f-11a7947a5ae5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_88195118-4893-4eea-801c-5affcae26009" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_49c21e1e-fc93-4904-a49f-11a7947a5ae5" xlink:to="loc_us-gaap_ValuationTechniqueDomain_88195118-4893-4eea-801c-5affcae26009" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BlackScholesOptionPricingMethodMember_79ed82c2-c1b0-4c43-8c40-12f2c600f40b" xlink:href="crdf-20200930.xsd#crdf_BlackScholesOptionPricingMethodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_88195118-4893-4eea-801c-5affcae26009" xlink:to="loc_crdf_BlackScholesOptionPricingMethodMember_79ed82c2-c1b0-4c43-8c40-12f2c600f40b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#DerivativeFinancialInstrumentsWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails" xlink:type="extended" id="i7a4c965b23bf47868747bfc050919bbe_DerivativeFinancialInstrumentsWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_85446928-e8a5-4a9e-a33b-37ffeed5df42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_f4461128-d2d8-4178-8bbd-fe0370c0fa5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_85446928-e8a5-4a9e-a33b-37ffeed5df42" xlink:to="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_f4461128-d2d8-4178-8bbd-fe0370c0fa5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EstimatedFairValueOfWarrant_117c591e-32df-4f06-8be4-2bd9031dce6a" xlink:href="crdf-20200930.xsd#crdf_EstimatedFairValueOfWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_f4461128-d2d8-4178-8bbd-fe0370c0fa5d" xlink:to="loc_crdf_EstimatedFairValueOfWarrant_117c591e-32df-4f06-8be4-2bd9031dce6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_daee8c45-536e-4393-a414-3ddbb6953cf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_f4461128-d2d8-4178-8bbd-fe0370c0fa5d" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_daee8c45-536e-4393-a414-3ddbb6953cf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_e0273be8-32c4-4aeb-938a-527b62f70095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_f4461128-d2d8-4178-8bbd-fe0370c0fa5d" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_e0273be8-32c4-4aeb-938a-527b62f70095" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_2ddaa54e-9f17-4682-8f5f-848d0195ea4b" xlink:href="crdf-20200930.xsd#crdf_DerivativeFinancialInstrumentsLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_85446928-e8a5-4a9e-a33b-37ffeed5df42" xlink:to="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_2ddaa54e-9f17-4682-8f5f-848d0195ea4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9db783e9-4a78-49be-beca-30f7f0732d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_2ddaa54e-9f17-4682-8f5f-848d0195ea4b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9db783e9-4a78-49be-beca-30f7f0732d6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b2c9ca1c-592f-43d5-baa4-6ce3a1959701" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_1c62edc4-30bd-46ff-bf06-c05844ca74cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_2ddaa54e-9f17-4682-8f5f-848d0195ea4b" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_1c62edc4-30bd-46ff-bf06-c05844ca74cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_be0e5b19-e9e8-4b5b-9fb5-9a65b0556aba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_2ddaa54e-9f17-4682-8f5f-848d0195ea4b" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_be0e5b19-e9e8-4b5b-9fb5-9a65b0556aba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_cc576bca-0aed-4ef6-84a3-ec74710de6a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_f7faa99c-a7ca-4f1f-87ef-32b34d686777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_85446928-e8a5-4a9e-a33b-37ffeed5df42" xlink:to="loc_us-gaap_DerivativeTable_f7faa99c-a7ca-4f1f-87ef-32b34d686777" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_6a49c0ab-d2b4-4db2-b2ff-f2165593b128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f7faa99c-a7ca-4f1f-87ef-32b34d686777" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_6a49c0ab-d2b4-4db2-b2ff-f2165593b128" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6a49c0ab-d2b4-4db2-b2ff-f2165593b128_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6a49c0ab-d2b4-4db2-b2ff-f2165593b128" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6a49c0ab-d2b4-4db2-b2ff-f2165593b128_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_548ca420-4edd-45df-b807-c494fbc673a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6a49c0ab-d2b4-4db2-b2ff-f2165593b128" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_548ca420-4edd-45df-b807-c494fbc673a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_ec773d4c-a320-48fe-9c70-62c142aef5f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_548ca420-4edd-45df-b807-c494fbc673a7" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_ec773d4c-a320-48fe-9c70-62c142aef5f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1d4520b8-c0f1-4386-8537-9f9012afe4b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_548ca420-4edd-45df-b807-c494fbc673a7" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1d4520b8-c0f1-4386-8537-9f9012afe4b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_b95b90b0-fb67-45db-8860-42a5840e9568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_548ca420-4edd-45df-b807-c494fbc673a7" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_b95b90b0-fb67-45db-8860-42a5840e9568" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_0c90cc1f-022a-4cc4-9629-f0c20efdaf2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_548ca420-4edd-45df-b807-c494fbc673a7" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_0c90cc1f-022a-4cc4-9629-f0c20efdaf2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_28c51a10-0746-4f2a-ae09-05b6f4c56e33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f7faa99c-a7ca-4f1f-87ef-32b34d686777" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_28c51a10-0746-4f2a-ae09-05b6f4c56e33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_28c51a10-0746-4f2a-ae09-05b6f4c56e33_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_28c51a10-0746-4f2a-ae09-05b6f4c56e33" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_28c51a10-0746-4f2a-ae09-05b6f4c56e33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b2ecc1ae-cc7b-4a75-96fb-5aa4d6b54132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_28c51a10-0746-4f2a-ae09-05b6f4c56e33" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b2ecc1ae-cc7b-4a75-96fb-5aa4d6b54132" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_0bf6e035-c337-4bc5-a614-9486792ad832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b2ecc1ae-cc7b-4a75-96fb-5aa4d6b54132" xlink:to="loc_us-gaap_WarrantMember_0bf6e035-c337-4bc5-a614-9486792ad832" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_00b63b8f-d453-479f-81ad-195dfed1737d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f7faa99c-a7ca-4f1f-87ef-32b34d686777" xlink:to="loc_us-gaap_ValuationTechniqueAxis_00b63b8f-d453-479f-81ad-195dfed1737d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_00b63b8f-d453-479f-81ad-195dfed1737d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_00b63b8f-d453-479f-81ad-195dfed1737d" xlink:to="loc_us-gaap_ValuationTechniqueDomain_00b63b8f-d453-479f-81ad-195dfed1737d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_8a0eacaa-c529-4796-b92b-3b289a386aca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_00b63b8f-d453-479f-81ad-195dfed1737d" xlink:to="loc_us-gaap_ValuationTechniqueDomain_8a0eacaa-c529-4796-b92b-3b289a386aca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BlackScholesOptionPricingMethodMember_b4f4d122-48c3-4f5c-9fcd-a4da194ba256" xlink:href="crdf-20200930.xsd#crdf_BlackScholesOptionPricingMethodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_8a0eacaa-c529-4796-b92b-3b289a386aca" xlink:to="loc_crdf_BlackScholesOptionPricingMethodMember_b4f4d122-48c3-4f5c-9fcd-a4da194ba256" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a1155138-f393-4d76-8d49-e59747539a5c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f7faa99c-a7ca-4f1f-87ef-32b34d686777" xlink:to="loc_srt_RangeAxis_a1155138-f393-4d76-8d49-e59747539a5c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a1155138-f393-4d76-8d49-e59747539a5c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a1155138-f393-4d76-8d49-e59747539a5c" xlink:to="loc_srt_RangeMember_a1155138-f393-4d76-8d49-e59747539a5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b27564f7-ce71-4ab9-9995-c46401767d16" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a1155138-f393-4d76-8d49-e59747539a5c" xlink:to="loc_srt_RangeMember_b27564f7-ce71-4ab9-9995-c46401767d16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4de55e66-dc53-4068-901b-ce7dd28e327f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b27564f7-ce71-4ab9-9995-c46401767d16" xlink:to="loc_srt_MinimumMember_4de55e66-dc53-4068-901b-ce7dd28e327f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e918acbf-913e-4414-9566-4f134199543f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b27564f7-ce71-4ab9-9995-c46401767d16" xlink:to="loc_srt_MaximumMember_e918acbf-913e-4414-9566-4f134199543f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_f254e985-37bd-4a41-862a-5e41ac02811c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b27564f7-ce71-4ab9-9995-c46401767d16" xlink:to="loc_srt_WeightedAverageMember_f254e985-37bd-4a41-862a-5e41ac02811c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquity" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquity" xlink:type="extended" id="i11f85414cb8c4f56bf058b8b7994618b_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityTables" xlink:type="extended" id="i9fff05f670e243189bb9b7a7ed84de61_StockholdersEquityTables"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquityStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="extended" id="i7ff1037afc544fee85de34f5a724700b_StockholdersEquityStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3e6d520-56db-403b-8c6b-137030ad9c12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_195a2837-344b-4823-8eb5-8346f1bd25b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3e6d520-56db-403b-8c6b-137030ad9c12" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_195a2837-344b-4823-8eb5-8346f1bd25b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4b617ba2-df0e-4a33-92b6-db9961daff4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3e6d520-56db-403b-8c6b-137030ad9c12" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4b617ba2-df0e-4a33-92b6-db9961daff4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0e851b3d-d7bd-4823-bac1-9979463c94d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3e6d520-56db-403b-8c6b-137030ad9c12" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0e851b3d-d7bd-4823-bac1-9979463c94d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8382e983-b444-4767-a0d2-933dc6f0e6d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3e6d520-56db-403b-8c6b-137030ad9c12" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8382e983-b444-4767-a0d2-933dc6f0e6d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_09e918f4-8604-4d98-85dd-6fd6ffef7bae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3e6d520-56db-403b-8c6b-137030ad9c12" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_09e918f4-8604-4d98-85dd-6fd6ffef7bae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3abd05f1-b4c3-4741-b53d-063fda4ece48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3e6d520-56db-403b-8c6b-137030ad9c12" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3abd05f1-b4c3-4741-b53d-063fda4ece48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_09f3a7cf-0331-46c8-8e12-b0ff5fae172b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3abd05f1-b4c3-4741-b53d-063fda4ece48" xlink:to="loc_us-gaap_AwardTypeAxis_09f3a7cf-0331-46c8-8e12-b0ff5fae172b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09f3a7cf-0331-46c8-8e12-b0ff5fae172b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_09f3a7cf-0331-46c8-8e12-b0ff5fae172b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09f3a7cf-0331-46c8-8e12-b0ff5fae172b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9917e0e-aefc-4b4c-82aa-6aa4cf3a9700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_09f3a7cf-0331-46c8-8e12-b0ff5fae172b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9917e0e-aefc-4b4c-82aa-6aa4cf3a9700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_686ca104-c7f5-49c3-a8e7-5ef4f9f72215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9917e0e-aefc-4b4c-82aa-6aa4cf3a9700" xlink:to="loc_us-gaap_EmployeeStockOptionMember_686ca104-c7f5-49c3-a8e7-5ef4f9f72215" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_097b6316-59d1-4ad7-bdda-9eab0ac83487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3abd05f1-b4c3-4741-b53d-063fda4ece48" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_097b6316-59d1-4ad7-bdda-9eab0ac83487" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_097b6316-59d1-4ad7-bdda-9eab0ac83487_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_097b6316-59d1-4ad7-bdda-9eab0ac83487" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_097b6316-59d1-4ad7-bdda-9eab0ac83487_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_89c5ec0f-f37e-4a86-8bf1-31eed556c67b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_097b6316-59d1-4ad7-bdda-9eab0ac83487" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_89c5ec0f-f37e-4a86-8bf1-31eed556c67b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_36fee6c2-fc9b-4f7b-9152-e8a270d337ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_89c5ec0f-f37e-4a86-8bf1-31eed556c67b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_36fee6c2-fc9b-4f7b-9152-e8a270d337ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_124c40b9-ce60-4289-8c0c-534074977182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_89c5ec0f-f37e-4a86-8bf1-31eed556c67b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_124c40b9-ce60-4289-8c0c-534074977182" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquityStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="extended" id="i8ed972ca4dd040a5a4cc3f831f7df8a8_StockholdersEquityStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8c041d4-fb27-4276-adce-49f5cbf44676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_465194c7-5a0d-41f2-9620-abd565e24c31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8c041d4-fb27-4276-adce-49f5cbf44676" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_465194c7-5a0d-41f2-9620-abd565e24c31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_33e2c8b2-b1ec-4538-956a-951f64144a51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_465194c7-5a0d-41f2-9620-abd565e24c31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_33e2c8b2-b1ec-4538-956a-951f64144a51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1b5bcc82-b14e-480d-8f2e-c2d0fccc9381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_465194c7-5a0d-41f2-9620-abd565e24c31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1b5bcc82-b14e-480d-8f2e-c2d0fccc9381" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9f2f2a44-f0b6-41f6-8c87-37540757396a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_465194c7-5a0d-41f2-9620-abd565e24c31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9f2f2a44-f0b6-41f6-8c87-37540757396a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fc6ff51f-0cfb-41a6-8c31-1ca3f37e1776" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_465194c7-5a0d-41f2-9620-abd565e24c31" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fc6ff51f-0cfb-41a6-8c31-1ca3f37e1776" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1b8398a-20ce-4cd4-829c-568a6d35298f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8c041d4-fb27-4276-adce-49f5cbf44676" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1b8398a-20ce-4cd4-829c-568a6d35298f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1df593cb-34df-483b-9316-b708803ea492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1b8398a-20ce-4cd4-829c-568a6d35298f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1df593cb-34df-483b-9316-b708803ea492" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_131ec51c-4f73-4249-84a1-8b408d4b5ced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1b8398a-20ce-4cd4-829c-568a6d35298f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_131ec51c-4f73-4249-84a1-8b408d4b5ced" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_de7a80bb-6a01-4cfe-8d54-10477d8622e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1b8398a-20ce-4cd4-829c-568a6d35298f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_de7a80bb-6a01-4cfe-8d54-10477d8622e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_64ab995d-04e9-4164-b48c-b871589f09ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1b8398a-20ce-4cd4-829c-568a6d35298f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_64ab995d-04e9-4164-b48c-b871589f09ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_bd08311a-25b3-4f69-8b29-ccf092a7a848" xlink:href="crdf-20200930.xsd#crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1b8398a-20ce-4cd4-829c-568a6d35298f" xlink:to="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_bd08311a-25b3-4f69-8b29-ccf092a7a848" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f131ad2c-4689-4a2f-840d-6df5740a1e85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8f9bfd87-eb04-4948-bfa9-9caf79a7b783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1b8398a-20ce-4cd4-829c-568a6d35298f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8f9bfd87-eb04-4948-bfa9-9caf79a7b783" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51697352-577b-4aca-857c-4c7b99bf9406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8c041d4-fb27-4276-adce-49f5cbf44676" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51697352-577b-4aca-857c-4c7b99bf9406" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4d84ae21-40f8-46b1-81c7-240d39782ae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51697352-577b-4aca-857c-4c7b99bf9406" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4d84ae21-40f8-46b1-81c7-240d39782ae6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fee0acf7-6547-4a9e-a2da-bb882b3477c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51697352-577b-4aca-857c-4c7b99bf9406" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fee0acf7-6547-4a9e-a2da-bb882b3477c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_76362744-9010-4833-805c-3168354414e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51697352-577b-4aca-857c-4c7b99bf9406" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_76362744-9010-4833-805c-3168354414e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6a649716-dd9d-4a7e-b450-a242f5a7a83c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51697352-577b-4aca-857c-4c7b99bf9406" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6a649716-dd9d-4a7e-b450-a242f5a7a83c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_29855ace-608d-4c0c-8f72-5b466d8f25f6" xlink:href="crdf-20200930.xsd#crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51697352-577b-4aca-857c-4c7b99bf9406" xlink:to="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_29855ace-608d-4c0c-8f72-5b466d8f25f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2423c1f1-b378-4e53-8c4a-da5588c8cc3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_dfe66423-dbff-4c65-8b38-faf261e24503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51697352-577b-4aca-857c-4c7b99bf9406" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_dfe66423-dbff-4c65-8b38-faf261e24503" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0bd1be41-f423-4363-80cc-d5c0a65cd0cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8c041d4-fb27-4276-adce-49f5cbf44676" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0bd1be41-f423-4363-80cc-d5c0a65cd0cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9a1f7ad4-83c0-44e3-a0c7-e429fe7e1ea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0bd1be41-f423-4363-80cc-d5c0a65cd0cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9a1f7ad4-83c0-44e3-a0c7-e429fe7e1ea0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c1d10993-ceea-4d79-b48b-525b712f34f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0bd1be41-f423-4363-80cc-d5c0a65cd0cf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c1d10993-ceea-4d79-b48b-525b712f34f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_94886018-a82f-438f-8e33-59739457e683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8c041d4-fb27-4276-adce-49f5cbf44676" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_94886018-a82f-438f-8e33-59739457e683" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5ea211a4-81bc-41ab-8ebf-5494e8b5d52c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8c041d4-fb27-4276-adce-49f5cbf44676" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5ea211a4-81bc-41ab-8ebf-5494e8b5d52c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57ac5cdc-d954-4dde-a850-61c054ea6a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8c041d4-fb27-4276-adce-49f5cbf44676" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57ac5cdc-d954-4dde-a850-61c054ea6a8d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_24782df9-5bdc-469f-a720-4d3aa912d9af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57ac5cdc-d954-4dde-a850-61c054ea6a8d" xlink:to="loc_us-gaap_PlanNameAxis_24782df9-5bdc-469f-a720-4d3aa912d9af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_24782df9-5bdc-469f-a720-4d3aa912d9af_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_24782df9-5bdc-469f-a720-4d3aa912d9af" xlink:to="loc_us-gaap_PlanNameDomain_24782df9-5bdc-469f-a720-4d3aa912d9af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_683fae77-370d-4de0-8fbe-425be3cc4e4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_24782df9-5bdc-469f-a720-4d3aa912d9af" xlink:to="loc_us-gaap_PlanNameDomain_683fae77-370d-4de0-8fbe-425be3cc4e4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityIncentivePlan2014Member_90b6e40b-1d3c-4062-8caa-1ac007d9b90b" xlink:href="crdf-20200930.xsd#crdf_EquityIncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_683fae77-370d-4de0-8fbe-425be3cc4e4d" xlink:to="loc_crdf_EquityIncentivePlan2014Member_90b6e40b-1d3c-4062-8caa-1ac007d9b90b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8ba280d2-7b76-4807-990c-672f3da23571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57ac5cdc-d954-4dde-a850-61c054ea6a8d" xlink:to="loc_us-gaap_AwardTypeAxis_8ba280d2-7b76-4807-990c-672f3da23571" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8ba280d2-7b76-4807-990c-672f3da23571_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8ba280d2-7b76-4807-990c-672f3da23571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8ba280d2-7b76-4807-990c-672f3da23571_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcea36a4-e4ef-4e05-8df7-51cc670f291b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8ba280d2-7b76-4807-990c-672f3da23571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcea36a4-e4ef-4e05-8df7-51cc670f291b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ed0ea8e4-b37d-406b-bd79-d2c29a572595" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcea36a4-e4ef-4e05-8df7-51cc670f291b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ed0ea8e4-b37d-406b-bd79-d2c29a572595" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquityRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails" xlink:type="extended" id="i69f58bfb3a0d47edb8e312f6ee0dcf60_StockholdersEquityRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c0678b7-36b1-42aa-9868-47191799c405" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e514da66-de0c-47d4-ade6-43a1bf441bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c0678b7-36b1-42aa-9868-47191799c405" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e514da66-de0c-47d4-ade6-43a1bf441bd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2942ceef-23c4-48c6-a986-c79f9020b90f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e514da66-de0c-47d4-ade6-43a1bf441bd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2942ceef-23c4-48c6-a986-c79f9020b90f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e1749556-5724-47c1-8017-ba52a5537630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e514da66-de0c-47d4-ade6-43a1bf441bd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e1749556-5724-47c1-8017-ba52a5537630" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_45fa524f-32db-407b-8c72-e443da70e19e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5ac5b8b-baca-4dab-a9ba-08308ceb820b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c0678b7-36b1-42aa-9868-47191799c405" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5ac5b8b-baca-4dab-a9ba-08308ceb820b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_16bca7f4-3f89-4a8b-8fb4-5f01ae29e43b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5ac5b8b-baca-4dab-a9ba-08308ceb820b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_16bca7f4-3f89-4a8b-8fb4-5f01ae29e43b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5541c679-7b4e-41c4-943f-d88ff4306433" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5ac5b8b-baca-4dab-a9ba-08308ceb820b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5541c679-7b4e-41c4-943f-d88ff4306433" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_435ec17f-a598-444b-9b88-159d4e1d8f57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_bb448953-46ed-4c96-b5c9-2cca1a3ff13d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c0678b7-36b1-42aa-9868-47191799c405" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_bb448953-46ed-4c96-b5c9-2cca1a3ff13d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_1c3a259a-d542-4a5a-a33c-0046c708d812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c0678b7-36b1-42aa-9868-47191799c405" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_1c3a259a-d542-4a5a-a33c-0046c708d812" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ca1eba71-92df-424c-b6ec-ba58cfbcb6bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c0678b7-36b1-42aa-9868-47191799c405" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ca1eba71-92df-424c-b6ec-ba58cfbcb6bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e026597c-dc52-47f6-bcde-54b96dfc7c74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c0678b7-36b1-42aa-9868-47191799c405" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e026597c-dc52-47f6-bcde-54b96dfc7c74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d85d8f4a-021a-4649-9713-4b97770a7ea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e026597c-dc52-47f6-bcde-54b96dfc7c74" xlink:to="loc_us-gaap_AwardTypeAxis_d85d8f4a-021a-4649-9713-4b97770a7ea5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d85d8f4a-021a-4649-9713-4b97770a7ea5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d85d8f4a-021a-4649-9713-4b97770a7ea5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d85d8f4a-021a-4649-9713-4b97770a7ea5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_010e9551-7051-4d3d-8983-45e2197073c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d85d8f4a-021a-4649-9713-4b97770a7ea5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_010e9551-7051-4d3d-8983-45e2197073c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_611caa53-2485-485d-ba40-327ffab1d490" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_010e9551-7051-4d3d-8983-45e2197073c7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_611caa53-2485-485d-ba40-327ffab1d490" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquityWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails" xlink:type="extended" id="iaccbc13e2b7e4f718ef5e653818eb4b7_StockholdersEquityWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06680826-8850-4b8e-b1eb-c58d7859ff8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_WarrantsAndRightsRollForward_3cba60fa-4b00-4bee-b0d2-e0a77d3034e1" xlink:href="crdf-20200930.xsd#crdf_WarrantsAndRightsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06680826-8850-4b8e-b1eb-c58d7859ff8a" xlink:to="loc_crdf_WarrantsAndRightsRollForward_3cba60fa-4b00-4bee-b0d2-e0a77d3034e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_aa69ae92-e7af-4a7d-9546-7116a8a73f4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_WarrantsAndRightsRollForward_3cba60fa-4b00-4bee-b0d2-e0a77d3034e1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_aa69ae92-e7af-4a7d-9546-7116a8a73f4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightNumberGranted_5c4bc2fd-3abb-403c-8287-276bb311e5d8" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightNumberGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_WarrantsAndRightsRollForward_3cba60fa-4b00-4bee-b0d2-e0a77d3034e1" xlink:to="loc_crdf_ClassOfWarrantOrRightNumberGranted_5c4bc2fd-3abb-403c-8287-276bb311e5d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightNumberExercised_5313bdd9-a82e-46f5-b7bf-a15e9cc3b9ff" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightNumberExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_WarrantsAndRightsRollForward_3cba60fa-4b00-4bee-b0d2-e0a77d3034e1" xlink:to="loc_crdf_ClassOfWarrantOrRightNumberExercised_5313bdd9-a82e-46f5-b7bf-a15e9cc3b9ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_194d02ff-c97c-416d-8a24-152fa5c75327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_898d02d0-c815-4e47-8f63-36932ff83678" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06680826-8850-4b8e-b1eb-c58d7859ff8a" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_898d02d0-c815-4e47-8f63-36932ff83678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_b6a751d5-be2f-495f-a897-fcd41144f2c9" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_898d02d0-c815-4e47-8f63-36932ff83678" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_b6a751d5-be2f-495f-a897-fcd41144f2c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted_cc60c827-05d6-41f8-b243-d9ccaa71b2d0" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_898d02d0-c815-4e47-8f63-36932ff83678" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted_cc60c827-05d6-41f8-b243-d9ccaa71b2d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_28bfee16-472f-40f1-8fd3-287975eb21e5" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_898d02d0-c815-4e47-8f63-36932ff83678" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_28bfee16-472f-40f1-8fd3-287975eb21e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_39ee6dd1-100e-442d-8544-70e017b0b80e" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_08e8f097-d33f-42a1-a800-c861a0e7b3cc" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06680826-8850-4b8e-b1eb-c58d7859ff8a" xlink:to="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_08e8f097-d33f-42a1-a800-c861a0e7b3cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_645c131f-2511-4121-9f91-084fcc364b40" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_08e8f097-d33f-42a1-a800-c861a0e7b3cc" xlink:to="loc_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_645c131f-2511-4121-9f91-084fcc364b40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e29ce4e-c998-4efb-87c2-a24c06a539b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06680826-8850-4b8e-b1eb-c58d7859ff8a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e29ce4e-c998-4efb-87c2-a24c06a539b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5ca20139-34bc-4f36-afdc-2186f94b1e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e29ce4e-c998-4efb-87c2-a24c06a539b7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5ca20139-34bc-4f36-afdc-2186f94b1e96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5ca20139-34bc-4f36-afdc-2186f94b1e96_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ca20139-34bc-4f36-afdc-2186f94b1e96" xlink:to="loc_us-gaap_EquityComponentDomain_5ca20139-34bc-4f36-afdc-2186f94b1e96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8b866ecd-7c35-4fe7-8059-f6e5009b138b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ca20139-34bc-4f36-afdc-2186f94b1e96" xlink:to="loc_us-gaap_EquityComponentDomain_8b866ecd-7c35-4fe7-8059-f6e5009b138b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreFundedWarrantsMember_97e28edd-30ca-4ed5-8c70-74397a8d3844" xlink:href="crdf-20200930.xsd#crdf_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8b866ecd-7c35-4fe7-8059-f6e5009b138b" xlink:to="loc_crdf_PreFundedWarrantsMember_97e28edd-30ca-4ed5-8c70-74397a8d3844" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquityPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails" xlink:type="extended" id="ic3848608122748f68f71323814e26109_StockholdersEquityPreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d0dc390c-9ac9-4c10-996c-763437da8565" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_17914f48-cfac-4675-aefc-60992ee9720c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0dc390c-9ac9-4c10-996c-763437da8565" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_17914f48-cfac-4675-aefc-60992ee9720c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2cd061b8-b1e0-48b4-bb7d-ce2e9bdeb43f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0dc390c-9ac9-4c10-996c-763437da8565" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2cd061b8-b1e0-48b4-bb7d-ce2e9bdeb43f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_20e51b08-e095-458e-9a2e-1dc51e9a8b92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0dc390c-9ac9-4c10-996c-763437da8565" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_20e51b08-e095-458e-9a2e-1dc51e9a8b92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_cd27cf38-6edb-4a8b-b8e6-4e25cac835b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0dc390c-9ac9-4c10-996c-763437da8565" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_cd27cf38-6edb-4a8b-b8e6-4e25cac835b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_58c7d11a-446a-4d9d-b53f-576a8b44ee1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0dc390c-9ac9-4c10-996c-763437da8565" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_58c7d11a-446a-4d9d-b53f-576a8b44ee1a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2c55cf06-3b3d-4fdb-8a93-612bfe73a382" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_58c7d11a-446a-4d9d-b53f-576a8b44ee1a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2c55cf06-3b3d-4fdb-8a93-612bfe73a382" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2c55cf06-3b3d-4fdb-8a93-612bfe73a382_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2c55cf06-3b3d-4fdb-8a93-612bfe73a382" xlink:to="loc_us-gaap_ClassOfStockDomain_2c55cf06-3b3d-4fdb-8a93-612bfe73a382_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_366652a1-5895-4c83-a7e9-3a5eb162eac1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2c55cf06-3b3d-4fdb-8a93-612bfe73a382" xlink:to="loc_us-gaap_ClassOfStockDomain_366652a1-5895-4c83-a7e9-3a5eb162eac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesAConvertiblePreferredStockMember_c53d52df-2214-498a-8239-7b795b7953f5" xlink:href="crdf-20200930.xsd#crdf_SeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_366652a1-5895-4c83-a7e9-3a5eb162eac1" xlink:to="loc_crdf_SeriesAConvertiblePreferredStockMember_c53d52df-2214-498a-8239-7b795b7953f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesBConvertiblePreferredStockMember_268de979-a4e1-43ae-9984-a61bb5ce7959" xlink:href="crdf-20200930.xsd#crdf_SeriesBConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_366652a1-5895-4c83-a7e9-3a5eb162eac1" xlink:to="loc_crdf_SeriesBConvertiblePreferredStockMember_268de979-a4e1-43ae-9984-a61bb5ce7959" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_0c44383d-2808-4d3b-b000-d055173ca341" xlink:href="crdf-20200930.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_366652a1-5895-4c83-a7e9-3a5eb162eac1" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_0c44383d-2808-4d3b-b000-d055173ca341" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_1610cdd4-b66a-4f67-b92d-5a6e0a8c7551" xlink:href="crdf-20200930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_366652a1-5895-4c83-a7e9-3a5eb162eac1" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_1610cdd4-b66a-4f67-b92d-5a6e0a8c7551" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_dc65ba9f-67aa-4f0a-9c4d-f729940bea07" xlink:href="crdf-20200930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_366652a1-5895-4c83-a7e9-3a5eb162eac1" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_dc65ba9f-67aa-4f0a-9c4d-f729940bea07" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquitySeriesCConvertiblePreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails" xlink:type="extended" id="id0fb45b8d3d443558c2f93c485e86281_StockholdersEquitySeriesCConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AmountFinancedUnderAgreement_9c6bb36d-ddb0-4fee-83e0-32473c7f6577" xlink:href="crdf-20200930.xsd#crdf_AmountFinancedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:to="loc_crdf_AmountFinancedUnderAgreement_9c6bb36d-ddb0-4fee-83e0-32473c7f6577" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0aad4c68-45b5-4ef2-80b3-8e6ace71bd2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0aad4c68-45b5-4ef2-80b3-8e6ace71bd2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightNumberGranted_26cbcaff-e0fa-4df0-be59-bd56aefb36e1" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightNumberGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:to="loc_crdf_ClassOfWarrantOrRightNumberGranted_26cbcaff-e0fa-4df0-be59-bd56aefb36e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f2fedf06-4a45-4733-9dc9-61e48ca19fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f2fedf06-4a45-4733-9dc9-61e48ca19fd4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_bfaf944a-523f-481c-858e-9d1129d17c85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_bfaf944a-523f-481c-858e-9d1129d17c85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_18eb6af3-c752-48ad-8e93-90aa32ae4637" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_18eb6af3-c752-48ad-8e93-90aa32ae4637" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_b55ed622-bce0-4265-91ec-765293f6f4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_b55ed622-bce0-4265-91ec-765293f6f4f3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Servicereceivable_e8cfd6d3-a10c-443b-b158-05651dd28875" xlink:href="crdf-20200930.xsd#crdf_Servicereceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:to="loc_crdf_Servicereceivable_e8cfd6d3-a10c-443b-b158-05651dd28875" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_0041bf87-d141-4c35-b206-0036315adc1f" xlink:href="crdf-20200930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:to="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_0041bf87-d141-4c35-b206-0036315adc1f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_190d4ce3-d56b-4268-9860-5415345ca51d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_190d4ce3-d56b-4268-9860-5415345ca51d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_096709ea-0314-442c-91b3-7d761584847d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_190d4ce3-d56b-4268-9860-5415345ca51d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_096709ea-0314-442c-91b3-7d761584847d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_096709ea-0314-442c-91b3-7d761584847d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_096709ea-0314-442c-91b3-7d761584847d" xlink:to="loc_us-gaap_EquityComponentDomain_096709ea-0314-442c-91b3-7d761584847d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9fa8581a-88fa-414d-a773-dbe574024d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_096709ea-0314-442c-91b3-7d761584847d" xlink:to="loc_us-gaap_EquityComponentDomain_9fa8581a-88fa-414d-a773-dbe574024d72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_943021aa-02a3-473f-b7da-b01d0bd829c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9fa8581a-88fa-414d-a773-dbe574024d72" xlink:to="loc_us-gaap_CommonStockMember_943021aa-02a3-473f-b7da-b01d0bd829c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_98a6b0d0-74c5-49c3-8048-9650105dd0b3" xlink:href="crdf-20200930.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9fa8581a-88fa-414d-a773-dbe574024d72" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_98a6b0d0-74c5-49c3-8048-9650105dd0b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9903c41a-52e9-4607-bd86-96bdfb803eda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_190d4ce3-d56b-4268-9860-5415345ca51d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9903c41a-52e9-4607-bd86-96bdfb803eda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9903c41a-52e9-4607-bd86-96bdfb803eda_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9903c41a-52e9-4607-bd86-96bdfb803eda" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9903c41a-52e9-4607-bd86-96bdfb803eda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4c9659bb-a3af-4cd7-b045-24c3705652b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9903c41a-52e9-4607-bd86-96bdfb803eda" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4c9659bb-a3af-4cd7-b045-24c3705652b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_75c3de15-138b-46cb-8247-cb35105853dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4c9659bb-a3af-4cd7-b045-24c3705652b5" xlink:to="loc_us-gaap_PrivatePlacementMember_75c3de15-138b-46cb-8247-cb35105853dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_58eed49f-b0f1-4a74-b659-887c55efd8d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_190d4ce3-d56b-4268-9860-5415345ca51d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_58eed49f-b0f1-4a74-b659-887c55efd8d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_58eed49f-b0f1-4a74-b659-887c55efd8d6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_58eed49f-b0f1-4a74-b659-887c55efd8d6" xlink:to="loc_us-gaap_ClassOfStockDomain_58eed49f-b0f1-4a74-b659-887c55efd8d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c7f451b6-f20b-417f-8f89-11428fccc689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_58eed49f-b0f1-4a74-b659-887c55efd8d6" xlink:to="loc_us-gaap_ClassOfStockDomain_c7f451b6-f20b-417f-8f89-11428fccc689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_d6fd3f15-c9ca-410c-ab8e-3107c35ca780" xlink:href="crdf-20200930.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c7f451b6-f20b-417f-8f89-11428fccc689" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_d6fd3f15-c9ca-410c-ab8e-3107c35ca780" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquitySeriesDConvertiblePreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails" xlink:type="extended" id="icece0e9e558e45aa9ce13047e2433f65_StockholdersEquitySeriesDConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6267a4f2-ee73-45d2-9157-5ae042ca8ea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AmountFinancedUnderAgreement_75b52c68-34cf-4940-a4b1-38db40281349" xlink:href="crdf-20200930.xsd#crdf_AmountFinancedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6267a4f2-ee73-45d2-9157-5ae042ca8ea5" xlink:to="loc_crdf_AmountFinancedUnderAgreement_75b52c68-34cf-4940-a4b1-38db40281349" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f5facc93-b545-4793-9cf8-e93a350b994c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6267a4f2-ee73-45d2-9157-5ae042ca8ea5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f5facc93-b545-4793-9cf8-e93a350b994c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_654a001e-97d0-4dce-be7f-62db0687cd06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6267a4f2-ee73-45d2-9157-5ae042ca8ea5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_654a001e-97d0-4dce-be7f-62db0687cd06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_47cdd5d0-0a01-4bc0-8ac2-242922e8dd5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6267a4f2-ee73-45d2-9157-5ae042ca8ea5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_47cdd5d0-0a01-4bc0-8ac2-242922e8dd5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_d50754f9-7b19-4b4b-a1fe-7a497f0f487b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6267a4f2-ee73-45d2-9157-5ae042ca8ea5" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_d50754f9-7b19-4b4b-a1fe-7a497f0f487b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_f788dd99-c9f1-4045-9241-4a58c9422100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6267a4f2-ee73-45d2-9157-5ae042ca8ea5" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_f788dd99-c9f1-4045-9241-4a58c9422100" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Servicereceivable_2d11cddb-ec50-4034-b5ac-3767aaa6cec5" xlink:href="crdf-20200930.xsd#crdf_Servicereceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6267a4f2-ee73-45d2-9157-5ae042ca8ea5" xlink:to="loc_crdf_Servicereceivable_2d11cddb-ec50-4034-b5ac-3767aaa6cec5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_ee7590d2-4144-456e-999e-f4579a7030ea" xlink:href="crdf-20200930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6267a4f2-ee73-45d2-9157-5ae042ca8ea5" xlink:to="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_ee7590d2-4144-456e-999e-f4579a7030ea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a43d0b49-84f0-4d46-901e-9333e36bbbb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6267a4f2-ee73-45d2-9157-5ae042ca8ea5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a43d0b49-84f0-4d46-901e-9333e36bbbb6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_150d25a1-c2ab-45d9-9c73-1b84ac999c29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a43d0b49-84f0-4d46-901e-9333e36bbbb6" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_150d25a1-c2ab-45d9-9c73-1b84ac999c29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_150d25a1-c2ab-45d9-9c73-1b84ac999c29_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_150d25a1-c2ab-45d9-9c73-1b84ac999c29" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_150d25a1-c2ab-45d9-9c73-1b84ac999c29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_64be4d4c-cb1f-44d3-ba80-868a4ffd0a49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_150d25a1-c2ab-45d9-9c73-1b84ac999c29" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_64be4d4c-cb1f-44d3-ba80-868a4ffd0a49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_09b85224-4827-4902-bbf2-14b939b4e0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_64be4d4c-cb1f-44d3-ba80-868a4ffd0a49" xlink:to="loc_us-gaap_PrivatePlacementMember_09b85224-4827-4902-bbf2-14b939b4e0c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f5d2f421-a446-4589-bbd4-c63eefa5c1d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a43d0b49-84f0-4d46-901e-9333e36bbbb6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f5d2f421-a446-4589-bbd4-c63eefa5c1d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f5d2f421-a446-4589-bbd4-c63eefa5c1d6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f5d2f421-a446-4589-bbd4-c63eefa5c1d6" xlink:to="loc_us-gaap_EquityComponentDomain_f5d2f421-a446-4589-bbd4-c63eefa5c1d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ec97c53e-4bc1-4e92-b603-22b329739a43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f5d2f421-a446-4589-bbd4-c63eefa5c1d6" xlink:to="loc_us-gaap_EquityComponentDomain_ec97c53e-4bc1-4e92-b603-22b329739a43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ec43cf57-cfca-4192-9ecf-5ec9e967c9b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ec97c53e-4bc1-4e92-b603-22b329739a43" xlink:to="loc_us-gaap_CommonStockMember_ec43cf57-cfca-4192-9ecf-5ec9e967c9b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_54a46ed4-72ca-49a4-92cd-5a13a06c7e5f" xlink:href="crdf-20200930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ec97c53e-4bc1-4e92-b603-22b329739a43" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_54a46ed4-72ca-49a4-92cd-5a13a06c7e5f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquitySeriesEConvertiblePreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" xlink:type="extended" id="i416c5e103d3d49f2907b2ff83e3c4cc3_StockholdersEquitySeriesEConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b886136b-ec79-46a0-8d91-89435457cb4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b886136b-ec79-46a0-8d91-89435457cb4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d0e1d109-b79f-4405-b4e0-601839ad6c13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d0e1d109-b79f-4405-b4e0-601839ad6c13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_154ec7b6-07b5-491a-b0ae-217ffb609a1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_154ec7b6-07b5-491a-b0ae-217ffb609a1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockConvertibleConversionPrice_e9bc5b0d-fe8b-46da-83aa-da03e6ebad0a" xlink:href="crdf-20200930.xsd#crdf_PreferredStockConvertibleConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_crdf_PreferredStockConvertibleConversionPrice_e9bc5b0d-fe8b-46da-83aa-da03e6ebad0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_fc4ebe37-2454-440a-84cf-57348d877b7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_fc4ebe37-2454-440a-84cf-57348d877b7a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightMonthsUntilExercisable_44d2f767-9dc2-4d89-bb2f-0c6e43e2a725" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightMonthsUntilExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_crdf_ClassOfWarrantOrRightMonthsUntilExercisable_44d2f767-9dc2-4d89-bb2f-0c6e43e2a725" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5c34d0e6-c156-4978-9bf2-671458e229b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5c34d0e6-c156-4978-9bf2-671458e229b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_92b22a95-69e1-46be-8d4d-adf30b6bdf6f" xlink:href="crdf-20200930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_92b22a95-69e1-46be-8d4d-adf30b6bdf6f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightIssued_99d877bf-2e31-4015-b1c2-5cd69c69f283" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_crdf_ClassOfWarrantOrRightIssued_99d877bf-2e31-4015-b1c2-5cd69c69f283" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightExpirationTerm_9272089e-5e85-4a93-9486-81d138271b39" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightExpirationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_crdf_ClassOfWarrantOrRightExpirationTerm_9272089e-5e85-4a93-9486-81d138271b39" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_WarrantsFairValue_d5949ac6-f095-42f4-bfcc-49153fc7c48a" xlink:href="crdf-20200930.xsd#crdf_WarrantsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_crdf_WarrantsFairValue_d5949ac6-f095-42f4-bfcc-49153fc7c48a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_229005cc-d13c-46a4-aad8-e57f5f9e7b91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_229005cc-d13c-46a4-aad8-e57f5f9e7b91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ae41da3e-9575-407c-868b-af6d3ae52ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_229005cc-d13c-46a4-aad8-e57f5f9e7b91" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ae41da3e-9575-407c-868b-af6d3ae52ef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ae41da3e-9575-407c-868b-af6d3ae52ef2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ae41da3e-9575-407c-868b-af6d3ae52ef2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ae41da3e-9575-407c-868b-af6d3ae52ef2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ed8b08b-be19-45b3-9cb4-77562adc027e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ae41da3e-9575-407c-868b-af6d3ae52ef2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ed8b08b-be19-45b3-9cb4-77562adc027e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_RegisteredDirectOfferingMember_144de2bb-b186-4ae1-8202-8b3de35253e5" xlink:href="crdf-20200930.xsd#crdf_RegisteredDirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ed8b08b-be19-45b3-9cb4-77562adc027e" xlink:to="loc_crdf_RegisteredDirectOfferingMember_144de2bb-b186-4ae1-8202-8b3de35253e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_181f957c-dab4-454d-bfd3-1e95c7c29b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ed8b08b-be19-45b3-9cb4-77562adc027e" xlink:to="loc_us-gaap_PrivatePlacementMember_181f957c-dab4-454d-bfd3-1e95c7c29b9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c3423347-e774-4870-a4bf-7770841cccb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_229005cc-d13c-46a4-aad8-e57f5f9e7b91" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c3423347-e774-4870-a4bf-7770841cccb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c3423347-e774-4870-a4bf-7770841cccb0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c3423347-e774-4870-a4bf-7770841cccb0" xlink:to="loc_us-gaap_ClassOfStockDomain_c3423347-e774-4870-a4bf-7770841cccb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cba91edf-f595-492e-bc21-5c14f9dc9ffa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c3423347-e774-4870-a4bf-7770841cccb0" xlink:to="loc_us-gaap_ClassOfStockDomain_cba91edf-f595-492e-bc21-5c14f9dc9ffa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_d871530a-62fa-4316-9425-fcaffa0c9584" xlink:href="crdf-20200930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cba91edf-f595-492e-bc21-5c14f9dc9ffa" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_d871530a-62fa-4316-9425-fcaffa0c9584" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_74993a6d-d7b6-48f5-8d7b-60c63eef1c65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_229005cc-d13c-46a4-aad8-e57f5f9e7b91" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_74993a6d-d7b6-48f5-8d7b-60c63eef1c65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_74993a6d-d7b6-48f5-8d7b-60c63eef1c65_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_74993a6d-d7b6-48f5-8d7b-60c63eef1c65" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_74993a6d-d7b6-48f5-8d7b-60c63eef1c65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_346c8847-9899-4937-ba85-00ec95531800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_74993a6d-d7b6-48f5-8d7b-60c63eef1c65" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_346c8847-9899-4937-ba85-00ec95531800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesNWarrantMember_b097f0e2-d98a-495d-a1b2-3ac5e0c73847" xlink:href="crdf-20200930.xsd#crdf_SeriesNWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_346c8847-9899-4937-ba85-00ec95531800" xlink:to="loc_crdf_SeriesNWarrantMember_b097f0e2-d98a-495d-a1b2-3ac5e0c73847" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquitySecuritiesPurchaseAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" xlink:type="extended" id="i6ffc0d3d175b4de589e56cb70a50726f_StockholdersEquitySecuritiesPurchaseAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5ab9d72b-79a8-4aa2-8bd2-f2ba11453f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ee7965d7-bbf7-41de-9b6d-a59592943a55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5ab9d72b-79a8-4aa2-8bd2-f2ba11453f0a" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ee7965d7-bbf7-41de-9b6d-a59592943a55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_45a3c58a-4c68-4e53-9024-b73eb05a03d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5ab9d72b-79a8-4aa2-8bd2-f2ba11453f0a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_45a3c58a-4c68-4e53-9024-b73eb05a03d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_b914f4de-223c-425d-9b26-b749409b8424" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5ab9d72b-79a8-4aa2-8bd2-f2ba11453f0a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_b914f4de-223c-425d-9b26-b749409b8424" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightMonthsUntilExercisable_159e3d0d-2293-49c3-bbde-295d797146a5" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightMonthsUntilExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5ab9d72b-79a8-4aa2-8bd2-f2ba11453f0a" xlink:to="loc_crdf_ClassOfWarrantOrRightMonthsUntilExercisable_159e3d0d-2293-49c3-bbde-295d797146a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8ed31533-7e4f-4a18-8119-db24839570a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5ab9d72b-79a8-4aa2-8bd2-f2ba11453f0a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8ed31533-7e4f-4a18-8119-db24839570a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightExpirationTerm_4d18f0d9-2a32-4404-a16e-d4f8ed120d56" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightExpirationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5ab9d72b-79a8-4aa2-8bd2-f2ba11453f0a" xlink:to="loc_crdf_ClassOfWarrantOrRightExpirationTerm_4d18f0d9-2a32-4404-a16e-d4f8ed120d56" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5eeb9648-8342-4591-9087-4ab169c015a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5ab9d72b-79a8-4aa2-8bd2-f2ba11453f0a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5eeb9648-8342-4591-9087-4ab169c015a3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_e3ca6af5-8d76-4cbf-8631-4079d903dd46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5ab9d72b-79a8-4aa2-8bd2-f2ba11453f0a" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_e3ca6af5-8d76-4cbf-8631-4079d903dd46" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4606c1ef-6df8-44af-bd35-ecafac698d05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_5ab9d72b-79a8-4aa2-8bd2-f2ba11453f0a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4606c1ef-6df8-44af-bd35-ecafac698d05" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9e66a6a5-4e86-4ff2-a4a5-91b097f38bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4606c1ef-6df8-44af-bd35-ecafac698d05" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9e66a6a5-4e86-4ff2-a4a5-91b097f38bdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9e66a6a5-4e86-4ff2-a4a5-91b097f38bdd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9e66a6a5-4e86-4ff2-a4a5-91b097f38bdd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_9e66a6a5-4e86-4ff2-a4a5-91b097f38bdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3cbf91dd-aaab-46c6-85a0-a47c6e6bf592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9e66a6a5-4e86-4ff2-a4a5-91b097f38bdd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3cbf91dd-aaab-46c6-85a0-a47c6e6bf592" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesIWarrantMember_dcd3d60f-6ad3-41e1-afb8-6d9c7b264e0e" xlink:href="crdf-20200930.xsd#crdf_SeriesIWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3cbf91dd-aaab-46c6-85a0-a47c6e6bf592" xlink:to="loc_crdf_SeriesIWarrantMember_dcd3d60f-6ad3-41e1-afb8-6d9c7b264e0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesJWarrantMember_92eb7aa4-ca0e-4853-9ea0-780610cb94d8" xlink:href="crdf-20200930.xsd#crdf_SeriesJWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3cbf91dd-aaab-46c6-85a0-a47c6e6bf592" xlink:to="loc_crdf_SeriesJWarrantMember_92eb7aa4-ca0e-4853-9ea0-780610cb94d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesKWarrantMember_2a794c6d-5e77-4a50-89cf-87b735611fb2" xlink:href="crdf-20200930.xsd#crdf_SeriesKWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3cbf91dd-aaab-46c6-85a0-a47c6e6bf592" xlink:to="loc_crdf_SeriesKWarrantMember_2a794c6d-5e77-4a50-89cf-87b735611fb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesLWarrantsMember_5948c0e8-641e-42f0-bf7b-402888fadfb8" xlink:href="crdf-20200930.xsd#crdf_SeriesLWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3cbf91dd-aaab-46c6-85a0-a47c6e6bf592" xlink:to="loc_crdf_SeriesLWarrantsMember_5948c0e8-641e-42f0-bf7b-402888fadfb8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesMWarrantMember_749658ff-428e-4b75-ace6-c8f7677bd5fe" xlink:href="crdf-20200930.xsd#crdf_SeriesMWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3cbf91dd-aaab-46c6-85a0-a47c6e6bf592" xlink:to="loc_crdf_SeriesMWarrantMember_749658ff-428e-4b75-ace6-c8f7677bd5fe" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="crdf-20200930.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/CommitmentsandContingencies" xlink:type="extended" id="i1c5f9903a83d41bfa1c9ac4423a813dc_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="ic3ebc10da6fe4166956fb005918b8d65_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_e984c799-4c20-4737-b7e3-96ed6899ebc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6e395bfc-db30-414c-8cb0-740c757479e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e984c799-4c20-4737-b7e3-96ed6899ebc3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6e395bfc-db30-414c-8cb0-740c757479e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_1753ea1e-f20f-40a7-bf6e-e6b540ca3201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e984c799-4c20-4737-b7e3-96ed6899ebc3" xlink:to="loc_us-gaap_PurchaseObligation_1753ea1e-f20f-40a7-bf6e-e6b540ca3201" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_fee9128f-6058-4a01-b5f7-814b8ed93fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e984c799-4c20-4737-b7e3-96ed6899ebc3" xlink:to="loc_us-gaap_OtherCommitmentsTable_fee9128f-6058-4a01-b5f7-814b8ed93fd8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_01619527-06e8-4de3-b5b3-e9b257063133" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_fee9128f-6058-4a01-b5f7-814b8ed93fd8" xlink:to="loc_srt_CounterpartyNameAxis_01619527-06e8-4de3-b5b3-e9b257063133" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_01619527-06e8-4de3-b5b3-e9b257063133_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_01619527-06e8-4de3-b5b3-e9b257063133" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_01619527-06e8-4de3-b5b3-e9b257063133_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db407c74-b1b0-451a-bf39-ace2d2536907" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_01619527-06e8-4de3-b5b3-e9b257063133" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db407c74-b1b0-451a-bf39-ace2d2536907" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_NorvianoMember_50dcc4aa-45b7-4e22-8268-82f1f98ed5fc" xlink:href="crdf-20200930.xsd#crdf_NorvianoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db407c74-b1b0-451a-bf39-ace2d2536907" xlink:to="loc_crdf_NorvianoMember_50dcc4aa-45b7-4e22-8268-82f1f98ed5fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis_a5864702-bb95-49fd-94f3-ad62a777f908" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_fee9128f-6058-4a01-b5f7-814b8ed93fd8" xlink:to="loc_us-gaap_NatureOfExpenseAxis_a5864702-bb95-49fd-94f3-ad62a777f908" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_a5864702-bb95-49fd-94f3-ad62a777f908_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NatureOfExpenseAxis_a5864702-bb95-49fd-94f3-ad62a777f908" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_a5864702-bb95-49fd-94f3-ad62a777f908_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_c6a570da-74a3-40a0-978c-71677a77339a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NatureOfExpenseAxis_a5864702-bb95-49fd-94f3-ad62a777f908" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_c6a570da-74a3-40a0-978c-71677a77339a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_f8b828ad-e816-48b6-b947-117606d97c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_c6a570da-74a3-40a0-978c-71677a77339a" xlink:to="loc_us-gaap_LicensingAgreementsMember_f8b828ad-e816-48b6-b947-117606d97c72" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="crdf-20200930.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/RelatedPartyTransactions" xlink:type="extended" id="ibfc026c1bb5c4738be4e70e1e9f990f9_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i862e9e49940b47079e1a133a4c9b1966_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6e8c5c5c-c57b-4cef-b75a-fd87207b479b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f5e939de-8c5a-4d30-95a6-9b6c2acddeaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6e8c5c5c-c57b-4cef-b75a-fd87207b479b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f5e939de-8c5a-4d30-95a6-9b6c2acddeaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c3c9b40e-3416-42a2-a5a5-61404569a077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6e8c5c5c-c57b-4cef-b75a-fd87207b479b" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c3c9b40e-3416-42a2-a5a5-61404569a077" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f850d934-26e0-443f-ba29-807ca296f63c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c3c9b40e-3416-42a2-a5a5-61404569a077" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f850d934-26e0-443f-ba29-807ca296f63c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f850d934-26e0-443f-ba29-807ca296f63c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f850d934-26e0-443f-ba29-807ca296f63c" xlink:to="loc_us-gaap_RelatedPartyDomain_f850d934-26e0-443f-ba29-807ca296f63c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0f9516ae-29a1-4f2c-8cb4-13590ca5b1a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f850d934-26e0-443f-ba29-807ca296f63c" xlink:to="loc_us-gaap_RelatedPartyDomain_0f9516ae-29a1-4f2c-8cb4-13590ca5b1a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAffiliatesMember_593e8a7d-ce3d-4793-8c27-21f657285811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAffiliatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_0f9516ae-29a1-4f2c-8cb4-13590ca5b1a9" xlink:to="loc_us-gaap_OtherAffiliatesMember_593e8a7d-ce3d-4793-8c27-21f657285811" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/COVID19" xlink:type="simple" xlink:href="crdf-20200930.xsd#COVID19"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/COVID19" xlink:type="extended" id="i7623c18c30f14cefaee2df6fb5dda5f1_COVID19"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/COVID19Details" xlink:type="simple" xlink:href="crdf-20200930.xsd#COVID19Details"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/COVID19Details" xlink:type="extended" id="ic82afd096dad4757bf2b28e3f4baeb9b_COVID19Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems_d7d42521-cdbd-4b48-9d33-e7d6e0d71028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_ac15cbe1-c7bd-44da-853a-9cbbd71526ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_d7d42521-cdbd-4b48-9d33-e7d6e0d71028" xlink:to="loc_us-gaap_NotesPayable_ac15cbe1-c7bd-44da-853a-9cbbd71526ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3bce996e-86dd-47d6-b291-2acdf2cce346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_d7d42521-cdbd-4b48-9d33-e7d6e0d71028" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3bce996e-86dd-47d6-b291-2acdf2cce346" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable_ec21c865-e2df-4914-9560-d751b4bbb22a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_d7d42521-cdbd-4b48-9d33-e7d6e0d71028" xlink:to="loc_us-gaap_UnusualOrInfrequentItemTable_ec21c865-e2df-4914-9560-d751b4bbb22a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a8419f37-2488-4262-859b-f4fce1f1b984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_ec21c865-e2df-4914-9560-d751b4bbb22a" xlink:to="loc_us-gaap_DebtInstrumentAxis_a8419f37-2488-4262-859b-f4fce1f1b984" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a8419f37-2488-4262-859b-f4fce1f1b984_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a8419f37-2488-4262-859b-f4fce1f1b984" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a8419f37-2488-4262-859b-f4fce1f1b984_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9f323d07-3c8f-4569-a819-85ac8415c588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a8419f37-2488-4262-859b-f4fce1f1b984" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9f323d07-3c8f-4569-a819-85ac8415c588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PaycheckProtectionProgramCARESActMember_c697dbc5-f5c7-473d-836c-c5592bf057f5" xlink:href="crdf-20200930.xsd#crdf_PaycheckProtectionProgramCARESActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9f323d07-3c8f-4569-a819-85ac8415c588" xlink:to="loc_crdf_PaycheckProtectionProgramCARESActMember_c697dbc5-f5c7-473d-836c-c5592bf057f5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SubsequentEvents" xlink:type="simple" xlink:href="crdf-20200930.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/SubsequentEvents" xlink:type="extended" id="i1f702496aa2e4f018166ed7ccc33d3c7_SubsequentEvents"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/SubsequentEventsDetails" xlink:type="extended" id="i0a3e917098f4401ba59b208c66a75b3e_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_3a8417f8-820e-4a87-a059-13864ee516c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_164c1ccd-6f15-41f8-ac8e-1c7a63e117a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3a8417f8-820e-4a87-a059-13864ee516c3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_164c1ccd-6f15-41f8-ac8e-1c7a63e117a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_b2f3e520-d840-43db-8352-82f27e8ba164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3a8417f8-820e-4a87-a059-13864ee516c3" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_b2f3e520-d840-43db-8352-82f27e8ba164" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SaleOfStockConsiderationReceivedOnTransactionGross_063b4269-89c3-412b-b1f5-4c248f948067" xlink:href="crdf-20200930.xsd#crdf_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3a8417f8-820e-4a87-a059-13864ee516c3" xlink:to="loc_crdf_SaleOfStockConsiderationReceivedOnTransactionGross_063b4269-89c3-412b-b1f5-4c248f948067" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_65a7ff67-199b-4042-b5c1-f4eb739311c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3a8417f8-820e-4a87-a059-13864ee516c3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_65a7ff67-199b-4042-b5c1-f4eb739311c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_3c1f1c81-9c94-4fc6-8932-ec18c30565c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3a8417f8-820e-4a87-a059-13864ee516c3" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_3c1f1c81-9c94-4fc6-8932-ec18c30565c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightNumberExercised_eeecb8cd-334a-4e0c-8951-9480c19a6eab" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightNumberExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3a8417f8-820e-4a87-a059-13864ee516c3" xlink:to="loc_crdf_ClassOfWarrantOrRightNumberExercised_eeecb8cd-334a-4e0c-8951-9480c19a6eab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_63f51e13-ffb9-408e-990f-ff03ef66c2ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3a8417f8-820e-4a87-a059-13864ee516c3" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_63f51e13-ffb9-408e-990f-ff03ef66c2ef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_423f8c83-3b5f-4e47-b9b6-55cbec2b67c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_3a8417f8-820e-4a87-a059-13864ee516c3" xlink:to="loc_us-gaap_SubsequentEventTable_423f8c83-3b5f-4e47-b9b6-55cbec2b67c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f31cb1ca-a5a7-4ab7-847c-06405d71d9c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_423f8c83-3b5f-4e47-b9b6-55cbec2b67c1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f31cb1ca-a5a7-4ab7-847c-06405d71d9c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f31cb1ca-a5a7-4ab7-847c-06405d71d9c9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f31cb1ca-a5a7-4ab7-847c-06405d71d9c9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f31cb1ca-a5a7-4ab7-847c-06405d71d9c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_98329e12-34fe-4874-8b04-4329c3279915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f31cb1ca-a5a7-4ab7-847c-06405d71d9c9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_98329e12-34fe-4874-8b04-4329c3279915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_605ef3d1-de7a-417b-882c-876bf4fdaac4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_98329e12-34fe-4874-8b04-4329c3279915" xlink:to="loc_us-gaap_SubsequentEventMember_605ef3d1-de7a-417b-882c-876bf4fdaac4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2c6f1ba7-b0ed-4797-8c50-1017c119b7eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_423f8c83-3b5f-4e47-b9b6-55cbec2b67c1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2c6f1ba7-b0ed-4797-8c50-1017c119b7eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2c6f1ba7-b0ed-4797-8c50-1017c119b7eb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2c6f1ba7-b0ed-4797-8c50-1017c119b7eb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2c6f1ba7-b0ed-4797-8c50-1017c119b7eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43753336-4f87-462f-9cc4-5950f9ebe646" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2c6f1ba7-b0ed-4797-8c50-1017c119b7eb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43753336-4f87-462f-9cc4-5950f9ebe646" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_e837bd08-281c-441a-941a-d940be0791ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43753336-4f87-462f-9cc4-5950f9ebe646" xlink:to="loc_us-gaap_OverAllotmentOptionMember_e837bd08-281c-441a-941a-d940be0791ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e12c2611-36fb-4c98-89e0-6179e659c4ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_423f8c83-3b5f-4e47-b9b6-55cbec2b67c1" xlink:to="loc_us-gaap_DebtInstrumentAxis_e12c2611-36fb-4c98-89e0-6179e659c4ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e12c2611-36fb-4c98-89e0-6179e659c4ff_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e12c2611-36fb-4c98-89e0-6179e659c4ff" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e12c2611-36fb-4c98-89e0-6179e659c4ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0cab694c-e751-421d-bc3a-247c047b553e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e12c2611-36fb-4c98-89e0-6179e659c4ff" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0cab694c-e751-421d-bc3a-247c047b553e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PaycheckProtectionProgramCARESActMember_0ced5a1a-cd3c-414d-8d78-e8f5a5aca0c7" xlink:href="crdf-20200930.xsd#crdf_PaycheckProtectionProgramCARESActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cab694c-e751-421d-bc3a-247c047b553e" xlink:to="loc_crdf_PaycheckProtectionProgramCARESActMember_0ced5a1a-cd3c-414d-8d78-e8f5a5aca0c7" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>crdf-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:899aa37a-8922-454a-a94d-f1f600203a5a,g:092e8a26-8aea-4f93-acda-3be57db43dca-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_cd4489ab-3a00-46a2-aec7-4eb928750894_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_e100b3f9-9005-4517-abc0-ca7ac0a8c894_negatedTerseLabel_en-US" xlink:label="lab_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</link:label>
    <link:label id="lab_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_15235dc4-a056-4ada-9c64-ca9325c91e3a_terseLabel_en-US" xlink:label="lab_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</link:label>
    <link:label id="lab_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_label_en-US" xlink:label="lab_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock</link:label>
    <link:label id="lab_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_documentation_en-US" xlink:label="lab_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:href="crdf-20200930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:to="lab_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4c19a22f-d746-4fec-a741-ec4d84b5640f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f1235229-c5b4-46ea-9731-58831576b98f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ec2f3853-0363-4971-b0a0-77cc90741272_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6a80663d-6ec0-42e0-b7c1-eb4b189362f4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_15dbbb67-c1b2-4211-8dc3-ac359bceb62d_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series&#160;A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_46f8b79f-4e37-445a-ab36-c9efbc348be1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesJWarrantMember_811f74cd-aef8-444b-a837-e28413d2de19_terseLabel_en-US" xlink:label="lab_crdf_SeriesJWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series J Warrant</link:label>
    <link:label id="lab_crdf_SeriesJWarrantMember_label_en-US" xlink:label="lab_crdf_SeriesJWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series J Warrant [Member]</link:label>
    <link:label id="lab_crdf_SeriesJWarrantMember_documentation_en-US" xlink:label="lab_crdf_SeriesJWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series J Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesJWarrantMember" xlink:href="crdf-20200930.xsd#crdf_SeriesJWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesJWarrantMember" xlink:to="lab_crdf_SeriesJWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_543f3589-c5ee-4f7a-b57e-adc36b8289bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested, weighted average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_50bd0007-86cc-48cf-88e3-59ffe903a105_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised_afb24eec-9f54-4ce5-9ede-6f2aea50ee02_terseLabel_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of warrants</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Warrants Exercised</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The equity impact during the period due to the cash exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="crdf-20200930.xsd#crdf_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_9bc0623d-e2bc-4d00-bb9a-266271f49f6d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Warrant Activity and Changes in Warrants Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_13eefc20-735b-44e5-a04e-5e972e644f8c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_abb4ee52-541e-41b3-a2ce-1a1eccca17c7_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrant exercise</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_e9077d76-1010-4cfb-a898-0c9ee59b9472_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_4e201a8a-b830-4d6a-b391-056876e15c87_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c68c0d4e-d0e0-4c52-a9a1-2ec298fdb2e5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2f39c394-47d4-4b40-bfd1-cf1acc0f68d5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability_3a05fac0-5b72-4c67-9c9d-f78bb856afd9_terseLabel_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Liability</link:label>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability_documentation_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="crdf-20200930.xsd#crdf_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_crdf_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_838a5e69-47f4-40f2-9d5f-1356457a2940_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments - Warrants</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_097504c1-272e-41de-b106-e07779bfec07_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_58970ebc-6669-4f2d-ab2a-6ca7afbf9802_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_4355540a-4f3f-4e8a-b7ee-dd303fa00507_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings under note payable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_fcec8d42-57d1-4ed3-a277-f1db84b8f623_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived_a234d547-5b04-48b1-b59f-5fa63d03b33e_terseLabel_en-US" xlink:label="lab_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of clinical trial funding commitment</link:label>
    <link:label id="lab_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived_label_en-US" xlink:label="lab_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of clinical trial funding commitment for services received</link:label>
    <link:label id="lab_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived_documentation_en-US" xlink:label="lab_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of clinical trial funding commitment for services received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived" xlink:href="crdf-20200930.xsd#crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived" xlink:to="lab_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4cee30d7-f87d-43ab-9baf-1c7b8811db2e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_28b36f7d-c3b2-48d9-81ae-a07c3735796c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightNumberGranted_2987187c-62e9-499e-a374-21e76715e010_verboseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightNumberGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightNumberGranted_c04fe86d-da3a-46a5-beac-1aef5ed506fc_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightNumberGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in shares)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightNumberGranted_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightNumberGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Number Granted</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightNumberGranted_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightNumberGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of warrants or rights granted during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightNumberGranted" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightNumberGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightNumberGranted" xlink:to="lab_crdf_ClassOfWarrantOrRightNumberGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d1288298-f8db-4ced-a541-949cd8c6ca00_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, weighted average grant date fair value at end of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ea5387a8-a76f-422e-899b-7e4964a2e42a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, weighted average grant date fair value at end of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_a017a3e1-6fc1-46eb-99aa-dcb782673e83_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_e3a3cb40-f9fb-41b1-b821-3e2179981b4b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7faf3cc3-1f72-4bc5-87d0-6052efac6449_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_001540ce-53ac-42f3-9e0c-a1111f0ba508_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b429e5f4-7a05-4882-9940-cc460ddafcf1_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_74839e33-cfab-4ca9-87f2-b20542806e7b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_74ed2ed3-0ab0-4fb5-8e7e-a5badfa6a585_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ec55b7bd-920a-411b-a0bb-76d26794327b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b23762ca-6b7d-4e22-8702-c1e5889a3a93_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_8cb407a3-d2e0-4d78-9f13-535563a71789_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_690c12b7-a066-491a-a363-db1196754c7d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemLineItems_abdf7db4-872e-4269-b1d5-1a0b9cadebf9_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Line Items]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemLineItems_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems" xlink:to="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_4ad9b98e-201d-42a2-99be-774911541be0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5ebe071e-7c9a-4227-9865-c2c803b9ff18_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_PreferredStockConvertibleConversionPrice_f536b27c-c348-46dc-b70c-f4ea2ceaf374_terseLabel_en-US" xlink:label="lab_crdf_PreferredStockConvertibleConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_crdf_PreferredStockConvertibleConversionPrice_label_en-US" xlink:label="lab_crdf_PreferredStockConvertibleConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price</link:label>
    <link:label id="lab_crdf_PreferredStockConvertibleConversionPrice_documentation_en-US" xlink:label="lab_crdf_PreferredStockConvertibleConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockConvertibleConversionPrice" xlink:href="crdf-20200930.xsd#crdf_PreferredStockConvertibleConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_PreferredStockConvertibleConversionPrice" xlink:to="lab_crdf_PreferredStockConvertibleConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_7a9a7207-cd10-4998-b4fa-d78c2f1c38d1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (excluding the nine months ended September 30, 2020)</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_c1255f2d-3bff-408c-b12b-2fd930429174_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_63893ed9-1abf-4e6a-a19b-7ec06a432580_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_090f2456-dcf9-44c8-b8c5-21814e819993_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease ROU assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DenominatorAbstract_1e0291d9-6f77-4434-b1f9-14e24d04c328_terseLabel_en-US" xlink:label="lab_crdf_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_crdf_DenominatorAbstract_label_en-US" xlink:label="lab_crdf_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_crdf_DenominatorAbstract_documentation_en-US" xlink:label="lab_crdf_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DenominatorAbstract" xlink:href="crdf-20200930.xsd#crdf_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DenominatorAbstract" xlink:to="lab_crdf_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_e6016186-7af7-407c-b8c0-9756157ed943_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market fund</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0c681dd8-89ce-4327-8ead-872aa21d2a10_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_789528b0-2a15-45dd-8b1a-7bad52628fa8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_629c44cb-a531-4d36-9812-4ba4e59f0551_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0eabc62f-e8fc-47fa-846a-7073975362ad_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_16a586ea-3249-4f8f-b70f-61b625c6ecab_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, 20,000,000 shares authorized; (Note 7)</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_74b13f03-488e-47f2-82de-c9b9b51e3608_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_9f702b1e-3f9e-40c1-bcb6-81aa972a861c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_be80f4fb-9728-48ee-9dfe-07fc5c367d78_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_84e0e3f3-aed8-46a5-8e2f-381c2880264c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_f42a52ae-6da5-42da-be68-b503054c89ca_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightIssued_7936260b-0bb0-4493-a538-6c5814fb942d_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued (in shares)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightIssued_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightIssued_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightIssued" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightIssued" xlink:to="lab_crdf_ClassOfWarrantOrRightIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_3395c58d-0ce2-4ddf-aff4-e17b5c33a367_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_9d860b8b-f9f6-4867-841a-768f1f831927_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_NumeratorAbstract_8d3e43d2-7d51-48f1-b294-3819333ea9c8_terseLabel_en-US" xlink:label="lab_crdf_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_crdf_NumeratorAbstract_label_en-US" xlink:label="lab_crdf_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_crdf_NumeratorAbstract_documentation_en-US" xlink:label="lab_crdf_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_NumeratorAbstract" xlink:href="crdf-20200930.xsd#crdf_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_NumeratorAbstract" xlink:to="lab_crdf_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_864f71de-a97e-4b87-8998-d706a5188a96_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested, fair value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f4d894eb-3666-4118-b7ac-ace8353cd3d1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_2c6ec470-5f76-4d95-82ac-e0365c81cdba_terseLabel_en-US" xlink:label="lab_crdf_DerivativeFinancialInstrumentsLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in the Company's derivative financial instruments liability balance</link:label>
    <link:label id="lab_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_label_en-US" xlink:label="lab_crdf_DerivativeFinancialInstrumentsLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward" xlink:href="crdf-20200930.xsd#crdf_DerivativeFinancialInstrumentsLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward" xlink:to="lab_crdf_DerivativeFinancialInstrumentsLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9c06f64b-c610-49f2-a565-5c2e476e9b2a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_42e9ec25-751a-4ab2-a344-c5621e9e206e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a3a6591d-1a7b-418a-a500-542b8e5cd450_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_66f581b2-7550-4bb8-9232-f3d2c8d26288_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_WarrantsAndRightsRollForward_519c6b77-ce8c-4f1c-8a0c-ea4090bc612f_terseLabel_en-US" xlink:label="lab_crdf_WarrantsAndRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Warrants</link:label>
    <link:label id="lab_crdf_WarrantsAndRightsRollForward_label_en-US" xlink:label="lab_crdf_WarrantsAndRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_WarrantsAndRightsRollForward" xlink:href="crdf-20200930.xsd#crdf_WarrantsAndRightsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_WarrantsAndRightsRollForward" xlink:to="lab_crdf_WarrantsAndRightsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitment_54c9ebce-5646-403a-802f-2567757a0581_terseLabel_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of clinical trial funding commitment</link:label>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitment_label_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release Of Clinical Trial Funding Commitment</link:label>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitment_documentation_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release Of Clinical Trial Funding Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:href="crdf-20200930.xsd#crdf_ReleaseOfClinicalTrialFundingCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:to="lab_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a031faa8-f487-41a5-bb1b-795b007c6f61_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_b4bdbc63-ebf3-4b94-9f06-1bf00ea919d2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a06637d2-5c23-46e0-89ba-16e92e487c59_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_decabadb-618b-4d18-9524-dcca28079ffc_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_1cf32721-95e4-416d-981a-6cbe40d79e6b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_21c61fe3-f4c7-4cad-8194-6c1494b79f34_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_2d6cdc42-1b64-435f-9c9e-2cf8c83ccf77_terseLabel_en-US" xlink:label="lab_crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount of issuance of common stock, preferred stock and warrants for clinical trial funding commitment</link:label>
    <link:label id="lab_crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_label_en-US" xlink:label="lab_crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment</link:label>
    <link:label id="lab_crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_documentation_en-US" xlink:label="lab_crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:href="crdf-20200930.xsd#crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:to="lab_crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_c9c581a8-b2a2-481d-9e4d-17482d893d2c_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract_1b9a0fb5-bc71-4826-b674-b007012d95be_terseLabel_en-US" xlink:label="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Items, or Both [Abstract]</link:label>
    <link:label id="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract_label_en-US" xlink:label="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Items, or Both [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:to="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_8482fe10-4fd9-4df2-a873-1675b634046b_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual rent increase, percentage</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rent Increase, Percentage</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rent Increase, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:to="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_0e210e86-71b4-4b59-af06-98c3cad97111_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments&#8212;warrants</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_74802021-6168-4c80-8f90-10ca943bcc12_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments - warrants</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_2b98c55f-09a3-4073-8403-4e110ba59f78_periodStartLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance of derivative financial instruments liability at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_1698bf11-547f-44d0-8f1a-b837ca636076_periodEndLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance of derivative financial instruments liability at the end of the period</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c5026c69-0dc1-4599-9ccd-fcc055afaf63_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_eea67967-f853-43c1-ab88-4b025ff33a11_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_bbb8f387-4ae5-4ae6-8725-f7a54798ee67_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_cd123f24-ed94-4db5-8a15-c8b0dbb5d545_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_1a396293-ea32-4a7c-ab26-b16466e37b7f_periodStartLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of warrants at the beginning of the period (in USD per share)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_3c381b31-2f8b-45ee-a3f6-b15482d910ab_periodEndLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of warrants at the end of the period (in USD per share)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the weighted average exercise price of each class of warrants or rights outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:to="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightNumberExercised_2e93a3bf-b486-40cd-8a42-f2e86f828f8b_negatedTerseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightNumberExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightNumberExercised_ec5bcf44-add9-41b8-afd7-70edd634d777_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightNumberExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightNumberExercised_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightNumberExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Number Exercised</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightNumberExercised_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightNumberExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of warrants or rights exercised during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightNumberExercised" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightNumberExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightNumberExercised" xlink:to="lab_crdf_ClassOfWarrantOrRightNumberExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_5fe3fdbc-80fa-4901-9acb-257d427e5b0c_terseLabel_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of warrants (in shares)</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Warrants Exercised</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of shares issued during the period upon cash exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="crdf-20200930.xsd#crdf_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1e2e3e94-f508-44cb-a783-5b76a5156f6f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa5e8255-83b0-4eea-8307-c233b8907050_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0398a41c-61b9-4fb4-bea4-135fd4c71761_negatedLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock, preferred stock and warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e6689e9b-100c-4e6a-8d63-efd11289e60e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8867c801-8893-4a1e-a49a-c5da8bcabebf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_d1e6d18e-56d8-4fad-8a1a-523686c570d0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_89bb8b17-8fb2-4322-a7b3-6762f996e11c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of common stock, preferred stock and warrants, net of expenses of $633,807 and $97,260, respectively</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b4366351-02ae-423c-81ab-3f7354133302_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_373b3132-7f17-4797-b875-6483d4119ff0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Earnings per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_71e61029-0171-4c18-8ccc-e4dedec67055_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average assumptions</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesMWarrantMember_4233f68c-3359-44f9-88f5-d3bedffe5996_terseLabel_en-US" xlink:label="lab_crdf_SeriesMWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series M Warrant</link:label>
    <link:label id="lab_crdf_SeriesMWarrantMember_label_en-US" xlink:label="lab_crdf_SeriesMWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series M Warrant [Member]</link:label>
    <link:label id="lab_crdf_SeriesMWarrantMember_documentation_en-US" xlink:label="lab_crdf_SeriesMWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series M Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesMWarrantMember" xlink:href="crdf-20200930.xsd#crdf_SeriesMWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesMWarrantMember" xlink:to="lab_crdf_SeriesMWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_03d1ffba-c1c5-44de-ad1a-b876c436c3b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized shares under the plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_WarrantsFairValue_f9b229ed-5d50-41f7-9778-78da311ebc2f_terseLabel_en-US" xlink:label="lab_crdf_WarrantsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, fair value</link:label>
    <link:label id="lab_crdf_WarrantsFairValue_label_en-US" xlink:label="lab_crdf_WarrantsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Fair Value</link:label>
    <link:label id="lab_crdf_WarrantsFairValue_documentation_en-US" xlink:label="lab_crdf_WarrantsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_WarrantsFairValue" xlink:href="crdf-20200930.xsd#crdf_WarrantsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_WarrantsFairValue" xlink:to="lab_crdf_WarrantsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesIWarrantMember_0a601819-6656-4729-91cf-685e86db8b86_terseLabel_en-US" xlink:label="lab_crdf_SeriesIWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series I Warrant</link:label>
    <link:label id="lab_crdf_SeriesIWarrantMember_label_en-US" xlink:label="lab_crdf_SeriesIWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series I Warrant [Member]</link:label>
    <link:label id="lab_crdf_SeriesIWarrantMember_documentation_en-US" xlink:label="lab_crdf_SeriesIWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series I Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesIWarrantMember" xlink:href="crdf-20200930.xsd#crdf_SeriesIWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesIWarrantMember" xlink:to="lab_crdf_SeriesIWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_731c48c0-1465-463f-89f1-326abb564feb_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8c1d4106-c8cc-43ba-860a-38d1b707acea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of remaining shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed6d2e42-921a-49c2-a356-52d28745c3fe_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_5bad4fcf-528c-4ff2-8182-06479eeb0a69_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_c8725de0-f5b7-4b7f-a53d-90aa41af235a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment_9fb0d99b-2691-4ac1-ac51-e8a0eb00c8ff_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly rent payments</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent Payment</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseMonthlyRentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:to="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_029ca511-d05c-470c-9086-6435769d0ac8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_ddbce843-9c5a-42bc-ae4b-e243451c6d84_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_df2810cf-9b39-456f-a735-52612dd2e940_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_35b26e3b-4556-4eb0-a334-64185075953c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c028bcd2-17d7-4d57-bdaf-19b8a6adc1fd_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3f488aca-36e9-4103-b035-3cf1aa781a89_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_6342d8ed-1201-4912-80ee-675e91b1cdac_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_0634eb82-45a6-4eec-8b64-9e11ae53e91e_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining&#160;Contractual Term</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Term of Outstanding Warrants or Rights</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period over which each class of warrants or rights outstanding may be exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:to="lab_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_ff7740df-d307-4c2d-af15-92a5404d1de1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_4339654d-209a-4be9-b575-9670aba440c4_negatedTerseLabel_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="crdf-20200930.xsd#crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e2f7706d-d579-4948-8e98-4b7cb2bf9a9f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_f1cf7bcb-e2cb-4dfd-b357-0073e59335c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_c001abbc-5de5-4986-a52f-d51d7982437e_totalLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Two</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" xlink:to="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ea5087a3-9d56-4f62-9e91-2c037320631c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_c14863a0-3757-4233-84e0-36de7b79cafd_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c985f274-8fa5-471b-8b99-75ff1db08a5c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f01b12af-2017-414e-8e4f-bfaed0829164_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_f01c5bc8-9abc-4db7-b050-ee90ee49e08f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_021848a1-53f3-4127-83ab-1e92c8342b16_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_cfafa3cb-0b8d-4c97-9031-0e840748d0fb_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_97c27c1a-17b5-46cb-9659-498b71eebf5e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lease Expense and Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_fa3f6d9f-4d80-4b60-83bd-a0f26c020237_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_33e548ad-2006-422f-bdaa-9b4c14c94f1b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_a6bb4aa8-5e64-469e-b252-1ed7576e6de9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_7028aa2f-0571-4f97-97c6-f06c53c5618a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_f17f7ca0-7eb5-4f00-9695-42bc22f79ddf_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_29a0024a-8070-4232-9e09-fccc84ee0202_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased_757abb0b-15d5-44b3-8534-0fb5125cadc7_terseLabel_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased_label_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Restricted Stock Units Released</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased_documentation_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Restricted Stock Units Released</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased" xlink:href="crdf-20200930.xsd#crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased" xlink:to="lab_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_3458b65e-a3b6-42cd-84d1-056dd85c7214_terseLabel_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in USD per share)</link:label>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expired in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:href="crdf-20200930.xsd#crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_2ccff22e-8505-4009-9536-3064ceb85f23_negatedLabel_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_label_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expired in Period</link:label>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_documentation_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares under options that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:href="crdf-20200930.xsd#crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:to="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_731c5dfb-2326-48ad-b221-6f20f8d6b855_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_18fe8630-090f-4550-a15e-6395fefd4e98_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_89f1ac75-c539-41f5-b8a3-8c1ecb7c21fa_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SaleOfStockCommonAndWarrantsNetShares_55db3411-3146-46b2-9945-8a02f68cef2f_terseLabel_en-US" xlink:label="lab_crdf_SaleOfStockCommonAndWarrantsNetShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock and warrants (in shares)</link:label>
    <link:label id="lab_crdf_SaleOfStockCommonAndWarrantsNetShares_label_en-US" xlink:label="lab_crdf_SaleOfStockCommonAndWarrantsNetShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Common And Warrants, Net, Shares</link:label>
    <link:label id="lab_crdf_SaleOfStockCommonAndWarrantsNetShares_documentation_en-US" xlink:label="lab_crdf_SaleOfStockCommonAndWarrantsNetShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Common And Warrants, Net, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SaleOfStockCommonAndWarrantsNetShares" xlink:href="crdf-20200930.xsd#crdf_SaleOfStockCommonAndWarrantsNetShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SaleOfStockCommonAndWarrantsNetShares" xlink:to="lab_crdf_SaleOfStockCommonAndWarrantsNetShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4e0d6fe1-fcbe-42ab-8ad7-2deb9c4e307d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_56b98de1-41fd-4d2a-8b2e-deaff811a29e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_b78441dd-37f6-4eca-84b1-1b62cb653fbd_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_b2fd6a59-c1bb-44ea-9b4d-7ab8f992361f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_bbefd06d-555d-411e-84a1-fe97d23fdba2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ff7660df-4c43-4b5d-83af-baa0d88246dc_negatedLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock, preferred stock and warrants</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2eb803bb-c906-45fd-b24f-04a09251928e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_64db2c84-72d2-47a6-925d-0d8ea4ddbeb3_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_00d8b684-2a9a-442f-bb4e-5cfa99be0fe5_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_c5777ee0-6662-43ec-8afa-17f15641e578_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Not from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueNotFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LessorNumberOfSubleases_b4f8244a-9978-4c4f-a7c6-a271734057ba_terseLabel_en-US" xlink:label="lab_crdf_LessorNumberOfSubleases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of subleases</link:label>
    <link:label id="lab_crdf_LessorNumberOfSubleases_label_en-US" xlink:label="lab_crdf_LessorNumberOfSubleases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Number Of Subleases</link:label>
    <link:label id="lab_crdf_LessorNumberOfSubleases_documentation_en-US" xlink:label="lab_crdf_LessorNumberOfSubleases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Number Of Subleases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LessorNumberOfSubleases" xlink:href="crdf-20200930.xsd#crdf_LessorNumberOfSubleases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LessorNumberOfSubleases" xlink:to="lab_crdf_LessorNumberOfSubleases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c30f7dd5-2669-488e-9dca-84e26bb7c5be_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_70f4f364-2472-4074-8d4a-5436766db2da_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_e5a8c3f0-705d-4ee1-9e9b-be8634a08dd1_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Leases</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:to="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_89f53801-6bc9-48c2-803f-eed51d1b57f1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining vesting period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_fb65b79e-98e5-4f7c-a08a-11e10d362054_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_39fda35f-6bf4-404e-af18-37c0551b1fc5_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_28a5504c-9f72-4db8-9087-b681eacfbaec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2531ca90-c2c0-4e3b-89fb-a2bca4a1f6c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_e07039fb-8957-4ad0-b97a-4991183585fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5af3c152-541e-40b4-93a3-e8386d0be5e9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_af2e6e87-47f5-4c04-a5b8-9f2924e9b7d8_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_271dd736-677f-43a5-8b68-b499a9f95e79_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember_ca02686d-207b-4dd2-a5af-ccf6a7ec265b_terseLabel_en-US" xlink:label="lab_crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember_label_en-US" xlink:label="lab_crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02, Elimination Of Cease-Use Loss Liability [Member]</link:label>
    <link:label id="lab_crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember_documentation_en-US" xlink:label="lab_crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02, Elimination Of Cease-Use Loss Liability [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember" xlink:href="crdf-20200930.xsd#crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember" xlink:to="lab_crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bed7d8f6-f55b-4774-9619-acf2f9bcd005_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_79c6179a-a5da-4002-a0a0-6f537fda2719_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c234e3af-53b5-4b30-8fa0-857551d375e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_9a993a95-70f8-4eb5-a486-3e4b8c2746d1_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) from change in fair value of derivative financial instruments&#8212;warrants</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_c4f5cc2c-4f72-43b3-b647-76c53d35f0cb_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative financial instruments&#8212;warrants</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_731c7122-1617-4a1f-b726-65d7c208a610_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative financial instruments&#8212;warrants during the period recognized as a loss in the condensed statements of operations</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_4bdcd7ec-f42f-4e02-a38b-50fc46f036d3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne_fa935e27-3eb1-483b-a545-3b1314fc910a_totalLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year One</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne" xlink:to="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_35ca45ea-352c-4fb0-8f81-3794f4f5415e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_5e8ce904-fd97-46f4-8adb-fd663fde600e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected warrant term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_8cf5e38c-79d2-4f6e-bb68-232332297760_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3ad87c06-d74b-4008-accf-38d14a152443_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f7221119-620d-48ee-86df-87f6ebdb6e8d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_1052bcfe-dc21-4ec0-8caa-1b5086881049_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_9d5e7460-647c-4d93-bfee-fe40351519d0_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7d609756-6d5e-4931-8e2d-035f4856ba81_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7822d545-f47d-4a6c-b426-00f35dc159c4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_51c80a1c-86f4-4076-bb52-a7ec4797606b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c644e400-5694-4d3a-97a8-3d2c13e30ebd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance outstanding at the beginning of the period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_63f70519-94b3-48c6-b682-5b9ab74aef97_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance outstanding at the end of the period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ee3074cc-12b5-451b-8e93-ccaeafe8e966_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_07bed6e2-59b7-404c-95da-488965f4e4db_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_e305aa30-1a2b-440a-a747-b684182f32a7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesLWarrantsMember_880251ca-fed4-4d1a-bb79-5d9935e67f16_terseLabel_en-US" xlink:label="lab_crdf_SeriesLWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series L Warrants</link:label>
    <link:label id="lab_crdf_SeriesLWarrantsMember_label_en-US" xlink:label="lab_crdf_SeriesLWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series L Warrants [Member]</link:label>
    <link:label id="lab_crdf_SeriesLWarrantsMember_documentation_en-US" xlink:label="lab_crdf_SeriesLWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series L Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesLWarrantsMember" xlink:href="crdf-20200930.xsd#crdf_SeriesLWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesLWarrantsMember" xlink:to="lab_crdf_SeriesLWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear_c9bcaba3-3755-4cf4-ae42-12485dbe4ca0_totalLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (excluding the nine months ended September 30, 2020)</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Remainder Of Fiscal Year</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Remainder Of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear" xlink:to="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_a0b9a511-fbcc-4d2c-9170-faa5dd4d75b3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6d5585c4-aa7e-4476-bef3-e02822975fa6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_235bdb25-26ae-44cd-aa25-6c63e6863549_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e09303ab-2409-4d35-9edd-d0f5ca816443_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_1503f622-2d0c-43c2-ba5f-04ad0ba69cbb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_64a53fa6-acba-44cb-b198-f89262e45f36_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon conversion of convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:to="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_342e6ffd-a9f5-4725-b928-139e1a574291_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4e5448fe-d322-47a9-ae1f-e4429ac309be_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_EquityIncentivePlan2014Member_d48e76a0-e27e-4212-8a26-311b16ce42c1_terseLabel_en-US" xlink:label="lab_crdf_EquityIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 EIP</link:label>
    <link:label id="lab_crdf_EquityIncentivePlan2014Member_label_en-US" xlink:label="lab_crdf_EquityIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2014 [Member]</link:label>
    <link:label id="lab_crdf_EquityIncentivePlan2014Member_documentation_en-US" xlink:label="lab_crdf_EquityIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the 2014 Equity Incentive Plan under which common shares will be issued to the members.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityIncentivePlan2014Member" xlink:href="crdf-20200930.xsd#crdf_EquityIncentivePlan2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_EquityIncentivePlan2014Member" xlink:to="lab_crdf_EquityIncentivePlan2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_6a96c161-c431-48fa-b153-3f5e6f7e782a_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_FurnitureAndOfficeEquipmentMember_a54bf24c-ec6b-4583-bbd7-f7045b11033c_terseLabel_en-US" xlink:label="lab_crdf_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and office equipment</link:label>
    <link:label id="lab_crdf_FurnitureAndOfficeEquipmentMember_label_en-US" xlink:label="lab_crdf_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture And Office Equipment [Member]</link:label>
    <link:label id="lab_crdf_FurnitureAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_crdf_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to furniture and office equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_FurnitureAndOfficeEquipmentMember" xlink:href="crdf-20200930.xsd#crdf_FurnitureAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_FurnitureAndOfficeEquipmentMember" xlink:to="lab_crdf_FurnitureAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_619cbecc-b0e4-4316-8717-e997e481ed2f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_5122b2cf-d55e-45cd-ac61-ef3461f72b13_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_e3104617-6976-4589-9674-5cd92f0914ee_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Per Share</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights [Abstract]</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:to="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8d9da00c-b42f-42e6-aacf-fb7e52ea0994_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_a96ad296-e8cc-4eba-b69f-4b1ff67b7892_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_fbd1bd3f-24a8-4014-b5b2-137642e23736_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d5caa55b-0b36-4a20-b789-e0ec2d3c0858_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3f61e4ec-c397-4129-ac94-6a7e81cbbeb4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SaleOfStockConsiderationReceivedOnTransactionGross_f312372c-e1af-4019-b13f-4596e9734bd9_terseLabel_en-US" xlink:label="lab_crdf_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from sale of stock</link:label>
    <link:label id="lab_crdf_SaleOfStockConsiderationReceivedOnTransactionGross_label_en-US" xlink:label="lab_crdf_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Consideration Received On Transaction, Gross</link:label>
    <link:label id="lab_crdf_SaleOfStockConsiderationReceivedOnTransactionGross_documentation_en-US" xlink:label="lab_crdf_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Consideration Received On Transaction, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:href="crdf-20200930.xsd#crdf_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:to="lab_crdf_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_a50d6c9e-ca4c-404d-9862-3a537c3d0ba2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesKWarrantMember_d457326c-f82b-4008-8219-922645fcb754_terseLabel_en-US" xlink:label="lab_crdf_SeriesKWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series K Warrant</link:label>
    <link:label id="lab_crdf_SeriesKWarrantMember_label_en-US" xlink:label="lab_crdf_SeriesKWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series K Warrant [Member]</link:label>
    <link:label id="lab_crdf_SeriesKWarrantMember_documentation_en-US" xlink:label="lab_crdf_SeriesKWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series K Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesKWarrantMember" xlink:href="crdf-20200930.xsd#crdf_SeriesKWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesKWarrantMember" xlink:to="lab_crdf_SeriesKWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_e229eebe-b6bf-4ca4-b6a3-bf01b3111896_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_3204d1bf-0046-4df1-9de2-6ba16ffc053c_totalLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" xlink:to="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_42d33cfc-fb78-4e03-abce-26b305fb3edd_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_bd288d14-acb9-427a-b572-35a73479459a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_2b5c0635-f851-4323-b739-0c4f565bacee_totalLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Three</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" xlink:to="lab_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_d027ae0b-ca0a-4074-9d01-4a50ca59b73d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_717feff2-4266-4d42-a1db-d410268f812a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfExpenseAxis_787193dc-1784-4c54-a303-6adc7ad712e4_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfExpenseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:label id="lab_us-gaap_NatureOfExpenseAxis_label_en-US" xlink:label="lab_us-gaap_NatureOfExpenseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfExpenseAxis" xlink:to="lab_us-gaap_NatureOfExpenseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_a6c62602-6bcf-45b7-8383-ecd4e2d7cb96_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs related to the clinical trial funding commitment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_9563de48-8fc9-4c9c-bd57-6e044265087f_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Term of Warrants or Rights [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:to="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_66840b79-5e21-4bc3-bdf9-966f1fad2243_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_62558097-0eee-4340-975e-79ff6771af28_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_d27ef972-750a-4504-ba76-287133c65f8e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_c46bba86-5918-4620-b450-300c00585c9e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SaleOfStockValueCommonAndWarrantsNet_8fb892d9-178e-4a29-ac91-de6c6fee4efd_terseLabel_en-US" xlink:label="lab_crdf_SaleOfStockValueCommonAndWarrantsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock and warrants</link:label>
    <link:label id="lab_crdf_SaleOfStockValueCommonAndWarrantsNet_label_en-US" xlink:label="lab_crdf_SaleOfStockValueCommonAndWarrantsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Value, Common And Warrants, Net</link:label>
    <link:label id="lab_crdf_SaleOfStockValueCommonAndWarrantsNet_documentation_en-US" xlink:label="lab_crdf_SaleOfStockValueCommonAndWarrantsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Value, Common And Warrants, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SaleOfStockValueCommonAndWarrantsNet" xlink:href="crdf-20200930.xsd#crdf_SaleOfStockValueCommonAndWarrantsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SaleOfStockValueCommonAndWarrantsNet" xlink:to="lab_crdf_SaleOfStockValueCommonAndWarrantsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_b5379c7f-d37d-4a61-b73c-7f54b6a4e44c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d7c71c0f-ab00-4c5b-9c13-5e85f81f83b4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5892123d-9f3e-47e4-b627-eb181eb6b9d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f76a1836-db25-4057-9dc6-625b442a99d1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0599473c-595d-4c30-aae5-4af40e5230ac_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e34568a5-5f33-4be6-9cf6-1dccfed53770_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee168388-1ef7-49f6-999f-c2da2744d1c9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c7570bca-c7ba-4fd3-88b3-babeafbcf5d9_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_5abd7923-d921-4e37-841e-914c362dca50_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of note</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_452621d0-8c92-4735-a0c2-fd29fc689bbe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_67ea6253-40b1-4875-9bb5-f98ed369c906_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_dd66139c-fe6c-4775-bff3-7f729a03b7ad_terseLabel_en-US" xlink:label="lab_crdf_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of issuance of common stock, preferred stock and warrants</link:label>
    <link:label id="lab_crdf_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_label_en-US" xlink:label="lab_crdf_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment</link:label>
    <link:label id="lab_crdf_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_documentation_en-US" xlink:label="lab_crdf_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:href="crdf-20200930.xsd#crdf_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:to="lab_crdf_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_28770374-b198-410f-92f2-4ed5b6618ea3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_27879b4d-d922-4c84-a7db-c78517983980_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_7676c139-6283-4e33-a18c-30c10ecff329_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Company&#8217;s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2ac08085-f080-4633-9a4c-1ffc91a90a17_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions to Estimate Fair Value of Stock Option Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_131d0334-c06f-410d-a501-81340fba98b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_50fcd6c2-c248-4396-abc9-18f16c3369df_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightMonthsUntilExercisable_71fb9f28-85d3-46a6-8e25-111604530b40_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightMonthsUntilExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Months until exercisable</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightMonthsUntilExercisable_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightMonthsUntilExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Months Until Exercisable</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightMonthsUntilExercisable_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightMonthsUntilExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Months Until Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightMonthsUntilExercisable" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightMonthsUntilExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightMonthsUntilExercisable" xlink:to="lab_crdf_ClassOfWarrantOrRightMonthsUntilExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_639a7bf2-53ee-43f9-a6d1-e48bca0c082d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6348551d-e929-47ef-a435-1db827d665b5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_cc3f8310-817f-4389-ae8d-d86ece40a7e3_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other commitment</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e4b11665-b2b2-401b-b933-5647e3302f59_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity and of Changes in Stock Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreferenceValue_ef8c8ad8-a506-487a-87e3-012a282434c4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation preference</link:label>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreferenceValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_b6deb92f-bdb4-466d-bfa9-eacddf19a04a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_0d538f5c-a54e-41bc-a12c-1b52de34fa21_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_1d2ff47a-d4ab-4cc6-bc43-7b720b0c7b5e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_30abe905-5a1b-40f6-8816-5c0443218710_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7a0acd36-24f9-434d-bee5-ea9e2b7b614d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate&#8211;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_49fecf67-d367-43fd-a897-0d8029d0f2f9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0891f31c-b94c-476d-b061-a6aeae69c79a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d4c18b82-12bb-4b37-9ed6-757d974cf2f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_42ce2c3c-b2a9-4d3f-825d-ca45b6625868_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_7e0028ce-3fa0-452f-a7a5-28d9933ff6ba_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon conversion of Series D Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_30fb417b-ce2b-4696-98ae-f9432f9d2774_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable and unbilled receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_68fe24ca-763d-4a56-94a4-0d9ca5bb93b9_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockSplits_0d656d40-f053-4ff7-bb81-acb9781bb542_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for share rounding as a result of reverse stock split (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockSplits_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Splits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_9fdddbfc-d3a4-4be1-899e-83ec21581f01_negatedLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend payable on Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_da8117e0-752e-4a0e-a3d2-ac72070eb6c8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightExpirationTerm_0c3447dd-c8bc-43a7-8ddf-873516ca8d81_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration term</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightExpirationTerm_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Expiration Term</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightExpirationTerm_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Expiration Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightExpirationTerm" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightExpirationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightExpirationTerm" xlink:to="lab_crdf_ClassOfWarrantOrRightExpirationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_2a8bb600-a1b2-43f3-bf08-7d4d0b97338a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9639f21b-4f9e-48ee-9be2-6eb8790dfeff_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_211e6c57-f63d-4ba7-9725-d5652f1c5685_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used to compute basic and diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_cfb7fb43-64a1-488a-8c00-ef8ec21ee409_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used to Determine the Fair Value of the Warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ac449231-9e36-4834-94c3-7db38c2696be_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_751420d4-deb9-42b6-9c61-318041d6e11b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance of warrants outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0c4db032-e87a-4019-85d4-bd489110f6a1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance of warrants outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_e91b35c4-4843-4158-ad6b-8258b7bdd7aa_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted_e7e5dab5-07a3-46fc-a870-3ba605f05bdf_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights Granted</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the weighted average exercise price of each class of warrants or rights granted during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" xlink:to="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_PreferredStockDividendAccrued_249dde42-e460-4621-964f-5d706a8092e8_terseLabel_en-US" xlink:label="lab_crdf_PreferredStockDividendAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend payable on Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_PreferredStockDividendAccrued_label_en-US" xlink:label="lab_crdf_PreferredStockDividendAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividend Accrued</link:label>
    <link:label id="lab_crdf_PreferredStockDividendAccrued_documentation_en-US" xlink:label="lab_crdf_PreferredStockDividendAccrued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the value of preferred stock dividend accrued during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockDividendAccrued" xlink:href="crdf-20200930.xsd#crdf_PreferredStockDividendAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_PreferredStockDividendAccrued" xlink:to="lab_crdf_PreferredStockDividendAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_31b6f13f-9190-4d95-bdfc-e21b94180b6e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_35dfb237-4ee8-4b86-b73e-8027f14d42a7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_11f6167c-abc9-4fe1-b7b0-0249a3854298_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled / Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_334d6a60-d99c-4b6c-adb5-a8d471eb30d0_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_660f63f8-579d-4c61-bd8a-3713c4ad4ee9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseNumberOfRenewalOptions_14ad0ba2-5a03-41d6-9e1d-39dd69cf6b9b_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lease renewals</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseNumberOfRenewalOptions_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:to="lab_crdf_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_99d70640-d7d4-425b-b845-0b1e0492e2df_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e2f6b877-83c1-4e44-88e2-bf2d86d390a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2eb02785-7961-4e3a-bd11-96612e7b8825_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_35190b89-5f5f-4785-a4fa-255757e42c6b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_c46df5e1-d3d7-4aaa-aa3a-986eeedf94d9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7d655768-948d-4cea-a9a5-1e9cb3f9fccc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_a2e827e8-b287-4ab0-b7e6-4ffea543bec8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e62ea21b-e910-4268-b772-b58a98b9a097_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5d97aab4-b794-415c-adae-740e0f160951_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term&#8211;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_80d41321-0d64-497e-ae4b-61bac79c9eed_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_PaycheckProtectionProgramCARESActMember_9643f2be-3e06-4d06-981e-9dd40fb1549a_terseLabel_en-US" xlink:label="lab_crdf_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program</link:label>
    <link:label id="lab_crdf_PaycheckProtectionProgramCARESActMember_label_en-US" xlink:label="lab_crdf_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act [Member]</link:label>
    <link:label id="lab_crdf_PaycheckProtectionProgramCARESActMember_documentation_en-US" xlink:label="lab_crdf_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PaycheckProtectionProgramCARESActMember" xlink:href="crdf-20200930.xsd#crdf_PaycheckProtectionProgramCARESActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_PaycheckProtectionProgramCARESActMember" xlink:to="lab_crdf_PaycheckProtectionProgramCARESActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d4d0bb14-5965-4e32-b9ab-2a71b3aee430_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_f4d53eb9-082a-4306-abce-2b88ad7b76be_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f5ef424f-ed44-41fd-866b-0598c9fd73ab_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f2822813-44a7-4248-b642-a40a416338bc_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value, 150,000,000 shares authorized; 26,285,743 and 8,593,633 shares issued and outstanding at September 30, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_e341d4b5-de10-487c-bb0d-236c5189b2e3_terseLabel_en-US" xlink:label="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Changes in the Company&#8217;s Derivative Financial Instruments Liability Balance</link:label>
    <link:label id="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_label_en-US" xlink:label="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Changes in Derivative Financial Liability [Table Text Block]</link:label>
    <link:label id="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_documentation_en-US" xlink:label="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the reconciliation of a concept from the beginning of a period to the end of the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:href="crdf-20200930.xsd#crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:to="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bcef6a8f-74cd-43c0-bc8f-a69bd82cc72b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable at the end of the period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_eb8e53b0-a1e1-469f-948e-64ae08c3fa59_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_RegisteredDirectOfferingMember_7c151ff8-2d7e-4529-a32e-8c9c10b489db_terseLabel_en-US" xlink:label="lab_crdf_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering</link:label>
    <link:label id="lab_crdf_RegisteredDirectOfferingMember_label_en-US" xlink:label="lab_crdf_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
    <link:label id="lab_crdf_RegisteredDirectOfferingMember_documentation_en-US" xlink:label="lab_crdf_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to registered direct offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_RegisteredDirectOfferingMember" xlink:href="crdf-20200930.xsd#crdf_RegisteredDirectOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_RegisteredDirectOfferingMember" xlink:to="lab_crdf_RegisteredDirectOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_ed3d9c09-45fe-4e8a-a473-b0f2519c378a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility of Cardiff Oncology common stock</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_ef18e87d-cdd6-446b-b4fa-938f4f449c16_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_f377df56-5619-485d-bb13-1ba009740eb9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_4b0f8ef8-ba27-43fe-81b7-67f7930f6227_terseLabel_en-US" xlink:label="lab_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment</link:label>
    <link:label id="lab_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_label_en-US" xlink:label="lab_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment</link:label>
    <link:label id="lab_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_documentation_en-US" xlink:label="lab_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" xlink:href="crdf-20200930.xsd#crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" xlink:to="lab_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ServiceReceivableMember_b5e63a73-3c54-4e0c-84de-98b33785348e_terseLabel_en-US" xlink:label="lab_crdf_ServiceReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Receivable</link:label>
    <link:label id="lab_crdf_ServiceReceivableMember_label_en-US" xlink:label="lab_crdf_ServiceReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Receivable [Member]</link:label>
    <link:label id="lab_crdf_ServiceReceivableMember_documentation_en-US" xlink:label="lab_crdf_ServiceReceivableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivableMember" xlink:href="crdf-20200930.xsd#crdf_ServiceReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ServiceReceivableMember" xlink:to="lab_crdf_ServiceReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_91224a27-9065-4e3f-94bd-f7598b6355bc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3d3bd4eb-707f-4f41-af2c-7d79122589e1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_b3a06fd1-146f-4683-a473-3afc803687cd_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_167562c8-c68c-4077-9562-1e0f03fbcfc3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_25876798-1191-4612-9cb3-9e63eccd312f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_5428a80c-8578-4261-ab3e-3e046a3b96bc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_Servicereceivable_c430af1f-bc36-41df-a137-7bf1edffc195_negatedTerseLabel_en-US" xlink:label="lab_crdf_Servicereceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service receivables</link:label>
    <link:label id="lab_crdf_Servicereceivable_977abf40-13a1-4537-942c-0747f169446b_terseLabel_en-US" xlink:label="lab_crdf_Servicereceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service receivable</link:label>
    <link:label id="lab_crdf_Servicereceivable_label_en-US" xlink:label="lab_crdf_Servicereceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service receivable</link:label>
    <link:label id="lab_crdf_Servicereceivable_documentation_en-US" xlink:label="lab_crdf_Servicereceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monetary value of future clinical trial services to be received in connection with issuance of common stock, preferred stock and warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Servicereceivable" xlink:href="crdf-20200930.xsd#crdf_Servicereceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_Servicereceivable" xlink:to="lab_crdf_Servicereceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_dc1cc169-857d-4615-81a5-8f1d69b02bc8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable and unbilled receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_cfc63d25-b81e-432e-97fd-9e72c863d3fa_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c0fc3a59-f84f-4cf9-89bd-f84acc66cd96_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_60ebd3a1-01da-4abc-a153-50e6ac8147e2_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_6d8ba2bd-a157-44f8-af0a-092b2dfefcf6_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance expenses</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_a0168b15-9e03-482d-babf-40c83d7ec007_terseLabel_en-US" xlink:label="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="crdf-20200930.xsd#crdf_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_baede568-f763-42f8-9cbe-11dc7b235cc3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_8f77c6bc-1c1c-44b1-958d-91b0d72e9f3a_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_01cfc696-2ca8-4242-a8c3-9fc78c070710_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_880b775f-e301-49eb-862d-3258c780370a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_38bac268-b9b4-4d8e-8e87-0ea55b259032_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_e9704f01-fbb9-42c8-adcf-864ebd1303e9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_EstimatedFairValueOfWarrant_fb4c6128-32df-4cf9-9490-63273b65eb8a_terseLabel_en-US" xlink:label="lab_crdf_EstimatedFairValueOfWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of Trovagene common stock (in dollars per share)</link:label>
    <link:label id="lab_crdf_EstimatedFairValueOfWarrant_label_en-US" xlink:label="lab_crdf_EstimatedFairValueOfWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value of Warrant</link:label>
    <link:label id="lab_crdf_EstimatedFairValueOfWarrant_documentation_en-US" xlink:label="lab_crdf_EstimatedFairValueOfWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the estimated fair value of warrant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EstimatedFairValueOfWarrant" xlink:href="crdf-20200930.xsd#crdf_EstimatedFairValueOfWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_EstimatedFairValueOfWarrant" xlink:to="lab_crdf_EstimatedFairValueOfWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_d1753693-9cf2-4f9e-b640-f44a3251cec4_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_05f75339-fb08-474c-b1bd-dda8053acd26_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_2f57fe90-6f8c-4312-bb36-876c528451df_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_950914e4-49ae-4889-84c7-5b1e370c5244_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5ead5e21-4e17-4258-8282-ad3b55c468c3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_553ef431-ed6e-43fe-b7bb-c2bc5942b6fa_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_dd05ac12-94fe-4356-bfaf-32fd59e9c050_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected warrant term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_2242b672-f2e9-4dd4-9628-305912b9c490_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d01b026a-af52-408c-9d10-205d019ec53a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2c108e13-3fba-4f18-b008-9ab77000879f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_cd8b967b-6556-4752-98e1-63ca021df1b8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3b1750f4-1cac-4724-9b95-de163f7fd52f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4b65a8c0-62af-467c-97ae-08766004add5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (excluding the nine months ended September 30, 2020)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_4ecc8020-9022-4a89-857a-28b0cd171255_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_9f9d9e37-0fc0-4276-870d-e6fd19615a8e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_3eb36130-f451-4c6a-a4a6-bfcbbc4f7f4e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_e24f189c-2060-40d1-8116-f6899b777f5b_terseLabel_en-US" xlink:label="lab_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance</link:label>
    <link:label id="lab_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_label_en-US" xlink:label="lab_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Conversion Feature For Issuance Of Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_documentation_en-US" xlink:label="lab_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Conversion Feature For Issuance Of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" xlink:href="crdf-20200930.xsd#crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" xlink:to="lab_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_348c81db-b0ed-4f89-ba70-1656100d506f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_75a60e96-b4ac-4def-9350-05ed82926c61_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesCConvertiblePreferredStockMember_0026fabd-4a9e-4e5f-8d20-23bb018bd66f_terseLabel_en-US" xlink:label="lab_crdf_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesCConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesCConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock that may be exchanged into common shares at the owner's option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember" xlink:href="crdf-20200930.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesCConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesCConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_78ab7037-c1b9-42ad-b585-8e9b83f1a613_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ce1b0c15-836a-4676-a177-c2540bd4e91b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b502de44-816d-44ee-851b-7a36b2588652_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_43d1981d-fa69-4c31-be23-6fa83017f477_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1aaea06e-527c-4f85-9e5d-e2ad197e4731_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_ee5760be-9006-4c07-9b2a-8048d7892565_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1eb1079d-9dff-4263-9f89-79e356d033ea_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_97cbfebb-d634-4201-ab52-d55639bb76d5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity instruments other than options, aggregate intrinsic value, vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_487f7dda-d5e1-4fac-8a82-fb5235747d42_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss used for basic and diluted loss per share</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_78a36512-8f3e-48d2-8c53-3fb9153e7a39_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosure of cash flow activity:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d8196853-c974-4d0d-91c8-6310a702013b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_419a102e-d144-49db-9b24-72640e00a535_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_cf8aa1a0-71e3-42c0-b4ef-405c28ec22ba_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_c58fcf23-9ed2-4548-81da-954fecce700e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesBConvertiblePreferredStockMember_d32d9a38-9a58-4ec7-bce9-34d61d3548e7_terseLabel_en-US" xlink:label="lab_crdf_SeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesBConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesBConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesBConvertiblePreferredStockMember" xlink:href="crdf-20200930.xsd#crdf_SeriesBConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesBConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesBConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_82603600-6b63-429f-b9d0-59ad56d24521_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights Exercised</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the weighted average exercise price of each class of warrants or rights exercised during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:to="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_ca226f07-407e-494e-b729-1a9d8a654a52_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases_c07cfe66-821c-4402-a907-7dc4f53d547b_terseLabel_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases_label_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Units Releases</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases_documentation_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Units Releases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases" xlink:href="crdf-20200930.xsd#crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases" xlink:to="lab_crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_b57eba37-39f8-4e0a-845b-ec5aaad59f90_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_caf00e14-71a7-44cf-948a-eecc1209f654_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_f72da70e-98c0-4a57-99d2-122288edca3e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_f94ffb9d-c9ed-45b0-8d86-2ec5c30ae6e8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9ac9ece0-6512-463c-93bc-d645c8443e5c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon conversion of Series D Convertible Preferred Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b85e5cfa-ac6a-4be4-99a5-45101175832b_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less&#8212;accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_9fc6c927-f440-403a-86dd-3e45e9c95277_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesNWarrantMember_b295992d-84b3-401b-bf7e-51bb15f3457c_terseLabel_en-US" xlink:label="lab_crdf_SeriesNWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series N Warrant</link:label>
    <link:label id="lab_crdf_SeriesNWarrantMember_label_en-US" xlink:label="lab_crdf_SeriesNWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series N Warrant [Member]</link:label>
    <link:label id="lab_crdf_SeriesNWarrantMember_documentation_en-US" xlink:label="lab_crdf_SeriesNWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series N Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesNWarrantMember" xlink:href="crdf-20200930.xsd#crdf_SeriesNWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesNWarrantMember" xlink:to="lab_crdf_SeriesNWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4e1ddc59-0357-459c-94f1-076ce9e2baae_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_98ef825a-efe8-4067-8c43-1d16ad648072_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_fcf74689-dc32-4fc7-b0f2-01e3cbca34fe_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c0222327-58db-46ca-9279-a54880c13eaa_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_83d88cff-4e79-48c8-aedb-e372bb014486_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPreferredStock_223d5bdc-8dc6-41b4-aa0f-1878744661f5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend payable on Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStock_label_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStock" xlink:to="lab_us-gaap_DividendsPreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract_4c761112-7349-4f80-a8ae-e3f380673e8c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of assumptions used to determine the fair value of warrants</link:label>
    <link:label id="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:to="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2c3f7bd3-35af-4758-a13b-24ff70f9ea1e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6c41f85d-fb06-4009-95cb-c0d878c4cddc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_749d8b29-be23-4447-9d31-bcf6742d9c5a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesAConvertiblePreferredStockMember_863d9719-fa6b-4e7d-ab41-8a2a742dafc0_terseLabel_en-US" xlink:label="lab_crdf_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesAConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesAConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesAConvertiblePreferredStockMember" xlink:href="crdf-20200930.xsd#crdf_SeriesAConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesAConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesAConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_53a01529-4d93-4b10-878d-9e9af3790f89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled / Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_ef9c06c2-8468-4fa8-a1ec-4742f578fe0d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_08c7388a-d8d7-4b11-833a-c0ce34ef0eb3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares called by each warrant</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_bded2321-7727-4e3d-874f-6010499d39c5_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_b163287f-45c9-44aa-afec-45e93c19e4f8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_73d0aa5b-2474-4275-b489-b0e52c63650f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAffiliatesMember_3c14d1be-e648-402d-9401-2af195c1b9d1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAffiliatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_us-gaap_OtherAffiliatesMember_label_en-US" xlink:label="lab_us-gaap_OtherAffiliatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Affiliates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAffiliatesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAffiliatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAffiliatesMember" xlink:to="lab_us-gaap_OtherAffiliatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_7d4e0184-eb65-4694-8c0c-b8c28e754571_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_2ff983df-0216-4b74-b6f8-db865afff622_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_044afb67-5acf-4970-b47e-ae2f77849530_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_02609a52-6f80-4ce9-8b76-f425e7ac4841_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents&#8212;Beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee68bd7a-a385-4076-a6d7-7e54fd9c3cc7_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents&#8212;End of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_PreFundedWarrantsMember_0e847ce1-b7ee-403b-a710-b84cf90bafb0_terseLabel_en-US" xlink:label="lab_crdf_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:label id="lab_crdf_PreFundedWarrantsMember_label_en-US" xlink:label="lab_crdf_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_crdf_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_crdf_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreFundedWarrantsMember" xlink:href="crdf-20200930.xsd#crdf_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_PreFundedWarrantsMember" xlink:to="lab_crdf_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_d60e3240-977f-4a61-8ecf-1e52f0fa3880_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c68f2d4a-7b8e-47a2-ac2c-72d0902d0db4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7b1566ab-2294-40b7-85e8-b4a598ffd032_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_5d163c8e-cfd4-49fe-be3e-3525c6a3ba99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_56335eae-eb09-4626-978c-f4ba8f296b74_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_113a952e-0714-41c9-b7ab-bca29c71fe1f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_9dbf0f3d-9477-4206-9e7d-05d3fffb2c59_terseLabel_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_label_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_BlackScholesOptionPricingMethodMember_0717053d-fa1d-4958-aeee-4cae8f367845_terseLabel_en-US" xlink:label="lab_crdf_BlackScholesOptionPricingMethodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black Scholes Option Pricing Method</link:label>
    <link:label id="lab_crdf_BlackScholesOptionPricingMethodMember_label_en-US" xlink:label="lab_crdf_BlackScholesOptionPricingMethodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black Scholes Option Pricing Method [Member]</link:label>
    <link:label id="lab_crdf_BlackScholesOptionPricingMethodMember_documentation_en-US" xlink:label="lab_crdf_BlackScholesOptionPricingMethodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the Black-Scholes option pricing method which is used for valuation of derivative instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BlackScholesOptionPricingMethodMember" xlink:href="crdf-20200930.xsd#crdf_BlackScholesOptionPricingMethodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_BlackScholesOptionPricingMethodMember" xlink:to="lab_crdf_BlackScholesOptionPricingMethodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_AmountFinancedUnderAgreement_988559ee-429e-451d-8778-79adaeb333af_verboseLabel_en-US" xlink:label="lab_crdf_AmountFinancedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount financed under agreement</link:label>
    <link:label id="lab_crdf_AmountFinancedUnderAgreement_label_en-US" xlink:label="lab_crdf_AmountFinancedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Financed Under Agreement</link:label>
    <link:label id="lab_crdf_AmountFinancedUnderAgreement_documentation_en-US" xlink:label="lab_crdf_AmountFinancedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Financed Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AmountFinancedUnderAgreement" xlink:href="crdf-20200930.xsd#crdf_AmountFinancedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_AmountFinancedUnderAgreement" xlink:to="lab_crdf_AmountFinancedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4fab509d-1652-4d7d-8bdf-54bdad0e3540_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_268b5b44-98ab-417f-abc7-da24871e81ed_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesDConvertiblePreferredStockMember_67b38d43-476a-4391-aa87-086d272dc282_terseLabel_en-US" xlink:label="lab_crdf_SeriesDConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesDConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesDConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesDConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesDConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember" xlink:href="crdf-20200930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesDConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesDConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemTable_1e386959-4ae3-4baa-a490-6c5f1467b33c_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Table]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemTable_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable" xlink:to="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_cc2da0ec-8d8a-4740-9c82-a491c6f5bd7b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3f61a189-571d-4fa0-92eb-1b38b47d7f92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value Per&#160;Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesEConvertiblePreferredStockMember_ea3ec6f2-e4a2-4ffa-ae27-ce3feae205f9_terseLabel_en-US" xlink:label="lab_crdf_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series&#160;E Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesEConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesEConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember" xlink:href="crdf-20200930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesEConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesEConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_104d24b8-395c-49d3-9d1d-b6383a552753_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity instruments other than options, vested in period, fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_32202732-4af2-48a1-a043-93fc4e1b7dee_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_e0423f75-dec2-4284-8363-dc8e6bf8320c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_55b07816-9c45-42a5-ac79-6bfdf9b787dd_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares designated (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_9a2e7062-f558-41f0-89c3-c1b894df8c31_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity instruments other than options, aggregate intrinsic value, nonvested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_95ecc319-96e6-4cee-bd8c-b65220d2e512_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Items, or Both, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:to="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_50ffaf0c-414b-4b1a-b260-93da45b78f42_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_6f54b0c9-50ee-4f2f-9791-78772d8f8bec_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_69f3403d-01d5-47ee-9d15-67df802ff36c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_054b86c5-ea4d-4242-a480-7d316c7bbe8d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4af85f2-601c-4161-9870-0a44e582c9c0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_116590ac-f252-413a-964a-38a81fcc084f_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a172ec7d-cd3b-469b-9d71-e54a79434295_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1a4f6128-788c-400f-854c-df09a7477f21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec3ce189-f182-4cdc-97dc-ae68529be55f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5ea9c3d0-f4be-4956-8482-1e95ce7ddca7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, weighted average contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_76df6b0b-a79f-4efa-bc42-e8a7b45c5951_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23a7a104-850e-4eb6-91c0-9acf90ad5709_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c6bd3658-49c3-4a53-b22b-f68683f614b3_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e324c190-9d2a-4328-a060-eee3f51cb75a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_b6eb5766-8aa3-4e59-b0c1-5d9497333a6e_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_be1a5b61-8f72-41d7-9b1a-4130c484f8ae_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_d1babd80-fa68-45dc-a8cd-0751374ea055_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_NorvianoMember_c75bc1c8-cf0b-4d5d-b6bd-43eae4ffd3a4_terseLabel_en-US" xlink:label="lab_crdf_NorvianoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nerviano</link:label>
    <link:label id="lab_crdf_NorvianoMember_label_en-US" xlink:label="lab_crdf_NorvianoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norviano [Member]</link:label>
    <link:label id="lab_crdf_NorvianoMember_documentation_en-US" xlink:label="lab_crdf_NorvianoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nerviano [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_NorvianoMember" xlink:href="crdf-20200930.xsd#crdf_NorvianoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_NorvianoMember" xlink:to="lab_crdf_NorvianoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cc5f3ea6-4061-4013-a957-5ffbe36a7cf5_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_d7bf4ff4-f527-4531-a978-c70207b0ae36_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_87a4c181-49a2-4bc4-8f08-667c7b48cb9f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b95dc224-fff1-46ff-8e7d-a848f912ad8f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_7b184e30-6793-48c1-a9eb-65f5228ff3ee_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_e6390c76-ef30-4177-9098-66fcf7965605_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_e93e8a9b-d253-411a-ab91-ebee4f3288d6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_44d058ed-aed2-4e98-b073-49230a5346e4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncement</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_cbb5c2dd-07b4-4cda-b042-b11a555a7253_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>crdf-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:899aa37a-8922-454a-a94d-f1f600203a5a,g:092e8a26-8aea-4f93-acda-3be57db43dca-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CoverPage" xlink:type="simple" xlink:href="crdf-20200930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_cfa634f1-edf8-41ae-aacc-6a9169d9cb78" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_DocumentType_cfa634f1-edf8-41ae-aacc-6a9169d9cb78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_402187cf-2b86-4e78-b27f-e44c0c4d41eb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_DocumentQuarterlyReport_402187cf-2b86-4e78-b27f-e44c0c4d41eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b5ee7a60-729d-4bfb-a56a-062dfcc38111" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_DocumentTransitionReport_b5ee7a60-729d-4bfb-a56a-062dfcc38111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_fc425f87-58f3-43b4-9d08-0c1005899e28" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_DocumentPeriodEndDate_fc425f87-58f3-43b4-9d08-0c1005899e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b22690de-d199-4e58-96c4-61711cf7dd2a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_EntityFileNumber_b22690de-d199-4e58-96c4-61711cf7dd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_df888d01-d868-4086-bb1f-f7fa918356fb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_EntityRegistrantName_df888d01-d868-4086-bb1f-f7fa918356fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_49379e81-fe50-4db3-af20-663fde3065ca" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_49379e81-fe50-4db3-af20-663fde3065ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3d19144b-328a-4ecd-a728-54c098879b76" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_EntityTaxIdentificationNumber_3d19144b-328a-4ecd-a728-54c098879b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_345a37d0-44ab-4d36-b885-ace0d0339df8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_EntityAddressAddressLine1_345a37d0-44ab-4d36-b885-ace0d0339df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_bc3bb642-1b0c-4eda-a292-45fce650e0ba" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_EntityAddressCityOrTown_bc3bb642-1b0c-4eda-a292-45fce650e0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_534f54e6-dead-44d5-992d-d19dbe4fde0d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_EntityAddressStateOrProvince_534f54e6-dead-44d5-992d-d19dbe4fde0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d2b6df40-a4da-48eb-82ba-2cbc1f321aa6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_EntityAddressPostalZipCode_d2b6df40-a4da-48eb-82ba-2cbc1f321aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_05078a49-227e-45b8-852e-7c9ed70ac81a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_CityAreaCode_05078a49-227e-45b8-852e-7c9ed70ac81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_379d2b39-d79e-4c63-90fd-b4356453e3a6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_LocalPhoneNumber_379d2b39-d79e-4c63-90fd-b4356453e3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5dd17ab6-a346-435a-a818-3997535918e3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_Security12bTitle_5dd17ab6-a346-435a-a818-3997535918e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_323e0776-6de1-4b47-b19c-b4d977985db2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_TradingSymbol_323e0776-6de1-4b47-b19c-b4d977985db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ff487958-94cf-4657-ac91-f14f11eb0849" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_EntityCurrentReportingStatus_ff487958-94cf-4657-ac91-f14f11eb0849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_093b6b12-79f0-4f46-8ea4-de762d8760e2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_EntityInteractiveDataCurrent_093b6b12-79f0-4f46-8ea4-de762d8760e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e59439da-6bf2-4a12-a05c-0165cdcec279" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_EntityFilerCategory_e59439da-6bf2-4a12-a05c-0165cdcec279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_5fe87373-6aea-47c7-8eca-666a2e551579" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_EntitySmallBusiness_5fe87373-6aea-47c7-8eca-666a2e551579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b60b7df8-ab18-46fd-9693-5aaca4a9139e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_EntityEmergingGrowthCompany_b60b7df8-ab18-46fd-9693-5aaca4a9139e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5ccce0b3-bae1-4544-ab78-199150fdf7b7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_EntityShellCompany_5ccce0b3-bae1-4544-ab78-199150fdf7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ae3688db-53f8-457d-9c48-2b4e559eaf20" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ae3688db-53f8-457d-9c48-2b4e559eaf20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3257eede-b942-44ef-8ede-b50786c636a1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_EntityCentralIndexKey_3257eede-b942-44ef-8ede-b50786c636a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_01211c66-fe6c-408d-9cc0-dcc3328c1250" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_AmendmentFlag_01211c66-fe6c-408d-9cc0-dcc3328c1250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5f3ca234-6a79-42ab-8767-a403dddab1f5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_CurrentFiscalYearEndDate_5f3ca234-6a79-42ab-8767-a403dddab1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ddfa3a16-f730-4ce8-ae95-b5698609b0eb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_DocumentFiscalYearFocus_ddfa3a16-f730-4ce8-ae95-b5698609b0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1416dc10-f72f-4a37-9a12-390fdc508c43" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8037833f-a511-42d1-91f9-dc53cc100cd2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1416dc10-f72f-4a37-9a12-390fdc508c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2c3866c7-3ad6-4a62-bf46-5fa319e7573e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0403058b-e842-4779-a2b5-8f31699f190a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2c3866c7-3ad6-4a62-bf46-5fa319e7573e" xlink:to="loc_us-gaap_AssetsAbstract_0403058b-e842-4779-a2b5-8f31699f190a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6be37da5-fda0-4912-a592-cbf84aff5644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0403058b-e842-4779-a2b5-8f31699f190a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6be37da5-fda0-4912-a592-cbf84aff5644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5a9d3bef-8b70-45e8-896e-9df1be427dd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6be37da5-fda0-4912-a592-cbf84aff5644" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5a9d3bef-8b70-45e8-896e-9df1be427dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_053e15f0-7563-49da-8bf2-8f521507586f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6be37da5-fda0-4912-a592-cbf84aff5644" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_053e15f0-7563-49da-8bf2-8f521507586f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_886134b4-14d3-4d00-967c-6bba9a33185e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6be37da5-fda0-4912-a592-cbf84aff5644" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_886134b4-14d3-4d00-967c-6bba9a33185e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5abcee37-2c0e-4ffe-8d30-db36d310932b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6be37da5-fda0-4912-a592-cbf84aff5644" xlink:to="loc_us-gaap_AssetsCurrent_5abcee37-2c0e-4ffe-8d30-db36d310932b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2ecd34d5-833f-4c4a-b639-4f1d07214681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0403058b-e842-4779-a2b5-8f31699f190a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2ecd34d5-833f-4c4a-b639-4f1d07214681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_76ca21b6-c8a0-4465-b868-f05c12b1d30c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0403058b-e842-4779-a2b5-8f31699f190a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_76ca21b6-c8a0-4465-b868-f05c12b1d30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8a2fa73f-e38e-4534-bda4-de2cf3c93494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0403058b-e842-4779-a2b5-8f31699f190a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8a2fa73f-e38e-4534-bda4-de2cf3c93494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7dfcde75-7a91-4365-a722-5c7f97604b19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0403058b-e842-4779-a2b5-8f31699f190a" xlink:to="loc_us-gaap_Assets_7dfcde75-7a91-4365-a722-5c7f97604b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_66cf9ff7-4e0a-42fe-8881-c4db516a4971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2c3866c7-3ad6-4a62-bf46-5fa319e7573e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_66cf9ff7-4e0a-42fe-8881-c4db516a4971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_45c06c0a-7077-453a-8a65-4ddca59a7fa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_66cf9ff7-4e0a-42fe-8881-c4db516a4971" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_45c06c0a-7077-453a-8a65-4ddca59a7fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_03e2b085-6772-4311-9968-2ad34ccaef6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45c06c0a-7077-453a-8a65-4ddca59a7fa7" xlink:to="loc_us-gaap_AccountsPayableCurrent_03e2b085-6772-4311-9968-2ad34ccaef6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_80d43362-cfa4-4e49-b9d8-889b59d24849" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45c06c0a-7077-453a-8a65-4ddca59a7fa7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_80d43362-cfa4-4e49-b9d8-889b59d24849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_8926c01a-5944-4cce-847f-1d165084b5af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45c06c0a-7077-453a-8a65-4ddca59a7fa7" xlink:to="loc_us-gaap_NotesPayableCurrent_8926c01a-5944-4cce-847f-1d165084b5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bb207a0a-e12a-4946-b5c5-37c8b2f092e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45c06c0a-7077-453a-8a65-4ddca59a7fa7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bb207a0a-e12a-4946-b5c5-37c8b2f092e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5095b9c1-6827-44e2-85ce-5f980d306fcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45c06c0a-7077-453a-8a65-4ddca59a7fa7" xlink:to="loc_us-gaap_LiabilitiesCurrent_5095b9c1-6827-44e2-85ce-5f980d306fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_a143761e-562a-4f42-938d-71173c1e8882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_66cf9ff7-4e0a-42fe-8881-c4db516a4971" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_a143761e-562a-4f42-938d-71173c1e8882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c626e9d8-31be-4d8e-9351-6dadd2ed7ede" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_66cf9ff7-4e0a-42fe-8881-c4db516a4971" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c626e9d8-31be-4d8e-9351-6dadd2ed7ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_aa21200b-f477-45bc-9ab2-c2d96e9e5e1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_66cf9ff7-4e0a-42fe-8881-c4db516a4971" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_aa21200b-f477-45bc-9ab2-c2d96e9e5e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_56998f12-c801-4653-9482-638da4ec263a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_66cf9ff7-4e0a-42fe-8881-c4db516a4971" xlink:to="loc_us-gaap_Liabilities_56998f12-c801-4653-9482-638da4ec263a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5986a0df-fd11-46b4-866d-cb41c07bf71d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_66cf9ff7-4e0a-42fe-8881-c4db516a4971" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5986a0df-fd11-46b4-866d-cb41c07bf71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_9e5437d6-79be-4245-af9a-8470bf942912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_66cf9ff7-4e0a-42fe-8881-c4db516a4971" xlink:to="loc_us-gaap_StockholdersEquityAbstract_9e5437d6-79be-4245-af9a-8470bf942912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f6e8e112-9114-4f68-adde-30790ece59a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9e5437d6-79be-4245-af9a-8470bf942912" xlink:to="loc_us-gaap_PreferredStockValue_f6e8e112-9114-4f68-adde-30790ece59a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_150f82dd-f390-4988-81d4-398e55d473cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9e5437d6-79be-4245-af9a-8470bf942912" xlink:to="loc_us-gaap_CommonStockValue_150f82dd-f390-4988-81d4-398e55d473cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c848d414-5b23-4aa7-b2b0-5c88f91c5fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9e5437d6-79be-4245-af9a-8470bf942912" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c848d414-5b23-4aa7-b2b0-5c88f91c5fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Servicereceivable_6b2c95e5-d6b9-456d-b93f-d8e041b4c933" xlink:href="crdf-20200930.xsd#crdf_Servicereceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9e5437d6-79be-4245-af9a-8470bf942912" xlink:to="loc_crdf_Servicereceivable_6b2c95e5-d6b9-456d-b93f-d8e041b4c933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d930bfb6-35fc-473c-bc30-662a23b05ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9e5437d6-79be-4245-af9a-8470bf942912" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d930bfb6-35fc-473c-bc30-662a23b05ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0c377cf4-4cf9-424d-99fa-0431e36c2aeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9e5437d6-79be-4245-af9a-8470bf942912" xlink:to="loc_us-gaap_StockholdersEquity_0c377cf4-4cf9-424d-99fa-0431e36c2aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_698d60bf-c184-433d-a3db-008965fcf5f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_66cf9ff7-4e0a-42fe-8881-c4db516a4971" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_698d60bf-c184-433d-a3db-008965fcf5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7eac9dd2-9007-4f24-91d7-0c3495956bfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b29544c6-03fb-4c91-8f6d-933c96901644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7eac9dd2-9007-4f24-91d7-0c3495956bfe" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b29544c6-03fb-4c91-8f6d-933c96901644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0fc3e5d7-7e0e-403e-b39f-ec40aa78d3e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7eac9dd2-9007-4f24-91d7-0c3495956bfe" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0fc3e5d7-7e0e-403e-b39f-ec40aa78d3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_dc26328e-0be4-47ae-8568-b808cb4c103c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7eac9dd2-9007-4f24-91d7-0c3495956bfe" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_dc26328e-0be4-47ae-8568-b808cb4c103c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d0f5ec1d-20ff-4e7c-a711-fc17cce83699" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7eac9dd2-9007-4f24-91d7-0c3495956bfe" xlink:to="loc_us-gaap_CommonStockSharesIssued_d0f5ec1d-20ff-4e7c-a711-fc17cce83699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ae09bf51-6edc-4f56-926d-a8bfe13c6f72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7eac9dd2-9007-4f24-91d7-0c3495956bfe" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ae09bf51-6edc-4f56-926d-a8bfe13c6f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_d4579958-cde5-4542-9c6f-6b19cc97eada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5bcf293f-549b-4413-bd1a-3192ae1e1171" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d4579958-cde5-4542-9c6f-6b19cc97eada" xlink:to="loc_us-gaap_StatementTable_5bcf293f-549b-4413-bd1a-3192ae1e1171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_88086a12-1e43-4ba3-a231-a29cb2d44ade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5bcf293f-549b-4413-bd1a-3192ae1e1171" xlink:to="loc_us-gaap_StatementClassOfStockAxis_88086a12-1e43-4ba3-a231-a29cb2d44ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_164e3e98-97dd-42b4-9b23-dfe21c7416f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_88086a12-1e43-4ba3-a231-a29cb2d44ade" xlink:to="loc_us-gaap_ClassOfStockDomain_164e3e98-97dd-42b4-9b23-dfe21c7416f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_5632bbf3-957c-4426-82d3-15cfaec53b07" xlink:href="crdf-20200930.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_164e3e98-97dd-42b4-9b23-dfe21c7416f1" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_5632bbf3-957c-4426-82d3-15cfaec53b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_ddff7d3b-b9c5-4179-96ad-bfba10fe14bb" xlink:href="crdf-20200930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_164e3e98-97dd-42b4-9b23-dfe21c7416f1" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_ddff7d3b-b9c5-4179-96ad-bfba10fe14bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_98cf9022-c349-49bd-a011-0fb4c2e4eb1c" xlink:href="crdf-20200930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_164e3e98-97dd-42b4-9b23-dfe21c7416f1" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_98cf9022-c349-49bd-a011-0fb4c2e4eb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5bcf293f-549b-4413-bd1a-3192ae1e1171" xlink:to="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1acee142-2cea-4099-9a73-691a72c1d8db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_RevenuesAbstract_1acee142-2cea-4099-9a73-691a72c1d8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_27a4c8b6-49b7-4d54-b705-4f79ed933c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1acee142-2cea-4099-9a73-691a72c1d8db" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_27a4c8b6-49b7-4d54-b705-4f79ed933c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_644e9396-5082-4ca2-80d6-f03e81b0b190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1acee142-2cea-4099-9a73-691a72c1d8db" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_644e9396-5082-4ca2-80d6-f03e81b0b190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b1b08b67-abc7-47e1-89e5-c875ff91581a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1acee142-2cea-4099-9a73-691a72c1d8db" xlink:to="loc_us-gaap_Revenues_b1b08b67-abc7-47e1-89e5-c875ff91581a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6a8fb4bf-baab-4a4a-ae5c-7d6880edad74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6a8fb4bf-baab-4a4a-ae5c-7d6880edad74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ac96ccba-36ee-4b8d-919c-5e6fc6d8ec55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6a8fb4bf-baab-4a4a-ae5c-7d6880edad74" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ac96ccba-36ee-4b8d-919c-5e6fc6d8ec55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_14897bd1-75de-41cb-94f4-c999f24657ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6a8fb4bf-baab-4a4a-ae5c-7d6880edad74" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_14897bd1-75de-41cb-94f4-c999f24657ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_50c33d10-3eed-407e-be7f-6a82390e3b8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6a8fb4bf-baab-4a4a-ae5c-7d6880edad74" xlink:to="loc_us-gaap_OperatingExpenses_50c33d10-3eed-407e-be7f-6a82390e3b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0ea6b3d5-5131-4a33-a408-90b4fe48e97b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_OperatingIncomeLoss_0ea6b3d5-5131-4a33-a408-90b4fe48e97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_036ed423-59fe-471a-b517-a47ac1c8f7a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_InterestIncomeOperating_036ed423-59fe-471a-b517-a47ac1c8f7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_3fa4c28c-ae93-492c-90db-aeb41f62981e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_3fa4c28c-ae93-492c-90db-aeb41f62981e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_eee84673-1fcd-4535-ba99-bff7258d389e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_eee84673-1fcd-4535-ba99-bff7258d389e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6444aeb1-f644-46bb-8e1a-d5d3883310ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_NetIncomeLoss_6444aeb1-f644-46bb-8e1a-d5d3883310ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_94d87724-878d-4d94-b681-144ac5017a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_94d87724-878d-4d94-b681-144ac5017a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_c378bf9b-0022-44b5-9f26-242e8ffa64ae" xlink:href="crdf-20200930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_c378bf9b-0022-44b5-9f26-242e8ffa64ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5d0d481d-ea72-4573-af5b-ce6d713a8b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5d0d481d-ea72-4573-af5b-ce6d713a8b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_5f7b9a2f-c1e3-4339-a269-1bd48f9719a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_5f7b9a2f-c1e3-4339-a269-1bd48f9719a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_edd584f5-618a-4586-82d5-2bec36af6a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1fc7df34-3ab6-4541-8554-b58f208e202c" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_edd584f5-618a-4586-82d5-2bec36af6a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_09de4609-2d80-4e50-8877-9245bd4b9870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d3071484-af33-4d74-8e58-a0590df02ca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_09de4609-2d80-4e50-8877-9245bd4b9870" xlink:to="loc_us-gaap_StatementTable_d3071484-af33-4d74-8e58-a0590df02ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2823bd7c-9b38-4836-b595-16ee1c52278a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d3071484-af33-4d74-8e58-a0590df02ca2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2823bd7c-9b38-4836-b595-16ee1c52278a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d7778e4d-371c-4730-b7b5-696d95e5dd41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2823bd7c-9b38-4836-b595-16ee1c52278a" xlink:to="loc_us-gaap_EquityComponentDomain_d7778e4d-371c-4730-b7b5-696d95e5dd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_c4473f38-55ae-4bc0-9831-838d484cc1d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d7778e4d-371c-4730-b7b5-696d95e5dd41" xlink:to="loc_us-gaap_PreferredStockMember_c4473f38-55ae-4bc0-9831-838d484cc1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b4e656e9-252d-4997-8adc-d1526cabfa2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d7778e4d-371c-4730-b7b5-696d95e5dd41" xlink:to="loc_us-gaap_CommonStockMember_b4e656e9-252d-4997-8adc-d1526cabfa2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1125cd69-1cf0-43df-9076-01b8fe954f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d7778e4d-371c-4730-b7b5-696d95e5dd41" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1125cd69-1cf0-43df-9076-01b8fe954f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivableMember_a1f5ff86-394d-4e28-bd05-d9e815af40f3" xlink:href="crdf-20200930.xsd#crdf_ServiceReceivableMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d7778e4d-371c-4730-b7b5-696d95e5dd41" xlink:to="loc_crdf_ServiceReceivableMember_a1f5ff86-394d-4e28-bd05-d9e815af40f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_fcb6b65e-a412-492e-9344-4c44a43c136a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d7778e4d-371c-4730-b7b5-696d95e5dd41" xlink:to="loc_us-gaap_RetainedEarningsMember_fcb6b65e-a412-492e-9344-4c44a43c136a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f0cda30f-e75c-4e4c-b878-025439e206d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d3071484-af33-4d74-8e58-a0590df02ca2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f0cda30f-e75c-4e4c-b878-025439e206d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f0671912-fd6a-498d-a318-e48d5b699874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f0cda30f-e75c-4e4c-b878-025439e206d8" xlink:to="loc_us-gaap_ClassOfStockDomain_f0671912-fd6a-498d-a318-e48d5b699874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_9f38dc83-3f6f-4a4b-85fa-e098da16f127" xlink:href="crdf-20200930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f0671912-fd6a-498d-a318-e48d5b699874" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_9f38dc83-3f6f-4a4b-85fa-e098da16f127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_48bc956f-71c5-4e74-b261-adfa30f014de" xlink:href="crdf-20200930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f0671912-fd6a-498d-a318-e48d5b699874" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_48bc956f-71c5-4e74-b261-adfa30f014de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_c2bfb423-5999-4d45-b95e-231e71a99b9f" xlink:href="crdf-20200930.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f0671912-fd6a-498d-a318-e48d5b699874" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_c2bfb423-5999-4d45-b95e-231e71a99b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_828d1362-8168-41ce-83dd-4f1cf3298fd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d3071484-af33-4d74-8e58-a0590df02ca2" xlink:to="loc_us-gaap_StatementLineItems_828d1362-8168-41ce-83dd-4f1cf3298fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_828d1362-8168-41ce-83dd-4f1cf3298fd3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_52c2fab1-984b-4bf0-8dab-f89aff9a140b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_SharesIssued_52c2fab1-984b-4bf0-8dab-f89aff9a140b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_27f63b76-846f-4123-bfd1-4faf4b92cb57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_StockholdersEquity_27f63b76-846f-4123-bfd1-4faf4b92cb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e8d082d2-e2bc-4636-b603-9aee4cbf381f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e8d082d2-e2bc-4636-b603-9aee4cbf381f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SaleOfStockCommonAndWarrantsNetShares_0fd3c552-7af4-40ba-9e51-34c4d92c7914" xlink:href="crdf-20200930.xsd#crdf_SaleOfStockCommonAndWarrantsNetShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_crdf_SaleOfStockCommonAndWarrantsNetShares_0fd3c552-7af4-40ba-9e51-34c4d92c7914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SaleOfStockValueCommonAndWarrantsNet_d5fd8cb1-e05e-4bf1-a9b4-d18ac2461de7" xlink:href="crdf-20200930.xsd#crdf_SaleOfStockValueCommonAndWarrantsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_crdf_SaleOfStockValueCommonAndWarrantsNet_d5fd8cb1-e05e-4bf1-a9b4-d18ac2461de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_86b8362c-45d3-4407-bc42-85b3243c9873" xlink:href="crdf-20200930.xsd#crdf_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_86b8362c-45d3-4407-bc42-85b3243c9873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised_7879479e-e5b9-4989-8aca-7e1b808eb820" xlink:href="crdf-20200930.xsd#crdf_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised_7879479e-e5b9-4989-8aca-7e1b808eb820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased_dc1499a2-77e5-49d6-877b-6b7d13d64e5e" xlink:href="crdf-20200930.xsd#crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased_dc1499a2-77e5-49d6-877b-6b7d13d64e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases_d7dcef22-58cd-4a1b-a30f-495ab7f3dbd7" xlink:href="crdf-20200930.xsd#crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases_d7dcef22-58cd-4a1b-a30f-495ab7f3dbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_9d5a9661-1d8e-4399-b9e9-4b7f86347df9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_DividendsPreferredStock_9d5a9661-1d8e-4399-b9e9-4b7f86347df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitment_c6cc1c7a-ac7e-49e9-af17-653a6d322b6d" xlink:href="crdf-20200930.xsd#crdf_ReleaseOfClinicalTrialFundingCommitment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_crdf_ReleaseOfClinicalTrialFundingCommitment_c6cc1c7a-ac7e-49e9-af17-653a6d322b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4757a2f5-737a-45c8-9137-c1e118a0fff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_NetIncomeLoss_4757a2f5-737a-45c8-9137-c1e118a0fff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_b0f66044-3130-4348-8d8a-bc8e72251855" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_b0f66044-3130-4348-8d8a-bc8e72251855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_530ec235-b85c-4f09-b0d0-ef9e393ddc65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_530ec235-b85c-4f09-b0d0-ef9e393ddc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_985fac38-ae8e-4d09-9ffd-20e2cf6df8a0" xlink:href="crdf-20200930.xsd#crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_985fac38-ae8e-4d09-9ffd-20e2cf6df8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7ec3182a-b714-4dd5-85c1-481452627980" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7ec3182a-b714-4dd5-85c1-481452627980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c51a9d05-d8f8-47fc-b4eb-e02a0f6a206c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c51a9d05-d8f8-47fc-b4eb-e02a0f6a206c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_733f77ec-dcb9-4e62-98e1-bf5abd9ed014" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_733f77ec-dcb9-4e62-98e1-bf5abd9ed014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_4e680ee0-09e0-43a3-992e-a9cf9510313d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_4e680ee0-09e0-43a3-992e-a9cf9510313d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_23401bc2-8685-4e8f-8660-4ad80ad16d37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_23401bc2-8685-4e8f-8660-4ad80ad16d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ed785297-3d61-494a-93cb-d726f07071d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ed785297-3d61-494a-93cb-d726f07071d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_e7d5de11-7295-4348-a545-639dd8c6a5f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_e7d5de11-7295-4348-a545-639dd8c6a5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_520ca675-e64a-43d3-bd37-fe55623e0937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_SharesIssued_520ca675-e64a-43d3-bd37-fe55623e0937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_af4842ae-2810-45e6-ba8b-5fe3d24b7a8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27bd102a-caf9-464e-96e8-ee6e11a86cf4" xlink:to="loc_us-gaap_StockholdersEquity_af4842ae-2810-45e6-ba8b-5fe3d24b7a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_23ead29f-ca98-45b0-80fd-f57beaf385f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_962ee16d-7265-493b-864c-6c6565e370a4" xlink:href="crdf-20200930.xsd#crdf_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_23ead29f-ca98-45b0-80fd-f57beaf385f6" xlink:to="loc_crdf_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_962ee16d-7265-493b-864c-6c6565e370a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_WarrantsFairValue_f51e9c45-538b-4ac2-8d66-5d364ca0b6a0" xlink:href="crdf-20200930.xsd#crdf_WarrantsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_23ead29f-ca98-45b0-80fd-f57beaf385f6" xlink:to="loc_crdf_WarrantsFairValue_f51e9c45-538b-4ac2-8d66-5d364ca0b6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_e642ae9a-252d-4be4-90fc-6dcfbccacc2c" xlink:href="crdf-20200930.xsd#crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_23ead29f-ca98-45b0-80fd-f57beaf385f6" xlink:to="loc_crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_e642ae9a-252d-4be4-90fc-6dcfbccacc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_299b7107-7707-416a-90e4-a2c72b2abc32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_37aba0f8-d1d6-465b-a88a-f51241d17c87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_299b7107-7707-416a-90e4-a2c72b2abc32" xlink:to="loc_us-gaap_StatementTable_37aba0f8-d1d6-465b-a88a-f51241d17c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_21433e89-3afb-4035-8efd-1a8d4af4e154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_37aba0f8-d1d6-465b-a88a-f51241d17c87" xlink:to="loc_us-gaap_StatementClassOfStockAxis_21433e89-3afb-4035-8efd-1a8d4af4e154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b12d24c2-134c-4adf-b479-9d1d39e91baa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_21433e89-3afb-4035-8efd-1a8d4af4e154" xlink:to="loc_us-gaap_ClassOfStockDomain_b12d24c2-134c-4adf-b479-9d1d39e91baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_2853bfb1-7416-4889-b47a-b8c6beb9956a" xlink:href="crdf-20200930.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b12d24c2-134c-4adf-b479-9d1d39e91baa" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_2853bfb1-7416-4889-b47a-b8c6beb9956a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_ddcd9505-905f-4286-ae50-ffb70bb63250" xlink:href="crdf-20200930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b12d24c2-134c-4adf-b479-9d1d39e91baa" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_ddcd9505-905f-4286-ae50-ffb70bb63250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_c08e042c-4476-4d3d-b9d6-98d1603d456e" xlink:href="crdf-20200930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b12d24c2-134c-4adf-b479-9d1d39e91baa" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_c08e042c-4476-4d3d-b9d6-98d1603d456e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6a083088-35d5-4dfa-8790-65bdccf9f886" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_37aba0f8-d1d6-465b-a88a-f51241d17c87" xlink:to="loc_us-gaap_StatementLineItems_6a083088-35d5-4dfa-8790-65bdccf9f886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_91d45d40-e9d6-4bd5-84f8-01b64d88a7e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a083088-35d5-4dfa-8790-65bdccf9f886" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_91d45d40-e9d6-4bd5-84f8-01b64d88a7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ff6474af-8bac-4e90-b9b0-2a3adfb45109" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_91d45d40-e9d6-4bd5-84f8-01b64d88a7e9" xlink:to="loc_us-gaap_NetIncomeLoss_ff6474af-8bac-4e90-b9b0-2a3adfb45109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c02cf9a-7336-4931-9cc9-633a1507f816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_91d45d40-e9d6-4bd5-84f8-01b64d88a7e9" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c02cf9a-7336-4931-9cc9-633a1507f816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_567107b0-175c-4bb4-8ebc-fee66f7a8140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c02cf9a-7336-4931-9cc9-633a1507f816" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_567107b0-175c-4bb4-8ebc-fee66f7a8140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_85ec136f-3e90-465e-bc53-935f15ca1f00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c02cf9a-7336-4931-9cc9-633a1507f816" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_85ec136f-3e90-465e-bc53-935f15ca1f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_04732b6f-1a5e-438e-892f-96e2fbf80bd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c02cf9a-7336-4931-9cc9-633a1507f816" xlink:to="loc_us-gaap_ShareBasedCompensation_04732b6f-1a5e-438e-892f-96e2fbf80bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_b505950d-8ec1-491f-b0a2-476918284510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c02cf9a-7336-4931-9cc9-633a1507f816" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_b505950d-8ec1-491f-b0a2-476918284510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived_5c2ed2e5-86f8-4927-aa95-b6599f0ef4f5" xlink:href="crdf-20200930.xsd#crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c02cf9a-7336-4931-9cc9-633a1507f816" xlink:to="loc_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived_5c2ed2e5-86f8-4927-aa95-b6599f0ef4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c28ad4e0-2ba9-4d1f-a1d4-cd983035a509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c02cf9a-7336-4931-9cc9-633a1507f816" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c28ad4e0-2ba9-4d1f-a1d4-cd983035a509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_32d00772-bf47-4ec8-b449-27c94f9cf51d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c28ad4e0-2ba9-4d1f-a1d4-cd983035a509" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_32d00772-bf47-4ec8-b449-27c94f9cf51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ed362dc6-387c-45a2-9152-a62c48a87a61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c28ad4e0-2ba9-4d1f-a1d4-cd983035a509" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ed362dc6-387c-45a2-9152-a62c48a87a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_6e084ada-a543-4752-b885-de0c9331b0cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c28ad4e0-2ba9-4d1f-a1d4-cd983035a509" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_6e084ada-a543-4752-b885-de0c9331b0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_6fdb6a17-8ec2-46bf-97b2-6e0b0a13edf5" xlink:href="crdf-20200930.xsd#crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c28ad4e0-2ba9-4d1f-a1d4-cd983035a509" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_6fdb6a17-8ec2-46bf-97b2-6e0b0a13edf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0629d373-4f96-4513-9678-87e25524b338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c28ad4e0-2ba9-4d1f-a1d4-cd983035a509" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0629d373-4f96-4513-9678-87e25524b338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability_bdbb68e8-19ce-4937-97c5-90f64b1f736e" xlink:href="crdf-20200930.xsd#crdf_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c28ad4e0-2ba9-4d1f-a1d4-cd983035a509" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseLiability_bdbb68e8-19ce-4937-97c5-90f64b1f736e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_88fbde45-9833-4269-a04a-558c7cf1f925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c28ad4e0-2ba9-4d1f-a1d4-cd983035a509" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_88fbde45-9833-4269-a04a-558c7cf1f925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70082ede-0ab1-47ef-9084-5c014d91e223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_91d45d40-e9d6-4bd5-84f8-01b64d88a7e9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70082ede-0ab1-47ef-9084-5c014d91e223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2489ba82-81c5-41ed-bc5a-f886ea0c9c8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a083088-35d5-4dfa-8790-65bdccf9f886" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2489ba82-81c5-41ed-bc5a-f886ea0c9c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b43b280c-66ce-4a79-b86e-48be9bbe0551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2489ba82-81c5-41ed-bc5a-f886ea0c9c8e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b43b280c-66ce-4a79-b86e-48be9bbe0551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_03c4a5e4-04ff-4e43-8afd-728c32f7105d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2489ba82-81c5-41ed-bc5a-f886ea0c9c8e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_03c4a5e4-04ff-4e43-8afd-728c32f7105d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_38d5a68b-653f-4ed6-94a3-7557fb0df24f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a083088-35d5-4dfa-8790-65bdccf9f886" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_38d5a68b-653f-4ed6-94a3-7557fb0df24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cc161005-5293-4cd3-86cb-322419ce7948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_38d5a68b-653f-4ed6-94a3-7557fb0df24f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cc161005-5293-4cd3-86cb-322419ce7948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_101ad24f-9b66-4102-b2f5-5a0cef150f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_38d5a68b-653f-4ed6-94a3-7557fb0df24f" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_101ad24f-9b66-4102-b2f5-5a0cef150f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_46068466-a5d3-447a-a9c2-daa5100954b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_38d5a68b-653f-4ed6-94a3-7557fb0df24f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_46068466-a5d3-447a-a9c2-daa5100954b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_5e8ea592-b976-463c-a789-8764262aee5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_38d5a68b-653f-4ed6-94a3-7557fb0df24f" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_5e8ea592-b976-463c-a789-8764262aee5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3350a6ba-6467-42d1-915d-54c1e944912e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_38d5a68b-653f-4ed6-94a3-7557fb0df24f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3350a6ba-6467-42d1-915d-54c1e944912e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19e27075-a532-4945-a598-c070610a381e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_38d5a68b-653f-4ed6-94a3-7557fb0df24f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19e27075-a532-4945-a598-c070610a381e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0841d5f8-849c-4d6f-8441-e2f2ccaca4d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a083088-35d5-4dfa-8790-65bdccf9f886" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0841d5f8-849c-4d6f-8441-e2f2ccaca4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9fa8f46b-8bc5-4a6f-a184-812b09719ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a083088-35d5-4dfa-8790-65bdccf9f886" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9fa8f46b-8bc5-4a6f-a184-812b09719ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4504e91e-6d35-401f-9582-b1e67698793d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a083088-35d5-4dfa-8790-65bdccf9f886" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4504e91e-6d35-401f-9582-b1e67698793d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6fff5643-2d69-4910-a340-26666ffbec01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a083088-35d5-4dfa-8790-65bdccf9f886" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6fff5643-2d69-4910-a340-26666ffbec01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_cdfdbe38-39f6-467c-be7c-db0f6ba17a5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6fff5643-2d69-4910-a340-26666ffbec01" xlink:to="loc_us-gaap_IncomeTaxesPaid_cdfdbe38-39f6-467c-be7c-db0f6ba17a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_899369ab-3093-436a-9c69-d985892a66d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a083088-35d5-4dfa-8790-65bdccf9f886" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_899369ab-3093-436a-9c69-d985892a66d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockDividendAccrued_573c9049-8d50-4f34-891f-9f936e89d827" xlink:href="crdf-20200930.xsd#crdf_PreferredStockDividendAccrued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_899369ab-3093-436a-9c69-d985892a66d8" xlink:to="loc_crdf_PreferredStockDividendAccrued_573c9049-8d50-4f34-891f-9f936e89d827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_9cbf18c5-2d6b-4cc2-a3bd-6bd76b246f93" xlink:href="crdf-20200930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_899369ab-3093-436a-9c69-d985892a66d8" xlink:to="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_9cbf18c5-2d6b-4cc2-a3bd-6bd76b246f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_9106582b-b990-4fad-926d-91a3d292ff24" xlink:href="crdf-20200930.xsd#crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_899369ab-3093-436a-9c69-d985892a66d8" xlink:to="loc_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_9106582b-b990-4fad-926d-91a3d292ff24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_224920ac-2666-415b-ba2c-3d3446ae5350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_899369ab-3093-436a-9c69-d985892a66d8" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_224920ac-2666-415b-ba2c-3d3446ae5350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="simple" xlink:href="crdf-20200930.xsd#CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_bd6e0be8-b207-49c7-aa2e-c77cb8966286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ffa0aed8-1ed8-4a19-82fb-50a1d4fb2927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bd6e0be8-b207-49c7-aa2e-c77cb8966286" xlink:to="loc_us-gaap_StatementTable_ffa0aed8-1ed8-4a19-82fb-50a1d4fb2927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9ce4d871-cb83-47fe-a5a9-436af25e7105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ffa0aed8-1ed8-4a19-82fb-50a1d4fb2927" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9ce4d871-cb83-47fe-a5a9-436af25e7105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b240580b-0bc1-4bf6-bc89-2afde2af7cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9ce4d871-cb83-47fe-a5a9-436af25e7105" xlink:to="loc_us-gaap_ClassOfStockDomain_b240580b-0bc1-4bf6-bc89-2afde2af7cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_aca69b82-319e-4612-8d2e-54112dfa8e27" xlink:href="crdf-20200930.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b240580b-0bc1-4bf6-bc89-2afde2af7cb4" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_aca69b82-319e-4612-8d2e-54112dfa8e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_b01a2f1d-05d5-4be0-93b8-9ddd9c27628a" xlink:href="crdf-20200930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b240580b-0bc1-4bf6-bc89-2afde2af7cb4" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_b01a2f1d-05d5-4be0-93b8-9ddd9c27628a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3b316630-4e6d-47b0-bb88-f822b639e85e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ffa0aed8-1ed8-4a19-82fb-50a1d4fb2927" xlink:to="loc_us-gaap_StatementLineItems_3b316630-4e6d-47b0-bb88-f822b639e85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_e0212bda-db5f-4667-8e8d-b002e73a2345" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3b316630-4e6d-47b0-bb88-f822b639e85e" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_e0212bda-db5f-4667-8e8d-b002e73a2345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_39acdbf4-d191-4926-98be-6d3f45d8162a" xlink:href="crdf-20200930.xsd#crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3b316630-4e6d-47b0-bb88-f822b639e85e" xlink:to="loc_crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_39acdbf4-d191-4926-98be-6d3f45d8162a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="crdf-20200930.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1f692d61-fbdf-4324-b28b-10dc9ee031ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_057a5f8a-c004-4a50-8ee1-ed931cd58a38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1f692d61-fbdf-4324-b28b-10dc9ee031ba" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_057a5f8a-c004-4a50-8ee1-ed931cd58a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6edfe3ea-c949-4244-bc69-558a91f8951f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_eb4f97e4-c202-4c08-9335-08da01d59bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6edfe3ea-c949-4244-bc69-558a91f8951f" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_eb4f97e4-c202-4c08-9335-08da01d59bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a99d3128-d7fb-4c2f-afa5-dcd50ae667e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_eb4f97e4-c202-4c08-9335-08da01d59bb1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a99d3128-d7fb-4c2f-afa5-dcd50ae667e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a098b54a-3ea5-45d2-9331-adfef633fd24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a99d3128-d7fb-4c2f-afa5-dcd50ae667e9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a098b54a-3ea5-45d2-9331-adfef633fd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5b39f3f4-555d-4766-9a50-692458659974" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a098b54a-3ea5-45d2-9331-adfef633fd24" xlink:to="loc_us-gaap_SubsequentEventMember_5b39f3f4-555d-4766-9a50-692458659974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_061693f2-74d6-425a-b637-af2e265db1da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_eb4f97e4-c202-4c08-9335-08da01d59bb1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_061693f2-74d6-425a-b637-af2e265db1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41181ea6-d01f-49f7-8d3f-1fc27bda82dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_061693f2-74d6-425a-b637-af2e265db1da" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41181ea6-d01f-49f7-8d3f-1fc27bda82dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SaleOfStockConsiderationReceivedOnTransactionGross_f766aea0-9a60-4fe5-8735-559eab42f708" xlink:href="crdf-20200930.xsd#crdf_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_061693f2-74d6-425a-b637-af2e265db1da" xlink:to="loc_crdf_SaleOfStockConsiderationReceivedOnTransactionGross_f766aea0-9a60-4fe5-8735-559eab42f708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="crdf-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b2422c9b-f332-4b5b-b8e0-3d877169c1f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_56a874b7-848e-462f-85a5-8997c629b692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b2422c9b-f332-4b5b-b8e0-3d877169c1f2" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_56a874b7-848e-462f-85a5-8997c629b692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="crdf-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e8312e01-d970-4c9c-9049-a89eacd9f1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_9b899454-2ce2-47ad-b78d-cdf0e6444874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8312e01-d970-4c9c-9049-a89eacd9f1a2" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_9b899454-2ce2-47ad-b78d-cdf0e6444874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_33363a34-f831-4742-9610-9f57a269c19b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8312e01-d970-4c9c-9049-a89eacd9f1a2" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_33363a34-f831-4742-9610-9f57a269c19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="crdf-20200930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_414896de-5d22-4d2e-b99f-2bd879681a54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b128f22f-9537-495f-b42e-9364d638883d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_414896de-5d22-4d2e-b99f-2bd879681a54" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b128f22f-9537-495f-b42e-9364d638883d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_877549ba-276d-4f66-8b4c-d0b8c7169d28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_414896de-5d22-4d2e-b99f-2bd879681a54" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_877549ba-276d-4f66-8b4c-d0b8c7169d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesNetLossPerShareDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#SummaryofSignificantAccountingPoliciesNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_30e4ba25-c8fb-4f09-8ed4-2c86e9e4d529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_43643261-a55b-4a57-a601-441343453836" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30e4ba25-c8fb-4f09-8ed4-2c86e9e4d529" xlink:to="loc_us-gaap_EarningsPerShareAbstract_43643261-a55b-4a57-a601-441343453836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_NumeratorAbstract_1a4c993d-0785-401a-a252-c8d4e5657b33" xlink:href="crdf-20200930.xsd#crdf_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_43643261-a55b-4a57-a601-441343453836" xlink:to="loc_crdf_NumeratorAbstract_1a4c993d-0785-401a-a252-c8d4e5657b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_f7751240-6947-4d5e-884e-c84be19b8b77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_NumeratorAbstract_1a4c993d-0785-401a-a252-c8d4e5657b33" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_f7751240-6947-4d5e-884e-c84be19b8b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DenominatorAbstract_8697638c-acee-41d8-8b7f-af31fdb67d5f" xlink:href="crdf-20200930.xsd#crdf_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_43643261-a55b-4a57-a601-441343453836" xlink:to="loc_crdf_DenominatorAbstract_8697638c-acee-41d8-8b7f-af31fdb67d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_082af6ec-cfcd-44d4-b897-b77a03487781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DenominatorAbstract_8697638c-acee-41d8-8b7f-af31fdb67d5f" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_082af6ec-cfcd-44d4-b897-b77a03487781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_f4550317-6d85-4524-8678-c79c451fe393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_43643261-a55b-4a57-a601-441343453836" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_f4550317-6d85-4524-8678-c79c451fe393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_335fb669-7de5-4087-9554-43dcba1489ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_f4550317-6d85-4524-8678-c79c451fe393" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_335fb669-7de5-4087-9554-43dcba1489ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3931de20-b8ad-4f9c-abc1-e98497b08966" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5b7fddad-8fce-4a4b-b585-64d416699558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3931de20-b8ad-4f9c-abc1-e98497b08966" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5b7fddad-8fce-4a4b-b585-64d416699558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93af4579-d038-49a7-b039-ca221a826e95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5b7fddad-8fce-4a4b-b585-64d416699558" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93af4579-d038-49a7-b039-ca221a826e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7619f52-7083-48bc-ab21-cab5df404d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93af4579-d038-49a7-b039-ca221a826e95" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7619f52-7083-48bc-ab21-cab5df404d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5a9674e5-5395-461d-aa07-a6cbe8817dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7619f52-7083-48bc-ab21-cab5df404d8c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5a9674e5-5395-461d-aa07-a6cbe8817dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4d785191-99b4-4ef5-9e20-dcdfd1b49ed9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7619f52-7083-48bc-ab21-cab5df404d8c" xlink:to="loc_us-gaap_WarrantMember_4d785191-99b4-4ef5-9e20-dcdfd1b49ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3f3e67e0-5170-447d-a533-3637211c9c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7619f52-7083-48bc-ab21-cab5df404d8c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3f3e67e0-5170-447d-a533-3637211c9c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_f6bf559f-432e-4c12-b7a3-5eac728b2f35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7619f52-7083-48bc-ab21-cab5df404d8c" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_f6bf559f-432e-4c12-b7a3-5eac728b2f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_4ef76b55-2133-41ce-9bd8-f05368760caf" xlink:href="crdf-20200930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7619f52-7083-48bc-ab21-cab5df404d8c" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_4ef76b55-2133-41ce-9bd8-f05368760caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_715e3842-7178-429d-b66d-3c6bd1e60d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5b7fddad-8fce-4a4b-b585-64d416699558" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_715e3842-7178-429d-b66d-3c6bd1e60d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f4bb6b00-95fe-4001-94d6-baf341732b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_715e3842-7178-429d-b66d-3c6bd1e60d19" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f4bb6b00-95fe-4001-94d6-baf341732b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="crdf-20200930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_06f98c45-9797-4649-a9f7-1483d7c7d341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_aaf41639-6aca-4c8b-af3d-4b13a760638f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_06f98c45-9797-4649-a9f7-1483d7c7d341" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_aaf41639-6aca-4c8b-af3d-4b13a760638f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="crdf-20200930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e1ff8ce5-3fdb-40f6-9ef6-6b2df4229376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_6b53ff8e-ea8e-4db4-a3e6-3afdfca7c67a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e1ff8ce5-3fdb-40f6-9ef6-6b2df4229376" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_6b53ff8e-ea8e-4db4-a3e6-3afdfca7c67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ad76a070-a329-4b63-a9cf-a4ea927541a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eeadf1c4-109b-4dd2-b5bf-fa13c9c64fb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ad76a070-a329-4b63-a9cf-a4ea927541a6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eeadf1c4-109b-4dd2-b5bf-fa13c9c64fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_c043797c-daa3-45fe-81e5-1d7af6bbc482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eeadf1c4-109b-4dd2-b5bf-fa13c9c64fb9" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_c043797c-daa3-45fe-81e5-1d7af6bbc482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_99ebc217-2a62-4e75-bdcd-821b23a2b042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_c043797c-daa3-45fe-81e5-1d7af6bbc482" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_99ebc217-2a62-4e75-bdcd-821b23a2b042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_bdafb923-b506-46a3-ba4a-6d109f0df01c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_99ebc217-2a62-4e75-bdcd-821b23a2b042" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_bdafb923-b506-46a3-ba4a-6d109f0df01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_54fc2f18-3138-469b-b594-1cae5b038074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_99ebc217-2a62-4e75-bdcd-821b23a2b042" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_54fc2f18-3138-469b-b594-1cae5b038074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1359ef9c-603a-4829-b244-b4f726cf0e38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eeadf1c4-109b-4dd2-b5bf-fa13c9c64fb9" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1359ef9c-603a-4829-b244-b4f726cf0e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8142fb61-3a04-4854-8ee1-9e9384e39f76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1359ef9c-603a-4829-b244-b4f726cf0e38" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8142fb61-3a04-4854-8ee1-9e9384e39f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_003c8f63-9420-4c21-af25-ff5ebdfac6e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8142fb61-3a04-4854-8ee1-9e9384e39f76" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_003c8f63-9420-4c21-af25-ff5ebdfac6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b4345f9-1db7-4a2e-b668-49ddc657e660" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eeadf1c4-109b-4dd2-b5bf-fa13c9c64fb9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b4345f9-1db7-4a2e-b668-49ddc657e660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_80ca45e0-734a-4384-a1d6-e60bf2fcf8a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b4345f9-1db7-4a2e-b668-49ddc657e660" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_80ca45e0-734a-4384-a1d6-e60bf2fcf8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_973d0594-aab2-46c0-b8a7-b753af588d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_80ca45e0-734a-4384-a1d6-e60bf2fcf8a5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_973d0594-aab2-46c0-b8a7-b753af588d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_35b9fbcc-60b1-4439-8d89-4e60e0b22ee1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_80ca45e0-734a-4384-a1d6-e60bf2fcf8a5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_35b9fbcc-60b1-4439-8d89-4e60e0b22ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e0c7db48-1f94-4a44-98f7-4eef372317a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_80ca45e0-734a-4384-a1d6-e60bf2fcf8a5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e0c7db48-1f94-4a44-98f7-4eef372317a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916d060f-0cd8-489d-8c15-696dec85ae0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eeadf1c4-109b-4dd2-b5bf-fa13c9c64fb9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916d060f-0cd8-489d-8c15-696dec85ae0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_e246eb13-63a4-40da-b17f-3ce3521b567a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916d060f-0cd8-489d-8c15-696dec85ae0e" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_e246eb13-63a4-40da-b17f-3ce3521b567a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_b24fca6f-7876-47fc-99b0-d9356e007706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e246eb13-63a4-40da-b17f-3ce3521b567a" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_b24fca6f-7876-47fc-99b0-d9356e007706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_75f527e2-4ace-4d4b-b1cf-c368b42b5046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e246eb13-63a4-40da-b17f-3ce3521b567a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_75f527e2-4ace-4d4b-b1cf-c368b42b5046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_cb3dc4d9-6b0e-476b-9bd4-d889ebaf6e04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916d060f-0cd8-489d-8c15-696dec85ae0e" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_cb3dc4d9-6b0e-476b-9bd4-d889ebaf6e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_e10381e1-1ad5-42e4-9fdb-7430ce6a9223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_cb3dc4d9-6b0e-476b-9bd4-d889ebaf6e04" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_e10381e1-1ad5-42e4-9fdb-7430ce6a9223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_97e297bc-50d2-49d1-a503-4a31331bd828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_cb3dc4d9-6b0e-476b-9bd4-d889ebaf6e04" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_97e297bc-50d2-49d1-a503-4a31331bd828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="crdf-20200930.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3cd58f5d-7b11-42dd-b0a4-358c9aa982ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_49d79f44-3032-434d-af43-c342d0c89a65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3cd58f5d-7b11-42dd-b0a4-358c9aa982ba" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_49d79f44-3032-434d-af43-c342d0c89a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="crdf-20200930.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8f229c39-6230-4611-b800-90c872fb63d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_232ad5b8-b81b-4631-8020-4925f7f6a650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8f229c39-6230-4611-b800-90c872fb63d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_232ad5b8-b81b-4631-8020-4925f7f6a650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a7871b9b-8e9c-444a-a1aa-a6f6b74d7e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_020cafba-13e3-41cc-8bec-9b5960470a7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a7871b9b-8e9c-444a-a1aa-a6f6b74d7e72" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_020cafba-13e3-41cc-8bec-9b5960470a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bd412e43-d624-44c5-a6bb-feeff879d411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_020cafba-13e3-41cc-8bec-9b5960470a7b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bd412e43-d624-44c5-a6bb-feeff879d411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b2206d82-e725-4683-b2a7-b3f78db8f66d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bd412e43-d624-44c5-a6bb-feeff879d411" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b2206d82-e725-4683-b2a7-b3f78db8f66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_FurnitureAndOfficeEquipmentMember_4567b451-1a28-43b2-aa44-10dd3d3b9667" xlink:href="crdf-20200930.xsd#crdf_FurnitureAndOfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b2206d82-e725-4683-b2a7-b3f78db8f66d" xlink:to="loc_crdf_FurnitureAndOfficeEquipmentMember_4567b451-1a28-43b2-aa44-10dd3d3b9667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2a4bd4bc-d4eb-49ea-a6e9-052b99d78d7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b2206d82-e725-4683-b2a7-b3f78db8f66d" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2a4bd4bc-d4eb-49ea-a6e9-052b99d78d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_0515360f-bcac-4c78-bfd9-88479f2ea7e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b2206d82-e725-4683-b2a7-b3f78db8f66d" xlink:to="loc_us-gaap_EquipmentMember_0515360f-bcac-4c78-bfd9-88479f2ea7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5f0202dd-6fd3-44dd-bc7a-f0887d6257bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_020cafba-13e3-41cc-8bec-9b5960470a7b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5f0202dd-6fd3-44dd-bc7a-f0887d6257bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ff0edf1a-37c3-4900-aa3b-727866e61032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5f0202dd-6fd3-44dd-bc7a-f0887d6257bb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ff0edf1a-37c3-4900-aa3b-727866e61032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_99f64cc1-1afe-41bf-9fc6-fdee022a3b24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5f0202dd-6fd3-44dd-bc7a-f0887d6257bb" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_99f64cc1-1afe-41bf-9fc6-fdee022a3b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ff4de8ea-2ad9-405b-97c6-0e639af43684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5f0202dd-6fd3-44dd-bc7a-f0887d6257bb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ff4de8ea-2ad9-405b-97c6-0e639af43684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/Leases" xlink:type="simple" xlink:href="crdf-20200930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_79fa7324-2166-4e59-ac5a-df7a7b001077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_aa87909a-b0ab-4db7-b622-abcb4b86c123" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79fa7324-2166-4e59-ac5a-df7a7b001077" xlink:to="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_aa87909a-b0ab-4db7-b622-abcb4b86c123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_cdbdcd91-e80d-459d-a9ee-db6cd93f370d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79fa7324-2166-4e59-ac5a-df7a7b001077" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_cdbdcd91-e80d-459d-a9ee-db6cd93f370d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesTables" xlink:type="simple" xlink:href="crdf-20200930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1cfc9b36-d740-4117-a2f5-8d2091bb9965" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_ba552af2-53a2-4dc1-851c-14c35a8dac5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1cfc9b36-d740-4117-a2f5-8d2091bb9965" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_ba552af2-53a2-4dc1-851c-14c35a8dac5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_0a4094d1-b2e5-4cab-b2e1-d7fbcdb918f1" xlink:href="crdf-20200930.xsd#crdf_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1cfc9b36-d740-4117-a2f5-8d2091bb9965" xlink:to="loc_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_0a4094d1-b2e5-4cab-b2e1-d7fbcdb918f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_20ac5cb6-f3c2-4448-b3a7-c80f0b24d016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1cfc9b36-d740-4117-a2f5-8d2091bb9965" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_20ac5cb6-f3c2-4448-b3a7-c80f0b24d016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_16eafd6e-f16e-47f5-bb85-5d1532be76a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_b1e2a935-4bb0-4aa2-9e56-4f50a42f3f54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_16eafd6e-f16e-47f5-bb85-5d1532be76a1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_b1e2a935-4bb0-4aa2-9e56-4f50a42f3f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a3862411-30c0-4115-ac14-73004ee1607f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b1e2a935-4bb0-4aa2-9e56-4f50a42f3f54" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a3862411-30c0-4115-ac14-73004ee1607f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_245d34e1-76fc-47a1-aa69-c931a3222a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a3862411-30c0-4115-ac14-73004ee1607f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_245d34e1-76fc-47a1-aa69-c931a3222a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember_33b70379-6903-4f88-9392-8486e5cd93da" xlink:href="crdf-20200930.xsd#crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_245d34e1-76fc-47a1-aa69-c931a3222a6d" xlink:to="loc_crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember_33b70379-6903-4f88-9392-8486e5cd93da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_34330868-7a2b-43b6-8235-0e76bcac613e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b1e2a935-4bb0-4aa2-9e56-4f50a42f3f54" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_34330868-7a2b-43b6-8235-0e76bcac613e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LessorNumberOfSubleases_ac20435e-1c75-445e-b6c1-a0cd8f3f255b" xlink:href="crdf-20200930.xsd#crdf_LessorNumberOfSubleases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_34330868-7a2b-43b6-8235-0e76bcac613e" xlink:to="loc_crdf_LessorNumberOfSubleases_ac20435e-1c75-445e-b6c1-a0cd8f3f255b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment_210e6c62-af5c-452e-9e21-c2c216b937f0" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseMonthlyRentPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_34330868-7a2b-43b6-8235-0e76bcac613e" xlink:to="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment_210e6c62-af5c-452e-9e21-c2c216b937f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_1d23075b-953b-4e42-908f-5620702bf664" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_34330868-7a2b-43b6-8235-0e76bcac613e" xlink:to="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_1d23075b-953b-4e42-908f-5620702bf664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseNumberOfRenewalOptions_91ab1dcf-e6e0-46a1-b17b-dbedf273cb42" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_34330868-7a2b-43b6-8235-0e76bcac613e" xlink:to="loc_crdf_LesseeOperatingLeaseNumberOfRenewalOptions_91ab1dcf-e6e0-46a1-b17b-dbedf273cb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d635a4a7-15f7-42d7-b8f9-c5d01e3e102c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_34330868-7a2b-43b6-8235-0e76bcac613e" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d635a4a7-15f7-42d7-b8f9-c5d01e3e102c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c4277eed-3b71-481c-8269-4a34aefc8b8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_34330868-7a2b-43b6-8235-0e76bcac613e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c4277eed-3b71-481c-8269-4a34aefc8b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_ff3a1bdd-f9dc-46e5-a5e9-8d64e53920b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_34330868-7a2b-43b6-8235-0e76bcac613e" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_ff3a1bdd-f9dc-46e5-a5e9-8d64e53920b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_52fbab18-945c-400e-b2d8-cbef4fc3dc87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_80c59ee0-793a-4d91-8a95-8f51945ecb80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_52fbab18-945c-400e-b2d8-cbef4fc3dc87" xlink:to="loc_us-gaap_OperatingLeaseCost_80c59ee0-793a-4d91-8a95-8f51945ecb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_6c7fd7c0-7781-4787-bc96-a2d16850b18e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_52fbab18-945c-400e-b2d8-cbef4fc3dc87" xlink:to="loc_us-gaap_SubleaseIncome_6c7fd7c0-7781-4787-bc96-a2d16850b18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_266d20ed-eec6-4000-ab5a-7ba8205d2018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_52fbab18-945c-400e-b2d8-cbef4fc3dc87" xlink:to="loc_us-gaap_LeaseCost_266d20ed-eec6-4000-ab5a-7ba8205d2018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_963fe010-fb93-458c-bcbe-f9801e9138a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c718aa26-c606-4ee8-88cd-46ad6f2825f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_963fe010-fb93-458c-bcbe-f9801e9138a8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c718aa26-c606-4ee8-88cd-46ad6f2825f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_196cfddb-8d73-4bb3-b13f-db68428f9c0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_963fe010-fb93-458c-bcbe-f9801e9138a8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_196cfddb-8d73-4bb3-b13f-db68428f9c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_78bcf100-c48f-4b61-8117-1432b5de113b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_963fe010-fb93-458c-bcbe-f9801e9138a8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_78bcf100-c48f-4b61-8117-1432b5de113b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a165cb87-368f-426d-93fc-228a6ef890b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_963fe010-fb93-458c-bcbe-f9801e9138a8" xlink:to="loc_us-gaap_OperatingLeaseLiability_a165cb87-368f-426d-93fc-228a6ef890b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ac97cd66-11bb-453a-a24b-fb0749794ccb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_963fe010-fb93-458c-bcbe-f9801e9138a8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ac97cd66-11bb-453a-a24b-fb0749794ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ea840490-b4fb-4f28-9555-023243565bff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_963fe010-fb93-458c-bcbe-f9801e9138a8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ea840490-b4fb-4f28-9555-023243565bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#LeasesSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b24b58a8-bd48-44e7-9834-a46932e368be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5eb00882-79c7-464d-b958-d38d6411b3db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b24b58a8-bd48-44e7-9834-a46932e368be" xlink:to="loc_us-gaap_OperatingLeasePayments_5eb00882-79c7-464d-b958-d38d6411b3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b57dc874-71be-41cd-b64a-ce7d42468f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6a27e41a-d8c7-4d73-a3d1-0595d4d74812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b57dc874-71be-41cd-b64a-ce7d42468f8d" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6a27e41a-d8c7-4d73-a3d1-0595d4d74812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d1b34cb6-e791-4050-b4a7-1e92f57563b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6a27e41a-d8c7-4d73-a3d1-0595d4d74812" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d1b34cb6-e791-4050-b4a7-1e92f57563b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a3b32bd5-9ee9-4dc7-a134-75d498866a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6a27e41a-d8c7-4d73-a3d1-0595d4d74812" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a3b32bd5-9ee9-4dc7-a134-75d498866a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bdfd91ed-f7d6-4586-b644-c7a3df2cc9d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6a27e41a-d8c7-4d73-a3d1-0595d4d74812" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bdfd91ed-f7d6-4586-b644-c7a3df2cc9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8d347f04-22f6-4da6-b4ae-d7eb7fdfb915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6a27e41a-d8c7-4d73-a3d1-0595d4d74812" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8d347f04-22f6-4da6-b4ae-d7eb7fdfb915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_46368428-396e-4995-9bc0-3d88584c06e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6a27e41a-d8c7-4d73-a3d1-0595d4d74812" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_46368428-396e-4995-9bc0-3d88584c06e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cc106cb2-e361-4b63-ae5a-86c789d9c4d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6a27e41a-d8c7-4d73-a3d1-0595d4d74812" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cc106cb2-e361-4b63-ae5a-86c789d9c4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ac2d723c-8c5b-47d2-a1a2-04060363ef5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6a27e41a-d8c7-4d73-a3d1-0595d4d74812" xlink:to="loc_us-gaap_OperatingLeaseLiability_ac2d723c-8c5b-47d2-a1a2-04060363ef5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_befa0ed8-cf3c-492c-b2a9-bdfa5e3b8c12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b57dc874-71be-41cd-b64a-ce7d42468f8d" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_befa0ed8-cf3c-492c-b2a9-bdfa5e3b8c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_1d5a4c1d-4041-46f7-9118-10350bc30d28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_befa0ed8-cf3c-492c-b2a9-bdfa5e3b8c12" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_1d5a4c1d-4041-46f7-9118-10350bc30d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_3a9ad6b3-67d2-45c5-94d2-b265c723df43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_befa0ed8-cf3c-492c-b2a9-bdfa5e3b8c12" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_3a9ad6b3-67d2-45c5-94d2-b265c723df43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_d76bc82d-ca58-435e-81cc-38900e96395f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_befa0ed8-cf3c-492c-b2a9-bdfa5e3b8c12" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_d76bc82d-ca58-435e-81cc-38900e96395f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_3567662a-dc21-4f47-a2a5-501a6ff60d54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_befa0ed8-cf3c-492c-b2a9-bdfa5e3b8c12" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_3567662a-dc21-4f47-a2a5-501a6ff60d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_4945df99-f211-455f-925f-aa95c8e3c444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_befa0ed8-cf3c-492c-b2a9-bdfa5e3b8c12" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_4945df99-f211-455f-925f-aa95c8e3c444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_af88cad7-8440-4e03-99cb-f04fb2d4c937" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b57dc874-71be-41cd-b64a-ce7d42468f8d" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_af88cad7-8440-4e03-99cb-f04fb2d4c937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear_4f0aad81-a1ea-458a-8b04-f969d03765fd" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_af88cad7-8440-4e03-99cb-f04fb2d4c937" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear_4f0aad81-a1ea-458a-8b04-f969d03765fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne_b27b1e80-bc11-4491-a003-f98c52079ac7" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_af88cad7-8440-4e03-99cb-f04fb2d4c937" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne_b27b1e80-bc11-4491-a003-f98c52079ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_1826e148-7160-48fb-a321-5b6519a1072c" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_af88cad7-8440-4e03-99cb-f04fb2d4c937" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_1826e148-7160-48fb-a321-5b6519a1072c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_57862d0c-ad5c-4690-823e-ccca01c25d5a" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_af88cad7-8440-4e03-99cb-f04fb2d4c937" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_57862d0c-ad5c-4690-823e-ccca01c25d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_6a782c43-c042-4c4d-83be-0c1c9d9cffdf" xlink:href="crdf-20200930.xsd#crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_af88cad7-8440-4e03-99cb-f04fb2d4c937" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_6a782c43-c042-4c4d-83be-0c1c9d9cffdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="crdf-20200930.xsd#LeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants" xlink:type="simple" xlink:href="crdf-20200930.xsd#DerivativeFinancialInstrumentsWarrants"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0ba6bc46-1a1d-4715-8a63-82049fb7cf38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_bea407dc-9bd7-4e85-9b72-cfb5ba78ae3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0ba6bc46-1a1d-4715-8a63-82049fb7cf38" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_bea407dc-9bd7-4e85-9b72-cfb5ba78ae3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables" xlink:type="simple" xlink:href="crdf-20200930.xsd#DerivativeFinancialInstrumentsWarrantsTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7a711e0b-e876-4f77-91fb-1e8071d599eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_21b2d620-5a63-4aff-b0ae-7c63710f586a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7a711e0b-e876-4f77-91fb-1e8071d599eb" xlink:to="loc_us-gaap_DerivativeTable_21b2d620-5a63-4aff-b0ae-7c63710f586a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_49c21e1e-fc93-4904-a49f-11a7947a5ae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_21b2d620-5a63-4aff-b0ae-7c63710f586a" xlink:to="loc_us-gaap_ValuationTechniqueAxis_49c21e1e-fc93-4904-a49f-11a7947a5ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_88195118-4893-4eea-801c-5affcae26009" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_49c21e1e-fc93-4904-a49f-11a7947a5ae5" xlink:to="loc_us-gaap_ValuationTechniqueDomain_88195118-4893-4eea-801c-5affcae26009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BlackScholesOptionPricingMethodMember_79ed82c2-c1b0-4c43-8c40-12f2c600f40b" xlink:href="crdf-20200930.xsd#crdf_BlackScholesOptionPricingMethodMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_88195118-4893-4eea-801c-5affcae26009" xlink:to="loc_crdf_BlackScholesOptionPricingMethodMember_79ed82c2-c1b0-4c43-8c40-12f2c600f40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_ddf4d715-acf6-4eaa-acf3-b795cad08a9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_21b2d620-5a63-4aff-b0ae-7c63710f586a" xlink:to="loc_us-gaap_DerivativeLineItems_ddf4d715-acf6-4eaa-acf3-b795cad08a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_dd0e40b7-ed42-4327-8762-e5194d6b5366" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_ddf4d715-acf6-4eaa-acf3-b795cad08a9a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_dd0e40b7-ed42-4327-8762-e5194d6b5366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_1cc979ca-3427-422a-bf73-86d8229c252e" xlink:href="crdf-20200930.xsd#crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_ddf4d715-acf6-4eaa-acf3-b795cad08a9a" xlink:to="loc_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_1cc979ca-3427-422a-bf73-86d8229c252e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#DerivativeFinancialInstrumentsWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_50e870e3-5e50-4ddb-ba8d-764fdd6944dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_f7faa99c-a7ca-4f1f-87ef-32b34d686777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_50e870e3-5e50-4ddb-ba8d-764fdd6944dc" xlink:to="loc_us-gaap_DerivativeTable_f7faa99c-a7ca-4f1f-87ef-32b34d686777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_6a49c0ab-d2b4-4db2-b2ff-f2165593b128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f7faa99c-a7ca-4f1f-87ef-32b34d686777" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_6a49c0ab-d2b4-4db2-b2ff-f2165593b128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_548ca420-4edd-45df-b807-c494fbc673a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6a49c0ab-d2b4-4db2-b2ff-f2165593b128" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_548ca420-4edd-45df-b807-c494fbc673a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_ec773d4c-a320-48fe-9c70-62c142aef5f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_548ca420-4edd-45df-b807-c494fbc673a7" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_ec773d4c-a320-48fe-9c70-62c142aef5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1d4520b8-c0f1-4386-8537-9f9012afe4b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_548ca420-4edd-45df-b807-c494fbc673a7" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1d4520b8-c0f1-4386-8537-9f9012afe4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_b95b90b0-fb67-45db-8860-42a5840e9568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_548ca420-4edd-45df-b807-c494fbc673a7" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_b95b90b0-fb67-45db-8860-42a5840e9568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_0c90cc1f-022a-4cc4-9629-f0c20efdaf2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_548ca420-4edd-45df-b807-c494fbc673a7" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_0c90cc1f-022a-4cc4-9629-f0c20efdaf2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_28c51a10-0746-4f2a-ae09-05b6f4c56e33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f7faa99c-a7ca-4f1f-87ef-32b34d686777" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_28c51a10-0746-4f2a-ae09-05b6f4c56e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b2ecc1ae-cc7b-4a75-96fb-5aa4d6b54132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_28c51a10-0746-4f2a-ae09-05b6f4c56e33" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b2ecc1ae-cc7b-4a75-96fb-5aa4d6b54132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_0bf6e035-c337-4bc5-a614-9486792ad832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b2ecc1ae-cc7b-4a75-96fb-5aa4d6b54132" xlink:to="loc_us-gaap_WarrantMember_0bf6e035-c337-4bc5-a614-9486792ad832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_00b63b8f-d453-479f-81ad-195dfed1737d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f7faa99c-a7ca-4f1f-87ef-32b34d686777" xlink:to="loc_us-gaap_ValuationTechniqueAxis_00b63b8f-d453-479f-81ad-195dfed1737d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_8a0eacaa-c529-4796-b92b-3b289a386aca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_00b63b8f-d453-479f-81ad-195dfed1737d" xlink:to="loc_us-gaap_ValuationTechniqueDomain_8a0eacaa-c529-4796-b92b-3b289a386aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BlackScholesOptionPricingMethodMember_b4f4d122-48c3-4f5c-9fcd-a4da194ba256" xlink:href="crdf-20200930.xsd#crdf_BlackScholesOptionPricingMethodMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_8a0eacaa-c529-4796-b92b-3b289a386aca" xlink:to="loc_crdf_BlackScholesOptionPricingMethodMember_b4f4d122-48c3-4f5c-9fcd-a4da194ba256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a1155138-f393-4d76-8d49-e59747539a5c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f7faa99c-a7ca-4f1f-87ef-32b34d686777" xlink:to="loc_srt_RangeAxis_a1155138-f393-4d76-8d49-e59747539a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b27564f7-ce71-4ab9-9995-c46401767d16" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a1155138-f393-4d76-8d49-e59747539a5c" xlink:to="loc_srt_RangeMember_b27564f7-ce71-4ab9-9995-c46401767d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4de55e66-dc53-4068-901b-ce7dd28e327f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b27564f7-ce71-4ab9-9995-c46401767d16" xlink:to="loc_srt_MinimumMember_4de55e66-dc53-4068-901b-ce7dd28e327f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e918acbf-913e-4414-9566-4f134199543f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b27564f7-ce71-4ab9-9995-c46401767d16" xlink:to="loc_srt_MaximumMember_e918acbf-913e-4414-9566-4f134199543f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_f254e985-37bd-4a41-862a-5e41ac02811c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b27564f7-ce71-4ab9-9995-c46401767d16" xlink:to="loc_srt_WeightedAverageMember_f254e985-37bd-4a41-862a-5e41ac02811c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_85446928-e8a5-4a9e-a33b-37ffeed5df42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f7faa99c-a7ca-4f1f-87ef-32b34d686777" xlink:to="loc_us-gaap_DerivativeLineItems_85446928-e8a5-4a9e-a33b-37ffeed5df42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_f4461128-d2d8-4178-8bbd-fe0370c0fa5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_85446928-e8a5-4a9e-a33b-37ffeed5df42" xlink:to="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_f4461128-d2d8-4178-8bbd-fe0370c0fa5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EstimatedFairValueOfWarrant_117c591e-32df-4f06-8be4-2bd9031dce6a" xlink:href="crdf-20200930.xsd#crdf_EstimatedFairValueOfWarrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_f4461128-d2d8-4178-8bbd-fe0370c0fa5d" xlink:to="loc_crdf_EstimatedFairValueOfWarrant_117c591e-32df-4f06-8be4-2bd9031dce6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_daee8c45-536e-4393-a414-3ddbb6953cf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_f4461128-d2d8-4178-8bbd-fe0370c0fa5d" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_daee8c45-536e-4393-a414-3ddbb6953cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_e0273be8-32c4-4aeb-938a-527b62f70095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_f4461128-d2d8-4178-8bbd-fe0370c0fa5d" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_e0273be8-32c4-4aeb-938a-527b62f70095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_2ddaa54e-9f17-4682-8f5f-848d0195ea4b" xlink:href="crdf-20200930.xsd#crdf_DerivativeFinancialInstrumentsLiabilityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_85446928-e8a5-4a9e-a33b-37ffeed5df42" xlink:to="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_2ddaa54e-9f17-4682-8f5f-848d0195ea4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9db783e9-4a78-49be-beca-30f7f0732d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_2ddaa54e-9f17-4682-8f5f-848d0195ea4b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9db783e9-4a78-49be-beca-30f7f0732d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b2c9ca1c-592f-43d5-baa4-6ce3a1959701" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_2ddaa54e-9f17-4682-8f5f-848d0195ea4b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b2c9ca1c-592f-43d5-baa4-6ce3a1959701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_1c62edc4-30bd-46ff-bf06-c05844ca74cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_2ddaa54e-9f17-4682-8f5f-848d0195ea4b" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_1c62edc4-30bd-46ff-bf06-c05844ca74cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_be0e5b19-e9e8-4b5b-9fb5-9a65b0556aba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_2ddaa54e-9f17-4682-8f5f-848d0195ea4b" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_be0e5b19-e9e8-4b5b-9fb5-9a65b0556aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_cc576bca-0aed-4ef6-84a3-ec74710de6a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_2ddaa54e-9f17-4682-8f5f-848d0195ea4b" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_cc576bca-0aed-4ef6-84a3-ec74710de6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquity" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_20fab54c-c84a-4eb1-9efd-159f40fdd753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_72cf0a3b-7d8b-420a-9f68-cfde3e4bf822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_20fab54c-c84a-4eb1-9efd-159f40fdd753" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_72cf0a3b-7d8b-420a-9f68-cfde3e4bf822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_d3a0afc5-10fc-43e0-94eb-5b2ee9f355dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_765308cc-463a-406d-ae28-78ca6f56fe75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d3a0afc5-10fc-43e0-94eb-5b2ee9f355dd" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_765308cc-463a-406d-ae28-78ca6f56fe75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_796a66ad-4d77-437e-8634-90c60c4ddc1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d3a0afc5-10fc-43e0-94eb-5b2ee9f355dd" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_796a66ad-4d77-437e-8634-90c60c4ddc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_80a5e90c-405f-43cf-836c-24d7fc27af54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d3a0afc5-10fc-43e0-94eb-5b2ee9f355dd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_80a5e90c-405f-43cf-836c-24d7fc27af54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_9f1ce3e3-d226-4574-8994-57c789da18dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d3a0afc5-10fc-43e0-94eb-5b2ee9f355dd" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_9f1ce3e3-d226-4574-8994-57c789da18dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_4ee00270-a7e7-43be-9380-59c1a3756f37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d3a0afc5-10fc-43e0-94eb-5b2ee9f355dd" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_4ee00270-a7e7-43be-9380-59c1a3756f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_3b3a6020-1ee4-4141-b942-f378f1afea3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d3a0afc5-10fc-43e0-94eb-5b2ee9f355dd" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_3b3a6020-1ee4-4141-b942-f378f1afea3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquityStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_cb1ccf86-d9f6-4acd-8ace-d3fefbb74103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3abd05f1-b4c3-4741-b53d-063fda4ece48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_cb1ccf86-d9f6-4acd-8ace-d3fefbb74103" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3abd05f1-b4c3-4741-b53d-063fda4ece48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_09f3a7cf-0331-46c8-8e12-b0ff5fae172b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3abd05f1-b4c3-4741-b53d-063fda4ece48" xlink:to="loc_us-gaap_AwardTypeAxis_09f3a7cf-0331-46c8-8e12-b0ff5fae172b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9917e0e-aefc-4b4c-82aa-6aa4cf3a9700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_09f3a7cf-0331-46c8-8e12-b0ff5fae172b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9917e0e-aefc-4b4c-82aa-6aa4cf3a9700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_686ca104-c7f5-49c3-a8e7-5ef4f9f72215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9917e0e-aefc-4b4c-82aa-6aa4cf3a9700" xlink:to="loc_us-gaap_EmployeeStockOptionMember_686ca104-c7f5-49c3-a8e7-5ef4f9f72215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_097b6316-59d1-4ad7-bdda-9eab0ac83487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3abd05f1-b4c3-4741-b53d-063fda4ece48" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_097b6316-59d1-4ad7-bdda-9eab0ac83487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_89c5ec0f-f37e-4a86-8bf1-31eed556c67b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_097b6316-59d1-4ad7-bdda-9eab0ac83487" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_89c5ec0f-f37e-4a86-8bf1-31eed556c67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_36fee6c2-fc9b-4f7b-9152-e8a270d337ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_89c5ec0f-f37e-4a86-8bf1-31eed556c67b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_36fee6c2-fc9b-4f7b-9152-e8a270d337ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_124c40b9-ce60-4289-8c0c-534074977182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_89c5ec0f-f37e-4a86-8bf1-31eed556c67b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_124c40b9-ce60-4289-8c0c-534074977182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3e6d520-56db-403b-8c6b-137030ad9c12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3abd05f1-b4c3-4741-b53d-063fda4ece48" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3e6d520-56db-403b-8c6b-137030ad9c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_195a2837-344b-4823-8eb5-8346f1bd25b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3e6d520-56db-403b-8c6b-137030ad9c12" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_195a2837-344b-4823-8eb5-8346f1bd25b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4b617ba2-df0e-4a33-92b6-db9961daff4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3e6d520-56db-403b-8c6b-137030ad9c12" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4b617ba2-df0e-4a33-92b6-db9961daff4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0e851b3d-d7bd-4823-bac1-9979463c94d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3e6d520-56db-403b-8c6b-137030ad9c12" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0e851b3d-d7bd-4823-bac1-9979463c94d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8382e983-b444-4767-a0d2-933dc6f0e6d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3e6d520-56db-403b-8c6b-137030ad9c12" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8382e983-b444-4767-a0d2-933dc6f0e6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_09e918f4-8604-4d98-85dd-6fd6ffef7bae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e3e6d520-56db-403b-8c6b-137030ad9c12" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_09e918f4-8604-4d98-85dd-6fd6ffef7bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquityStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_5da01e2f-5908-4b05-b8d2-a29aa18ee32a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57ac5cdc-d954-4dde-a850-61c054ea6a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5da01e2f-5908-4b05-b8d2-a29aa18ee32a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57ac5cdc-d954-4dde-a850-61c054ea6a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_24782df9-5bdc-469f-a720-4d3aa912d9af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57ac5cdc-d954-4dde-a850-61c054ea6a8d" xlink:to="loc_us-gaap_PlanNameAxis_24782df9-5bdc-469f-a720-4d3aa912d9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_683fae77-370d-4de0-8fbe-425be3cc4e4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_24782df9-5bdc-469f-a720-4d3aa912d9af" xlink:to="loc_us-gaap_PlanNameDomain_683fae77-370d-4de0-8fbe-425be3cc4e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityIncentivePlan2014Member_90b6e40b-1d3c-4062-8caa-1ac007d9b90b" xlink:href="crdf-20200930.xsd#crdf_EquityIncentivePlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_683fae77-370d-4de0-8fbe-425be3cc4e4d" xlink:to="loc_crdf_EquityIncentivePlan2014Member_90b6e40b-1d3c-4062-8caa-1ac007d9b90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8ba280d2-7b76-4807-990c-672f3da23571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57ac5cdc-d954-4dde-a850-61c054ea6a8d" xlink:to="loc_us-gaap_AwardTypeAxis_8ba280d2-7b76-4807-990c-672f3da23571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcea36a4-e4ef-4e05-8df7-51cc670f291b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8ba280d2-7b76-4807-990c-672f3da23571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcea36a4-e4ef-4e05-8df7-51cc670f291b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ed0ea8e4-b37d-406b-bd79-d2c29a572595" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcea36a4-e4ef-4e05-8df7-51cc670f291b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ed0ea8e4-b37d-406b-bd79-d2c29a572595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8c041d4-fb27-4276-adce-49f5cbf44676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57ac5cdc-d954-4dde-a850-61c054ea6a8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8c041d4-fb27-4276-adce-49f5cbf44676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_465194c7-5a0d-41f2-9620-abd565e24c31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8c041d4-fb27-4276-adce-49f5cbf44676" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_465194c7-5a0d-41f2-9620-abd565e24c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_33e2c8b2-b1ec-4538-956a-951f64144a51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_465194c7-5a0d-41f2-9620-abd565e24c31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_33e2c8b2-b1ec-4538-956a-951f64144a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1b5bcc82-b14e-480d-8f2e-c2d0fccc9381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_465194c7-5a0d-41f2-9620-abd565e24c31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1b5bcc82-b14e-480d-8f2e-c2d0fccc9381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9f2f2a44-f0b6-41f6-8c87-37540757396a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_465194c7-5a0d-41f2-9620-abd565e24c31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9f2f2a44-f0b6-41f6-8c87-37540757396a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fc6ff51f-0cfb-41a6-8c31-1ca3f37e1776" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_465194c7-5a0d-41f2-9620-abd565e24c31" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fc6ff51f-0cfb-41a6-8c31-1ca3f37e1776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1b8398a-20ce-4cd4-829c-568a6d35298f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8c041d4-fb27-4276-adce-49f5cbf44676" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1b8398a-20ce-4cd4-829c-568a6d35298f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1df593cb-34df-483b-9316-b708803ea492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1b8398a-20ce-4cd4-829c-568a6d35298f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1df593cb-34df-483b-9316-b708803ea492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_131ec51c-4f73-4249-84a1-8b408d4b5ced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1b8398a-20ce-4cd4-829c-568a6d35298f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_131ec51c-4f73-4249-84a1-8b408d4b5ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_de7a80bb-6a01-4cfe-8d54-10477d8622e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1b8398a-20ce-4cd4-829c-568a6d35298f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_de7a80bb-6a01-4cfe-8d54-10477d8622e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_64ab995d-04e9-4164-b48c-b871589f09ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1b8398a-20ce-4cd4-829c-568a6d35298f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_64ab995d-04e9-4164-b48c-b871589f09ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_bd08311a-25b3-4f69-8b29-ccf092a7a848" xlink:href="crdf-20200930.xsd#crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1b8398a-20ce-4cd4-829c-568a6d35298f" xlink:to="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_bd08311a-25b3-4f69-8b29-ccf092a7a848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f131ad2c-4689-4a2f-840d-6df5740a1e85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1b8398a-20ce-4cd4-829c-568a6d35298f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f131ad2c-4689-4a2f-840d-6df5740a1e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8f9bfd87-eb04-4948-bfa9-9caf79a7b783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1b8398a-20ce-4cd4-829c-568a6d35298f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8f9bfd87-eb04-4948-bfa9-9caf79a7b783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51697352-577b-4aca-857c-4c7b99bf9406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8c041d4-fb27-4276-adce-49f5cbf44676" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51697352-577b-4aca-857c-4c7b99bf9406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4d84ae21-40f8-46b1-81c7-240d39782ae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51697352-577b-4aca-857c-4c7b99bf9406" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4d84ae21-40f8-46b1-81c7-240d39782ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fee0acf7-6547-4a9e-a2da-bb882b3477c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51697352-577b-4aca-857c-4c7b99bf9406" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fee0acf7-6547-4a9e-a2da-bb882b3477c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_76362744-9010-4833-805c-3168354414e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51697352-577b-4aca-857c-4c7b99bf9406" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_76362744-9010-4833-805c-3168354414e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6a649716-dd9d-4a7e-b450-a242f5a7a83c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51697352-577b-4aca-857c-4c7b99bf9406" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6a649716-dd9d-4a7e-b450-a242f5a7a83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_29855ace-608d-4c0c-8f72-5b466d8f25f6" xlink:href="crdf-20200930.xsd#crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51697352-577b-4aca-857c-4c7b99bf9406" xlink:to="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_29855ace-608d-4c0c-8f72-5b466d8f25f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2423c1f1-b378-4e53-8c4a-da5588c8cc3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51697352-577b-4aca-857c-4c7b99bf9406" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2423c1f1-b378-4e53-8c4a-da5588c8cc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_dfe66423-dbff-4c65-8b38-faf261e24503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51697352-577b-4aca-857c-4c7b99bf9406" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_dfe66423-dbff-4c65-8b38-faf261e24503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0bd1be41-f423-4363-80cc-d5c0a65cd0cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8c041d4-fb27-4276-adce-49f5cbf44676" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0bd1be41-f423-4363-80cc-d5c0a65cd0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9a1f7ad4-83c0-44e3-a0c7-e429fe7e1ea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0bd1be41-f423-4363-80cc-d5c0a65cd0cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9a1f7ad4-83c0-44e3-a0c7-e429fe7e1ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c1d10993-ceea-4d79-b48b-525b712f34f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0bd1be41-f423-4363-80cc-d5c0a65cd0cf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c1d10993-ceea-4d79-b48b-525b712f34f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_94886018-a82f-438f-8e33-59739457e683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8c041d4-fb27-4276-adce-49f5cbf44676" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_94886018-a82f-438f-8e33-59739457e683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5ea211a4-81bc-41ab-8ebf-5494e8b5d52c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8c041d4-fb27-4276-adce-49f5cbf44676" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5ea211a4-81bc-41ab-8ebf-5494e8b5d52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquityRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2c52eea6-3582-448f-b478-c16fd667ad2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e026597c-dc52-47f6-bcde-54b96dfc7c74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2c52eea6-3582-448f-b478-c16fd667ad2f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e026597c-dc52-47f6-bcde-54b96dfc7c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d85d8f4a-021a-4649-9713-4b97770a7ea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e026597c-dc52-47f6-bcde-54b96dfc7c74" xlink:to="loc_us-gaap_AwardTypeAxis_d85d8f4a-021a-4649-9713-4b97770a7ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_010e9551-7051-4d3d-8983-45e2197073c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d85d8f4a-021a-4649-9713-4b97770a7ea5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_010e9551-7051-4d3d-8983-45e2197073c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_611caa53-2485-485d-ba40-327ffab1d490" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_010e9551-7051-4d3d-8983-45e2197073c7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_611caa53-2485-485d-ba40-327ffab1d490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c0678b7-36b1-42aa-9868-47191799c405" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e026597c-dc52-47f6-bcde-54b96dfc7c74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c0678b7-36b1-42aa-9868-47191799c405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e514da66-de0c-47d4-ade6-43a1bf441bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c0678b7-36b1-42aa-9868-47191799c405" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e514da66-de0c-47d4-ade6-43a1bf441bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2942ceef-23c4-48c6-a986-c79f9020b90f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e514da66-de0c-47d4-ade6-43a1bf441bd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2942ceef-23c4-48c6-a986-c79f9020b90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e1749556-5724-47c1-8017-ba52a5537630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e514da66-de0c-47d4-ade6-43a1bf441bd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e1749556-5724-47c1-8017-ba52a5537630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_45fa524f-32db-407b-8c72-e443da70e19e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e514da66-de0c-47d4-ade6-43a1bf441bd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_45fa524f-32db-407b-8c72-e443da70e19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5ac5b8b-baca-4dab-a9ba-08308ceb820b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c0678b7-36b1-42aa-9868-47191799c405" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5ac5b8b-baca-4dab-a9ba-08308ceb820b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_16bca7f4-3f89-4a8b-8fb4-5f01ae29e43b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5ac5b8b-baca-4dab-a9ba-08308ceb820b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_16bca7f4-3f89-4a8b-8fb4-5f01ae29e43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5541c679-7b4e-41c4-943f-d88ff4306433" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5ac5b8b-baca-4dab-a9ba-08308ceb820b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5541c679-7b4e-41c4-943f-d88ff4306433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_435ec17f-a598-444b-9b88-159d4e1d8f57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5ac5b8b-baca-4dab-a9ba-08308ceb820b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_435ec17f-a598-444b-9b88-159d4e1d8f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_bb448953-46ed-4c96-b5c9-2cca1a3ff13d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c0678b7-36b1-42aa-9868-47191799c405" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_bb448953-46ed-4c96-b5c9-2cca1a3ff13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_1c3a259a-d542-4a5a-a33c-0046c708d812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c0678b7-36b1-42aa-9868-47191799c405" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_1c3a259a-d542-4a5a-a33c-0046c708d812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ca1eba71-92df-424c-b6ec-ba58cfbcb6bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c0678b7-36b1-42aa-9868-47191799c405" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ca1eba71-92df-424c-b6ec-ba58cfbcb6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquityWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_8fd8a67f-48cf-4b05-b824-dcd58ae6fa54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e29ce4e-c998-4efb-87c2-a24c06a539b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8fd8a67f-48cf-4b05-b824-dcd58ae6fa54" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e29ce4e-c998-4efb-87c2-a24c06a539b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5ca20139-34bc-4f36-afdc-2186f94b1e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e29ce4e-c998-4efb-87c2-a24c06a539b7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5ca20139-34bc-4f36-afdc-2186f94b1e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8b866ecd-7c35-4fe7-8059-f6e5009b138b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ca20139-34bc-4f36-afdc-2186f94b1e96" xlink:to="loc_us-gaap_EquityComponentDomain_8b866ecd-7c35-4fe7-8059-f6e5009b138b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreFundedWarrantsMember_97e28edd-30ca-4ed5-8c70-74397a8d3844" xlink:href="crdf-20200930.xsd#crdf_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8b866ecd-7c35-4fe7-8059-f6e5009b138b" xlink:to="loc_crdf_PreFundedWarrantsMember_97e28edd-30ca-4ed5-8c70-74397a8d3844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06680826-8850-4b8e-b1eb-c58d7859ff8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e29ce4e-c998-4efb-87c2-a24c06a539b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06680826-8850-4b8e-b1eb-c58d7859ff8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_WarrantsAndRightsRollForward_3cba60fa-4b00-4bee-b0d2-e0a77d3034e1" xlink:href="crdf-20200930.xsd#crdf_WarrantsAndRightsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06680826-8850-4b8e-b1eb-c58d7859ff8a" xlink:to="loc_crdf_WarrantsAndRightsRollForward_3cba60fa-4b00-4bee-b0d2-e0a77d3034e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_aa69ae92-e7af-4a7d-9546-7116a8a73f4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_WarrantsAndRightsRollForward_3cba60fa-4b00-4bee-b0d2-e0a77d3034e1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_aa69ae92-e7af-4a7d-9546-7116a8a73f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightNumberGranted_5c4bc2fd-3abb-403c-8287-276bb311e5d8" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightNumberGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_WarrantsAndRightsRollForward_3cba60fa-4b00-4bee-b0d2-e0a77d3034e1" xlink:to="loc_crdf_ClassOfWarrantOrRightNumberGranted_5c4bc2fd-3abb-403c-8287-276bb311e5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightNumberExercised_5313bdd9-a82e-46f5-b7bf-a15e9cc3b9ff" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightNumberExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_WarrantsAndRightsRollForward_3cba60fa-4b00-4bee-b0d2-e0a77d3034e1" xlink:to="loc_crdf_ClassOfWarrantOrRightNumberExercised_5313bdd9-a82e-46f5-b7bf-a15e9cc3b9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_194d02ff-c97c-416d-8a24-152fa5c75327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_WarrantsAndRightsRollForward_3cba60fa-4b00-4bee-b0d2-e0a77d3034e1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_194d02ff-c97c-416d-8a24-152fa5c75327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_898d02d0-c815-4e47-8f63-36932ff83678" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06680826-8850-4b8e-b1eb-c58d7859ff8a" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_898d02d0-c815-4e47-8f63-36932ff83678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_b6a751d5-be2f-495f-a897-fcd41144f2c9" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_898d02d0-c815-4e47-8f63-36932ff83678" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_b6a751d5-be2f-495f-a897-fcd41144f2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted_cc60c827-05d6-41f8-b243-d9ccaa71b2d0" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_898d02d0-c815-4e47-8f63-36932ff83678" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted_cc60c827-05d6-41f8-b243-d9ccaa71b2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_28bfee16-472f-40f1-8fd3-287975eb21e5" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_898d02d0-c815-4e47-8f63-36932ff83678" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_28bfee16-472f-40f1-8fd3-287975eb21e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_39ee6dd1-100e-442d-8544-70e017b0b80e" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_898d02d0-c815-4e47-8f63-36932ff83678" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_39ee6dd1-100e-442d-8544-70e017b0b80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_08e8f097-d33f-42a1-a800-c861a0e7b3cc" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06680826-8850-4b8e-b1eb-c58d7859ff8a" xlink:to="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_08e8f097-d33f-42a1-a800-c861a0e7b3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_645c131f-2511-4121-9f91-084fcc364b40" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_08e8f097-d33f-42a1-a800-c861a0e7b3cc" xlink:to="loc_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights_645c131f-2511-4121-9f91-084fcc364b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquityPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e4cd1c0b-3b25-4893-b837-28d40a910d6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_58c7d11a-446a-4d9d-b53f-576a8b44ee1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e4cd1c0b-3b25-4893-b837-28d40a910d6d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_58c7d11a-446a-4d9d-b53f-576a8b44ee1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2c55cf06-3b3d-4fdb-8a93-612bfe73a382" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_58c7d11a-446a-4d9d-b53f-576a8b44ee1a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2c55cf06-3b3d-4fdb-8a93-612bfe73a382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_366652a1-5895-4c83-a7e9-3a5eb162eac1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2c55cf06-3b3d-4fdb-8a93-612bfe73a382" xlink:to="loc_us-gaap_ClassOfStockDomain_366652a1-5895-4c83-a7e9-3a5eb162eac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesAConvertiblePreferredStockMember_c53d52df-2214-498a-8239-7b795b7953f5" xlink:href="crdf-20200930.xsd#crdf_SeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_366652a1-5895-4c83-a7e9-3a5eb162eac1" xlink:to="loc_crdf_SeriesAConvertiblePreferredStockMember_c53d52df-2214-498a-8239-7b795b7953f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesBConvertiblePreferredStockMember_268de979-a4e1-43ae-9984-a61bb5ce7959" xlink:href="crdf-20200930.xsd#crdf_SeriesBConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_366652a1-5895-4c83-a7e9-3a5eb162eac1" xlink:to="loc_crdf_SeriesBConvertiblePreferredStockMember_268de979-a4e1-43ae-9984-a61bb5ce7959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_0c44383d-2808-4d3b-b000-d055173ca341" xlink:href="crdf-20200930.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_366652a1-5895-4c83-a7e9-3a5eb162eac1" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_0c44383d-2808-4d3b-b000-d055173ca341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_1610cdd4-b66a-4f67-b92d-5a6e0a8c7551" xlink:href="crdf-20200930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_366652a1-5895-4c83-a7e9-3a5eb162eac1" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_1610cdd4-b66a-4f67-b92d-5a6e0a8c7551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_dc65ba9f-67aa-4f0a-9c4d-f729940bea07" xlink:href="crdf-20200930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_366652a1-5895-4c83-a7e9-3a5eb162eac1" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_dc65ba9f-67aa-4f0a-9c4d-f729940bea07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d0dc390c-9ac9-4c10-996c-763437da8565" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_58c7d11a-446a-4d9d-b53f-576a8b44ee1a" xlink:to="loc_us-gaap_ClassOfStockLineItems_d0dc390c-9ac9-4c10-996c-763437da8565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_17914f48-cfac-4675-aefc-60992ee9720c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0dc390c-9ac9-4c10-996c-763437da8565" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_17914f48-cfac-4675-aefc-60992ee9720c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2cd061b8-b1e0-48b4-bb7d-ce2e9bdeb43f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0dc390c-9ac9-4c10-996c-763437da8565" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2cd061b8-b1e0-48b4-bb7d-ce2e9bdeb43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_20e51b08-e095-458e-9a2e-1dc51e9a8b92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0dc390c-9ac9-4c10-996c-763437da8565" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_20e51b08-e095-458e-9a2e-1dc51e9a8b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_cd27cf38-6edb-4a8b-b8e6-4e25cac835b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0dc390c-9ac9-4c10-996c-763437da8565" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_cd27cf38-6edb-4a8b-b8e6-4e25cac835b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquitySeriesCConvertiblePreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_10265544-33d8-471a-bb2d-cd4ba876bdb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_190d4ce3-d56b-4268-9860-5415345ca51d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_10265544-33d8-471a-bb2d-cd4ba876bdb4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_190d4ce3-d56b-4268-9860-5415345ca51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_096709ea-0314-442c-91b3-7d761584847d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_190d4ce3-d56b-4268-9860-5415345ca51d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_096709ea-0314-442c-91b3-7d761584847d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9fa8581a-88fa-414d-a773-dbe574024d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_096709ea-0314-442c-91b3-7d761584847d" xlink:to="loc_us-gaap_EquityComponentDomain_9fa8581a-88fa-414d-a773-dbe574024d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_943021aa-02a3-473f-b7da-b01d0bd829c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9fa8581a-88fa-414d-a773-dbe574024d72" xlink:to="loc_us-gaap_CommonStockMember_943021aa-02a3-473f-b7da-b01d0bd829c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_98a6b0d0-74c5-49c3-8048-9650105dd0b3" xlink:href="crdf-20200930.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9fa8581a-88fa-414d-a773-dbe574024d72" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_98a6b0d0-74c5-49c3-8048-9650105dd0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9903c41a-52e9-4607-bd86-96bdfb803eda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_190d4ce3-d56b-4268-9860-5415345ca51d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9903c41a-52e9-4607-bd86-96bdfb803eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4c9659bb-a3af-4cd7-b045-24c3705652b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9903c41a-52e9-4607-bd86-96bdfb803eda" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4c9659bb-a3af-4cd7-b045-24c3705652b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_75c3de15-138b-46cb-8247-cb35105853dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4c9659bb-a3af-4cd7-b045-24c3705652b5" xlink:to="loc_us-gaap_PrivatePlacementMember_75c3de15-138b-46cb-8247-cb35105853dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_58eed49f-b0f1-4a74-b659-887c55efd8d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_190d4ce3-d56b-4268-9860-5415345ca51d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_58eed49f-b0f1-4a74-b659-887c55efd8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c7f451b6-f20b-417f-8f89-11428fccc689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_58eed49f-b0f1-4a74-b659-887c55efd8d6" xlink:to="loc_us-gaap_ClassOfStockDomain_c7f451b6-f20b-417f-8f89-11428fccc689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_d6fd3f15-c9ca-410c-ab8e-3107c35ca780" xlink:href="crdf-20200930.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c7f451b6-f20b-417f-8f89-11428fccc689" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_d6fd3f15-c9ca-410c-ab8e-3107c35ca780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_190d4ce3-d56b-4268-9860-5415345ca51d" xlink:to="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AmountFinancedUnderAgreement_9c6bb36d-ddb0-4fee-83e0-32473c7f6577" xlink:href="crdf-20200930.xsd#crdf_AmountFinancedUnderAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:to="loc_crdf_AmountFinancedUnderAgreement_9c6bb36d-ddb0-4fee-83e0-32473c7f6577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0aad4c68-45b5-4ef2-80b3-8e6ace71bd2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0aad4c68-45b5-4ef2-80b3-8e6ace71bd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightNumberGranted_26cbcaff-e0fa-4df0-be59-bd56aefb36e1" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightNumberGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:to="loc_crdf_ClassOfWarrantOrRightNumberGranted_26cbcaff-e0fa-4df0-be59-bd56aefb36e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f2fedf06-4a45-4733-9dc9-61e48ca19fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f2fedf06-4a45-4733-9dc9-61e48ca19fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_bfaf944a-523f-481c-858e-9d1129d17c85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_bfaf944a-523f-481c-858e-9d1129d17c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_18eb6af3-c752-48ad-8e93-90aa32ae4637" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_18eb6af3-c752-48ad-8e93-90aa32ae4637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_b55ed622-bce0-4265-91ec-765293f6f4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_b55ed622-bce0-4265-91ec-765293f6f4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Servicereceivable_e8cfd6d3-a10c-443b-b158-05651dd28875" xlink:href="crdf-20200930.xsd#crdf_Servicereceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:to="loc_crdf_Servicereceivable_e8cfd6d3-a10c-443b-b158-05651dd28875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_0041bf87-d141-4c35-b206-0036315adc1f" xlink:href="crdf-20200930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6bc592da-485b-47f1-a86a-574050485096" xlink:to="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_0041bf87-d141-4c35-b206-0036315adc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquitySeriesDConvertiblePreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7547b087-cad8-4ef7-8008-9daca08808c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a43d0b49-84f0-4d46-901e-9333e36bbbb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7547b087-cad8-4ef7-8008-9daca08808c6" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a43d0b49-84f0-4d46-901e-9333e36bbbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_150d25a1-c2ab-45d9-9c73-1b84ac999c29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a43d0b49-84f0-4d46-901e-9333e36bbbb6" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_150d25a1-c2ab-45d9-9c73-1b84ac999c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_64be4d4c-cb1f-44d3-ba80-868a4ffd0a49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_150d25a1-c2ab-45d9-9c73-1b84ac999c29" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_64be4d4c-cb1f-44d3-ba80-868a4ffd0a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_09b85224-4827-4902-bbf2-14b939b4e0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_64be4d4c-cb1f-44d3-ba80-868a4ffd0a49" xlink:to="loc_us-gaap_PrivatePlacementMember_09b85224-4827-4902-bbf2-14b939b4e0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f5d2f421-a446-4589-bbd4-c63eefa5c1d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a43d0b49-84f0-4d46-901e-9333e36bbbb6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f5d2f421-a446-4589-bbd4-c63eefa5c1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ec97c53e-4bc1-4e92-b603-22b329739a43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f5d2f421-a446-4589-bbd4-c63eefa5c1d6" xlink:to="loc_us-gaap_EquityComponentDomain_ec97c53e-4bc1-4e92-b603-22b329739a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ec43cf57-cfca-4192-9ecf-5ec9e967c9b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ec97c53e-4bc1-4e92-b603-22b329739a43" xlink:to="loc_us-gaap_CommonStockMember_ec43cf57-cfca-4192-9ecf-5ec9e967c9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_54a46ed4-72ca-49a4-92cd-5a13a06c7e5f" xlink:href="crdf-20200930.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ec97c53e-4bc1-4e92-b603-22b329739a43" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_54a46ed4-72ca-49a4-92cd-5a13a06c7e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6267a4f2-ee73-45d2-9157-5ae042ca8ea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a43d0b49-84f0-4d46-901e-9333e36bbbb6" xlink:to="loc_us-gaap_ClassOfStockLineItems_6267a4f2-ee73-45d2-9157-5ae042ca8ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AmountFinancedUnderAgreement_75b52c68-34cf-4940-a4b1-38db40281349" xlink:href="crdf-20200930.xsd#crdf_AmountFinancedUnderAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6267a4f2-ee73-45d2-9157-5ae042ca8ea5" xlink:to="loc_crdf_AmountFinancedUnderAgreement_75b52c68-34cf-4940-a4b1-38db40281349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f5facc93-b545-4793-9cf8-e93a350b994c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6267a4f2-ee73-45d2-9157-5ae042ca8ea5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f5facc93-b545-4793-9cf8-e93a350b994c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_654a001e-97d0-4dce-be7f-62db0687cd06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6267a4f2-ee73-45d2-9157-5ae042ca8ea5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_654a001e-97d0-4dce-be7f-62db0687cd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_47cdd5d0-0a01-4bc0-8ac2-242922e8dd5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6267a4f2-ee73-45d2-9157-5ae042ca8ea5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_47cdd5d0-0a01-4bc0-8ac2-242922e8dd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_d50754f9-7b19-4b4b-a1fe-7a497f0f487b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6267a4f2-ee73-45d2-9157-5ae042ca8ea5" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_d50754f9-7b19-4b4b-a1fe-7a497f0f487b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_f788dd99-c9f1-4045-9241-4a58c9422100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6267a4f2-ee73-45d2-9157-5ae042ca8ea5" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_f788dd99-c9f1-4045-9241-4a58c9422100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Servicereceivable_2d11cddb-ec50-4034-b5ac-3767aaa6cec5" xlink:href="crdf-20200930.xsd#crdf_Servicereceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6267a4f2-ee73-45d2-9157-5ae042ca8ea5" xlink:to="loc_crdf_Servicereceivable_2d11cddb-ec50-4034-b5ac-3767aaa6cec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_ee7590d2-4144-456e-999e-f4579a7030ea" xlink:href="crdf-20200930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6267a4f2-ee73-45d2-9157-5ae042ca8ea5" xlink:to="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_ee7590d2-4144-456e-999e-f4579a7030ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquitySeriesEConvertiblePreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1449e793-ab62-40a5-b06b-f67dc3279317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_229005cc-d13c-46a4-aad8-e57f5f9e7b91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1449e793-ab62-40a5-b06b-f67dc3279317" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_229005cc-d13c-46a4-aad8-e57f5f9e7b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ae41da3e-9575-407c-868b-af6d3ae52ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_229005cc-d13c-46a4-aad8-e57f5f9e7b91" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ae41da3e-9575-407c-868b-af6d3ae52ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ed8b08b-be19-45b3-9cb4-77562adc027e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ae41da3e-9575-407c-868b-af6d3ae52ef2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ed8b08b-be19-45b3-9cb4-77562adc027e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_RegisteredDirectOfferingMember_144de2bb-b186-4ae1-8202-8b3de35253e5" xlink:href="crdf-20200930.xsd#crdf_RegisteredDirectOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ed8b08b-be19-45b3-9cb4-77562adc027e" xlink:to="loc_crdf_RegisteredDirectOfferingMember_144de2bb-b186-4ae1-8202-8b3de35253e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_181f957c-dab4-454d-bfd3-1e95c7c29b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ed8b08b-be19-45b3-9cb4-77562adc027e" xlink:to="loc_us-gaap_PrivatePlacementMember_181f957c-dab4-454d-bfd3-1e95c7c29b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c3423347-e774-4870-a4bf-7770841cccb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_229005cc-d13c-46a4-aad8-e57f5f9e7b91" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c3423347-e774-4870-a4bf-7770841cccb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cba91edf-f595-492e-bc21-5c14f9dc9ffa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c3423347-e774-4870-a4bf-7770841cccb0" xlink:to="loc_us-gaap_ClassOfStockDomain_cba91edf-f595-492e-bc21-5c14f9dc9ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_d871530a-62fa-4316-9425-fcaffa0c9584" xlink:href="crdf-20200930.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cba91edf-f595-492e-bc21-5c14f9dc9ffa" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_d871530a-62fa-4316-9425-fcaffa0c9584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_74993a6d-d7b6-48f5-8d7b-60c63eef1c65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_229005cc-d13c-46a4-aad8-e57f5f9e7b91" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_74993a6d-d7b6-48f5-8d7b-60c63eef1c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_346c8847-9899-4937-ba85-00ec95531800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_74993a6d-d7b6-48f5-8d7b-60c63eef1c65" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_346c8847-9899-4937-ba85-00ec95531800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesNWarrantMember_b097f0e2-d98a-495d-a1b2-3ac5e0c73847" xlink:href="crdf-20200930.xsd#crdf_SeriesNWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_346c8847-9899-4937-ba85-00ec95531800" xlink:to="loc_crdf_SeriesNWarrantMember_b097f0e2-d98a-495d-a1b2-3ac5e0c73847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_229005cc-d13c-46a4-aad8-e57f5f9e7b91" xlink:to="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b886136b-ec79-46a0-8d91-89435457cb4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b886136b-ec79-46a0-8d91-89435457cb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d0e1d109-b79f-4405-b4e0-601839ad6c13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d0e1d109-b79f-4405-b4e0-601839ad6c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_154ec7b6-07b5-491a-b0ae-217ffb609a1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_154ec7b6-07b5-491a-b0ae-217ffb609a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockConvertibleConversionPrice_e9bc5b0d-fe8b-46da-83aa-da03e6ebad0a" xlink:href="crdf-20200930.xsd#crdf_PreferredStockConvertibleConversionPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_crdf_PreferredStockConvertibleConversionPrice_e9bc5b0d-fe8b-46da-83aa-da03e6ebad0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_fc4ebe37-2454-440a-84cf-57348d877b7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_fc4ebe37-2454-440a-84cf-57348d877b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightMonthsUntilExercisable_44d2f767-9dc2-4d89-bb2f-0c6e43e2a725" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightMonthsUntilExercisable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_crdf_ClassOfWarrantOrRightMonthsUntilExercisable_44d2f767-9dc2-4d89-bb2f-0c6e43e2a725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5c34d0e6-c156-4978-9bf2-671458e229b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5c34d0e6-c156-4978-9bf2-671458e229b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_92b22a95-69e1-46be-8d4d-adf30b6bdf6f" xlink:href="crdf-20200930.xsd#crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_92b22a95-69e1-46be-8d4d-adf30b6bdf6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightIssued_99d877bf-2e31-4015-b1c2-5cd69c69f283" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_crdf_ClassOfWarrantOrRightIssued_99d877bf-2e31-4015-b1c2-5cd69c69f283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightExpirationTerm_9272089e-5e85-4a93-9486-81d138271b39" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightExpirationTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_crdf_ClassOfWarrantOrRightExpirationTerm_9272089e-5e85-4a93-9486-81d138271b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_WarrantsFairValue_d5949ac6-f095-42f4-bfcc-49153fc7c48a" xlink:href="crdf-20200930.xsd#crdf_WarrantsFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ce4fe731-2db7-47a1-972e-993ac8ccb498" xlink:to="loc_crdf_WarrantsFairValue_d5949ac6-f095-42f4-bfcc-49153fc7c48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#StockholdersEquitySecuritiesPurchaseAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e5a3fe70-1261-49b5-888f-811361e7b78c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4606c1ef-6df8-44af-bd35-ecafac698d05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e5a3fe70-1261-49b5-888f-811361e7b78c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4606c1ef-6df8-44af-bd35-ecafac698d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9e66a6a5-4e86-4ff2-a4a5-91b097f38bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4606c1ef-6df8-44af-bd35-ecafac698d05" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9e66a6a5-4e86-4ff2-a4a5-91b097f38bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3cbf91dd-aaab-46c6-85a0-a47c6e6bf592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9e66a6a5-4e86-4ff2-a4a5-91b097f38bdd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3cbf91dd-aaab-46c6-85a0-a47c6e6bf592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesIWarrantMember_dcd3d60f-6ad3-41e1-afb8-6d9c7b264e0e" xlink:href="crdf-20200930.xsd#crdf_SeriesIWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3cbf91dd-aaab-46c6-85a0-a47c6e6bf592" xlink:to="loc_crdf_SeriesIWarrantMember_dcd3d60f-6ad3-41e1-afb8-6d9c7b264e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesJWarrantMember_92eb7aa4-ca0e-4853-9ea0-780610cb94d8" xlink:href="crdf-20200930.xsd#crdf_SeriesJWarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3cbf91dd-aaab-46c6-85a0-a47c6e6bf592" xlink:to="loc_crdf_SeriesJWarrantMember_92eb7aa4-ca0e-4853-9ea0-780610cb94d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesKWarrantMember_2a794c6d-5e77-4a50-89cf-87b735611fb2" xlink:href="crdf-20200930.xsd#crdf_SeriesKWarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3cbf91dd-aaab-46c6-85a0-a47c6e6bf592" xlink:to="loc_crdf_SeriesKWarrantMember_2a794c6d-5e77-4a50-89cf-87b735611fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesLWarrantsMember_5948c0e8-641e-42f0-bf7b-402888fadfb8" xlink:href="crdf-20200930.xsd#crdf_SeriesLWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3cbf91dd-aaab-46c6-85a0-a47c6e6bf592" xlink:to="loc_crdf_SeriesLWarrantsMember_5948c0e8-641e-42f0-bf7b-402888fadfb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesMWarrantMember_749658ff-428e-4b75-ace6-c8f7677bd5fe" xlink:href="crdf-20200930.xsd#crdf_SeriesMWarrantMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3cbf91dd-aaab-46c6-85a0-a47c6e6bf592" xlink:to="loc_crdf_SeriesMWarrantMember_749658ff-428e-4b75-ace6-c8f7677bd5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5ab9d72b-79a8-4aa2-8bd2-f2ba11453f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4606c1ef-6df8-44af-bd35-ecafac698d05" xlink:to="loc_us-gaap_ClassOfStockLineItems_5ab9d72b-79a8-4aa2-8bd2-f2ba11453f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ee7965d7-bbf7-41de-9b6d-a59592943a55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5ab9d72b-79a8-4aa2-8bd2-f2ba11453f0a" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ee7965d7-bbf7-41de-9b6d-a59592943a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_45a3c58a-4c68-4e53-9024-b73eb05a03d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5ab9d72b-79a8-4aa2-8bd2-f2ba11453f0a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_45a3c58a-4c68-4e53-9024-b73eb05a03d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_b914f4de-223c-425d-9b26-b749409b8424" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5ab9d72b-79a8-4aa2-8bd2-f2ba11453f0a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_b914f4de-223c-425d-9b26-b749409b8424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightMonthsUntilExercisable_159e3d0d-2293-49c3-bbde-295d797146a5" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightMonthsUntilExercisable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5ab9d72b-79a8-4aa2-8bd2-f2ba11453f0a" xlink:to="loc_crdf_ClassOfWarrantOrRightMonthsUntilExercisable_159e3d0d-2293-49c3-bbde-295d797146a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8ed31533-7e4f-4a18-8119-db24839570a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5ab9d72b-79a8-4aa2-8bd2-f2ba11453f0a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8ed31533-7e4f-4a18-8119-db24839570a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightExpirationTerm_4d18f0d9-2a32-4404-a16e-d4f8ed120d56" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightExpirationTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5ab9d72b-79a8-4aa2-8bd2-f2ba11453f0a" xlink:to="loc_crdf_ClassOfWarrantOrRightExpirationTerm_4d18f0d9-2a32-4404-a16e-d4f8ed120d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5eeb9648-8342-4591-9087-4ab169c015a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5ab9d72b-79a8-4aa2-8bd2-f2ba11453f0a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5eeb9648-8342-4591-9087-4ab169c015a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_e3ca6af5-8d76-4cbf-8631-4079d903dd46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5ab9d72b-79a8-4aa2-8bd2-f2ba11453f0a" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_e3ca6af5-8d76-4cbf-8631-4079d903dd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="crdf-20200930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d4e1e791-1726-46f4-b83b-6ccfe7f76aad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a317106c-a6e3-499a-a7d9-254020ff6afc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d4e1e791-1726-46f4-b83b-6ccfe7f76aad" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a317106c-a6e3-499a-a7d9-254020ff6afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f6c71200-59a2-4399-a99e-62f8da702daa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_fee9128f-6058-4a01-b5f7-814b8ed93fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f6c71200-59a2-4399-a99e-62f8da702daa" xlink:to="loc_us-gaap_OtherCommitmentsTable_fee9128f-6058-4a01-b5f7-814b8ed93fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_01619527-06e8-4de3-b5b3-e9b257063133" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_fee9128f-6058-4a01-b5f7-814b8ed93fd8" xlink:to="loc_srt_CounterpartyNameAxis_01619527-06e8-4de3-b5b3-e9b257063133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db407c74-b1b0-451a-bf39-ace2d2536907" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_01619527-06e8-4de3-b5b3-e9b257063133" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db407c74-b1b0-451a-bf39-ace2d2536907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_NorvianoMember_50dcc4aa-45b7-4e22-8268-82f1f98ed5fc" xlink:href="crdf-20200930.xsd#crdf_NorvianoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db407c74-b1b0-451a-bf39-ace2d2536907" xlink:to="loc_crdf_NorvianoMember_50dcc4aa-45b7-4e22-8268-82f1f98ed5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis_a5864702-bb95-49fd-94f3-ad62a777f908" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_fee9128f-6058-4a01-b5f7-814b8ed93fd8" xlink:to="loc_us-gaap_NatureOfExpenseAxis_a5864702-bb95-49fd-94f3-ad62a777f908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_c6a570da-74a3-40a0-978c-71677a77339a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NatureOfExpenseAxis_a5864702-bb95-49fd-94f3-ad62a777f908" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_c6a570da-74a3-40a0-978c-71677a77339a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_f8b828ad-e816-48b6-b947-117606d97c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_c6a570da-74a3-40a0-978c-71677a77339a" xlink:to="loc_us-gaap_LicensingAgreementsMember_f8b828ad-e816-48b6-b947-117606d97c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_e984c799-4c20-4737-b7e3-96ed6899ebc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_fee9128f-6058-4a01-b5f7-814b8ed93fd8" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_e984c799-4c20-4737-b7e3-96ed6899ebc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6e395bfc-db30-414c-8cb0-740c757479e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e984c799-4c20-4737-b7e3-96ed6899ebc3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6e395bfc-db30-414c-8cb0-740c757479e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_1753ea1e-f20f-40a7-bf6e-e6b540ca3201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_e984c799-4c20-4737-b7e3-96ed6899ebc3" xlink:to="loc_us-gaap_PurchaseObligation_1753ea1e-f20f-40a7-bf6e-e6b540ca3201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="crdf-20200930.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_95feae0e-bb77-406d-9bf2-b928eb354e68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_bc0c85b8-e089-4a6e-ae7d-1c14fef2b3a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_95feae0e-bb77-406d-9bf2-b928eb354e68" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_bc0c85b8-e089-4a6e-ae7d-1c14fef2b3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_75cf876b-49a7-4c62-b1e2-f9a1ddc153e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c3c9b40e-3416-42a2-a5a5-61404569a077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_75cf876b-49a7-4c62-b1e2-f9a1ddc153e9" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c3c9b40e-3416-42a2-a5a5-61404569a077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f850d934-26e0-443f-ba29-807ca296f63c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c3c9b40e-3416-42a2-a5a5-61404569a077" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f850d934-26e0-443f-ba29-807ca296f63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0f9516ae-29a1-4f2c-8cb4-13590ca5b1a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f850d934-26e0-443f-ba29-807ca296f63c" xlink:to="loc_us-gaap_RelatedPartyDomain_0f9516ae-29a1-4f2c-8cb4-13590ca5b1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAffiliatesMember_593e8a7d-ce3d-4793-8c27-21f657285811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAffiliatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_0f9516ae-29a1-4f2c-8cb4-13590ca5b1a9" xlink:to="loc_us-gaap_OtherAffiliatesMember_593e8a7d-ce3d-4793-8c27-21f657285811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6e8c5c5c-c57b-4cef-b75a-fd87207b479b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c3c9b40e-3416-42a2-a5a5-61404569a077" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_6e8c5c5c-c57b-4cef-b75a-fd87207b479b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f5e939de-8c5a-4d30-95a6-9b6c2acddeaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6e8c5c5c-c57b-4cef-b75a-fd87207b479b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f5e939de-8c5a-4d30-95a6-9b6c2acddeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/COVID19" xlink:type="simple" xlink:href="crdf-20200930.xsd#COVID19"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/COVID19" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_b60ce5c8-f844-4c75-a195-bdd5e64be6d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_20ea1d99-a6d8-4abd-9d5f-46ae0f1f1bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_b60ce5c8-f844-4c75-a195-bdd5e64be6d1" xlink:to="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_20ea1d99-a6d8-4abd-9d5f-46ae0f1f1bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/COVID19Details" xlink:type="simple" xlink:href="crdf-20200930.xsd#COVID19Details"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/COVID19Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_90c02923-9887-4894-b235-1f6c7c403ce5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable_ec21c865-e2df-4914-9560-d751b4bbb22a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_90c02923-9887-4894-b235-1f6c7c403ce5" xlink:to="loc_us-gaap_UnusualOrInfrequentItemTable_ec21c865-e2df-4914-9560-d751b4bbb22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a8419f37-2488-4262-859b-f4fce1f1b984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_ec21c865-e2df-4914-9560-d751b4bbb22a" xlink:to="loc_us-gaap_DebtInstrumentAxis_a8419f37-2488-4262-859b-f4fce1f1b984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9f323d07-3c8f-4569-a819-85ac8415c588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a8419f37-2488-4262-859b-f4fce1f1b984" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9f323d07-3c8f-4569-a819-85ac8415c588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PaycheckProtectionProgramCARESActMember_c697dbc5-f5c7-473d-836c-c5592bf057f5" xlink:href="crdf-20200930.xsd#crdf_PaycheckProtectionProgramCARESActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9f323d07-3c8f-4569-a819-85ac8415c588" xlink:to="loc_crdf_PaycheckProtectionProgramCARESActMember_c697dbc5-f5c7-473d-836c-c5592bf057f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems_d7d42521-cdbd-4b48-9d33-e7d6e0d71028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_ec21c865-e2df-4914-9560-d751b4bbb22a" xlink:to="loc_us-gaap_UnusualOrInfrequentItemLineItems_d7d42521-cdbd-4b48-9d33-e7d6e0d71028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_ac15cbe1-c7bd-44da-853a-9cbbd71526ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_d7d42521-cdbd-4b48-9d33-e7d6e0d71028" xlink:to="loc_us-gaap_NotesPayable_ac15cbe1-c7bd-44da-853a-9cbbd71526ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3bce996e-86dd-47d6-b291-2acdf2cce346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_d7d42521-cdbd-4b48-9d33-e7d6e0d71028" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3bce996e-86dd-47d6-b291-2acdf2cce346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SubsequentEvents" xlink:type="simple" xlink:href="crdf-20200930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_5b91a847-2cdd-49d6-9a7d-87f8ee087e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_e6788e4c-c682-4b59-a52b-494369d8f8a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_5b91a847-2cdd-49d6-9a7d-87f8ee087e5d" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_e6788e4c-c682-4b59-a52b-494369d8f8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="crdf-20200930.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_c9e03083-6646-4b9a-a75d-ad12e0c1e37e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_423f8c83-3b5f-4e47-b9b6-55cbec2b67c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_c9e03083-6646-4b9a-a75d-ad12e0c1e37e" xlink:to="loc_us-gaap_SubsequentEventTable_423f8c83-3b5f-4e47-b9b6-55cbec2b67c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f31cb1ca-a5a7-4ab7-847c-06405d71d9c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_423f8c83-3b5f-4e47-b9b6-55cbec2b67c1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f31cb1ca-a5a7-4ab7-847c-06405d71d9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_98329e12-34fe-4874-8b04-4329c3279915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f31cb1ca-a5a7-4ab7-847c-06405d71d9c9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_98329e12-34fe-4874-8b04-4329c3279915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_605ef3d1-de7a-417b-882c-876bf4fdaac4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_98329e12-34fe-4874-8b04-4329c3279915" xlink:to="loc_us-gaap_SubsequentEventMember_605ef3d1-de7a-417b-882c-876bf4fdaac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2c6f1ba7-b0ed-4797-8c50-1017c119b7eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_423f8c83-3b5f-4e47-b9b6-55cbec2b67c1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2c6f1ba7-b0ed-4797-8c50-1017c119b7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43753336-4f87-462f-9cc4-5950f9ebe646" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2c6f1ba7-b0ed-4797-8c50-1017c119b7eb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43753336-4f87-462f-9cc4-5950f9ebe646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_e837bd08-281c-441a-941a-d940be0791ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43753336-4f87-462f-9cc4-5950f9ebe646" xlink:to="loc_us-gaap_OverAllotmentOptionMember_e837bd08-281c-441a-941a-d940be0791ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e12c2611-36fb-4c98-89e0-6179e659c4ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_423f8c83-3b5f-4e47-b9b6-55cbec2b67c1" xlink:to="loc_us-gaap_DebtInstrumentAxis_e12c2611-36fb-4c98-89e0-6179e659c4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0cab694c-e751-421d-bc3a-247c047b553e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e12c2611-36fb-4c98-89e0-6179e659c4ff" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0cab694c-e751-421d-bc3a-247c047b553e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PaycheckProtectionProgramCARESActMember_0ced5a1a-cd3c-414d-8d78-e8f5a5aca0c7" xlink:href="crdf-20200930.xsd#crdf_PaycheckProtectionProgramCARESActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cab694c-e751-421d-bc3a-247c047b553e" xlink:to="loc_crdf_PaycheckProtectionProgramCARESActMember_0ced5a1a-cd3c-414d-8d78-e8f5a5aca0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_3a8417f8-820e-4a87-a059-13864ee516c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_423f8c83-3b5f-4e47-b9b6-55cbec2b67c1" xlink:to="loc_us-gaap_SubsequentEventLineItems_3a8417f8-820e-4a87-a059-13864ee516c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_164c1ccd-6f15-41f8-ac8e-1c7a63e117a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3a8417f8-820e-4a87-a059-13864ee516c3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_164c1ccd-6f15-41f8-ac8e-1c7a63e117a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_b2f3e520-d840-43db-8352-82f27e8ba164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3a8417f8-820e-4a87-a059-13864ee516c3" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_b2f3e520-d840-43db-8352-82f27e8ba164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SaleOfStockConsiderationReceivedOnTransactionGross_063b4269-89c3-412b-b1f5-4c248f948067" xlink:href="crdf-20200930.xsd#crdf_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3a8417f8-820e-4a87-a059-13864ee516c3" xlink:to="loc_crdf_SaleOfStockConsiderationReceivedOnTransactionGross_063b4269-89c3-412b-b1f5-4c248f948067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_65a7ff67-199b-4042-b5c1-f4eb739311c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3a8417f8-820e-4a87-a059-13864ee516c3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_65a7ff67-199b-4042-b5c1-f4eb739311c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_3c1f1c81-9c94-4fc6-8932-ec18c30565c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3a8417f8-820e-4a87-a059-13864ee516c3" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_3c1f1c81-9c94-4fc6-8932-ec18c30565c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightNumberExercised_eeecb8cd-334a-4e0c-8951-9480c19a6eab" xlink:href="crdf-20200930.xsd#crdf_ClassOfWarrantOrRightNumberExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3a8417f8-820e-4a87-a059-13864ee516c3" xlink:to="loc_crdf_ClassOfWarrantOrRightNumberExercised_eeecb8cd-334a-4e0c-8951-9480c19a6eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_63f51e13-ffb9-408e-990f-ff03ef66c2ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3a8417f8-820e-4a87-a059-13864ee516c3" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_63f51e13-ffb9-408e-990f-ff03ef66c2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>crdf-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:crdf="http://www.cardiffoncology.com/20200930"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="crdf-20200930.xsd" xlink:type="simple"/>
    <context id="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic23a800c65404ec9a95b7240a59525a9_I20201030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2020-10-30</instant>
        </period>
    </context>
    <context id="if99a8ed180cc459681d3588755b7784f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie1f73b5fbce249928d3fd6362296a372_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if2d6ca3e50fe457a9eb38c4d29349a61_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if77d4dc67bc04941b7ea951868ce010e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i64433fb437b14e2797a35696e3126e7f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1d39276c8b7149b69b1e0641629d29d6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i63c477ad569243b4b07aafdf89f0eb4a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2f3c98f923a849c790c797406aeb0d7a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7ac167662d264ce29cc6bdaf26de9a0b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i60ddc19ccbda40389020c27451bc6aab_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3f397383420f42f49ba5adbf81294e83_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6a0e35fa886e4b33918433a1b304329c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib8c5bb2609e8479dad4e32ccd15c3b2a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i206237eca5cf411b89a567e3e300cf34_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i440ceb711f7c45eaab28660fa0a6c49c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4a1c6cfd3bf54dffbfab3dca4b84b7ce_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i355e679510824d7b8627423cf0866836_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iacd4e3fe0e164beea6824f1f787dbb03_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib8558b18d83f4b29acd586d939030fb4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i969cd75c1e19434b854579b8223eca1f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7a4d70afca204fcbbdba84e5be3dd359_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i44c0a4463d8b467eb6707129cf69494a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1aea61419554483ab22c33a2aa6fdddc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie81e092c24a3460ca593f690506ba45c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1e4e419343594d71afb1d77399f4daad_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id6962b9056174c398b78bd1a322ad590_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8e7a4e37750d41c2b7bd2a4475f50b9d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i892bb4bca35e42edb3fbf0ca66a798a4_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2a5b54961e1a408da4efa7c4a015db44_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i105b5086b9d140d382a2cf18218bbcdf_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i986c4f37b62f4001bb38dfa79cf80042_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7a78e5a7b2ff488abd9e098d74a099e8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibd6fb8040cf1408a9b85618f489130ce_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2007c264c51a44a98c0f645dc1f8ba51_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5c0977b1d8e8404aaa3b657703fb8dd5_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8c907bcbc06d4d318ec339547451ef5b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i70a77dc066834b05be99f8161e3fb65c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4334ae12820e4b96abd660da1706eef0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibaa519b044634475a9a19ebc2fdfafde_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8646b250083b422d8f1430bffcbe6b73_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6160228ffe834aa18b13f335f5d812ad_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i00b92270816642589793666319d5f182_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if5b2f533f0534d78844b49d29954c8e4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i37f5de467cd94aab8302da68767238f2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icf1a9dc0b4284431b4cef397cfcd0b83_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i179c2b18280246c8ada7c878931742fb_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if5ff2e0258b7445fb9a110a10dccadb7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic6d7f037cf0b4b8792ebe716a72da81c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6c90af801967473ab9d203d9d12c323f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4056f199424143e290a92a502f0c74a0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i249b89eeb0194442ab7d9ffdd4dc0dc1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i01fc0539599a4354836f19a58664e5a7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4aff4ec96d0b44fd96cf76b82d788da4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i54a56210ecbf42aea170e8ae37fe336e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i068dca4a9a24460485c15359caa4f37b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3585b22f6f334b64b4a9a946e0b1754f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iacde1c89795341d7a6585a9ca67ff1ef_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i68416144d86546848c61077e3daaae71_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie8388a4c16204624a7b7ce5524a8ab3d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idf7bcf08b2e0459b88c7b9896849b386_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i20ddc05282304186b85c0c5e82d9c3dc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iec08f4c1e8014a62bb515c9760634ec7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if04bc8a88dbf4923b75de662fba8bcac_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ia7f9daee734141178c3262a70ac3d9f9_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i4094a45bf8304a038d7489696b49f0ee_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ibe3da09bc10142fa86a695704e95333d_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i686b763ed80c42debf1673b939ce8436_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ie3e995f613e04a30b83a190600e73d1d_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i795f824a2e0848ec9e08218e1e384119_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i4ab978b16413492fa60c4cc6dc4f989a_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="if2b9bfad02a04a619ec5166a7e949cf7_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i1fbe7725163e40c4a4a41af38a99b6e5_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="iad21cf8f4ef74076934e4cd2f244fe43_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i869616a16b38489397727b402aca4049_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i7d83f131001e47c7b941410eeb7dfb34_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie62f103ee8e84d74b05d78ebcb684bb0_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia6408fd73dd948b2bedb47f26bd26ece_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8356a82f43e649ce8d9fc4f3bdeaf910_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2dd92383a8974c29a26c20ba1c50c24e_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="idd90d3836ae44a5288cf14214ce01d23_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i98ee69498ef64ee98c7d13fd73810b69_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i102d06ccc049420ea4a988739f4e1f5a_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0bcee1f60daa4ba798ca5869fb08d829_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i963638cbd5724619a756ba6fac98c0d7_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i40293b1c801f4325997aad38bcf3edfe_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i73a60988cd7742b186d790b4be820c3a_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i3bfc5f134f7e4fb0b0329e2e588c22d9_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i7a44d42518d247568f1e2b1a8b580163_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ida7da958772f451988cb48e47b519200_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8d0f3a37ba3f419f9e5fc2d23d7be984_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0315ca5a43e14290ba86e2502d1e7df3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1d41d866570f426f80638fbc27922861_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib2a52fc6ccc044c4b200ae25cc1f0627_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i713cb493491f49ab95402bed132c3427_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i70118ce382b54129a01f304d79e91011_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ie295404f651a43699515699a65360c65_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i6a436b27140f418b9f00effe44febb9a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i601506d900b640889cfe25c06b9517ad_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i5c512dc917a44fa4935298acc4757d46_D20201002-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-02</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="id02c2a45ee9d4832a6e43bb343c46f06_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i9ae86bd676e644578010b6922e11b5af_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id797d8f2971c433b85a9c8e933191c14_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i922cd50fe23c43afbd32e28dc822bb14_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9deeeca3150647ec9217fa02ab61c9ad_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2c1dff24e4584a7c84ebc91d6aae1001_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9b110679c7614e04bf79a89353cde89c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i14bb2d1b3ff242f28e82eda2a47f119b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iff6cc44df61b4043b78740d1bee0959b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic763b33eacc24b9da821d145ed6ebff6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if44f824383a040f084fa2c0d3ddf921b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i86a4592371ee47e585775ef7ab0a392a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5366ec380ebb435dbfde066020aa5925_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i66b2709deee64adcb18d9c2af9b4467b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i58bccc712f204dd9aa339aff63845a18_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ieb19cb296ec14221a57f41b82c172241_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3207f5a1740243bcb1976b54a554df1c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie609985fe35541f19bd9585994dad17f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1be75556eccc47a1806b67aaab547b18_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic730906a9b7146d1b973c557bc30b530_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie1fd079695bc43f594a3fe0cf305011d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i13bcac6c13f146b59174b71aabe0cc5b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i186aff4c8c0e467286405c76465b4ba0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1235b538bb13457d894f3ca7cec6739c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3da0359f941e46dfada6dc17aa275971_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3ffb8f629fcb46718f4c859a146c71fd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">crdf:AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib123867495f94547b6cb9b6106e13878_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia632870d35b34e9dbf2630ee46469e33_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i252b5a3294c7458b81a17c82715f2098_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib1791fb1fc4d4c5d9d1db0ecd2bdad61_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i16ba3ca0f0224c749930d1fc21651e07_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i90efbe055b164d5c97f3d098c16522c7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iad3f1104f4364db7ab0e9e5d2154e3b1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ieef3ac4d1b1741f39df174c71b480929_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="id831883b118a48e387be55b132ff3344_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i048344a9062f4510a9cbff0eebd42e0b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i578319d576ac40ef82ce89b1e70413e3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i30cf812ae8ab4b1fabcfb5a73eeb1c7d_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="icfd53102430c43678b9eae10ab1d3201_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="id2ccfbfb002346579e7acceabf1ee362_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i344555a942b24c73861cf579aa6c6b32_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if89380272ed24b2cbde3226e6b36b53d_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="id9154e610b334767a4b96b097661f34f_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i142d89ee985546c591160d9c6e366b3a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic6d4972e6afd4ac69b9a8f6a86fcc5fb_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ifb6ee131f889432ba4524b13c5e5ca50_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i83ac99d4b3ff4e2fb15a26aced83a7a1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if51ce0d70552424db9d6267694e4b4e3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i412c95ab862b4b7aad07c1a3835d9cb8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic64a7bb878fa4c36bcfb2c9240e8fd4c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifcd94fffab0343acb682f8189e2a383b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4f3906c2627e45ebbf6c1fd90f256031_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5a725951ef874d2f949c21c129a5effc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icd6b8b4cf5a542a297c33f23f0231c1b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0b057edf8d344b4491e948f3e69dfbe2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2deab4e6786544879aa966ac0a102502_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i55f43f9e04394c4795b66f2466f5c7a4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iade2911f07fe4bd58a7771f4d8ff5609_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5631259573e042a39f4be4eceee56516_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i87383483b52740ad89c088078af10f5e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8ecb4a9d6a954fab97ac2a9e46298476_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i959cddd1d9ca46a1ae94c9e574311f33_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i046408524fc84867a0e1a4a0d4d161cc_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia8619936082e4b66a9d9afbba2b5f205_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ida9ccce01325454aa5cdd8a070b92b32_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i892b1dd1549d490f9a6e0de63da8493e_I20190605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crdf:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-05</instant>
        </period>
    </context>
    <context id="ibcaf805475824b1c97f6e483866ff34f_I20190606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crdf:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-06</instant>
        </period>
    </context>
    <context id="i8a5cf127866f4450ba5177b5b209e29e_I20200415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crdf:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-15</instant>
        </period>
    </context>
    <context id="iabec5ed6104d47f69e84008a3df403c9_I20200416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crdf:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-16</instant>
        </period>
    </context>
    <context id="i972ffd28b08d461a8a8f34ee29c25c72_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crdf:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia0736ee7158d4ee1952c5ed8ecafc35d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia8e40e0994bb469c98f27ccf0cf198f8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icd88fd532f594f72a9d627dfe035ac48_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i57c92be504a54fbda158b82418700c3b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i85c6c9f6f5d545a68d3ccd6f9971a221_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7b1f3d6a8b304f008d1560110f698bb3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idea78c0fd4d44a8084b8b53c668496d2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i488747dd585c416195aa8719cfb75a37_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia99ee4a1746f4fe4ab0a83e29d9ebce8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie25dc1818267487abf4d33e2c6debe5c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6788da5ccc444936ac79910ced50285e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2758eaad8b58491c9ca8fda860044695_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6045af669a3745cd84ac6c08b964f8db_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i87e30ab734dd4d1c81c49063fddfc61c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i89e52a934cce4337b884a4e1340a6e33_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6a73b848ad3a456ab8efe3f435c2cc17_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5dd384648729485e814847bb936c3e19_D20190125-20190125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-25</startDate>
            <endDate>2019-01-25</endDate>
        </period>
    </context>
    <context id="i42c394bde6f545e8b27bd5ddd62298f4_D20190125-20190125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-25</startDate>
            <endDate>2019-01-25</endDate>
        </period>
    </context>
    <context id="i6306bd3082c44e75b9d4bb83e91ac1d5_I20190125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-25</instant>
        </period>
    </context>
    <context id="i9473042322684048b0e1c330a634200d_D20190125-20190125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-25</startDate>
            <endDate>2019-01-25</endDate>
        </period>
    </context>
    <context id="if90d90503a6a456396e7a7c6dd952122_I20190125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-25</instant>
        </period>
    </context>
    <context id="i39ceaeb412fa40d2948c4049aa876acc_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="ica50461d886a437e9c053eb1e77b24bf_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i1e9dce01464f42658cfd49145c156296_I20190125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2019-01-25</instant>
        </period>
    </context>
    <context id="ic492c1a7e6d541e3879728394630480b_D20190125-20190125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-25</startDate>
            <endDate>2019-01-25</endDate>
        </period>
    </context>
    <context id="i802925f6b20a4ab883a3e64399b2625e_D20200508-20200508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-08</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="iafcaa2b479f245d0bd1d92340c68caa8_D20200508-20200508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-08</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="i76014c469f9d4b79ad388b4bd5ef655f_D20200508-20200508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-08</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="i237b058632024beea09d8f721dc6c2fb_I20200508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-08</instant>
        </period>
    </context>
    <context id="if6bd6d0b8e894e96b013f0f9d4a47eb5_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4fa6df7a14994c2f9f5cf33cda5a8363_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0134e1c7efdb4726b66acda8a7eadf9b_I20200508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-08</instant>
        </period>
    </context>
    <context id="i6b91e6f08a864448b74ef428e982d96b_D20200508-20200508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-08</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="ie5c36764fe274b08925b71b22a4d62aa_D20200615-20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crdf:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="i4c6e0349b8984c0c91135effa1fe723b_D20200615-20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="i1f789e5648a44a9ebd4b303e67d1385f_I20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2020-06-15</instant>
        </period>
    </context>
    <context id="if1ab4f2aeab147b0810f2c0e9bca7283_I20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-15</instant>
        </period>
    </context>
    <context id="i5e16f37428d6480ca95ace2934d30b33_D20200615-20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesNWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="i8f44ab1b15204ed1b2aa74e76adaa3eb_I20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesNWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-15</instant>
        </period>
    </context>
    <context id="i3a1b1259103d4e9aae05e28f31feec2a_D20200615-20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="ib02c4909f8dd4c1390ce2b2d6f67d719_D20200330-20200330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-03-30</endDate>
        </period>
    </context>
    <context id="i5ec1ce35bd704b2a8bec37b6d629c0a9_I20200330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesIWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-30</instant>
        </period>
    </context>
    <context id="ifba3ba46775046ecb40386b74aace6e0_I20200330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesJWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-30</instant>
        </period>
    </context>
    <context id="i974ceaa146934ff9a98da6f12360fc49_D20200330-20200330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesJWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-03-30</endDate>
        </period>
    </context>
    <context id="ieef62941a8724a6eb7609cc6f162b59d_D20200409-20200409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-04-09</startDate>
            <endDate>2020-04-09</endDate>
        </period>
    </context>
    <context id="ibfd5397c17484e7d996cff5cd20825d2_I20200409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesKWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-09</instant>
        </period>
    </context>
    <context id="i97c8fab924224323b855bff2be4699fb_I20200409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesLWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-09</instant>
        </period>
    </context>
    <context id="i6178fac3fa4f4c6e91065959e9e43ff8_D20200409-20200409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesLWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-09</startDate>
            <endDate>2020-04-09</endDate>
        </period>
    </context>
    <context id="iae68d7d006fe4e14b9a1eeee4dd8bc44_D20200511-20200511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-05-11</startDate>
            <endDate>2020-05-11</endDate>
        </period>
    </context>
    <context id="i6ed3fc7af1634151b2096d32abc0f74d_I20200511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2020-05-11</instant>
        </period>
    </context>
    <context id="i2cca101c80a44226a89c8c35200266b8_D20200514-20200514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-05-14</startDate>
            <endDate>2020-05-14</endDate>
        </period>
    </context>
    <context id="ieda19dd800d74d44bd5230900bc96c90_I20200514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2020-05-14</instant>
        </period>
    </context>
    <context id="if100dfb4b4384fd0bb32098df385547f_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="i8617217253414190b2251159121acc8a_I20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesMWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-26</instant>
        </period>
    </context>
    <context id="i0f94e8c81c344800b60b03a24b2933a5_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesMWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="ibff09abd8c4041f78419c55803eaf58b_D20170301-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crdf:NorvianoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i24aa660d59c2466faf23e2429d2aa751_I20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crdf:NorvianoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="if25db31f1cc14bd8ad1940aa6a08ec7e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i17f7e87656404afa93a7d1e1581c3052_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i608690ce785549468033da705f15e7f0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i58ff4aad5faa4a528942057efea92b13_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9a08aa2fda7c4db799f75bc79a5a0e5b_I20200415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crdf:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-15</instant>
        </period>
    </context>
    <context id="ic032311ae02d403789f39a7132fe94f9_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="icbbee8b1f9a244e8ad1c0673daa3a0b1_D20201002-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-02</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i4884eb0a36754efda6090e87871a157e_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i2917c1b61fd347ec893f35bbe6cd7228_D20201019-20201019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crdf:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-19</startDate>
            <endDate>2020-10-19</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="lease">
        <measure>crdf:lease</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="renewal_option">
        <measure>crdf:renewal_option</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80L2ZyYWc6NWQ4NTQzMDhjMjMwNDlmMDk2YjNmNWFkNzkxMDAxMzcvdGFibGU6MDViNDk4MjJlNjZhNGM5YWEwMTJlOTNjOTRmYmYzZDIvdGFibGVyYW5nZTowNWI0OTgyMmU2NmE0YzlhYTAxMmU5M2M5NGZiZjNkMl80LTEtMS0xLTA_40125a37-4d6c-47a5-bc41-64f22422fbe8">0001213037</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80L2ZyYWc6NWQ4NTQzMDhjMjMwNDlmMDk2YjNmNWFkNzkxMDAxMzcvdGFibGU6MDViNDk4MjJlNjZhNGM5YWEwMTJlOTNjOTRmYmYzZDIvdGFibGVyYW5nZTowNWI0OTgyMmU2NmE0YzlhYTAxMmU5M2M5NGZiZjNkMl83LTEtMS0xLTA_db645fee-ee93-4e37-83da-c6fbf87a7c34">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80L2ZyYWc6NWQ4NTQzMDhjMjMwNDlmMDk2YjNmNWFkNzkxMDAxMzcvdGFibGU6MDViNDk4MjJlNjZhNGM5YWEwMTJlOTNjOTRmYmYzZDIvdGFibGVyYW5nZTowNWI0OTgyMmU2NmE0YzlhYTAxMmU5M2M5NGZiZjNkMl84LTEtMS0xLTA_5f1b863b-57f9-4174-9c3c-753b3373fa7c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80L2ZyYWc6NWQ4NTQzMDhjMjMwNDlmMDk2YjNmNWFkNzkxMDAxMzcvdGFibGU6MDViNDk4MjJlNjZhNGM5YWEwMTJlOTNjOTRmYmYzZDIvdGFibGVyYW5nZTowNWI0OTgyMmU2NmE0YzlhYTAxMmU5M2M5NGZiZjNkMl8xMi0xLTEtMS0w_d5357793-aa49-4d53-916a-a2068b227fe1">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80L2ZyYWc6NWQ4NTQzMDhjMjMwNDlmMDk2YjNmNWFkNzkxMDAxMzcvdGFibGU6MDViNDk4MjJlNjZhNGM5YWEwMTJlOTNjOTRmYmYzZDIvdGFibGVyYW5nZTowNWI0OTgyMmU2NmE0YzlhYTAxMmU5M2M5NGZiZjNkMl8xMy0xLTEtMS0w_d4b1f678-8004-448b-b370-7050fa380d32">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGV4dHJlZ2lvbjo2ZjliYTBiODgwNGY0OGE1YWE4MTBjZDM2YmRkNmE1OV8xODY0_3f46f769-611e-4634-88bb-c6d834f008a2">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6MGYyNDA4ZmNmZGM3NGQ2Y2JlNjg3NTlmOGU3ZGQ1ZDEvdGFibGVyYW5nZTowZjI0MDhmY2ZkYzc0ZDZjYmU2ODc1OWY4ZTdkZDVkMV8wLTAtMS0xLTA_f5a8acf9-104d-4984-9091-d1ac94afce12">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGV4dHJlZ2lvbjo2ZjliYTBiODgwNGY0OGE1YWE4MTBjZDM2YmRkNmE1OV8xMzg_0a38ff2c-4caf-49dc-83ba-88d3670552e1">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6MmY1NDBhMWEzNTFmNGI2YTk0MzI2MTJhODc3MzYyNGMvdGFibGVyYW5nZToyZjU0MGExYTM1MWY0YjZhOTQzMjYxMmE4NzczNjI0Y18wLTAtMS0xLTA_be7aa431-516b-4d22-a5ce-55c566f3dd33">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGV4dHJlZ2lvbjo2ZjliYTBiODgwNGY0OGE1YWE4MTBjZDM2YmRkNmE1OV8xODY1_bb6006e1-77a4-4319-9a09-d89738a33353">001-35558</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGV4dHJlZ2lvbjo2ZjliYTBiODgwNGY0OGE1YWE4MTBjZDM2YmRkNmE1OV8xODYw_c0b91d2b-6348-4e04-8ae3-8522543078c8">CARDIFF ONCOLOGY,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6YTdkMmZkMGZkNWNhNDMxYmFlMTE5YWI5MjdlY2U0ZjIvdGFibGVyYW5nZTphN2QyZmQwZmQ1Y2E0MzFiYWUxMTlhYjkyN2VjZTRmMl8wLTAtMS0xLTA_1bcd50ba-4772-4c4c-80cd-86ce0957bebc">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6YTdkMmZkMGZkNWNhNDMxYmFlMTE5YWI5MjdlY2U0ZjIvdGFibGVyYW5nZTphN2QyZmQwZmQ1Y2E0MzFiYWUxMTlhYjkyN2VjZTRmMl8wLTItMS0xLTA_76af0fb9-6c7b-4446-bbdd-7b12c013e0c5">27-2004382</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6YTdkMmZkMGZkNWNhNDMxYmFlMTE5YWI5MjdlY2U0ZjIvdGFibGVyYW5nZTphN2QyZmQwZmQ1Y2E0MzFiYWUxMTlhYjkyN2VjZTRmMl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpjNWU2ODVhNzkyNzY0YzI2OWUwMWRjMWE3ZTFmMGVkZV80_60f9d3a0-59c2-461e-998d-7ef7df1ad9fe">11055 Flintkote Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6YTdkMmZkMGZkNWNhNDMxYmFlMTE5YWI5MjdlY2U0ZjIvdGFibGVyYW5nZTphN2QyZmQwZmQ1Y2E0MzFiYWUxMTlhYjkyN2VjZTRmMl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpjNWU2ODVhNzkyNzY0YzI2OWUwMWRjMWE3ZTFmMGVkZV84_72348bf7-55c0-49c7-b110-fe9f09851c9b">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6YTdkMmZkMGZkNWNhNDMxYmFlMTE5YWI5MjdlY2U0ZjIvdGFibGVyYW5nZTphN2QyZmQwZmQ1Y2E0MzFiYWUxMTlhYjkyN2VjZTRmMl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpjNWU2ODVhNzkyNzY0YzI2OWUwMWRjMWE3ZTFmMGVkZV8xMg_3ac26502-021f-460d-86db-ed6c109901cd">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6YTdkMmZkMGZkNWNhNDMxYmFlMTE5YWI5MjdlY2U0ZjIvdGFibGVyYW5nZTphN2QyZmQwZmQ1Y2E0MzFiYWUxMTlhYjkyN2VjZTRmMl8zLTItMS0xLTA_e70b6266-5208-43bd-881c-c2cb0803db88">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6YTdkMmZkMGZkNWNhNDMxYmFlMTE5YWI5MjdlY2U0ZjIvdGFibGVyYW5nZTphN2QyZmQwZmQ1Y2E0MzFiYWUxMTlhYjkyN2VjZTRmMl82LTAtMS0xLTAvdGV4dHJlZ2lvbjpiMjQzMmYyZGQyMzg0MmIyOTEwYTlmMjA0NGQ2NzU3Yl81_b3166f97-f1d4-4ee3-b266-26a12c4af748">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6YTdkMmZkMGZkNWNhNDMxYmFlMTE5YWI5MjdlY2U0ZjIvdGFibGVyYW5nZTphN2QyZmQwZmQ1Y2E0MzFiYWUxMTlhYjkyN2VjZTRmMl82LTAtMS0xLTAvdGV4dHJlZ2lvbjpiMjQzMmYyZGQyMzg0MmIyOTEwYTlmMjA0NGQ2NzU3Yl85_74cb4d0f-8f95-45be-952b-04385dd98ced">952-7570</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6MDg2MzZiY2M4ZmU4NGRhNjlhMTFjNjM0ZWUxMWUwZjAvdGFibGVyYW5nZTowODYzNmJjYzhmZTg0ZGE2OWExMWM2MzRlZTExZTBmMF8xLTAtMS0xLTA_a2364e60-3762-49e1-8628-32552b79dc2b">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6MDg2MzZiY2M4ZmU4NGRhNjlhMTFjNjM0ZWUxMWUwZjAvdGFibGVyYW5nZTowODYzNmJjYzhmZTg0ZGE2OWExMWM2MzRlZTExZTBmMF8xLTItMS0xLTA_a5ae9a3c-14fa-43f3-9082-d06044d3cefc">CRDF</dei:TradingSymbol>
    <dei:EntityCurrentReportingStatus
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGV4dHJlZ2lvbjo2ZjliYTBiODgwNGY0OGE1YWE4MTBjZDM2YmRkNmE1OV8xODYx_4b8c770a-bbf5-48e6-8cc6-6a12a7ac1dd3">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGV4dHJlZ2lvbjo2ZjliYTBiODgwNGY0OGE1YWE4MTBjZDM2YmRkNmE1OV8xODYy_3562cbbe-fd20-41a2-b3ad-0cec803b477b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6OTQ2YTNjZjViNDVlNDUxMjk4ZDc3ZGQ3YTY2YjE4MTUvdGFibGVyYW5nZTo5NDZhM2NmNWI0NWU0NTEyOThkNzdkZDdhNjZiMTgxNV8wLTQtMS0xLTAvdGV4dHJlZ2lvbjozMjY5NDNkYjJlMDk0N2Q2YjNiYTA1MTM0YjQ3ZTI5M180_75221fc8-ba54-46dd-8c58-910ec2078782">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6OTQ2YTNjZjViNDVlNDUxMjk4ZDc3ZGQ3YTY2YjE4MTUvdGFibGVyYW5nZTo5NDZhM2NmNWI0NWU0NTEyOThkNzdkZDdhNjZiMTgxNV8wLTYtMS0xLTAvdGV4dHJlZ2lvbjo1YzUyNzdjNjNlOTU0MDhmOTFlN2Y3NmY3ZDJhMjcxM18zMA_7d9f1d51-6c7f-4981-890b-3c7535702244">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGFibGU6OTQ2YTNjZjViNDVlNDUxMjk4ZDc3ZGQ3YTY2YjE4MTUvdGFibGVyYW5nZTo5NDZhM2NmNWI0NWU0NTEyOThkNzdkZDdhNjZiMTgxNV8wLTgtMS0xLTAvdGV4dHJlZ2lvbjowMDlmMDFhZjIwYjQ0YmY1OWNlNDMyNzBlNGFjZmU4Yl8yOA_e6690835-0917-4eff-9675-451abdbf700c">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGV4dHJlZ2lvbjo2ZjliYTBiODgwNGY0OGE1YWE4MTBjZDM2YmRkNmE1OV8xODYz_10e34622-46bb-4cb7-9a72-d250bb343fab">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic23a800c65404ec9a95b7240a59525a9_I20201030"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xL2ZyYWc6NmY5YmEwYjg4MDRmNDhhNWFhODEwY2QzNmJkZDZhNTkvdGV4dHJlZ2lvbjo2ZjliYTBiODgwNGY0OGE1YWE4MTBjZDM2YmRkNmE1OV8xODA4_2573e1c1-42e5-41e7-9ef2-540bc21db5c5"
      unitRef="shares">35324607</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMy0xLTEtMS0w_020cfc48-c5b3-471f-9194-860a94515924"
      unitRef="usd">36405432</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMy0zLTEtMS0w_3c23091f-855b-4c70-824f-aeda0642f323"
      unitRef="usd">10195292</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfNC0xLTEtMS0w_89984d52-f823-42ec-ae16-a7cae8223fdf"
      unitRef="usd">204366</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfNC0zLTEtMS0w_cffdcd99-e6b2-4260-87b3-51fb6d779904"
      unitRef="usd">203480</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfNS0xLTEtMS0w_8129cbb5-fbc0-4c02-8d34-b30cdb2921b4"
      unitRef="usd">1578859</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfNS0zLTEtMS0w_3f6eb429-0b4c-40dd-ad4e-b7276822ef45"
      unitRef="usd">954957</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfNi0xLTEtMS0w_1c36d3fe-ba78-4a7d-aaed-835e280d53e5"
      unitRef="usd">38188657</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfNi0zLTEtMS0w_85663a25-2b9e-4da0-899b-417c5d78b872"
      unitRef="usd">11353729</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfNy0xLTEtMS0w_9d4bc052-592c-4899-890c-65d99ec6eaae"
      unitRef="usd">682859</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfNy0zLTEtMS0w_d792d098-2312-4009-b360-799d6217454e"
      unitRef="usd">877823</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfOC0xLTEtMS0w_c425ddd8-c5af-490b-b76c-09bec6a216e8"
      unitRef="usd">423163</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfOC0zLTEtMS0w_e4f312ce-e189-4865-825f-ab1f02937cdf"
      unitRef="usd">697418</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfOS0xLTEtMS0w_0105e7a4-791a-4709-8bd6-c53c8a2f8942"
      unitRef="usd">155770</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfOS0zLTEtMS0w_c3d8cc55-ba84-4a21-bca5-da06d21acb2e"
      unitRef="usd">157576</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTAtMS0xLTEtMA_e3e04ec4-a3ef-4aab-8d27-6bb82658cf52"
      unitRef="usd">39450449</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTAtMy0xLTEtMA_1e22f284-e525-4c2d-b6db-aa8e947cd24e"
      unitRef="usd">13086546</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTQtMS0xLTEtMA_b0413ec9-ac54-4648-8f5c-a4bcca3cb608"
      unitRef="usd">610236</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTQtMy0xLTEtMA_b46df5c1-3462-43e6-ad9b-11f426d31aae"
      unitRef="usd">656304</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTUtMS0xLTEtMA_879e74b5-9c3d-4aa2-833d-02bdad82c893"
      unitRef="usd">3643300</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTUtMy0xLTEtMA_3bca3fb5-7818-4965-a22e-840dbbc18e35"
      unitRef="usd">3260061</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTYtMS0xLTEtMA_fa6f9b09-22b1-4fc8-bfbf-7ef6a827ac7a"
      unitRef="usd">305000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTYtMy0xLTEtMA_5ad0842e-6354-4405-b76c-674e825a190e"
      unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTctMS0xLTEtMA_21540351-46e1-4ce9-a57f-1b42bbefe6cb"
      unitRef="usd">883534</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTctMy0xLTEtMA_3ccd2d9b-1ddb-4273-a1ba-da442dee3a83"
      unitRef="usd">865379</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTktMS0xLTEtMA_b7eaaf21-2fc0-4110-b154-311058f770d0"
      unitRef="usd">5442070</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMTktMy0xLTEtMA_efdda2e9-5379-4729-9a35-c9056f43e588"
      unitRef="usd">4781744</us-gaap:LiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMjAtMS0xLTEtMA_d2e01387-015b-4479-a02a-521cef88b8bd"
      unitRef="usd">190199</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMjAtMy0xLTEtMA_e53ad50c-82a4-4f4d-ad20-f5a3faee55ce"
      unitRef="usd">4127</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMjItMS0xLTEtMA_984da937-bfe7-43bd-ba6d-4f0b5deb477d"
      unitRef="usd">207178</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMjItMy0xLTEtMA_e68b7a12-2f97-4404-b0c1-4fc0a490034a"
      unitRef="usd">860963</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMjQtMS0xLTEtMA_ce8f3441-ed4f-4f05-bf08-7134ae1b41ad"
      unitRef="usd">88452</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMjQtMy0xLTEtMA_8f0733cf-4d73-4d0f-aa05-93ebfb6b835d"
      unitRef="usd">128368</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMjUtMS0xLTEtMA_80b3bfa2-858d-42da-b8ae-9f2df30331ec"
      unitRef="usd">5927899</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMjUtMy0xLTEtMA_894cb7ee-3dce-4278-bc0d-0777870ed555"
      unitRef="usd">5775202</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMjctMS0xLTEtMA_66a6c99d-3c36-4994-9fbd-ab93a92623ef"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMjctMy0xLTEtMA_1cb526e2-74a1-4cf3-ae9b-52b0cd727931"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmUyMTc2NDE2OGFjOTQzYzE4YjBmNDM5MzNiZmRhYzEzXzIx_6c1bdc6a-a705-46b9-902b-69cb0f830c53"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmUyMTc2NDE2OGFjOTQzYzE4YjBmNDM5MzNiZmRhYzEzXzIx_daa393b1-2c02-4717-84ee-0ea60106f8b6"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzAtMS0xLTEtMA_40bd6981-99b7-4b80-9890-be538ce33770"
      unitRef="usd">926</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzAtMy0xLTEtMA_16873f02-7748-4c80-98db-5d1472cbf1c1"
      unitRef="usd">60</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBjMThiYzk0OTRmMDQxNmY5Y2I3ZjQzYzMwOGQ1YTljXzE5_98f7f002-6610-44d8-849e-67d7136bb48a"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBjMThiYzk0OTRmMDQxNmY5Y2I3ZjQzYzMwOGQ1YTljXzE5_9bfa225f-f4f5-4771-ad5d-0c83948af2a4"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBjMThiYzk0OTRmMDQxNmY5Y2I3ZjQzYzMwOGQ1YTljXzMz_8b02efd1-cd98-41e1-9835-ea31ef8af8cd"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBjMThiYzk0OTRmMDQxNmY5Y2I3ZjQzYzMwOGQ1YTljXzMz_edd5df38-460d-4da5-b908-29733c18f83a"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBjMThiYzk0OTRmMDQxNmY5Y2I3ZjQzYzMwOGQ1YTljXzU1_9b5e30bc-0ba5-4318-bbad-316c5bd85aeb"
      unitRef="shares">26285743</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBjMThiYzk0OTRmMDQxNmY5Y2I3ZjQzYzMwOGQ1YTljXzU1_f41f5180-e47a-4d25-8b06-7edc918af62c"
      unitRef="shares">26285743</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBjMThiYzk0OTRmMDQxNmY5Y2I3ZjQzYzMwOGQ1YTljXzYy_66964b14-1db8-41f2-8853-674b1ca47b64"
      unitRef="shares">8593633</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBjMThiYzk0OTRmMDQxNmY5Y2I3ZjQzYzMwOGQ1YTljXzYy_a5b84f57-527b-42fd-abf9-4adc60c77bfb"
      unitRef="shares">8593633</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzEtMS0xLTEtMA_91d42959-a00e-4427-a81c-b3c65bd9edfa"
      unitRef="usd">10081</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzEtMy0xLTEtMA_c02399eb-d1dd-4f7a-9726-0600686d24ba"
      unitRef="usd">8312</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzItMS0xLTEtMA_66d791bc-13ab-4526-82d4-42b110e0b61a"
      unitRef="usd">260807295</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzItMy0xLTEtMA_cb3072aa-81f2-4277-9663-0026e7eb1bf3"
      unitRef="usd">217172528</us-gaap:AdditionalPaidInCapital>
    <crdf:Servicereceivable
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzMtMS0xLTEtMA_b5d84ed2-16d6-4d91-b283-b04befdd67f3"
      unitRef="usd">2403580</crdf:Servicereceivable>
    <crdf:Servicereceivable
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzMtMy0xLTEtMA_e592a2f2-044c-483a-81ba-ef2bb3fafa3e"
      unitRef="usd">971673</crdf:Servicereceivable>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzQtMS0xLTEtMA_ca0f882d-1d3c-4161-b568-ef0b56be7a8a"
      unitRef="usd">-224892172</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzQtMy0xLTEtMA_3f75610e-19ee-4659-bfd8-769fef98d9e0"
      unitRef="usd">-208897883</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzUtMS0xLTEtMA_7075879d-aa31-49eb-a904-0d109a36a81b"
      unitRef="usd">33522550</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzUtMy0xLTEtMA_87c4f00c-4838-40d3-ba9e-dc7d50e44742"
      unitRef="usd">7311344</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzYtMS0xLTEtMA_cee6a17c-b62e-4521-9859-8621ed921286"
      unitRef="usd">39450449</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8xNi9mcmFnOmNiNzUzMDRmNjk1OTQ1ZjU4YjcyMjczMWM0ZTQ0MzY4L3RhYmxlOmFiMGI0MzU1MWE5NTQwNDBhMzk4ZmE3MTc0ZjdjYWEzL3RhYmxlcmFuZ2U6YWIwYjQzNTUxYTk1NDA0MGEzOThmYTcxNzRmN2NhYTNfMzYtMy0xLTEtMA_2d3110df-f44b-4b0b-8e81-2dac140af974"
      unitRef="usd">13086546</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMy0xLTEtMS0w_10fdabf0-0536-4279-9ca5-57d3e1e73d95"
      unitRef="usd">136401</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMy0zLTEtMS0w_43fb2993-4c8a-49b5-a0cf-919e0fc3fcf0"
      unitRef="usd">51687</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMy01LTEtMS0w_b555ed6b-0934-4453-8c14-6438c7c3bf18"
      unitRef="usd">246738</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMy03LTEtMS0w_d80e93ab-548b-4e52-8091-30f6528d9724"
      unitRef="usd">150560</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfNC0xLTEtMS0w_916a96e4-68f0-4515-a790-dacb979d6cc9"
      unitRef="usd">0</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfNC0zLTEtMS0w_e9ab7753-6807-4466-b433-a65a4dd07e16"
      unitRef="usd">0</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfNC01LTEtMS0w_da21cd75-cb09-4696-abe8-e6192864a46b"
      unitRef="usd">0</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfNC03LTEtMS0w_2579de74-51ab-4795-8754-07356573a536"
      unitRef="usd">1495</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfNS0xLTEtMS0w_af6f7c4e-bbb4-4460-b2c6-6fc60aa41f97"
      unitRef="usd">136401</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfNS0zLTEtMS0w_b644110a-4e6a-4acc-ad85-741b825b3401"
      unitRef="usd">51687</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfNS01LTEtMS0w_8767ea6b-5653-4f1a-9495-14d4aea3139f"
      unitRef="usd">246738</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfNS03LTEtMS0w_3f66c64b-3877-4990-9921-575517a890c4"
      unitRef="usd">152055</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfOC0xLTEtMS0w_b1cc103d-d96f-4517-874b-6e2dc85d75b9"
      unitRef="usd">2854812</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfOC0zLTEtMS0w_b66b22fb-a470-4f6e-a0f1-0760081e3532"
      unitRef="usd">2818824</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfOC01LTEtMS0w_8a5e0fa6-30fa-404a-a18d-1ba20c740bcc"
      unitRef="usd">8036225</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfOC03LTEtMS0w_dca9d5df-6710-4b16-b3b9-f66125b030ca"
      unitRef="usd">8297763</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfOS0xLTEtMS0w_144802a8-3b90-4b79-a7d6-3a3d05079ac9"
      unitRef="usd">1644211</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfOS0zLTEtMS0w_45acc83c-f8bc-4f44-9a9b-3ad18537fa46"
      unitRef="usd">1440339</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfOS01LTEtMS0w_2627ff96-38d0-4772-98a0-e19cb752d75a"
      unitRef="usd">4799457</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfOS03LTEtMS0w_0396556d-55c6-4169-88fd-dff10307c2af"
      unitRef="usd">4243490</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTItMS0xLTEtMA_f001389a-e845-4bf5-bdaa-4dda3f1c68f5"
      unitRef="usd">4499023</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTItMy0xLTEtMA_86da6b3b-8441-4000-9822-5239d1b8181b"
      unitRef="usd">4259163</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTItNS0xLTEtMA_69b3c4f7-b954-4872-a318-b34d92dde7ee"
      unitRef="usd">12835682</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTItNy0xLTEtMA_3431aa82-9d0d-40c4-adec-2b58de9448b3"
      unitRef="usd">12541253</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTQtMS0xLTEtMA_276c5f61-1cd6-4b3b-84f6-b1c6aab0eca5"
      unitRef="usd">-4362622</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTQtMy0xLTEtMA_df604be0-3059-4d5b-979a-a5552a1d5c5b"
      unitRef="usd">-4207476</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTQtNS0xLTEtMA_2b28f540-2523-4c37-bf53-e8534f70fe3a"
      unitRef="usd">-12588944</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTQtNy0xLTEtMA_ee887822-4d02-41e3-97a5-8151119569a4"
      unitRef="usd">-12389198</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTYtMS0xLTEtMA_7104c953-1d32-4e35-8fd6-44ec17c4b08c"
      unitRef="usd">15864</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTYtMy0xLTEtMA_b37de085-e8cd-44e1-a87f-0cfccebd56f1"
      unitRef="usd">53700</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTYtNS0xLTEtMA_6cda0b76-1844-45ab-8014-a858bafbb3db"
      unitRef="usd">67358</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTYtNy0xLTEtMA_c360f246-85b0-4eaa-a5cd-55e1809fd0fd"
      unitRef="usd">188204</us-gaap:InterestIncomeOperating>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTgtMS0xLTEtMA_1c2b2f85-48eb-42f4-a8d8-bd0a6aa47f00"
      unitRef="usd">-144035</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTgtMy0xLTEtMA_97da3d28-6c90-4808-ab28-c783cc4dfa81"
      unitRef="usd">13330</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTgtNS0xLTEtMA_84b294f9-6ee8-42f7-b5de-e31b31378054"
      unitRef="usd">-186072</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMTgtNy0xLTEtMA_a32181a4-10a9-47d6-b2eb-a95627b7f877"
      unitRef="usd">27359</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjAtMS0xLTEtMA_6ef71712-4d4e-45e3-a35f-4d698a5660b3"
      unitRef="usd">-5738</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjAtMy0xLTEtMA_9c11a798-8ca0-4537-8892-c96e54f0cb24"
      unitRef="usd">-1103</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjAtNS0xLTEtMA_cd221f8b-4dd5-4807-9c73-892692443c5f"
      unitRef="usd">-1967</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjAtNy0xLTEtMA_d66eefee-73b5-49f5-8d6a-fdd9710febc0"
      unitRef="usd">2012</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjEtMS0xLTEtMA_dffc0d9a-6030-4bed-9de1-1d07def27c97"
      unitRef="usd">-4496531</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjEtMy0xLTEtMA_0a08f6e7-8d17-4c9b-a2a0-727140d8d78c"
      unitRef="usd">-4141549</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjEtNS0xLTEtMA_72839286-a363-462f-a25c-9478a8e6021f"
      unitRef="usd">-12709625</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjEtNy0xLTEtMA_54545e13-da0c-4aba-81f3-a9bf9d6dc84a"
      unitRef="usd">-12171623</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjMtMS0xLTEtMA_fb380ebf-20a1-4d79-bd7c-92fbc8f83821"
      unitRef="usd">6060</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjMtMy0xLTEtMA_c3ab970d-2d47-49e3-934f-125d8693becb"
      unitRef="usd">6060</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjMtNS0xLTEtMA_3e4188b6-2939-4507-8371-bc10286d3a80"
      unitRef="usd">18180</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjMtNy0xLTEtMA_7f325bd6-9b10-43bf-9429-c62a856e0a40"
      unitRef="usd">18180</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="if2d6ca3e50fe457a9eb38c4d29349a61_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjUtMS0xLTEtMA_06b5d1e8-6786-4733-91a9-e706fb115f0d"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="if77d4dc67bc04941b7ea951868ce010e_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjUtMy0xLTEtMA_f186101d-100c-4c56-84ad-91be759c500b"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i64433fb437b14e2797a35696e3126e7f_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjUtNS0xLTEtMA_f52621aa-d929-4d09-ab11-9804cd2f5b87"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i1d39276c8b7149b69b1e0641629d29d6_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjUtNy0xLTEtMA_a3fad938-5eec-4d20-b087-19affcebb47a"
      unitRef="usd">268269</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i63c477ad569243b4b07aafdf89f0eb4a_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjYtMS0xLTEtMA_101193ab-b128-45c0-b976-76a008d11754"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i2f3c98f923a849c790c797406aeb0d7a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjYtMy0xLTEtMA_eec397d9-7f61-4717-91a8-ff60cde0549c"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i7ac167662d264ce29cc6bdaf26de9a0b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjYtNS0xLTEtMA_b8286bd8-ce07-49d3-a189-f24fb14dca8e"
      unitRef="usd">601767</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i60ddc19ccbda40389020c27451bc6aab_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjYtNy0xLTEtMA_6ac0a4e3-61c8-424d-a8de-e1f211939923"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i3f397383420f42f49ba5adbf81294e83_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjctMS0xLTEtMA_2a8f035a-cd20-406b-9bae-ba452be50f91"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i6a0e35fa886e4b33918433a1b304329c_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjctMy0xLTEtMA_692036e1-11c1-435c-a57f-d7c9f19bb237"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="ib8c5bb2609e8479dad4e32ccd15c3b2a_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjctNS0xLTEtMA_843daf3b-b310-4513-939f-d46c5662dd73"
      unitRef="usd">2664717</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i206237eca5cf411b89a567e3e300cf34_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjctNy0xLTEtMA_62ebc515-b1aa-4faa-8571-ba63e953b24c"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjktMS0xLTEtMA_950a49fe-a5d4-4878-95a5-6424e50a4b39"
      unitRef="usd">-4502591</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjktMy0xLTEtMA_65c2d2a1-7f51-450b-b1cf-6ba3a0a0efb5"
      unitRef="usd">-4147609</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjktNS0xLTEtMA_cfdfcd76-3e4d-4657-9764-4682d6568959"
      unitRef="usd">-15994289</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMjktNy0xLTEtMA_69e4ca27-d484-4e4e-94da-ac935490b08d"
      unitRef="usd">-12458072</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMzEtMS0xLTEtMA_4037322e-6773-420c-9a81-e90136248bdb"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMzEtMy0xLTEtMA_801f0d55-cb88-4f41-8b83-bc0c12baf3a2"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMzEtNS0xLTEtMA_b9e50df9-c1b3-4e2c-9874-39a426ef3d77"
      unitRef="usdPerShare">-1.00</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMzEtNy0xLTEtMA_19160ee6-d17c-4b4c-bbae-915723dff06f"
      unitRef="usdPerShare">-2.40</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMzQtMS0xLTEtMA_a1fae025-478b-494c-a747-5bb4c7e8a8d3"
      unitRef="shares">23341218</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMzQtMy0xLTEtMA_a46de72b-8618-4312-a058-893a76f987d0"
      unitRef="shares">6024679</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMzQtNS0xLTEtMA_a0cdc9e3-370a-4725-9923-79aac143eee8"
      unitRef="shares">15941665</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yMi9mcmFnOjJlNjFhZjZjZjUxZDQxZjU4YmU2NDFmZDMyZGQ3MDk0L3RhYmxlOmJlZmI2NDE0NDBmZTQ1ZDdhNzljOWYwMDJkYWQ0NDk0L3RhYmxlcmFuZ2U6YmVmYjY0MTQ0MGZlNDVkN2E3OWM5ZjAwMmRhZDQ0OTRfMzQtNy0xLTEtMA_2a62c5a5-c38c-4976-ae21-aeca5d44281d"
      unitRef="shares">5180221</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="i440ceb711f7c45eaab28660fa0a6c49c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMS0xLTEtMS0w_9940ac53-b2a2-4e46-a6af-b4674a4abd20"
      unitRef="shares">60600</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i440ceb711f7c45eaab28660fa0a6c49c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMS0zLTEtMS0w_65494afa-6bfa-4e9c-b469-1f2ca43b48ff"
      unitRef="usd">60</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i4a1c6cfd3bf54dffbfab3dca4b84b7ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMS01LTEtMS0w_730f4f7c-33d6-44a0-a511-c164034c72a2"
      unitRef="shares">8593633</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i4a1c6cfd3bf54dffbfab3dca4b84b7ce_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMS03LTEtMS0w_6303b0ea-c9bc-4099-a5fd-12d842a1bde0"
      unitRef="usd">8312</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i355e679510824d7b8627423cf0866836_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMS05LTEtMS0w_05c2399f-f542-47e7-b6df-f342644ceb1e"
      unitRef="usd">217172528</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iacd4e3fe0e164beea6824f1f787dbb03_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMS0xMS0xLTEtMA_73c24bcd-8646-4a0a-86e4-28290acc1b7a"
      unitRef="usd">-971673</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib8558b18d83f4b29acd586d939030fb4_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMS0xMy0xLTEtMA_54492993-0ffc-4153-8c87-a2bc012e5787"
      unitRef="usd">-208897883</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMS0xNS0xLTEtMA_8ab8189f-df66-4d6e-bd0a-cb055f0ccb2d"
      unitRef="usd">7311344</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i969cd75c1e19434b854579b8223eca1f_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMi05LTEtMS0w_e06b335b-1005-4246-835e-e9dd4491e0c6"
      unitRef="usd">177309</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7a4d70afca204fcbbdba84e5be3dd359_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMi0xNS0xLTEtMA_3905dbb1-e334-41ce-b892-1f3c1a78499f"
      unitRef="usd">177309</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <crdf:SaleOfStockCommonAndWarrantsNetShares
      contextRef="i44c0a4463d8b467eb6707129cf69494a_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMy01LTEtMS0w_f53cadf9-ecc1-4102-aeed-89786d894feb"
      unitRef="shares">-800000</crdf:SaleOfStockCommonAndWarrantsNetShares>
    <crdf:SaleOfStockValueCommonAndWarrantsNet
      contextRef="i44c0a4463d8b467eb6707129cf69494a_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMy03LTEtMS0w_850648ba-3630-40ba-9935-62f81b7bdbdb"
      unitRef="usd">-80</crdf:SaleOfStockValueCommonAndWarrantsNet>
    <crdf:SaleOfStockValueCommonAndWarrantsNet
      contextRef="i969cd75c1e19434b854579b8223eca1f_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMy05LTEtMS0w_86ad3744-19d1-4ff1-bc18-e643cb8fc632"
      unitRef="usd">-999921</crdf:SaleOfStockValueCommonAndWarrantsNet>
    <crdf:SaleOfStockValueCommonAndWarrantsNet
      contextRef="i7a4d70afca204fcbbdba84e5be3dd359_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMy0xNS0xLTEtMA_864e9396-352f-4b09-966f-0a9cdb666214"
      unitRef="usd">-1000001</crdf:SaleOfStockValueCommonAndWarrantsNet>
    <crdf:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i44c0a4463d8b467eb6707129cf69494a_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfNC01LTEtMS0w_a9de07ba-55df-4a84-9267-bec4ba39d944"
      unitRef="shares">1610144</crdf:StockIssuedDuringPeriodSharesWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i44c0a4463d8b467eb6707129cf69494a_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfNC03LTEtMS0w_3532f122-9923-451a-bf5f-b9bfa608bfc7"
      unitRef="usd">161</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i969cd75c1e19434b854579b8223eca1f_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfNC05LTEtMS0w_b95ee26e-b25e-4980-b1fb-42e430515249"
      unitRef="usd">1456208</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i7a4d70afca204fcbbdba84e5be3dd359_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfNC0xNS0xLTEtMA_1ea26c47-8629-417f-9dd1-949d4c5ea73e"
      unitRef="usd">1456369</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased
      contextRef="i44c0a4463d8b467eb6707129cf69494a_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfNS01LTEtMS0w_f2b2afac-ac70-493f-8ed6-5fac727efe34"
      unitRef="shares">6810</crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased>
    <crdf:StockIssuedDuringPeriodValueRestrictedStockUnitsReleases
      contextRef="i44c0a4463d8b467eb6707129cf69494a_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfNS03LTEtMS0w_2648f34f-2e79-440a-aff6-4fcd071bc424"
      unitRef="usd">1</crdf:StockIssuedDuringPeriodValueRestrictedStockUnitsReleases>
    <crdf:StockIssuedDuringPeriodValueRestrictedStockUnitsReleases
      contextRef="i969cd75c1e19434b854579b8223eca1f_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfNS05LTEtMS0w_e78e874d-7c74-452b-b18a-4725020b06b8"
      unitRef="usd">-1</crdf:StockIssuedDuringPeriodValueRestrictedStockUnitsReleases>
    <us-gaap:DividendsPreferredStock
      contextRef="i1aea61419554483ab22c33a2aa6fdddc_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfNi0xMy0xLTEtMA_87269283-6b22-4d68-8b58-6eb5945dec3b"
      unitRef="usd">6060</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="i7a4d70afca204fcbbdba84e5be3dd359_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfNi0xNS0xLTEtMA_a03bb9d3-d30e-4b71-88e1-acad1cab180d"
      unitRef="usd">6060</us-gaap:DividendsPreferredStock>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="ie81e092c24a3460ca593f690506ba45c_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfOC0xMS0xLTEtMA_fe441af1-b935-4491-a536-b9f50122eddd"
      unitRef="usd">293017</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i7a4d70afca204fcbbdba84e5be3dd359_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfOC0xNS0xLTEtMA_443efa08-b8af-451e-a47b-057b5aaa217a"
      unitRef="usd">293017</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <us-gaap:NetIncomeLoss
      contextRef="i1aea61419554483ab22c33a2aa6fdddc_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfOS0xMy0xLTEtMA_e4f952ca-5ad1-4992-a84c-8bb8b352bb19"
      unitRef="usd">-4088562</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7a4d70afca204fcbbdba84e5be3dd359_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfOS0xNS0xLTEtMA_d0eab07e-a3cb-4ec3-916a-afebcf1eb2ac"
      unitRef="usd">-4088562</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i1e4e419343594d71afb1d77399f4daad_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTAtMS0xLTEtMA_b1738aa6-40df-4e57-bc56-332c59862340"
      unitRef="shares">60600</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i1e4e419343594d71afb1d77399f4daad_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTAtMy0xLTEtMA_1ff7fb7c-13e3-41fe-a8e7-0c7c76b95089"
      unitRef="usd">60</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="id6962b9056174c398b78bd1a322ad590_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTAtNS0xLTEtMA_8810b13d-e715-4b31-b029-acc7f92fd37a"
      unitRef="shares">11010587</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="id6962b9056174c398b78bd1a322ad590_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTAtNy0xLTEtMA_ee22ca43-5aa0-4930-9826-746b3244b2fd"
      unitRef="usd">8554</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8e7a4e37750d41c2b7bd2a4475f50b9d_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTAtOS0xLTEtMA_269868f8-a5db-451b-bc88-9301315819e4"
      unitRef="usd">219805965</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i892bb4bca35e42edb3fbf0ca66a798a4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTAtMTEtMS0xLTA_3f46292d-5a7b-471a-b413-f0602efd4596"
      unitRef="usd">-678656</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2a5b54961e1a408da4efa7c4a015db44_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTAtMTMtMS0xLTA_c6daaa98-5e58-478f-aafd-e35f50e05b7b"
      unitRef="usd">-212992505</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i105b5086b9d140d382a2cf18218bbcdf_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTAtMTUtMS0xLTA_d2cbe47c-ce5b-4f4c-8bf6-a250c37beeef"
      unitRef="usd">6143418</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i986c4f37b62f4001bb38dfa79cf80042_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTEtOS0xLTEtMA_186e6508-ba9f-43a4-8d74-c59b1b44d878"
      unitRef="usd">281776</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTEtMTUtMS0xLTA_a4aa213a-b2bf-4ade-8f59-b2fe2e14b481"
      unitRef="usd">281776</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="i7a78e5a7b2ff488abd9e098d74a099e8_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTItMS0xLTEtMA_59d51080-974f-493d-8a74-cad1ef90a2e1"
      unitRef="shares">154670</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i7a78e5a7b2ff488abd9e098d74a099e8_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTItMy0xLTEtMA_23ff41cf-5d02-479d-89db-4cb57b7f2011"
      unitRef="usd">15</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="ibd6fb8040cf1408a9b85618f489130ce_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTItNS0xLTEtMA_b59e92ce-991e-4da9-84d3-a104ce97fa80"
      unitRef="shares">602833</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="ibd6fb8040cf1408a9b85618f489130ce_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTItNy0xLTEtMA_22c4a930-8941-4a20-ad16-a053b64db4a5"
      unitRef="usd">60</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i986c4f37b62f4001bb38dfa79cf80042_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTItOS0xLTEtMA_db714c41-94e8-4a78-aa9f-a86395f62b33"
      unitRef="usd">2292425</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i2007c264c51a44a98c0f645dc1f8ba51_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTItMTEtMS0xLTA_2c01a8fa-1d39-46c7-9748-068c1c370ac1"
      unitRef="usd">-2300000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTItMTUtMS0xLTA_f52e5a8a-cb8a-4eef-847b-77ff588bb606"
      unitRef="usd">-7500</us-gaap:StockIssuedDuringPeriodValueOther>
    <crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
      contextRef="i5c0977b1d8e8404aaa3b657703fb8dd5_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTMtOS0xLTEtMA_3b589d66-99aa-4377-903e-c48f1381e4c0"
      unitRef="usd">601767</crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock>
    <crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
      contextRef="i8c907bcbc06d4d318ec339547451ef5b_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTMtMTMtMS0xLTA_73d8be87-7870-499a-9318-3cd8298a92e2"
      unitRef="usd">-601767</crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock>
    <crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
      contextRef="i70a77dc066834b05be99f8161e3fb65c_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTQtOS0xLTEtMA_997902b3-811e-4535-a1d0-42db066f013d"
      unitRef="usd">2664717</crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock>
    <crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
      contextRef="i4334ae12820e4b96abd660da1706eef0_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTQtMTMtMS0xLTA_a7de9347-4d64-4651-8a8c-d810c7514071"
      unitRef="usd">-2664717</crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i7a78e5a7b2ff488abd9e098d74a099e8_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtMS0xLTEtMA_4c625304-18b6-48ac-a97f-84c5bf85ccfd"
      unitRef="shares">-865824</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i7a78e5a7b2ff488abd9e098d74a099e8_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtMy0xLTEtMA_785dc728-fb40-48ed-8571-ce68880992ec"
      unitRef="usd">-866</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ibd6fb8040cf1408a9b85618f489130ce_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtNS0xLTEtMA_7e0aca0a-36dd-4ec7-9639-c05471553428"
      unitRef="shares">-4689313</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ibd6fb8040cf1408a9b85618f489130ce_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtNy0xLTEtMA_1d5eb083-686d-4d30-b1b9-5da8e39d29d5"
      unitRef="usd">-469</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i986c4f37b62f4001bb38dfa79cf80042_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtOS0xLTEtMA_4eafee9b-816d-4fd7-9875-e9faaca48aa5"
      unitRef="usd">-17277093</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtMTUtMS0xLTA_af12d379-5662-465f-8a93-94f0111d55cd"
      unitRef="usd">17278428</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <crdf:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="ibd6fb8040cf1408a9b85618f489130ce_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTYtNS0xLTEtMA_aa7bc6e1-15d5-42f7-bacf-6a803cc09322"
      unitRef="shares">3473393</crdf:StockIssuedDuringPeriodSharesWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ibd6fb8040cf1408a9b85618f489130ce_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTYtNy0xLTEtMA_63ccb7a5-3646-429d-a280-71cf8fd52e9a"
      unitRef="usd">347</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i986c4f37b62f4001bb38dfa79cf80042_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTYtOS0xLTEtMA_f4bae235-bfab-4725-bf32-b6830d853c2e"
      unitRef="usd">4604670</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTYtMTUtMS0xLTA_8b51e67b-8ca5-425f-abd4-195ad796bda5"
      unitRef="usd">4605017</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased
      contextRef="ibd6fb8040cf1408a9b85618f489130ce_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTctNS0xLTEtMA_c8a7d040-2de9-4279-ab5d-b5ff158ff900"
      unitRef="shares">2250</crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ibaa519b044634475a9a19ebc2fdfafde_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTgtMS0xLTEtMA_1804698b-73f6-4fc1-bce9-695982c0c9ba"
      unitRef="shares">-154670</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ibaa519b044634475a9a19ebc2fdfafde_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTgtMy0xLTEtMA_ba6a3012-c375-46cc-8c46-fcd66ec12ddc"
      unitRef="usd">-15</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i8646b250083b422d8f1430bffcbe6b73_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTgtNS0xLTEtMA_420b6f54-d27e-49d2-a826-557ef2beeae2"
      unitRef="shares">1546700</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i8646b250083b422d8f1430bffcbe6b73_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTgtNy0xLTEtMA_838df534-8611-4b33-9218-a22304ccdaec"
      unitRef="usd">155</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i5c0977b1d8e8404aaa3b657703fb8dd5_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTgtOS0xLTEtMA_0b777b17-5c3e-4a45-bb60-93322e1886f3"
      unitRef="usd">-140</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:DividendsPreferredStock
      contextRef="i6160228ffe834aa18b13f335f5d812ad_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTktMTMtMS0xLTA_eb9ad7ec-3dc5-4c26-93c2-e1b605a57f64"
      unitRef="usd">6060</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTktMTUtMS0xLTA_36f9ee03-62cd-4c64-8784-123d37841d26"
      unitRef="usd">6060</us-gaap:DividendsPreferredStock>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i2007c264c51a44a98c0f645dc1f8ba51_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjAtMTEtMS0xLTA_ade7a87d-e0ae-465c-a657-3ffad02a0bb7"
      unitRef="usd">213492</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjAtMTUtMS0xLTA_c6946183-2719-4a5d-80eb-f7befe10da9d"
      unitRef="usd">213492</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <us-gaap:NetIncomeLoss
      contextRef="i6160228ffe834aa18b13f335f5d812ad_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjEtMTMtMS0xLTA_03d1bf5c-1e69-4505-8186-a65c31ddbad3"
      unitRef="usd">-4124532</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjEtMTUtMS0xLTA_7338fe07-4386-4eca-97ba-94fab2786a56"
      unitRef="usd">-4124532</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i00b92270816642589793666319d5f182_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjItMS0xLTEtMA_2e594e6d-fbb3-410a-9bfa-1acbbc3c5d2a"
      unitRef="shares">926424</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i00b92270816642589793666319d5f182_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjItMy0xLTEtMA_78729be6-13e2-421e-81c6-6a5c080cb96b"
      unitRef="usd">926</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="if5b2f533f0534d78844b49d29954c8e4_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjItNS0xLTEtMA_e990d0c9-659b-4e59-9fbd-932eb22618d8"
      unitRef="shares">21325076</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="if5b2f533f0534d78844b49d29954c8e4_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjItNy0xLTEtMA_3510a9ba-1899-485e-84b5-e733c0ab5214"
      unitRef="usd">9585</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i37f5de467cd94aab8302da68767238f2_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjItOS0xLTEtMA_fc49946e-3c46-41b0-ae3f-0e9b0eba13f3"
      unitRef="usd">247528273</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icf1a9dc0b4284431b4cef397cfcd0b83_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjItMTEtMS0xLTA_a61a7080-42f1-41e9-8207-9e44a121da40"
      unitRef="usd">-2765164</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i179c2b18280246c8ada7c878931742fb_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjItMTMtMS0xLTA_661fa2b2-0291-4418-ab9c-07331f8c90f6"
      unitRef="usd">-220389581</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if5ff2e0258b7445fb9a110a10dccadb7_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjItMTUtMS0xLTA_5a787e2a-4c5f-4f69-854a-6d6db729d3e3"
      unitRef="usd">24384039</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic6d7f037cf0b4b8792ebe716a72da81c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjMtOS0xLTEtMzA1_878e976b-2897-4c63-99b1-b3b53241739f"
      unitRef="usd">361884</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjMtMTUtMS0xLTMwNQ_ac5576bb-d77f-44f9-825d-ad527bfff714"
      unitRef="usd">361884</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <crdf:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i6c90af801967473ab9d203d9d12c323f_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjUtNS0xLTEtMzA1_7376108c-695d-4f9f-961b-02f1cac92bab"
      unitRef="shares">4956084</crdf:StockIssuedDuringPeriodSharesWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i6c90af801967473ab9d203d9d12c323f_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjUtNy0xLTEtMzA1_e7018653-5977-4ec0-a2af-3fd39a6a0b38"
      unitRef="usd">496</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ic6d7f037cf0b4b8792ebe716a72da81c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjUtOS0xLTEtMzA1_a2e43f73-7356-4713-884d-7776a80efedf"
      unitRef="usd">12910306</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjUtMTUtMS0xLTMwNQ_84a6fd5c-72d4-4b82-b682-7d689d470f4c"
      unitRef="usd">12910802</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6c90af801967473ab9d203d9d12c323f_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjYtNS0xLTEtNDMz_5a9d9f3b-14a9-483a-a4f7-8c54ec4c9d01"
      unitRef="shares">3333</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic6d7f037cf0b4b8792ebe716a72da81c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjYtOS0xLTEtNDMz_73e9ae6d-1d2a-468d-8052-1043a63b2675"
      unitRef="usd">6832</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjYtMTUtMS0xLTQzMw_eaa05525-11d4-4ea6-ba10-81ecc8465921"
      unitRef="usd">6832</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased
      contextRef="i6c90af801967473ab9d203d9d12c323f_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjYtNS0xLTEtMzA1_a1e82e9c-5434-4a05-85fe-5075d25a68a4"
      unitRef="shares">1250</crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased>
    <us-gaap:DividendsPreferredStock
      contextRef="i4056f199424143e290a92a502f0c74a0_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjctMTMtMS0xLTMwNQ_5fb3ff3a-e226-4fd5-81ad-07af7de47bf9"
      unitRef="usd">6060</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjctMTUtMS0xLTMwNQ_d98b81c8-67ff-4921-b14e-243484300a16"
      unitRef="usd">6060</us-gaap:DividendsPreferredStock>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i249b89eeb0194442ab7d9ffdd4dc0dc1_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjgtMTEtMS0xLTMwNQ_04d63874-475d-49c9-9b14-10938abb6124"
      unitRef="usd">361584</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjgtMTUtMS0xLTMwNQ_3b075c3f-4674-429c-9823-05b3464230dd"
      unitRef="usd">361584</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <us-gaap:NetIncomeLoss
      contextRef="i4056f199424143e290a92a502f0c74a0_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjktMTMtMS0xLTMwNQ_317e9f67-4893-4b8f-9d8a-3db6199b2677"
      unitRef="usd">-4496531</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMjktMTUtMS0xLTMwNQ_699efedb-6630-42b5-ae4b-ae779f5dd72d"
      unitRef="usd">-4496531</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i01fc0539599a4354836f19a58664e5a7_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMzAtMS0xLTEtMzA1_98246375-9c98-4e4b-822b-2c53c051575f"
      unitRef="shares">926424</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i01fc0539599a4354836f19a58664e5a7_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMzAtMy0xLTEtMzA1_2e1ea900-bc82-4621-bcbb-f6df5aa3a926"
      unitRef="usd">926</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i4aff4ec96d0b44fd96cf76b82d788da4_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMzAtNS0xLTEtMzA1_b9ce230f-ab08-497b-8ed9-5e7fd967c848"
      unitRef="shares">26285743</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i4aff4ec96d0b44fd96cf76b82d788da4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMzAtNy0xLTEtMzA1_3a06ed4e-7151-4b8a-802d-c8b0a4120830"
      unitRef="usd">10081</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i54a56210ecbf42aea170e8ae37fe336e_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMzAtOS0xLTEtMzA1_69a1bf24-6db7-4fd8-a482-d21cdb77d5c7"
      unitRef="usd">260807295</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i068dca4a9a24460485c15359caa4f37b_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMzAtMTEtMS0xLTMwNQ_3493deaa-80a1-4451-a8dc-20c2daf0610e"
      unitRef="usd">-2403580</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3585b22f6f334b64b4a9a946e0b1754f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMzAtMTMtMS0xLTMwNQ_f274b990-123d-4e86-9d3b-348a6c7bf9b5"
      unitRef="usd">-224892172</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMzAtMTUtMS0xLTMwNQ_c6adf9c6-1c3b-458b-bd4e-3308c02af705"
      unitRef="usd">33522550</us-gaap:StockholdersEquity>
    <crdf:CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment
      contextRef="i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RleHRyZWdpb246ZTA5MGZmN2Q3Zjc4NDBjM2E4N2ZmYzlkNjJhM2M4YjVfMTEw_01b63ad6-0e1a-48ed-a8cd-ab8aedc19ca3"
      unitRef="usd">616143</crdf:CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment>
    <crdf:WarrantsFairValue
      contextRef="i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RleHRyZWdpb246ZTA5MGZmN2Q3Zjc4NDBjM2E4N2ZmYzlkNjJhM2M4YjVfMjA4_54838357-e9fb-47d6-9566-2b8ff53ccea3"
      unitRef="usd">370666</crdf:WarrantsFairValue>
    <us-gaap:SharesIssued
      contextRef="iacde1c89795341d7a6585a9ca67ff1ef_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMS0xLTEtMS0w_acbe2232-55fe-4fb6-bd26-8418fa35c3cd"
      unitRef="shares">60600</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="iacde1c89795341d7a6585a9ca67ff1ef_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMS0zLTEtMS0w_2d17f66a-6e71-47cf-b0ed-bd11b5e68963"
      unitRef="usd">60</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i68416144d86546848c61077e3daaae71_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMS01LTEtMS0w_93916a79-19de-4908-9822-34ea55b85963"
      unitRef="shares">3831879</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i68416144d86546848c61077e3daaae71_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMS03LTEtMS0w_830eead3-a0c0-4c26-b8af-6f0bf6c21313"
      unitRef="usd">7742</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie8388a4c16204624a7b7ce5524a8ab3d_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMS05LTEtMS0w_ac940e16-2a0a-4b69-9699-83b7a7dcf4be"
      unitRef="usd">202267605</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idf7bcf08b2e0459b88c7b9896849b386_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMS0xMS0xLTEtMA_e5a7fc9c-a931-49d6-896a-286b34c553fe"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i20ddc05282304186b85c0c5e82d9c3dc_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMS0xMy0xLTEtMA_e53989e4-b66e-4d8e-ade4-68283cfa6728"
      unitRef="usd">-192191215</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iec08f4c1e8014a62bb515c9760634ec7_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMS0xNS0xLTEtMA_db2b72f3-dc8f-40ff-86ed-638fa86f1b5f"
      unitRef="usd">10084192</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if04bc8a88dbf4923b75de662fba8bcac_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMi05LTEtMS0w_d6442acf-e7ab-4124-b9e1-868574b05a4c"
      unitRef="usd">200067</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia7f9daee734141178c3262a70ac3d9f9_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMi0xNS0xLTEtMA_2c16e985-32b0-46cc-bea8-571bc78931cf"
      unitRef="usd">200067</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <crdf:CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment
      contextRef="ia7f9daee734141178c3262a70ac3d9f9_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNS0wLTEtMS0wL3RleHRyZWdpb246MjNjNjY0Y2I1ZWNlNDlkY2JlYzBlNGFmZTExYzdlZWRfMTMw_7897e4e3-2e29-4cd2-a397-15ed6102a18d"
      unitRef="usd">40000</crdf:CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment>
    <crdf:DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment
      contextRef="ia7f9daee734141178c3262a70ac3d9f9_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNS0wLTEtMS0wL3RleHRyZWdpb246MjNjNjY0Y2I1ZWNlNDlkY2JlYzBlNGFmZTExYzdlZWRfMTM3_c917adb6-48cc-4f8b-a90a-01186732ae0a"
      unitRef="usd">235640</crdf:DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="i4094a45bf8304a038d7489696b49f0ee_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNS0xLTEtMS0w_39f7a667-b09e-4d04-aaa2-cab2632af995"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i4094a45bf8304a038d7489696b49f0ee_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNS0zLTEtMS0w_6c53ab99-d080-449c-916a-8648a38a1ae6"
      unitRef="usd">200</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="ibe3da09bc10142fa86a695704e95333d_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNS01LTEtMS0w_a9ee6bf4-3133-499b-9d02-4a90a2541279"
      unitRef="shares">183334</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="ibe3da09bc10142fa86a695704e95333d_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNS03LTEtMS0w_3bd80a0a-8d5e-4518-a7fe-300fdbf32770"
      unitRef="usd">110</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="if04bc8a88dbf4923b75de662fba8bcac_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNS05LTEtMS0w_1047e271-58a4-4b5e-8d52-ae92a4befbd1"
      unitRef="usd">1634690</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i686b763ed80c42debf1673b939ce8436_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNS0xMS0xLTEtMA_9d303485-4202-4628-857b-bf8258b7d58e"
      unitRef="usd">-1675000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="ia7f9daee734141178c3262a70ac3d9f9_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNS0xNS0xLTEtMA_4b9cdac4-3cd1-46c3-b717-4b9bfa66f66f"
      unitRef="usd">-40000</us-gaap:StockIssuedDuringPeriodValueOther>
    <crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
      contextRef="if04bc8a88dbf4923b75de662fba8bcac_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNi05LTEtMS0w_55297423-e02c-4558-b10f-7832d3a04c39"
      unitRef="usd">268269</crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock>
    <crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
      contextRef="ie3e995f613e04a30b83a190600e73d1d_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNi0xMy0xLTEtMA_995479e9-5a42-4b53-8b55-56b58472a53a"
      unitRef="usd">-268269</crdf:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock>
    <crdf:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="ibe3da09bc10142fa86a695704e95333d_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNy01LTEtMS0w_b930724c-2115-4baf-9ecd-60ddd160d470"
      unitRef="shares">497313</crdf:StockIssuedDuringPeriodSharesWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ibe3da09bc10142fa86a695704e95333d_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNy03LTEtMS0w_1730abad-aa4c-4d1e-a53c-cc9d646125b4"
      unitRef="usd">50</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="if04bc8a88dbf4923b75de662fba8bcac_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNy05LTEtMS0w_955855ce-a24d-4464-8f87-3e3f8b176eda"
      unitRef="usd">3282216</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ia7f9daee734141178c3262a70ac3d9f9_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfNy0xNS0xLTEtMA_5841c8fb-7d24-4c01-91e9-fcfdc1e28035"
      unitRef="usd">3282266</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased
      contextRef="ibe3da09bc10142fa86a695704e95333d_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfOC01LTEtMS0w_e1608faa-54c7-4fd6-9ef3-35e7c9762af0"
      unitRef="shares">6362</crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased>
    <crdf:StockIssuedDuringPeriodValueRestrictedStockUnitsReleases
      contextRef="ibe3da09bc10142fa86a695704e95333d_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfOC03LTEtMS0w_1b8f5a0d-afdd-4bf1-8437-1386e87fe68d"
      unitRef="usd">4</crdf:StockIssuedDuringPeriodValueRestrictedStockUnitsReleases>
    <crdf:StockIssuedDuringPeriodValueRestrictedStockUnitsReleases
      contextRef="if04bc8a88dbf4923b75de662fba8bcac_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfOC05LTEtMS0w_c8cd1877-9d95-458d-9d5e-3b9785cdce6f"
      unitRef="usd">-4</crdf:StockIssuedDuringPeriodValueRestrictedStockUnitsReleases>
    <us-gaap:DividendsPreferredStock
      contextRef="ie3e995f613e04a30b83a190600e73d1d_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTAtMTMtMS0xLTA_056ae514-e702-4a3e-aaa0-73b9f7056cea"
      unitRef="usd">6060</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="ia7f9daee734141178c3262a70ac3d9f9_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTAtMTUtMS0xLTA_3b6f6fbf-ede2-4135-88fc-08bc24220417"
      unitRef="usd">6060</us-gaap:DividendsPreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="ibe3da09bc10142fa86a695704e95333d_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTEtNS0xLTEtMA_986476b5-4b26-4c00-a635-2a9d6c60a5ce"
      unitRef="shares">6466</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i686b763ed80c42debf1673b939ce8436_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTMtMTEtMS0xLTA_28f59fc4-a059-4d5c-98f1-81f3a4049ae2"
      unitRef="usd">70487</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="ia7f9daee734141178c3262a70ac3d9f9_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTMtMTUtMS0xLTA_e8347a60-ad7a-4058-9e39-466a18a684de"
      unitRef="usd">70487</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <us-gaap:NetIncomeLoss
      contextRef="ie3e995f613e04a30b83a190600e73d1d_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTQtMTMtMS0xLTA_84b60369-e306-44d7-a04e-61122d53770f"
      unitRef="usd">-3904771</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia7f9daee734141178c3262a70ac3d9f9_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTQtMTUtMS0xLTA_d6b15ba6-8cc2-46f7-9748-b38c94aec400"
      unitRef="usd">-3904771</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i795f824a2e0848ec9e08218e1e384119_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTUtMS0xLTEtMA_15faab81-a7fe-4f93-a512-73d00d054690"
      unitRef="shares">260600</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i795f824a2e0848ec9e08218e1e384119_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTUtMy0xLTEtMA_0f8a5a23-1776-4660-adfa-1484d1a9c429"
      unitRef="usd">260</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i4ab978b16413492fa60c4cc6dc4f989a_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTUtNS0xLTEtMA_10943c0b-e7ee-4fe6-9f09-c354a8e343f3"
      unitRef="shares">4525354</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i4ab978b16413492fa60c4cc6dc4f989a_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTUtNy0xLTEtMA_4b23945b-338b-4113-ae56-a07071ae6bcb"
      unitRef="usd">7906</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if2b9bfad02a04a619ec5166a7e949cf7_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTUtOS0xLTEtMA_8f932126-6818-4fca-9566-2e1218e93795"
      unitRef="usd">207652843</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1fbe7725163e40c4a4a41af38a99b6e5_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTUtMTEtMS0xLTA_1ac499c8-8b99-4cac-832c-9ef24045510f"
      unitRef="usd">-1604513</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iad21cf8f4ef74076934e4cd2f244fe43_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTUtMTMtMS0xLTA_b413a89e-5c51-4308-8ef6-958923300c19"
      unitRef="usd">-196370315</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i869616a16b38489397727b402aca4049_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTUtMTUtMS0xLTA_75dc0c68-c006-4817-9021-6185dff2cfd9"
      unitRef="usd">9686181</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7d83f131001e47c7b941410eeb7dfb34_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTYtOS0xLTEtMA_b43499ba-0e65-423a-9e00-76915e8005b7"
      unitRef="usd">148834</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie62f103ee8e84d74b05d78ebcb684bb0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTYtMTUtMS0xLTA_73e6535d-4dec-4fc5-a564-bfa4bcfa963e"
      unitRef="usd">148834</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <crdf:SaleOfStockCommonAndWarrantsNetShares
      contextRef="ia6408fd73dd948b2bedb47f26bd26ece_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTctNS0xLTEtMA_c474444a-9dd5-49f3-bb99-7b8645d79ed2"
      unitRef="shares">-421917</crdf:SaleOfStockCommonAndWarrantsNetShares>
    <crdf:SaleOfStockValueCommonAndWarrantsNet
      contextRef="ia6408fd73dd948b2bedb47f26bd26ece_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTctNy0xLTEtMA_59d525ee-8856-4176-a8e2-d9a49da45f55"
      unitRef="usd">-42</crdf:SaleOfStockValueCommonAndWarrantsNet>
    <crdf:SaleOfStockValueCommonAndWarrantsNet
      contextRef="i7d83f131001e47c7b941410eeb7dfb34_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTctOS0xLTEtMA_dd575d7b-44b7-41d3-b726-d28c9bb4da01"
      unitRef="usd">-2902698</crdf:SaleOfStockValueCommonAndWarrantsNet>
    <crdf:SaleOfStockValueCommonAndWarrantsNet
      contextRef="ie62f103ee8e84d74b05d78ebcb684bb0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTctMTUtMS0xLTA_7e1dbd26-56a1-4ddf-9119-4fbffaf4655c"
      unitRef="usd">-2902740</crdf:SaleOfStockValueCommonAndWarrantsNet>
    <crdf:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="ia6408fd73dd948b2bedb47f26bd26ece_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTgtNS0xLTEtMA_c7460913-71db-4db7-b580-b5f292a5045d"
      unitRef="shares">156353</crdf:StockIssuedDuringPeriodSharesWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ia6408fd73dd948b2bedb47f26bd26ece_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTgtNy0xLTEtMA_ac070147-c7b3-45d1-9745-c027504289c6"
      unitRef="usd">16</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i7d83f131001e47c7b941410eeb7dfb34_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTgtOS0xLTEtMA_e7ea36ba-a0ff-4cbd-a6ca-ee812a496928"
      unitRef="usd">1548</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ie62f103ee8e84d74b05d78ebcb684bb0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTgtMTUtMS0xLTA_4b9c08e1-4de8-45c7-83b4-366175fe2f31"
      unitRef="usd">1564</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased
      contextRef="ia6408fd73dd948b2bedb47f26bd26ece_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMTktNS0xLTEtMA_99959c6f-b5ee-4f6e-b15a-249f7733950e"
      unitRef="shares">4433</crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i8356a82f43e649ce8d9fc4f3bdeaf910_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjAtMS0xLTEtMA_b7579f18-152f-4b8c-9f76-73934f2b07fc"
      unitRef="shares">-200000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i8356a82f43e649ce8d9fc4f3bdeaf910_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjAtMy0xLTEtMA_f483216f-f21e-4646-a1a3-9be01eaa74b1"
      unitRef="usd">-200</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i2dd92383a8974c29a26c20ba1c50c24e_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjAtNS0xLTEtMA_3249eef3-047a-4966-a466-4743cd4455d4"
      unitRef="shares">333333</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i2dd92383a8974c29a26c20ba1c50c24e_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjAtNy0xLTEtMA_e2c79538-820a-4e90-b237-b5f9c8c14bb1"
      unitRef="usd">33</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="idd90d3836ae44a5288cf14214ce01d23_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjAtOS0xLTEtMA_f51fe125-4a25-417f-b9b1-dfe4001011cf"
      unitRef="usd">167</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:DividendsPreferredStock
      contextRef="i98ee69498ef64ee98c7d13fd73810b69_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjEtMTMtMS0xLTA_1f30498e-a8cb-43b6-9820-f9becfcd3df5"
      unitRef="usd">6060</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="ie62f103ee8e84d74b05d78ebcb684bb0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjEtMTUtMS0xLTA_a1f011ce-2731-49e5-a913-6bb978dc6cc3"
      unitRef="usd">6060</us-gaap:DividendsPreferredStock>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i102d06ccc049420ea4a988739f4e1f5a_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjItMTEtMS0xLTA_bf6c582e-0502-4475-9fa9-6345a04441f1"
      unitRef="usd">240279</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="ie62f103ee8e84d74b05d78ebcb684bb0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjItMTUtMS0xLTA_2a902f4b-5f8e-4dd3-83b1-04d6ad81d75b"
      unitRef="usd">240279</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <us-gaap:NetIncomeLoss
      contextRef="i98ee69498ef64ee98c7d13fd73810b69_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjMtMTMtMS0xLTA_6802f2dd-c0fe-412e-8b18-6d0375354a89"
      unitRef="usd">-4125303</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie62f103ee8e84d74b05d78ebcb684bb0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjMtMTUtMS0xLTA_81dbf013-4c65-4dfd-9809-58efb645ea71"
      unitRef="usd">-4125303</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i0bcee1f60daa4ba798ca5869fb08d829_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjQtMS0xLTEtMA_aec61df1-d765-4901-b917-b3a863a59865"
      unitRef="shares">60600</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i0bcee1f60daa4ba798ca5869fb08d829_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjQtMy0xLTEtMA_87e70759-a6b8-44c0-a1c6-d7ef5bc486d1"
      unitRef="usd">60</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i963638cbd5724619a756ba6fac98c0d7_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjQtNS0xLTEtMA_b6403a08-b67e-4046-a61f-2c649ee94912"
      unitRef="shares">5441390</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i963638cbd5724619a756ba6fac98c0d7_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjQtNy0xLTEtMA_b9f5f915-7015-4cc1-ac2c-938a6a963c8d"
      unitRef="usd">7997</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i40293b1c801f4325997aad38bcf3edfe_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjQtOS0xLTEtMA_7ccec530-de40-4669-9eac-9ffb76d03eda"
      unitRef="usd">210706090</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i73a60988cd7742b186d790b4be820c3a_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjQtMTEtMS0xLTA_37d03dd2-0661-46ac-a401-5ab0250dee85"
      unitRef="usd">-1364234</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3bfc5f134f7e4fb0b0329e2e588c22d9_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjQtMTMtMS0xLTA_b9d3b4fb-2c7c-4be1-a929-2763591908e6"
      unitRef="usd">-200501678</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7a44d42518d247568f1e2b1a8b580163_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjQtMTUtMS0xLTA_693b82db-f360-4e53-86fc-b5e3211c2a77"
      unitRef="usd">8848235</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ida7da958772f451988cb48e47b519200_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjUtOS0xLTEtMA_1f23df98-91fa-49e4-aa92-e183c74cfaf6"
      unitRef="usd">266325</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjUtMTUtMS0xLTA_bfa46409-e637-4394-b74d-da178916b039"
      unitRef="usd">266325</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <crdf:SaleOfStockCommonAndWarrantsNetShares
      contextRef="i8d0f3a37ba3f419f9e5fc2d23d7be984_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjYtNS0xLTEtMA_fcd9df26-63c3-4982-8056-3a6bcc1d2441"
      unitRef="shares">-271744</crdf:SaleOfStockCommonAndWarrantsNetShares>
    <crdf:SaleOfStockValueCommonAndWarrantsNet
      contextRef="i8d0f3a37ba3f419f9e5fc2d23d7be984_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjYtNy0xLTEtMA_efe31155-e3d5-41f6-a706-c822c00270b9"
      unitRef="usd">-27</crdf:SaleOfStockValueCommonAndWarrantsNet>
    <crdf:SaleOfStockValueCommonAndWarrantsNet
      contextRef="ida7da958772f451988cb48e47b519200_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjYtOS0xLTEtMA_35df548d-2930-4ef8-a62d-c0306ce6dbed"
      unitRef="usd">-1483554</crdf:SaleOfStockValueCommonAndWarrantsNet>
    <crdf:SaleOfStockValueCommonAndWarrantsNet
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjYtMTUtMS0xLTA_9b7366ec-45d2-4b89-bc02-f237cfe8a3d1"
      unitRef="usd">-1483581</crdf:SaleOfStockValueCommonAndWarrantsNet>
    <crdf:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i8d0f3a37ba3f419f9e5fc2d23d7be984_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjctNS0xLTEtMA_dbbb12a4-f862-4ac1-b4cb-413b18c149f6"
      unitRef="shares">717969</crdf:StockIssuedDuringPeriodSharesWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i8d0f3a37ba3f419f9e5fc2d23d7be984_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjctNy0xLTEtMA_8568c99c-353f-4b37-903d-0ed519f143b2"
      unitRef="usd">72</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ida7da958772f451988cb48e47b519200_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjctOS0xLTEtMA_bc15c77f-04da-4282-b51c-8a0e5ba2bd60"
      unitRef="usd">7108</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjctMTUtMS0xLTA_02bf20ea-922a-44fd-95bb-027292146901"
      unitRef="usd">7180</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased
      contextRef="i8d0f3a37ba3f419f9e5fc2d23d7be984_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjgtNS0xLTEtMA_4e26757e-c946-4809-9a41-8d72f59245e4"
      unitRef="shares">5402</crdf:StockIssuedDuringPeriodRestrictedStockUnitsReleased>
    <us-gaap:DividendsPreferredStock
      contextRef="i0315ca5a43e14290ba86e2502d1e7df3_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjktMTMtMS0xLTA_ba7c52c0-375e-45a5-ac81-af2a6006995c"
      unitRef="usd">6060</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMjktMTUtMS0xLTA_a136c111-982e-4adb-8f9c-cb405bad6163"
      unitRef="usd">6060</us-gaap:DividendsPreferredStock>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i1d41d866570f426f80638fbc27922861_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzAtMTEtMS0xLTEyMTg_683a03af-fcbd-4d73-bae3-a872fa77f709"
      unitRef="usd">198268</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzAtMTUtMS0xLTEyMTg_dc6c1a04-f5f9-4285-99cb-6771cb92d8f3"
      unitRef="usd">198268</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <us-gaap:NetIncomeLoss
      contextRef="i0315ca5a43e14290ba86e2502d1e7df3_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzEtMTMtMS0xLTA_6a15a3f2-d9ce-484c-a215-df037eda3f7d"
      unitRef="usd">-4141549</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzEtMTUtMS0xLTA_a9d8ee6e-7edc-4530-91f7-438c779a959b"
      unitRef="usd">-4141549</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="ib2a52fc6ccc044c4b200ae25cc1f0627_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzItMS0xLTEtMA_d6cb6d65-e2a4-4b87-84dc-960d2175e728"
      unitRef="shares">60600</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ib2a52fc6ccc044c4b200ae25cc1f0627_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzItMy0xLTEtMA_a9c2fde0-40fb-406c-b752-63331f86eb28"
      unitRef="usd">60</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i713cb493491f49ab95402bed132c3427_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzItNS0xLTEtMA_6acde8a6-f061-4432-97a0-cdaf45fd622e"
      unitRef="shares">6436505</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i713cb493491f49ab95402bed132c3427_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzItNy0xLTEtMA_592f602b-87d0-46bc-b9da-b1ee10691bd1"
      unitRef="usd">8096</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i70118ce382b54129a01f304d79e91011_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzItOS0xLTEtMA_8d9068d6-c878-4b4f-84a1-283ea1971bf5"
      unitRef="usd">212463077</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie295404f651a43699515699a65360c65_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzItMTEtMS0xLTA_6ae7e1a9-90bb-4fdf-b712-d99db92b536e"
      unitRef="usd">-1165966</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a436b27140f418b9f00effe44febb9a_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzItMTMtMS0xLTA_60970ea8-e9de-4735-b9ad-79446af93d24"
      unitRef="usd">-204649287</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i601506d900b640889cfe25c06b9517ad_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmJkNGI1MDk5YzU0MDQ4MjM4ZjgzYWQ3MWFiNmVkZjE1L3RhYmxlcmFuZ2U6YmQ0YjUwOTljNTQwNDgyMzhmODNhZDcxYWI2ZWRmMTVfMzItMTUtMS0xLTA_d60ffda1-c0bc-41c7-b3a2-41293d59d942"
      unitRef="usd">6655980</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMy0xLTEtMS0w_d04d6544-acea-4a75-bf8e-015cedcffad1"
      unitRef="usd">-12709625</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMy0zLTEtMS0w_f3bf0f1e-6cab-4b9c-9057-6365e1ff24b1"
      unitRef="usd">-12171623</us-gaap:NetIncomeLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNi0xLTEtMS0w_06366568-fd78-4913-8074-cb040cef7467"
      unitRef="usd">34169</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNi0zLTEtMS0w_a8463575-fcbb-432f-b0cc-82eb0d3075ca"
      unitRef="usd">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNy0xLTEtMS0w_fa185617-26fb-45aa-9933-28a014ea8de3"
      unitRef="usd">348748</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNy0zLTEtMS0w_c037c1b2-b633-4278-9a27-25032de018b6"
      unitRef="usd">372828</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfOC0xLTEtMS0w_8cb0205e-450b-4111-bde9-a4dd3a46b860"
      unitRef="usd">820969</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfOC0zLTEtMS0w_d87f489d-af2d-4db4-82b7-ee24817e0097"
      unitRef="usd">615226</us-gaap:ShareBasedCompensation>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMTYtMS0xLTEtMA_32c0490d-0a41-445b-b695-5a8c13c1af0e"
      unitRef="usd">-186072</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMTYtMy0xLTEtMA_70998c19-1cff-424c-bb2c-259e9c583a1c"
      unitRef="usd">27359</us-gaap:UnrealizedGainLossOnDerivatives>
    <crdf:Releaseofclinicaltrialfundingcommitmentforservicesreceived
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMTctMS0xLTEtMA_eff88bb3-48d3-4f04-84d8-4b958135cac2"
      unitRef="usd">868093</crdf:Releaseofclinicaltrialfundingcommitmentforservicesreceived>
    <crdf:Releaseofclinicaltrialfundingcommitmentforservicesreceived
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMTctMy0xLTEtMA_aca802ae-6cb8-4aa0-9b4c-177860debd56"
      unitRef="usd">509034</crdf:Releaseofclinicaltrialfundingcommitmentforservicesreceived>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMTktMS0xLTEtMA_83c11d7b-51ec-48d3-bf12-49ba76e5e1e1"
      unitRef="usd">-1806</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMTktMy0xLTEtMA_89382f7f-52c7-4365-a423-6150994109c7"
      unitRef="usd">68145</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjAtMS0xLTEtMA_cf3baa8c-0350-4538-9386-3e3b72278793"
      unitRef="usd">886</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjAtMy0xLTEtMA_2fbec4c9-7bbb-4a5c-a304-8eca822d2ba0"
      unitRef="usd">-15717</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjEtMS0xLTEtMA_59bdb0e7-f4e8-41af-900a-4d5b961640a6"
      unitRef="usd">623902</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjEtMy0xLTEtMA_55bbe483-2e83-4451-96fe-ec16797cc301"
      unitRef="usd">-277876</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjItMS0xLTEtMA_3246c5d3-ba96-4d7e-aba2-516df36f1439"
      unitRef="usd">-240086</crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjItMy0xLTEtMA_1f8b0043-6f48-4a35-b2a3-0a7f056ac6de"
      unitRef="usd">-224400</crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjMtMS0xLTEtMA_ecd15e8a-2f67-4c85-9905-4d8d098e1953"
      unitRef="usd">318991</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjMtMy0xLTEtMA_18da7c57-4aec-4d67-a7eb-1b507315350b"
      unitRef="usd">837551</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <crdf:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjQtMS0xLTEtMA_0481a8ed-5b3e-42b2-911e-0272075aad66"
      unitRef="usd">-635630</crdf:IncreaseDecreaseInOperatingLeaseLiability>
    <crdf:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjQtMy0xLTEtMA_8095946c-73b7-40e4-95d7-2f641c9cc184"
      unitRef="usd">-576141</crdf:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjUtMS0xLTEtMA_f5c1e66f-075e-405b-9fe7-6bc465a11c29"
      unitRef="usd">-39916</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjUtMy0xLTEtMA_03da71de-d88a-4e05-85b1-e08e7dde64fa"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjYtMS0xLTEtMA_db514af0-c8f4-4f0e-9cc4-6742ec93fd88"
      unitRef="usd">-11191025</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMjYtMy0xLTEtMA_0abc40eb-9106-414e-a6c6-cd3ef377f98c"
      unitRef="usd">-9990636</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMzAtMS0xLTEtMA_8087b244-8aed-4b9e-ab6e-8868868f23dc"
      unitRef="usd">153784</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMzAtMy0xLTEtMA_178ae92e-03eb-4a69-b9db-faa0dfbc47f9"
      unitRef="usd">67622</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMzQtMS0xLTEtMA_db2d39de-0c35-44d7-9cad-f5d8e09c3834"
      unitRef="usd">-153784</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMzQtMy0xLTEtMA_1a2ab7d8-0281-495e-afb3-8559218a9c79"
      unitRef="usd">-67622</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjRiMDViNzVkNTk3MTQzZDc5ZDBlMTFiZDczOTJiZDkxXzkw_aeb4a3e6-791e-4261-89f8-79f68b9ad5cc"
      unitRef="usd">633807</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjRiMDViNzVkNTk3MTQzZDc5ZDBlMTFiZDczOTJiZDkxXzk3_996bd915-a006-4277-bca3-c69a54f41275"
      unitRef="usd">97260</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMzctMS0xLTEtMA_5dd3b1ed-d1fb-4257-b427-c00112aa5c9f"
      unitRef="usd">18278429</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMzctMy0xLTEtMA_63a94f93-6cfc-4626-96b1-5fe28af3c431"
      unitRef="usd">4386321</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMzktMS0xLTEtMA_145782f4-abba-4b65-b650-dbf81c5f8286"
      unitRef="usd">-7500</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfMzktMy0xLTEtMA_d5f80fe8-ed94-4f6b-aec2-03e47e6072cc"
      unitRef="usd">-40000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNDAtMS0xLTEtMA_8750aed8-af2f-4da2-b211-f162b8e05521"
      unitRef="usd">6832</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNDAtMy0xLTEtMA_574bd6d5-b3ff-45fb-ba9f-ab02cd2c2def"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNDEtMS0xLTEtMA_45d16c47-87a1-4b84-b263-c88a54fba8c8"
      unitRef="usd">18972188</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNDEtMy0xLTEtMA_f4307e77-32dc-4555-90d6-c77f1d8acbfd"
      unitRef="usd">3291010</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNDMtMS0xLTEtMA_fb0b9bed-6904-4fea-93f7-ed7727c63cf7"
      unitRef="usd">305000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNDMtMy0xLTEtMA_88ae1b19-b96a-4e48-b5dd-21374c190f0b"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNDctMS0xLTEtMA_bef6893e-7d03-460c-9758-03fc595d27af"
      unitRef="usd">37554949</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNDctMy0xLTEtMA_fc359da4-17ed-4d00-9019-4d2737b7183f"
      unitRef="usd">7637331</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNDktMS0xLTEtMA_4ae55e32-69ee-4b22-ad98-adcd7f8410ab"
      unitRef="usd">26210140</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNDktMy0xLTEtMA_dc9f2241-82e4-4ab3-b7a6-12199fb7edef"
      unitRef="usd">-2420927</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNTAtMS0xLTEtMA_8c8cece7-07b2-4c33-9591-34337f646a77"
      unitRef="usd">10195292</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iec08f4c1e8014a62bb515c9760634ec7_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNTAtMy0xLTEtMA_39794a42-dd1c-4042-8e11-11f68ac84dc5"
      unitRef="usd">11453133</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNTEtMS0xLTEtMA_3025aaa6-e6fd-4ef4-9aba-b2d7642b4e6e"
      unitRef="usd">36405432</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i601506d900b640889cfe25c06b9517ad_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNTEtMy0xLTEtMA_1397d070-9a04-4b3f-89f7-374776f251d2"
      unitRef="usd">9032206</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNTQtMS0xLTEtMA_b8cf9d51-c1e0-4e90-a4c3-4a2c2381fd17"
      unitRef="usd">800</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNTQtMy0xLTEtMA_47513dd8-dda5-471c-bf9d-fa5ed48fdc03"
      unitRef="usd">800</us-gaap:IncomeTaxesPaid>
    <crdf:PreferredStockDividendAccrued
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjAtMS0xLTEtMA_e2a08900-ceb4-48cf-8f5f-69f57ca99cba"
      unitRef="usd">18180</crdf:PreferredStockDividendAccrued>
    <crdf:PreferredStockDividendAccrued
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjAtMy0xLTEtMA_e61454e5-e8d2-4a6b-b3e0-bcdaa5ae45bf"
      unitRef="usd">18180</crdf:PreferredStockDividendAccrued>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i64433fb437b14e2797a35696e3126e7f_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjItMS0xLTEtMA_cf5cf451-28d3-436c-8281-f91f00b38d00"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i1d39276c8b7149b69b1e0641629d29d6_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjItMy0xLTEtMA_9c2d0cea-5717-457c-a748-75edc4ffe232"
      unitRef="usd">268269</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i7ac167662d264ce29cc6bdaf26de9a0b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjMtMS0xLTEtMA_abaac088-d467-4b71-8504-115a9c70e6fc"
      unitRef="usd">601767</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i60ddc19ccbda40389020c27451bc6aab_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjMtMy0xLTEtMA_c99d17ae-1440-404c-9dac-7542244b89e6"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="ib8c5bb2609e8479dad4e32ccd15c3b2a_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjQtMS0xLTEtMA_d6e8be0e-f065-483e-97eb-aac5c66f3741"
      unitRef="usd">2664717</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i206237eca5cf411b89a567e3e300cf34_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjQtMy0xLTEtMA_b77613e5-7f5a-41a5-ad5a-931fbee7e534"
      unitRef="usd">0</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment
      contextRef="i1d39276c8b7149b69b1e0641629d29d6_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOjRkMTlkM2IyOGE0MjQ5NmI5NzlhN2VlMjMwOGI1NGQwXzE0OA_13e6af16-98c6-4801-9482-a6d2db90ebf2"
      unitRef="usd">235640</crdf:DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment>
    <crdf:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment
      contextRef="i64433fb437b14e2797a35696e3126e7f_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjUtMS0xLTEtMA_b51f5569-1fe8-4efb-8694-2851729352f9"
      unitRef="usd">0</crdf:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment>
    <crdf:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment
      contextRef="i1d39276c8b7149b69b1e0641629d29d6_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjUtMy0xLTEtMA_aa495ca5-7aa1-4407-b12f-1ed1fe89ce2b"
      unitRef="usd">1675000</crdf:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment>
    <crdf:DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment
      contextRef="i7ac167662d264ce29cc6bdaf26de9a0b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjYtMC0xLTEtMC90ZXh0cmVnaW9uOmFmMDM1ZTE2ZWJiMjRlOGVhZmRiMzcyOTdlMzVhYzNiXzE0OA_95a38dba-ddde-4021-a032-829be0145cc6"
      unitRef="usd">488270</crdf:DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment>
    <crdf:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment
      contextRef="i7ac167662d264ce29cc6bdaf26de9a0b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjYtMS0xLTEtMA_5ceb2e4c-bcb6-4fbb-bf49-2750c5cf1302"
      unitRef="usd">2300000</crdf:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment>
    <crdf:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment
      contextRef="i60ddc19ccbda40389020c27451bc6aab_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjYtMy0xLTEtMA_70762c1b-d1bd-489b-882d-ae103c08b16b"
      unitRef="usd">0</crdf:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="i64433fb437b14e2797a35696e3126e7f_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjgtMS0xLTEtMA_cf6f7a80-835b-422d-bd17-ff0acb7c6d2c"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="i1d39276c8b7149b69b1e0641629d29d6_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjgtMy0xLTEtMA_f8ed3497-95fd-4e0a-93e9-1e29a7287f57"
      unitRef="usd">33</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="i7ac167662d264ce29cc6bdaf26de9a0b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjktMS0xLTEtMA_3d59858b-c7b5-43a3-8f0f-79c7c010b31d"
      unitRef="usd">155</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="i60ddc19ccbda40389020c27451bc6aab_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8zMS9mcmFnOmYyMTA1MjY5MTdhZDRiZGI5MzBiMWYxY2ZiMGMyMjQ4L3RhYmxlOjE2YmJkMmM4YjcyYTQ2ZTE4MjBhZTY1ZjEwNGQxMGM2L3RhYmxlcmFuZ2U6MTZiYmQyYzhiNzJhNDZlMTgyMGFlNjVmMTA0ZDEwYzZfNjktMy0xLTEtMA_4626c89c-846c-4df7-b94b-6437f87ef578"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80MC9mcmFnOmIxOGMzMDI4Y2VjZjQ0ZmM5Mjc3ZDNkMWE4ZTBiMmFhL3RleHRyZWdpb246YjE4YzMwMjhjZWNmNDRmYzkyNzdkM2QxYThlMGIyYWFfMzE4OQ_c7896124-5f4a-48d9-86e6-51e6ac8635f5">Organization and Basis of Presentation&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Organization and Overview&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cardiff Oncology,&#160;Inc. (&#x201c;Cardiff Oncology&#x201d; or the &#x201c;Company&#x201d;) headquartered in San Diego, California, is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, Zytiga&#xae;-resistant metastatic castration-resistant prostate cancer and relapsed or refractory acute myeloid leukemia. Our goal is to overcome resistance, improve response to treatment and increase overall survival. Through the integration of tumor genomics and biomarker technology, we are able to assess patient response to treatment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim condensed financial statements of Cardiff Oncology have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and the rules&#160;and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) related to a quarterly report on Form&#160;10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules&#160;and regulations. The unaudited interim condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company&#x2019;s financial position and the results of its operations and cash flows for the periods presented. The unaudited condensed balance sheet at December&#160;31, 2019 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December&#160;31, 2019 included in the Company&#x2019;s annual report on Form&#160;10-K filed with the SEC on February&#160;27, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred net losses since its inception and has negative operating cash flows. As of September&#160;30, 2020, the Company had $36.4&#160;million in cash and cash equivalents and believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 2, 2020 the Company closed an underwritten public offering of its common stock for gross proceeds of approximately $100.9&#160;million. See Note 11 to the condensed financial statements for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the foreseeable future, the Company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company&#x2019;s stockholders may experience additional dilution. The economic effects of COVID-19 could also have an adverse effect on the Company's ability to raise additional capital. See Note 10 to the condensed financial statements for further information.&lt;/span&gt;&lt;/div&gt;As of October 31, 2020 the Company had $131.8&#160;million in cash and cash equivalents.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80MC9mcmFnOmIxOGMzMDI4Y2VjZjQ0ZmM5Mjc3ZDNkMWE4ZTBiMmFhL3RleHRyZWdpb246YjE4YzMwMjhjZWNmNDRmYzkyNzdkM2QxYThlMGIyYWFfMjM1Ng_34759b75-2c4b-45e7-b1e7-fb9df579fce1"
      unitRef="usd">36400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <crdf:SaleOfStockConsiderationReceivedOnTransactionGross
      contextRef="i5c512dc917a44fa4935298acc4757d46_D20201002-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80MC9mcmFnOmIxOGMzMDI4Y2VjZjQ0ZmM5Mjc3ZDNkMWE4ZTBiMmFhL3RleHRyZWdpb246YjE4YzMwMjhjZWNmNDRmYzkyNzdkM2QxYThlMGIyYWFfMTA5OTUxMTYzMTg0Mw_6f7bb485-10bc-4d54-ab53-638b0e77d9c8"
      unitRef="usd">100900000</crdf:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id02c2a45ee9d4832a6e43bb343c46f06_I20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80MC9mcmFnOmIxOGMzMDI4Y2VjZjQ0ZmM5Mjc3ZDNkMWE4ZTBiMmFhL3RleHRyZWdpb246YjE4YzMwMjhjZWNmNDRmYzkyNzdkM2QxYThlMGIyYWFfMTA5OTUxMTYzMTgyOQ_7fa969c4-0fbc-46a6-a55b-c3d4215f9c14"
      unitRef="usd">131800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RleHRyZWdpb246ZjVhZjgxYzI3NGQxNDIyNjk1MTIyZjgyMTEwNzZmODVfMTcyNg_09ef5dbf-2668-49a4-867f-c10aef1c6dc9">Summary of Significant Accounting Policies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2020, there have been no changes to the Company&#x2019;s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share. Shares used in calculating diluted net loss per common share exclude as anti-dilutive the following share equivalents:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per share:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months&lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss used for basic and diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,502,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,147,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,994,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,458,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used to compute basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,341,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,024,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,941,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,180,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to common stockholders:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,920,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,870,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,548,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,844,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,901,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU&#160;No. 2018-13 ("ASU 2018-13"), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;. This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard is effective for all entities for financial statements issued for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company has prospectively adopted ASU 2018-13 as of January 1, 2020 for periods presented after adoption. The adoption of ASU 2018-13 did not have a material impact on the Company's financial statements.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RleHRyZWdpb246ZjVhZjgxYzI3NGQxNDIyNjk1MTIyZjgyMTEwNzZmODVfMTcyOQ_6fed67c8-3e76-486f-95ef-ee8875575b3e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RleHRyZWdpb246ZjVhZjgxYzI3NGQxNDIyNjk1MTIyZjgyMTEwNzZmODVfMTcyNA_f2f7c9c6-895b-45a2-8e6f-d40539490bdb">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per share:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months&lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss used for basic and diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,502,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,147,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,994,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,458,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used to compute basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,341,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,024,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,941,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,180,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to common stockholders:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfNS0xLTEtMS0w_5f9f0a26-5e3a-4e06-a4e2-b0a0e9b5f0af"
      unitRef="usd">-4502591</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfNS0zLTEtMS0w_cbafbfe0-09e6-49be-aa76-6d2a51db66b1"
      unitRef="usd">-4147609</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfNS01LTEtMS0w_2d4d10ee-25cb-46e9-af2f-f707525a4baf"
      unitRef="usd">-15994289</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfNS03LTEtMS0w_d3799bcd-800f-4e80-af04-72c3a31cafed"
      unitRef="usd">-12458072</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfOC0xLTEtMS0w_a1fae025-478b-494c-a747-5bb4c7e8a8d3"
      unitRef="shares">23341218</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfOC0zLTEtMS0w_a46de72b-8618-4312-a058-893a76f987d0"
      unitRef="shares">6024679</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfOC01LTEtMS0w_a0cdc9e3-370a-4725-9923-79aac143eee8"
      unitRef="shares">15941665</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfOC03LTEtMS0w_2a62c5a5-c38c-4976-ae21-aeca5d44281d"
      unitRef="shares">5180221</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfMTMtMS0xLTEtMA_4037322e-6773-420c-9a81-e90136248bdb"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfMTMtMy0xLTEtMA_801f0d55-cb88-4f41-8b83-bc0c12baf3a2"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfMTMtNS0xLTEtMA_b9e50df9-c1b3-4e2c-9874-39a426ef3d77"
      unitRef="usdPerShare">-1.00</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOmY5YjEwMGQ4MTU5ODQ2M2E5NWQ3YmZmMmVkZWIwNDBiL3RhYmxlcmFuZ2U6ZjliMTAwZDgxNTk4NDYzYTk1ZDdiZmYyZWRlYjA0MGJfMTMtNy0xLTEtMA_19160ee6-d17c-4b4c-bbae-915723dff06f"
      unitRef="usdPerShare">-2.40</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RleHRyZWdpb246ZjVhZjgxYzI3NGQxNDIyNjk1MTIyZjgyMTEwNzZmODVfMTc0MQ_cb719f2c-12e8-4c5a-91a7-d8fdd844daf9">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,920,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,870,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,548,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,844,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,901,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9ae86bd676e644578010b6922e11b5af_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfMi0xLTEtMS0w_74788ab5-afe6-4787-8e7d-da3c754fd159"
      unitRef="shares">1920706</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id797d8f2971c433b85a9c8e933191c14_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfMi0zLTEtMS0w_96057f1d-4b6f-44e0-9d87-1c0a899adb39"
      unitRef="shares">1016426</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i922cd50fe23c43afbd32e28dc822bb14_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfMy0xLTEtMS0w_f16ecc32-09a0-48e9-a2e9-37280bddd5fe"
      unitRef="shares">7373351</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9deeeca3150647ec9217fa02ab61c9ad_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfMy0zLTEtMS0w_065f678d-f414-4283-962a-661c1d7c771e"
      unitRef="shares">4870076</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2c1dff24e4584a7c84ebc91d6aae1001_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfNC0xLTEtMS0w_a6dc47b5-13f4-4182-bbc2-fb7fdc56a47b"
      unitRef="shares">991</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9b110679c7614e04bf79a89353cde89c_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfNC0zLTEtMS0w_a55b8e9c-7561-41f4-9315-3c4d61a8c944"
      unitRef="shares">14161</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i14bb2d1b3ff242f28e82eda2a47f119b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfNS0xLTEtMS0w_e64d3c57-d934-4c3e-97ad-288913f939ca"
      unitRef="shares">877</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iff6cc44df61b4043b78740d1bee0959b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfNS0zLTEtMS0w_1c4dcd22-66f6-4fd2-a2e7-1fcde8893a30"
      unitRef="shares">877</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic763b33eacc24b9da821d145ed6ebff6_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfNy0xLTEtMS0w_64dc17a3-1967-4a02-b962-a05d5dda78bf"
      unitRef="shares">3548459</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if44f824383a040f084fa2c0d3ddf921b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfNy0zLTEtMS0w_adee745a-be5e-4c40-9d4b-82944aa1c550"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfOC0xLTEtMS0w_d1d44da8-ddfe-45a2-a993-bb4984e303b9"
      unitRef="shares">12844384</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RhYmxlOjlmMjQ5Yjk3YWRiMzRhYzE4YmYyN2U5NTZjNmM0YzJjL3RhYmxlcmFuZ2U6OWYyNDliOTdhZGIzNGFjMThiZjI3ZTk1NmM2YzRjMmNfOC0zLTEtMS0w_e4843ee1-68ff-4fc1-a4f6-e630e7091a95"
      unitRef="shares">5901540</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80My9mcmFnOmY1YWY4MWMyNzRkMTQyMjY5NTEyMmY4MjExMDc2Zjg1L3RleHRyZWdpb246ZjVhZjgxYzI3NGQxNDIyNjk1MTIyZjgyMTEwNzZmODVfMTc0Mw_ba2e6fea-6561-4b5d-be84-e108099de9c5">Recently Adopted Accounting Pronouncement&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU&#160;No. 2018-13 ("ASU 2018-13"), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;. This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard is effective for all entities for financial statements issued for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company has prospectively adopted ASU 2018-13 as of January 1, 2020 for periods presented after adoption. The adoption of ASU 2018-13 did not have a material impact on the Company's financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RleHRyZWdpb246YjNlZTAyY2Y5NzE2NDVmZjgzNTAyODMxY2YxMmZmZjBfODU3_535dda22-de0b-43a0-ba58-015db4314c98">Fair Value Measurements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market fund (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,536,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,536,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,536,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,536,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market fund (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,131,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,131,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,131,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,131,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;Included as a component of cash and cash equivalents on the accompanying condensed balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments that trade infrequently and therefore have little or no price transparency are classified as Level 3. See Note 6 to the condensed financial statements for further information.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RleHRyZWdpb246YjNlZTAyY2Y5NzE2NDVmZjgzNTAyODMxY2YxMmZmZjBfODU0_3c689aad-1459-46a2-9dc8-8b2c5d1b8dd2">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market fund (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,536,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,536,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,536,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,536,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market fund (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,131,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,131,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,131,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,131,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;Included as a component of cash and cash equivalents on the accompanying condensed balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments that trade infrequently and therefore have little or no price transparency are classified as Level 3. See Note 6 to the condensed financial statements for further information.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i86a4592371ee47e585775ef7ab0a392a_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMy0xLTEtMS0w_64f0c42d-33e9-483e-a974-ef244467ed76"
      unitRef="usd">35536630</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i5366ec380ebb435dbfde066020aa5925_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMy0zLTEtMS0w_123774bb-32bf-481e-9a8f-db3c62978947"
      unitRef="usd">0</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i66b2709deee64adcb18d9c2af9b4467b_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMy01LTEtMS0w_b7e5bf62-c611-4ff0-9103-e8e081f93435"
      unitRef="usd">0</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i58bccc712f204dd9aa339aff63845a18_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMy03LTEtMS0w_88182f25-4048-4466-bad7-404b491c912b"
      unitRef="usd">35536630</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i86a4592371ee47e585775ef7ab0a392a_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfOC0xLTEtMS0w_c01594af-ff32-4dab-8567-542334fdd0af"
      unitRef="usd">35536630</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5366ec380ebb435dbfde066020aa5925_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfOC0zLTEtMS0w_ee84ee88-7324-4cc7-8344-4aee946b40ec"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i66b2709deee64adcb18d9c2af9b4467b_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfOC01LTEtMS0w_4ff85d0d-807c-4035-9b5d-baf2af87954c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i58bccc712f204dd9aa339aff63845a18_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfOC03LTEtMS0w_0abf35c7-355a-49e1-b6f4-e132358b38ea"
      unitRef="usd">35536630</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i86a4592371ee47e585775ef7ab0a392a_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMTAtMS0xLTEtMA_6a3c07fc-c91c-4865-8254-bcb5cc114fb6"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i5366ec380ebb435dbfde066020aa5925_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMTAtMy0xLTEtMA_1a064f53-6e25-4991-bde5-f6cdc4fcf1db"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i66b2709deee64adcb18d9c2af9b4467b_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMTAtNS0xLTEtMA_fb66035a-9f17-46ee-8800-f10bfd8b5da2"
      unitRef="usd">190199</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i58bccc712f204dd9aa339aff63845a18_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMTAtNy0xLTEtMA_c84ba16d-9f0a-4efc-98ea-bc7fd453e1a7"
      unitRef="usd">190199</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i86a4592371ee47e585775ef7ab0a392a_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMTEtMS0xLTEtMA_92c20864-f177-4c34-866c-3b131402b2d8"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5366ec380ebb435dbfde066020aa5925_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMTEtMy0xLTEtMA_8e6d0488-c021-4ef9-b77c-4304364b63a6"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i66b2709deee64adcb18d9c2af9b4467b_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMTEtNS0xLTEtMA_1bd0706c-919f-405c-967c-e93315e60598"
      unitRef="usd">190199</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i58bccc712f204dd9aa339aff63845a18_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjE2OTFhZTRiZTk3NDQ5YTg4OGRiMzA4YmRkOGM4NGE1L3RhYmxlcmFuZ2U6MTY5MWFlNGJlOTc0NDlhODg4ZGIzMDhiZGQ4Yzg0YTVfMTEtNy0xLTEtMA_ad0f4b32-78eb-4b84-a15e-0fd1c4f831e5"
      unitRef="usd">190199</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="ieb19cb296ec14221a57f41b82c172241_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfMy0xLTEtMS0w_dbcaab73-228e-48ca-aa7f-5973f3a70a01"
      unitRef="usd">10131240</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i3207f5a1740243bcb1976b54a554df1c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfMy0zLTEtMS0w_6e45a4ed-bcd0-426d-9fa0-92bbeb22b187"
      unitRef="usd">0</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="ie609985fe35541f19bd9585994dad17f_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfMy01LTEtMS0w_e9df899f-1489-4a7c-bbf3-50d368519e3e"
      unitRef="usd">0</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i1be75556eccc47a1806b67aaab547b18_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfMy03LTEtMS0w_0fdaa368-7e6b-436c-ae79-857046477767"
      unitRef="usd">10131240</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieb19cb296ec14221a57f41b82c172241_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfNy0xLTEtMS0w_a857d598-e36f-48f0-8777-55bd9716b3eb"
      unitRef="usd">10131240</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3207f5a1740243bcb1976b54a554df1c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfNy0zLTEtMS0w_f6ef5095-123e-4c61-a531-9daf95bcfaec"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie609985fe35541f19bd9585994dad17f_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfNy01LTEtMS0w_517bb4a3-d3dd-424f-8ca6-6dc244b7d9ac"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1be75556eccc47a1806b67aaab547b18_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfNy03LTEtMS0w_81a1a7a1-e742-4920-8373-1a2ad16da95a"
      unitRef="usd">10131240</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ieb19cb296ec14221a57f41b82c172241_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfOS0xLTEtMS0w_4b267911-0727-4087-8aca-ec6e8aa79870"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i3207f5a1740243bcb1976b54a554df1c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfOS0zLTEtMS0w_b732d3c0-fb29-4bcd-8be3-37cbcaf89ed3"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ie609985fe35541f19bd9585994dad17f_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfOS01LTEtMS0w_7cc8b222-2d26-4e2c-b22d-7e3637dfbe9d"
      unitRef="usd">4127</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i1be75556eccc47a1806b67aaab547b18_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfOS03LTEtMS0w_d38b2c1c-b890-4db6-bd17-eec4225659bd"
      unitRef="usd">4127</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ieb19cb296ec14221a57f41b82c172241_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfMTAtMS0xLTEtMA_9ca0d6d8-386c-4ea6-b4d1-d0ff02c1bd10"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3207f5a1740243bcb1976b54a554df1c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfMTAtMy0xLTEtMA_defa9c4a-8ab6-45db-b78a-82363bce8e7d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie609985fe35541f19bd9585994dad17f_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfMTAtNS0xLTEtMA_736368f0-949c-483c-90f1-53e8e7e7423f"
      unitRef="usd">4127</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1be75556eccc47a1806b67aaab547b18_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80Ni9mcmFnOmIzZWUwMmNmOTcxNjQ1ZmY4MzUwMjgzMWNmMTJmZmYwL3RhYmxlOjA3MDZmMDQ4N2EzODQ5MTU4OTQ5YjdjYmIyNzVlYWM0L3RhYmxlcmFuZ2U6MDcwNmYwNDg3YTM4NDkxNTg5NDliN2NiYjI3NWVhYzRfMTAtNy0xLTEtMA_777be175-35ec-405b-815d-530a24e0264a"
      unitRef="usd">4127</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RleHRyZWdpb246M2JlMjYzZjhkOTYxNDg2NjgwY2MxYjk1MzJmNjFjNGVfODk_b28d6a69-852e-4bc1-bbc2-4624b5cd1717">Property and Equipment&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,635,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,482,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#x2014;accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,953,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,604,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RleHRyZWdpb246M2JlMjYzZjhkOTYxNDg2NjgwY2MxYjk1MzJmNjFjNGVfOTI_45779f46-50f6-44c6-8c67-adbd3ad0d251">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,635,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,482,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#x2014;accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,953,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,604,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic730906a9b7146d1b973c557bc30b530_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfMS0xLTEtMS0w_70be0cac-489c-41c0-9fcd-1f3adf59d6e9"
      unitRef="usd">805920</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie1fd079695bc43f594a3fe0cf305011d_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfMS0zLTEtMS0w_202167dc-9df4-4185-be9b-5596ed9b086d"
      unitRef="usd">775030</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i13bcac6c13f146b59174b71aabe0cc5b_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfMi0xLTEtMS0w_f40f65af-b322-41ac-a250-3e1ee0be5084"
      unitRef="usd">1962230</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i186aff4c8c0e467286405c76465b4ba0_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfMi0zLTEtMS0w_27c74d2e-c968-4d60-9df9-e337d5d9b272"
      unitRef="usd">1962230</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1235b538bb13457d894f3ca7cec6739c_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfMy0xLTEtMS0w_a480cebb-0456-4c35-b98b-7d0569778b66"
      unitRef="usd">867750</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3da0359f941e46dfada6dc17aa275971_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfMy0zLTEtMS0w_1f5f3062-d790-416d-8fb4-fb271f3bc64b"
      unitRef="usd">744856</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfNC0xLTEtMS0w_4078264b-11cf-4d26-a35d-17541616719b"
      unitRef="usd">3635900</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfNC0zLTEtMS0w_c67e26ec-4d59-4223-851e-80f960e4886e"
      unitRef="usd">3482116</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfNS0xLTEtMS0w_36caf9ad-cce7-4222-9e74-7636610428e0"
      unitRef="usd">2953041</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfNS0zLTEtMS0w_ffbc9627-a7dd-419b-be46-baea3c3b522a"
      unitRef="usd">2604293</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfNi0xLTEtMS0w_a29711e5-3ab7-44ed-973f-0c59ea7ac1c0"
      unitRef="usd">682859</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV80OS9mcmFnOjNiZTI2M2Y4ZDk2MTQ4NjY4MGNjMWI5NTMyZjYxYzRlL3RhYmxlOjdlZDliYTM0NGQyYTRjZDU4Y2Q2MjY2NjUwMzBjNjhlL3RhYmxlcmFuZ2U6N2VkOWJhMzQ0ZDJhNGNkNThjZDYyNjY2NTAzMGM2OGVfNi0zLTEtMS0w_89af86df-e8c0-4b6d-a4c8-405e72bc6794"
      unitRef="usd">877823</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMjkwOQ_e1bdda56-392f-4799-8666-9dab5690dbcb">Leases&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;As a lessee, the Company&#x2019;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company (as a sublessor) also subleases portions of its facility to third parties under three separate subleases. All of these subleases have been determined to be operating leases and are accounted for separately from the head lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Master Facility Lease &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases a building in San Diego under an operating lease that expires on December&#160;31, 2021. The lease currently requires fixed monthly rent payments of approximately $78,000, with 3% annual escalation. The lease also contains one five-year renewal option with minimum monthly rent equal to the then-current fair market value, subject to a 3% annual increase. As the Company is not reasonably certain to exercise this option, it has not been included in the calculation of the lease liability or right-of-use asset related to this lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Facility Subleases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased the space to third parties under three separate sublease agreements, which all expire December 31, 2021. The Company recorded a cease-use loss liability and expense in 2018 pursuant to ASC 420, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exit or Disposal Cost Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, representing the total expected shortfall in sublease income for two of the subleases as compared to its required payments for those spaces under the remainder of the master lease term. This liability was being amortized over the remaining lease term until the adoption of ASC 842, whereupon the remaining cease-use loss liability of approximately $487,000 was eliminated and treated as a reduction to the beginning ROU asset value for the master lease as of January 1, 2019. Income will continue to be recognized on a straight-line basis over the term of the sublease.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of Right-of-Use Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recorded an impairment loss of $0 and $34,169 for the three and  nine months ended September 30, 2020, respectively.  The loss related to a vacated portion of the facility that was no longer being subleased. The Company determined that the prolonged loss of sublease income and an adverse commercial real estate market caused by COVID-19 were indicators of impairment. A fair value approach using quoted prices for similar assets was used to determine the impairment loss.  The loss was recorded within operating expenses in the condensed statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(299,812)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;883,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Sublease Income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Net Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 (excluding the nine months ended September 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(476,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeasesOfLessorDisclosureTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMjkyNA_5ddfc3b9-5f95-43f4-a870-491a1ea7821b">Leases&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;As a lessee, the Company&#x2019;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company (as a sublessor) also subleases portions of its facility to third parties under three separate subleases. All of these subleases have been determined to be operating leases and are accounted for separately from the head lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Master Facility Lease &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases a building in San Diego under an operating lease that expires on December&#160;31, 2021. The lease currently requires fixed monthly rent payments of approximately $78,000, with 3% annual escalation. The lease also contains one five-year renewal option with minimum monthly rent equal to the then-current fair market value, subject to a 3% annual increase. As the Company is not reasonably certain to exercise this option, it has not been included in the calculation of the lease liability or right-of-use asset related to this lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Facility Subleases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased the space to third parties under three separate sublease agreements, which all expire December 31, 2021. The Company recorded a cease-use loss liability and expense in 2018 pursuant to ASC 420, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exit or Disposal Cost Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, representing the total expected shortfall in sublease income for two of the subleases as compared to its required payments for those spaces under the remainder of the master lease term. This liability was being amortized over the remaining lease term until the adoption of ASC 842, whereupon the remaining cease-use loss liability of approximately $487,000 was eliminated and treated as a reduction to the beginning ROU asset value for the master lease as of January 1, 2019. Income will continue to be recognized on a straight-line basis over the term of the sublease.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of Right-of-Use Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recorded an impairment loss of $0 and $34,169 for the three and  nine months ended September 30, 2020, respectively.  The loss related to a vacated portion of the facility that was no longer being subleased. The Company determined that the prolonged loss of sublease income and an adverse commercial real estate market caused by COVID-19 were indicators of impairment. A fair value approach using quoted prices for similar assets was used to determine the impairment loss.  The loss was recorded within operating expenses in the condensed statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(299,812)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;883,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Sublease Income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Net Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 (excluding the nine months ended September 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(476,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
    <crdf:LessorNumberOfSubleases
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMTY0OTI2NzQ0NTU1Ng_116d99d8-2a66-4516-be81-efb5be01a622"
      unitRef="lease">3</crdf:LessorNumberOfSubleases>
    <crdf:LesseeOperatingLeaseMonthlyRentPayment
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfNjE0_9c0a4558-0bae-4f45-b9a3-e6bd0299cdde"
      unitRef="usd">78000</crdf:LesseeOperatingLeaseMonthlyRentPayment>
    <crdf:LesseeOperatingLeaseAnnualRentIncreasePercentage
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfNjIz_e55965e6-5488-4d2d-bc85-304e19a5e2fd"
      unitRef="number">0.03</crdf:LesseeOperatingLeaseAnnualRentIncreasePercentage>
    <crdf:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfNjY5_45b02aec-3cbb-4549-86ce-6df0af1b45b4"
      unitRef="renewal_option">1</crdf:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMjkxMQ_3aa7936c-4a07-4952-8fb7-6d328615ba78">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <crdf:LesseeOperatingLeaseAnnualRentIncreasePercentage
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfNzc5_38e08069-8817-4bb1-b191-223b5d5f4cde"
      unitRef="number">0.03</crdf:LesseeOperatingLeaseAnnualRentIncreasePercentage>
    <crdf:LessorNumberOfSubleases
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMTE1NA_df6e18c1-4eb7-4926-9ba1-1948fa61bdbd"
      unitRef="lease">3</crdf:LessorNumberOfSubleases>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i3ffb8f629fcb46718f4c859a146c71fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMTc2OA_5fd1693f-b8e1-46e7-a523-10e9f026d790"
      unitRef="usd">487000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMTA5OTUxMTYzMTY0OQ_eb1e4332-20a1-4ce7-a50c-7d39126f4143"
      unitRef="usd">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMjA2Mw_39c0e6e8-a117-4eb1-aced-d69505431eb8"
      unitRef="usd">34169</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMjkyNQ_247fbf5b-cd71-4f0f-af8f-8a85830fc6f7">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(299,812)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfMi0xLTEtMS0w_155b94e7-8bcc-4680-a0a7-c1db7bc6aadd"
      unitRef="usd">98808</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfMi0zLTEtMS0w_561dcf6d-8e7c-4d48-a82d-3817cb222de5"
      unitRef="usd">191472</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfMi01LTEtMS0w_b41863da-5988-4db2-a290-2c944b014ad7"
      unitRef="usd">344836</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfMi03LTEtMS0w_414dea1d-701e-4ec0-b384-c777d67287da"
      unitRef="usd">578919</us-gaap:OperatingLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfMy0xLTEtMS0w_0ebde78f-1830-40f4-9ed7-9f336010e986"
      unitRef="usd">72793</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfMy0zLTEtMS0w_a2b56999-0a51-457f-a485-dfa411b2f7be"
      unitRef="usd">99937</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfMy01LTEtMS0w_7a0c6886-8c48-401e-bb37-ef393c3686d3"
      unitRef="usd">218380</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfMy03LTEtMS0w_c30824e7-36e9-4fe4-b7ab-f3d56656ddc8"
      unitRef="usd">299812</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfNC0xLTEtMS0w_5caae347-0abd-4753-a26b-e0e7640d512e"
      unitRef="usd">26015</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfNC0zLTEtMS0w_f4d705a6-bf9f-483d-8b06-17cd13d039e3"
      unitRef="usd">91535</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfNC01LTEtMS0w_5fd6e232-d22f-44cd-9a9f-65e25de0c3ca"
      unitRef="usd">126456</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjZjODM5YTNlMTM4NTQzNmZiNmJkZTllNTE3ZmFhOTRlL3RhYmxlcmFuZ2U6NmM4MzlhM2UxMzg1NDM2ZmI2YmRlOWU1MTdmYWE5NGVfNC03LTEtMS0w_dbdc14b0-1414-4674-bbd7-9e58b32f9696"
      unitRef="usd">279107</us-gaap:LeaseCost>
    <crdf:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMjkwNQ_fc537d0f-c576-41ca-ac29-3260bf9c6769">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;883,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</crdf:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfMS0xLTEtMS0w_abcc3464-48f0-40cc-a937-5a164235ffeb"
      unitRef="usd">423163</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfMS0zLTEtMS0w_9aceb7e3-b12c-47fd-bb7d-49d1b92b7006"
      unitRef="usd">697418</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfMy0xLTEtMS0w_6e16dd25-511e-4d04-9902-13c8ca54a825"
      unitRef="usd">883534</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfMy0zLTEtMS0w_d2431c72-7b24-45f7-8621-33bc40f3044b"
      unitRef="usd">865379</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfNC0xLTEtMS0w_191c1818-bd64-4527-9495-b7817f743b54"
      unitRef="usd">207178</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfNC0zLTEtMS0w_2aa403b1-b020-486f-b0a1-1d7fc556bad9"
      unitRef="usd">860963</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfNS0xLTEtMS0w_782ac0ce-955d-4d44-b0fd-bf9be70cd4f4"
      unitRef="usd">1090712</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfNS0zLTEtMS0w_6062cfff-1363-4a09-a44c-950244d292d2"
      unitRef="usd">1726342</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfNy0xLTEtMS0w_821fdcd1-4677-42a7-85df-e3d66efa2f5a">P1Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfNy0zLTEtMS0w_f5fc7a3e-a379-4fab-8c91-e0047a9f4697">P2Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfOC0xLTEtMS0w_8227b566-26ad-4760-a2e5-5dbd2b759ca4"
      unitRef="number">0.065</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOmVhYTViZDY5NmE1NTQ2ZDc4ZjUzY2EwMGNhZjZlNDBiL3RhYmxlcmFuZ2U6ZWFhNWJkNjk2YTU1NDZkNzhmNTNjYTAwY2FmNmU0MGJfOC0zLTEtMS0w_804a7bd1-51ee-4b64-95de-c5ad07385cc2"
      unitRef="number">0.065</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjY3Mjc5M2ZhMTlmMzQxZWM5Mzk5MTY0NjI0OWFhYjgzL3RhYmxlcmFuZ2U6NjcyNzkzZmExOWYzNDFlYzkzOTkxNjQ2MjQ5YWFiODNfMy0xLTEtMS0w_d2d13dfe-6cbc-4d62-9be2-1287582759df"
      unitRef="usd">236748</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjY3Mjc5M2ZhMTlmMzQxZWM5Mzk5MTY0NjI0OWFhYjgzL3RhYmxlcmFuZ2U6NjcyNzkzZmExOWYzNDFlYzkzOTkxNjQ2MjQ5YWFiODNfMy0zLTEtMS0w_1e83b3ef-796c-4690-9981-568b73d191fd"
      unitRef="usd">229927</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjY3Mjc5M2ZhMTlmMzQxZWM5Mzk5MTY0NjI0OWFhYjgzL3RhYmxlcmFuZ2U6NjcyNzkzZmExOWYzNDFlYzkzOTkxNjQ2MjQ5YWFiODNfMy01LTEtMS0w_e88bfd83-5c31-4552-a510-28783f93d88a"
      unitRef="usd">706211</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjY3Mjc5M2ZhMTlmMzQxZWM5Mzk5MTY0NjI0OWFhYjgzL3RhYmxlcmFuZ2U6NjcyNzkzZmExOWYzNDFlYzkzOTkxNjQ2MjQ5YWFiODNfMy03LTEtMS0w_ba8e7d36-89a0-4873-bffe-8f72a8f7192e"
      unitRef="usd">685865</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RleHRyZWdpb246MzVlYjQxMzI4MGUwNDVjZThiYzAwYmVjNmI4ZGQyNWNfMjkxNA_a870dc6d-d130-4991-b7fb-83c3c31a1d72">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Sublease Income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Net Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 (excluding the nine months ended September 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(476,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfMi0xLTEtMS0w_4069354b-9015-4970-acec-714e78b15f16"
      unitRef="usd">159167</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfMi0zLTEtMS0w_ff47ec26-cc16-4742-9148-905a451daed9"
      unitRef="usd">72793</us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear>
    <crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfMi01LTEtMS0w_c129ace0-1fc9-48f9-8baf-aa6e72da3471"
      unitRef="usd">86374</crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfMy0xLTEtMS0w_8af22723-6b75-460e-98ae-00f6c62315d0"
      unitRef="usd">968165</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfMy0zLTEtMS0w_68733e90-5176-4d3d-bd3e-97a9f58aef7f"
      unitRef="usd">403345</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfMy01LTEtMS0w_3c88ed1b-d5b3-484a-9179-667e22b2bafa"
      unitRef="usd">564820</crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfNC0xLTEtMS0w_8291f4b3-2462-43ab-bf2d-fbef7ce23a03"
      unitRef="usd">5868</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfNC0zLTEtMS0w_cb16d3c7-3398-428f-a9f4-fceecb6a2a7d"
      unitRef="usd">0</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfNC01LTEtMS0w_3a28371d-60b4-4f61-ad19-bca8b15b8511"
      unitRef="usd">5868</crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfNS0xLTEtMS0w_715419c1-b72a-484c-8c1c-5706341d97d5"
      unitRef="usd">3423</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfNS0zLTEtMS0w_16d09eab-26a9-4fb0-8424-f0123d47a119"
      unitRef="usd">0</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfNS01LTEtMS0w_7fcd3c8b-f0fb-4f4f-a3c1-a63cc930d65e"
      unitRef="usd">3423</crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfNi0xLTEtMS0w_7afbddc5-7d2b-41b1-aaf1-0608c0d03ba9"
      unitRef="usd">1136623</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfNi0zLTEtMS0w_cd206ab6-7f7c-473c-b7c1-86d7dd8e5539"
      unitRef="usd">476138</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfNi01LTEtMS0w_91860c5e-2b71-4363-bc54-e70a96ecf167"
      unitRef="usd">660485</crdf:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfNy0xLTEtMS0w_b1e2a091-c29a-48a8-81e4-e2b58a01d688"
      unitRef="usd">45911</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81Mi9mcmFnOjM1ZWI0MTMyODBlMDQ1Y2U4YmMwMGJlYzZiOGRkMjVjL3RhYmxlOjE3NGE2MDNlYjk5MjQ2NTk5MTFhYzQ5Yjk1ODkzYmM3L3RhYmxlcmFuZ2U6MTc0YTYwM2ViOTkyNDY1OTkxMWFjNDliOTU4OTNiYzdfOC0xLTEtMS0w_fa9ba3c7-e896-4468-8226-4d9fc5528440"
      unitRef="usd">1090712</us-gaap:OperatingLeaseLiability>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RleHRyZWdpb246NTY3OTM0MzkxZDQzNDQ2YjliYzE5NDBlMGRjOGMyZWJfMTkzMA_2f380153-26e9-4c4a-97f6-1b19b9a90236">Derivative Financial Instruments &#x2014; Warrants&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based upon the Company&#x2019;s analysis of the criteria contained in ASC Topic 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 815-40&#x201d;) or ASC Topic 480-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 480-10&#x201d;), Cardiff Oncology determined that certain warrants issued in connection with the execution of certain equity financings must be recorded as derivative liabilities.&#160;In accordance with ASC 815-40 and ASC 480-10, the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant change in fair value is being recorded in the Company&#x2019;s condensed statements of operations.&#160;The Company estimates the fair value of these warrants using the Black-Scholes option pricing model.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The range of assumptions and weighted averages used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated were:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Range:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated fair value of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.01 - $14.19&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.51 - $3.75&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected warrant term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3 - 3.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3 - 4.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14 - 1.62%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.56 - 2.49%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110 - 118%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102 - 106%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$14.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected warrant term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Weighted average is only disclosed for periods after January 1, 2020 under the adoption of ASU 2018-13. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) The weighted average was calculated using the relative fair value method. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility is based on historical volatility of Cardiff Oncology&#x2019;s common stock.&#160;The warrants have a transferability provision and based on guidance provided in Staff Accounting Bulletin (&#x201c;SAB&#x201d;) No. 107, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Payment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;SAB No. 107&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for instruments issued with such a provision, Cardiff Oncology used the remaining contractual term as the expected term of the warrants.&#160;The risk-free rate is based on the U.S.&#160;Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of changes in the Company&#x2019;s derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;Instrument&lt;br/&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants during the period recognized as a loss in the condensed statements of operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="ib123867495f94547b6cb9b6106e13878_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RleHRyZWdpb246NTY3OTM0MzkxZDQzNDQ2YjliYzE5NDBlMGRjOGMyZWJfMTkxNg_820e4a92-a94c-4e20-be85-464b93ff575e">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The range of assumptions and weighted averages used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated were:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Range:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated fair value of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.01 - $14.19&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.51 - $3.75&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected warrant term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3 - 3.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3 - 4.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14 - 1.62%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.56 - 2.49%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110 - 118%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102 - 106%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$14.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected warrant term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Weighted average is only disclosed for periods after January 1, 2020 under the adoption of ASU 2018-13. &lt;/span&gt;&lt;/div&gt;(2) The weighted average was calculated using the relative fair value method.</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <crdf:EstimatedFairValueOfWarrant
      contextRef="ia632870d35b34e9dbf2630ee46469e33_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfMy0xLTEtMS0wL3RleHRyZWdpb246MDVjYmFiN2ZkOTRhNDIyNjk4OTgwN2Y3YzZhMWE0YTBfNA_87340382-7880-42d5-9e85-39a02091b567"
      unitRef="usdPerShare">1.01</crdf:EstimatedFairValueOfWarrant>
    <crdf:EstimatedFairValueOfWarrant
      contextRef="i252b5a3294c7458b81a17c82715f2098_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfMy0xLTEtMS0wL3RleHRyZWdpb246MDVjYmFiN2ZkOTRhNDIyNjk4OTgwN2Y3YzZhMWE0YTBfOQ_b3ab0677-f6d7-40a9-9f84-fb6a40d37cfd"
      unitRef="usdPerShare">14.19</crdf:EstimatedFairValueOfWarrant>
    <crdf:EstimatedFairValueOfWarrant
      contextRef="ib1791fb1fc4d4c5d9d1db0ecd2bdad61_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfMy0zLTEtMS0wL3RleHRyZWdpb246MTdiYWNiMmQ3ZWU2NGRiMDhhNWJjZjVjY2MxNzI2MDNfNA_01dd34f5-c300-4765-8508-d88fdb9ee9e4"
      unitRef="usdPerShare">1.51</crdf:EstimatedFairValueOfWarrant>
    <crdf:EstimatedFairValueOfWarrant
      contextRef="i16ba3ca0f0224c749930d1fc21651e07_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfMy0zLTEtMS0wL3RleHRyZWdpb246MTdiYWNiMmQ3ZWU2NGRiMDhhNWJjZjVjY2MxNzI2MDNfOQ_f4603d2a-13ea-4eaa-8ad9-b6670c979ed4"
      unitRef="usdPerShare">3.75</crdf:EstimatedFairValueOfWarrant>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i90efbe055b164d5c97f3d098c16522c7_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNC0xLTEtMS0wL3RleHRyZWdpb246MDQ1NTNlMDg0NDkyNDM4MGFiNzVmYTc5YTQ3NjdjNGRfNA_b2367153-400b-4be2-aa67-b5fc983c006c">P2Y3M18D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="iad3f1104f4364db7ab0e9e5d2154e3b1_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNC0xLTEtMS0wL3RleHRyZWdpb246MDQ1NTNlMDg0NDkyNDM4MGFiNzVmYTc5YTQ3NjdjNGRfOQ_d331ca13-00ce-45a9-9ef2-9f9285a0f165">P3Y1M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ieef3ac4d1b1741f39df174c71b480929_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNC0zLTEtMS0wL3RleHRyZWdpb246ZjI3Y2RhZjA3NmM3NGQ3YzkyY2FjODFjZTU1YTA5MDRfNA_118c05d9-4778-43fd-afe2-0b16558cfda0">P3Y3M18D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="id831883b118a48e387be55b132ff3344_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNC0zLTEtMS0wL3RleHRyZWdpb246ZjI3Y2RhZjA3NmM3NGQ3YzkyY2FjODFjZTU1YTA5MDRfOQ_a72049ce-9301-4784-a525-ca6ab237a00c">P4Y1M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i048344a9062f4510a9cbff0eebd42e0b_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNS0xLTEtMS0wL3RleHRyZWdpb246NWVjNGZlYjUzNmQ1NDBiNTg2MDdkM2Y4ZWNiNTMyY2FfNA_10b2983e-cf03-4822-94ed-5015b128d59d"
      unitRef="number">0.0014</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i578319d576ac40ef82ce89b1e70413e3_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNS0xLTEtMS0wL3RleHRyZWdpb246NWVjNGZlYjUzNmQ1NDBiNTg2MDdkM2Y4ZWNiNTMyY2FfOQ_4be43429-afa9-477a-a024-f94b41819669"
      unitRef="number">0.0162</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i30cf812ae8ab4b1fabcfb5a73eeb1c7d_I20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNS0zLTEtMS0wL3RleHRyZWdpb246N2ViZDIwM2M5ZTljNGY5MmIyOGZlZDY0MjcxYTYxYjBfNA_6de43eba-47f6-4a03-b6d0-034a76308e3f"
      unitRef="number">0.0156</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="icfd53102430c43678b9eae10ab1d3201_I20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNS0zLTEtMS0wL3RleHRyZWdpb246N2ViZDIwM2M5ZTljNGY5MmIyOGZlZDY0MjcxYTYxYjBfOQ_11ab9f62-152e-49f0-b610-b618205edcc9"
      unitRef="number">0.0249</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="id2ccfbfb002346579e7acceabf1ee362_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNi0xLTEtMS0wL3RleHRyZWdpb246OGNiN2RiZjNjZTllNGMyMWEwNGQyZWQyOTBiMjc3YzhfNA_9b0be662-1860-41ab-bd68-bc0b1fdff78c"
      unitRef="number">1.10</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i344555a942b24c73861cf579aa6c6b32_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNi0xLTEtMS0wL3RleHRyZWdpb246OGNiN2RiZjNjZTllNGMyMWEwNGQyZWQyOTBiMjc3YzhfOQ_995a5e05-3591-4717-9727-d1d2600c6714"
      unitRef="number">1.18</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="if89380272ed24b2cbde3226e6b36b53d_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNi0zLTEtMS0wL3RleHRyZWdpb246NTFhOWZlYzk3YWI2NDlmMjhmZTFhZDE2ZGNiMTYxNTZfNA_bc28885c-cb2f-4f5c-84cb-d5cfce6ef086"
      unitRef="number">1.02</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="id9154e610b334767a4b96b097661f34f_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNi0zLTEtMS0wL3RleHRyZWdpb246NTFhOWZlYzk3YWI2NDlmMjhmZTFhZDE2ZGNiMTYxNTZfOQ_e443d7b7-ac6a-4a25-affe-ee8856820776"
      unitRef="number">1.06</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i142d89ee985546c591160d9c6e366b3a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNy0xLTEtMS0w_d30ed84d-02b8-4d7f-aad7-e4e60808d36a"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ic6d4972e6afd4ac69b9a8f6a86fcc5fb_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfNy0zLTEtMS0w_29480b31-d298-449c-ae71-92e5d6836ef7"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <crdf:EstimatedFairValueOfWarrant
      contextRef="ifb6ee131f889432ba4524b13c5e5ca50_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfMTEtMS0xLTEtMA_08c56c4c-a0a7-4793-84a0-d902341fd4a0"
      unitRef="usdPerShare">14.19</crdf:EstimatedFairValueOfWarrant>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i83ac99d4b3ff4e2fb15a26aced83a7a1_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfMTItMS0xLTEtMA_e13fe102-5b90-4217-97e9-7c7935769c51">P2Y3M18D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="if51ce0d70552424db9d6267694e4b4e3_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfMTMtMS0xLTEtMA_cd8ef034-4110-4ed3-b9ff-3614c0e71c7c"
      unitRef="number">0.0014</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i412c95ab862b4b7aad07c1a3835d9cb8_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfMTQtMS0xLTEtMA_dc4619b6-2035-466c-92f6-dc74c0a4fcf1"
      unitRef="number">1.10</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ic64a7bb878fa4c36bcfb2c9240e8fd4c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmI5NjVmMzVjMjI4NjQ2Y2Q4MDVjMzUyZjAyYTdlMTM2L3RhYmxlcmFuZ2U6Yjk2NWYzNWMyMjg2NDZjZDgwNWMzNTJmMDJhN2UxMzZfMTUtMS0xLTEtMA_23399231-00f3-490f-ac58-3f98e7dd37b4"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <crdf:ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock
      contextRef="ib123867495f94547b6cb9b6106e13878_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RleHRyZWdpb246NTY3OTM0MzkxZDQzNDQ2YjliYzE5NDBlMGRjOGMyZWJfMTkyOQ_e64af923-0727-4322-b9dd-5a26483d62fa">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of changes in the Company&#x2019;s derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;Instrument&lt;br/&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants during the period recognized as a loss in the condensed statements of operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</crdf:ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ifcd94fffab0343acb682f8189e2a383b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmIxZDI2MmQwZjQxZDQwYzZiMGUxNzQ4MTdjMmYwY2YyL3RhYmxlcmFuZ2U6YjFkMjYyZDBmNDFkNDBjNmIwZTE3NDgxN2MyZjBjZjJfMS00LTEtMS0w_5127655a-ff9e-4b59-8cc4-818e53ef6703"
      unitRef="shares">64496</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ifcd94fffab0343acb682f8189e2a383b_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmIxZDI2MmQwZjQxZDQwYzZiMGUxNzQ4MTdjMmYwY2YyL3RhYmxlcmFuZ2U6YjFkMjYyZDBmNDFkNDBjNmIwZTE3NDgxN2MyZjBjZjJfMS02LTEtMS0w_3951acdf-3665-4508-b05f-fb80d75091c1"
      unitRef="usd">4127</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i4f3906c2627e45ebbf6c1fd90f256031_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmIxZDI2MmQwZjQxZDQwYzZiMGUxNzQ4MTdjMmYwY2YyL3RhYmxlcmFuZ2U6YjFkMjYyZDBmNDFkNDBjNmIwZTE3NDgxN2MyZjBjZjJfMy02LTEtMS0w_72fb9abd-6318-4298-9e05-d5850cb2a394"
      unitRef="usd">186072</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i5a725951ef874d2f949c21c129a5effc_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmIxZDI2MmQwZjQxZDQwYzZiMGUxNzQ4MTdjMmYwY2YyL3RhYmxlcmFuZ2U6YjFkMjYyZDBmNDFkNDBjNmIwZTE3NDgxN2MyZjBjZjJfNC00LTEtMS0w_df9b61dc-4129-43a9-b392-d8e9cb3dd4ef"
      unitRef="shares">64496</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i5a725951ef874d2f949c21c129a5effc_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81NS9mcmFnOjU2NzkzNDM5MWQ0MzQ0NmI5YmMxOTQwZTBkYzhjMmViL3RhYmxlOmIxZDI2MmQwZjQxZDQwYzZiMGUxNzQ4MTdjMmYwY2YyL3RhYmxlcmFuZ2U6YjFkMjYyZDBmNDFkNDBjNmIwZTE3NDgxN2MyZjBjZjJfNC02LTEtMS0w_65e0a884-bb6b-4bfc-893d-5374829cf86b"
      unitRef="usd">190199</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTEwNTk_62a82b34-64e1-40ca-8637-4e37cfae63d3">Stockholders&#x2019; Equity&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrecognized compensation cost related to non-vested stock options outstanding at September&#160;30, 2020 and 2019, net of estimated forfeitures, was $2,388,077 and $1,476,725, respectively, which is expected to be recognized over a weighted-average remaining vesting period of 2.2 and 2.4 years, respectively.&#160;The weighted-average remaining contractual term of outstanding options as of September&#160;30, 2020 was approximately 9.1 years. The total fair value of stock options vested during the nine months ended September 30, 2020 and 2019 were $770,582 and $321,870, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity and changes in stock options outstanding is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled / Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,920,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,766,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,507,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 6, 2019, the number of authorized shares in the Cardiff Oncology 2014 Equity Incentive Plan (&#x201c;2014 EIP&#x201d;) was increased from 243,056 to 1,243,056. On April 16, 2020 the 2014 EIP was amended to increase the number of shares of common stock reserved for issuance thereunder to 2,243,056 from 1,243,056. As of September&#160;30, 2020, there were 258,497 shares available for issuance under the 2014 EIP.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the RSU activity is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair Value&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSUs outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSUs outstanding, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of vested RSUs during the nine months ended September 30, 2020 and 2019 were $100,585 and $169,563, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&#160;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&#160;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,589,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,831,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,047,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluded from the table above are 992,039 pre-funded warrants that were exercised during the nine months ended September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our Company's classes of preferred stock is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Par value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares designated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidation preference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series C Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series D Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series C Convertible Preferred Stock and Service Receivable&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 25, 2019, the Company entered into a Master Services Agreement and a Stock and Warrant Subscription Agreement with PoC Capital, LLC (&#x201c;PoC&#x201d;), whereby PoC agreed to finance $1.675 million for the development costs associated with Phase 1b/2 study of onvansertib in combination with FOLFIRI and Avastin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in patients with metastatic Colorectal Cancer (&#x201c;mCRC&#x201d;) harboring KRAS mutation in exchange for (i)183,334 shares of common stock, (ii) warrants to purchase an aggregate of 150,000 shares of common stock, with an exercise price of $3.762 per share, expiring on January 25, 2024, and (iii) 200,000 shares of Series C Convertible Preferred Stock, each share of which was convertible into 1.67 shares of common stock. In April of 2019, all 200,000 shares of Series C Convertible Preferred Stock were converted into 333,333 shares of the Company's common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the awards issued under this transaction and determined they should be classified as equity. These equity awards were fully vested and non-forfeitable. Since the equity awards were for clinical trial services yet to be provided, the Company recognized $1.675 million service receivables as contra equity. The Company releases the service receivables as clinical trial services are performed. The conversion feature of the Series C Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series C Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $0.3 million related to the beneficial conversion feature arising from the issuance of Series C Convertible Preferred Stock. This non-cash deemed dividend increased the Company&#x2019;s net loss attributable to common stockholders and net loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series D Convertible Preferred Stock and Service Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 8, 2020, the Company entered into a Stock and Warrant Subscription Agreement with PoC, whereby PoC agreed to finance an additional $2.3 million for a clinical trial in exchange for (i) 602,833 shares of its common stock (the &#x201c;Common Stock&#x201d;), (ii) 154,670 shares of its Series D Preferred Stock (as defined below) and (iii) a warrant exercisable for 859,813 shares of its Common Stock. In exchange, PoC is funding our clinical development of onvansertib in metastatic colorectal cancer pursuant to a Master Services Agreement dated as of January 25, 2019 by and among the Company, Integrium, LLC and PoC, as amended. The warrant will be exercisable six months following the date of issuance at an exercise price of $1.50 per share and will expire on November 7, 2025. In June of 2020, all 154,670 Series D Preferred Stock were converted to 1,546,700 shares of Common Stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the awards issued under this transaction and determined they should be classified as equity. These equity awards were fully vested and non-forfeitable. Since the equity awards were for clinical trial services yet to be provided, the Company recognized $2.3&#160;million service receivables as contra equity. The Company releases the service receivables as clinical trial services are performed. The conversion feature of the Series D Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series D Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $0.6&#160;million related to the beneficial conversion feature arising from the issuance of Series D Convertible Preferred Stock. This non-cash deemed dividend increased the Company&#x2019;s net loss attributable to common stockholders and net loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series E Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 15, 2020 the Company entered into a Securities Purchase Agreement with Acorn Bioventures LP ("Acorn"), CDK Associates, L.L.C. (&#x201c;CDK&#x201d;) and Third Street Holdings LLC (&#x201c;Third Street&#x201d;), pursuant to which the Company agreed to offer, issue and sell to Acorn, CDK and Third Street, (i) in a registered direct offering, an aggregate of 1,984,328 shares of common stock and (ii) in a concurrent private placement, (a) an aggregate of 865,824 shares of Series E Preferred Stock (&#x201c;Series E Preferred Stock&#x201d;) and (b) Series N warrants to purchase up to 2,213,115 shares of Common Stock. The Series E Preferred Stock is convertible at any time determined by dividing the $10 stated value per share of the Series E Preferred Stock by a conversion price of $2.44 per share, subject to adjustment in accordance with the Certificate of Designation. The Series N Warrants will be exercisable six months following the date of issuance at an exercise price of $2.39 per share and will expire on December 16, 2025. As of September&#160;30, 2020, there were 865,824 shares of Series E Convertible Preferred Stock outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The conversion feature of the Series E Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series E Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $2.7&#160;million related to the beneficial conversion feature arising from the issuance of Series E Convertible Preferred Stock. This non-cash deemed dividend increased the Company&#x2019;s net loss attributable to common stockholders and net loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In conjunction with the June 15, 2020 offering, we issued 184,426 warrants as an advisory fee. These warrants are exercisable six months following the date of issuance at an exercise price of $3.05 per share and will expire 5.5 years following the date of issuance. These warrants are classified as equity and its estimated fair value of $370,666 was recognized as additional paid in capital on the issuance date. The estimated fair value is determined using the Black-Scholes Option Pricing Model which is based on the value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Purchase Agreements with Lincoln Park Capital Fund, LLC&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 30, 2020, the Company entered into a Securities Purchase Agreement with Lincoln Park Capital Fund, LLC (&#x201c;LPC&#x201d;), pursuant to which the Company agreed to offer, issue and sell to LPC, (i) in a registered direct offering, an aggregate of (a) 800,000 shares of common stock and (b) Series I warrants to purchase up to 131,967 shares (the &#x201c;Series I Warrant Shares&#x201d;) of  common stock. In a concurrent private placement, the Company also sold to LPC Series J warrants (the &#x201c;Series J Warrants&#x201d;) to purchase one share of common stock for each Share and for each Series I Warrant purchased for cash in the registered direct offering. The Series J Warrants are exercisable six months following the date of issuance at an exercise price of $0.948 per share and will expire 5.5 years following the date of issuance. The gross proceeds from this purchase were $1.0&#160;million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On April 9, 2020, the Company entered into a Securities Purchase Agreement with LPC, pursuant to which the Company agreed to offer, issue and sell to LPC, (i) in a registered direct offering, an aggregate of (a) 904,970 shares of common stock and (b) Series K warrants to purchase up to 255,000 shares (the &#x201c;Series K Warrant Shares&#x201d;) of common stock. In a concurrent private placement, the Company also sold to LPC Series L warrants (the &#x201c;Series L Warrants&#x201d;) to purchase one share of Common Stock for each Share and for each Series K Warrant purchased for cash in the registered direct offering. The Series L Warrants are exercisable six months following the date of issuance at an exercise price of $0.81 per share and will expire 5.5 years following the date of issuance. The gross proceeds from this purchase were $1.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Purchase Agreement With Certain Directors and Executives&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On May 11, 2020 and May 14, 2020, the Company entered into Securities Purchase Agreements with certain directors and executives of the Company pursuant to which the Company sold 447,761 shares of common stock at a purchase price of $1.34 per share and 146,854 shares of common stock at a purchase price of $1.43 per share. The gross proceeds from these purchases were $810,000. &lt;/span&gt;&lt;/div&gt;Securities Purchase Agreement with Acorn Bioventures LPOn May 26, 2020, the Company entered into a Securities Purchase Agreement with Acorn, pursuant to which the Company agreed to offer, issue and sell to Acorn, (i) in a registered direct offering, an aggregate of 1,205,400 shares of common stock and (ii) in a concurrent private placement, Series M warrants to purchase up to 482,160 shares of common stock. The Series M Warrants are exercisable six months following the date of issuance at an exercise price of $2.024 per share and will expire 5.5 years following the date of issuance. The gross proceeds from this purchase were $2.5&#160;million.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTEwNTM_43919ad6-808a-4fad-a86e-98913b756742">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icd6b8b4cf5a542a297c33f23f0231c1b_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfMy0xLTEtMS0w_873a5a29-31a3-4c6b-a943-179c40271852"
      unitRef="usd">104259</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0b057edf8d344b4491e948f3e69dfbe2_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfMy0zLTEtMS0w_8e904f9f-67d2-4a92-83f7-d2dc75f7bf2d"
      unitRef="usd">104153</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2deab4e6786544879aa966ac0a102502_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfMy01LTEtMS0w_efc33c57-bcd7-4456-95a1-84f977e444ab"
      unitRef="usd">251212</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i55f43f9e04394c4795b66f2466f5c7a4_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfMy03LTEtMS0w_0e603535-3dfb-4afb-b951-fc60a06fdf77"
      unitRef="usd">300291</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iade2911f07fe4bd58a7771f4d8ff5609_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfNC0xLTEtMS0w_1136134f-4785-4273-80ce-cd09b1ed463a"
      unitRef="usd">257625</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5631259573e042a39f4be4eceee56516_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfNC0zLTEtMS0w_c51cdfff-ad2d-4138-a41a-25b5c9863301"
      unitRef="usd">162172</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i87383483b52740ad89c088078af10f5e_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfNC01LTEtMS0w_fd18e313-5578-44ce-8f7c-62d443f76a13"
      unitRef="usd">569757</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8ecb4a9d6a954fab97ac2a9e46298476_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfNC03LTEtMS0w_8ebf5203-af04-4f28-9d9b-620bce66fb51"
      unitRef="usd">314935</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfNy0xLTEtMS0w_a9710908-dd68-4124-b711-ba31e6aaf35e"
      unitRef="usd">361884</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i50f9b358f38d4a4ea69aeba8dafa1e90_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfNy0zLTEtMS0w_94eb8614-c9d2-4f4a-b0ec-e5e5fa77710a"
      unitRef="usd">266325</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfNy01LTEtMS0w_a7cf48e3-3e6b-4632-ac8a-544c534df594"
      unitRef="usd">820969</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmM1MjM2MGRiOTRhODRmZjdiNzgyYjlkNWI5NDIwN2NlL3RhYmxlcmFuZ2U6YzUyMzYwZGI5NGE4NGZmN2I3ODJiOWQ1Yjk0MjA3Y2VfNy03LTEtMS0w_59d91162-df79-45b8-9c37-0cd47c3b0ec9"
      unitRef="usd">615226</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i959cddd1d9ca46a1ae94c9e574311f33_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMzEz_e1fda553-2ab2-4e11-832a-eed4887edeae"
      unitRef="usd">2388077</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i046408524fc84867a0e1a4a0d4d161cc_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMzIw_c49e7dd9-8383-429d-9b51-d3bd3320cb92"
      unitRef="usd">1476725</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNDI1_025d0856-1803-4beb-a226-9b960e7160e9">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ia8619936082e4b66a9d9afbba2b5f205_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNDMy_eff0284c-490e-4215-a548-450ae5d11b6f">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNTQ4_1c40a17e-978a-448c-a56c-06f8f6bd2493">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNjIz_4d5efb58-db2f-43f6-9418-a25bd4092140"
      unitRef="usd">770582</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i1df742f0e8d1405ba7a8301ef7385b32_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNjMw_8c6946c6-8c4e-48a1-8b4a-d880426a008b"
      unitRef="usd">321870</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTEwNTQ_59be20dd-6fc0-4d40-89e5-41b49dbb8b5d">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmY0YjNkZTM5YWZmYTRhYWZhZTQ1OGU4ZDhkZDRkZWJjL3RhYmxlcmFuZ2U6ZjRiM2RlMzlhZmZhNGFhZmFlNDU4ZThkOGRkNGRlYmNfMi0xLTEtMS0w_e72b81d1-383f-4c4b-8af3-66cc37fb02bb"
      unitRef="number">0.0044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia8619936082e4b66a9d9afbba2b5f205_D20190101-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmY0YjNkZTM5YWZmYTRhYWZhZTQ1OGU4ZDhkZDRkZWJjL3RhYmxlcmFuZ2U6ZjRiM2RlMzlhZmZhNGFhZmFlNDU4ZThkOGRkNGRlYmNfMi0zLTEtMS0w_c86dfd50-1bf1-4990-b9eb-90e7e65f3292"
      unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmY0YjNkZTM5YWZmYTRhYWZhZTQ1OGU4ZDhkZDRkZWJjL3RhYmxlcmFuZ2U6ZjRiM2RlMzlhZmZhNGFhZmFlNDU4ZThkOGRkNGRlYmNfMy0xLTEtMS0w_ddbb02c9-08ce-43a8-9685-ba0d1908dc3e"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia8619936082e4b66a9d9afbba2b5f205_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmY0YjNkZTM5YWZmYTRhYWZhZTQ1OGU4ZDhkZDRkZWJjL3RhYmxlcmFuZ2U6ZjRiM2RlMzlhZmZhNGFhZmFlNDU4ZThkOGRkNGRlYmNfMy0zLTEtMS0w_a810b66f-1227-441b-95df-692bfaf84d1f"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmY0YjNkZTM5YWZmYTRhYWZhZTQ1OGU4ZDhkZDRkZWJjL3RhYmxlcmFuZ2U6ZjRiM2RlMzlhZmZhNGFhZmFlNDU4ZThkOGRkNGRlYmNfNC0xLTEtMS0w_0e5af2e8-5617-4b4d-b35b-01abada33b01"
      unitRef="number">1.047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia8619936082e4b66a9d9afbba2b5f205_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmY0YjNkZTM5YWZmYTRhYWZhZTQ1OGU4ZDhkZDRkZWJjL3RhYmxlcmFuZ2U6ZjRiM2RlMzlhZmZhNGFhZmFlNDU4ZThkOGRkNGRlYmNfNC0zLTEtMS0w_80d9d422-0c0d-4a45-b75d-85eeda01ea30"
      unitRef="number">0.955</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmY0YjNkZTM5YWZmYTRhYWZhZTQ1OGU4ZDhkZDRkZWJjL3RhYmxlcmFuZ2U6ZjRiM2RlMzlhZmZhNGFhZmFlNDU4ZThkOGRkNGRlYmNfNS0xLTEtMS0w_b7a6329a-86fd-41e1-914b-2c7986f2d517">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia8619936082e4b66a9d9afbba2b5f205_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmY0YjNkZTM5YWZmYTRhYWZhZTQ1OGU4ZDhkZDRkZWJjL3RhYmxlcmFuZ2U6ZjRiM2RlMzlhZmZhNGFhZmFlNDU4ZThkOGRkNGRlYmNfNS0zLTEtMS0w_d6822633-faf2-44cb-9a5e-e86a77c933eb">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTEwNDI_87302131-d4ff-477b-b7fb-f416f77729bf">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity and changes in stock options outstanding is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled / Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,920,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,766,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,507,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ida9ccce01325454aa5cdd8a070b92b32_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfMS0xLTEtMS0w_7d0d4a14-9801-408f-a082-1040fbe13cab"
      unitRef="shares">1015418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ida9ccce01325454aa5cdd8a070b92b32_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfMS0zLTEtMS0w_be2244f2-d6f2-48fe-99e2-dbbb2617d12c"
      unitRef="usdPerShare">12.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ida9ccce01325454aa5cdd8a070b92b32_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfMS01LTEtMS0w_60085a8f-406e-42ee-ab77-8ddbaee30a2c"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfMi0xLTEtMS0w_dc95671e-89ee-4915-9b84-061c46bff21a"
      unitRef="shares">969965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfMi0zLTEtMS0w_83b9355a-40f1-405b-90fd-002656da7079"
      unitRef="usdPerShare">2.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfMy0xLTEtMS0w_a489a29b-af4d-4fe7-b9a2-479d94862959"
      unitRef="shares">3333</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfMy0zLTEtMS0w_c34c079a-77c8-4276-ad8e-07454cef0742"
      unitRef="usdPerShare">2.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfNC0xLTEtMS0w_01b2511f-b98e-4ef0-a892-7e431ef0f79a"
      unitRef="shares">46069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfNC0zLTEtMS0w_75c6e98b-6b90-4209-8c2c-6f1268e0767f"
      unitRef="usdPerShare">12.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <crdf:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
      contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfNS0xLTEtMS0w_06baa9c9-154e-43b7-b4b4-14c44a18fa8e"
      unitRef="shares">15275</crdf:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod>
    <crdf:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfNS0zLTEtMS0w_328c6b4d-35af-4a73-af9f-da2a64cdc02f"
      unitRef="usdPerShare">8.98</crdf:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i959cddd1d9ca46a1ae94c9e574311f33_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfNi0xLTEtMS0w_14dcb721-5164-463e-9cd3-4d3e50b5f308"
      unitRef="shares">1920706</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i959cddd1d9ca46a1ae94c9e574311f33_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfNi0zLTEtMS0w_8218039c-dad1-4680-b547-0225a7a60d2f"
      unitRef="usdPerShare">7.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i959cddd1d9ca46a1ae94c9e574311f33_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfNi01LTEtMS0w_4fa88497-ac84-4588-ae6d-52a9abbf1f36"
      unitRef="usd">21766326</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i959cddd1d9ca46a1ae94c9e574311f33_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfNy0xLTEtMS0w_cbbe4dc4-21c8-4de6-9740-05009c8ef90e"
      unitRef="shares">441434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i959cddd1d9ca46a1ae94c9e574311f33_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfNy0zLTEtMS0w_d0f755da-bc3e-4749-befb-c10136830522"
      unitRef="usdPerShare">24.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i959cddd1d9ca46a1ae94c9e574311f33_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjlhZWNmNzQ1MjBjOTQyNDk5MjliOWFkNjAxNjI2YzVlL3RhYmxlcmFuZ2U6OWFlY2Y3NDUyMGM5NDI0OTkyOWI5YWQ2MDE2MjZjNWVfNy01LTEtMS0w_0b856f1e-b133-4ed1-99b3-7a9dacb4c07b"
      unitRef="usd">4507516</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i892b1dd1549d490f9a6e0de63da8493e_I20190605"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTEwOA_66dc708a-5178-445e-a631-83d3ceb12a3c"
      unitRef="shares">243056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ibcaf805475824b1c97f6e483866ff34f_I20190606"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTExNA_c71d5fb1-507b-4a6f-9644-2305f2c70fed"
      unitRef="shares">1243056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i8a5cf127866f4450ba5177b5b209e29e_I20200415"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTI0Ng_fbfb3867-26e6-49a0-997a-32e9b8883770"
      unitRef="shares">2243056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="iabec5ed6104d47f69e84008a3df403c9_I20200416"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTI1NA_2a1ccfd6-9975-464a-901e-363f5118f139"
      unitRef="shares">1243056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i972ffd28b08d461a8a8f34ee29c25c72_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTI3OQ_b21abced-fe02-4ed9-b458-7f60f2e36ae8"
      unitRef="shares">258497</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTEwNjE_2ea323bb-ff66-48ee-a19f-a6ce31590386">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the RSU activity is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair Value&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSUs outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSUs outstanding, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="ia0736ee7158d4ee1952c5ed8ecafc35d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmQyN2E1MmFhMjg3ZDQzOTU4ZmFjYjRmNmY2NmRjNjA1L3RhYmxlcmFuZ2U6ZDI3YTUyYWEyODdkNDM5NThmYWNiNGY2ZjY2ZGM2MDVfMS0xLTEtMS0w_e6bf886e-4c2b-4797-8e3f-785dff783f18"
      unitRef="shares">11301</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia0736ee7158d4ee1952c5ed8ecafc35d_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmQyN2E1MmFhMjg3ZDQzOTU4ZmFjYjRmNmY2NmRjNjA1L3RhYmxlcmFuZ2U6ZDI3YTUyYWEyODdkNDM5NThmYWNiNGY2ZjY2ZGM2MDVfMS0zLTEtMS0w_1885a1e7-848a-4943-b1fd-ca8374991474"
      unitRef="usdPerShare">15.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="ia0736ee7158d4ee1952c5ed8ecafc35d_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmQyN2E1MmFhMjg3ZDQzOTU4ZmFjYjRmNmY2NmRjNjA1L3RhYmxlcmFuZ2U6ZDI3YTUyYWEyODdkNDM5NThmYWNiNGY2ZjY2ZGM2MDVfMS01LTEtMS0w_768ece1f-e575-41e4-9f91-104f65768fca"
      unitRef="usd">14013</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ia8e40e0994bb469c98f27ccf0cf198f8_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmQyN2E1MmFhMjg3ZDQzOTU4ZmFjYjRmNmY2NmRjNjA1L3RhYmxlcmFuZ2U6ZDI3YTUyYWEyODdkNDM5NThmYWNiNGY2ZjY2ZGM2MDVfMy0xLTEtMS0w_60bc90c1-5084-4e3e-b421-069a0695b32d"
      unitRef="shares">10310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia8e40e0994bb469c98f27ccf0cf198f8_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmQyN2E1MmFhMjg3ZDQzOTU4ZmFjYjRmNmY2NmRjNjA1L3RhYmxlcmFuZ2U6ZDI3YTUyYWEyODdkNDM5NThmYWNiNGY2ZjY2ZGM2MDVfMy0zLTEtMS0w_8949d327-3ea8-4359-ba36-5f7dee91a608"
      unitRef="usdPerShare">9.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="ia8e40e0994bb469c98f27ccf0cf198f8_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmQyN2E1MmFhMjg3ZDQzOTU4ZmFjYjRmNmY2NmRjNjA1L3RhYmxlcmFuZ2U6ZDI3YTUyYWEyODdkNDM5NThmYWNiNGY2ZjY2ZGM2MDVfMy01LTEtMS0w_2c69b443-e40f-4ace-8105-b8fc61848d84"
      unitRef="usd">22875</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="icd88fd532f594f72a9d627dfe035ac48_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmQyN2E1MmFhMjg3ZDQzOTU4ZmFjYjRmNmY2NmRjNjA1L3RhYmxlcmFuZ2U6ZDI3YTUyYWEyODdkNDM5NThmYWNiNGY2ZjY2ZGM2MDVfNS0xLTEtMS0w_c28e4f63-ed2a-4f2b-9b76-28c0582a26d9"
      unitRef="shares">991</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="icd88fd532f594f72a9d627dfe035ac48_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmQyN2E1MmFhMjg3ZDQzOTU4ZmFjYjRmNmY2NmRjNjA1L3RhYmxlcmFuZ2U6ZDI3YTUyYWEyODdkNDM5NThmYWNiNGY2ZjY2ZGM2MDVfNS0zLTEtMS0w_3fad2aec-91ab-4bb7-b407-1b06f86e01ef"
      unitRef="usdPerShare">73.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="icd88fd532f594f72a9d627dfe035ac48_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmQyN2E1MmFhMjg3ZDQzOTU4ZmFjYjRmNmY2NmRjNjA1L3RhYmxlcmFuZ2U6ZDI3YTUyYWEyODdkNDM5NThmYWNiNGY2ZjY2ZGM2MDVfNS01LTEtMS0w_47ffd7f8-84bc-4385-8d63-52c0064ef63c"
      unitRef="usd">14062</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ia8e40e0994bb469c98f27ccf0cf198f8_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTQ3Mw_ab18b0e4-0926-4897-aadc-b8b0edaa2caa"
      unitRef="usd">100585</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i57c92be504a54fbda158b82418700c3b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTQ4MA_649b8ad3-19a5-459e-afa3-3969fdef2d76"
      unitRef="usd">169563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTEwNDM_2214372c-d929-4466-a7e5-3d0e72398869">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&#160;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&#160;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,589,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,831,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,047,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmZlYWRkY2RmNWMwZTQ3MjZhNDIwNjJjYTczMjFkZmM0L3RhYmxlcmFuZ2U6ZmVhZGRjZGY1YzBlNDcyNmE0MjA2MmNhNzMyMWRmYzRfMS0xLTEtMS0w_b9cbfae0-537d-4f8d-9c95-cd27b4d44a69"
      unitRef="shares">10589482</us-gaap:ClassOfWarrantOrRightOutstanding>
    <crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="ie1f73b5fbce249928d3fd6362296a372_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmZlYWRkY2RmNWMwZTQ3MjZhNDIwNjJjYTczMjFkZmM0L3RhYmxlcmFuZ2U6ZmVhZGRjZGY1YzBlNDcyNmE0MjA2MmNhNzMyMWRmYzRfMS0zLTEtMS0w_618c7ab2-47c4-4834-98e1-e663946b5b8d"
      unitRef="usdPerShare">4.08</crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
      contextRef="i85c6c9f6f5d545a68d3ccd6f9971a221_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmZlYWRkY2RmNWMwZTQ3MjZhNDIwNjJjYTczMjFkZmM0L3RhYmxlcmFuZ2U6ZmVhZGRjZGY1YzBlNDcyNmE0MjA2MmNhNzMyMWRmYzRfMS01LTEtMS0w_8306cd3c-fefa-4558-868c-c36b85fae8ba">P3Y8M12D</crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights>
    <crdf:ClassOfWarrantOrRightNumberGranted
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmZlYWRkY2RmNWMwZTQ3MjZhNDIwNjJjYTczMjFkZmM0L3RhYmxlcmFuZ2U6ZmVhZGRjZGY1YzBlNDcyNmE0MjA2MmNhNzMyMWRmYzRfMi0xLTEtMS0w_08d9ca0f-e6d0-4f10-9bf5-0935c597b265"
      unitRef="shares">5831451</crdf:ClassOfWarrantOrRightNumberGranted>
    <crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmZlYWRkY2RmNWMwZTQ3MjZhNDIwNjJjYTczMjFkZmM0L3RhYmxlcmFuZ2U6ZmVhZGRjZGY1YzBlNDcyNmE0MjA2MmNhNzMyMWRmYzRfMi0zLTEtMS0w_9f86ba2c-3680-478e-9dbd-2284675b9bc6"
      unitRef="usdPerShare">1.70</crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted>
    <crdf:ClassOfWarrantOrRightNumberExercised
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmZlYWRkY2RmNWMwZTQ3MjZhNDIwNjJjYTczMjFkZmM0L3RhYmxlcmFuZ2U6ZmVhZGRjZGY1YzBlNDcyNmE0MjA2MmNhNzMyMWRmYzRfMy0xLTEtMS0w_71fa03dc-d2b2-4282-bdc7-189ed95e9a0b"
      unitRef="shares">9047582</crdf:ClassOfWarrantOrRightNumberExercised>
    <crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmZlYWRkY2RmNWMwZTQ3MjZhNDIwNjJjYTczMjFkZmM0L3RhYmxlcmFuZ2U6ZmVhZGRjZGY1YzBlNDcyNmE0MjA2MmNhNzMyMWRmYzRfMy0zLTEtMS0w_8fb76398-ca36-40c1-891b-40d03e543715"
      unitRef="usdPerShare">2.17</crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmZlYWRkY2RmNWMwZTQ3MjZhNDIwNjJjYTczMjFkZmM0L3RhYmxlcmFuZ2U6ZmVhZGRjZGY1YzBlNDcyNmE0MjA2MmNhNzMyMWRmYzRfNS0xLTEtMS0w_f66461de-cff6-491e-be8a-c805fb76e73e"
      unitRef="shares">7373351</us-gaap:ClassOfWarrantOrRightOutstanding>
    <crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="if99a8ed180cc459681d3588755b7784f_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmZlYWRkY2RmNWMwZTQ3MjZhNDIwNjJjYTczMjFkZmM0L3RhYmxlcmFuZ2U6ZmVhZGRjZGY1YzBlNDcyNmE0MjA2MmNhNzMyMWRmYzRfNS0zLTEtMS0w_b06e4aae-46d2-4f06-8dc8-c3287564c969"
      unitRef="usdPerShare">4.54</crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOmZlYWRkY2RmNWMwZTQ3MjZhNDIwNjJjYTczMjFkZmM0L3RhYmxlcmFuZ2U6ZmVhZGRjZGY1YzBlNDcyNmE0MjA2MmNhNzMyMWRmYzRfNS01LTEtMS0w_a520dec6-1e9c-4d27-b9b6-221742b1c863">P4Y3M18D</crdf:ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights>
    <crdf:ClassOfWarrantOrRightNumberGranted
      contextRef="i7b1f3d6a8b304f008d1560110f698bb3_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTA5OTUxMTYzOTU5OQ_cd33678e-ccc3-4185-958a-696fbd748bd6"
      unitRef="shares">992039</crdf:ClassOfWarrantOrRightNumberGranted>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTEwNDQ_d89b9293-3888-4ae8-b18d-81065285e1ea">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our Company's classes of preferred stock is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Par value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares designated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidation preference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series C Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series D Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="idea78c0fd4d44a8084b8b53c668496d2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfMi0yLTEtMS0w_6246cb37-cb4b-46de-b926-b21d4126dd88"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="idea78c0fd4d44a8084b8b53c668496d2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfMi00LTEtMS0w_81c055a5-a9e4-4bef-926e-039b090f48be"
      unitRef="shares">277100</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="idea78c0fd4d44a8084b8b53c668496d2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfMi02LTEtMS0w_406ea6ba-db7d-47fd-aa3f-4693e04ef7e6"
      unitRef="usd">606000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="idea78c0fd4d44a8084b8b53c668496d2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfMi04LTEtMS0w_2c21cf65-f952-4a92-b51b-a77d126cd1cd"
      unitRef="shares">60600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i488747dd585c416195aa8719cfb75a37_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfMi0xMC0xLTEtMA_65eb5189-2c6d-4bef-a2a4-e3fa834ae12e"
      unitRef="shares">60600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia99ee4a1746f4fe4ab0a83e29d9ebce8_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfMy0yLTEtMS0w_5933240e-3c8f-4cb3-ae7a-f501ce2094f1"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia99ee4a1746f4fe4ab0a83e29d9ebce8_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfMy00LTEtMS0w_0c541f25-3a53-483b-80e7-112d24347be4"
      unitRef="shares">8860</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia99ee4a1746f4fe4ab0a83e29d9ebce8_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfMy04LTEtMS0w_b9ed4145-130f-4d39-a2e4-600ce337cdcd"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie25dc1818267487abf4d33e2c6debe5c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfMy0xMC0xLTEtMA_a82fcd87-6a9f-43d8-9db8-7bea89c83141"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6788da5ccc444936ac79910ced50285e_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNC0yLTEtMS0w_cc534e83-4ded-471b-a9a8-23ac315a74ab"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6788da5ccc444936ac79910ced50285e_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNC00LTEtMS0w_3d4837bc-c5b7-41eb-af66-b57006220a92"
      unitRef="shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6788da5ccc444936ac79910ced50285e_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNC04LTEtMS0w_e1a865fd-aa6e-4927-ba59-5d15739d871c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2758eaad8b58491c9ca8fda860044695_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNC0xMC0xLTEtMA_af34e056-58c8-45e1-9402-f7babd19bafc"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6045af669a3745cd84ac6c08b964f8db_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNS0yLTEtMS0w_a166201c-0452-4f26-be15-95545160e7e7"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6045af669a3745cd84ac6c08b964f8db_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNS00LTEtMS0w_e6b0328b-b614-479c-9bcb-ce91e67e466b"
      unitRef="shares">154670</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6045af669a3745cd84ac6c08b964f8db_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNS04LTEtMS0w_2559eed5-fda6-48e3-9027-0fa1a9dddcf5"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i87e30ab734dd4d1c81c49063fddfc61c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNS0xMC0xLTEtMA_ad8d3acf-8f64-44a1-964b-4591bc72fc64"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i89e52a934cce4337b884a4e1340a6e33_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNi0yLTEtMS0w_de020208-eb89-49c3-8213-c7e7f9ffe55d"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i89e52a934cce4337b884a4e1340a6e33_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNi00LTEtMS0w_db55a1bb-218a-4fed-b3a8-ec29140d2741"
      unitRef="shares">865824</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i89e52a934cce4337b884a4e1340a6e33_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNi04LTEtMS0w_1adea359-74df-40b2-86cf-ab467970ea02"
      unitRef="shares">865824</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6a73b848ad3a456ab8efe3f435c2cc17_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RhYmxlOjllYzY4YTdiZGFjMDRlMmY5ZjU1NDU5NTIxZTYyNWVmL3RhYmxlcmFuZ2U6OWVjNjhhN2JkYWMwNGUyZjlmNTU0NTk1MjFlNjI1ZWZfNi0xMC0xLTEtMA_9b265408-dc04-4f06-a820-4aafaac2429e"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <crdf:AmountFinancedUnderAgreement
      contextRef="i5dd384648729485e814847bb936c3e19_D20190125-20190125"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTk5NA_05a277b1-0b56-44e2-b845-87e57fb7c2da"
      unitRef="usd">1675000</crdf:AmountFinancedUnderAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i42c394bde6f545e8b27bd5ddd62298f4_D20190125-20190125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMjIxMA_7a92d446-c696-4df0-8003-fbaa158e6edc"
      unitRef="shares">183334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <crdf:ClassOfWarrantOrRightNumberGranted
      contextRef="i5dd384648729485e814847bb936c3e19_D20190125-20190125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMjI3OQ_3c6a188b-e6f6-4945-91a2-24b29cd809bb"
      unitRef="shares">150000</crdf:ClassOfWarrantOrRightNumberGranted>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i6306bd3082c44e75b9d4bb83e91ac1d5_I20190125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMjMzMg_10efd2ef-6102-4e01-a416-69f6f8a87bd9"
      unitRef="usdPerShare">3.762</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i9473042322684048b0e1c330a634200d_D20190125-20190125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMjM4Ng_a0a60c80-1fa3-4a6b-88f1-5c3ec3e047b6"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="if90d90503a6a456396e7a7c6dd952122_I20190125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMjQ3OA_7419681d-4bb2-4c36-938f-abc2a09758c6"
      unitRef="shares">1.67</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="i39ceaeb412fa40d2948c4049aa876acc_D20190401-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMjUyNw_240cba9b-01d0-4b32-bf90-cf72507f03f9"
      unitRef="shares">200000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="ica50461d886a437e9c053eb1e77b24bf_D20190401-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMjU5Nw_b4f4c179-7735-4aed-be58-89b3c25eb0ff"
      unitRef="shares">333333</us-gaap:ConversionOfStockSharesIssued1>
    <crdf:Servicereceivable
      contextRef="i1e9dce01464f42658cfd49145c156296_I20190125"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMjk5Nw_64950b96-4288-488a-942b-4ec86d616252"
      unitRef="usd">1675000</crdf:Servicereceivable>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="ic492c1a7e6d541e3879728394630480b_D20190125-20190125"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMzQ4NQ_8b984d6c-e634-44e8-9934-d2a213c765fc"
      unitRef="usd">300000</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:AmountFinancedUnderAgreement
      contextRef="i802925f6b20a4ab883a3e64399b2625e_D20200508-20200508"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMzkyMw_5a52bccc-d8ff-47ea-b02d-94d11552a219"
      unitRef="usd">2300000</crdf:AmountFinancedUnderAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iafcaa2b479f245d0bd1d92340c68caa8_D20200508-20200508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMzk2Nw_f0e0808b-0798-497f-a012-310a883ca02a"
      unitRef="shares">602833</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i76014c469f9d4b79ad388b4bd5ef655f_D20200508-20200508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNDAyNA_71c4f2d0-468f-4130-8624-dbb1a8b8154f"
      unitRef="shares">154670</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i237b058632024beea09d8f721dc6c2fb_I20200508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNDEzNw_05de494a-c7e2-4ffc-97b3-0516671171ae"
      unitRef="shares">859813</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i237b058632024beea09d8f721dc6c2fb_I20200508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNDYzNQ_143712c8-1cb1-425f-bd81-ed0bd06b0616"
      unitRef="usdPerShare">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="if6bd6d0b8e894e96b013f0f9d4a47eb5_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNDcwNg_b63da646-ab49-4ce9-ae9d-71220ad24cae"
      unitRef="shares">154670</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="i4fa6df7a14994c2f9f5cf33cda5a8363_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNDc1Mg_8bc6ed3f-87f1-40fe-b2f2-1f4f5ebd9a7b"
      unitRef="shares">1546700</us-gaap:ConversionOfStockSharesIssued1>
    <crdf:Servicereceivable
      contextRef="i0134e1c7efdb4726b66acda8a7eadf9b_I20200508"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNTEzOA_a8be1a77-3c26-4d4e-a454-8d02f37a63ef"
      unitRef="usd">2300000</crdf:Servicereceivable>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i6b91e6f08a864448b74ef428e982d96b_D20200508-20200508"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNTYyNg_88e8c82b-40b6-469c-afe1-d6330373ea67"
      unitRef="usd">600000</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie5c36764fe274b08925b71b22a4d62aa_D20200615-20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNjI2Mw_ff9e74be-f316-4203-8bea-ccd120f255c5"
      unitRef="shares">1984328</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i4c6e0349b8984c0c91135effa1fe723b_D20200615-20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNjM1Mw_cd820b52-8ec1-439f-92d2-1663fffbb63d"
      unitRef="shares">865824</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i1f789e5648a44a9ebd4b303e67d1385f_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNjQ2NA_a4c78e1b-230a-4ab7-8b90-d7177195a270"
      unitRef="shares">2213115</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if1ab4f2aeab147b0810f2c0e9bca7283_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNjU3NA_a2ad3f7a-fb74-4a4c-a744-aa91f4468421"
      unitRef="usdPerShare">10</us-gaap:PreferredStockParOrStatedValuePerShare>
    <crdf:PreferredStockConvertibleConversionPrice
      contextRef="if1ab4f2aeab147b0810f2c0e9bca7283_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNjY1Nw_6dbd570d-4c2c-43b6-9af7-27e3759d171b"
      unitRef="usdPerShare">2.44</crdf:PreferredStockConvertibleConversionPrice>
    <crdf:ClassOfWarrantOrRightMonthsUntilExercisable
      contextRef="i5e16f37428d6480ca95ace2934d30b33_D20200615-20200615"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNjc4Ng_592ff86e-9dc8-43fd-a115-ae61f25bd953">P6M</crdf:ClassOfWarrantOrRightMonthsUntilExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i8f44ab1b15204ed1b2aa74e76adaa3eb_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNjg0NA_eb1170e9-ce39-4342-b6b4-1a84d5ab1a01"
      unitRef="usdPerShare">2.39</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i89e52a934cce4337b884a4e1340a6e33_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNjkxNg_112280e6-abf1-47b4-9134-f3850069fc93"
      unitRef="shares">865824</us-gaap:PreferredStockSharesOutstanding>
    <crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i3a1b1259103d4e9aae05e28f31feec2a_D20200615-20200615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNzM0MA_58eb30d8-b478-48fd-afd3-2dc8bbd0cd5f"
      unitRef="usd">2700000</crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <crdf:ClassOfWarrantOrRightIssued
      contextRef="i1f789e5648a44a9ebd4b303e67d1385f_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNzYzNw_b00edf90-1bd1-41f3-a4dc-f5560896b3be"
      unitRef="shares">184426</crdf:ClassOfWarrantOrRightIssued>
    <crdf:ClassOfWarrantOrRightMonthsUntilExercisable
      contextRef="i3a1b1259103d4e9aae05e28f31feec2a_D20200615-20200615"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNzcwMA_fcedde50-54ac-4ee1-a397-a28ea94588f4">P6M</crdf:ClassOfWarrantOrRightMonthsUntilExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i1f789e5648a44a9ebd4b303e67d1385f_I20200615"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNzc1OA_5793c808-64c8-4104-910a-ddaa4f015810"
      unitRef="usdPerShare">3.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <crdf:ClassOfWarrantOrRightExpirationTerm
      contextRef="i3a1b1259103d4e9aae05e28f31feec2a_D20200615-20200615"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNzc4Nw_d1d4e087-3b48-491d-bf34-23ed15d8cd81">P5Y6M</crdf:ClassOfWarrantOrRightExpirationTerm>
    <crdf:WarrantsFairValue
      contextRef="i3a1b1259103d4e9aae05e28f31feec2a_D20200615-20200615"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfNzg5NA_3f9509e6-fee3-4a9d-ae20-7564eea846a1"
      unitRef="usd">370666</crdf:WarrantsFairValue>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ib02c4909f8dd4c1390ce2b2d6f67d719_D20200330-20200330"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfODYyMA_731784b3-58de-45e4-bedf-cc790b227311"
      unitRef="shares">800000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i5ec1ce35bd704b2a8bec37b6d629c0a9_I20200330"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfODY5MA_dd2346af-0651-493d-b2c9-48ca3ea02455"
      unitRef="shares">131967</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="ifba3ba46775046ecb40386b74aace6e0_I20200330"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfODg3MA_f15527df-b3a8-4dee-a375-1b40a538702f"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <crdf:ClassOfWarrantOrRightMonthsUntilExercisable
      contextRef="i974ceaa146934ff9a98da6f12360fc49_D20200330-20200330"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTAzMg_b174b68c-58ff-4552-b808-02139805da56">P6M</crdf:ClassOfWarrantOrRightMonthsUntilExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ifba3ba46775046ecb40386b74aace6e0_I20200330"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTA5MA_d83fbde5-6e56-4d09-85f9-8b0618f67de0"
      unitRef="usdPerShare">0.948</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <crdf:ClassOfWarrantOrRightExpirationTerm
      contextRef="i974ceaa146934ff9a98da6f12360fc49_D20200330-20200330"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTExOQ_887f8371-b829-44db-9329-43d2be1ca753">P5Y6M</crdf:ClassOfWarrantOrRightExpirationTerm>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ib02c4909f8dd4c1390ce2b2d6f67d719_D20200330-20200330"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTE5Nw_9631f665-bab9-4219-8010-30e1ae6a78af"
      unitRef="usd">1000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ieef62941a8724a6eb7609cc6f162b59d_D20200409-20200409"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTQxNg_ba4e8438-992e-478c-ab30-d3a9ecc447f6"
      unitRef="shares">904970</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ibfd5397c17484e7d996cff5cd20825d2_I20200409"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTQ4Ng_607036b4-14d7-4188-adde-1524036ac95c"
      unitRef="shares">255000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i97c8fab924224323b855bff2be4699fb_I20200409"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTY2NQ_32ab74df-f4cd-4d81-81d2-5c7f662eebaa"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <crdf:ClassOfWarrantOrRightMonthsUntilExercisable
      contextRef="i6178fac3fa4f4c6e91065959e9e43ff8_D20200409-20200409"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTgyNw_ce363bd7-7fbb-429e-9be0-4e9ad34381b8">P6M</crdf:ClassOfWarrantOrRightMonthsUntilExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i97c8fab924224323b855bff2be4699fb_I20200409"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTg4NQ_755042bf-7ba1-463b-893f-564c29074740"
      unitRef="usdPerShare">0.81</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <crdf:ClassOfWarrantOrRightExpirationTerm
      contextRef="i6178fac3fa4f4c6e91065959e9e43ff8_D20200409-20200409"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTkxNA_cb86c7a8-7b9b-4d87-9fc2-a6280865cb30">P5Y6M</crdf:ClassOfWarrantOrRightExpirationTerm>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ieef62941a8724a6eb7609cc6f162b59d_D20200409-20200409"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfOTk5Mg_7808de89-d6f3-4c9a-94d4-200e0fd8c3e8"
      unitRef="usd">1100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iae68d7d006fe4e14b9a1eeee4dd8bc44_D20200511-20200511"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTAyNDQ_fe0561db-f2f8-4dfc-a572-530ac43d99f2"
      unitRef="shares">447761</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i6ed3fc7af1634151b2096d32abc0f74d_I20200511"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTAyOTM_e03e5596-b12a-4959-bf4b-a7d0f78d84fe"
      unitRef="usdPerShare">1.34</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i2cca101c80a44226a89c8c35200266b8_D20200514-20200514"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTAzMTA_17daabf5-59de-4a9b-821f-71afb40ee45c"
      unitRef="shares">146854</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ieda19dd800d74d44bd5230900bc96c90_I20200514"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTAzNTk_cf664c81-fb82-4adb-9457-61f9f6a5ed73"
      unitRef="usdPerShare">1.43</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i2cca101c80a44226a89c8c35200266b8_D20200514-20200514"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTA0MTg_6a553896-f0ba-4358-b5ae-1da9b268f11a"
      unitRef="usd">810000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="if100dfb4b4384fd0bb32098df385547f_D20200526-20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTA2OTI_4d9a3e15-27a1-4e29-8372-77290f0108b4"
      unitRef="shares">1205400</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i8617217253414190b2251159121acc8a_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTA3OTg_a28c5465-b3e4-4250-96ba-bf693f533663"
      unitRef="shares">482160</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <crdf:ClassOfWarrantOrRightMonthsUntilExercisable
      contextRef="i0f94e8c81c344800b60b03a24b2933a5_D20200526-20200526"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTA4NjM_e6d9edf4-2fb5-455b-bfbb-9cf13e42f73e">P6M</crdf:ClassOfWarrantOrRightMonthsUntilExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i8617217253414190b2251159121acc8a_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTA5MjE_17ad4f4f-f8cf-4984-8401-23bdca0242ef"
      unitRef="usdPerShare">2.024</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <crdf:ClassOfWarrantOrRightExpirationTerm
      contextRef="i0f94e8c81c344800b60b03a24b2933a5_D20200526-20200526"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTA5NTA_93aadb76-f56c-40f1-81dc-38d34268e728">P5Y6M</crdf:ClassOfWarrantOrRightExpirationTerm>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="if100dfb4b4384fd0bb32098df385547f_D20200526-20200526"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV81OC9mcmFnOmFhODg4M2YwYzJiMjRkZTA4MTY3YjU4YjAwNDgyYzExL3RleHRyZWdpb246YWE4ODgzZjBjMmIyNGRlMDgxNjdiNThiMDA0ODJjMTFfMTEwMjg_74ccc31f-6cf3-4b17-a6ae-0d27525d5e38"
      unitRef="usd">2500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82MS9mcmFnOjk0MTUxZGQwNzNiYjRhMDdiZWNkYmZjNzUzZDViZmI4L3RleHRyZWdpb246OTQxNTFkZDA3M2JiNGEwN2JlY2RiZmM3NTNkNWJmYjhfMjEzNg_effbbbb3-bc2b-4933-96c6-1481061f2d05">Commitments and Contingencies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Executive Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain executive agreements provide for severance payments in case of terminations without cause or certain change of control scenarios. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development and Clinical Trial Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Cardiff Oncology refers to as onvansertib.  Onvansertib is an oral, investigative drug and a highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine PLK1. The Company plans to develop onvansertib in patients with leukemias/lymphomas and solid tumor cancers. Upon execution of the agreement, the Company paid $2.0 million in license fees which were expensed to research and development costs. The Company was committed to order $1.0 million of future services provided by Nerviano, such as the cost to manufacture drug product, no later than June 30, 2019, and these services have been purchased. Terms of the agreement also provide for the Company to pay development milestones and royalties based on sales volume.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a party to various agreements under which it licenses technology on an exclusive basis in the field of human diagnostics and oncology therapeutics. License fees are generally calculated as a percentage of product revenues, with rates that vary by agreement. For the nine months ended September&#160;30, 2020 and 2019, payments have not been material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cardiff Oncology does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise from time to time that may harm the Company&#x2019;s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company&#x2019;s business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibff09abd8c4041f78419c55803eaf58b_D20170301-20170331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82MS9mcmFnOjk0MTUxZGQwNzNiYjRhMDdiZWNkYmZjNzUzZDViZmI4L3RleHRyZWdpb246OTQxNTFkZDA3M2JiNGEwN2JlY2RiZmM3NTNkNWJmYjhfNzYx_7a7c3600-ecc4-4475-9686-506ae38c8017"
      unitRef="usd">2000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PurchaseObligation
      contextRef="i24aa660d59c2466faf23e2429d2aa751_I20170331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82MS9mcmFnOjk0MTUxZGQwNzNiYjRhMDdiZWNkYmZjNzUzZDViZmI4L3RleHRyZWdpb246OTQxNTFkZDA3M2JiNGEwN2JlY2RiZmM3NTNkNWJmYjhfODcw_441b0e42-c23b-4c61-b9f6-dbf5f2dbe857"
      unitRef="usd">1000000.0</us-gaap:PurchaseObligation>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82NC9mcmFnOmIxMDI5ZTdhYjk3ODQ3MGM4ZjM2NjNlNTFlN2NhZGM5L3RleHRyZWdpb246YjEwMjllN2FiOTc4NDcwYzhmMzY2M2U1MWU3Y2FkYzlfODEx_b04aa050-6ce1-4775-9ede-fe1475816699">Related Party TransactionsIn November 2018, the Company entered into a Material Transfer Agreement (&#x201c;MTA&#x201d;) with Leucadia Life Sciences (&#x201c;Leucadia&#x201d;) pursuant to which Leucadia will develop a PCR-based assay for onvansertib for Acute Myeloid Leukemia (&#x201c;AML&#x201d;). The Company&#x2019;s Executive Chairman, Dr. Thomas Adams, is a principal stockholder of Leucadia.&#160;In connection with the MTA, the Company entered into a consulting agreement with Tommy Adams, Co-Founder &amp;amp; Chief Operating Officer of Leucadia, who is the son of Dr. Adams. During the three months ended September 30, 2020 and 2019 the Company incurred and recorded research and development expenses of approximately $281,000 and $242,000, respectively, during the nine months ended September 30, 2020 and 2019 the Company incurred and recorded approximately $810,000 and $745,000, respectively, for services performed by Leucadia and Tommy Adams.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if25db31f1cc14bd8ad1940aa6a08ec7e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82NC9mcmFnOmIxMDI5ZTdhYjk3ODQ3MGM4ZjM2NjNlNTFlN2NhZGM5L3RleHRyZWdpb246YjEwMjllN2FiOTc4NDcwYzhmMzY2M2U1MWU3Y2FkYzlfNjM5_a3e1cc0e-0889-4355-9ad8-95f864e46270"
      unitRef="usd">281000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i17f7e87656404afa93a7d1e1581c3052_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82NC9mcmFnOmIxMDI5ZTdhYjk3ODQ3MGM4ZjM2NjNlNTFlN2NhZGM5L3RleHRyZWdpb246YjEwMjllN2FiOTc4NDcwYzhmMzY2M2U1MWU3Y2FkYzlfNjQ2_5e26181d-5be1-4559-b63e-1aff538497d6"
      unitRef="usd">242000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i608690ce785549468033da705f15e7f0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82NC9mcmFnOmIxMDI5ZTdhYjk3ODQ3MGM4ZjM2NjNlNTFlN2NhZGM5L3RleHRyZWdpb246YjEwMjllN2FiOTc4NDcwYzhmMzY2M2U1MWU3Y2FkYzlfNzMz_f1aa6f90-19de-448e-966e-58ccbd990051"
      unitRef="usd">810000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i58ff4aad5faa4a528942057efea92b13_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82NC9mcmFnOmIxMDI5ZTdhYjk3ODQ3MGM4ZjM2NjNlNTFlN2NhZGM5L3RleHRyZWdpb246YjEwMjllN2FiOTc4NDcwYzhmMzY2M2U1MWU3Y2FkYzlfNzQw_7b97c789-54eb-4cc4-a678-d73e149e8732"
      unitRef="usd">745000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82Ny9mcmFnOjE1ODM4MTEwZWNhZDRjNDQ5MjUzMTYxZGYxNTZmNzY0L3RleHRyZWdpb246MTU4MzgxMTBlY2FkNGM0NDkyNTMxNjFkZjE1NmY3NjRfMzQ2Nw_fd3e702f-422a-4863-a731-e64ffdf62d68">COVID-19&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 outbreak in the United States has caused significant business disruption. The extent of the impact of COVID-19 on the Company's future operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, and impact on the Company's clinical trials, employees and vendors, all of which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may impact the Company's future financial condition or results of operations is uncertain. While there has not been a material impact on the Company's condensed financial statements for the three or nine months ended September&#160;30, 2020, a prolonged outbreak could have a material adverse impact on financial results and business operations of the Company, including the timing and ability of the Company to complete certain clinical trials and other efforts required to advance the development of its drugs and raise additional capital.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In response to the pandemic, the Coronavirus Aid, Relief and Economic Security Act (&#x201c;CARES Act&#x201d;) was signed into law on March 27, 2020.  The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#x2019;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company is utilizing the deferment of employer social security payments. The CARES Act did not have a material impact on our income tax provision for the three or nine months ended September&#160;30, 2020. We continue to monitor changes and revisions of the CARES Act and its impact on our financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Small Business Administration Payroll Protection Program Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;On April 15, 2020, the Company was granted a loan (the &#x201c;Loan&#x201d;) from JPMorgan Chase Bank, N.A. in the aggregate amount of $305,000, pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;) under Division A, Title I of the CARES Act with an interest rate of 0.98% per annum. On October 19, 2020 the Company repaid in full the outstanding principal and interest of the PPP Loan.&lt;/span&gt;&lt;/div&gt;</us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock>
    <us-gaap:NotesPayable
      contextRef="i9a08aa2fda7c4db799f75bc79a5a0e5b_I20200415"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82Ny9mcmFnOjE1ODM4MTEwZWNhZDRjNDQ5MjUzMTYxZGYxNTZmNzY0L3RleHRyZWdpb246MTU4MzgxMTBlY2FkNGM0NDkyNTMxNjFkZjE1NmY3NjRfMTgyOQ_ac1b1d8a-b617-4b38-a25c-1c42889a3c8f"
      unitRef="usd">305000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9a08aa2fda7c4db799f75bc79a5a0e5b_I20200415"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV82Ny9mcmFnOjE1ODM4MTEwZWNhZDRjNDQ5MjUzMTYxZGYxNTZmNzY0L3RleHRyZWdpb246MTU4MzgxMTBlY2FkNGM0NDkyNTMxNjFkZjE1NmY3NjRfMTA5OTUxMTYzNDUzMg_e6b5616c-cec9-44ec-8811-0d068a557d66"
      unitRef="number">0.0098</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ib5394ca29f974147b0c91ab506add48c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV83MC9mcmFnOjQxZDUyMjlhNDYxNzQ3MzFhOTQ0M2EyZGIzYWIwNDVkL3RleHRyZWdpb246NDFkNTIyOWE0NjE3NDczMWE5NDQzYTJkYjNhYjA0NWRfMzI4_e27a552f-9db4-4b33-803e-2021a252e94f">Subsequent Events&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Underwritten Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 2, 2020 the Company completed an underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $13.50 per share. In addition, the underwriters exercised in full an option to purchase an additional 975,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering were sold by the Company, with gross proceeds of approximately $100.9&#160;million, and net proceeds of approximately $94.0&#160;million, after deducting underwriting discounts, commissions and estimated offering expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exercise of Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From October 1 through October 31, 2020 the Company received proceeds of approximately $3.4&#160;million from the exercise of 1.6&#160;million warrants. The warrants exercised during the relevant period were from various prior equity offerings. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Repayment of Small Business Administration Payroll Protection Program Loan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 19, 2020 the Company repaid in full the PPP Loan principal of $305,000 and interest for the period the loan was outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i5c512dc917a44fa4935298acc4757d46_D20201002-20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV83MC9mcmFnOjQxZDUyMjlhNDYxNzQ3MzFhOTQ0M2EyZGIzYWIwNDVkL3RleHRyZWdpb246NDFkNTIyOWE0NjE3NDczMWE5NDQzYTJkYjNhYjA0NWRfMTA5OTUxMTYzMTYyOA_a624d00f-aa2d-462b-99e0-75cb71490161"
      unitRef="shares">6500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic032311ae02d403789f39a7132fe94f9_I20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV83MC9mcmFnOjQxZDUyMjlhNDYxNzQ3MzFhOTQ0M2EyZGIzYWIwNDVkL3RleHRyZWdpb246NDFkNTIyOWE0NjE3NDczMWE5NDQzYTJkYjNhYjA0NWRfMTA5OTUxMTYzMTYzOQ_2086a2bd-bdd3-4d32-bcba-b8a4e46237b5"
      unitRef="usdPerShare">13.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="icbbee8b1f9a244e8ad1c0673daa3a0b1_D20201002-20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV83MC9mcmFnOjQxZDUyMjlhNDYxNzQ3MzFhOTQ0M2EyZGIzYWIwNDVkL3RleHRyZWdpb246NDFkNTIyOWE0NjE3NDczMWE5NDQzYTJkYjNhYjA0NWRfMTA5OTUxMTYzMTY3OA_6bb9127b-0d7b-4f22-bf86-6a2254be1f79"
      unitRef="shares">975000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <crdf:SaleOfStockConsiderationReceivedOnTransactionGross
      contextRef="i5c512dc917a44fa4935298acc4757d46_D20201002-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV83MC9mcmFnOjQxZDUyMjlhNDYxNzQ3MzFhOTQ0M2EyZGIzYWIwNDVkL3RleHRyZWdpb246NDFkNTIyOWE0NjE3NDczMWE5NDQzYTJkYjNhYjA0NWRfMTA5OTUxMTYzMTY0Nw_a57a6aaa-7503-48fe-aac5-4885e8e920a9"
      unitRef="usd">100900000</crdf:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i5c512dc917a44fa4935298acc4757d46_D20201002-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV83MC9mcmFnOjQxZDUyMjlhNDYxNzQ3MzFhOTQ0M2EyZGIzYWIwNDVkL3RleHRyZWdpb246NDFkNTIyOWE0NjE3NDczMWE5NDQzYTJkYjNhYjA0NWRfMTA5OTUxMTYzMTY2Mw_c46a074c-2a06-4f9f-8dfb-01206315ba3b"
      unitRef="usd">94000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i4884eb0a36754efda6090e87871a157e_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV83MC9mcmFnOjQxZDUyMjlhNDYxNzQ3MzFhOTQ0M2EyZGIzYWIwNDVkL3RleHRyZWdpb246NDFkNTIyOWE0NjE3NDczMWE5NDQzYTJkYjNhYjA0NWRfMTA5OTUxMTYzMTYwMQ_4142c0de-3e05-41d8-bc49-95d38093a4be"
      unitRef="usd">3400000</us-gaap:ProceedsFromWarrantExercises>
    <crdf:ClassOfWarrantOrRightNumberExercised
      contextRef="i4884eb0a36754efda6090e87871a157e_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV83MC9mcmFnOjQxZDUyMjlhNDYxNzQ3MzFhOTQ0M2EyZGIzYWIwNDVkL3RleHRyZWdpb246NDFkNTIyOWE0NjE3NDczMWE5NDQzYTJkYjNhYjA0NWRfMTA5OTUxMTYzMTYxNQ_aa535ac2-b3aa-43b8-b8f4-b929a629fc4a"
      unitRef="shares">1600000</crdf:ClassOfWarrantOrRightNumberExercised>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i2917c1b61fd347ec893f35bbe6cd7228_D20201019-20201019"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV83MC9mcmFnOjQxZDUyMjlhNDYxNzQ3MzFhOTQ0M2EyZGIzYWIwNDVkL3RleHRyZWdpb246NDFkNTIyOWE0NjE3NDczMWE5NDQzYTJkYjNhYjA0NWRfMTA5OTUxMTYzMTU5MQ_2fc1633b-fbe0-4046-ac6d-c7098af58eea"
      unitRef="usd">305000</us-gaap:RepaymentsOfNotesPayable>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtNy0xLTEtMA_1d5eb083-686d-4d30-b1b9-5da8e39d29d5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtNy0xLTEtMA_1d5eb083-686d-4d30-b1b9-5da8e39d29d5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtMTUtMS0xLTA_af12d379-5662-465f-8a93-94f0111d55cd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtMTUtMS0xLTA_af12d379-5662-465f-8a93-94f0111d55cd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtMy0xLTEtMA_785dc728-fb40-48ed-8571-ce68880992ec"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtMy0xLTEtMA_785dc728-fb40-48ed-8571-ce68880992ec"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtMS0xLTEtMA_4c625304-18b6-48ac-a97f-84c5bf85ccfd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtMS0xLTEtMA_4c625304-18b6-48ac-a97f-84c5bf85ccfd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtOS0xLTEtMA_4eafee9b-816d-4fd7-9875-e9faaca48aa5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtOS0xLTEtMA_4eafee9b-816d-4fd7-9875-e9faaca48aa5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtNS0xLTEtMA_7e0aca0a-36dd-4ec7-9639-c05471553428"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtNS0xLTEtMA_7e0aca0a-36dd-4ec7-9639-c05471553428"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RleHRyZWdpb246ZTA5MGZmN2Q3Zjc4NDBjM2E4N2ZmYzlkNjJhM2M4YjVfMjg5_b065a1c7-ef82-41c7-88d8-90b2e32f5fef" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RleHRyZWdpb246ZTA5MGZmN2Q3Zjc4NDBjM2E4N2ZmYzlkNjJhM2M4YjVfMjg5_b065a1c7-ef82-41c7-88d8-90b2e32f5fef" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Net of expenses of $616,143, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $370,666.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtNy0xLTEtMA_1d5eb083-686d-4d30-b1b9-5da8e39d29d5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RleHRyZWdpb246ZTA5MGZmN2Q3Zjc4NDBjM2E4N2ZmYzlkNjJhM2M4YjVfMjg5_b065a1c7-ef82-41c7-88d8-90b2e32f5fef"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtMTUtMS0xLTA_af12d379-5662-465f-8a93-94f0111d55cd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RleHRyZWdpb246ZTA5MGZmN2Q3Zjc4NDBjM2E4N2ZmYzlkNjJhM2M4YjVfMjg5_b065a1c7-ef82-41c7-88d8-90b2e32f5fef"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtMy0xLTEtMA_785dc728-fb40-48ed-8571-ce68880992ec"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RleHRyZWdpb246ZTA5MGZmN2Q3Zjc4NDBjM2E4N2ZmYzlkNjJhM2M4YjVfMjg5_b065a1c7-ef82-41c7-88d8-90b2e32f5fef"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtMS0xLTEtMA_4c625304-18b6-48ac-a97f-84c5bf85ccfd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RleHRyZWdpb246ZTA5MGZmN2Q3Zjc4NDBjM2E4N2ZmYzlkNjJhM2M4YjVfMjg5_b065a1c7-ef82-41c7-88d8-90b2e32f5fef"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtOS0xLTEtMA_4eafee9b-816d-4fd7-9875-e9faaca48aa5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RleHRyZWdpb246ZTA5MGZmN2Q3Zjc4NDBjM2E4N2ZmYzlkNjJhM2M4YjVfMjg5_b065a1c7-ef82-41c7-88d8-90b2e32f5fef"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RhYmxlOmQxZDc3NjllNThlNTQ2ODc4ZjUyOTMzMzI2MmM2NTBkL3RhYmxlcmFuZ2U6ZDFkNzc2OWU1OGU1NDY4NzhmNTI5MzMzMjYyYzY1MGRfMTUtNS0xLTEtMA_7e0aca0a-36dd-4ec7-9639-c05471553428"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjBmZjI3ZTM0MDJmYzQ3Mjc4ZWI4NjE3ZTJhMDhiNzcxL3NlYzowZmYyN2UzNDAyZmM0NzI3OGViODYxN2UyYTA4Yjc3MV8yNS9mcmFnOmUwOTBmZjdkN2Y3ODQwYzNhODdmZmM5ZDYyYTNjOGI1L3RleHRyZWdpb246ZTA5MGZmN2Q3Zjc4NDBjM2E4N2ZmYzlkNjJhM2M4YjVfMjg5_b065a1c7-ef82-41c7-88d8-90b2e32f5fef"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209112318568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Oct. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CARDIFF ONCOLOGY,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-2004382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11055 Flintkote Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">952-7570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRDF<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,324,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001213037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209194117832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 36,405,432<span></span>
</td>
<td class="nump">$ 10,195,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable and unbilled receivable</a></td>
<td class="nump">204,366<span></span>
</td>
<td class="nump">203,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,578,859<span></span>
</td>
<td class="nump">954,957<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">38,188,657<span></span>
</td>
<td class="nump">11,353,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">682,859<span></span>
</td>
<td class="nump">877,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">423,163<span></span>
</td>
<td class="nump">697,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">155,770<span></span>
</td>
<td class="nump">157,576<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">39,450,449<span></span>
</td>
<td class="nump">13,086,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">610,236<span></span>
</td>
<td class="nump">656,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,643,300<span></span>
</td>
<td class="nump">3,260,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable</a></td>
<td class="nump">305,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">883,534<span></span>
</td>
<td class="nump">865,379<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,442,070<span></span>
</td>
<td class="nump">4,781,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments&#8212;warrants</a></td>
<td class="nump">190,199<span></span>
</td>
<td class="nump">4,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">207,178<span></span>
</td>
<td class="nump">860,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">88,452<span></span>
</td>
<td class="nump">128,368<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">5,927,899<span></span>
</td>
<td class="nump">5,775,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, 20,000,000 shares authorized; (Note 7)</a></td>
<td class="nump">926<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 150,000,000 shares authorized; 26,285,743 and 8,593,633 shares issued and outstanding at September 30, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="nump">10,081<span></span>
</td>
<td class="nump">8,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">260,807,295<span></span>
</td>
<td class="nump">217,172,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_Servicereceivable', window );">Service receivables</a></td>
<td class="num">(2,403,580)<span></span>
</td>
<td class="num">(971,673)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(224,892,172)<span></span>
</td>
<td class="num">(208,897,883)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">33,522,550<span></span>
</td>
<td class="nump">7,311,344<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 39,450,449<span></span>
</td>
<td class="nump">$ 13,086,546<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_Servicereceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monetary value of future clinical trial services to be received in connection with issuance of common stock, preferred stock and warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_Servicereceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209112351512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">26,285,743<span></span>
</td>
<td class="nump">8,593,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">26,285,743<span></span>
</td>
<td class="nump">8,593,633<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209188336136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalties</a></td>
<td class="nump">$ 136,401<span></span>
</td>
<td class="nump">$ 51,687<span></span>
</td>
<td class="nump">$ 246,738<span></span>
</td>
<td class="nump">$ 150,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">136,401<span></span>
</td>
<td class="nump">51,687<span></span>
</td>
<td class="nump">246,738<span></span>
</td>
<td class="nump">152,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">2,854,812<span></span>
</td>
<td class="nump">2,818,824<span></span>
</td>
<td class="nump">8,036,225<span></span>
</td>
<td class="nump">8,297,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">1,644,211<span></span>
</td>
<td class="nump">1,440,339<span></span>
</td>
<td class="nump">4,799,457<span></span>
</td>
<td class="nump">4,243,490<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,499,023<span></span>
</td>
<td class="nump">4,259,163<span></span>
</td>
<td class="nump">12,835,682<span></span>
</td>
<td class="nump">12,541,253<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(4,362,622)<span></span>
</td>
<td class="num">(4,207,476)<span></span>
</td>
<td class="num">(12,588,944)<span></span>
</td>
<td class="num">(12,389,198)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">15,864<span></span>
</td>
<td class="nump">53,700<span></span>
</td>
<td class="nump">67,358<span></span>
</td>
<td class="nump">188,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) from change in fair value of derivative financial instruments&#8212;warrants</a></td>
<td class="num">(144,035)<span></span>
</td>
<td class="nump">13,330<span></span>
</td>
<td class="num">(186,072)<span></span>
</td>
<td class="nump">27,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(5,738)<span></span>
</td>
<td class="num">(1,103)<span></span>
</td>
<td class="num">(1,967)<span></span>
</td>
<td class="nump">2,012<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,496,531)<span></span>
</td>
<td class="num">(4,141,549)<span></span>
</td>
<td class="num">(12,709,625)<span></span>
</td>
<td class="num">(12,171,623)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="num">(6,060)<span></span>
</td>
<td class="num">(6,060)<span></span>
</td>
<td class="num">(18,180)<span></span>
</td>
<td class="num">(18,180)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (4,502,591)<span></span>
</td>
<td class="num">$ (4,147,609)<span></span>
</td>
<td class="num">$ (15,994,289)<span></span>
</td>
<td class="num">$ (12,458,072)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (1.00)<span></span>
</td>
<td class="num">$ (2.40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding - basic and diluted (in shares)</a></td>
<td class="nump">23,341,218<span></span>
</td>
<td class="nump">6,024,679<span></span>
</td>
<td class="nump">15,941,665<span></span>
</td>
<td class="nump">5,180,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (268,269)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(601,767)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember', window );">Series&#160;E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (2,664,717)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209096700616">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series D Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Series C Convertible Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Series D Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Series C Convertible Preferred Stock</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Series D Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Series&#160;E Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Series C Convertible Preferred Stock</div>
</th>
<th class="th"><div>Service Receivable</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Series D Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Series&#160;E Convertible Preferred Stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, beginning (in shares) at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,831,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,084,192<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,267,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (192,191,215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,282,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,282,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases', window );">Issuance of common stock upon vesting of restricted stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ReleaseOfClinicalTrialFundingCommitment', window );">Release of clinical trial funding commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">70,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,904,771)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,904,771)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(40,000)<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,634,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,675,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock', window );">Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(268,269)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Issuance of common stock for share rounding as a result of reverse stock split (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, ending (in shares) at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,525,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,686,181<span></span>
</td>
<td class="nump">$ 260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,652,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,604,513)<span></span>
</td>
<td class="num">(196,370,315)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, beginning (in shares) at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,831,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,084,192<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,267,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(192,191,215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,171,623)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, ending (in shares) at Sep. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,436,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Sep. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,655,980<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,463,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,165,966)<span></span>
</td>
<td class="num">(204,649,287)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, beginning (in shares) at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,525,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,686,181<span></span>
</td>
<td class="nump">$ 260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,652,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,604,513)<span></span>
</td>
<td class="num">(196,370,315)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">148,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_SaleOfStockCommonAndWarrantsNetShares', window );">Sale of common stock and warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(421,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_SaleOfStockValueCommonAndWarrantsNet', window );">Sale of common stock and warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,902,740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,902,698)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ReleaseOfClinicalTrialFundingCommitment', window );">Release of clinical trial funding commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">240,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,125,303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,125,303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Series D Convertible Preferred Stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Series D Convertible Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, ending (in shares) at Jun. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,441,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Jun. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,848,235<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,706,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,364,234)<span></span>
</td>
<td class="num">(200,501,678)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">266,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_SaleOfStockCommonAndWarrantsNetShares', window );">Sale of common stock and warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(271,744)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_SaleOfStockValueCommonAndWarrantsNet', window );">Sale of common stock and warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,483,581)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,483,554)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">717,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ReleaseOfClinicalTrialFundingCommitment', window );">Release of clinical trial funding commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">198,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,141,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,141,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, ending (in shares) at Sep. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,436,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Sep. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,655,980<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,463,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,165,966)<span></span>
</td>
<td class="num">(204,649,287)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, beginning (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,593,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,311,344<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,172,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(971,673)<span></span>
</td>
<td class="num">(208,897,883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">177,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_SaleOfStockCommonAndWarrantsNetShares', window );">Sale of common stock and warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_SaleOfStockValueCommonAndWarrantsNet', window );">Sale of common stock and warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,000,001)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (80)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(999,921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,610,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,456,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,456,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases', window );">Issuance of common stock upon vesting of restricted stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ReleaseOfClinicalTrialFundingCommitment', window );">Release of clinical trial funding commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">293,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,088,562)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,088,562)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, ending (in shares) at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,010,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,143,418<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,805,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(678,656)<span></span>
</td>
<td class="num">(212,992,505)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, beginning (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,593,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,311,344<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,172,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(971,673)<span></span>
</td>
<td class="num">(208,897,883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,709,625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, ending (in shares) at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">926,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,285,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,522,550<span></span>
</td>
<td class="nump">$ 926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,807,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,403,580)<span></span>
</td>
<td class="num">(224,892,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, beginning (in shares) at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,010,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,143,418<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,805,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(678,656)<span></span>
</td>
<td class="num">(212,992,505)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">281,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,473,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,605,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,604,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ReleaseOfClinicalTrialFundingCommitment', window );">Release of clinical trial funding commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">213,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,124,532)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,124,532)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,500)<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,292,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock', window );">Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 601,767<span></span>
</td>
<td class="nump">$ 2,664,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (601,767)<span></span>
</td>
<td class="num">$ (2,664,717)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock, preferred stock and warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">865,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,689,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of common stock, preferred stock and warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(17,278,428)<span></span>
</td>
<td class="nump">$ 866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,277,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Series D Convertible Preferred Stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(154,670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,546,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Series D Convertible Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, ending (in shares) at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">926,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,325,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,384,039<span></span>
</td>
<td class="nump">$ 926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,528,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,765,164)<span></span>
</td>
<td class="num">(220,389,581)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">361,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,956,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,910,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,910,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ReleaseOfClinicalTrialFundingCommitment', window );">Release of clinical trial funding commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">361,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,496,531)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,496,531)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, ending (in shares) at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">926,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,285,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 33,522,550<span></span>
</td>
<td class="nump">$ 926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,807,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,403,580)<span></span>
</td>
<td class="num">$ (224,892,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="16"></td></tr>
<tr><td colspan="16"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Net of expenses of $616,143, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $370,666.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial Conversion Feature For Issuance Of Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ReleaseOfClinicalTrialFundingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Release Of Clinical Trial Funding Commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ReleaseOfClinicalTrialFundingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_SaleOfStockCommonAndWarrantsNetShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Common And Warrants, Net, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_SaleOfStockCommonAndWarrantsNetShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_SaleOfStockValueCommonAndWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Value, Common And Warrants, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_SaleOfStockValueCommonAndWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Restricted Stock Units Released</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares issued during the period upon cash exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Restricted Stock Units Releases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity impact during the period due to the cash exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of a stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209105368376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment', window );">Cost of issuance of common stock, preferred stock and warrants</a></td>
<td class="nump">$ 616,143<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_WarrantsFairValue', window );">Warrants, fair value</a></td>
<td class="nump">$ 370,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment', window );">Discount of issuance of common stock, preferred stock and warrants for clinical trial funding commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,640<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_WarrantsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_WarrantsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209113280216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,709,625)<span></span>
</td>
<td class="num">$ (12,171,623)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment loss</a></td>
<td class="nump">34,169<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">348,748<span></span>
</td>
<td class="nump">372,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">820,969<span></span>
</td>
<td class="nump">615,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative financial instruments&#8212;warrants</a></td>
<td class="nump">186,072<span></span>
</td>
<td class="num">(27,359)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived', window );">Release of clinical trial funding commitment</a></td>
<td class="nump">868,093<span></span>
</td>
<td class="nump">509,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">1,806<span></span>
</td>
<td class="num">(68,145)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable and unbilled receivable</a></td>
<td class="num">(886)<span></span>
</td>
<td class="nump">15,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(623,902)<span></span>
</td>
<td class="nump">277,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">240,086<span></span>
</td>
<td class="nump">224,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">318,991<span></span>
</td>
<td class="nump">837,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(635,630)<span></span>
</td>
<td class="num">(576,141)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(39,916)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(11,191,025)<span></span>
</td>
<td class="num">(9,990,636)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(153,784)<span></span>
</td>
<td class="num">(67,622)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(153,784)<span></span>
</td>
<td class="num">(67,622)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sales of common stock, preferred stock and warrants, net of expenses of $633,807 and $97,260, respectively</a></td>
<td class="nump">18,278,429<span></span>
</td>
<td class="nump">4,386,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Costs related to the clinical trial funding commitment</a></td>
<td class="num">(7,500)<span></span>
</td>
<td class="num">(40,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">6,832<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">18,972,188<span></span>
</td>
<td class="nump">3,291,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Borrowings under note payable</a></td>
<td class="nump">305,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">37,554,949<span></span>
</td>
<td class="nump">7,637,331<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">26,210,140<span></span>
</td>
<td class="num">(2,420,927)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents&#8212;Beginning of period</a></td>
<td class="nump">10,195,292<span></span>
</td>
<td class="nump">11,453,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents&#8212;End of period</a></td>
<td class="nump">36,405,432<span></span>
</td>
<td class="nump">9,032,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosure of cash flow activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_PreferredStockDividendAccrued', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="nump">18,180<span></span>
</td>
<td class="nump">18,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">268,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment', window );">Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,675,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Common stock issued upon conversion of convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="nump">601,767<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment', window );">Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Common stock issued upon conversion of convertible preferred stock</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember', window );">Series&#160;E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="nump">$ 2,664,717<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_PreferredStockDividendAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of preferred stock dividend accrued during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_PreferredStockDividendAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Release of clinical trial funding commitment for services received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121593497&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209112510600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance expenses</a></td>
<td class="nump">$ 633,807<span></span>
</td>
<td class="nump">$ 97,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment', window );">Discount of issuance of common stock, preferred stock and warrants for clinical trial funding commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment', window );">Discount of issuance of common stock, preferred stock and warrants for clinical trial funding commitment</a></td>
<td class="nump">$ 488,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209111960664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">Organization and Basis of Presentation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Organization and Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology,&#160;Inc. (&#8220;Cardiff Oncology&#8221; or the &#8220;Company&#8221;) headquartered in San Diego, California, is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, Zytiga&#174;-resistant metastatic castration-resistant prostate cancer and relapsed or refractory acute myeloid leukemia. Our goal is to overcome resistance, improve response to treatment and increase overall survival. Through the integration of tumor genomics and biomarker technology, we are able to assess patient response to treatment.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements of Cardiff Oncology have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and the rules&#160;and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form&#160;10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules&#160;and regulations. The unaudited interim condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company&#8217;s financial position and the results of its operations and cash flows for the periods presented. The unaudited condensed balance sheet at December&#160;31, 2019 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December&#160;31, 2019 included in the Company&#8217;s annual report on Form&#160;10-K filed with the SEC on February&#160;27, 2020.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net losses since its inception and has negative operating cash flows. As of September&#160;30, 2020, the Company had $36.4&#160;million in cash and cash equivalents and believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.  </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 2, 2020 the Company closed an underwritten public offering of its common stock for gross proceeds of approximately $100.9&#160;million. See Note 11 to the condensed financial statements for further information.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the foreseeable future, the Company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company&#8217;s stockholders may experience additional dilution. The economic effects of COVID-19 could also have an adverse effect on the Company's ability to raise additional capital. See Note 10 to the condensed financial statements for further information.</span></div>As of October 31, 2020 the Company had $131.8&#160;million in cash and cash equivalents.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209107667480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020, there have been no changes to the Company&#8217;s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2019.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share. Shares used in calculating diluted net loss per common share exclude as anti-dilutive the following share equivalents:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss used for basic and diluted loss per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,502,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,147,609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,994,289)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,458,072)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,341,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,024,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,941,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,180,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.00)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.40)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase Common Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,920,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase Common Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,870,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,548,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,844,384&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,901,540&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncement</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU&#160;No. 2018-13 ("ASU 2018-13"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes to the Disclosure Requirements for Fair Value Measurement</span>. This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard is effective for all entities for financial statements issued for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company has prospectively adopted ASU 2018-13 as of January 1, 2020 for periods presented after adoption. The adoption of ASU 2018-13 did not have a material impact on the Company's financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209193118088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:41.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,536,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,536,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,536,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,536,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants (2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:41.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund (1)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,131,240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,131,240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,131,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,131,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants (2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;Included as a component of cash and cash equivalents on the accompanying condensed balance sheets.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments that trade infrequently and therefore have little or no price transparency are classified as Level 3. See Note 6 to the condensed financial statements for further information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209107190296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,635,900&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,482,116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,953,041)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,604,293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682,859&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877,823&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209105565336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As a lessee, the Company&#8217;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company (as a sublessor) also subleases portions of its facility to third parties under three separate subleases. All of these subleases have been determined to be operating leases and are accounted for separately from the head lease. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Facility Lease </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases a building in San Diego under an operating lease that expires on December&#160;31, 2021. The lease currently requires fixed monthly rent payments of approximately $78,000, with 3% annual escalation. The lease also contains one five-year renewal option with minimum monthly rent equal to the then-current fair market value, subject to a 3% annual increase. As the Company is not reasonably certain to exercise this option, it has not been included in the calculation of the lease liability or right-of-use asset related to this lease.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility Subleases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased the space to third parties under three separate sublease agreements, which all expire December 31, 2021. The Company recorded a cease-use loss liability and expense in 2018 pursuant to ASC 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, representing the total expected shortfall in sublease income for two of the subleases as compared to its required payments for those spaces under the remainder of the master lease term. This liability was being amortized over the remaining lease term until the adoption of ASC 842, whereupon the remaining cease-use loss liability of approximately $487,000 was eliminated and treated as a reduction to the beginning ROU asset value for the master lease as of January 1, 2019. Income will continue to be recognized on a straight-line basis over the term of the sublease.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Right-of-Use Assets</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded an impairment loss of $0 and $34,169 for the three and  nine months ended September 30, 2020, respectively.  The loss related to a vacated portion of the facility that was no longer being subleased. The Company determined that the prolonged loss of sublease income and an adverse commercial real estate market caused by COVID-19 were indicators of impairment. A fair value approach using quoted prices for similar assets was used to determine the impairment loss.  The loss was recorded within operating expenses in the condensed statement of operations.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.885%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating sublease income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,793)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,937)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218,380)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299,812)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,015&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,535&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,456&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,107&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423,163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860,963&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090,712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.885%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,748&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,927&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706,211&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685,865&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Sublease Income </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Net Operating Leases </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (excluding the nine months ended September 30, 2020)</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,167&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,793)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,374&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136,623&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476,138)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,485&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090,712&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As a lessee, the Company&#8217;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company (as a sublessor) also subleases portions of its facility to third parties under three separate subleases. All of these subleases have been determined to be operating leases and are accounted for separately from the head lease. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Facility Lease </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases a building in San Diego under an operating lease that expires on December&#160;31, 2021. The lease currently requires fixed monthly rent payments of approximately $78,000, with 3% annual escalation. The lease also contains one five-year renewal option with minimum monthly rent equal to the then-current fair market value, subject to a 3% annual increase. As the Company is not reasonably certain to exercise this option, it has not been included in the calculation of the lease liability or right-of-use asset related to this lease.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility Subleases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased the space to third parties under three separate sublease agreements, which all expire December 31, 2021. The Company recorded a cease-use loss liability and expense in 2018 pursuant to ASC 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, representing the total expected shortfall in sublease income for two of the subleases as compared to its required payments for those spaces under the remainder of the master lease term. This liability was being amortized over the remaining lease term until the adoption of ASC 842, whereupon the remaining cease-use loss liability of approximately $487,000 was eliminated and treated as a reduction to the beginning ROU asset value for the master lease as of January 1, 2019. Income will continue to be recognized on a straight-line basis over the term of the sublease.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Right-of-Use Assets</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded an impairment loss of $0 and $34,169 for the three and  nine months ended September 30, 2020, respectively.  The loss related to a vacated portion of the facility that was no longer being subleased. The Company determined that the prolonged loss of sublease income and an adverse commercial real estate market caused by COVID-19 were indicators of impairment. A fair value approach using quoted prices for similar assets was used to determine the impairment loss.  The loss was recorded within operating expenses in the condensed statement of operations.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.885%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating sublease income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,793)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,937)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218,380)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299,812)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,015&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,535&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,456&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,107&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423,163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860,963&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090,712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.885%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,748&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,927&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706,211&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685,865&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Sublease Income </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Net Operating Leases </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (excluding the nine months ended September 30, 2020)</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,167&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,793)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,374&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136,623&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476,138)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,485&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090,712&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor's operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph Note 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph Note 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888252<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209107158824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Warrants<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Financial Instruments - Warrants</a></td>
<td class="text">Derivative Financial Instruments &#8212; Warrants<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon the Company&#8217;s analysis of the criteria contained in ASC Topic 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 815-40&#8221;) or ASC Topic 480-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 480-10&#8221;), Cardiff Oncology determined that certain warrants issued in connection with the execution of certain equity financings must be recorded as derivative liabilities.&#160;In accordance with ASC 815-40 and ASC 480-10, the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant change in fair value is being recorded in the Company&#8217;s condensed statements of operations.&#160;The Company estimates the fair value of these warrants using the Black-Scholes option pricing model.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of assumptions and weighted averages used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated were:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Range:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated fair value of Cardiff Oncology common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.01 - $14.19</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.51 - $3.75</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected warrant term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 - 3.1 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 - 4.1 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14 - 1.62%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.56 - 2.49%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 - 118%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 - 106%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Cardiff Oncology common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$14.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected warrant term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Weighted average is only disclosed for periods after January 1, 2020 under the adoption of ASU 2018-13. </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The weighted average was calculated using the relative fair value method. </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility is based on historical volatility of Cardiff Oncology&#8217;s common stock.&#160;The warrants have a transferability provision and based on guidance provided in Staff Accounting Bulletin (&#8220;SAB&#8221;) No. 107, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;SAB No. 107&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for instruments issued with such a provision, Cardiff Oncology used the remaining contractual term as the expected term of the warrants.&#160;The risk-free rate is based on the U.S.&#160;Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of changes in the Company&#8217;s derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative<br/>Instrument<br/>Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants during the period recognized as a loss in the condensed statements of operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209107166872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,884&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820,969&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615,226&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized compensation cost related to non-vested stock options outstanding at September&#160;30, 2020 and 2019, net of estimated forfeitures, was $2,388,077 and $1,476,725, respectively, which is expected to be recognized over a weighted-average remaining vesting period of 2.2 and 2.4 years, respectively.&#160;The weighted-average remaining contractual term of outstanding options as of September&#160;30, 2020 was approximately 9.1 years. The total fair value of stock options vested during the nine months ended September 30, 2020 and 2019 were $770,582 and $321,870, respectively.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 years</span></td></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity and changes in stock options outstanding is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.312%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.471%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled / Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,069)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,920,706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,766,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,507,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2019, the number of authorized shares in the Cardiff Oncology 2014 Equity Incentive Plan (&#8220;2014 EIP&#8221;) was increased from 243,056 to 1,243,056. On April 16, 2020 the 2014 EIP was amended to increase the number of shares of common stock reserved for issuance thereunder to 2,243,056 from 1,243,056. As of September&#160;30, 2020, there were 258,497 shares available for issuance under the 2014 EIP.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU activity is presented below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair Value<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding, September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of vested RSUs during the nine months ended September 30, 2020 and 2019 were $100,585 and $169,563, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.312%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.471%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining&#160;Contractual<br/>Term</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,589,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,831,451&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,047,582)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, September 30, 2020</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373,351&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 years</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluded from the table above are 992,039 pre-funded warrants that were exercised during the nine months ended September 30, 2020. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our Company's classes of preferred stock is presented below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares designated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation preference</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series C Convertible Preferred Stock and Service Receivable</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2019, the Company entered into a Master Services Agreement and a Stock and Warrant Subscription Agreement with PoC Capital, LLC (&#8220;PoC&#8221;), whereby PoC agreed to finance $1.675 million for the development costs associated with Phase 1b/2 study of onvansertib in combination with FOLFIRI and Avastin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with metastatic Colorectal Cancer (&#8220;mCRC&#8221;) harboring KRAS mutation in exchange for (i)183,334 shares of common stock, (ii) warrants to purchase an aggregate of 150,000 shares of common stock, with an exercise price of $3.762 per share, expiring on January 25, 2024, and (iii) 200,000 shares of Series C Convertible Preferred Stock, each share of which was convertible into 1.67 shares of common stock. In April of 2019, all 200,000 shares of Series C Convertible Preferred Stock were converted into 333,333 shares of the Company's common stock.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the awards issued under this transaction and determined they should be classified as equity. These equity awards were fully vested and non-forfeitable. Since the equity awards were for clinical trial services yet to be provided, the Company recognized $1.675 million service receivables as contra equity. The Company releases the service receivables as clinical trial services are performed. The conversion feature of the Series C Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series C Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $0.3 million related to the beneficial conversion feature arising from the issuance of Series C Convertible Preferred Stock. This non-cash deemed dividend increased the Company&#8217;s net loss attributable to common stockholders and net loss per share.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series D Convertible Preferred Stock and Service Receivable</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 8, 2020, the Company entered into a Stock and Warrant Subscription Agreement with PoC, whereby PoC agreed to finance an additional $2.3 million for a clinical trial in exchange for (i) 602,833 shares of its common stock (the &#8220;Common Stock&#8221;), (ii) 154,670 shares of its Series D Preferred Stock (as defined below) and (iii) a warrant exercisable for 859,813 shares of its Common Stock. In exchange, PoC is funding our clinical development of onvansertib in metastatic colorectal cancer pursuant to a Master Services Agreement dated as of January 25, 2019 by and among the Company, Integrium, LLC and PoC, as amended. The warrant will be exercisable six months following the date of issuance at an exercise price of $1.50 per share and will expire on November 7, 2025. In June of 2020, all 154,670 Series D Preferred Stock were converted to 1,546,700 shares of Common Stock. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the awards issued under this transaction and determined they should be classified as equity. These equity awards were fully vested and non-forfeitable. Since the equity awards were for clinical trial services yet to be provided, the Company recognized $2.3&#160;million service receivables as contra equity. The Company releases the service receivables as clinical trial services are performed. The conversion feature of the Series D Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series D Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $0.6&#160;million related to the beneficial conversion feature arising from the issuance of Series D Convertible Preferred Stock. This non-cash deemed dividend increased the Company&#8217;s net loss attributable to common stockholders and net loss per share.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series E Convertible Preferred Stock</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2020 the Company entered into a Securities Purchase Agreement with Acorn Bioventures LP ("Acorn"), CDK Associates, L.L.C. (&#8220;CDK&#8221;) and Third Street Holdings LLC (&#8220;Third Street&#8221;), pursuant to which the Company agreed to offer, issue and sell to Acorn, CDK and Third Street, (i) in a registered direct offering, an aggregate of 1,984,328 shares of common stock and (ii) in a concurrent private placement, (a) an aggregate of 865,824 shares of Series E Preferred Stock (&#8220;Series E Preferred Stock&#8221;) and (b) Series N warrants to purchase up to 2,213,115 shares of Common Stock. The Series E Preferred Stock is convertible at any time determined by dividing the $10 stated value per share of the Series E Preferred Stock by a conversion price of $2.44 per share, subject to adjustment in accordance with the Certificate of Designation. The Series N Warrants will be exercisable six months following the date of issuance at an exercise price of $2.39 per share and will expire on December 16, 2025. As of September&#160;30, 2020, there were 865,824 shares of Series E Convertible Preferred Stock outstanding.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion feature of the Series E Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series E Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $2.7&#160;million related to the beneficial conversion feature arising from the issuance of Series E Convertible Preferred Stock. This non-cash deemed dividend increased the Company&#8217;s net loss attributable to common stockholders and net loss per share.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In conjunction with the June 15, 2020 offering, we issued 184,426 warrants as an advisory fee. These warrants are exercisable six months following the date of issuance at an exercise price of $3.05 per share and will expire 5.5 years following the date of issuance. These warrants are classified as equity and its estimated fair value of $370,666 was recognized as additional paid in capital on the issuance date. The estimated fair value is determined using the Black-Scholes Option Pricing Model which is based on the value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Purchase Agreements with Lincoln Park Capital Fund, LLC</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 30, 2020, the Company entered into a Securities Purchase Agreement with Lincoln Park Capital Fund, LLC (&#8220;LPC&#8221;), pursuant to which the Company agreed to offer, issue and sell to LPC, (i) in a registered direct offering, an aggregate of (a) 800,000 shares of common stock and (b) Series I warrants to purchase up to 131,967 shares (the &#8220;Series I Warrant Shares&#8221;) of  common stock. In a concurrent private placement, the Company also sold to LPC Series J warrants (the &#8220;Series J Warrants&#8221;) to purchase one share of common stock for each Share and for each Series I Warrant purchased for cash in the registered direct offering. The Series J Warrants are exercisable six months following the date of issuance at an exercise price of $0.948 per share and will expire 5.5 years following the date of issuance. The gross proceeds from this purchase were $1.0&#160;million.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 9, 2020, the Company entered into a Securities Purchase Agreement with LPC, pursuant to which the Company agreed to offer, issue and sell to LPC, (i) in a registered direct offering, an aggregate of (a) 904,970 shares of common stock and (b) Series K warrants to purchase up to 255,000 shares (the &#8220;Series K Warrant Shares&#8221;) of common stock. In a concurrent private placement, the Company also sold to LPC Series L warrants (the &#8220;Series L Warrants&#8221;) to purchase one share of Common Stock for each Share and for each Series K Warrant purchased for cash in the registered direct offering. The Series L Warrants are exercisable six months following the date of issuance at an exercise price of $0.81 per share and will expire 5.5 years following the date of issuance. The gross proceeds from this purchase were $1.1&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Purchase Agreement With Certain Directors and Executives</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 11, 2020 and May 14, 2020, the Company entered into Securities Purchase Agreements with certain directors and executives of the Company pursuant to which the Company sold 447,761 shares of common stock at a purchase price of $1.34 per share and 146,854 shares of common stock at a purchase price of $1.43 per share. The gross proceeds from these purchases were $810,000. </span></div>Securities Purchase Agreement with Acorn Bioventures LPOn May 26, 2020, the Company entered into a Securities Purchase Agreement with Acorn, pursuant to which the Company agreed to offer, issue and sell to Acorn, (i) in a registered direct offering, an aggregate of 1,205,400 shares of common stock and (ii) in a concurrent private placement, Series M warrants to purchase up to 482,160 shares of common stock. The Series M Warrants are exercisable six months following the date of issuance at an exercise price of $2.024 per share and will expire 5.5 years following the date of issuance. The gross proceeds from this purchase were $2.5&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209108389336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain executive agreements provide for severance payments in case of terminations without cause or certain change of control scenarios. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development and Clinical Trial Agreements</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Cardiff Oncology refers to as onvansertib.  Onvansertib is an oral, investigative drug and a highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine PLK1. The Company plans to develop onvansertib in patients with leukemias/lymphomas and solid tumor cancers. Upon execution of the agreement, the Company paid $2.0 million in license fees which were expensed to research and development costs. The Company was committed to order $1.0 million of future services provided by Nerviano, such as the cost to manufacture drug product, no later than June 30, 2019, and these services have been purchased. Terms of the agreement also provide for the Company to pay development milestones and royalties based on sales volume.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to various agreements under which it licenses technology on an exclusive basis in the field of human diagnostics and oncology therapeutics. License fees are generally calculated as a percentage of product revenues, with rates that vary by agreement. For the nine months ended September&#160;30, 2020 and 2019, payments have not been material.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise from time to time that may harm the Company&#8217;s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company&#8217;s business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209105684312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party TransactionsIn November 2018, the Company entered into a Material Transfer Agreement (&#8220;MTA&#8221;) with Leucadia Life Sciences (&#8220;Leucadia&#8221;) pursuant to which Leucadia will develop a PCR-based assay for onvansertib for Acute Myeloid Leukemia (&#8220;AML&#8221;). The Company&#8217;s Executive Chairman, Dr. Thomas Adams, is a principal stockholder of Leucadia.&#160;In connection with the MTA, the Company entered into a consulting agreement with Tommy Adams, Co-Founder &amp; Chief Operating Officer of Leucadia, who is the son of Dr. Adams. During the three months ended September 30, 2020 and 2019 the Company incurred and recorded research and development expenses of approximately $281,000 and $242,000, respectively, during the nine months ended September 30, 2020 and 2019 the Company incurred and recorded approximately $810,000 and $745,000, respectively, for services performed by Leucadia and Tommy Adams.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209195904968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVID-19<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract', window );"><strong>Unusual or Infrequent Items, or Both [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock', window );">COVID-19</a></td>
<td class="text">COVID-19<div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 outbreak in the United States has caused significant business disruption. The extent of the impact of COVID-19 on the Company's future operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, and impact on the Company's clinical trials, employees and vendors, all of which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may impact the Company's future financial condition or results of operations is uncertain. While there has not been a material impact on the Company's condensed financial statements for the three or nine months ended September&#160;30, 2020, a prolonged outbreak could have a material adverse impact on financial results and business operations of the Company, including the timing and ability of the Company to complete certain clinical trials and other efforts required to advance the development of its drugs and raise additional capital.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the pandemic, the Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;) was signed into law on March 27, 2020.  The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#8217;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company is utilizing the deferment of employer social security payments. The CARES Act did not have a material impact on our income tax provision for the three or nine months ended September&#160;30, 2020. We continue to monitor changes and revisions of the CARES Act and its impact on our financial position, results of operations and cash flows.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Small Business Administration Payroll Protection Program Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On April 15, 2020, the Company was granted a loan (the &#8220;Loan&#8221;) from JPMorgan Chase Bank, N.A. in the aggregate amount of $305,000, pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under Division A, Title I of the CARES Act with an interest rate of 0.98% per annum. On October 19, 2020 the Company repaid in full the outstanding principal and interest of the PPP Loan.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtraordinaryAndUnusualItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=114868817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209105640584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Underwritten Public Offering</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 2, 2020 the Company completed an underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $13.50 per share. In addition, the underwriters exercised in full an option to purchase an additional 975,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering were sold by the Company, with gross proceeds of approximately $100.9&#160;million, and net proceeds of approximately $94.0&#160;million, after deducting underwriting discounts, commissions and estimated offering expenses. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise of Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From October 1 through October 31, 2020 the Company received proceeds of approximately $3.4&#160;million from the exercise of 1.6&#160;million warrants. The warrants exercised during the relevant period were from various prior equity offerings. </span></div><div style="text-align:justify;text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repayment of Small Business Administration Payroll Protection Program Loan</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 19, 2020 the Company repaid in full the PPP Loan principal of $305,000 and interest for the period the loan was outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209107995656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncement</a></td>
<td class="text">Recently Adopted Accounting Pronouncement<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU&#160;No. 2018-13 ("ASU 2018-13"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes to the Disclosure Requirements for Fair Value Measurement</span>. This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard is effective for all entities for financial statements issued for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company has prospectively adopted ASU 2018-13 as of January 1, 2020 for periods presented after adoption. The adoption of ASU 2018-13 did not have a material impact on the Company's financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209107489288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Earnings per Share</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss used for basic and diluted loss per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,502,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,147,609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,994,289)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,458,072)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,341,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,024,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,941,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,180,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.00)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.40)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase Common Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,920,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase Common Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,870,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,548,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,844,384&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,901,540&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209107700376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of the Company&#8217;s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:41.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,536,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,536,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,536,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,536,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants (2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:41.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund (1)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,131,240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,131,240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,131,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,131,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants (2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;Included as a component of cash and cash equivalents on the accompanying condensed balance sheets.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments that trade infrequently and therefore have little or no price transparency are classified as Level 3. See Note 6 to the condensed financial statements for further information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209105642808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Components of Property and Equipment</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,635,900&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,482,116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,953,041)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,604,293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682,859&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877,823&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209112295720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Expense and Supplemental Cash Flow Information</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.885%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating sublease income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,793)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,937)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218,380)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299,812)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,015&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,535&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,456&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,107&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.885%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,748&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,927&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706,211&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685,865&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423,163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860,963&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090,712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Lease Payments</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Sublease Income </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Net Operating Leases </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (excluding the nine months ended September 30, 2020)</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,167&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,793)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,374&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136,623&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476,138)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,485&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090,712&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209107013416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Warrants (Tables) - Black Scholes Option Pricing Method<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Assumptions Used to Determine the Fair Value of the Warrants</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of assumptions and weighted averages used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated were:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Range:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated fair value of Cardiff Oncology common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.01 - $14.19</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.51 - $3.75</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected warrant term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 - 3.1 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 - 4.1 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14 - 1.62%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.56 - 2.49%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 - 118%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 - 106%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Cardiff Oncology common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$14.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected warrant term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Weighted average is only disclosed for periods after January 1, 2020 under the adoption of ASU 2018-13. </span></div>(2) The weighted average was calculated using the relative fair value method.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock', window );">Schedule of Components of Changes in the Company&#8217;s Derivative Financial Instruments Liability Balance</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of changes in the Company&#8217;s derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative<br/>Instrument<br/>Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants during the period recognized as a loss in the condensed statements of operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of a concept from the beginning of a period to the end of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=crdf_BlackScholesOptionPricingMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=crdf_BlackScholesOptionPricingMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209112927528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,884&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820,969&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615,226&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions to Estimate Fair Value of Stock Option Awards</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity and of Changes in Stock Options Outstanding</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity and changes in stock options outstanding is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.312%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.471%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled / Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,069)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,920,706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,766,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,507,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU activity is presented below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair Value<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs outstanding, September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrant Activity and Changes in Warrants Outstanding</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.312%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.471%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining&#160;Contractual<br/>Term</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,589,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,831,451&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,047,582)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, September 30, 2020</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373,351&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Preferred Stock</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our Company's classes of preferred stock is presented below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares designated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation preference</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209112825064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,405,432<span></span>
</td>
<td class="nump">$ 10,195,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Gross proceeds from sale of stock</a></td>
<td class="nump">$ 100,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_SaleOfStockConsiderationReceivedOnTransactionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Consideration Received On Transaction, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_SaleOfStockConsiderationReceivedOnTransactionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209112342088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Net Loss Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss used for basic and diluted loss per share</a></td>
<td class="num">$ (4,502,591)<span></span>
</td>
<td class="num">$ (4,147,609)<span></span>
</td>
<td class="num">$ (15,994,289)<span></span>
</td>
<td class="num">$ (12,458,072)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used to compute basic and diluted net loss per share (in shares)</a></td>
<td class="nump">23,341,218<span></span>
</td>
<td class="nump">6,024,679<span></span>
</td>
<td class="nump">15,941,665<span></span>
</td>
<td class="nump">5,180,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Net loss per share attributable to common stockholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (1.00)<span></span>
</td>
<td class="num">$ (2.40)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209187930360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">12,844,384<span></span>
</td>
<td class="nump">5,901,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">1,920,706<span></span>
</td>
<td class="nump">1,016,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">7,373,351<span></span>
</td>
<td class="nump">4,870,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">991<span></span>
</td>
<td class="nump">14,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember', window );">Series&#160;A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">877<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=crdf_SeriesEConvertiblePreferredStockMember', window );">Series&#160;E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)</a></td>
<td class="nump">3,548,459<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=crdf_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=crdf_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209188604760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value of Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments - warrants</a></td>
<td class="nump">$ 190,199<span></span>
</td>
<td class="nump">$ 4,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market fund</a></td>
<td class="nump">35,536,630<span></span>
</td>
<td class="nump">10,131,240<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">35,536,630<span></span>
</td>
<td class="nump">10,131,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments - warrants</a></td>
<td class="nump">190,199<span></span>
</td>
<td class="nump">4,127<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">190,199<span></span>
</td>
<td class="nump">4,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market fund</a></td>
<td class="nump">35,536,630<span></span>
</td>
<td class="nump">10,131,240<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">35,536,630<span></span>
</td>
<td class="nump">10,131,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments - warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Recurring basis | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market fund</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments - warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Recurring basis | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market fund</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments - warrants</a></td>
<td class="nump">190,199<span></span>
</td>
<td class="nump">4,127<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">$ 190,199<span></span>
</td>
<td class="nump">$ 4,127<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209113150504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and depreciation and amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 3,635,900<span></span>
</td>
<td class="nump">$ 3,482,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less&#8212;accumulated depreciation and amortization</a></td>
<td class="num">(2,953,041)<span></span>
</td>
<td class="num">(2,604,293)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">682,859<span></span>
</td>
<td class="nump">877,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crdf_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and depreciation and amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">805,920<span></span>
</td>
<td class="nump">775,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and depreciation and amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,962,230<span></span>
</td>
<td class="nump">1,962,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and depreciation and amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 867,750<span></span>
</td>
<td class="nump">$ 744,856<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crdf_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=crdf_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209188641320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>lease </div>
<div>renewal_option</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LessorNumberOfSubleases', window );">Number of subleases | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseMonthlyRentPayment', window );">Monthly rent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage', window );">Annual rent increase, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of lease renewals | renewal_option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Decrease in operating lease right-of-use assets</a></td>
<td class="num">$ (423,163)<span></span>
</td>
<td class="num">$ (423,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (697,418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 34,169<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Decrease in operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (487,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Annual Rent Increase, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseMonthlyRentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Monthly Rent Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseMonthlyRentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LessorNumberOfSubleases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessor, Number Of Subleases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LessorNumberOfSubleases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121593497&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209112510600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 98,808<span></span>
</td>
<td class="nump">$ 191,472<span></span>
</td>
<td class="nump">$ 344,836<span></span>
</td>
<td class="nump">$ 578,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Operating sublease income</a></td>
<td class="num">(72,793)<span></span>
</td>
<td class="num">(99,937)<span></span>
</td>
<td class="num">(218,380)<span></span>
</td>
<td class="num">(299,812)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net operating lease cost</a></td>
<td class="nump">$ 26,015<span></span>
</td>
<td class="nump">$ 91,535<span></span>
</td>
<td class="nump">$ 126,456<span></span>
</td>
<td class="nump">$ 279,107<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209112733080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU assets</a></td>
<td class="nump">$ 423,163<span></span>
</td>
<td class="nump">$ 697,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">883,534<span></span>
</td>
<td class="nump">865,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">207,178<span></span>
</td>
<td class="nump">860,963<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 1,090,712<span></span>
</td>
<td class="nump">$ 1,726,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term&#8211;operating leases</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate&#8211;operating leases</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209206045528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 236,748<span></span>
</td>
<td class="nump">$ 229,927<span></span>
</td>
<td class="nump">$ 706,211<span></span>
</td>
<td class="nump">$ 685,865<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209113479560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (excluding the nine months ended September 30, 2020)</a></td>
<td class="nump">$ 159,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">968,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">5,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">3,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">1,136,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(45,911)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">1,090,712<span></span>
</td>
<td class="nump">$ 1,726,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract', window );"><strong>Sublease Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear', window );">2020 (excluding the nine months ended September 30, 2020)</a></td>
<td class="num">(72,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">2021</a></td>
<td class="num">(403,345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Total future minimum lease payments</a></td>
<td class="num">(476,138)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract', window );"><strong>Net Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear', window );">2020 (excluding the nine months ended September 30, 2020)</a></td>
<td class="nump">86,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne', window );">2021</a></td>
<td class="nump">564,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo', window );">2022</a></td>
<td class="nump">5,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree', window );">2023</a></td>
<td class="nump">3,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue', window );">Total future minimum lease payments</a></td>
<td class="nump">$ 660,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Remainder Of Fiscal Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209112111800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Warrants (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DerivativeFinancialInstrumentsLiabilityRollForward', window );"><strong>Changes in the Company's derivative financial instruments liability balance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the beginning of the period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,589,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the end of the period (in shares) | shares</a></td>
<td class="nump">7,373,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,373,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance of derivative financial instruments liability at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative financial instruments&#8212;warrants during the period recognized as a loss in the condensed statements of operations</a></td>
<td class="num">$ (144,035)<span></span>
</td>
<td class="nump">$ 13,330<span></span>
</td>
<td class="num">(186,072)<span></span>
</td>
<td class="nump">$ 27,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance of derivative financial instruments liability at the end of the period</a></td>
<td class="nump">$ 190,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_EstimatedFairValueOfWarrant', window );">Estimated fair value of Trovagene common stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock | Black Scholes Option Pricing Method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DerivativeFinancialInstrumentsLiabilityRollForward', window );"><strong>Changes in the Company's derivative financial instruments liability balance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the beginning of the period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the end of the period (in shares) | shares</a></td>
<td class="nump">64,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance of derivative financial instruments liability at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative financial instruments&#8212;warrants during the period recognized as a loss in the condensed statements of operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance of derivative financial instruments liability at the end of the period</a></td>
<td class="nump">$ 190,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock | Black Scholes Option Pricing Method | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_EstimatedFairValueOfWarrant', window );">Estimated fair value of Trovagene common stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.01<span></span>
</td>
<td class="nump">$ 1.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock | Black Scholes Option Pricing Method | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_EstimatedFairValueOfWarrant', window );">Estimated fair value of Trovagene common stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.19<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected warrant term | Warrants to purchase Common Stock | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected warrant term</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected warrant term | Warrants to purchase Common Stock | Black Scholes Option Pricing Method | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected warrant term</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected warrant term | Warrants to purchase Common Stock | Black Scholes Option Pricing Method | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected warrant term</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Warrants to purchase Common Stock | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.0014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Warrants to purchase Common Stock | Black Scholes Option Pricing Method | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.0014<span></span>
</td>
<td class="nump">0.0156<span></span>
</td>
<td class="nump">0.0014<span></span>
</td>
<td class="nump">0.0156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Warrants to purchase Common Stock | Black Scholes Option Pricing Method | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.0162<span></span>
</td>
<td class="nump">0.0249<span></span>
</td>
<td class="nump">0.0162<span></span>
</td>
<td class="nump">0.0249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility of Cardiff Oncology common stock | Warrants to purchase Common Stock | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility of Cardiff Oncology common stock | Warrants to purchase Common Stock | Black Scholes Option Pricing Method | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">1.10<span></span>
</td>
<td class="nump">1.02<span></span>
</td>
<td class="nump">1.10<span></span>
</td>
<td class="nump">1.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility of Cardiff Oncology common stock | Warrants to purchase Common Stock | Black Scholes Option Pricing Method | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">1.18<span></span>
</td>
<td class="nump">1.06<span></span>
</td>
<td class="nump">1.18<span></span>
</td>
<td class="nump">1.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield | Warrants to purchase Common Stock | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield | Warrants to purchase Common Stock | Black Scholes Option Pricing Method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DerivativeFinancialInstrumentsLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DerivativeFinancialInstrumentsLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_EstimatedFairValueOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the estimated fair value of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_EstimatedFairValueOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsQuantitativeInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsQuantitativeInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=crdf_BlackScholesOptionPricingMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=crdf_BlackScholesOptionPricingMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209187974904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock-based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation expense</a></td>
<td class="nump">$ 361,884<span></span>
</td>
<td class="nump">$ 266,325<span></span>
</td>
<td class="nump">$ 820,969<span></span>
</td>
<td class="nump">$ 615,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Options vested, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770,582<span></span>
</td>
<td class="nump">321,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation expense</a></td>
<td class="nump">104,259<span></span>
</td>
<td class="nump">104,153<span></span>
</td>
<td class="nump">251,212<span></span>
</td>
<td class="nump">300,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation expense</a></td>
<td class="nump">257,625<span></span>
</td>
<td class="nump">162,172<span></span>
</td>
<td class="nump">569,757<span></span>
</td>
<td class="nump">314,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 2,388,077<span></span>
</td>
<td class="nump">$ 1,476,725<span></span>
</td>
<td class="nump">$ 2,388,077<span></span>
</td>
<td class="nump">$ 1,476,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining vesting period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209108280744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Apr. 16, 2020</div></th>
<th class="th"><div>Apr. 15, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 06, 2019</div></th>
<th class="th"><div>Jun. 05, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.44%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">104.70%<span></span>
</td>
<td class="nump">95.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">1,015,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">969,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(3,333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled / Forfeited (in shares)</a></td>
<td class="num">(46,069)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(15,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance outstanding at the end of the period (in shares)</a></td>
<td class="nump">1,920,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at the end of the period (in shares)</a></td>
<td class="nump">441,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance outstanding at the beginning of the period (in USD per share)</a></td>
<td class="nump">$ 12.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">2.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">2.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled / Forfeited (in USD per share)</a></td>
<td class="nump">12.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice', window );">Expired (in USD per share)</a></td>
<td class="nump">8.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance outstanding at the end of the period (in USD per share)</a></td>
<td class="nump">7.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the period (in USD per share)</a></td>
<td class="nump">$ 24.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, intrinsic value</a></td>
<td class="nump">$ 21,766,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Vested and exercisable at the end of the period, intrinsic value</a></td>
<td class="nump">$ 4,507,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=crdf_EquityIncentivePlan2014Member', window );">2014 EIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized shares under the plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,243,056<span></span>
</td>
<td class="nump">2,243,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,243,056<span></span>
</td>
<td class="nump">243,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of remaining shares available for issuance (in shares)</a></td>
<td class="nump">258,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=crdf_EquityIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=crdf_EquityIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209113437912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Restricted Stock Units (Details) - Restricted Stock Units - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Total Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Non-vested at beginning of period (in shares)</a></td>
<td class="nump">11,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(10,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Non-vested at end of period (in shares)</a></td>
<td class="nump">991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value Per&#160;Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, weighted average grant date fair value at end of period (in USD per share)</a></td>
<td class="nump">$ 15.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, weighted average grant date fair value (in USD per share)</a></td>
<td class="nump">9.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, weighted average grant date fair value at end of period (in USD per share)</a></td>
<td class="nump">$ 73.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Equity instruments other than options, aggregate intrinsic value, nonvested</a></td>
<td class="nump">$ 14,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Equity instruments other than options, aggregate intrinsic value, vested</a></td>
<td class="nump">22,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Equity instruments other than options, vested in period, fair value</a></td>
<td class="nump">$ 100,585<span></span>
</td>
<td class="nump">$ 169,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209113438072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_WarrantsAndRightsRollForward', window );"><strong>Number of Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,373,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightNumberGranted', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,831,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightNumberExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,047,582)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">10,589,482<span></span>
</td>
<td class="nump">10,589,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights', window );">Weighted average exercise price of warrants at the beginning of the period (in USD per share)</a></td>
<td class="nump">$ 4.08<span></span>
</td>
<td class="nump">$ 4.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted', window );">Granted (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised', window );">Exercised (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights', window );">Weighted average exercise price of warrants at the end of the period (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract', window );"><strong>Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights', window );">Weighted-Average Remaining&#160;Contractual Term</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=crdf_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_WarrantsAndRightsRollForward', window );"><strong>Number of Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightNumberGranted', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">992,039<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightNumberExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightNumberExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightNumberGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightNumberGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period over which each class of warrants or rights outstanding may be exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of each class of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>No definition available</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of each class of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of each class of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_WarrantsAndRightsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_WarrantsAndRightsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=crdf_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=crdf_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209108151256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Preferred Stock (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 15, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">277,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation preference</a></td>
<td class="nump">$ 606,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">60,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">8,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">154,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember', window );">Series&#160;E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares designated (in shares)</a></td>
<td class="nump">865,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">865,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209108225560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Series C Convertible Preferred Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 15, 2020</div></th>
<th class="th"><div>May 08, 2020</div></th>
<th class="th"><div>Jan. 25, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightNumberGranted', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,831,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in USD per share)</a></td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,546,700<span></span>
</td>
<td class="nump">333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_Servicereceivable', window );">Service receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,403,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,403,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 971,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 268,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_AmountFinancedUnderAgreement', window );">Amount financed under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 1,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightNumberGranted', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="nump">$ 3.762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602,833<span></span>
</td>
<td class="nump">183,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=crdf_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=crdf_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_AmountFinancedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount Financed Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_AmountFinancedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightNumberGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightNumberGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_Servicereceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monetary value of future clinical trial services to be received in connection with issuance of common stock, preferred stock and warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_Servicereceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=crdf_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=crdf_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209188171976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Series D Convertible Preferred Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 15, 2020</div></th>
<th class="th"><div>May 08, 2020</div></th>
<th class="th"><div>Jan. 25, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="nump">2,213,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in USD per share)</a></td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,546,700<span></span>
</td>
<td class="nump">333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_Servicereceivable', window );">Service receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,403,580<span></span>
</td>
<td class="nump">$ 971,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=crdf_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_Servicereceivable', window );">Service receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_AmountFinancedUnderAgreement', window );">Amount financed under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 1,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">859,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="nump">$ 3.762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602,833<span></span>
</td>
<td class="nump">183,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_AmountFinancedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount Financed Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_AmountFinancedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_Servicereceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monetary value of future clinical trial services to be received in connection with issuance of common stock, preferred stock and warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_Servicereceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=crdf_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=crdf_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209103271224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Series E Convertible Preferred Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 15, 2020</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>May 14, 2020</div></th>
<th class="th"><div>May 11, 2020</div></th>
<th class="th"><div>Apr. 09, 2020</div></th>
<th class="th"><div>Mar. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>May 08, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 25, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,205,400<span></span>
</td>
<td class="nump">146,854<span></span>
</td>
<td class="nump">447,761<span></span>
</td>
<td class="nump">904,970<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="nump">2,213,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in USD per share)</a></td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightMonthsUntilExercisable', window );">Months until exercisable</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightIssued', window );">Warrants issued (in shares)</a></td>
<td class="nump">184,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightExpirationTerm', window );">Expiration term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_WarrantsFairValue', window );">Warrants, fair value</a></td>
<td class="nump">$ 370,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesNWarrantMember', window );">Series N Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in USD per share)</a></td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightMonthsUntilExercisable', window );">Months until exercisable</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember', window );">Series&#160;E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_PreferredStockConvertibleConversionPrice', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">865,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">865,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,664,717<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=crdf_RegisteredDirectOfferingMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued (in shares)</a></td>
<td class="nump">1,984,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">859,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Series&#160;E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued (in shares)</a></td>
<td class="nump">865,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Expiration Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightMonthsUntilExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Months Until Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightMonthsUntilExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Convertible, Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_WarrantsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_WarrantsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesNWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesNWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=crdf_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=crdf_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209191687288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Securities Purchase Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 15, 2020</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>May 14, 2020</div></th>
<th class="th"><div>May 11, 2020</div></th>
<th class="th"><div>Apr. 09, 2020</div></th>
<th class="th"><div>Mar. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,205,400<span></span>
</td>
<td class="nump">146,854<span></span>
</td>
<td class="nump">447,761<span></span>
</td>
<td class="nump">904,970<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="nump">2,213,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightMonthsUntilExercisable', window );">Months until exercisable</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in USD per share)</a></td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightExpirationTerm', window );">Expiration term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td colspan="2" class="nump">$ 17,278,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
<td class="nump">$ 1.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesIWarrantMember', window );">Series I Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,967<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesJWarrantMember', window );">Series J Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightMonthsUntilExercisable', window );">Months until exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.948<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightExpirationTerm', window );">Expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesKWarrantMember', window );">Series K Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesLWarrantsMember', window );">Series L Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightMonthsUntilExercisable', window );">Months until exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightExpirationTerm', window );">Expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesMWarrantMember', window );">Series M Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightMonthsUntilExercisable', window );">Months until exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightExpirationTerm', window );">Expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Net of expenses of $616,143, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $370,666.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Expiration Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightMonthsUntilExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Months Until Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightMonthsUntilExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesIWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesIWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesJWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesJWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesKWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesKWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesLWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesLWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesMWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesMWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209188548728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Nerviano<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Other commitment</a></td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=crdf_NorvianoMember', window );">Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=crdf_NorvianoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=crdf_NorvianoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209108275000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OtherAffiliatesMember', window );">Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 281<span></span>
</td>
<td class="nump">$ 242<span></span>
</td>
<td class="nump">$ 810<span></span>
</td>
<td class="nump">$ 745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OtherAffiliatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OtherAffiliatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209105669560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COVID-19 (Details) - Paycheck Protection Program<br></strong></div></th>
<th class="th">
<div>Apr. 15, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>Unusual or Infrequent Item, or Both [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Note payable</a></td>
<td class="nump">$ 305,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">0.98%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=crdf_PaycheckProtectionProgramCARESActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=crdf_PaycheckProtectionProgramCARESActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140209112069912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 19, 2020</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>May 14, 2020</div></th>
<th class="th"><div>May 11, 2020</div></th>
<th class="th"><div>Apr. 09, 2020</div></th>
<th class="th"><div>Mar. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,205,400<span></span>
</td>
<td class="nump">146,854<span></span>
</td>
<td class="nump">447,761<span></span>
</td>
<td class="nump">904,970<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
<td class="nump">$ 1.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">$ 17,278,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,972,188<span></span>
</td>
<td class="nump">$ 3,291,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightNumberExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">9,047,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightNumberExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Paycheck Protection Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of note</a></td>
<td class="nump">$ 305,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="13"></td></tr>
<tr><td colspan="13"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Net of expenses of $616,143, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $370,666.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightNumberExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightNumberExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_SaleOfStockConsiderationReceivedOnTransactionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Consideration Received On Transaction, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_SaleOfStockConsiderationReceivedOnTransactionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=crdf_PaycheckProtectionProgramCARESActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=crdf_PaycheckProtectionProgramCARESActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>62
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MY121<#0J&DUA>)[& 6OJBT_#A$TCQEZP6559Y6_6GMI4!@YLBQ(&P99M9/$
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M:7W"T[FO#YP^<K6$[1U*Q0*&PF<^I*JJSW#J"RW7U2'%H]1:9M77E>"@YDH
M_+Z04C]?E .T)VE7_P%02P,$%     @ $(!E4?+GJ/1D#P  RV,  !@   !X
M;"]W;W)K<VAE971S+W-H965T-2YX;6S%7=MRVS@2_166=VIWIBJ*<;_,)JE*
M)">Q,[&=.+-;6U/[P$BTS1I)]%"TD^S7+TC)@@@T0$IRXCPXNAP C5OWZ483
M>O:E*/]<7&=9E7R=3>>+YP?7577SZ^'A8GR=S=+%T^(FFYMO+HMREE;F;7EU
MN+@ILW32%)I-#PE"XG"6YO.#%\^:S\[+%\^*VVJ:S[/S,EG<SF9I^>U5-BV^
M/#_ !_<??,ROKJOZ@\,7SV[2J^PBJWZ_.2_-N\-U+9-\ELT7>3%/RNSR^<%+
M_.L'C$1=HH'\*\^^+#9>)W5?/A?%G_6;X\GS U2+E$VS<577D9K_[K)A-IW6
M51E!_EK5>K!NM"ZX^?J^]M=-[TUO/J>+;%A,_YU/JNOG!^H@F627Z>VT^EA\
M>9NM>L3K^L;%=-'\3;ZLL.@@&=\NJF*V*FPDF.7SY?_IU]5(]"E 5@6(4P#3
M0 &Z*D#= B)0@*T*,*< )X$"?%6 ]RT@5@5$WS[(50'I%& Z4$"M"JB^!?2J
M@'8*$!F:.'0_<\@I(D*]P.O)=F<[7.1^NK$[W^$B]Q..O1D/=1[?3SEVYYP$
MU^W]I&-OUD/K"M]/.W;G/5SD?N)Q,_.'RWW5;,I16J4OGI7%EZ2L\::^^D6S
MLYOR9B_F\UH+752E^38WY:H7P[/3T='IQ=$HN?CT\M/1^Z/33\G9:_/F;/CN
M[=EOHZ./%_](CC[\?OSI/\D@^?UBE/S\TR_/#BO3=%W!X7C5S'#9# DT\ZFH
MTBE0;!0O=FXT4E:6V22YJ(KQGT %1UM5<)&5>;9(1LFPF-]E995_GF9)=R.O
M=VEDN&4C;^*-#(O9S"CM4.FW_4OO. C'6[>P[0B<Q%MX.9GDM>%*I\EYFD\&
MQ_-DF-[D\,)ZMVM=.X[.;_NU]_>_88'^>;1EH^_W[.2V$W0:;\_4>I>/L^1C
M-L[RN]34"=1QUB'S>'P[NYVFE1%CE%WFX[P"*CG?NI(=I_7#C@UM/9^'1F^O
ME3=9*V_2-,\"S;]*I^E\G#U)/F=7^7R>SZ^2G_-YLKA.RVSQ2Y)61JCQTX3B
M)PE!6$'Z=]D ;QJH&>O="X$$0L\.[S95DX^BBF(E]1K7DI^NY:?;RM]#YN&R
M4K$A#49(,:Q)6^R1#Q1NSWR(E,RIY\0'$42(D +Q-O+41SH-GOF(@1$<:TPP
MAT>3K4>3-65I8#2/YV/CARRRY&<S@LVK7Y)\I9&OB^DD*Q?&E/]UFU??DC\^
M%M-I8FC\E[2<_#>R%/FZ<1Z=RJ:50>T.3))Q,3-.TB*M=0\T?]Q;3<9G0D(Z
MH]X):PDJUH**J*#'B\5MO>B2XK(6M+99BUKVY/;&O,R^9N4X7S3?FJ$ITWFU
MV-Q3D-T6GIQ,2XHI+*=<RRD?6$YHJ*6_<8DR2U<XVT!ZJY(["_<D4!46<#_5
MNI]JCW[>98NJ5@OF2S/\59F/:U6[ LSS[LE1OGZC@L BZ[7(^GN*#(FIO?%G
MSO!KKR,#!G<#(\O]4;0CUB(MQ9OD=_DDFT^2F_1;;;Z3FM M#>?++0WG<-5T
M2^#:M#CJL!/6[MJ&6X.C7?N831M=6$^1^2X?&Q)DYL+\O;R=3^KYJ6<NKV;9
M'"(8PU7UFW))Q)2CHTX[86WQK6''<<M^FE7)M%B >QK[UGA -6)28G=P>R#;
M EK+C>.F.[0'GB0WSJ)*S7I:J]++HNR>CXX]/5J)YEH&C[4 .*PHI:%]8PTM
M9H_6>7#&&;#Y_0Z/5K@V4?%&Q0=A["I[H$4L*!,:N1L $ T+R3>%:X^R910X
M3BE&638S [E62F4V+J[F^?_,9V; /V?SAG";01PWFJF)BUYF:75KUDT],WV<
MG"1?327HC@(,1"@BM+O-?-S  ;:'P'(5O"-9J9=2LT.2LE@MH721I+7%N9U6
M2]M3CTFVPB]NIGG7OGJ#?28CF C8=VR)#(XSF37+SY:".B[*^[1<TWT-;G>?
M>1#(20%PC!-.>6B_6XJ"XQS%[4$/J8?89QY:*($5=C>M\C>MYZ8 (*F1<'>M
MWR9!4G"B&'7WK0\U^Q8QCJF[NB&D%E0B&O)8L&52.$ZE'L"#Q3XS E>'#XOZ
ML,2R*!)G43MZL<1G/@$W=H6,^K$ !G!D@39#GBP =;D; .GR98DE< 3_>&^6
M;$16=B=@!*!5ILL2"Q)P^HCE5:1G2 16EA?9C5E5**PLB<]YP( . &-4<!2:
M-\N-2)P; ;JR2^@A\4F$$)QKY1(<XG,7?R?X&(6TJRJ!)@DF3% D78X/0 <8
M"ZY=+_H,0A+$!-,DY!(02X=(G YUJ\I.2TH@0@.M#A\7M:3$$AH2)S2PKNPT
MIL1G)K Q70'CQA0  <84:#-D3 %HP)B"R+@Q)99H$?D(*M.R)!)G2=N$ (E/
M*C!3BKI1CVY<6UA+/$B<>%RD4Y]5M[RU#K),H(!,;?L"&YU:/D'C?*)3-# F
M#MABHA&1S(MX^TQAX$>\ ]4)K0+=LX:=QB,S#Q^ I7X0!G-!>< 84TL":)P$
M/$P,EOITP8C'W&DAOEONJB2P)A::D8U3F-UB.0\4@J4^UV",AB;'$@T:)QK?
M,WA) 4,.!"\[8>VN65-/XZ9^W^ E!>P\,[K "5R<=N/:';!FGL;-?(P]4\ $
M,FS8!7*-91]D6T!K*ND^IRL; 24;1XH>'7?L@=?4CTT,H)CE,0"DS;] CZUU
MION<LVS?8["7?I1BX 4@CP$4=:;^/8#!H9,_:HT^[1EM@)VKD]MYW+FB_4(-
M (PSAJD.* 9FJ0'K&6JPSE67T$/FFW*EF"+4\?A'K$>8 <!(K=V36Z!)@I$T
M0^7%CP'H %/!B$L%SR"D65P<F841,(',DA+V"-$&9HD&BQ.-;:@S\TD $8(2
M[DY")ZXMK*4++$X7]J;.S"<$ R*Q9 %6SS8R(.*<8"?JS"#_GBG*7>_R#?-#
M"T9P=]Q#U86\9V9Y 8OS@H>GSLQG &8B=.CD@ED&P!XZS0*<&I\!2.Q&A=XP
MP)]W'1JP)A32&Y9'L'UXQ-[4F?EL@!N"%I#:<@$6YP+?DSHSX+@ H,Z=L';7
MK(EG<1._+W5FONW&6A&A7+O5B6NG45D3S^,F/D:=.6 "&6;&!W2/)/L@VP):
M4\GC_ON^$6KN>^L0B8)@L0@UM\:6]\R:W")"S8$\23!"S7TWWB-1  :(4 --
MAB+4 #00H8:0'1%J;HD!WSJ=,W*8!R^.?L<7 $QQ347(3>*60?">QQ?!PSQX
M??A&7U*,*6/N^NAQ@@%@%,6N10.:K,^@).'$558 =*"EX<VNQPT!"5)*2Z5"
M0[N1(<I_/,?FEI'P."/9*D/59PM82HJT.P>=N+:PEE?P.*_8FV-S(."@V@&'
MMFB6//".,/\N')M#202-."['YD ,P=6R)U!UVOPC@;PV;OD#WR>W<Q>*S0&F
M(##"(6]'6*H@XE3A83BV /(0&!?437-Z(WS?WW3$F9E ;21$M87E'6*?<X.]
MJ;8 ^(;"@=TB+-D0^QPA[)0K+("3 G<6($(0Z(HU[R)NWK^GUR" D #@-73"
MVEVS5E_$K?Z^7H, ;+&F"+M$K1O7[H"UK2(>&8AY#0)(3V3&J'-!W.'M@6P+
MN/'41<^#_\XD0((@8BB W$2 & (P;'0MXB%V*ZQ)%MNE,?:0>BA\*RPPHPP[
M#&TD_ <P/%H(8-1F4&FU]8%L2>.9(N,,N"E> '0@I!+<]1H@H/%%C+T-NF/"
M\@G1,[ER=Z]! $]Y0(O#AT6]!F%9@]@ZC;&/UR!\:@![#<)_/L1?'CX&\!J
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MG8?ZFXJZ*]<3Q2O;V.9<Z39IATM]D:$P 7H_YUQM)R9!>S5&?P%02P,$%
M  @ $(!E48*"]!Z=!P  ?Q(  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6RM6&MSX[85_2L8)9,V,[)>=K+9K.T9V[M)=M+4[CJ/F73Z 2*O1,0@P 5
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M B_ \Y5'FMT%.QC>.9W_!U!+ P04    "  0@&519G&]G0<%  ##"P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6RU5FUOVS80_BL';1A:0+$E6;;E
M- G@) U:;,V,>&T_#/M 2[1%5")5DHJ3?[\[4I:=-O&*8?N0F*3NY;F[A\<[
MVRK]Q92<6WBH*VG.@]+:YG0X-'G):V8&JN$2OZR5KIG%K=X,3:,Y*YQ270V3
M*)H,:R9D<''FSA;ZXDRUMA*2+S28MJZ9?KSDE=J>!W&P.[@3F]+2P?#BK&$;
MON3V8[/0N!OV5@I1<VF$DJ#Y^CR8QZ>7*<D[@4^";\W!&BB2E5)?:/.^. \B
M L0KGENRP/#GGE_QJB)#".-K9S/H79+BX7IG_<;%CK&LF.%7JOHL"EN>!UD
M!5^SMK)W:ON.=_&,R5ZN*N/^P];+IJ, \M9857?*B* 6TO^RARX/!PI9]()"
MTBDD#K=WY%!>,\LNSK3:@B9IM$8+%ZK31G!"4E&65N-7@7KV8NF+ 6H-2[&1
M8BUR)BW,\URUT@JY@86J1"ZX.1M:]$=:P[RS?>EM)R_8GL$')6UIX*TL>/%4
M?X@X>[#)#NQE<M3@DC<#&$4A)%$2';$WZH,?.7NC%^P]$R7\.5\9JY$L?QUQ
MD/8.4N<@_5^R^U_9ANM6T]Z6'"1:@=J7A5-9 )-J>;WBNL]L2)*:0\GN.:PX
MER 5Y"63&[1EE;-SI>J&R<=??LJ2>/K&@#F P/80FAT$9O"NF%R+%;H4$H0U
M,)>R917<\49I"WA%Z9Y!')W\"MAMG)NU,#F*/'*F.[C7/._0QH0VG@W@%GO7
M;\H86.#QLF0(_9(9D0.3!12B:BWJ212J2*A!H5S5F ,P3E80-,LUWBZ46SVB
MRKTH"'VOPYH&XV"KBE/\.VVK\B^EJ@JN#:D1WJWK KPXP=1I;&I//!G KF@L
MHB+CQ;XH"$FH8@ +[$A<:UYX"!@PNB:$,J_:PB=NC\E:S&9KCZ%">;*/GQH4
M=&T0Z;+Z+CF87B3&QB?'81WX1!IHC?>+9<C;BKFJ_G-.^8-#3&5'1H@3IX'M
MUQ=55?@6D*%.^&LK[EG%I36G\,<3 1^=X<@6I(0M_VTX9%=SOFM(MW0+NC4Q
MWA'I8'7;UE@^J_2I(Y>+T26">/F]OSX'/IZ?X54:CJ,D',_BUWX7I]-P$LW<
M+AZ'LUD:)EFW3<)TG(71-'F-Y)8*:>@]?_Z62^:@(K[@F ;^#)XG=?&8DE$X
M2N,PB3.8A%&2AI/I# @)'DXF8QB'<1:%21+O ]XK_P#53I^Y<AA<-(A]E-%@
MTH4[B"*W2 8I+GZ@W(>7IE$6:2)853U"SRG#<[Q+EMJ,+9D]Z%L=#8O^(NQ(
M[)ES)%\KGC-,-&D);#WK-4X1L/V6SJ?/=$_/H-\;<N+:9=-J;)[&]4Q*VY+2
M!G$XPTX[C2:XBN))F"83^,RT1OM'M*;A:(J5',>0AMDT0M9,L'_B@R5R"L0+
M?93476>S&&)DWB1&D)J2,T=;$KED!65YWVR\5C:=NK].^.U1X5$X3C/D[0S<
M"Y"\ :1QEJ;A*$N12[,H1H$(H>58+JS5O% - 3Q\G;22N,9NCB+P7L*\W>"\
M0^G+W L$-_/E)79GTY+B\B/<JH'[>A*/X%5 )]TN>!W"U=/WZ1H?#BQIBZ6\
MH_ZBG1M'*[AA6-)/K&JQ!W!&,O3MN>=^>#!884?8N/'1@(O!SUC]:3^ASOU@
MMA?WX^T'IC<""5'Q-:I&@^DX .U'1K^QJG%CVDI9'/K<LL0IFVL2P.]KA=SO
M-N2@G]LO_@902P,$%     @ $(!E4>[@8_\R!   7 L  !D   !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&ULW5;;CMLV$/V5@5L4"6#X(GNO\1KP;AIT@6RS
MS2;I0]$'6AI9Q%*D0E+KN%_?0\J6M6F\35KTI2\2+S.'9V8XPYFMC;UW!;.G
M3Z72[J)7>%^=#X<N+;@4;F JUMC)C2V%Q]2NAJZR++*H5*IA,AH=#TLA=6\^
MBVNW=CXSM5=2\ZTE5Y>EL)M+5F9]T1OW=@MOY:KP86$XGU5BQ7?LWU>W%K-A
MBY+)DK631I/E_**W&)]?3H-\%/@@>>TZ8PJ6+(VY#Y/K[*(W"H18<>H#@L#O
M@:]8J0 $&A^WF+WVR*#8'>_07T7;8<M2.+XRZE>9^>*B=]JCC'-1*__6K'_B
MK3U' 2\URL4OK1O9R;1':>V\*;?*8%!*W?S%IZT?.@JGHP,*R58AB;R;@R++
ME\*+^<R:-=D@#;0PB*9&;9"3.@3ESEOL2NCY^2LA+7T0JF:Z8>%JR_"X=[.A
M!W@0&:9;H,L&*#D =$8W1OO"T8\ZX^RQ_A"D6F;)CMEE\B3@'5<#FHSZE(R2
MT1-XD];22<2;_+VE+Z5+E0G&.OIML73>XG+\_L09T_:,:3QC^N^]^8^ Z%W!
ME!N%5))Z15XL%1.2T<5-C\TK4U9";W[X[C09G[QP))QC; F=D9)B*97TDH.H
M\"0L4]F@9U'"<FI66OX1II[RP.$A<@CI$W9K:\.Y2 /I*%4 E[F$=(V8VWB^
MJ"IK*BN%9U+\P(I,'C<Z:(5D*VQ:;, N;"/2GLLE$';ACFQ><KI='8?5\=DY
M'7(+V/Y2&P\FMU:FL$]J6L1\IQMA[X,'4+_H.H.T3(6BQ=XMKSMNN9,P/X>$
M]O0&K"V]63JV#]'/U[JJ_6.9]]K\9?^=\>T!YR$I>(.$#20HAY_HV?@Y?4^3
MH_[1Y+A_/!EA$J.5O'@TZ@AT$;]1M6/<.1QJY8.(7LFE%CJ5@)4:U[]NW+B#
M6 MK15AXECP_<,;X;-0?GYUU1@W+KC>_5O/_$]4Q#,)M3::'0M,1^"RJWZ+Z
MGT5UVA\G)^W_:R/Z6"MXXEJGJLY"&4$T*$5-@L/@621[*EP1(Q0'_+$&>15Y
MHLC$"I*F30T+E28UJ"S: 6DI%&QCBD^=&T0C%E^TN*U]3?U92U](?;@&H9*%
M9SW;G8_:RL[OBQ>8 !R7H"F:$'>=N^+-Y\CE_@H/:.&)15J@=E;&^F!1A7"9
MK$]"J4/%.5SJ=2&A=ACZ$>TNH;I[>65S>8'7O1#1#KQY61#(+6* 9;6)/$)Z
M, C 0P(W"HP\< "@#1X:9&%0U*["VZ'337Q".N\ POTZ^FTR0%5G^AG92\<[
M)^V#N0^;\W@I&EK![+RV,4'!*_9<:-P&7WJ7AYV.IV2[BGT=GB13:]\T/^UJ
MVSHNFHYI+][TG2@E*W@' <^A.AJ<'/7(-KU<,_&FBOW3TGAT8W%8H/UE&P2P
MGQM8N9V$ ]J&>OXG4$L#!!0    ( !" 95%K/?)-OP(  .T%   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;*54;6^;,!#^*Q:;IDU"Q1@22)9$2M^T
M2:T4M=KV8=H'!XY@%6QJFZ;=K]\9$II*2_9A7_#=^>ZY%_/<;*OT@RD!+'FN
M*VGF7FEM,PT"DY50<W.F&I!X4RA=<XNJW@2FT<#S+JBN D;I.*BYD-YBUME6
M>C%3K:V$A)4FIJUKKE_.H5+;N1=Z>\.=V)36&8+%K.$;N ?[K5EIU((!)1<U
M2".4)!J*N;<,I^>Q\^\<O@O8F@.9N$[62CTXY6L^]Z@K""K(K$/@>#S!!525
M \(R'G>8WI#2!1[*>_3KKG?L9<T-7*CJA\AM.?=2C^10\+:R=VK[!7;]C!Q>
MIBK3?<FV]XTQ8]8:J^I=,.JUD/W)GW=S. A(Z9$ M@M@7=U]HJ[*2V[Y8J;5
MEFCGC6A.Z%KMHK$X(=VCW%N-MP+C[&*E\7VU?2%<YN3JL14-3MS. HO8SB/(
M=CCG/0X[@C,AMTK:TI KF4/^-C[ FH;"V+ZP<W82\!Z:,Q)1GS#*Z F\:&@T
MZO"B?S3JDU7%I7W;+_FY7!NK\1?Y=2)5/*2*NU3Q?\_T)([CX]0T/(.YAX0S
MH)_ .P).WIAA,&<*Z6,L406Q)9!"5<A"(3=3LC3.B%.V4*]!=Z/N;9>0[4RA
M3ZY;+85M-73 JBA$!@?X[TE*1_Z$49229.33B)(;0):4JLJ)J!NMGL!Y&A+Z
MDS'S&3J\2C=\K32W2K\<8*;CQ$]&E"1Q[*>C,8G\<80Y*$4I3ID?AF/,8<R'
M=RD+V6>>96W=5MQ"CG3$066"]X3'@GFMM!6_>\-'YD]&D4_C\).3QS3VV23Z
M=&1V/I'@&AQCRG0T<:TFB9^RB/SM%PD.*%B#WG2+QN#\6VE[-@[689<M>PJ_
MNO>+\);KC9"&5%!@*#U+1A[1_7+I%:N:CM!K97$]=&*)^QBT<\#[0BF[5UR"
M8<,O_@!02P,$%     @ $(!E4=Y_5O;!"   $R4  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL[5I;;^.X%?XKA#M;)( 2Z^*+/),$R&1VL5-T+ICL
M[*(H^D!+M,V.)&I(*D[ZZ_L=DI85IPDZ!?KFEX22>.[?N9#PQ5;I;V8CA&7W
M==68R]'&VO;U>&R*C:BY.5>M:/!EI73-+1[U>FQ:+7CIB.IJG,;Q;%QSV8RN
M+MR[S_KJ0G6VDHWXK)GIZIKKA[>B4MO+43+:O?@BUQM++\97%RU?BUMAO[:?
M-9[&/9=2UJ(Q4C5,B]7EZ#IY_79*^]V&WZ78FL&:D25+I;[1P_OR<A230J(2
MA24.'/_NQ(VH*F($-;X'GJ->)!$.USONOSC;8<N2&W&CJC]D:3>7HWS$2K'B
M766_J.VO(MCC%"Q49=Q?MO5[$VPN.F-5'8BA02T;_Y_?!S\,"/+X&8(T$*1.
M;R_(:?F.6WYUH=66:=H-;K1PICIJ*"<;"LJMU?@J06>O_BI@DKD86_"B-^,B
MT+WU=.DS= OV035V8]C/32G*Q_1CZ- KDNX4>9N^R/!6M.<LBR.6QFG\ K^L
M-RQS_+(7#6-_OUX:JQ'[?[S <]+SG#B>DQ]VUHMTE%BO3<L+<3E"YABA[\1H
MI^"U89Q5PA@A(F8W@MVHNN7-PY__E*?)_(T!"+06C<4>MU\V1=65@DEK@ -C
MA68K7LA*V@>_A?&F9!(IAD^25TQ\[V1;[SE$C%<54RNVW<ABP[@6K%!(LE)H
M43)DN^96-NNP^YS]MM>)G7#2UG1+4ECI4[ RRC\[Y5JE*=<,L2<%>\VL@FU2
MEZSEV(&='6"C\4X+P8S 6ZB[9W3.KKV.<(@9O&<;?B?84H@&F0?[D!#0&<R7
MXHGFS@]D'2\*U346&U'#>F'5 UMI53N7;U#-/-4Y^^!]^LM.<Q>F1T[8L6?+
M3E8E"90-N^4->R?%6@7+\'B@$"1QR\1]*P$!AH+T3A2B7F)OECC4)][7?G.(
M.K34%$ B6<E[V%!3VKG7B&C+'RBRSM^\;;6ZE[6W[=4\C^(8Z;25=L.RGZ!0
MTQ$:3,$K3D$:2G-A! HLJCCI)B#L3IP]"*Y)D-B"4K6NC#I^\+NLN_JQ,M 3
MVURDR5C1G.V@N^)2 ZSZ&YK,':\Z(!TA_2<*,VWG _6 ;NWC@+P89 .3AC7*
M,OJH&KZ$S$)H4I<XB'NA"^E<C'U>T0@ !%P\F4-,R)R2PD6LX8BB\[X(4 O>
MJ"1?^N #+YK*^IE:G77D)Z0I*0$JCSLG,""GA\QM#U>7W(@=6@2)*)1&AA#2
M\<[JKK"=!CXHJ1D*PYU4G6'D=/.H%,!GA1/(=PGV)+\(ZV3L+E-*1^]JS@_F
M'N-KO'>HBG8E KGH<?L<9G>*:@$32Z=I0<R<TRIES,"GI"JXH:\+LCN-DYRU
MG38=;QP<KF]OV"0%<G^^1P01@7?2M,H '#?*6/9I6<DU]U4F@D!74!N79@YW
MRG*G+< %/<P&#EN1 1#5FP@DJ%JX<F"W:A?\?96!(PNR2/L@DZ=#%I;[E'/4
M&V6"F_=NI>C2.$1/@74HU*$.H&Z1V^30*UO(7 JR@M<4XW]1+;Y[Q&]02< !
MXJRLW&=>AMR$-/)>/DDI=*CG7:N: P[/QN5I"9GD<ZHA3C=1222]1R$":)&(
M;NT!7G9^Q@K)OQ1KV3AI7SY]#4GC\CXX[< AW-6OOW!4 /W '+"2Q3E[[Z.T
ME8@>U2;9="+4>L+9NO%.:J@CH<6[/*7.2U,:E8&=]YRW#F(,[HBOU*XOXMN7
M799_A3[7I+!Y!MBH(WM*YT*0OXJ=5UYEDRB9+7HK?8K1EX;TJOW$)&AB8IAW
M;$BE,/00F@WA%J6W>@CEF00,Z@WO:\&@$I"H?:>E+K-U=0_4S1H"/*[ZTO X
M98=]E$B)&5#@2,O>P,/4<;T5GB_A9.I6JJZI!"/U  SJ,I9J2BCY!>^H(BT?
MV,VGW]^_.TL6; MP@E<I88S2?E[HW8KB[UN&QXQ#)4<=Z@S9\;U3SGXM*>E<
M2P<T*W0J[N-&QCN!\%=OG;/K('(#%Q--'V-J<7+8OT.Y,GWG4 AA0R*<G3L0
M!0)4)L^9:@AZ:>C/WG^[RN<<P$G_"N<B\QH$A)7A4'T D8]DQ0O?"4(N<P:K
M3P<C2$$5]!5;Y%$>YU@DBR2:S%.LLLDDRK,95E-,#HM'M(?!/YFGT7R1G;*3
MQ2):9',LTB2/LCRF%=[E27K*/B+RAR-0D)_.HCB9DB))-,UHD>#59$KBT_DB
M2N(YFFC;5LZUP-,2,TN#5N;/J;+QAU%_+NQS(Q1O"N70L=?.^X]]Y=\]:F:'
MKNHKEX%2DS1#8F=8S1;S:(*.=1-&FT,+=_64^NPKEN<9#)S0:C:-LOF"?53[
ML>@EVC2>1\D\!UT<+2#Y-]?77I:61/$BCN9)ZM9SN#2;I.P/=S 5Y1E&9XUS
M]G_L)NZTD;QY,D,GYYD?2%AZ'H?5$X:E-&["9C1(/,=I=CYE/X6_CV);<+-A
M*\3*%16%_-(_&.'_2^K<D%HH%_[4@*;<41X?SI U-.IT7P&>1.7U %>]H<:?
M/)ZX".#/9M%\0IF9IDBM=([5/)Y%\"AA+Y]&P%' PCZ,87:F(BRM'T[\+-(0
MV"AQ*DS,_:S?SW?.,D&5-301'U_?GP;)X4]1 X?_C<X%<"0)?R:)PNEV-PKO
MFCD5A2>;G--/Q#VY=C?'_3<-\Y1P/D6YF)&?^JI$R89<F[CYE"UF.39,V<DD
MSI /TU,VG:'4N3"G*2./YLR!-GT3GO A8UF$I.\_^"?O^%6'L5WT9R!O7S\6
M)E&"(,Y2*A8GD_D,CSGI-$,B3_(I;$:[02/JK$,1D@_-$CNG*+K):1 QS.47
M[BVF_;W%]'^\MWB1[GAO<;RW.-Y;'.\MCO<6QWN+X[W%\=[B>&]QO+<XWEL<
M[RV.]Q;'>XOCO<7QWN+'[RW&@Q^JH/&NW<]Q:&@%2/UO5OJW_2]^KOT/7?;;
M_<^%/G"]ID-?)58@C<_GTY$_\^P>K&K=SUZ6REI5NR6=EX6F#?B^4NC'X8$$
M]+^#NOHW4$L#!!0    ( !" 95'HS]MK2 8  %@0   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$T+GAM;+58VW+;-A#]E1TU[B0S$D52LGSWC&0[DW2:Q&,E
MS4.G#Q )B1B3A * DM6O[P% 44PBVTTO#Y$)$GL[NWL6R/E:JGN=<6[HH<A+
M?=')C%F>]OLZR7C!=""7O,27N50%,UBJ15\O%6>I$RKR?AR&HW[!1-FY/'?O
M;M7EN:Q,+DI^JTA71<'49L)SN;[H1)WMBSNQR(Q]T;\\7[(%GW+S:7FKL.HW
M6E)1\%(+69+B\XO..#J=#.U^M^$WP=>Z]4PVDIF4]W;Q-KWHA-8AGO/$6 T,
M?U;\BN>Y500WOM0Z.XU)*]A^WFI_[6)'+#.F^97,/XO49!>=XPZE?,ZJW-S)
M]1M>QW-H]24RU^Z7UG[O")N32AM9U,+PH!"E_\L>:AQ: L?A(P)Q+1 [O[TA
MY^4U,^SR7,DU*;L;VNR#"]5)PSE1VJ1,C<)7 3ES><V56#&+#+T6)2L3P7)Z
M6VJC*D!O-/7H,U.*X?&\;V#0BO636OG$*X\?47Y"[V1I,DTW9<K3K^7[<+3Q
M-MYZ.XF?5#CERX &89?B, Z?T#=HHA\X?8/GHV_'S,J4WO!T(<H%C6W9"".X
MIFNADUSJ2G'Z?3S#=I34'T]X,6R\&#HOAO]/#IY4;IOZ5"]9PB\ZZ%K-U8IW
MGK?X\T_'<12?-79I@LI/J5JBD4S&Z4H62U9NW+:C,XL8RS=::))S]SU1PL &
MHP0% &J K"AI/+VBCW(I$CJ.#GM#Y/$*GRV,VGZ^*8TP.YT?UGCUI<(K>FE?
MQN&95>!%W8OH[!5)U5([/ Y[$=0B4P;)JX3.; Y_%6PF<I_$N9+%/K5>=*L6
MGC&5BOF</I1H,;G8H-414>%",1DSE'!E(Z/U%B*A=>7C1-!ES3IK83*'"'_@
M2>5> :*M+/=^S'T.RH6F BU/,PZ^2Z1"TQ#3L-QD*]]%$B!A(#6[#<+<6]H!
MY(IX%UC7.='XRE##+-<2IBQ BO<*SFQEPZ ASI(,7)<[O7XVI,QP1W\I(00.
M>,&(6,R94+1B><6[SB** MHT.!%V*,E8N> 6DMT^X-18K6,4^XL*,*:@?VS0
M!L9\90(]3"3%+)3 X.-.KO%*.VTMB[XH=2O^2EL'[+9)SI+[WC3)9 Y!N70I
M6BIATT&%3'GNC2@7"30QI+EPVSQ1K!WQ6^!6<&O!K7);(W)7,?O]V7GCWJ8_
MY!2EE=KN!AQ"IK:%4I&XK*RYXJ?TWIIN,S"!/X'CC*N&1/$3G="=#>Z4;O:D
MU3K[72\DLBC@$:93<D\OHB",P%$OHF$ 75@>NN4@.#JDFX<E.L&ZY(,E"PG%
MP0 [!D%$&\Z4QI-=#YOUG=#WO;GBMG0@@,0"?Q1@&$1#;(R"47R W\,1%G$P
M/#G8V5G)'+61V[9ZUO,H"JVVZ!C*PM@^AJ,#D,=*H.Y2V@B>IQ32@?LW=K7W
M-8*?M[D?^]S3R^C5R_@5G=+K'P+0 ?<X5'\#E'^!P-Z($<@NNKJR;>?*,@<5
M^D%HZP3TNRT_-H=7] LK*YSN**KKJT+A*5>F+*T+&5Z-IY]LY1WWHD% %C';
M8M]V$H  "; \J7)7E+O^4#SW?-BJTX*;3*;!7APLY6RY*\-LD&@E3+RGD6KQ
MT XQ3P9-YV9PE1AAAI5Z#J=G7MM2R95PYU;+$(UI#"3/U>Y[S7Q3PV!T#"*O
M2CNT:%+E.<=3,YZFXTDS[M[+ %5ZU*5I!@[O^;%\RS:6'-L"VXV-8-?E2K1F
M?#VOW-S0%1B?[?S>,_\\JSGP[6'?>IK4T[L"EJY8F:YG79T"]_(;MJOIM"EF
M5\/M!-G-GX(I]BDWDS:D,3J5Q54Y=H=9'#6,C;@U7FN3.^_V&7]BNGF_YC+'
M/<6)LUF.[QQ"0*XV@U+ $6@[B/QXTX_-K];<GC>G++'GE-5XMQWOFZU_W1^=
M#:X)?*[WCH: KBW>UUSCB.9EWU>.SQ!/<]IKG0^O>5+SG>MH\-2DA@X"_R;"
MT; [/!G1"QIVH_B(KO8=%?Z1B>\FHSMH+$KQIS].,0)W-4E[_I#16(B.1]WP
M*-XW1?]K3**3L!N=G-"^VT6_==LKN%JX.ZWM"O"'O_@U;YMK\]C?%G?;_9W[
M'5.XY, #/H=HB('=06>Z>ZQ?&+ET=\>9-+B)NL<,5W^N[ 9\GTMIM@MKH/G/
MA,N_ %!+ P04    "  0@&51U)^B2T4/  #T-0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6SM6UESVTB2_BL56NV.'0%#N$'ZBI!D>\9MM5LA]?&P
ML0]%L$A6&P0X."1K?_U^F853(FAYVI[IB=@'6R10E97GEP? E[=Y\:G<*%6)
MS]LT*U\=;:IJ]_SDI$PV:BM+.]^I#'=6>;&5%;X6ZY-R5RBYY$W;],1SG.AD
M*W5V]/HE7[LL7K_,ZRK5F;HL1%EOM[*X.U-I?OOJR#UJ+USI]::B"R>O7^[D
M6EVKZI?=98%O)QV5I=ZJK-1Y)@JU>G5TZCX_"V@]+_A5J]MR\%F0)(L\_T1?
MWB]?'3G$D$I54A$%B3\WZERE*1$"&W]O:!YU1]+&X>>6^CN6';(L9*G.\_0W
MO:PVKXYF1V*I5K).JZO\]F^JD2<D>DF>EOR_N#5K_?A()'59Y=MF,SC8ZLS\
ME9\;/0PVS)R)#5ZSP6.^S4',Y1M9R=<OB_Q6%+0:U.@#B\J[P9S.R"C758&[
M&ONJU]=5GGS:Y.E2%>5?Q-N_U[JZ>WE2@3+=/TD:*F>&BC=!92Y^S+-J4XJW
MV5(MQ_M/P%''EM>R=>8=)'BM=K;P'4MXCN<<H.=W8OI,S_\*,<7'O%+BOT\7
M957 .?[GP#%!=TS QP1_4)L'J5 </B]W,E&OCA!HI2INU-&(]'_]Q\QSXQ>M
M''Q+_+0C-R_-MV?DJ4N1Y%M$;RDY -1G^JP02JFL<+/*Q;DLEGJU$C]E\*-\
M?2>4H2AO<:,4&WFCQ$(I"K\D7V?Z?[%-9P*04(!FML;U$NY?"EF*59XBPLOG
MXN=-H=3((03,6:GM0A5LTX^0]]!]LCG^<^>#3^^S)*V7YGC2B2R2C9#9$A%X
M V39 2>J3L)CX3J!Y87SYI,;^OCDA:[EN1X^^8YC>7-W1!1  3NL+;%6&:1+
MF;A<(N0T^0=A1T??"V,K\D+A1I[EQIX(H[D5A['PW<":^Z'X.:] H/R2(<!(
MY%JS64#,19'E@^2QF'F.-8^(]<@-+<^+H% EZFQ@@A&U)"^KH4VS/'MVHTKZ
MQAS 6L8Q ,EE!:G(;K+:IW,2F;1MB0SI(%\)D-%;)@SX7RE=U="])6YA[F//
M\F<SRXECWG;L6D$<6;$76F2?G6*T3>^P>*-A*EVRV$G#Y$(-72J_ 1=2W#*$
MJN4SN%V!C( EE%:(7Q*(_L+Q=+XDUCS;,_S:@;B#.Y3C<VW6V@&*"?R/PKZ&
MI2I5;(GF4$.MUB J[NQ1%BE![G9%_IE5E-Z)N>T:5LSA%7O!2NI"W,BT5D1G
M;)'&3,NZH!,K[,DH-+8F--14:+1F@G@%O"B.'2N<&6T<^QX\"A?V*&-@S$F>
MVL@GX9:*] *&H.^,N5MB-^U8%Q+15I<MUV>IA*=?)X G5;:4B+[QT&V^5)37
MJ@VO-D!!>Q^81Y8H#AKE#+32[S#V+Q&P2YV0+,^_ DVN=/GIV8K 26<035'<
MD$2.'03B/X5KS_#_&WVCEU"]N-,J70H'E^C?V]9Y;W)$FDX)):&)!P"*T(3Y
M&IT">^P8F^>A'0YIL+^%]MQXR^#3:5L</;0+F9*A&:PE&YFM5<FP-1GBB#C.
M'AF=N*#JZWD#3&VF^*U5_VFC_O<("8UZ*Q%G,I59HH8$+?%&)8U:7<MHU+4<
M8%3@S@AH/1M8<"PX.7DOQ%_)27 TL QX1LCFV<#AMY]5D6C"Q">^Y?O^4[[A
MA% E#DQQ_42\,V!#:X+(<J+Y4T,_G)$.=4$W"!OCD&[,[/EL/\-[',&UYL#7
MV(FP,;8-6ZX5,_I&+7-RD:H)B P" )W/B!W8,THF@14ZL16Z$9Q _%##&2.K
M05&.Z)H)P)ZRKC9YP8!7;F1A[$=+'C@1=@=M<D>.@@DI^UQ"0O&$U.LY+\R2
M]Y?\U7WQE"-69PD*<]+MJLBWX-"WG# BO$7F,U]LXO)T5^@4V:N1B7AHZ1E8
MVQKLP<:6Y#U9&@'P:>3P3;7"Z0(.6-9L$VPM5 V*!5'T6E8,DP/.3B>@UC(4
M#-QYX<P*YG'+@;R1.F5[C8YL3AL(9HLK!'RA.0!-Q?1+IJM[,4<[KJY_Z<-M
M.HHFR!T(JE\9<3_V^1DGE5\,,=?R'9?\/[1]CK, 0>>+7PV))ZYC^:Y#<3"W
M8_)JST,"" \?L\>QYW,Z)/9M+D?HD,B;3&-#PG\P>[D.9:^P*2* %6'DW\]>
MO\F"P.2>K6[-U4EHO&UWC4377/,1QXL<"2G5<F'0G'8WY6^2(A'I%648!LII
M)^@X>V#V!Q<>"ZFDCKD5&&RQG9GPD4-,>F@A-;1F6!^$[!9V[ Q!=6XY04SU
M@ %6-WXT-,:6'P.2F6I@AP'^\YN#WWYN"F4.63)U93!R@=)-(!#A/I[E^'/2
MT[-5S;;O]%]M@*5L;=7Q^95>8XM+=.NJ*+IH&[E"7A?B'$6QS.[^4AKS&73:
M=;L,0.VSY'6#98/<>4X4Q*5L7;Y9LE2E7F=<0EUHN,K2U#?F$$4ZW@=AYMK(
MTM<H8Q2Y\WF>P3TJ3<J\+^$Q"A,'H>_%L84HH8; 03;$I\BQHOY/0^SL4<1F
MUBQR"!Q4EZC;OPV=\\<QA; E5@Y1>O,(2B#EAH$5Q8=)O7V<<!$BPPL,I?;+
M5XE'(("%-QJVO(+%] W[.65VF=7D;=3@]-F]<3JAN*"D1A(93HH?)?"Q:"G!
MT&M4G=RB<E<Y.*P!$'%=+\JDT*;8ZY=ST7R9@VFYTP <2UQ<G'=% &ZT^9_Z
M+'"PN./5D@AP_E[IC(/_V+4C9(6M1I>+$RA9<D4_Z)ZID:1^I\P3S3YN#M]0
M]G<7)QY"J%Z:<,MN)!I8TB$!+4J !8YAUGG/NY\NWKV_>L\"GMY(:MU@!C<.
M7M#R'58JP@5>NU45%N!2 F6F.;I"PE4N!HM.T.WY52>I0"PN<D:/#U>GUV);
M5^9H39VUP7^6[XE^ZLZHQ@PFRA4+2_33 4[E8E<7"0N,4DNNH<5UT_*XH?'W
M*4HLB\PZA ,HD ]AW3'P&ZD4G8O9;%$CK)G__+Y;>8'%2@-?8*R-L?[,Q_@P
MZ$LTW+R)TR3WWU36)8--[*CD$Q,2V:A;FCJ1FFUV>)FF_R!/!OV;\]LP0?%/
M#<" U""B",9'[/P\C#;36Y*'XVK3LE+MARMMY0>D1W^?E;*9_O*HJ&MHL>\.
M!^=U2FF@2_BX SV9*H"/A"''(S$69%6G:/>;(H@HT\REF9 07MCB6C>%[][M
M<,XDU1GJBQ1,:IH5M4AQIZIF/K(K<NI$EV.@&4Q-[H5T0X)6-+#%PPLSYQC*
M-*"54FE?\@%3VR?X).>"2]-3 ;4T9(UY>5J_4I)&1:U-'P>]E2DL]);W=:7\
MO5&$4<Y"90KU&;'4S";(6W3%0$9C"EN<J4363>/R.!_%01!IIW@FQ &=Y8*P
M"4NV)! 9DHB;(*U&,I.FR9OR)$$Q0NIE2;A@(F=@9!_;4F^A.VUF1V37@FH?
MR<Z4R'(#J9$$X+;M1(+ Q$%-UEI\,/0CL@.=[#&%+#3/:[H*KE/P(V.8C(R@
MFN2N;SX',C:3ZI('BFF.HDI6\*1%;>I'<#Z,\F:\;4*JW= !I_VXNF(ZA?\H
M[U#_]"WE5/;^ZNS\I>1+R62YU+0;QCGV!C8D+)#WHVQ/)D.QA[YNA);4;8ZZ
M[R<D4Y,QS\T-%J6O$3C?M?76F%*GV_OZ?,+QM^+@XXKYZ2!%R:X+4X/1"?$\
M"^?6S+W/[Y M3C&MG!:K#OY%S0/GQGH DL,RY6'],2@ADKZ$2$P)@8Q.?LZH
M>J@P6W(HF6GO_5I/+$Q[*,'[>N@Y%G7W:EWH>FLJ,UK%#M%/49I)=*.F6]B=
M &RHKE)_;ON??M(YG+=VH2JKB1K#M4.GCQ1F@T_B4D,11GY$I\;]1\P1$++V
M>5S%^9U"@O)[ZQR3[G OD_-L*0PB*QX5!6,[_W_N?I"[AQCPY\_<7T#<[Y^Y
M#S/P;Y*YH^^7N0_JY\^3N0^W\>W\W T'@^FI'*T2LBH1O6Q[MGN)^11VR<29
M!O!E_.!27%R*)T=\^0C)\/S-!W':=KLE\-N^L,_MKN?$[:[E)+&@PX(X+>A5
MF;]!7MBD'+7CPQ5]SATF(-.+#<7JBX5\!658!@KY0'HB33>88</N?3XL+@V0
M B5<:JU+HZ*EIA1H"/*P[T$S:\UG@>5[LZDY?I/@&]+P22B[(,4BX]P0D5TJ
M$U8U.)!/'QS0SEX>=(EO'Y87C?*F%HQL\&3QM*7T<7_?7N^:9PRN;[EN># E
M3?*DQ[TR9]T&%09XAJ* 0ZC-UL>NTV*.F1KV^7B,I@\/I/IB&/I]8O?HV>1@
M=E#6B]_)N!0$R]_KTN FF2DA&#*XVSYI/2<)>(RMS C2C"]QPD@!'_LQ]G<J
M3Y#MYH?+DVX\VCR5"A_Y..B IQV"FL&P]Y$I\#"]?T(*/,S OT4*].SX^Z7
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MW%'4643;1J]T1&&X<H@3#J$PBXTG9UGU]M7/BZEX-TI!9X"+$?>Y&,-F(G1
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M@Q\DY%D Y[5S<?_"#H:?.)=_ U!+ P04    "  0@&51;S?RI)0#   1"
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M2FI;!68$C?HWUP&8Y@%J)DY7ONEOM*,GQ ]S>K/1L 'M9UJ[=L(.NG\!\W\
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MI7V7"&A_K[4#DALC4O 3BF:A#=$U,X\^ FBK=)5!6J1,[BN+.P'Z.224HT]
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M#%]!L=-ZVY3UNG+N<:E,E0O"F@HJ[P$4907Z8/H5OB"!'],P*=I6D$30"I.
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MHKMF= /%&]NI/W*E^W[[6.JK&1$F0+_?<*[V [/ <-E;_ 102P,$%     @
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M=?P8[3;_OED8^H[K'"Y#W+*-7^A]]4E8L2P%-"\Y6Q--5O2D 3K;B]9YUP+
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M;2"WB+5=KIT(VNC/^)(*V13TL) _!I@I@'R^HE0<)BI!_ZN1_ %02P,$%
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M8EN035-L)EK4]M:OA<8>8H<%_D= &@#N;X30AXDQZ/Y,Z1]02P,$%     @
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M$<K4&J YB U6:[J]Z)4.0^-0[QAW*D6\,/!&D^&NC>M)A?:L7#]PG.MIOD3
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M<+U!O=\S)IN))FC_KBS_!U!+ P04    "  0@&51^O]?Q, #   [$@  &0
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M2+S51J8E&!FD(BM^^4.9B : ]CL K 2PEX"@ Q"4@.!4#_T2T#\5$): \%1
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M'=9_WZ9S4-:\7G.%K1GS),%.G#^2/5>*9T:3,Y&5=UO[L' 0Y@ZLI._&C-&
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M2S2FY(:EN9A V0"S7TB)NXD5Z*ZZ]#=02P,$%     @ $(!E430#6Z@4 @
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M(\KJ ]+Z1M"B.G%ZID+0K+J<$CPFK'20SR=4"JRZ*1,TQ]2#?P%02P,$%
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MQL&! 1)!A01*EX^6XQND>G9AWWFFLEH>1KB0-K?+X+Y7[?2]P-8S @FEG<
M.B .2Z04EOQ>.W:R!5^$0&LO-Z56F$NT\8,Y[!?802=9"9EBV:7QX1:*0XHS
M(T>2O#"C$J5G@DH)IHV4H%QP9#5L5[2&IDTPI8_FL?N5[7 WV>!>I^96>6=J
M0:WI:)QC^(=LCGM(&[R+%Y1D+=376F^'6]]4"WZ0.".-]9NL$S#&[H^SH[*D
MFR^4Y)QAM_F#$\8AVJX#A9#D66<SI9)H $L(UE@JD@R1/Q*52]RH;3DUV;CF
MX 0U_]MSSC''$M&A:%W[QWS*[U8\N_I?DNVORK[@5S6V[])C%SD_!9&+4Q!Y
M C4YNSE^C6W7='0BO?;]/6@2=EJ$#@6F%8O@3]/XT3XI6-6$*L);KR!IBOF+
M3D'3*[32;?\.OYZ?X@S55"V[8 1[^P=.2<UNNED/YB#:6;W]W6S/7]B$_7^+
M^"]02P,$%     @ $(!E49>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2
MN6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>
M:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEF
MM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;
M&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ
M8K3^-8+)#^Q^ %!+ P04    "  0@&51W#@U!6\$  " (0  #P   'AL+W=O
M<FMB;V]K+GAM;,6:77/:.!1 _XK&+YM]8,$?I$VF=(: V3 EP,1,^M@1M@!-
M9,F59-+DUU<VI96SYLZ^")Z,)6..K^Q[I&L^O0CYO!;B&?W(&5<#;Z=U<=OM
MJG1'<JS^$07AIF<C9(ZUV97;KBHDP9G:$:)SU@UZO>MNCBGW/G\ZGFLIN_:.
MT"355'#36#4\4?*B_O17NVA/%5U31O7KP*L_,^*AG'*:TS>2#;R>A]1.O-P+
M2=\$UY@EJ12,#3S_T/%$I*;I?YJ3"G*%UZINT7C]B W(P+ONF1-NJ%2Z/J(^
M/S:,>V(./NR56DPHTT2.L2;_2E$6E&^KTYBKZ%J74<?AN#T$\5;^GS"*S8:F
M9"S2,B=<'^(H":L N=K10GF(XYP,O)'8$XF6>$NJBS*_,LT.%Z@-F14N>4M-
MAYQF-:-#GL5\',^3>(SNAK/A?!2CY#Z.5XE%%P!TP67HT-422\(MR!" #,\%
M:3XEB]ET/%R9G61E-@_QW(*, ,CH7)!'KA5:3,S.8O3E?C&S(/L 9/^"D-\"
M"_(:@+P^.V1248Z&R3V:V)'\ $!^N"!D(Y(? <B/;B$7<HLY?:L[$.89NL.*
M*B0V:"F)LA/D#0!YXQ8R*?,<R]>**J%;3LW7,-=HF*:BY)K:6;P'I?&>6\P)
MIA(]8582]$"P*B6IOJ!L/- RCC5CY@V%L?IK/<SQ]Y(6U1=L.L@ROF/-S$S$
M2"-6D$Y\QSX9$TGWN)J_H GEF*<4,S3E2LOR?= @H?B.C9)HD3[O!,N(5'_5
M8ZI?;3;(([YKD8@\I[I^ NH[;F2FF6;&1TPLF^,,><1W+)+'JI%D9C)8/1@K
MB;G"]=2Z00A)Q'=ND:?IN./?V#R0+WS'PDC*M2+?2W,0BO?OTQOD"/^2DFCH
M-H D$3B6!(P9VIB0+ +'LCCA,G1EUG.L\?P&X-K$L37:G7:D_-O&A'02.-;)
M06ZM6) ^ L?Z "W7?&0@DP2.3=)FN=980B8)')L$G$@W8PGI)'"L$SC]1#8F
M9)G N64@S+Z-"3DG<.R<4UFR@^H>NS8".2=T[)Q367),-*;,3N8AY)S0L7-^
M9<D.FF,I#VGIB&@_YB$DG/ LRQ3#:*:WA>#U:)N;M&Y&\0\;$RR'G4<X'924
M1<'JN]*D]CO,3)(GR*XLAI" 0L<":L<<8;5#$R9>;$Q(0*%C ?W&G)3:/./H
MH:JCE_FO45_:F)""0L<*@G5N3RU#2$&A:P6UZ=S< E5S9XUM3$A!H6L% 9AH
M4=B8D()"U\N>=LQ'8H:=IG:E(H(4%+E>]K1C?JTR?7,1&4$*BAPKZ 2FF<)M
MB)1V.32"+!0YMM"I>],D ).G1C8F9*'(L85@S+&-";Z6N4 5[0]F;&-"%HHN
ML0RJ,--2TD85/((L%+E^-P/5_="5C0E9*')LH=.5OWK2:6-"%HH<6^A8_FN=
M"4>0>"+G];9WA<!6Q#XDG7XMG>[QC7]&-I23;&Y.KTQ[BEFZE*C:'-Y.1/VJ
MP+@I&1N9M@6?"9P=_T!P_//#YY]02P,$%     @ $(!E43B#;R;$ 0  #1X
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M*9_:F*X]/VM\_CVISN=[X_7QE^7/27Q?U!>< _S]77P#4$L#!!0    ( !"
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MJE!D52BR*A19%8JLP_^4]=V8U5__DVSN::6+^IC/VA^_TT]02P$"% ,4
M"  0@&51!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( !" 95$F5'I<[@   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( !" 95&97)PC
M$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ $(!E41HQ>184!0  O!0  !@              ("!#0@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !" 95$I(7DS
M 08  (,6   8              " @5<-  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    "  0@&51'VU*,*0"  "*!P  &
M@(&.$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ $(!E
M413MB .>!@  51L  !@              ("!:!8  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( !" 95'RYZCT9 \  ,MC   8
M      " @3P=  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M"  0@&510SEF7<H"  "C!@  &               @('6+   >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ $(!E43?X)>44"   X2,  !@
M             ("!UB\  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( !" 95$(L6H>LP(  "8'   8              " @2 X  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  0@&51@H+T'IT'  !_
M$@  &               @($).P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ $(!E469QO9T'!0  PPL  !D              ("!W$(
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  0@&51[N!C
M_S($  !<"P  &0              @($:2   >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( !" 95%K/?)-OP(  .T%   9
M  " @8-,  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
M$(!E4=Y_5O;!"   $R4  !D              ("!>4\  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    "  0@&51Z,_;:T@&  !8$   &0
M            @(%Q6   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( !" 95'4GZ)+10\  /0U   9              " @?!>  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ $(!E425>R%/.!0
M[@P  !D              ("!;&X  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    "  0@&51;S?RI)0#   1"   &0              @(%Q
M=   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( !" 95$,
M0U[*V 4  #H-   9              " @3QX  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ $(!E4=M"K,K$ P  F @  !D
M     ("!2WX  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !" 95']YF=&UP0   L,   9              "
M@?&0  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ $(!E
M48.?C %\!   OPL  !D              ("!_Y4  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    "  0@&51X:GL=* &  !*$@  &0
M        @(&RF@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   ( !" 95'$"!.-AP(  "X'   9              " @8FA  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ $(!E41G8\%=. P  UPD
M !D              ("!1Z0  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    "  0@&51 ++%4(,#  #X#0  &0              @(',IP
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( !" 95&K4V&A
M)P0  ! 4   9              " @8:K  !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ $(!E43H0;7+[ @  B H  !D
M ("!Y*\  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  0
M@&518\"XYG0#  "J"P  &0              @($6LP  >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( !" 95$B"K@DS@(  '8(   9
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M970S-RYX;6Q02P$"% ,4    "  0@&51&(3]I!($  "Z#@  &0
M    @(&(R@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M !" 95$ NHJFM 4  /H7   9              " @='.  !X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ $(!E4<<:O'2) P  I@L  !D
M             ("!O-0  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4    "  0@&51J435(IX#  "Z#   &0              @(%\V   >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( !" 95'Z_U_$P ,
M #L2   9              " @5'<  !X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#%     @ $(!E402LB%RK!   LA0  !D              ("!
M2.   'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  0@&51
MS)63J&0$  #M$0  &0              @($JY0  >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;%!+ 0(4 Q0    ( !" 95&Z3!1^AP4  .09   9
M      " @<7I  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%
M  @ $(!E43^4$Y<:!@  7!P  !D              ("!@^\  'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  0@&51N:%Z9E0"  "C!0
M&0              @('4]0  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+
M 0(4 Q0    ( !" 95'\?3N6A0(  /8&   9              " @5_X  !X
M;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ $(!E430#6Z@4
M @  9 0  !D              ("!&_L  'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6Q02P$"% ,4    "  0@&51*P\3NTD%  "R%@  &0
M@(%F_0  >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( !"
M95&\F2>#5 (  &@,   -              "  >8" 0!X;"]S='EL97,N>&UL
M4$L! A0#%     @ $(!E49>*NQS     $P(   L              ( !904!
M %]R96QS+RYR96QS4$L! A0#%     @ $(!E4=PX-05O!   @"$   \
M         ( !3@8! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( !" 95$X
M@V\FQ $   T>   :              "  >H* 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( !" 95& A/B=P $    >   3
M      "  >8, 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     Z #H S0\
' -<. 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>242</ContextCount>
  <ElementCount>318</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>55</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Derivative Financial Instruments - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants</Role>
      <ShortName>Derivative Financial Instruments - Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2135108 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2137109 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - COVID-19</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/COVID19</Role>
      <ShortName>COVID-19</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2141111 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/PropertyandEquipment</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2315304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/Leases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Derivative Financial Instruments - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables</Role>
      <ShortName>Derivative Financial Instruments - Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2325306 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/StockholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesNetLossPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Fair Value Measurements - Fair Value of Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value of Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Derivative Financial Instruments - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails</Role>
      <ShortName>Derivative Financial Instruments - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Stockholders' Equity - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails</Role>
      <ShortName>Stockholders' Equity - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Stockholders' Equity - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - Stockholders' Equity - Series C Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Series C Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2432418 - Disclosure - Stockholders' Equity - Series D Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Series D Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2433419 - Disclosure - Stockholders' Equity - Series E Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Series E Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2434420 - Disclosure - Stockholders' Equity - Securities Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails</Role>
      <ShortName>Stockholders' Equity - Securities Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2436421 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/CommitmentsandContingencies</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/RelatedPartyTransactions</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2440423 - Disclosure - COVID-19 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/COVID19Details</Role>
      <ShortName>COVID-19 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/COVID19</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="crdf-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2442424 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/SubsequentEvents</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="crdf-20200930.htm">crdf-20200930.htm</File>
    <File>crdf-093020exhibit311.htm</File>
    <File>crdf-093020exhibit312.htm</File>
    <File>crdf-093020exhibit321.htm</File>
    <File>crdf-093020exhibit322.htm</File>
    <File>crdf-20200930.xsd</File>
    <File>crdf-20200930_cal.xml</File>
    <File>crdf-20200930_def.xml</File>
    <File>crdf-20200930_lab.xml</File>
    <File>crdf-20200930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>67
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "crdf-20200930.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "contextCount": 242,
   "dts": {
    "calculationLink": {
     "local": [
      "crdf-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "crdf-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "crdf-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "crdf-20200930_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crdf-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "crdf-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 427,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 5
   },
   "keyCustom": 44,
   "keyStandard": 274,
   "memberCustom": 20,
   "memberStandard": 29,
   "nsprefix": "crdf",
   "nsuri": "http://www.cardiffoncology.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cardiffoncology.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Fair Value Measurements",
     "role": "http://www.cardiffoncology.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Property and Equipment",
     "role": "http://www.cardiffoncology.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Leases",
     "role": "http://www.cardiffoncology.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Derivative Financial Instruments - Warrants",
     "role": "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants",
     "shortName": "Derivative Financial Instruments - Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Stockholders' Equity",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135108 - Disclosure - Commitments and Contingencies",
     "role": "http://www.cardiffoncology.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137109 - Disclosure - Related Party Transactions",
     "role": "http://www.cardiffoncology.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - COVID-19",
     "role": "http://www.cardiffoncology.com/role/COVID19",
     "shortName": "COVID-19",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141111 - Disclosure - Subsequent Events",
     "role": "http://www.cardiffoncology.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "if99a8ed180cc459681d3588755b7784f_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED BALANCE SHEETS",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
     "shortName": "CONDENSED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "if99a8ed180cc459681d3588755b7784f_I20200930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerSharePolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerSharePolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.cardiffoncology.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.cardiffoncology.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315304 - Disclosure - Leases (Tables)",
     "role": "http://www.cardiffoncology.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib123867495f94547b6cb9b6106e13878_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Derivative Financial Instruments - Warrants (Tables)",
     "role": "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables",
     "shortName": "Derivative Financial Instruments - Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib123867495f94547b6cb9b6106e13878_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325306 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "if99a8ed180cc459681d3588755b7784f_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization and Basis of Presentation (Details)",
     "role": "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails",
     "shortName": "Organization and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "id02c2a45ee9d4832a6e43bb343c46f06_I20201031",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Share (Details)",
     "role": "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesNetLossPerShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities (Details)",
     "role": "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "if99a8ed180cc459681d3588755b7784f_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "if99a8ed180cc459681d3588755b7784f_I20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "if99a8ed180cc459681d3588755b7784f_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Fair Value Measurements - Fair Value of Assets and Liabilities (Details)",
     "role": "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
     "shortName": "Fair Value Measurements - Fair Value of Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i58bccc712f204dd9aa339aff63845a18_I20200930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "if99a8ed180cc459681d3588755b7784f_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Property and Equipment (Details)",
     "role": "http://www.cardiffoncology.com/role/PropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "if99a8ed180cc459681d3588755b7784f_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "crdf:LessorNumberOfSubleases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lease",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.cardiffoncology.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "crdf:LessorNumberOfSubleases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lease",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "crdf:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "if99a8ed180cc459681d3588755b7784f_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)",
     "role": "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Leases - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "crdf:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "if99a8ed180cc459681d3588755b7784f_I20200930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Leases - Supplemental Cash Flow Information (Details)",
     "role": "http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails",
     "shortName": "Leases - Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "if99a8ed180cc459681d3588755b7784f_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Leases - Future Minimum Lease Payments (Details)",
     "role": "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails",
     "shortName": "Leases - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "if99a8ed180cc459681d3588755b7784f_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ie1f73b5fbce249928d3fd6362296a372_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Derivative Financial Instruments - Warrants (Details)",
     "role": "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
     "shortName": "Derivative Financial Instruments - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ifb6ee131f889432ba4524b13c5e5ca50_D20200101-20200930",
      "decimals": "2",
      "lang": "en-US",
      "name": "crdf:EstimatedFairValueOfWarrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails",
     "shortName": "Stockholders' Equity - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails",
     "shortName": "Stockholders' Equity - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i693ed24b7709470984d4dd326d3a6f87_D20200101-20200930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i245896d1bc104cb588f32c2cc4062e73_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ia0736ee7158d4ee1952c5ed8ecafc35d_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Stockholders' Equity - Restricted Stock Units (Details)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails",
     "shortName": "Stockholders' Equity - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ia0736ee7158d4ee1952c5ed8ecafc35d_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "if99a8ed180cc459681d3588755b7784f_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Stockholders' Equity - Warrants (Details)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails",
     "shortName": "Stockholders' Equity - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": "2",
      "lang": "en-US",
      "name": "crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "if99a8ed180cc459681d3588755b7784f_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Stockholders' Equity - Preferred Stock (Details)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails",
     "shortName": "Stockholders' Equity - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "idea78c0fd4d44a8084b8b53c668496d2_I20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "crdf:ClassOfWarrantOrRightNumberGranted",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - Stockholders' Equity - Series C Convertible Preferred Stock (Details)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
     "shortName": "Stockholders' Equity - Series C Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ic492c1a7e6d541e3879728394630480b_D20190125-20190125",
      "decimals": "-5",
      "lang": "en-US",
      "name": "crdf:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i1f789e5648a44a9ebd4b303e67d1385f_I20200615",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432418 - Disclosure - Stockholders' Equity - Series D Convertible Preferred Stock (Details)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
     "shortName": "Stockholders' Equity - Series D Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "if6bd6d0b8e894e96b013f0f9d4a47eb5_D20200601-20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ConversionOfStockSharesConverted1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "if100dfb4b4384fd0bb32098df385547f_D20200526-20200526",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433419 - Disclosure - Stockholders' Equity - Series E Convertible Preferred Stock (Details)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails",
     "shortName": "Stockholders' Equity - Series E Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i1f789e5648a44a9ebd4b303e67d1385f_I20200615",
      "decimals": "INF",
      "lang": "en-US",
      "name": "crdf:ClassOfWarrantOrRightIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "if100dfb4b4384fd0bb32098df385547f_D20200526-20200526",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434420 - Disclosure - Stockholders' Equity - Securities Purchase Agreement (Details)",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails",
     "shortName": "Stockholders' Equity - Securities Purchase Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i5ec1ce35bd704b2a8bec37b6d629c0a9_I20200330",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i24aa660d59c2466faf23e2429d2aa751_I20170331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436421 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i24aa660d59c2466faf23e2429d2aa751_I20170331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "if25db31f1cc14bd8ad1940aa6a08ec7e_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "if25db31f1cc14bd8ad1940aa6a08ec7e_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i9a08aa2fda7c4db799f75bc79a5a0e5b_I20200415",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440423 - Disclosure - COVID-19 (Details)",
     "role": "http://www.cardiffoncology.com/role/COVID19Details",
     "shortName": "COVID-19 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i9a08aa2fda7c4db799f75bc79a5a0e5b_I20200415",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "iacde1c89795341d7a6585a9ca67ff1ef_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ia7f9daee734141178c3262a70ac3d9f9_D20190101-20190331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "if100dfb4b4384fd0bb32098df385547f_D20200526-20200526",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442424 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.cardiffoncology.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i5c512dc917a44fa4935298acc4757d46_D20201002-20201002",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "crdf:CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "i9b10fca920cd45739f9f13508bdc0747_D20200401-20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "crdf:CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED STATEMENTS OF CASH FLOWS",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical)",
     "role": "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20200930.htm",
      "contextRef": "ib5394ca29f974147b0c91ab506add48c_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 55,
   "tag": {
    "crdf_AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02, Elimination Of Cease-Use Loss Liability [Member]",
        "label": "Accounting Standards Update 2016-02, Elimination Of Cease-Use Loss Liability [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602EliminationOfCeaseUseLossLiabilityMember",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_AmountFinancedUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount Financed Under Agreement",
        "label": "Amount Financed Under Agreement",
        "verboseLabel": "Amount financed under agreement"
       }
      }
     },
     "localname": "AmountFinancedUnderAgreement",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Beneficial Conversion Feature For Issuance Of Convertible Preferred Stock",
        "label": "Beneficial Conversion Feature For Issuance Of Convertible Preferred Stock",
        "terseLabel": "Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance"
       }
      }
     },
     "localname": "BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_BlackScholesOptionPricingMethodMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the Black-Scholes option pricing method which is used for valuation of derivative instruments.",
        "label": "Black Scholes Option Pricing Method [Member]",
        "terseLabel": "Black Scholes Option Pricing Method"
       }
      }
     },
     "localname": "BlackScholesOptionPricingMethodMember",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_ClassOfWarrantOrRightExpirationTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Expiration Term",
        "label": "Class Of Warrant Or Right, Expiration Term",
        "terseLabel": "Expiration term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpirationTerm",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "crdf_ClassOfWarrantOrRightIssued": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Issued",
        "label": "Class Of Warrant Or Right, Issued",
        "terseLabel": "Warrants issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssued",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_ClassOfWarrantOrRightMonthsUntilExercisable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Months Until Exercisable",
        "label": "Class Of Warrant Or Right, Months Until Exercisable",
        "terseLabel": "Months until exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightMonthsUntilExercisable",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "crdf_ClassOfWarrantOrRightNumberExercised": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of warrants or rights exercised during the period.",
        "label": "Class of Warrant or Right Number Exercised",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberExercised",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails",
      "http://www.cardiffoncology.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_ClassOfWarrantOrRightNumberGranted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of warrants or rights granted during the period.",
        "label": "Class of Warrant or Right Number Granted",
        "terseLabel": "Warrants granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberGranted",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The period over which each class of warrants or rights outstanding may be exercised.",
        "label": "Class of Warrant or Right Term of Outstanding Warrants or Rights",
        "terseLabel": "Weighted-Average Remaining\u00a0Contractual Term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Class of Warrant or Right Term of Warrants or Rights [Abstract]",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the weighted average exercise price of each class of warrants or rights outstanding.",
        "label": "Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights",
        "periodEndLabel": "Weighted average exercise price of warrants at the end of the period (in USD per share)",
        "periodStartLabel": "Weighted average exercise price of warrants at the beginning of the period (in USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "No definition available",
        "label": "Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights [Abstract]",
        "terseLabel": "Weighted Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the weighted average exercise price of each class of warrants or rights exercised during the period.",
        "label": "Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights Exercised",
        "terseLabel": "Exercised (in USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the weighted average exercise price of each class of warrants or rights granted during the period.",
        "label": "Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights Granted",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment",
        "label": "Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment",
        "terseLabel": "Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment"
       }
      }
     },
     "localname": "Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cost of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment",
        "label": "Cost of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment",
        "terseLabel": "Cost of issuance of common stock, preferred stock and warrants"
       }
      }
     },
     "localname": "CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance",
        "label": "Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock",
        "negatedTerseLabel": "Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance",
        "terseLabel": "Deemed dividend recognized for beneficial conversion features of Convertible Preferred Stock issuance"
       }
      }
     },
     "localname": "DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "No definition available.",
        "label": "Denominator [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_DerivativeFinancialInstrumentsLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Derivative Financial Instruments Liability [Roll Forward]",
        "terseLabel": "Changes in the Company's derivative financial instruments liability balance"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilityRollForward",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discount of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment",
        "label": "Discount of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment",
        "terseLabel": "Discount of issuance of common stock, preferred stock and warrants for clinical trial funding commitment"
       }
      }
     },
     "localname": "DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_EquityIncentivePlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the 2014 Equity Incentive Plan under which common shares will be issued to the members.",
        "label": "Equity Incentive Plan 2014 [Member]",
        "terseLabel": "2014 EIP"
       }
      }
     },
     "localname": "EquityIncentivePlan2014Member",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_EstimatedFairValueOfWarrant": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the estimated fair value of warrant.",
        "label": "Estimated Fair Value of Warrant",
        "terseLabel": "Estimated fair value of Trovagene common stock (in dollars per share)"
       }
      }
     },
     "localname": "EstimatedFairValueOfWarrant",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to furniture and office equipment.",
        "label": "Furniture And Office Equipment [Member]",
        "terseLabel": "Furniture and office equipment"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Liability",
        "label": "Increase (Decrease) In Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Annual Rent Increase, Percentage",
        "label": "Lessee, Operating Lease, Annual Rent Increase, Percentage",
        "terseLabel": "Annual rent increase, percentage"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAnnualRentIncreasePercentage",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due",
        "label": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year One",
        "label": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year One",
        "totalLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Three",
        "label": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Three",
        "totalLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Two",
        "label": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Two",
        "totalLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Remainder Of Fiscal Year",
        "label": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Remainder Of Fiscal Year",
        "totalLabel": "2020 (excluding the nine months ended September 30, 2020)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity [Abstract]",
        "label": "Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Net Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_LesseeOperatingLeaseMonthlyRentPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Monthly Rent Payment",
        "label": "Lessee, Operating Lease, Monthly Rent Payment",
        "terseLabel": "Monthly rent payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyRentPayment",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Options",
        "label": "Lessee, Operating Lease, Number Of Renewal Options",
        "terseLabel": "Number of lease renewals"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "crdf_LessorNumberOfSubleases": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessor, Number Of Subleases",
        "label": "Lessor, Number Of Subleases",
        "terseLabel": "Number of subleases"
       }
      }
     },
     "localname": "LessorNumberOfSubleases",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "crdf_NorvianoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nerviano [Member]",
        "label": "Norviano [Member]",
        "terseLabel": "Nerviano"
       }
      }
     },
     "localname": "NorvianoMember",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "No definition available.",
        "label": "Numerator [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_PaycheckProtectionProgramCARESActMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Paycheck Protection Program, CARES Act",
        "label": "Paycheck Protection Program, CARES Act [Member]",
        "terseLabel": "Paycheck Protection Program"
       }
      }
     },
     "localname": "PaycheckProtectionProgramCARESActMember",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/COVID19Details",
      "http://www.cardiffoncology.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pre-Funded Warrants [Member]",
        "label": "Pre-Funded Warrants [Member]",
        "terseLabel": "Pre-Funded Warrants"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_PreferredStockConvertibleConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred Stock, Convertible, Conversion Price",
        "label": "Preferred Stock, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionPrice",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_PreferredStockDividendAccrued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the value of preferred stock dividend accrued during the reporting period.",
        "label": "Preferred Stock Dividend Accrued",
        "terseLabel": "Preferred stock dividend payable on Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockDividendAccrued",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to registered direct offering",
        "label": "Registered Direct Offering [Member]",
        "terseLabel": "Registered Direct Offering"
       }
      }
     },
     "localname": "RegisteredDirectOfferingMember",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_ReleaseOfClinicalTrialFundingCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Release Of Clinical Trial Funding Commitment",
        "label": "Release Of Clinical Trial Funding Commitment",
        "terseLabel": "Release of clinical trial funding commitment"
       }
      }
     },
     "localname": "ReleaseOfClinicalTrialFundingCommitment",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Release of clinical trial funding commitment for services received",
        "label": "Release of clinical trial funding commitment for services received",
        "terseLabel": "Release of clinical trial funding commitment"
       }
      }
     },
     "localname": "Releaseofclinicaltrialfundingcommitmentforservicesreceived",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_SaleOfStockCommonAndWarrantsNetShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Stock, Common And Warrants, Net, Shares",
        "label": "Sale Of Stock, Common And Warrants, Net, Shares",
        "terseLabel": "Sale of common stock and warrants (in shares)"
       }
      }
     },
     "localname": "SaleOfStockCommonAndWarrantsNetShares",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_SaleOfStockConsiderationReceivedOnTransactionGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Stock, Consideration Received On Transaction, Gross",
        "label": "Sale Of Stock, Consideration Received On Transaction, Gross",
        "terseLabel": "Gross proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransactionGross",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.cardiffoncology.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_SaleOfStockValueCommonAndWarrantsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Stock, Value, Common And Warrants, Net",
        "label": "Sale Of Stock, Value, Common And Warrants, Net",
        "terseLabel": "Sale of common stock and warrants"
       }
      }
     },
     "localname": "SaleOfStockValueCommonAndWarrantsNet",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of a concept from the beginning of a period to the end of the period.",
        "label": "Schedule of Components of Changes in Derivative Financial Liability [Table Text Block]",
        "terseLabel": "Schedule of Components of Changes in the Company\u2019s Derivative Financial Instruments Liability Balance"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "crdf_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series A Convertible Preferred Stock [Member]",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series B Convertible Preferred Stock",
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesCConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares at the owner's option.",
        "label": "Series C Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesCConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical",
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesDConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series D Convertible Preferred Stock",
        "label": "Series D Convertible Preferred Stock [Member]",
        "terseLabel": "Series D Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesDConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical",
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesEConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series E Convertible Preferred Stock",
        "label": "Series E Convertible Preferred Stock [Member]",
        "terseLabel": "Series\u00a0E Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesEConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesIWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series I Warrant",
        "label": "Series I Warrant [Member]",
        "terseLabel": "Series I Warrant"
       }
      }
     },
     "localname": "SeriesIWarrantMember",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesJWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series J Warrant",
        "label": "Series J Warrant [Member]",
        "terseLabel": "Series J Warrant"
       }
      }
     },
     "localname": "SeriesJWarrantMember",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesKWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series K Warrant",
        "label": "Series K Warrant [Member]",
        "terseLabel": "Series K Warrant"
       }
      }
     },
     "localname": "SeriesKWarrantMember",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesLWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series L Warrants [Member]",
        "label": "Series L Warrants [Member]",
        "terseLabel": "Series L Warrants"
       }
      }
     },
     "localname": "SeriesLWarrantsMember",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesMWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series M Warrant",
        "label": "Series M Warrant [Member]",
        "terseLabel": "Series M Warrant"
       }
      }
     },
     "localname": "SeriesMWarrantMember",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesNWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series N Warrant",
        "label": "Series N Warrant [Member]",
        "terseLabel": "Series N Warrant"
       }
      }
     },
     "localname": "SeriesNWarrantMember",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_ServiceReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Service Receivable",
        "label": "Service Receivable [Member]",
        "terseLabel": "Service Receivable"
       }
      }
     },
     "localname": "ServiceReceivableMember",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_Servicereceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Monetary value of future clinical trial services to be received in connection with issuance of common stock, preferred stock and warrants",
        "label": "Service receivable",
        "negatedTerseLabel": "Service receivables",
        "terseLabel": "Service receivable"
       }
      }
     },
     "localname": "Servicereceivable",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expired in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expired in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period Restricted Stock Units Released",
        "label": "Stock Issued During Period Restricted Stock Units Released",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodRestrictedStockUnitsReleased",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of shares issued during the period upon cash exercise of warrants.",
        "label": "Stock Issued During Period Shares Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Restricted Stock Units Releases",
        "label": "Stock Issued During Period, Value, Restricted Stock Units Releases",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockUnitsReleases",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The equity impact during the period due to the cash exercise of warrants.",
        "label": "Stock Issued During Period Value Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_WarrantsAndRightsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Warrants and Rights [Roll Forward]",
        "terseLabel": "Number of Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsRollForward",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_WarrantsFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants, Fair Value",
        "label": "Warrants, Fair Value",
        "terseLabel": "Warrants, fair value"
       }
      }
     },
     "localname": "WarrantsFairValue",
     "nsuri": "http://www.cardiffoncology.com/20200930",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r40",
      "r73"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r174",
      "r175",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r337",
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r174",
      "r175",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r337",
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r164",
      "r174",
      "r175",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r337",
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r164",
      "r174",
      "r175",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r337",
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r298",
      "r300",
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r16",
      "r125",
      "r126"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable and unbilled receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r24",
      "r138"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/PropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less\u2014accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r214"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r82",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r220",
      "r221",
      "r222",
      "r223",
      "r306",
      "r307",
      "r308",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r176",
      "r178",
      "r217",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r178",
      "r203",
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r71",
      "r111",
      "r114",
      "r120",
      "r128",
      "r225",
      "r227",
      "r256",
      "r321",
      "r330"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r38",
      "r71",
      "r128",
      "r225",
      "r227",
      "r256"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r179",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r22",
      "r62"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r56",
      "r62",
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents\u2014End of period",
        "periodStartLabel": "Cash and cash equivalents\u2014Beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r56",
      "r257"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r69",
      "r71",
      "r93",
      "r94",
      "r95",
      "r98",
      "r100",
      "r105",
      "r106",
      "r107",
      "r128",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical",
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r160",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants (in USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of shares called by each warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares called by warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Balance of warrants outstanding at the end of the period (in shares)",
        "periodStartLabel": "Balance of warrants outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r34",
      "r145",
      "r325",
      "r335"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r76",
      "r77"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.0001 par value, 150,000,000 shares authorized; 26,285,743 and 8,593,633 shares issued and outstanding at September 30, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "auth_ref": [
      "r64",
      "r65",
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Issued",
        "terseLabel": "Common stock issued upon conversion of convertible preferred stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r64",
      "r65",
      "r66"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Shares converted (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r64",
      "r65",
      "r66"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Shares issued upon conversion (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r13",
      "r14",
      "r152",
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Shares issued upon conversion (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r322",
      "r323",
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/COVID19Details",
      "http://www.cardiffoncology.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/COVID19Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/COVID19Details",
      "http://www.cardiffoncology.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r60",
      "r110"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r235",
      "r236",
      "r238",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Financial Instruments - Warrants"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "periodEndLabel": "Balance of derivative financial instruments liability at the end of the period",
        "periodStartLabel": "Balance of derivative financial instruments liability at the beginning of the period",
        "terseLabel": "Derivative financial instruments - warrants",
        "verboseLabel": "Derivative financial instruments\u2014warrants"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPreferredStock": {
     "auth_ref": [
      "r159",
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Preferred Stock",
        "negatedTerseLabel": "Preferred stock dividend payable on Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "DividendsPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per common share - basic and diluted (in dollars per share)",
        "verboseLabel": "Basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r68",
      "r101",
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Net loss per share attributable to common stockholders:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average remaining vesting period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase Common Stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails",
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r80",
      "r87",
      "r89",
      "r104",
      "r132",
      "r151",
      "r159",
      "r211",
      "r212",
      "r213",
      "r222",
      "r223",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtraordinaryAndUnusualItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Unusual or Infrequent Items, or Both [Abstract]",
        "terseLabel": "Unusual or Infrequent Items, or Both [Abstract]"
       }
      }
     },
     "localname": "ExtraordinaryAndUnusualItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Determine the Fair Value of the Warrants"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r173",
      "r245",
      "r295",
      "r296",
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r244",
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r244",
      "r245",
      "r248",
      "r249",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r165",
      "r166",
      "r171",
      "r173",
      "r245",
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted\u00a0Prices in\u00a0Active Markets\u00a0for Identical\u00a0Assets and\u00a0Liabilities (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r165",
      "r166",
      "r171",
      "r173",
      "r245",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r173",
      "r245",
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsQuantitativeInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]",
        "terseLabel": "Range of assumptions used to determine the fair value of warrants"
       }
      }
     },
     "localname": "FairValueInputsQuantitativeInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r244",
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of the Company\u2019s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r173",
      "r295",
      "r296",
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r250",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r57",
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable and unbilled receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterimPeriodCostsNotAllocableDomain": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred.",
        "label": "Interim Period, Costs Not Allocable [Domain]",
        "terseLabel": "Interim Period, Costs Not Allocable [Domain]"
       }
      }
     },
     "localname": "InterimPeriodCostsNotAllocableDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r278",
      "r280"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Net operating lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Lease Expense and Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2020 (excluding the nine months ended September 30, 2020)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Sublease Income"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "negatedTotalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year One",
        "negatedTerseLabel": "2021"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "crdf_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year",
        "negatedTerseLabel": "2020 (excluding the nine months ended September 30, 2020)"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Three",
        "negatedTerseLabel": "2023"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "negatedTerseLabel": "2022"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28",
      "r71",
      "r115",
      "r128",
      "r226",
      "r227",
      "r228",
      "r256"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r71",
      "r128",
      "r256",
      "r324",
      "r333"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r71",
      "r128",
      "r226",
      "r227",
      "r228",
      "r256"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected warrant term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected volatility of Cardiff Oncology common stock"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Money market fund"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NatureOfExpenseAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cost or expense.",
        "label": "Nature of Expense [Axis]",
        "terseLabel": "Nature of Expense [Axis]"
       }
      }
     },
     "localname": "NatureOfExpenseAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r56",
      "r58",
      "r61"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r41",
      "r42",
      "r44",
      "r61",
      "r71",
      "r79",
      "r83",
      "r84",
      "r85",
      "r86",
      "r88",
      "r89",
      "r96",
      "r111",
      "r113",
      "r116",
      "r119",
      "r121",
      "r128",
      "r256",
      "r326",
      "r336"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r86",
      "r90",
      "r91",
      "r97",
      "r100",
      "r111",
      "r113",
      "r116",
      "r119",
      "r121"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r92",
      "r97",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss used for basic and diluted loss per share"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncement"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r12",
      "r323",
      "r331"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Note payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/COVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Note payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r111",
      "r113",
      "r116",
      "r119",
      "r121"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r273",
      "r280"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Impairment loss"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r269"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails",
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r269"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r269"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "verboseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r270",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "negatedLabel": "Decrease in operating lease right-of-use assets",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails",
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r277",
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate\u2013operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r276",
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term\u2013operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": {
     "auth_ref": [
      "r265",
      "r266",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for lessor's operating leases.",
        "label": "Lessor, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "OperatingLeasesOfLessorDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAffiliatesMember": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A category that identifies other affiliates.",
        "label": "Other Affiliates [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "OtherAffiliatesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Stock issuance expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r179",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "negatedLabel": "Preferred stock dividend payable on Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.",
        "label": "Preferred Stock, Liquidation Preference, Value",
        "terseLabel": "Liquidation preference"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "verboseLabel": "Shares designated (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETSParenthetical",
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "verboseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, 20,000,000 shares authorized; (Note 7)"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r135",
      "r136"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from sales of common stock, preferred stock and warrants, net of expenses of $633,807 and $97,260, respectively"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Borrowings under note payable"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r53",
      "r55",
      "r74"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Costs related to the clinical trial funding commitment"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r51",
      "r206"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrants",
        "verboseLabel": "Proceeds from warrant exercise"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r24",
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r141",
      "r352",
      "r353",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r23",
      "r137"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/PropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, equipment and depreciation and amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r8",
      "r9",
      "r139",
      "r334"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/PropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r8",
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Components of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r8",
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Other commitment"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r172",
      "r286",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r172",
      "r286",
      "r289",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r284",
      "r285",
      "r287",
      "r290",
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "terseLabel": "Repayment of note"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r219",
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingenciesDetails",
      "http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r219"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails",
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r159",
      "r214",
      "r332",
      "r345",
      "r350"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r80",
      "r87",
      "r89",
      "r132",
      "r211",
      "r212",
      "r213",
      "r222",
      "r223",
      "r341",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r108",
      "r109",
      "r112",
      "r117",
      "r118",
      "r122",
      "r123",
      "r124",
      "r162",
      "r163",
      "r305"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue that is not accounted for under Topic 606.",
        "label": "Revenue Not from Contract with Customer",
        "terseLabel": "Services"
       }
      }
     },
     "localname": "RevenueNotFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r43",
      "r71",
      "r108",
      "r109",
      "r112",
      "r117",
      "r118",
      "r122",
      "r123",
      "r124",
      "r128",
      "r256",
      "r327"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "negatedLabel": "Sale of common stock, preferred stock and warrants",
        "terseLabel": "Proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails",
      "http://www.cardiffoncology.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "negatedLabel": "Sale of common stock, preferred stock and warrants (in shares)",
        "terseLabel": "Sale of stock, number of shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails",
      "http://www.cardiffoncology.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Earnings per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r178",
      "r202",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r178",
      "r202",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r24",
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r72",
      "r288",
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r179",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r183",
      "r192",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Summary of Stock Option Activity and of Changes in Stock Options Outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions to Estimate Fair Value of Stock Option Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r35",
      "r69",
      "r105",
      "r106",
      "r147",
      "r149",
      "r150",
      "r152",
      "r153",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r148",
      "r149",
      "r150",
      "r152",
      "r153",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Preferred Stock"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r160",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of Warrant Activity and Changes in Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series\u00a0A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Total Restricted Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested, weighted average grant date fair value at end of period (in USD per share)",
        "periodStartLabel": "Nonvested, weighted average grant date fair value at end of period (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value Per\u00a0Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Equity instruments other than options, vested in period, fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested, weighted average grant date fair value (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted-average assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r184",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Non-vested at end of period (in shares)",
        "periodStartLabel": "Non-vested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Authorized shares under the plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of remaining shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at the end of the period (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Cancelled / Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r185",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance outstanding at the end of the period (in shares)",
        "periodStartLabel": "Balance outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance outstanding at the end of the period (in USD per share)",
        "periodStartLabel": "Balance outstanding at the beginning of the period (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r177",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled / Forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Equity instruments other than options, aggregate intrinsic value, nonvested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Equity instruments other than options, aggregate intrinsic value, vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r197",
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Vested and exercisable at the end of the period, intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, weighted average contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Options vested, fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance, ending (in shares)",
        "periodStartLabel": "Balance, beginning (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r69",
      "r71",
      "r93",
      "r94",
      "r95",
      "r98",
      "r100",
      "r105",
      "r106",
      "r107",
      "r128",
      "r151",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical",
      "http://www.cardiffoncology.com/role/StockholdersEquityPreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r37",
      "r76",
      "r77",
      "r78",
      "r80",
      "r87",
      "r89",
      "r104",
      "r132",
      "r151",
      "r159",
      "r211",
      "r212",
      "r213",
      "r222",
      "r223",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r104",
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r36",
      "r151",
      "r152",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon conversion of Series D Convertible Preferred Stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r151",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Shares of common stock issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Issuance of common stock, preferred stock and warrants for clinical trial funding commitment (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r151",
      "r159",
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.cardiffoncology.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockSplits": {
     "auth_ref": [
      "r14",
      "r15",
      "r151",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of a stock split.",
        "label": "Stock Issued During Period, Shares, Stock Splits",
        "terseLabel": "Issuance of common stock for share rounding as a result of reverse stock split (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSplits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r37",
      "r151",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon conversion of Series D Convertible Preferred Stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Issuance of common stock, preferred stock and warrants for clinical trial funding commitment"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r37",
      "r151",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r19",
      "r20",
      "r71",
      "r127",
      "r128",
      "r256"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance, ending",
        "periodStartLabel": "Balance, beginning",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r159",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r274",
      "r280"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Operating sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r264",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.cardiffoncology.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r264",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r264",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.cardiffoncology.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r264",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.cardiffoncology.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r292",
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosure of cash flow activity:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r82",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r220",
      "r221",
      "r222",
      "r223",
      "r306",
      "r307",
      "r308",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "negatedLabel": "Change in fair value of derivative financial instruments\u2014warrants",
        "terseLabel": "Gain (loss) from change in fair value of derivative financial instruments\u2014warrants",
        "verboseLabel": "Change in fair value of derivative financial instruments\u2014warrants during the period recognized as a loss in the condensed statements of operations"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualOrInfrequentItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Unusual or Infrequent Item, or Both [Line Items]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Line Items]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/COVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemTable": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the nature and financial statement effect of an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Table]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Table]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/COVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Items, or Both, Disclosure [Text Block]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/COVID19"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase Common Stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Expected warrant term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average shares outstanding - basic and diluted (in shares)",
        "verboseLabel": "Weighted-average shares used to compute basic and diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardiffoncology.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.cardiffoncology.com/role/SummaryofSignificantAccountingPoliciesNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e639-108305"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "Note 1",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "Note 3",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121593497&loc=SL77918431-209957"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919396-209981"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888252"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(1)(a)(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611322-123010"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r356": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r357": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r358": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r359": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/subtopic&trid=114868817"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>68
<FILENAME>0001628280-20-015726-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-20-015726-xbrl.zip
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MO&-@# PI7<&',5 @%AH*/(CET!TL85R3>2KBE)@2/];]YUSS2@E.(!-& A-
M4C$7-H4)FH+'SD#46X!IBL$T9]"-D6BQN0RO"ZB='P>HG"0B!R@@JM:N#P"E
M( [->J-=Y GD+HIL%;['LF2@$^"UX>< H"DPWQ6 #@0V E[*-7(KT)@G0T-P
M,$># Y0H)0@ 7!5@R@UGG#TQ-2E)I)J;)9;U*B,2BB^]W6!EL %)LS1FR]K7
MA<KNP:%R\LB%6-3"_M!4N*LH#*8;E20"'IUSQX1J[F $L!"1Y.ANP@&[D10F
M17$4RR#58KK%9R9,+)4IH1\F8:VDQU.A5<P9O#;D'<"'<<"CQ\CE0YS2?,K)
M&>2WNU)R4U7L#JV'O7?\O7]$)6&/^5?OG4Z!3#KWB,:1"*;##:![X*%5+QLR
MV1XR@2%Q[D\# 220BNRF?7\AN/OM P(W/1QPAXU6']?A@AO87(%W75W],@@#
M+/DQ+<W^7;#V1AQ@5(WDJ[DJ-2B Y#<3QJ54D.*YTX/[@74RWDSHFDOJ<%F5
M\S6B@BK98Z. Q RV&"4%<X<,IHR,8()J@1,0GG2X$I.CIM(@$7 !;1QK< E8
M&0X&64CXV*D CBSB4E*L&S M9\2:4$ /3T\V615\BS@*0FJ'_IR]()4C;G]P
MM$>'@_8JE3\&^]Y9< OS^^?/O:$/X3(3#!%-C<HIE@QJ(!J0 "/,<?=500Z"
M0-!(2&$72#%V#8L!Z-#I@.=CYY'H!H%VE>FAFE!1Z@* ;QPEBF.EF3/ 4>DI
MSX'I2, _M/ " PM%8)O@,0X!* I7$EX3RN/#0?DRIU_.J"Q=XD,,\"0!+BMF
MX#VS@Y.N",T>B=P_[J:I#M70$9*P\60X4J5]WH)]2@U=27-D^LF7MW D6NXA
M7*!ROQ)@CP,E#O!J@,D.!YC+].M=O@T=/&VHB*5KV8G/%R1=Y \JCDN- -DH
MUCNT9LI8>(^'RZ#+Q*"H.@_SIUH[NB2 =$B'3Z0KPV'[Q]U!"9ZAY.7*KO?>
MJI2:%;/!1.HB@S-78=QZ5-E_0:2XY[(Z-7DB'_S/2_1-HN&@]I6]@XN&/[>O
M=.>W;!E(P3K?8?K=!/,Z]2$<7\!UMJCURC0*]-HJ;5;TPKT E5F&!_O\#XI+
MI(# 8#L38)]3\@X@#[G<8*V _TCREW'*?RL%F.]BLLQC=[CR]8^1#RI['^!6
M\4P";P0>*P"/N(?'<X%8< !010U66[8YI_=8ZSV/=-7>,6!W7+P\+GL1+*O=
ME3]5V9$C*8..AJ]2Y+,0KG@S= $< KT-/.$PP#9,F66P1?R=N\E4I6GGP>+K
M(Q.'MY<[ \Z0:,A  6"#NZ0)Z'(_ 50P#'S)%?E,R1G'NIO3:?5+AJ[R+,\*
MJ18<6N>I\LF5/@(Y@/(O(26-9YW^[7_B_E._Q$-H3$5>CY2U*AO@G8CJC57%
MP'ED9-VVM9*/(+BXKH/UDA:&#Y9?AE"\"DD7 Y$[&URGX0SK'="I:B% 9W7E
MXN2DT6_U\=:%A<"Q;*F^NI#1<!<RFI9MMW5/&MWCHV>;6XWPV;8_5'O<Z(3=
MO=0VG<G>;)B^*6C^H=:I/8GV0;MX(&%A"?YO=_U]DPU0(.IWK,^W1XF[_'(-
M ,\BP'@O<)=S5GBI%N/+\SS<N;U]TX68=I];MQ4>S?-ECOT>$]YSOH\B_GD/
M5K&,D8Y =0>K9&G> <QV/_?^WZ6'-:&5UYS&@; P5+S'''^]#<B5J["<;/NP
MZ0K*"^\0/;GM5RA_W7'@?V^8\:W[?^O(<.6PM>Y"(PB/TFYW^<*5P>K37V!T
M5RE/_PM02P,$%     @ $(!E43"<+.L%!0  TA<  !D   !C<F1F+3 Y,S R
M,&5X:&EB:70S,C$N:'1M[5AM;]LV$/Z^7W%UL#8%;+W9CA/9#> J*FH@M5-;
M6=M/ RU2-E%)U"@ZCO?K=]1+ZM3QEA;MZ@T- EDBC\=[[N[AD1P\N9AXP8<K
M'Y8JB>'J^N7ER(-&RS3?M3W3O @NX'7PYA(ZAF5#($F:<\5%2F+3],<-:"R5
MRES37*_7QKIM"+DP@ZFI577,6(B<&531QOE M^"3$7K^R^!)JP47(EPE+%40
M2D84H[#*>;J =Y3E'Z'5JJ0\D6TD7RP5.)9CP3LA/_(;4O8KKF)V7NL9F.7W
MP"PF&<P%W9P/*+\!3E\T..TZW1Z-VG.K>]JA[9"<=.A)+YR3,]8)*26_VVBD
MB>+EF%QM8O:BD?"TM61Z?K?C&+UNIOIK3M72M2WKUT8A>CZ(1*IP/HGCR]=2
MS8XRQ6Y5B\1\D;H%I$8YM.X.12RD>V05?WW=TXI(PN.-^RS@"<MAS-8P%0E)
MGS5S#$,K9Y)'I6#._V1H$YI7?*Y+DWNH)^8IJR'8CC;:OUWR.5=/C^P3J]]V
M#/N^V7>0OI]=G0?M*@W:,>8![X48;B9_D/L\?QJ,7HV\83":C&'R"JZFH[$W
MNAI>@O_>]ZZ#T6\^-J.$/SUX,%?7T]GU<!Q , '[%*Z-F>$9,/,]#:X,B-WN
M6LV#!S*<P?!B<A7X%["%Z>#-ON?I,^M$YU/PVH?9</IR./9GK<G[2_\##+T
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M$<+]^EO)=DI">DT[[96[:29C9&NU>O;ET4KJ/;N8#/QWTR&L9!+#]/K5U6@
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M!1)F+?>'?.;:N'P6E]CZ.OW\;U!+ P04    "  0@&51!7**926[ 0"BZA4
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MI261BV2UEA$<YX9JC)0L=9P 1ZI>.=L[+WCG8WN=]L(Y)HF)&I0)-D#DS/M
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M^5+8KR5=SJ+[;!S)&0MYP-\:2TUTGJ60; HK&"K="]/2/#[$^9(@'1.$:.Z
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MDHM*,82&1T#EL?@_:A/7UA@GHUAZF.92AGY:Z-C J$\Z04P*B)*&0P0?6&(
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M:H8TC9!YL00C:G=":W+R&Z3!>-1MA>WV2:_[:<2'2Z)85$N;$GCM202IF)9
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M7KBE"'C[I-4]CW&XE_=H/&-)AC (2"!:,$A>@Y;*DD@M6!(@4$F]7_QDWL6
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M8_,9.=#"2V^23"(($%;JP+T/,AFCJ&7LJUQ4^?A@/BXWR>GTFW(T\2"M=IQ
M0O\8(WU)*"7H,&OGEFG+M\OIH)%']K+;/NEVXO5-&O_IQ5>GG1##. =S)2?Z
M0K1*>Y("!CY@-='@M!/<2ZG!R+ $;O8EE"];MM_?24/ZN@+C'G9&[&^\['8^
MQ=Z@Z5H1@4VQUQLSW9)8(-!:@0I!('MA'(K.M[5:4>.34\)RM?C.]R(#-4UW
MW)@8P5(%,D'"3XY8S3%N#28Z'Y? @[L;4"^67:,B$\%33363"K2R+D'@")27
M(:*KYU=%H^8#U!0U2BJM@Q7>>P P7%JOC*'$QR (TR*NBD:]7':-8DKH:&U
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M+D9+3-!),1J\]"Q-9E(76:@6 <CK4SU7L7E(-6+I@D3CH:,V$/-V:)0GDFG
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MZD.6^<3 DU<6C2L'*FBND2L#9]9YDA2$R3SE0G37S<D_.HUED,Q[2PGUFEA
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M'! DT1@*+10M?)1::V(,B[[LT!]UZ,X5JQ1MBM&X0M-,HBF@SFLEBFB213)
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M G&H0F97ZF2(#K0.90RF;ICN4M?%FB*S<991Q?':<;Q@&RGC-#).>+*Z9,T
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MB2-L;=-'F>S.]W4^[[H<X:CWL4BVBR&9A8U8_>=.;,#G7]X81WE,@1$?;#9
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MVR<%/DV-BCWT?GB8O_MS*>8:#"?YTR?#WN1=S!2!QZ%?3D4S/80X&.='J3_
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M'%F07DX#9%0WH%5%\OU$\NHAKHKDNT#R0K2+.VZ2!$JXY&7BH=#$)2E(-%)
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MNFK,I33F\S-#P9PP-+J4!8:,0-"6N*"SP<R3\R8983C;VE8-5>=K&6K*\[U
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MI"$J.FE!9D$(5\Z_Z 5S[J\>;ZL([C*";[%W:47P>A"\D.2&5#AG@R!!T$C
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MO3CI'0S'M4-E/3RK<JIRJG*J<JIRJG*J<JIRNE=RNMTTNJO/4SC)QLEV^.[
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MA-XG'(TP8ZP \^$T4E^5&2],_=>H32Q']CPE, 9=L)':8G8BM3::[Y#CDC4
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M'/VT,&V;:HW;%XEQ438X>IO%,]NH13JSOY2.)/*LPCG=CRU(YGN\[6"2E^H
MC\;Q\<F#'T]2XON#]H;;-WT-P?PML^U@[:-L1Y<=,3M5F'W\;+,\:C?+5WPP
M?4ZP1T+!I4_31^S2Y[[UL?*1E?I:G_KMYP3P!WVMZI&B=D.N=9/6U3QB?%/6
M53_*OO.&7.MFK2M35[N>[YS?;M(Q[<4FXT7NVE13S73=V79;%W3<.J_Z;N>V
MS5=WK2^\ZU^S81!'HQAZK0_S3S?Z87MZ%'.%E?BN?_J %NW)878H)G71+EVT
MI]/4A[K-KK]B=8]]9\7F[0%Z[8*5)@%D=]";M0FH*W?IRLU:)/1>1!_['XN/
M51?K\FWF_?'A\0%.L@;8B:GO^Q64EZ_6JV&!7LOX"[UFVUB\_K$W[3E[9OEJ
MP?O'.)[D.RE/9A4Y&?5]V6JS%PSZM?J])J)7,54QW9_DP&\5#;PX9<#V!;\7
M_GL1#R+6,[;KIP9.Z^Q8-#Q:3R0(((!4$B-3)))J&;A$91"VMEG#)>U0S4 %
M>>7B*J8JIBJF*J8JIBJF6G;XG4.*:=P@]#_V0QR$WA%^GF9X#'HO\T?G;WQ2
M4CW::R]___ITH]8AUAS1*J8JIBJF*J8JIBJF*J8JIOL@IF7&# .5*C%K@0,#
M$;FE:#E*RA/U&I"NL<YD9V:GCT_M\-8,KY'NI2+=?F'6<-LD1R8G4A)((N>*
M0 J2&(:!4(U)APC:)5NJ2:@Z'^N^^J#A"N(.@_@6B\4JB-<%XC.=KH(USC!O
MB-(I$;"<$<<@$@X"# A*D:E.@?@AI++,SF+;3);\;+FLWF34SS]3OK&2QE(2
M7/KM")^:MU+CT55,54Q53%5,54Q53%5,:VV&89VQ,3K*+ !P=#K8E$* X&GP
M;%W-?6<&WWYZ.C/W7A5K[^>IL??TU-:KSLY2SL[;[.P\6W1V* 0EC 8"N@RH
ML=X2F[T=PK+@##JG&)\-5I1U/,W&X;K2[T:(J5OAI4J_-TJ_9V)-PE$MO4@$
M5.%@;CVQA@M"I1.@@ L:0A?I]R'D-NW%2>]@.*X]TNN91!53%5,54Q53%5,5
M4Q53%=/]$-/MYB:-\_W^SQ99(K\A&^"[ S\\C/_.5GCU-)?R-#]\G9HDF(XV
M*4W 6%'F=R5B@T$B@E-9KJ4SO"Z3J,&J1@K6C<R&BN/NI2=5'-\VCL]$C)2U
M932M(TH)2H [23""RS^TMDF&H'GH'(X?0H;23WA0>NTTO9?Q:!(/71SU!&UZ
M!46K)"2=[=(DL@#"\+A4T)W<T>P%I0?RMWLX;0B;+=<XA++DJ1166HL@)!A1
MS!241BF($O6;W34,$VN_>-HSI-+7,O3UY<F,NF:]0*SAH(26Q'IK"!3>,IP[
MPKT468Q,:IFVMBU73;8SUQ3N7A^ [O@0[(Z9HG.$^[>[VPE+[(!.4>AY>_!Z
M_$DOG%LR:[HW;;97B7)9HOR\0)0\LHB64N*\X014R4'WSI&D0I*((CO?JB7*
M2I+7SQ2HIM4W32O E"#Z["U2!Y""53YIY0P/VIB 4$VK.V:,,VW6G/61"YH(
M.II-*ZNS:16#)3+J(CKM#9BM[6Q9<2,;#2N/8;UOQ%&MJVI=K=VZNAZ%+CTP
MKAI>*]'HHN$ED*H8(!+-)"MA<B2&\KS7C:,(C%.39;7-:$/-^=A:I=!*H95"
MUTNA$E!F]X=&[Q)PC,@TC0:CT"D*H6*ET Y0Z/ZB):HL,I<X$!6<+DT0#$'(
M7FS@S.>_Z""]+I8H;0S5#;>R\FCET<JC-WWR2Y4)'@$M<@!%P4C/I)#6(T(2
MVEU*I,L?^%9&73T:>+9,2X 5(6(Q1C&;I9!M4\SB))QZ'C!1E15DYM0&J&BD
M6:4O12732J:53+]'ID(:Z3A/*@D!3H$KO&I!1>J8EI JF7:+3,^DPB6NP5E+
M">,B$(A&$1N$(P(,*E]Z=#F9R91#8RQOF#X_^;W2::732J=K\_&3M6AB8(9Z
M#](JPT(F6*.ES.ZB^0:;5A*]31(]DX?H%89DO2+,9^H$:1QQ)6XJ!#6><DR:
M9A(5V1SEO)%KF^US]T3ZG5S&T!\?'>#G<JOQV]Q;7UE?>9.OK!NUOG(C7EDW
M:GWE1KRR;M3ZRHUX9=VH]94;\<IVH_XP*:/"\K^A_W'[G_G'R3MF[AHI49_'
M0IV$@OJ#$ >3QX29-C1UR\$-WL:*V6D(\/:__L<SZZ(>"6C7(?O7:3B<#(:3
MN)$1C8/X_UY\_O./<.0XJ#]?/9'/?_GS<(__)O[,U[:W\]/[Y_P9[/%\)5\.
M/NR]S]?(G^?O_$_IJR7?.*HD,J])3"5COCPR)AABJ>-1\"133"5@-%V@%\,B
MKG>3R='C'W[X].G3H[_<Z.#1</3V!TZI^&&4G_[AY+733E##U(M_'<7!.$LQ
M/_[;$N$MZQA-'BVG/H#4PB:;F)#4N."I!CVKN863FEMUS9YM3X?CR3"59.I2
MB#A,I4W;<-"&OLY.",!!^ -'(QQ,QOF3[W>'M^OOJE?//KVAS"F!01$:&1(P
M,1 T/O]P!F/PS'H46]N*J89=D%+=]/)*]Q+V1[V/>'#<=J__-%OX7K]->N_A
MN(>]2?[3>+:1,'SLCX>CS[T48WDVOV?R+O8"3MKW]V?B[>HF/-E8/^>[_D^Y
MZ8>[@=X_@3>EHLH(F6G))D= YZUDI5*$.Y.2%-['LH&$IHU2YXMY'K5_.2&B
M[=-@Z=>*<J8<0&;M<30<]\N;'X_B 4[Z'^./G_IA\NXD*K_PKED0E<[?@FX\
M/#B>7/Z6A5"IS^001W>D?]79I5C\^6XT-Q_>1N)&$3\03/E:'^/!)_P\WOKA
MS"T=]@=D<?V^OO5+;S"E&SH]$?\]M7,RO(8C; 6363F.RJOR-6%GKJ7W;E2X
MY;_Z^?NYC@(H3QXTUR8ZHYB.'#._:,W>Z*WM5]-YL*F,@9WDO3/^YP^X?9$8
M%V6#H[=9/+.-6J0S^TL)[\NS1X.G^[&U)N=[O#T.R$MU@$?C^/CDP8\GUFA_
MT-YP^Z:O __Y6V;;P=I'2LNR(V9>U>SC9YOE4;M9OCK#F#XGV"/0XM*GZ2-V
MZ7/?^ECYR$I]K4_]]G,"^ U<JP&S(=>J'BEJ-^1:-VD/F$>,;\JZZD<4KH?8
MNJ[?7E>FKG8]WXE?;5);F(N/N2]*Q3ESLOW=L^OSJN]V;MM\==?ZPKO^>KR[
M&_VP/:WUO<)*?+>V^P$MVI/#X?$W)IK519L&.>HV6V'%ZA[[SHH]R==:7!\\
MZ+4+]BOV ]D=])[B47^"!W7E+EVYEW'TL>]C[T7TL?^Q^%AUL2[?9MX?'QX?
MX"1K@)V8^KY?07GY:KT:%NBUC+^0W-FV'M8_]J9)GF>6[T$U(?P7#HYQ]+G'
M2@="9M?0@?"!=L%!'R+SQFHK!;"@44DCT7HLTX%9;'.3F6%<L-H%9R$O^5\?
M]O+OSW<^R-=??L_7]QL\?_\<_GS_]LOK/_)U_O%S?^_P/Q_^?/^,?9V7_/KP
M-_KZ??G.@_=[KW[[M+?S]O/S+^\.]W?VWOVYX_]Z_<<N__./%X?/7_TGG387
M?$D_O4'O(N>"$RE3))"<(BYP10PPDU!(+WS8VE:T473-V<CWI6KCH1=E/*2:
MB^OQVL-I_'=K!/;EE,!X8#HIA41%S0AHGXBC,6068\S)J(Q5Y;#YH9%7M56N
M:JNHK.H4 PA&2<B_&*\8U3J*@(AY3U5;Y6ZASDZA;H5E"K4ES(9LJUAJRMP_
M3@1$E-(9V4)=-$:PQFC[P!!?S95JKJR%VFJ)Z&W2FSBE-R-HC!@$0>HI 9^]
M,&<P$96H2\IS)EBF-]UH.%];7ZFM4MN#HK9HA#$(GBE.07% [;2/4N9'!IT(
ME=KNGMKD0I3) HU,$8X4"3AEB576$B.<1AU\ A>WMCGE#5>Z473-W>TJP74+
MYY7@OD]P(6GG$S6.1PK2.F.\=M;8;,99)XRZ$L%]B:-AP/&[RFUKCZ"?1M&?
MO"DC/Y*WGJ 5+/NE09$L)R3<*"? 2RE2/)WO69FM,ML]9+:EQBG2$#R5W'!!
M@660&.FIE]'P8+T(_E)JJWW@[H+H/B\0G<@:* )Q2D4"P42"(?^J##?")U2:
MFZUM5OJ_6=9P=MZ,NVX/N,ISW8+[@^6Y95Q43TW*'FHTE $J[IQDTENMJ!(0
MO:XN:@?8;6]NQ@7'G>9)D.!-(D!3(D;%0)0P"8U*S)4YB^T4"\@$MS%!N'M4
M%]!N>.)P',NM');*\K:\[@J96AMXCCGS&+ZYK6Y.!2YQLES7MJYM7=NZMAN^
MMLLTWZ7@O$%C@DM@N7!:AJ@43PZ-\^A+8PAF*6L;0^0'XOI&WI/P_GC<=A49
MOQK.BRI*.<7N8%9,T>:7M&KQZ8)6?!&S33CN3^*LH.#7O"S#\"+ZX=M!^RGW
MHM7$[9J,_853C:  ./I$HD9'@/'L&-O(LM5HI 9')8(OIQK98E1Z.6NQ0KC2
M8UW;A[.VR^0@ZV0#QJ@%,&!,&R^XXJ@I>A%LLE7UW%O5LQBMX)ZI:(TD@CM*
M0'E/7$1#I&;.:V,%\^D.E4]MIEE?N1&OK!NUOG(C7GG;E;C?ZN)VH[;0[D*S
M1C]MNS N<=^F=W3:ZZ/]0]LH\K0U9+9J_G_VWK2IC61;%_XK"NZ^\9X=H?3.
M>>@^+Q$TX+[LVT#;IMO'_N+(T<@6$EN#;?SK[\HJ"8G)1B"@)+('+*.2*BM7
MKB>?M7(-+3^IRMD:Y;*<K537Y:R^I2[,V6[U+I4ES=\!T^US-8=%RT,^ A4K
M-4H;0;Z >'V=VOV7RUON?SJ ?]_A=W2/O'][T#W8Z7Y^1_\-\_!;]^#WER?O
MCW:_O?L>NO!=:?]H_^L'8&<J\L@0C=0@[@-%EAF%B(A!$DPMT6%CDP-SNR;G
MMEJP35RD.Q,E*@MU318J^^ -438XB;@&\X(G[9 UV"),B):*41NQ!1N#B;;D
M5U=JNS6(P]/H<SG5[JRJ1%VT\@YIBNMDUE^;B<BQX98+ES3#W&*F@^+:2",=
M-PG'^!--73 E,:MAG9&X,Q[ O-8F>IVI>#@ZCH.B=XOIW:RH C-)62D5<MCD
M."G,D;66(F\=E: VR1@QL<V75E6A0;%0SU6IK^Z]]]3HZPL'7%7:RIE6=/8.
M.CNK(R"]8-89@P+6&'%N/,K9QDA+KBW3EM@H*YTM^KHN^GKM)NQR=BPVSH-2
M<IH#OZPT0F$>C6",A;()-UJA9]4"K(E1NL01(XPA;HQ#)F"*>*:P5'!"E=G8
M))JU&>-%J==%J:]NPO?4Z+()/[3.SE+@F0L:YQ11'0009T$TLBI%Q#!.P25&
ME<*@LZ1LPFNLKX\86U54><FJ/ N.(IBK2!5!0EN.N -]!J6FR$9#+7<QN4!
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M[^B44"81C8B@"7&G/0(+2"+%#..).JQ2CLO$N(VOZ>]8.CH_707E>VKJU3S
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M@(%9>3">.,71<FNT5LPD'DD2=EF%3B8$XS!M3^C%4687+VMRL7W.+0J!7HA
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M*9\X8^F GBH;BFW?" 2=!1P&B5,*8,U[[#SBQ"ODF*4H.V98$"883O,!DQ3
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MP1K3M&Y%$,S/,Q+ %:V=8XCK #\2YKD3<&X=8H0F3'CKZ<:FEKGETM4(\.(
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M.8=<X@91); 7/A&&LU>GS3!>!KLI9V@%U=8G]+P 6E, ;6:N*:PD]<2A0%Q
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ML;F[ECTWCV+>R##K*5SZ(<2MN>54IENU2 _&.<;M,%5!\X>SW(M+\?.%8"Y
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M<81@J8Q7DH#ES5U2!JQN)I@/41M?Z,AJ:_Q<Q2<A'-@>'BDA"6@\J+T!%HK
M_ R26.T-YQN;A+>);)+2K[T;Y0U\+ [K"=YJ;?=[U<AR5,*?@YCB8# E*<6=
M\J.Z-MPY&HACF:/01'74- 9+81]+A!A7Z$GCP6J^$U:4/# O% J& 3WQ+"*C
M;$!4:P.,Q3#C[<:F5JI!5E/QEBQ?K5.2WG,>DB2.8\Z<THICT/,8L1&U6O^8
MGA2U?G*UGG$0 ES#!TJ1E$DBG@+-KE"%2,IL,]>>!/DU3*U7+F1[[;TW\XQI
M=^F,Z;E8?F#Q,<=8M-Y3[DRPFI) N(A!1@>X6PZ@5AEUYP^@@$MYHBQ#Q$B%
MN,44.2.K@K]!A&"5=FECD[4%UVTN2JW?]=;[Q'G2E#/-+.8X8<V3I1X'%D(R
ME-R"4LWK_?<XZ <[/"XJWP"5GW/VA!@5%Q:Y*"+83SS'U'"'-#6<6TN\$#BG
M3P#FTU\;I/#W]?;<QYCZ:0+@SUL*K2UH/&*!\((<CXT<%UJ !!)R'IU&L!T
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MTYE^L"KA0J,U"1<^7.Q__7(&87-GM^E_-(X^DOT<)ES 9T<'%_6O$%@W_^S
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M#,&Y5=5_&3&E[2R=URYQLU8*OOPQDL6[U(<;E_"![V0#*%HCS;VB-1P4'3N
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M"L[*!X["JY<775V&59=Y@9<<696Y-XAL3MNCFA6]_DFO#-WALV'_U ]/^X
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M"AF"U^!L,+-I,K]P\9C.]AIVPC3B<$Y0[@&[8:I:'4_00:L-UZL9\E>YQ?L
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MP35U@X; BJX_5,J?%0"^)CY: >!B #AEH1)+ZE-*B##)$+?8(,NY!SS$E/-
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MD"+!% EGLF9,N=P;#5(>,$@H:;P@-Y_.O'H^HV)(:W \I,HE AL2Q$<<%!;
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M6[$=*B6\QV-\'QKO'A5'WX[WE4Q&M,+1A7%T]DAL" YXG3<(:Q\19U8C([5
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M)<*SE3?V)^I7M[!X]/SX[+MX91]W]:B1QH<0:##>"F6IC49X$V4I.*6)<RP
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M](FR$HD26*)P%KBC=-*QPD1F8JU\";I"LJ4@TJUBYV _N>0 1DK"5%1$&%N
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M2,P1XTI%F/:%U,PR%0PHON:>LP[NQ&]+GI#P,^O+/U=3APO\ [>#OE5:P4\
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M39F(!9V(<%I88%]O"V9QF!QKZ\MM[LYHWM)N_8*050?!GU8?Y".9IL+\<O/
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MLCY7%;W]CUV:M;0.!XC&_^C \UD9N0"I[D&Q*G5T6M$R,EL -)=T'SA\+_-
MUM:!<GJCX?_\VSY9=(RWUMC/L$B%MD9H58*YYZ4N!%BCSGI#RV29-*R40E>"
M!;X3PP9*@U@PEV)RD7DNJ#6:<DZ3CH413)E"7$$4/R90?KT6?S^A/;1;.XYH
M59U27!H2G_C16R^;\K@S<? -(/)>ZX]._Q/\:8S6Y8N7K5_6\I_7?FVWGF[^
MI[715-\.VZT7ZR_6GZY/RCKAXTE5)Z(ZB) !'@(\8]3Z7X![$$G#N2KPV2NF
M,;!9AW!5)3'[6M/8?#_!.;<KFR\_<!B[7?P@+[A:[MEUM'.(M@.V($C4@\ZP
MVJ+009=T=4-89/N.=8-1>JY*)5)DI7"%-DRZDCK&K B*6=NX6:@DS0]WB,B!
M=E4[6"8ADQE'RU9O;VH!/UZGR]$6V_Z\GY*)<"*1)$XQQ[+@!$PT2[P/P%")
M2>DE.EV,%FW.]'5K-IJP6TU80 O :@-DJY,!&%Q 0B==ZS.C ?W97^](7L*K
M6'!AG(9U^@( G7(94[(TQ9)QMR*O[T]>VQ3(RP?-"B<9T=%3(KA)Q+# "%6*
MIY0<NH4O[M=TOL[CV?F0;PV<%UTPA[^_N%^;.^TL+H\>G]S<ATQ3B4W%E-!6
M"&NB"\*!)1-5&2C7,M5>I#L1W2H@?%LZ?,5V-O:M\*"#4D<8+RP!M:\$F#,%
M"24%;=1@>XYB[0EK,\K;E"[()+_(M[PW=;B<I\W.?"5CCH36KI(9)X\[K:S(
M)H)ZF\!HHJ#))F:C=524(& I8+<OHG'>8F+S)23X&!OPWH&<WG(D)V8#3Z4E
MR94"R$EX8DLAB+6&)B&4%HR"U%P4HZ@\;.BICS-!T7G?X7E*PF#^K%OC3E'T
M.Q-+=H3-4\J,N3%U@.5 ^B.FE?<4"UB""[(L A&>>1"!3A%C4TG0/BZE"13T
M8'1YBP7R;Z8$?SAV1ZB1H^42CL;#RON+VI5'9VKE/4:3)5L&>!2IXVME:C,.
M.P=5LY\YQ-II<H&'"W,\_F>NM]F91B"1JL1+P70 N5=X"QCJ(S-<!%XXSA=J
M7#/2#NP[_UL8#S[#VH>Q=W7KC^V<;/(6+//NL^D:'QU)>:S2EX:EI%4D)N ,
M3HXS=4%J$1L5!97=!2/YVI-IBL[9+G7?,V5' QX"SC@J62%B )O/ E3&4ME@
M+8_NVI)IE;)S,THY*$!014=I"<A.?.0&*$4PXI03A%HM@H1SL07-\39SPY2=
MS>BKE!VJFIR=C5I1/QGE3RIG/2]F:A/@JSG2NVK8^W#(Z.,7 !Q*&=-%Q.P=
M3,TH@8(,[#])8-X [YKD#;^9&7=9;+(_W?B?OA+[RCCRY5OU'>+(ER_@9XLC
M<PNBBDE#"QY$--;&0D:F$Z<I1L^N<E2NXLC? Y2^PGML[$L='2^")DZ46!F.
M6E *G#!0BIP+A0\RYY*<;S3SC>/(EW+,LL61[QU2U8_ 4RH!3[>PK6GO:-SS
MT[:FN(GS :%I2.-S;++CEL??=[$!5'F7'Z\F\O4]5G:XHH@!.P51%T 3H8D3
M*X(G24I5:*,<=YA'K$5;L/,))%.?+]8Z8 'KI\ZP/S@%]HY-8N/TDL'US>%;
MB8V5.7QGFO"?01 D'T.(LB!26$]$C)18;DIBF8[6"*G!!ET6<_AVV,%6QO =
MZ83N@L)0&NYUH8D2Z#:A!5HQA24A6"M20:6F!7;#+!;X_R\VAK\'+)Q&.[@:
M$Y[A@K*7;P\4_\=WQ@+D0Z"PT84N"7<"*Y5I("Z!I<IX#%0&[8.F:T_DNCP'
M KC'5Q6S+901B[+D,Y5@\6 <@D63U<MD.X/:[_]];9+BNFI' QC/8:4YW/.(
M >, V_;S9&1AHB*PS]@-U8"%$5E!2L#O&*T6R@(Q\;)H*[50V1C.%B:@RC%M
MF'%B.R$WXJ]F0306^43H5/8XN@@6DE!GSKX?#QN*_:-K_4?RQH,- (KU;M7<
M P4"7K#=#[%;)Q#!#5PV,^H'3R@3?ZDR^D[Q._-9':/)M55&W3&8*F 633P(
ME:T.?["=7O5M3,CWV3F JVT>4#-0NP7FU$>2!C'W>8V@:X]:@RJ5"N U^M&,
M:509-),_?^IC.FL7F:V^Z40P7_(*YZV?!]+_YI)4M7K0P LP'?M=.&T[^-B,
M&&D]AWW(9;[W,+7EQUEVN<\-O'9KSIU\A[R^R_=JDE3RXN73>TS"@[O=,MD.
M,Z1N9J.Z@N'$=)-T",)3;@H?F6-!)= TRZI1/X@*S@O2_+#*B/JF,@76<(H#
M'S@M->C\1.H0B9!1$ <6+?&^-(5C##['V9U7=[X]GVXW36[:NK_D)AD]]9%+
M%\I".(8%7)Z73@7%C"^LJ0V6.]'/*KGIUB0E@:1"8!Q4D40*)2GHO!QT7N8-
M$=I;CA,1A<0<3D[;YI*NV[.=>"9D-.D5EJ^9Y-(!^9UOT7U5FN<<6G:'_=:P
MWPTU+C:$^]>4<!>LYZ])OL)D);/D?</^ ,YR9X4J2VSM'+T3!=?*E<+"BE4L
MKD?8V4(#XC[CN+DE93^S_G#^VD=,VP<<?3O8BZP$?,P#CD6(D5A>2D+AN*SD
MNBQ86GN2Y^8NI.MS2(E5QGGLP)N)-3_]TUFR;TBKNB;[ZSN]6L6]2'K/9=A,
M*?9&[D13"A^MI4(9+E(RUNA@5:*,JR*!7%\HO5?NQ+N2W-X&#DUQM!1.:0\2
M&COC ?T1AUZC@H$:I0L9K%3+XDZ\ XBM'(IWHI0L>#5/+D1)5,2Q?J$P1,L$
M_V K'(V:=BRPDM6(!843M_,HWA<RK#R*USCD9U]V7^UK72;-2PH@P$"G$L$1
MP_$G'IB+U-L2D^WNY%%L'0QRB';0]V!##IO@<F<XU6URWM1-G(9W- "OE<BP
MP/Y[VN\-.R%61%,UX8UA=Z$!^-C2%H">L*&]49PFI21QU@$5,0IX4=""\")2
M&Y4MM<5.B.OGC;^YM(7UUC7[VJ@'%L7?;8;]F'MR]:#7Y4'Y;F),8%P+:G7)
MA%71E:HPW@/**^:D"37K"A WS0\KW\TW9MU7F 8)FE;4@F,#>A:)*$%'M X
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M%23$8*D!R5$4 0! X.PUQ@M3%,X;Y4TQ@02Q@H2;$L#.WL=]GQ16,5&2G&9
M !B5%K(DBB:3E)4QE!PA02P8;S4M!;[$A,$REX84AC<W8NX('=>I6;F;#?,(
M":?8WCO8!]J07(,L284#6<*E)D[:2&BP.'Y5)TKMVA--%^<?GQVF<FD7\MN%
MH1]?[W*SZEV^!&OY9KW+E\" SP;LXG;H5[8W/],.G04?,,=0F*!$H H=V-%8
MH:VBS)?T*D?!A6VU%V#)0W87+-[MJW>O=C,P=3_9+W7C[_MJ(/X=6H4G0*L
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MKIL18'E,U.].2[N;_O.^$-0543#B&0=-WBM*G$F*!)<DJ/$N:EDN;B8PH24
MF33.LPV&B/\^3E2:/)JP$0HX@0PI:5B/\!CF6"((K7'"_IZ#&HKAJV'L :E
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M#NX"[8_J*W.Z#^9W9+(&Y7!0>;&K>\#[ "S#GSK-3.'183]4[/]?4("JT=K
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M33_8%D!67\&2+ [10@%]^!6+=\<J:++UO#(?$"-4@66+EN9EQ,4?LOX0;+$
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M5[-;K;;DC;-;IUG'OG/URPI_P4SS$CC6:O/KFV>NFZ''>)XQWKR-^X/^@:@
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MKP2-_&U@J94:0C<YM!CA:WE<,<*)6XVF 7/V$1!<'ILPWIM$H#(V86BRW'G
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MNBF8KY@)A],+P"OVID0B'Q5D3D9A/-P;8EZ><L<=!?A)P!.YX<VH6_)\23,
M_33RP_ML&T%,C9A1/V>R$RM2O.HGTEMS',^I"0_<E;BL)KCD=UIFK]_& T^>
M?<O)6$%-='L@I79E80!1Z<04YP7EN.!SXI#A;@J<#.A:;0,3;$,%"+7_X$*@
MBTN[(([B"AYH]<Q.IVT.VH,GL@%P 8S5:ED/<4+#6'YZ*TZ'"VCQA"''Y[W5
M;[24_P0:#=[L,C;,Y?+&#D_#RWM0YIQSCRI2I:^2Q<F''^2B'97#LU\L<CU^
MV,@!7HP28(Y5$:'U& VJ)DFK?-]NM-5/'R19@4*+C#BMN-<S&I&VBS+SA4%Y
M'T8_^;'+U2M9&&!'M;MFI]_CFPE_[5GFH-^AT@!XCGMPT,\::Y-I:XQR5<HB
M()MGJ.Q-> 782QAY2;$0C<NFRF"C'P1LS*-P)<,&K1J0XZ6-_9P8/63N<REB
MX 'Z'EA)? #X,TY'&)A$8XU^ DIWPICTN&2$"<;AM0VX*^# $L$<3#++R[*E
M_N"IIE*SJ/C3$.P_89+'>2=.Y>?#FM<Y"+>&44[$^07T PHP"EQSEY:[P8=X
M[ 4S80;'U7:P8"PJ8<$WI<++QL=':42%P\!5)_)[,&+)(P%E/8Z<B:AFEDZG
MX$70<[SD6,ZTIT"!G%\629#Q!5ZU)9N&9!L*DL!SSIWC^3PG/<#*+L#3/&S/
MH@F8_IR?'-^']X2%B ".FQ1?/1]:P+?%&$%%5J,H-= EF8$O  2CDZY 7X(9
M]#['_&R1UQ 8:D#"1R (;F%X B' 7Q='2U2\8JE(26XJ_R=>+F;R_%*Q>V4L
M!D5:Z#(6;ZN,Q4;4/8U85>*BF@>_I3?PH'$!J@ -[_E2%V_CL+,ZL-:+0-T,
MV3F3!8\.C,<.19&>R=1G,FH%DR1&N0>E#=MM3#FY0D$N? 2LS&;3A)GG[JLH
MVE3P%N L$26BQ'6B&@F\JE:CT\QNX<#D. V4SN7GA)H$G@O2?>%>5(KEI@)1
M0A1'GZ:1>^O$0M4KS3WH=4JS+,^P,"VQ0)JS"895'!<G@E\.O=CE)3WDG9Q'
M7?K0:CK@H7_RG_@;Q36)&II")*"JZ:8QQ7";E]P:XXBN)*7/-G=#^!YT6F.0
M7;D'W+A]X >#=N:T@F^!.M08\I*N,(OE%D3_QM#2A"*&:@VRCNYSGH>;N2D\
MO#B_OCPXO/Y^<&9<?#D[_?W@^O3B7-\0KF%0.\1'*7%.I@V")'*P=!R(!8C8
M6-P%@=%M['D?^/KPP:S*Y95R0HC[SD.\5@3YKGP"OS6LW%5V/8Z70W6QP!=Q
M2,[#&.Q9C[U2>;CJB?$@PYXG27\*A#1ZQE<G '.++D*.LCW$1P] A\YBCQ1,
MM@.'ZK8/G[G,KOLNLNN^35<)7;0S&4->Y!B2[Y+:M<WN$;^L%K<Z(!P'O'SU
M)2.W$*@.XC;A&V@U]_^)1:6H9FQ5Z(A\I4@$&&X8'.9!:* Z)[]35FH$^7I(
M7,4\2J^546"\X1&AR@5S>!F@27_S0)/3Z^.O1JMA_.O[P?GUZ34<'G\>$^8$
M/CB3_SXZO3H\N[CZ?GE\91Q\N?A^;7P]N/SG\;5Q>7KUSVV_" <-C)8'2!^Z
M""^STX-V37:ZW3#(8+@XNZ)=_G9Y<7A\A!M;;X-A,R0[1IRCN@G'@\4/L2XK
M'8=1Z'.M^PU-V"'>#]:;AO43/1GN%F H1"8&!LN(3C8^=T72*?9M4*<ZN1SD
M]V#G!P($Y(RVB;(&\K@I_ ;<H@"?QGM=YJ8\9(XQ:WC/WN'QQ0?144$^E866
MU5-_?C.%(<$^F-)5XB$Y&(WP8F(:PXQAW#S#3!7#F+P:-;R%GY67J<_$^=1R
M]JW.'A-F#O[,Z@SS'V7$N5+!2>/XEP!F''! FC5HM>DESH2?;WOX [1L[.;G
M_,/TD?7Y@[AD^4+0D5"$8[,M,1^EXF/T TH(VX"&7HY.W.=41!;VPJ*RR.A+
M\_M* W$FX$5C[,>)95L+>K$7$/Z.V$9$O^F2^(;)^3#AX$H'."+K)88U^4@;
M\/K3FPF&%^1SV8X4ML'+ -4F7U,<XU_C=(+7G_\EMA^*X1GG;?%*\%OE]32X
M'%/F>B./*1CSU?&A"D!'P#EQQBNXMK7@"EMS;%\LQS@(7APR;%[#M_=!QL 8
MA'OKL3MQX>1%8$3^+^>Y&)DNVP+G)KQCC;S?,0SA&;S,X'<NIG$;WB."R%R-
MT?&:8QK!#Q'3A0&/!&/]",AD411&\E;?28<-,*MG<B CGL4@#*8PCC%6 N_G
M1<W5^JD%##DXR'_ EQPA1D7'%;X3J#&99CX%7I-(HH6!/\M1SJ3ERK"].2=A
MZ%%EY),7.!.6-(P3?J-$TV6%4U81)O]B^8[R*S#,D_G2HEL'T0EI1U3B[\6)
MABY>>I')SZ^(%.VH<P!?+N8N4'8$SH4& $)A/'%F2L$404*Z1,J<$KY1;%AS
M3,&&@E19/7WJ_A)P%QR)+R(H("@Y]YP[BB"%]29F_;0B=Y417 ."5<1H>I+P
MDNN)YMD!'4F:Y[$\R2VV-7@<3HNG+@FD\,L1.DNG-2H:$#DZ X7>F!F^]Q,C
MO$DX_[RYVEP7'W$[=RO9:BZ^E5S!4^TI3U5?9;ZQJ\Q79=+J@^#;P>6U"-R>
M"E?#N+C^X_C2.#T_N;C\2I<7+Q*" 3ZL20S&:AAGQ[\?G/'@R_'1Z?GO-8^^
MU.^<.P^#%PK5@:36A4\.&A1@-4X.#J\O+C6/K&4+/7QMH+#"V,,)NV4FZ&)E
M 8 GWAN8X PB0DW]0N$9G]$WKTO7E>M\HI_,EPHQ10=./+#\[KPH)=IB4I.I
MD&ZF@+KE34$.=/,+&7LR&]-<D)U7S*]4Z7SE"& I!7+K\_A. ^,?3I!B6]BL
M0=V/, **_L$</[DU+J*Q$\B,+C _?)X/4=HM!3RD/F(B0BA01F*@XPF+\ H8
MN^Q*/TZ 5, 4<>&?I@@CBF0:"3FEZSF1I2IRNN'5-(5[FBG',<=S&P_S'/OA
M#>WG9(+H&4RDY5D',X'U"'CM!A[>R7<IQJ4BQ_#45M6S+9?" (--G.@G2R0J
M=2Y%&'\Z1N<CH!@/PM%#ZK^,<27,8I/P$Y$?C(.+&2,(%A8"FL83W%E>'?YT
M@E$$8*0T3K 9,)]'*5V6XS\5-3-148C0+,M784KQA7QQF2SP:<"+QF.,U.8Z
MD(HYJU_'H*6&X7W0,'ZP G(87$$O$<HLRWM.*HE'.M2?%5*F56)N]4\H6),3
M^IQ\AT4'D*N AU-RWU"XL\ 6):X4W0)!RIR?C%A0\JE@'0XBQC(;>?G@9#8-
M\'EO@84CBC-2"(S_PZ1:(T+KL@Q:!6)(P3[*Y2#P&_CBSIARY_$BP.6Y"Y]+
M$I +E7%QP4=*_:FG42A;=F>/QVD\I4/VL\A8G8@(MXI9CD.,CQ/R7'3WQN@Z
MIJ['0)PAJ7OYC0*H^P3FOJ6HKO<3XQ3 F#[+C\^QZP^-GD0P39\/,X*SBZ'$
MT# YZ/E<F8 "[P,SP2L1NQ<4SKG2@5;%\69!*P@"^B%8-D,)"+SEJML%^P9^
MJ:9=.8&"MIG3,<7\_.PTKDJAY_<9%:<TI:*4DZKG9D+PSA**/E>#@8>:^&PI
M27>!I< YMESR0)D#B_N7K:TO1&VO?2R8^*G5E:7,Q%!69[/9P7 T=S?86/-S
M@3I65Q!CR'QG1NI]Z.$=(9:?X:%B%@ W^Y1H2/R$+$_85N E)OIS5IAT+Y A
MIO?U.?=5[5?L)1B>!IWAE$WU\F_@0(I2#O8M_YQ2Q\=.(B_'BM_'B3,::9:H
M!TMXLE@9:'Y^,KD.M86.08[I<+YW<O6F\$!)^9&Y6(WS>CB%D<.8DIUB?F!3
M58H*14'\P5E&_H)SB\Q?DX/GIJ'535UYBZZ,I!<&._63S<K[G:6K9P9<!4M@
M=JDC'1UXD2DOEGUO DPBO)% V'YH>%"HB,H&D7U, :$;X&,VI (B"!7!6^J<
MS9Z57A)*BTQ-TI;EA91GF-*5NH%@* '.CI-T.,N#"/;DZK">4^R&4U2B_-:;
MX!!471#KSJ!A#^:CXW^0]2]R99)X$;F$C2/TFL.1>C71IZAI:0;P-JK$I$6B
MCB*!6!(ZD64^3\ZUYG;XR=&!H;R>B(U3'P_5F>&D";AX0G#FV"1B=QXL@@(<
MF,!SAZP*:Z/8RV>]JR^LZ,SBSH(*8MX=:2WIY,IS2SC7"*P9>I1!3P=M'C:/
MX:@4H^ < 1#F(H<*7D-')'ZK_'XS[[?+R%',U5XXG5)H@)=@SUPXJF_GXZD]
M$] EK37JP5^E4TY6",P9:722W)/[3;KB'G/-;_!RPTT5;/0QLREOP=TPJKA(
M9XSG_I08VJPX(0\X>I%!9/#4)P1MBUCQ8>!1YR[T>&P8F9K PKX3C1EF*:93
M&GS*PJG/-,_5@N<6G%0BJ8?S7<[<R PY"@GJ/:S#'KH9QJ_H@>?1N%FI$9%;
M&'.(JA/G#8ZY$C%"E12\?ZY&\F U&3Y<\TYO]Q!CEJYC48.YO&X=B^XFLWW0
M;;AAA7P+4>58%BOV.9@^7[FF5&@H]+'"U!QP/@_ROV7^%+\CZ+SP6G-8#W7?
M0(B$!J([#/;+P9>C56)\=2)P<;+;=/2+""(^-,8I6,X!WG]Q/PB_@A?$L""8
MMC\STNF0H^L14K^2UI)#PD+<R+O!%1I!2E7S."P^]H;*8T.E2%=\&/2<#X_-
M%8//7E*,F^4TK:@+A;DYTD4LD9ZC;L6-$P<"J*M'M75\!W@&%H<0XV]-4;QU
MEK\K%VZG",XL<2\$I[WA>S'OY^#[V=9*K+%<[OS=EBRKRR,5N4E@ZD[@P?:I
M\ ;V7$@PRX,G,V$Q*!5CYBQ)QYKL6X"[I=:#.1<\;C+$Y@VIXZL,G6*F&D*T
M'1_['(AK38?RU-4U:\2O<(>RND4JZEG(\EB1+.R1W2KFMZ!RC_988]PPLXD@
M1@(+9] %(I\6R4AYN=)QA)E])*<.2&CRV0>\ZEQ.#LD#H')COH_4=#%P0+:
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M$/V(21SZLUEPC@<ZM] 1YS"&$X2\.]<F=+K%HEUN>#6U5X9<0D^F=ED+"-4
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MHHM'5L<7,D'X+B]YBG(=^:QT\G.B;&$,^^T='@E]Q= E:J>WGJIT7Y=H>7)
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M$G*/OM5897N1GD]YAGS*.PF+^P)LHOFEJVHSS2!8NLT&5V.W5B[D#CI(>5W
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M$5W'>8,3BY)Y;\LQD2N-VA"(R\X0+M!C).>3;--1O#Z)NQ0J[C#:5Q1NM<!
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MRN%%("IP*]'$!.::V.8-Z7P"Y]LM 59;DTW@]H?O.E]ZEZ"+X]+'PB7GEN9
M7#E.E<X;8H71Q&1-33+69MMDJ^0^HI[ L7=+(/7241/4?+>=KV?3]R?0G1Y
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M;C%&G]E0NNM.UM:P;L-Q<PT<#*F!AR<;0 ,;<MQ< X=#:N#AR0;0P(8<-]5
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MK%'_83H;-A'X<: @K$:%P;/@,GGN,FH6HE0L%Y0B.2UL:7)(' L"]ZJ=3HB
M7>3<H>:G7OE['/5Q_&SF>T_ZM-/=][G_/K6N>L8J&6-1+!B7:/>34_-%,6%2
M 4Q&1>ZVBH)L][[C6XF'JF785J8=9HS?(?'Y)A)S+L5E%5D,R3 M7&#!0F:Q
M1!"\H- Q[J#V3>]["FKO5*9M5ON+320&GTJH(;:D=*CYYYD!%X+Q$G62J#&*
MM(/:-[WO*:B]4YFNS*?XMU\61$0.S3^[*E2[+:]Z\_+]AS?/_K__>//;\Q?O
MWK_X7[^_^O!_[I.V8XW:^B<W*$_;@96%RK04LR>7D YX1,V=]]&($H3,04!
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M<-)0XB?PM.Y"V/L2,VI3*WD)Q](&!EP#,\8GEXHH039I8+X#C4\.3:WUU.$
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M>HZ16%>&@XW K+:.:9E%S<O(S.@D,&@=A&P2*MM,VG>/I@XTUB"+='LA]41
MZ;@SM'^JVF1.U^^"9XD[3D8B*"^.&8;]85<UU6"#V\Q*9OU?C=-]@4N<II21
M!/II@KG^X6*0[__BSB=G,TL>7K2ER^N:JOWBS_0)!A_Q';GE+TI!$BKW6F13
M//,Z)/+';:'OM& HBTP)$N@VO0>/R^:C#WV<,2H:6($'<=L+!7S1-C(?:T@3
M;+VC]IIY(2,/CCQR:%),?A#5WS="=])9 Z/Q,.*UX1J#0&:S(N*Y('?<>#*
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M>)H;OL[UNRU^#E3.J7 D)2>76S)TLK89]8I%62/_JCB?HR_6-AFX?C+\;+C
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M!B.Q:G8N30A@E%-\/&*":FHF667"S=4M/0Z=0Z:*YM/RB\?+:&EW.$8>(WI
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M[;]_?Y@%3S(OIHOYO_\!_B7\0R#G?"&F\[M__\/7+^\ ^<-__X]_^9=_^W\
M^-^O/KT/WBSXZD'.E\'K7-*E%,&WZ?(^^$7(XA^!RA</P2^+_!_3)PK ?Y0O
MO5X\/N?3N_ME$(51N/_7_*\DRRB-4PI(%D4 840!S9  "JHDU&_$%-.KN[^&
M620)C1) J*0 J2P&E L*8B9Q*AB*!:\:G4WG__BK^0^CA0RT<O.B_.>__^%^
MN7S\ZX\_?OOV[2_?63[[RR*_^S$*P_C'YND_U(]_/WC^6UP^#;,L^['\Z_K1
M8GKL0=TL_/%___S^,[^7#Q1,Y\62SKGIH)C^M2A_^7[!Z;+$_*Q<P<DGS+]
M\Q@POP(P C'\R_="_.$__B4(*CCRQ4Q^DBHP__OUT\W)+K,?S1,_SN6=&=F/
M,I\NQ.<ES9?O*9,S+7W9VO+Y4?[['XKIP^-,-K^[SZ4ZWNPLSW=:-5)F1DJ8
M&"G_>*JS'R\0OR-YEX>R=B!<J>Z'KF1LP_1#9^)^T?P@^Q=XJYN+1:X^J+=S
M,=2WN^[J8M'[E[BKSV*QI+,!/HM--ULBS\POWNN?ZFY,0RUD6O934_>6J/+[
M4LZ%K-ARI^E@*O[]#_JGR:H =Y0^3C[?TUR^TD0K7B\>'N6\*/G[.L_I_$Z:
M)?'5\^:1C_39_.KZ&\W%[:-YL+A=+<TR8%;6F_DRUXO"E/^=SE9RP@5")*,,
MQ#0, 4IH!*CD*4"291%)<4@R-%FN)\=$SL'7SXT>I; #2?H'!ZR7)S@CE\5B
ME?/-:OLP.[:$ZM73K+?DQSE]D,4CK5_0ZAK#I$+@/VIY@\5&X*M@VH@</!F9
M_^W'#4PO.<BSW\_0S?H=M5(!8$P6$6QK&6RI&;#G8/NY6M6@U/4JJ+75/VR/
M_%KCX.^M([_@.[K-C"FVR/='9<&'&Y4=CBQ'1-&"E9#6,OQHS.<?Y6Q9-+\!
MYC<@A+6]]\?^A?WQ8/Y<YPV4-.=G/JWZB1_Y0IO"CTNP\Y69K</ F"\7 T^]
MZFO3,/PA6.1"YGJ[=032-27Q7*C)&ZF[%F^F3U.AUZE/<E8MB*_D7*HIG]+9
MZ\6\WKV]T_NQ52YOU4?],<D\E]J<7O!_3"0,0Q:K#&1AB/4."Z: ,AX"3E/*
M0TJX65T.++"33-616%9\9&>%=LE-E6*!J#4+<LD7=_/I?^G?J44>L+6" 5]K
M&*A*1;T.J:!2?#EE,QFL-0Y*E8-I4:S,/M!N2>IJ_"&.8BPX C3$"4!4[YHS
MGB ]_ED<89Y!&5,;ZV+(@1_0AO@G'/%V4^,%QK%G@Z(>PD:;H%8G^+((-@H%
M&XV"6J7@5NV/V+ #)6IG6KG2C&G =@1[D;FG1^G\U/NL=][ZIU>7S4%K<[#C
M@:B,/M-H:<J%61R6AEQ7W0QBKG6,26.4==VLF^G5F(2WRWN9?UC,%X\RUU/!
M&'9\\2#??C?FH9P@#C,:10J(%.F554D.:(H@D!P)@AA.4*A<]NWMW8UMX2RE
MU;MM(V+P@ZR$_/-5,)=+MSWW&93M-L[=8=?S8E7!MBUI<%-C6 O[Y^XVKG:H
M=+G[/-/CH%M(.^WW]X&6;_DQBMY:/DR79FDMKN=ZHSDW'<@YU\O8FVG!9XM"
ML]@7^7WY:F8,! 6U[1Y%&>"8(8 2J6WW-(8 $Q)#G"8L(TX,X];]V!AG2_I
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MZ\-^L_^37%)-)*(Q=ZXY7SVL9L;M\$:J*9\N)UCJN9Y"/?=Y1DVBB!1D),&
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M>@A]ILMASY_M]#\X>K9\S>/4^:CMN+?&G#$E)Y#&61)E,9 TCO3RD')M^9G
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MI;X*&KF#-;I&\O-EG9QYQQVP+FG(H?=!6<D=E7V2\FBA4WNGSB'!,X)5E")
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M<92 ,L:811$$B8I"142B%WOL<O;8WMW8?!25<,&T<D26'GF^5L!].;?$W.[
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M$0!CK'<B$$IM!5 (E,Q2$<5*,!HUH=Q?W!)(NLAA-5-V8[:_#, S?F7)G ;
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M<+RD%0 OLC0E;.DF8O+'?+DTK*+IJ19B>)_W<=X'A!%A4!B/HGX+.(: (L$
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MHSD!"D,%(%>:YXD)K<*0<EX47)!B5E>=^Z9-A,T8P!X/%P[>IASNS;XFY]6
M%K%DPFPPXD10 "GC>L>69R"/94$Y3B"2:0/HAZ7E@ND#SNU@(X IJR#HJY&T
M='M=A4WH;4=+N'_;>J%N-]J:9L^;RH+0EO0O=.TEZZ ?$:\>I=-1QO4+7=3R
MQ+MS^<IA*U-3$J]L7$*?FJW.W:K<E+-"8$93S:#ZJT< 0H4!53$%,4E9*I14
M7#E5%N@:;'(^AVI#M]OZ-7V=' ]..]&UXP1?F 5FAZV8>\?U5M*H$M4?)=@
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MP ^>/C4?>%T4EM?"-9LWQP24 _#LOMK!D 3^:&NY;J)&,H\)'><4]IJ8<3#
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M 6\[4@F#8F".,4*W2CS=1#M$C>!-34 1[67WQSKN>/DD(8?11^4D=U2.*6K
M$P+LR.J0L;)*<6R%C^U["\T(U?3%90RJXARPR#@@&>- %##G&,),YMRYB^-@
M<2;';)WG,7RG3MW5JXJ3?-\9BAIFP]<_S1XV@EXG;P(;Q+N#V6M/VEZED;:.
MUM".MJ7LEV@Z6TUK])RVH/9/'<;;MYP_/SXOS%KPOI45J7]>R"H[?2EN6\F1
M%T_Q9PSGFJ,5!92;]IA,0KV/I;FV2),X25".LY1M#R+L.-R7: /.)()O?,NZ
M8V_Z-[I7TF=:JK=IM6/L4:=J'.YNJ12U=;J)=EI5<]36ZR8ZBD^ZL8SP<N9Q
MWX#[9'1OLHW*[;X1/69Y[\\?6$%4HT'+AT_+)HI'/_KC?*F-2_USE02\*\]&
M%"\X21%0$,8 QAD%N! "9!+FDG"2I\@J0<YYY*E9WP?UW YKY2U72U#5RYMO
MM:H^>+75:UM"3Z_3CD7T[.?)CJ&#H!^8@AN9HT\'X.[$KBL,!*FEYXR6UQJA
MUH./6QO4%9.3FJ#.#QB<_?NE"7QO#@)82G)"4@$P9)FFLH0!II $><)8DJL,
MYLC*NW!QA,E15NT$^+)-"')..3T"L)MCO, 2>BM^A,CP;-PC:)QS;X=#-&ZF
M;?_+,R2K]KSV%CFT1S>.G3%[7NXS^;$7+@S@5:W^V!2=WZ?;09D(P7,"XBQ'
M>O=-."!0)2!&!9=$IHQ2I_-D=Q&F1H;=WM-=TIW^:_WKIDU*("?I^5DC6"J<
MYA1();%>H0H$,(<92$124%% '*/4S7L2:-Y&]9,<9B:/-1<>G-17?Q>A5T./
M':.W^I5Z$]1XMT?R5W>B/)J/^KP4T_%+=Z+DY(ON?M*P%>ZKK%PBO]#UYO6[
M?O=*LV,V752VVUO%%8(%)D#P+ 50F3H]L4KU+,F,,TXSJ)S6L[X!I[9Z-?)&
ME<!16V*;G>\PS.T8T">2@?GN.A"=6<L6&9\<U3OFJ(QDB\ Q_UC?-[ $,BT?
MS/^,-_6%+DR\UCZIQ_SA=BD.?]&ZLJ;"3TN^-G%?[V7]7_WOQ;-I)_WA#_Y@
MUDX37/%!*:F_(QZG:9JE".18,  +3@%)$0$TAQC'/,DDI;/-:D,7=MPUKOA.
M3+A3(J [4&ZB6D9C:52>0>,/K'Z0>ST=ZSJ/^T;8,>MTYSDP3QM5;NJ>*2V-
M#A(I[[;S?OR[@QMJ$*(M"M%/6QS^8J+:&BBB+195?%M4H^&Q_O6;S*+7XMKC
M:C!NY>XWF9V3LN!O(\7P)%4I#Y.]/L\IFR_FF]>?Z<9$I+Q6)3CV-4AP)C#F
MID&YU L?Q!P#*O5B*#.4,A8G$.+"+;W!68:I6?3?GA\?3=NME8H^/F_,2>+/
M\^7\\?FQ3J#<;K2=$R'<)\=N-0H,>> EI9;^3)KJ3H6;:*M$T (R5\#H.T_5
M58S14U0'XG0N.W7HHP8F;LQ?YD(N17E8&G.FMP$B9X(#+'@!8,(@H#16(,$(
M(PB+(E'Y@#3]"\,-\.2.D86_CT*N'>VBD3YZHJ_5=V>:D=2'3[?7UR3NFQ([
M\KL&X9&R-K82WO@OAVN)@M=<C M#C9MXT:WO299%S^7#N.0CG:^KNB.?ED_/
MF_)_/]/E9FX.?U_DN7::D*,B29(4H QJ2TOA&%!,I;:T5(;C F42.Z50N T_
M-2/K:[6OTR86+<OGQ^9$KVKYO%E%0FH1'DV3$E,N4VE%HQ>C:;O(IAO).,Z5
M'?>$FX' E&0$KVL@13_K-5>;N-7)4:U&M7DW?ZQ/G+Y+_K"<__-9AG'%#L/0
M)Z$Y2C JSPU#YYC^!CYE&"ON>NKM#Z.:2)R49PHQD8$LIWJ_B7*]U4PR!E*H
M%(H5D31Q.BFZ.-+4N*XYDC/,]J2?^6 VD<,[W5T&V(ZUO, VXOGWV2ZAM=P!
MTNM[T?%)/9<'&Y5E>G4^)I3^&P:&4YUOP+F?^'>O^TN:]Z(*=]@QW.W>FO@Z
M+__Q<2UE.ZEV5G"8*)P+H%BL]WEZEP5(SAG@L= [/0ZY$&YYK*$EGAJ7&1F!
MTD)&\^'I_.'GV3)&:$JS-_V0HI;9V-+[)C*:1T;UPX($'J.,QIHGKT%)P84>
M-X9IK#DX"7D:;>"!B]8S*Z7>'RTW'U[,L<!N$XD@$9BE!#"99@!"B  160(8
M5P6"J2 \=^KO>FF@J2T1>SFC6M#!@5 7H;6D=P^ A6;E(5BY\V</$%YI[])8
MX[)5C\8G)--W_>!4I]N^YG"XR 1!"0&*%LP<PPI &4P IBDU-$$5CQV3G_K&
MG!QC>#M4< &^FT0"P1F:3RR0')Y:U0NI<[*53VC'3;^Z$N(AN5FV8%ED:_4^
M:NS\+5O=SF1T6=\:R"E17C) &[_?Q]5:R;D))"D_+>N8H*ZN4+,\HW&2:[L1
M"J+M1I;$ ",L )&$J@R16&'BU4?A68&IK2YW)KELH3_-?X\:3:YHI?AF;X4G
MC\8;SO4$'!RE;=)4"X9]VM1-7XO'$3T>@>9Q5 >(;QVFY0\)-$/.[I%0<@Q<
M3>E"WJMJ=?ZB/^9[U<HBJ7O+SZ0B/"YX"C L,("*FG-"R0'4NR&5(ZQD+)S6
MO]XAI[9B&8FK6I&U+5D+Z>H[Z0?:<DGQ"E_H1< -.7=>M@;#*Y/VCSHN]UFC
M<,)6]G<.S" [UX3UR[/9!^AQ=U49[^A"6X3O7C]0_G!X[2S&'&484R"P0,;\
M3@#.,@IXS&4&I8HERUSHYVJ)IL9.M>Q5/8:Z:PFO1#>F5=4/^7>7FC;^YLV.
MS4:=C<!D=[$5^4VTGZ.]3M'=;IZ,6B=W><RL\@6RUV2IJX4:-__)%X8G*4W>
M'CRP-[5^APWW-T8($U*D69H A%)-MS(3 ".H0!$G,21$9(3G3GVH#QX_->XT
MTD5&O(%6W1%X=IPW')+ !.: AGL_Z+-*>^W]?#C"N'V>SVIWTM/Y_%4!:EW=
M;QY,';^DR%*,%( Y)P!"2@%59N>62Y+QA$BHG'J=] \YM>_[4BVKF^CI*+G&
M1%EO8]DCI==@KD6::U,JVJSG^O_5\[+*@39/F6\J)U68(DOUU%GN!;U.2.B]
MH$5U_TKFD<HA'> S6OFC>M3IE#LZ0,&IO-'AG<-(['[]@RZ;$LYWJV6Y6LP%
M;<H[_Z+'V!X?WJNF]"E=5(U8*D?:^UUMX7V*+LI$3&ENHM@1!#!%.6 0$\!B
MF:>\R(H\5BZ4YUO J1%D6[^* ]_1<EYM8MK:N=&;]TFU(\.WG*K U-E6K6J!
MLE>NFK2V>E6>_%;!:*]AM%<Q^BU(QG:H"?#)S=YE')7)0R%\S/O!QAFX2IB5
MYE:I^6*N!]FVJ]06+!0)DT 6T-0 304@4,]X2E5"<IXP(A(GJC\WRM3X>B>?
MB#Z8K+%71VH^BZ0EOUZ+3VB2-/)%>P$#9"-U0N"5ILX.-"[7=.EZ0AB=%P]L
MM23$W) ,7?Q"Y^+3\HX^S3=T,4,"RCC!$$A6Y  6! +,8PX8YBF6*(<Y<OKN
M+XPSN2]_)V;TI.4$54VW2E+'5D<78+4C 0]@!::!%DY&1!,N<M>#DWL[H6X4
MO'8'NC#4N,U^NO4]Z=W3<_G0TK<O<ODLRUFJ%,&94"!.DP) IC=ZK% 8"(:+
MG"JEBC1U*1.Y?;#3%S]" <?O9HQHW4CG6K.V <ONLQX"0>#O^&N?W@/*S!XJ
MZ;><;//LD<O&'FIT6A[VZ.]#7<V-;=^<555NH=L_YN4LAI J5B"04ZX )"@&
M#"()J$P50AB2/+-*EN@=:6JK\>ZLMXEL,3*Z1@1=1-76^>L!J[&.Q*U@&N#?
M[8' KUOWTF C>W-[=#YUXO;=\ ;%H6=Q6L2$YBDH3.4ER"4!F*$"*)CF$E$.
M,4QF3[6[>4/7&SO^N$HFE^_F6+* G]"EPLU-1]1W\L=\N32'*?HS>^KN)Q%@
M'J4L,!.( IIAO1N+]1320B" 9 Z5(#SC'#7S^&%IV8MEY%G<RO5V<Z@E>)O9
MLUMI1IN/T*N1GW+9$REY'20HZRJ!_CP%J2\&8WEYZ(#DY%_6\N/S4DC1Q'9M
M7;.QQ!!QF0"&I#1=91F@*-%6-H9<D9AIZ]L^&_G"(%.SK;68H)9S&Q-IN?GM
M1+*;ZGSA$YC!SD S)'WX$D8.^<(>L!HI07@09F[YP#U@="8 7[IWO(S?'ND/
M4GS[KAU8*;\I,CV7Y:Y*S/X8<2:*6&8IC %!)IB-%@G DBN0R#Q5L=*6)XY=
M''[=PTW3#=B2V;'0?3>V=A:@/\0"$^0^\L$8<5]62[7[14N'@]I9>ST\%J^W
MPLMKG?KN$<<M26^E_4GU>;N[!AXF<KY^EJ(UQMWS>JT7GQDOL$H%I  QK"TL
M1%- ><H!2D5,8OU_@D&GX\1+(TW-S&H$C>0?)DW5E58N VIYD.@#IM!'B0U"
M!\S1B.GQ,+$/":_'B1<'&_= L4_GDR/%WAL&-J"0:[U]JTLOZVU=98^6>I/W
MGU+\F"]_W'+]IVJX/1/M"\JQ)"\*RD":$JCW9@P!G$L,&*0YP4J).$M=F.,*
M6:;&+7M5HI8NU9K<:!/MU3F(3!Q8FNZ:>;0CK)%F)S"EA9P8]S89UT/JM97&
M%>*,VV[C>MQ.6G)X>.3 PV7^(,7S+@W]W6MU3%5U&9KE(BDRKLTRKH1F6*(D
M8#*3(,O3G!<T8Y2XE5ZZ/-;4&'0KZO[PE+U&]7%JW77+];2Y V;+\V8_X 4F
MN"MP<S]^[D?$ZP%TQW#C'D'WZWUR"&UQRS#^V#JBC&?>I$.7]\^;<D.K;+U6
M-Y6JU\8L+[(LEZ;+#XL)@$5: ((P!PHRJK>!I&#(:;/G,OC4&*;=:F9N!'0C
M%"?<[1@F%)J!*6?G5:[.#2O!HY;D-Z=-??Q1T!#(?'*2T_BCDM009(Y9:] S
MKMV(?IXOY:>-?"QG29)1DJ<2Q"C1YD_""6!([S<9IRGA*%$R<4IF/#/&U$BI
MM3_9>V[G>Y-TZ*YP#ZKK;F\05./MXGXS\D65@$%V9B?JA]EQ[8=YHYW4B9Z7
M=TBGEP[[Y*NF!_/'.J?Z;E5NRB^KS>W"S(XVBYJ2(D0P%:O,Y+8A!& ::XO%
MU"2/<Y$II5C*<Z<MD,V@4R.%1N9=M8!*[$C+'>T$'UB_Q6H*[!C#-["!*<0+
MILZ\X@*23Z*Q&G=4YG%!XIB*G.X=$(ST;D'Y/_2.3:M3UE5)3:G1RN;9/*S$
M-C0))2C.-3,IF@@ B>D?*$V0$J<2JZQ &%I5BK(?<FJ\5 D=-5)O>^ U<D>U
MX Y!.7:H=Y-1&"P#4Y$%C$."G.SP= AY\H[K2 %07^53G;-?5OU[*S7 %NY5
M#?=3 _=C#??O#W/^$,V;%L"F'-++K@/M2D5B;W^V;/._>HJF<L*Y,[;*[DGC
M15HY:780=^5VYP#.OWU</2\W=?B,%+\N]6VW/]:RVM_.",9Y3@RWIT3_7YZ8
MHH ( T2HH))E64;5[$6NV<J*[+O&<OE^VB,&C *HI&VVH_IK,.%OZXAN!79@
MI$Z,+8C=%VZ!^;P!;"MG5 D:W?H&S(&Y?0$W$F$/!="-9FU Z637S@>,1ZHV
M>AQPJ=4-0[?T?"UI*=_+^K^?EE5EC/LGN=;OS/+';5G*33F#BK(\)@(D19X"
M*/1^'C.-<0Z9H"*660[CV5+^,'5>;+?U-@-;O>ND?M?;PX=[U>NB+;22SG7K
M;@6U[>;=&WQC;=]K0:.?MB+_Q52ZJ.'<B1W==@,[8/_N@I/?';S5R"/OX5W0
M.-W%.]WMM4IL%5S;:A=>;GN*B%E:8)8S" '!E &8( 4HXP@(FD*,$HD3Z=;N
MPU6"J>WR+]60C9Z?](]RVW'(U-^O?EWOJ!S9S'V>[(@M*/J!.:ZK8&REP$T3
MX='HL.O^=-GKXJN";#]^(Q24[1!B"O5E^S&R+#=K\:#![6#?][70+!#+L( 9
M@*B@ &8D 91B!&)<B!2E@J?8*LC78<RI$6#38?.]UW:PO<!;[(?]PQF:T2R0
M'-X.MA=2YW:P/J$=MQWLL)=U2!=86XPLNL#V/FKL+K"VNIWI FM]ZS"[]M?E
ML[;*%O?K3TNUKCN%FR/Y.IXUD1DN2$X I-)T;#5]#R")0<%SE4##Z!EW,6&[
M!IL:63>RFBY">VFK^) ;\[MWJ\W#L #B3L3MC%%?. 9F:1\0.AN:-MCXM"D[
MQQO5?+31_-A2M+IG8*:HZ<7Y7=];E6+C/!4TEAQ@@:EI>1D#PG%J^"3AA<J9
M0,PI.[3]]*EQ1R5<9*0;5-#N$#D[2AB,1^@S#&LHW/,]SZGL-<?S8(!Q\SK/
MZ7:2RWGVHD#=X"]UVS5U>S:OK62GROGV_8$NFTWF%V._E!MYW'WW/TQ$\'NZ
MD;LD]:^KQ>+C:FV>.LM4D= $$Y C$Q2CJ.:+5#*0Z%TD@T@@19QR0B>FW]08
M:RL[V#8 KZ2/C/CM$@^_R/6__DM2Q'^KL/+<67[D-\S2[S<MJ2?$[#9]Z7O:
MTM<8'230U@<OF__;W;7MN(TCT??Y"CW. ,U=74B1W(<!DG0&")!-@DS/ (M]
M,'A-C.VV LN=I.?KEY2L2_M*RI2L#!!TW U+574H'1:+Q2H#4]>TOD7J0*/Z
MP\_I&(=L9_HD3-K9?F(3Y]7X_CKCNQ?;G:F:@R/'K\]%VQ3+E%DBI$!!EAI7
M0#-;%AL#H3*MS*<8::?,?0^9<YN>:ZWKJ?=UT/#Q6?2=P\<A,9TF?'P2R>'A
MX[.0>H>/0T([;?AXV,,Z)'SLBI%#^/CLK:8.'[O:=B!\['SIW):-?U93T9M5
MO759U>YKYY]%$D.90DY 1I$ D,H,4&G6B3S/2,802C'*YK$Z/&7&W&:9K3O>
MRT2/BLX=+QIWO'82;);4EVT2@;:>MTULG\V2\.33<^V57ZAGXF^SP/NS?:*:
MM)1N+?<C+.!<!O3'6*>=M.1OLAQS&:WI5EU.VOA-SN5ZL_@W^[Y\>'QH6GRF
MYDG"F5D],;..@H0E@,703)J9%E E'$NE7.;+O3O/;0K;*N<V#>WC='IFN,CZ
MD<EZJU? @MQ'K3W!9.::'HN9WW89;/^FDY#*45N:]_SX%X;YQ<]=[;K/^XO'
MS>=BO?Q+R86*89IIC(!4PKR/*8& 9'D&I" JYYID:>R56'%:W-Q>TFX96"7Z
MWD1EI7#$6HVCGXTO4/_U%S^7\@SP"/$8DR0'5$!D@&<(,($I,*!+33DF6$JW
M WCAH9_F%%ZM8215N?RTJOH?CX6UFYL=#K^1&78G>'$3;9'LE WGJKJ!$M*E
M/"-Q4M?/S?I=%\WQJ@OB'/R\_\>]_;\7GSZMJQ-B;U:;M5EZ+T7E^K7!^ 5E
MJ<)QG@*-$ $PT3$@5&1 ))Q0*#41F5>;YNN9,K=YR#'>P1JSS#>W=M7!CIMH
MU9@V(.YQG:?)(_8Q^V?D;Q/_:$&)6E2:@SGOSCYAP^(@5QW<X+&0ZU@S?3SD
MJJ-V,"9R78V"YKSW2G+?J>^;EP;]_RTH4L),L!307.6VO:IYTR41@.<H36.9
M*I1XY:%YR)[;=/GJ_9]O;D%"@Z2['P3;;7(:"<*19Y/CR?!EFPU_\ZQ1@+4B
MJLP8/SW^%'@39,L?%#^'Y/E3N#CFTI^\Q3 "^Z@V;+E2\C5;VX;%3==!%&O-
M="S,(@%R 'G" $_S&-!,,H@X)AIZ<=5A,7.CI1="/#X\WE>AC%NEEV+I68#[
M")IN9'0Y1B/S3J-@U&@8,$3L!D)(_C@B:5*J.&WM+BN<^7:X\'*OI/8BUPCR
M6%" 8EML3*<:4$P3@ G&J22:<"4N#W/V),XVSEET.H8-=#Z#F^H,QIDT#ZQ$
M -H.PU0F".18:A*G6F?YQ>'\@6!?,YX_"?;#H\P#$;U2F+FG[;AQY@.PC!UH
M[HN\>J3Y@/TNH>9#EPTC]W;[_^53KS?"2U8NR^I 8&RXG>0" <6@!#"%]A0E
MB0&669(+S+DB7H6%SLB;&]OTFX!42@XZ8WD.9#=:"0C=V/D!OJAY<XDC%B&Y
MY)S(2;G$T?Y=+G&][$(NJ8N@O5CU.W]NY<GWJX]*/*YMH2#SA7?%:MW\6JGQ
MMFWY(2'3!.D4Y'%B5YEY BC!9F08A J15% 1#V*>$-K-C:=^:Y-BHX=N8#W+
MF84=/T]2FWI41J; +J?T9EO/L6HTU3.N:3 EHV(5M?8U'=!;"QL"?3M&QYA1
MT!^%=(,H>!V*#HGM44(/*F1@VL+RTVJIEX*M-B^$L-5Z;3&XXGXIC"Y=W#U)
M<D1C)H!.;1G=)&. YI"!C#"2:"%B KWZ8[F)G1MA__[X\,#63U7#R\Z J+,@
M:DSPW.UW&P3'G?G@T(Z]BWX:RI&V.?Q@"KH?[29YVKUC+S3V]GG]KA[&5._4
MYA4K/W]8%U^74LF73W^4-BO^3;7C^ZQQ\H(E.%4"2R!DQ@',*0=4X@0H!!FF
M,(,I18N-3:1W8RMWT5Z,U2HPWKME-(^$4;WN+K)<F7];G2/6*NU'5A[CX$98
MXZ [,FE98*W64:.VS?/Y^8\:Y5^B5OE>C_=PW.6/6$C^\I ^*8?YH[++8P/N
M,/&AV";]1<JE_<#NNZWCLJEHLD@8U'F2$H ),8OP.-: ("B U#%E&&*L4_]\
MT+&TG9V/=WE.7Y>UUQK>2]OP]0U'?50<7<JY/ !C>Z*CC_V\Z@[Y#,\L3J<Z
M*?QC'$+UP3[865,OH0.G-O%9R<=[]5Z?U;(\IF9=Z5:)3"A;X$\G) 502 $H
M-C^8R@E**5<(^<4<0FDVNREK:U@5EW"@L/(DAPVK61QNV!VGI&L,YMC3S[3C
MZ#_/A,8\Z)P23+EIYX_0F.[-%<$%3'P^;CMG];(G=JK/?52V"[/Y^ZMB5<U@
MC^S^3JT?T@52C(I,QD!#KFS?Y!P0:.:21%$D%)92,#S)P;CA-LQMKFD: /4R
MMVZB;TW-3;:MN2DZ*Z+[I1Y2]&?B1\5C(33?!^ '6AZ][S\_>S5;6S2B'AR1
MQ6,&A]PN'\M9G&Z[P(P?XUC;Y>,4[#Q; %6&S;IO55D67:/#M[;[X5:Q\JYX
M:>0*M?RJY)UY)-5_%%N7"YQ+G?.8 X:I!E!I!KB *5"$80Z10!0E3<?4._>Y
MTU\3)^9[WD+U;H(9T+R'F=]\-F 0W*:CD3"=9C:IE;_IM5"M]+]IIXQ-$7$[
M%=0VW$36@*@R)=PD,!S!D!P^0(M)*7@X2KL,>L&=1MII.;KHZ7IGK.0'\^2^
M,\_R;6%I>I%F#+,DAH"@V*PK%,\!340,*!.:QDPB'#O5FQY3R;DM'/IM7FH-
M?2-,8XQDH/V/D<=G9";V&9KPFQ,78#?IGL00/>>U%7$!TMX[$)?(\F-ZJ9:+
MVVW)\CLCOZRV-CZJ+\5ZLQ YEUENJR+9@DB0H0SP-.5 YR0GMH,0Y$YEH$\)
MF1O3-GI&G:)1K:D;X9X$]#1AAH)I9,(;@) S[[E T/%6V1!7J<0_/A5?_VDN
M-S@DU'X ]D./JD[>>A*J<3&NH0JG[UXG?6;;U=I&M7?6X4V_ZP_KI5 +E:50
M)-0X=C*U':E3 EB<QT IE6F4"(X1FS*1QE'ON1%23^V(F77=9Q6IE;2[7/9C
M72*^.O[[Q^^W]M?Z&+#G*>"IGHEI,F9&&.D?*#C<L_Y <+A!(*H@F$\:C>>8
MS2FAQE7U>?FS8<<C=)*-K_B!6?'%1I5&NA7SZG&]-DHL>*XXPGD."&/&Z56(
M AZ+!"!)(<59EK'<J9;["1ESFV*LBM&76D7/=/8# +IQ_(6PC,S'E7;15KV;
M:*M@P!STX]8'338_(&;:K/+C=NZECY_XZM J/H7QAS9/=J&\,0MF6Q?QBR6:
M0[7QN$H8XGD"B,;VC)[$@-H*7S#)8@$)U(1YO?8^PN?&!XWNU<G<5G'?NC(>
MX+M1QEB0CLPEC=HW4:7X<U#'KT@X!+6P!6D\Y$]<G<8?F?U2-0/N,93.EE_9
M1AE)HO*@FFZ'"6=<DAAHEA, D<WQ)4*"&*,DPU"Q&"$_XCHD9GX456D9M6KZ
MLM-!+%UYZ%*$1F><'7!&J$EX&H2P!')0TL14<<K:?5(X^>T!K7S?%>NO2[8J
MML^IP(B+1! @=,P!E,BV9N02P$PQ!;66&8/.+7N?WWMN+_H[56OGT29V!ZS3
M+_6%$(R^#JD5&](M=P<&CZZXP^&8J/MM\U $Y+43AI]L:;MSR72M:P_K^JQ%
M[9&O#',_WJ\_L=7RKVID7Q6KLKA?RCJHLY(?S. VH_Y>_[9<L958LOO?S5_J
M_<SVR*002!N2R@&,S5H+QDD&&$48(*VYRG*&A?;R5H)H-3?.ZQMU$STSJUH]
M] VS&P&M:5%GF\M9R1''V<V3FGST1J;KJ0;.VUL+"G1(YRZ,8I/Z@D&QW'4=
MP]Y\&-.W:]C&<\!<&Z<2 HU2;%:866(X&QOG$YLQQ3QFAKA].'OG_G-C7W/[
M8FW?IZ=(#8M][0+H1H87P#(RK771JO#KR"-6A^2871&3LL41^W;?^V-?&WAP
MH:N(MPVEMQ,SP0R*A!C?B[(40"X@(#HF(,^QP!P2P:G7N?#CHN;V7F_5B^X[
MC?_E>13A.*QNKW@8L$9^VWM*MCM?HS@EY]$(>DS@N+1ICP.<M7HO[?_\%4&+
MPFT]BW[%)GNP:KEZ-'_;GCZP=3":9Y]3)$6:&O] :\,KN=: *"P!(Y!HFJ1,
M$B]*":/6W.BG5;]7.\Z3?P*-EQM733\*8\?23A>=Z\:GLZQ:PVUMBSKC1F'#
ML'A/4++.5[,YE+,;B*9CJ;NA=Q_:I:Q4YJ+/9F5XJ[ZJ^Z+R'U]_M]E6ZO5W
M<?\H*U6,9[FVVAEMA2J-1N5F@7E"H,IBD&.: >/UV26=XB!'9HV7$JTSY97M
M<($N<^/IQI0J8",[8WR;G@T?'#=^G@CRD4GY&=H].Z*M(='/K2E18XNMQ+JU
M)K+F',]U'M!I[6)0P[9C&Z[.Q#W;+L9MO[';Y;>\L*E'KV%(V=:3W\9T5)[1
M6. <*&UH%"88 QI3NX[60F.:HSSVVLAP$3H_JFPZ-G!;57]@ZXU3*+M186CL
M1N:\?J.,#L+PH34?6$;I8'%*[G4:4S@@<;3?A,NU T]DV39G;\KR4<G;1WO7
M#]6IGDIJU;M[H6BF"*,<R!09?RU)&&"<)D!QI:#.4D*D5PC^K,2Y48W5U?C6
M574_43P\%*NF&>*7Y]T1*T?B&[,'#39EI(MU)(Q*2\'NH\W:[K3IQ[ICHKW+
M<N/OV9T?+#?2"CH$(S-6I6M4*QO5VD:UNC<-D54J!SQ.Y(I.T(- 9X5.>X3'
M%8.]PS?.%PZ-&W[K=:I8%ROSL<YT*ZN^%4_USRZ_&T(9(Z(D8$JF "KC)_$8
M&R*C:18SE,%<.>6K#55@;FQF"[6L-O=/T0M9?*E.Y_4ZM_3-\8T/>HZ+:R1P
M/+1'C_E].XIM>5-WR7F*_KO]?Y3\^Z'HA8W@>>HP<:QN&$+[4;F!]QGJM6WS
M+GJY&!^*^J!^E^_&.1*IM.GX'-HRW,PP'TP!-RX<0HAAX\_Y.6[GA<Z-[5J=
MGZ<\-6H/SE1S&@!79RPLK*/[8Q<C.L C<X<HK%/F('=BO\P=B7W7S./:8[S4
M']2WYM.O/S5_,3]L<8!??_H_4$L#!!0    ( !" 95&(B&+?D'P  *W.!0 5
M    8W)D9BTR,#(P,#DS,%]P<F4N>&ULY+U9DUQ);B;ZKE]1M^?UHLOW129I
M+(M+BS9L)D6RU*/[$N8+G(SI9 0[(I)5U*^_\,A]C^5X',\:62LKF1EY#I;/
MX0 <#OS+__S]Z\E/WW&QG,YG__HG_F?VIY]PEN9Y.OO\KW_Z]=-K<'_ZG__V
M3__T+_\/P/_^Y</;GU[.T^E7G*U^>K' L,+\TV_3U9>?_I9Q^?>?RF+^]:>_
MS1=_GWX/ /^V_J,7\V\_%M//7U8_"2;8[=\N_MEY'X*T 9P7 I16 8)7&0HO
MAM%?R*##__OYGYD7Z((PX (&4,5+""D'D!&US5')G,X>>C*=_?V?ZY<8EO@3
M,3=;KO_YKW_ZLEI]^^>??_[MM]_^_'M<G/QYOOC\LV!,_GSQZ3^=?_SW.Y__
M3:X_S;WW/Z]_>_G1Y?2^#])C^<__^Z]O/Z8O^#7 =+9<A5FJ+UA._WFY_N';
M>0JKM<R?I.NG!S]1_P47'X/Z(^ ")/_S[\O\IW_[IY]^.A/'8GZ"'[#\5/_[
MZX<W-UZ9PB)/2YF3SD_FGW_\.<V__EP_]_.+.:'B??A<J5X_9?7C&_[KGY;3
MK]].+G_V98'E7_^4%KE 52_SDM5W_X^K/_[YBHQO"UP2<M9LOZ4?G#^COFTO
MDO#W%<XRGG%\\;*3>;KQH9,J[_GBXB]/0L23]4\G&:>3]9./XG*U"&DU<4Q:
M)V6!H#D')3('SXN'G+1,B3.6LK@I@4K]DLA?JV>)Z<^?Y]]_I@>3FKBOWT#]
M!A@_5\[_N//2,T'M1OW%FOQ$GYVD$HQ4A0/FXD#Q@!!"2F""Y\9GGZ)U Q!_
M_9TW:;^NYJ-%^FF^R+@@TW+QTK!(=U1^$];GG_CY6UC0@R!]F9[DB[^N-F8(
MO:WF \CO3#E$[I]^(JX++A:8WY[IYD'FUIRMR.#B^I-#Z/T_3L."GGCRXP-^
MFR]6$\4$=S;1FHS.@$+K( I; )5*+*FL.,8!(7#K]1NA0?2/AGVDV@DP/BW"
M;#FMHC_G(6I$&PP#*WP&%4LDZ9@ S(A<4I*.<SZD<;CU_HV@(?N'QEYR[00;
M[W$QG>=7L_R2W+A)24KHXBQH5R0H&17XS!RP*@U-3AJ*(7>-&R_?"!6J?U3L
M+M&1(?%JMIJN?KR>GN"[TZ\1%Y,HA/$L(V1R><G4:0?>) 6&6\Y3L3F+,  :
M;K]W(R#H?H&PEQR[P, '_#RM0IBMWH6O."$/R+E,2LO.D"_$:-^+D1<HMI W
MY*0V90A'XKYW;X0%TSL6]I!G%WAX0S'8@G:XM> _DOSQQ?QTMEK\>#'/.%%>
M6H^.0T'-0.5(07D1#(R1):-D1J?AS,2CI&R$%ML[6H:3=A?@^11^?Y-)?-,R
M/<MUG%M%2=:0*Q5!"A?(*J8,P0H'FOQH[YSUT9K!8/, $1L!QO4.F"$DW 54
MCG(F%2S/__-V.D,^D4H':3-!785(>)=D+)W3$!*RS*3T9$T'@\D]!&P$$=\[
M1/:5;$_P>$'?'B\^S7^;36*2,1HE@$>6".$Y0!"^)I!+0J,9LCC<UG/G]9LE
MO-@SP<:.8NT)&>O-\GCQ?C'_/ITEG&BIBE9H(&.@>%QE#=Z+7/WP'%'1?LGR
MT/"X1<-F&.DX*SJ8@'L"ROOY<A5._K_IM[5+E44TN2@&01'2E<,(3L0 (L7$
MBQ0\A.$\D?LHV PD'2=+!Q+NR!"I%O!H@6%--]/,NJ \"&&1+%]TX+1 L,EC
MMBPDQX?86JZ_<S,8=)P8W5F (RN^GL*>O/\RGUUD;"C$(MQ*XIAB+5#)2/"L
M9(B*@G.E)<I!+,+M]VX&@(YSH'L)<F00?,1TNB  <Q$_35<GM+GES&V(!H)4
M!HA@\H(<=R"]MUIJSQW* 4!P^[V;@:#C_.=>@AP9!)\6H=:\?/SQ-<Y/)E)(
M9-8:,!E) E%9B-PG0F_VUGJG<QRB N#&2S=3?\<IS]U%V(6'^.)T4>5T=J)7
M^2#AGRXGI2AG?<W<JU1 &6TI3O8<"E>%<XS,*3^8CW@_#9LAH_OTY@ "[@(H
M;V;T-!+']#N^#*MPSM:$>1E-Y *L+PQ4(8OG,"B*D*P1V5G#< B;\1@-FP&E
M^[3F  +N BCU)'#Q@@+GS_/%CPEJKZ2G4,C$(D %8B0PG4B]1J><, D[G"&Y
M\>K-8-%]*G-W<7:!AH]?P\G)+Z?+Z8Q"Y8DNZ*RT$LRZH-4F2V!.Q(TQ0:#6
M7 ^(AANOWJP^J_ODY>[B[ (-K[[BXC-M@G]9S'];?7DQ__HMS'Y,HF'1UKK#
M$,E-5H8")F^\!!U""BIX+CT.AHI[2=@,'=VG+?<7;Q<H^?@%3TXNJ-<I)611
M0@S5H]9*$1_6 ?>>:XJMBXUV.)-Q[<V;8:+[+.7.PNP""D3XUUH5,$]___B%
MY+8\/EW5:P4UY)H$E,:Y'$'+6K2L+0$[*0<B*C)^'FNAP'!!RB.4; :5CC.9
M PN[#^B0Y!;AY,TLX^__"W]0:*XM8D:(7I'KI+#09EG_61.W)AEIPA!5P/>^
M?#. =)SIW%^D(V/BZ"O.<JU7?7T2/D\8%YPG8Z"@2;4DK8(Y,1)#DE*XQ(4>
MPG+<>.EF&.@XT;F[",<^Z#H+I5]/ERF<_!>&Q46ULBXR!2$5^<_6DR1"! JH
M+03%9,Z9_*6B!X#!0^_?#!$=YSX'$6PG-P.NF'A-/UE.<BY!!D[XMI*!2DC^
M,WI-MLUX9YB/;-#K1+=>OQDT.DY^#B'6KI!Q=L_AC FNN,G$/#$A"J@@+?B:
MBI'UL"]IYI(:XJCL00(V0T?'&<]A1#L8/O[EYSN"?$L_V/<N\?&[EZ_>?7SU
M\I>CMT?O7KSZ^.^O7GWZ>)/X#2\6W_^D06\9;T#LGE>.3Y?P.81ODW555=7^
M<7D]G859FA($YF<WRRZ1)9)TQB0+,F1#.# "8LU]:S(?W*/55MZ3$[I8824L
MXUKGY^_\N8KS9SQ9+2]^LA;PM?6V#7&[&I6+=QPME[A:7K+*:%-DVD5 5[UH
M2SMF$%&#*Y(;[POW[)[2F_U9O4G&.->9FV'BPMH,(/,1MZ&;U)^[6Y=,F(C2
MYJ"AY$![J:^' =H+2+$X%4K11JEVP+E%S;CXV4>]]R)E'UEW )@78?GE:);K
M?U[]XW3Z/9P0,\NCU8NP6/R8SC[_9S@Y)3<]^"QCC=JC):8T.6/.&P2?"X^H
MA,WYGI3(_@#:B+H> +47"N:M5=(!SHY2JI>UEA\P(;$43_ =KBZ/KK5$K@L#
MJXTD:>5 7!5!JU +KIG5SI0F]ND1HL;IT] .58,IH ,PO5_@MS#-KW[_AK,E
M7C#AG.%2105<96(B,P;>V 0FQN"#E-SI)I[@O=2,T\NA'7SV%WD'N+DA%K*@
M,2%)!$1B"*H4!)<E@QRER9)34"7N2=P,[!6-T]VAH9G96<2[XV.^"B<#V97Y
M-URL?KP_"22.6:[;[[<:;)"IG A,6=:;/.L\ADHJ0#32$U<\,RNX,JZ)#_08
M43UL4H/XTH-)O@,K<TR<A%K!^1;#$C_4[G['Y=<EKL4UL28%P:.!Y.KB4D9#
MK.T."M.)B\AI>:06,'J4JAYVJT%P-)SL>P#2Z@LNSH3S;CY+%WMN$"586@@H
M7;T_)!7$O*[S%*G(Y*7R38+Y>ZGI8?L:!CA[R[H#P)S1/[&YI(Q6@PV>@Y($
M\V"% )UL\=8P%?D]Q9-#.3;CM"EJEM_92IH=^#!OIR%.3Z:K*2YI'UW7Z'R9
MGY#0EW5/7?VX\O),*KX4"PI9 "6J;^8<AZ1RU-P$Y6T3?V93 L?U;9KGF9OH
MJ0,;=(VOVW&%THF91$Q89FVUI@%<H.6D<DX48 1+MK8QXKK*1;>!P,,XVT<?
M'2#K(H/U/ORHZ:O+W)5$$9G38*PE$R\Y!^_)J1.!@H:4 A;3).US/SG=(&HO
M93^0.]Q#\GW@9W%*;[TCHXEC64E)UCL5<NX4*@_19T>+S$?MLU#W7F(<!$+W
M4S3NWM<.10/(OP,@O9NO\/9:<%Z07'@ [16QD!*9:&4+\,R-9DY%'9H<8=Q#
MR[C!?"/P["OS#F!S,S=Q(:>+>[^3& 6S@:2#7- F[\F/C#IID#:Y*$H=\=#$
M'W^<K'$#_$9@&E 3'>#J'H.JF=?1)P[&"5OK[04X3<M#%T^V5C)34I.CC1UW
MLF;9@$;XV5/B'60)7N)B^CW4*^37>+F6^ I<26LXT6_J$BA*@)<N@^7<RL21
MPH][;NOO#Z GZ.K&+VH7KPVIF9V!]AT7<=YVV[O&4C+"8/7W)(]("] AL:1I
M*>60L\!L,3>)X)ZDK!M/JAW<AM5.![OA.I'_P-()@M,K(Q2U-ODQ@0^1H@Z1
M/;&(&GF37?%ADKKQKAH";!A]=("L:TQ,M/'>%4ZT.M*W,EJ"5TZ (5,<%"9A
M9)-2[&LT=.-9'21WN97$.W"PZA7IZ>KKNG)SEE_,9]7&XBRM6?'.!)8+E%PO
MPYBHP!F3(47%$[.Q6'Y/^]T!JFD?IFF<>1('!=-0&NG"J7I$1F0WR4/,!JRO
M^[50&D+QH:9&6"Q>"<^;N.Y[GN0-?D7QH. :2!\=['+O+]Z[9NFLUKP8=,C)
M]GK.%<4<Q@'Y?@B26<\P(87+][1]':2R]C8M8]\^&D;-=XMK]Y)Y%R;I6E.0
M,PYJHQ@G<H8B?2TC=0X<SPJD=ZAU5A2N-MOFKA,R=B%!$\CL)>TN\'*4\[J:
M(IR\#]/\9O8B?)N2]S5)3KFL"/,Z"@DJ! M11 8Z.5<\3[JT@<T#](R; VB$
MGB%D/^)>52\^3S[BXOLTX>+R/LO$1)&\1@W91$_Q)#EPT<L"V2%3/*KDY:W;
M]G=O4-__Z''C](%!,(#TMM>]/]/]##_7L>B?!G-7/N J3&>87X7%C/SYY5%*
MIU]/3^I+7F*9INEJDDFWL40#DN +U1!"3+).!A-!R,AT:N.]/$W:N"%\(]LR
ML$8Z<(GO"FK"DK0VE7KJ7&K?&I7!^Q* *<E1FB3"?4U?6@19XT;NC3"TI\0[
MR/\\%75.C'?9D" @<4=,29DAR!R!,><-+8NB2Q.K]!1AXXS^&RNMN+]N!L/:
M(7O+O%\KXPNNIHD\W!N<[--HYN9CVW>=>82-0[:@L1B2SYE"=<8(D$4H"MJS
M!3)9RFNO32S/M@7-S=3$6;?/H]/5E_EB^M^8)U%XK50RP&2)9)H]!U?(<R1?
M,7GC&6_46>1QLL9.$@V,F<?317OII /OZEHF@];S\6(MOKQ.:KS'Q9J["2M)
MHB;Q6*SWB)E$B-(7P*08!:DN2VRR66Y V]C9I<98&UH[?0'NSMK)]1Q1. 06
MD79^&\BMT,9!=,PEBH$YDTUNYSY"T]@)J,,!;"]M] BL-\OE:66#%8V)9U)^
M*>2PV@3!<@XE<9L2.FE\D^L%#] S=C+KT(#:00L]@NEFCW7F8ZE%6)@3R4<;
M\(*V^.!(,%PF4VR3,]Z]>]LW3&8=&E:[ZN.Y-".E;SX>OWWS\NC3JY<?/]'7
MO[YZ]^GC\>OC]Z\^''UZ0[_=*W#<X/%- LAMV1HHD'Q#%'W%2Y1>0C(K;7T=
M[Y8RZCIH@\!)< %3IP$F3XC-30K)'J!G_U3I^0,_K<\4=$Q%U$,$K3R%(HI+
MB)D'(L:+@!PY;W/'_"89XX:#0VC^;GYT9S%WL+5=4O_B)"R7QV5M5(]^GRXG
MCAP[4[LX<U025 P2@I"<OO@4158JM*D$?Y"B3C().ZCY(<3L)?,.P'.=_I?S
MKV$ZFW"C4*)WX&W.H$2D;;V>7^>"@B>KN"EMNI/>(:43N.RGX]N.SWX"[Z!,
MH%[3>C&??<?%:DKKZ&;Z[*^X'LBM*=",L4CPF@(#I80!)[($KE,)F+2,S#[E
MVVSQOG&!LJ]*YVWEVP=D7C[%4LZEV"PC1)]H ^?6@S<A0RPQ<$9^OXIQ"\@\
M];YQ$XW#0V90^?8!F5=/L>1=*IX) 37@!-K%*41DG ,K426!"B-/6T#FJ?>-
MFSH<'C*#RK<#7^9RPZ:0%M_0M\L)+\GF(A7($$V-"C@XK15$[8I@#@D*31+0
M=TGIY&!C0-=W-REW@),/^!UGIWC5UHZ'A&3_!(A4Y_DR3Z8Q6 G&\V!%XMGE
M)N5'MPGIQ-_=4;%W"M?VD'(_*'E-<JJWFRH+?YNNOKPX7:[F7W'QZO=T<EJS
ME;6O(?TO?PJ_3X0-*KDJ*A\MJ%Q%91GMML5ZS.L3XR9M:W:@=5RL[0>.^Y'6
M3%/]@/'=?/40EQ.C%'KI#6CF!*@4!#B6#10FT?'((O?WS-8<#'N/D#;NUM<"
M:D/IH1]D+2>1:*,%82'$1"O"(MEZCQJ2L[H4S[7C35+G%P2,ZUVW0,EV,NV@
MRO:R>\7Y7(HK:9C@R.>/!6((Y# &%2"@3F"S<8YA#MFVZ9+]$$6=N-/#N$K#
MR+T+8[)$(J#.6WI):^!DOAXZ<,[5U3Z<_G$Z)>+>S-XOYHFVY!?SY6H2DC<I
M10I"#"*H6 <;<Y] HRG)9(=)WS,4> C[LS/-X_I0 Z'FCNTZC H[0.M'/*%?
M??X+SDB0)\3P4?XZG4VK$&O#J'.>)UPY;RD\!JLS<<53!*^*@N2]+T(9;6.3
MC7$S\L8UA&TPV$ Q'<#MCJPFFB4I,V<@$3/Y&!8AHBU LA/2,Y31M>W4=4')
MN+Y7&Q#M)^Z>O+&SDH>W\^5RPC"8*+,&S26O8YIEG>WNP+.H"BJ'M"":(N:*
MEDX*:0?VP':4=0=P>3,C4X7+U1D'EPQ-&&W&60D)VA>RDI8'D@BGD$39D'AR
MQ;:YK_L /9V4RPX#FR%DWL'.].ML@>&DUHC_)4QG%?S'LZO&F<N)+$$EX1(9
M7U_G68I$BR!'^F=4O!CA'6^R3SU!5R<ELL- :4@== "I=9_"=_/9_*9AO7#=
M$-$I8R60R')M%ZQIB_<>8BE6:)>E\VT\GT?)&OOR][!;VG :Z !/[W!U;6LV
M2BD"/H=B:JMZ$R,X)".;-='MI.0L-('/#2K&[<,V,%IVEV\'KL_-XH67T^_3
MC+.\O%4J_.;KMW4C!96=M4*!LXZ GST)R#@.G%A.FG$;6).&2-L0.6[7@(&A
MU4P[^[;-V;].Z242[?F"I0^X;LOR:?X+SM:M6<+)687-DA3W&L/J=(''Y:8X
M)DE:%XNOW1"$ *6B!E^$ :$$NE*"4;=-V0,U3/O3LA'J?.>H&T,O_?1ONF'&
MC[Z'Z4FM]_DTOW;=ZKPWQR]A.4T3G5E6CF? 4&=.:?('0M$1$IILN0PN^B;Y
MA"WIW"S1SCJ'YB&4U,%N?-&IZN)"^YJ)>IPP/3DEL$]TL=$'4=O!H*SM8.H0
M4>.!1^*R>,OIERTP]P1=FV'LN51?#:F$#MS_OV&=/8WYB*QV^(SO3FM]ZG%9
MLW;MYNAM+C%G[5318+@+)$&W+I/7("(F:4(QC7R]W<C=#('/Y5#[ "I[+G=_
M+R_&'K_^^.GXQ?_Z]^.W+U]]^/CJ/WY]\^F_;C*SY;7?QY_<Y,;O%LP,WS7J
MD19FS&=4AGD0V3%0J!DX"B7 "Z7)J$7O;)/ZMXVH&_@B<);,<N44^0&2K'>V
M%"^A=A"8]BP76I5MMM">+@(/CXHGK@5O(_0.MLQ+ZL\D0L[EM_D,Z[B&>H51
M."%CM@E\E Z4DW4HG]? #2)/6@CKVA0U/$95)X#:0=T/(6=OV7< I%L\G-\]
MRM9:ARJ#M'S==)9!M!0D&V]R[7N<LVIR2_A>:CH!SO[:ONW%[RWZ#O!S[]6R
MI(CN0@+1.M12L<3 .TGNI704@*B4>&ZR@_5W>W@ '3^:<-U!X!V YEHNY)R!
MJ-!H@[23:Y%!>6_!A9P@<RU,"K&$-E?Y[E R;L7=\'#93]0=8.6!\0OGS' N
M=,HUM9$*>8"28BG/K"%-1U?0:U7,(0=@]'"5>'@,#:>"#JZ>UTD.'RXG.9SS
M$'C1I3@#TI.(% H',3,-V:/C.A3%RE;3,&Z_8-RZJ.$0,9@0.S LMV<OG'-1
M4C31:(2@N*BE.'6$:STGISTV*)FX-(UN2MU'SKA54,.;D@&$W@%T'FX>5%C*
M0;(":#7)!E6"Z*P#)K22'@4SV;5 SWY-N0[5F6"0J'LOF7< GGM:?11F+/>$
M_))-J//(Z@P%[@"5RSK68:YM+N ]GZ9<6^GXZ:9<VPB\ Y]EDPY GL*_G)P$
M64RIMRDB.%T"("/N0FT6([9IRC5(AZ5#-N7:2J4[=%C:1KY]0.;)#D#*Q>0U
M<4/[N*Y=GA5$83B$7.I:8US=[B#9OL/2(9MR[0F90>7;!V2>;$V71"SQ[.Z#
M][2#*PV1?#X0DJ/EP?MXNP=*^]9_AVS*M2=D!I5O![[,/54%3KA,[KH QXVK
M]S81G*P-S I/10KO2I9-/>"W6S7E:G^';4#7=S<I=X"3-[.TP+#$EWCVWS>S
MNZ>Z'^8G)Z_GB]_"(D]$O?G+1( 4Z@ [HR@>-$C+# UR'IQ)I8E#O"6=G7C+
M.\+BSG6W=CKJ ((WYEMHD40)D8-WY,>I6!B0$Q>A.!]*\8$KUF8DY;:C15IV
M6F^G[=OV:U?1[PR;;[3;SFEC#8O50/O<G;F'PA8CHS7@5(T'..W9L61.2RT4
M%;U(4=LV^]Q.4RB;^=4'!=)^:N@&3D?Y_YPN5]5T+S_-'SA=62^:2 +--?^*
ML^5:HQ^0V%Y.5WB>A'^_INP#IOGGV?HI9P/NT67F1!: (B82<BU+,$R"#X@J
M10IE>9-6A:T9&]>E.R34NX+(Z,%I.,'S..SL//MHEO\6%HM TGF'J[/]9<+(
MN4E:"["ACCYF,8!'31A5266R!-;S6T[C0['I)J\;]TCO$%!L)/J.P+1>"?>Q
M-<FZ9)?(2T&F:T%-X1!\5)"Y"TDHPS-NF$W=X&WC'O*- :5A!#\ZDBHK9V[M
MR]/%=/;YS-2>K8D+IE[]CHLT)1L]<28ZBLW(V.HL02EF(29%L9J.4BB9O+,;
M%AEL]=YQ^QX<#EWME-$ISM:+Z"YGUEFOK$= '6M??^>!EDX B[S. L7H!-L'
M9O>_=MQ^"6.C; !5= JR#[A<+:9I=9ZF_I5<R.4'/*E"KC-GN?(^T+9OZU@V
MGRD,LS:"B39SF4FL>L,#I.U?/FX7A;$!-YA:.H7=>D$]PN1RDFU.6(0 [6J+
MF\ CK L$E-<AVB)SS!MZ:#M2,&Y#A;$!.*R".L@/7[8NN=4JPF<=O#$<>';D
MD,K:1<DCB9!X<$8JFTN3@=0/T#-RLX1#ID"&T,CXS3O6B^A\41R7%_3K:0HG
MGQ;3</+Z='U)NL9!TW6J9Y),2CS9 "%98JUR%0JW8+0,)DLAXNUR]@>,VH8O
M'+DMPL&,6 OY=V"S;O;U4E;;((H&*VV]7)\<>"YM;0+!*7IFI=PN8A^K;UJ[
M-@>'M$^[2[\#Z#P:+J^["TXB*\8PI4C?LE[L4 Y<=H'B9(=6",U=FY[]3Y.V
M&<C^$.<  ^NI7^2M'<HSAK1DF$3M6>EJL6]AM,&SS "+1^EESLD<$GA7E&V&
MNV>=]&^CI;&CS$=ZPY&P*IMAEJI[\%!YWL378M\D'02L3F<F;GTIF:"$(A63
M"YGXC3RSO4G9#(3/_[C@L#KKP3!>G8_<Z*=T7CGS9O9I$6;+D*JJ)Q:3Y([$
M&BU7Q%O60,N0@W)<:6&$]:Y-0YPMB-P,J<_ZZ*&Y[D9M@WH/=[3:EA25+\Y+
M#>H54,S'-]A+F@>_OOCIB@-E2X*H, *2;,E5"8*9-F-YMZ%R,VP^ZP.+]MKK
M YR/><A76\>-C>(C)OKH:HK+B96R6%J1D%,]HT$CP#OD$(L.,7O,[';5R &B
MG"?)W@R^S_KX8P3]]N $/.)W/\TLL><8(N'-8PT%@P1?+U,'GXK7G%&$V*0=
MQEY4;X;E9WV2<GCM]@OELX6[_N7QMZKE:P?F0BK&8Q+@C*LWYERA[PSQ&K)C
M(7.39;NBZJU(W:SH^@]Q#M-8C_TB=;TL[V<0LW5:> LR&W+<O0K@98J0K3"%
M669Y;G(JN#6EF^'T69_P'$:+_<+TVD+\^.UDNEI.T&:=25Y@A==G&>&@E08C
M?<XNF:!+D_:-FQ*X&2C_$(=$3736 Q9OWNEB*1BK 0TM(26SA$@6'@IJ;81$
MYAMMV]M>IQ-_C#.A766_YP6H5[,!(_:;U[A"44Z)@" <)S=!HX$87 1=4&:A
MHJ5_-+-8.]RF^^.<\>RNAT'1-&:3_O=KS7S!5:T,N<G=D!W[;[[F\.W['V'S
MH+W\R2B%+'PAR'I'&(L,'"L9BK810Y%.ER8S:YOV\E\?6;V8+U?S<G$T-2_7
MFJ_>/)H*5Y=>RGSQ1%&2-P*10B;R#$PMYY61@BF5P"2CC49I6=CL7EL3\CKI
M@3 8XFZ<08ZOT+%/SB^X>AVFB[.+HT5S](D\4RU='=M>H_QL#.@LB8G HMGP
M)/S.HSOI5=@&2OL)<FP8O)PNT_QTUF QD-M*_H8/Y^VH(RKPK-!BR*G$E$)*
MMSM_/S0BL16)G?01:@/+/A3[[&8]?3Q^_>+HX[^_?GO\MX_#>(PWGMC6.7R8
M^.']P!=A^>7UR?RWY154O8^6,PO6TA?%32!<$#B"2%9$$6*2;<<;W4/4P!.<
MI TQL.(@\VPH*-,1@G.!5B,7BF=NDVMTC-'E!*?],/#$X*9M9-U#WNS!%K>"
M*RG1>9"AD#O I :'9,(IB,^*XG+DNE$APCZMHP\UL&DK-6_<.GH;F7< GGL:
M4D8NLE#D.G))$80*M-%$93UXDI/TZ'D,3=K5/Y_6T5OI^.G6T=L(?&RO?<.F
MH\)I&4OD8,D2@W(D*V(I0'3)1(S>Z]LC#]HW=3UDZ^BM5+I#4]=MY-L'9)[L
MAIUSREXS3=NV+J"$,Q#J^,52HF4Q&BGTADTFANLV?LC6T7M"9E#Y]@&9)[MA
M)^:0J=IQ15E:!5EFB+4U@7>9&R:STN;@W<8/V3IZ3\@,*M\.?)E[NM>:P)QD
MSH'461,')8"SG@$Y>SFEXHMS;0\&WF[5.OI04U,&<7UWDW('.'F'JQH_OE_,
M:S> _,N/7Y?U/L7QMW45^^SS45I-OZ_K(VF!T ].Z6?GOYS/KB).SVD!9,4
MZYI0L=ZY4"13QJ-1F<1IL4G!UC#D=^);[PBBN_>F#ZW1/G!\[;9X*499BC[
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M_QF$M]>7BW,E9E3$BY.T9H3Q$)@*H+5+-A5>O&C2_GX+&GN;]C=*H+NKSCJ
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M<-EY4"0C9%$(<F4.A3#15=)E%(3MHI9.$2;/64&6;([* 2^T8E2@8,R[0EL
M8I%62&Y#6T?O+DV=>'>C(&P7M?2$L#U<XK>79>&>F\P,*\!2)A?$^0PN<0VF
M=GA/3@=DV!230W Q[K6\SF*4@\.B@S5QQO,]&?NK$CVA#$8NP<A BYSE )';
M C*AU()'W:C4\4G*.O$B#X^:VW=,!E5A!YC\ZWR&/_X:%G_'U>O36;XS)SD*
M55(P!:RS!I0MJ;8#8)"]U 89LY8U26X_0=?(UYV&1<&\G4HZ0-B#PII87;2P
M=2Q?J%<=<[WJR%.!)(V+2D3-5)L^?@]1-')KCZ:H&D8-N^-IO@HG@^#IFNE_
M3%8IRIQ4]F B(ZZLB?4RMX+LG,=8NS.S)H<DFY'72<P\^G[:0)D=F+R7N)A^
M#_4>ZC7^2()5?J2>"7(F'4<./&0-2B#%<O5.AE62)33!"]&DC?83=(V[J;:
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M^)\6I(\($>ME3D:!%+/D1;1I\_0482/..6B-BGE#%>T,N6_$]#Q_7(7%ZC#
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M8K_=B :7F.)908G"4@A$KB#D1,&0+SK%.O+%[C.?>'KONG/IO3#<YHP63@R
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M)P\BI<"#+(7+=H/99A'Y3+?[A.E[_TCKY5@^I:9NPYP+GF00V@?(6@G*:'2
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M'V+=5^":O\7SPL6"R$EF6_<T*YR4GR50)NBMQB@H#SP5K'M(K5X+L ^S\"N
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M<9G#Y ?II":;VZ<]*^%_K9;77ZY^7UXO+C?"#KF94ED4:VR==R! Y:'KB2C
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MYQ"M]PF>NZLQ)X5'+D"J4@<\6@4N,@6*_CA)8;WG;286;5M17P ZR-Z[,72
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MKO!__H__#U!+ 0(4 Q0    ( !" 95%20TMT*0@  ,(I   9
M  "  0    !C<F1F+3 Y,S R,&5X:&EB:70S,3$N:'1M4$L! A0#%     @
M$(!E4?!MNXDA"   I2D  !D              ( !8 @  &-R9&8M,#DS,#(P
M97AH:6)I=#,Q,BYH=&U02P$"% ,4    "  0@&51,)PLZP4%  #2%P  &0
M            @ &X$   8W)D9BTP.3,P,C!E>&AI8FET,S(Q+FAT;5!+ 0(4
M Q0    ( !" 95' H(>B^@0  *D7   9              "  ?05  !C<F1F
M+3 Y,S R,&5X:&EB:70S,C(N:'1M4$L! A0#%     @ $(!E405RBF4ENP$
MHNH5 !$              ( !)1L  &-R9&8M,C R,# Y,S N:'1M4$L! A0#
M%     @ $(!E4?&"/3^)#P  #JH  !$              ( !>=8! &-R9&8M
M,C R,# Y,S N>'-D4$L! A0#%     @ $(!E4=>EF?RL'   J"L! !4
M         ( !,>8! &-R9&8M,C R,# Y,S!?8V%L+GAM;%!+ 0(4 Q0    (
M !" 95&N,AH"J&   *%"!  5              "  1 # @!C<F1F+3(P,C P
M.3,P7V1E9BYX;6Q02P$"% ,4    "  0@&51B];U>SK+  #;B@@ %0
M        @ 'K8P( 8W)D9BTR,#(P,#DS,%]L86(N>&UL4$L! A0#%     @
M$(!E48B(8M^0?   K<X% !4              ( !6"\# &-R9&8M,C R,# Y
@,S!?<')E+GAM;%!+!08     "@ * *8"   ;K ,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
